<SEC-DOCUMENT>0001019687-14-000756.txt : 20140307
<SEC-HEADER>0001019687-14-000756.hdr.sgml : 20140307
<ACCEPTANCE-DATETIME>20140307152931
ACCESSION NUMBER:		0001019687-14-000756
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20140303
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140307
DATE AS OF CHANGE:		20140307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Stratus Media Group, Inc
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-AMUSEMENT & RECREATION SERVICES [7900]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24477
		FILM NUMBER:		14676881

	BUSINESS ADDRESS:	
		STREET 1:		1800 CENTURY PARK EAST, 6TH FLOOR
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		310.526.8700

	MAIL ADDRESS:	
		STREET 1:		1800 CENTURY PARK EAST, 6TH FLOOR
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TITAN MOTORCYCLE CO OF AMERICA INC
		DATE OF NAME CHANGE:	19980615
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>stratus_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt">FORM
8-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">PURSUANT TO SECTION 13 OR 15(d) OF THE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Date of Report (Date of earliest event reported):
March 3, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt">STRATUS
MEDIA GROUP, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 34%; text-align: center">NEVADA</td>
    <TD STYLE="width: 32%; text-align: center">000-24477</td>
    <TD STYLE="width: 34%; text-align: center">86-0776876</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation)</td>
    <TD STYLE="text-align: center">(Commission File Number)</td>
    <TD STYLE="text-align: center">(IRS Employer Identification No.)</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">1800 Century Park East</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">6<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Los Angeles, California 90067</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(310) 526-8700</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction
A.2. below):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1in; text-indent: -1in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1in; text-indent: -1in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1in; text-indent: -1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1in; text-indent: -1in">Item 1.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entry into a Material
Definitive Agreement</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">On March 3, 2013, the Company entered
into an Agreement and Plan of Merger with Paloma Acquisition, Inc., a wholly owned subsidiary of the Company (&ldquo;Paloma Merger
Sub&rdquo;), Paloma Pharmaceuticals, Inc. (&ldquo;Paloma&rdquo;) and David Sherris, Ph.D, as founding stockholder and Holder Representative
pursuant to which the Company agreed to acquire all of the capital stock of Paloma (the &ldquo;Paloma Merger&rdquo;) with Paloma
becoming a wholly owned subsidiary of the Company. At the closing, the Company will issue an aggregate of 2,500,000 post-reverse
stock split common shares to the holders of Paloma Common Stock and its derivative securities and will assume promissory notes
of Paloma (the &ldquo;Notes&rdquo;) in the aggregate amount (principal and interest) currently of approximately $1,130,500 to be
paid on the first anniversary of the closing of the Paloma Merger. The consummation of the Paloma Merger is subject to the satisfaction
of certain conditions, including an agreement from the holders of the Notes to accept the extension of the maturity of the Notes
to the first anniversary of the closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">Also on March 3, 2014, the Company entered
into an Agreement and Plan of Merger (the &ldquo;VasculoMedics Merger Agreement&rdquo;) with VasculoMedics Acquisition, Inc., a
wholly owned subsidiary of the Company (&ldquo;VasculoMedics Merger Sub&rdquo;), VasculoMedics, Inc. (&ldquo;VasculoMedics&rdquo;)
and Sherris pursuant to which the Company agreed to acquire all of the capital stock of VasculoMedics (the &ldquo;VasculoMedics
Merger&rdquo;) with VasculoMedics becoming a wholly owned subsidiary of the Company. The VasculoMedics Merger will be completed
concurrently with and as a condition to the closing of the Paloma Merger with the Company issuing an aggregate of 220,000 post-reverse
stock split common shares to the VasculoMedics stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">Paloma is a clinical stage drug development
company that is utilizing its existing technology to develop drugs that treat various diseases including dermatology (psoriasis,
atopic dermatitis, rosacea, scar formation, bullous diseases, Dupuytren&rsquo;s disease), cancer, ocular diseases (macular degeneration,
diabetic retinopathy, proliferative vitreoretinopathy), neurodegenerative and central nervous system (infantile spasm, Huntington&rsquo;s
disease), fibrotic disease (pulmonary), biodefense (radioprotective, radiomitigant) and anti-infectives (HIV), with initial focus
on dermatology, cancer and ocular diseases.. VasculoMedics is engaged in the business of developing orally available small molecular
inhibitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">At the closing, David Sherris, the president
and chief executive officer, will become a director of the Company, the president of the two new Company subsidiaries, and chief
scientific officer of the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1in; text-indent: -1in">Item 8.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Events</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">On March&nbsp;6, 2014, the Company issued
a press release with respect to the foregoing. A copy of the press release is furnished as Exhibit 99.1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">(d)&#9;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 15%"><u>Exhibit No.</u></td>
    <TD STYLE="width: 85%"><u>Description</u></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>2.1</td>
    <TD>Agreement and Plan of Merger by and among Stratus Media Group, Inc., Paloma Acquisition, Inc., Paloma Pharmaceuticals, Inc. and David Sherris, Ph.D.</td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>2.2</td>
    <TD>Agreement and Plan of Merger by and among Stratus Media Group, Inc., VasculoMedics Acquisition, Inc., VasculoMedics, Inc. and David Sherris, Ph.D.</td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>99.1</td>
    <TD>Press Release issued by the Company on March&nbsp;6, 2014.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">STRATUS MEDIA GROUP, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">Date: March 7, 2014</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ Stephen M. Simes</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Stephen M. Simes, Chief Executive
        Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Index of Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 15%"><u>Exhibit No.</u></td>
    <TD STYLE="width: 85%"><u>Description</u></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>2.1</td>
    <TD>Agreement and Plan of Merger by and among Stratus Media Group, Inc., Paloma Acquisition, Inc., Paloma Pharmaceuticals, Inc. and David Sherris, Ph.D.</td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>2.2</td>
    <TD>Agreement and Plan of Merger by and among Stratus Media Group, Inc., VasculoMedics Acquisition, Inc., VasculoMedics, Inc. and David Sherris, Ph.D.</td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>99.1</td>
    <TD>Press Release issued by the Company on March&nbsp;6, 2014.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>stratus_8k-ex0201.htm
<DESCRIPTION>AGREEMENT AND PLAN OF MERGER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><B>EXHIBIT 2.1</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">AGREEMENT AND PLAN OF MERGER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">THIS AGREEMENT AND PLAN OF MERGER (the
&ldquo;Agreement&rdquo;), dated as of February 25, 2014 (the &ldquo;Effective Date&rdquo;), by and among Stratus Media Group, Inc.,
a Nevada corporation (&ldquo;Stratus&rdquo;); Paloma Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of
Stratus (&ldquo;Paloma Merger Sub&rdquo;); Paloma Pharmaceuticals, Inc., a Delaware corporation (&ldquo;Paloma&rdquo;), David Sherris,
Ph.D (&ldquo;Sherris&rdquo;), and Sherris as Holder Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">WHEREAS, the parties hereto have determined
that it would be advisable and in the best interests of their respective companies and the security holders of their respective
companies that Paloma Merger Sub be merged with and into Paloma in a statutory reverse triangular merger (the &ldquo;Merger&rdquo;),
with Paloma surviving the Merger as the surviving entity and on the terms and subject to the conditions set forth in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">WHEREAS, the respective Boards of Directors
of Stratus, Paloma Merger Sub and Paloma have determined that the Merger, in the manner contemplated herein, is advisable and in
the best interests of their respective equity holders and, by resolutions duly adopted, have approved and adopted this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">WHEREAS, Sherris is the majority stockholder,
founder and President of Paloma; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">WHEREAS, Stratus, Paloma Merger Sub,
Sherris and Paloma desire to make certain representations, warranties, covenants and agreements in connection with the Merger and
also to prescribe various conditions to the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">NOW, THEREFORE, in consideration of the
representations, warranties, covenants and agreements contained in this Agreement, the receipt and legal sufficiency of which is
hereby acknowledged, accepted and agreed to, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE I<BR>
DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain Definitions. For purposes
of this Agreement, the following terms shall have the meanings specified in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Affiliate&rdquo; means, with respect
to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, or is controlled by,
or is under common control with, such Person, and the term &ldquo;control&rdquo; (including the terms &ldquo;controlled by&rdquo;
and &ldquo;under common control with&rdquo;) means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Closing&rdquo; has the meaning
ascribed to it in Section 2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Closing Date&rdquo; has the meaning
ascribed to it in Section 2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Cobra&rdquo; means the Consolidated
Omnibus Budget Reconciliation Act of 1985, as amended, or any successor statute thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Code&rdquo; means the Internal
Revenue Code of 1986, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Contract&rdquo; means any contract,
agreement, indenture, note, bond, loan, instrument, lease, commitment or other legally binding arrangement or agreement, whether
written or oral.</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;DGCL&rdquo; means the Delaware
General Corporation Law in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Dissenting Securities&rdquo; has
the meaning ascribed to it by Section 3.9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Effective Time&rdquo; has the
meaning ascribed to it by Section 2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;ERISA&rdquo; means the Employee
Retirement Income Security Act of 1974, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Escrow Agent&rdquo; means the
Person who will act as Escrow Agent pursuant to Section 9.4, which Person shall be subject to the approval of the Holder Representative
and Stratus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Escrow Shares&rdquo; means (a)
25,000,000 shares of Stratus Common Stock representing in the aggregate ten (10%) percent of the Merger Consideration held by the
former Paloma Stockholders except Sherris and (b) 104,134,560 shares of Stratus Common Stock representing, in the aggregate, seventy-five
(75%) percent of the shares of Stratus Common Stock issued to Sherris in the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;GAAP&rdquo; means generally accepted
accounting principles in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Governmental Body&rdquo; means
any government or governmental or regulatory body thereof, or political subdivision thereof, whether federal, state, local or foreign,
or any agency, instrumentality or authority thereof, or any court, arbitrator or mediator (public or private).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Holder Representative Reserve&rdquo;
means 7,000,000 shares of Stratus Common Stock intended to settle claims and to defray the costs and expenses incurred by the Holder
Representative in connection with such Person&rsquo;s obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Indebtedness&rdquo; of any Person
means, without duplication: (i) the principal of and premium (if any), prepayment penalties (if any) in respect of: (A) indebtedness
of such Person for money borrowed and (B) indebtedness evidenced by notes, debentures, bonds or other similar instruments for the
payment of which such Person is responsible or liable; (ii) all obligations of such Person issued or assumed as the deferred purchase
price of property, all conditional sale obligations of such Person and all obligations of such Person under any title retention
agreement; (iii) all obligations of such Person under leases required to be capitalized in accordance with GAAP; (iv) all obligations
of such Person for the reimbursement of any obligor on any letter of credit, banker&rsquo;s acceptance or similar credit transaction
and (v) all obligations of the type referred to in clauses (i) through (iv) of any Persons for the payment of which such Person
is responsible or liable or for which any property or asset of such Person is secured by a Lien, under any legally binding obligation,
including as obligor, guarantor, surety or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Intellectual Property or Intellectual
Property Rights&rdquo; shall mean all of the rights arising from or in respect of the following, whether protected, created or
arising under the Laws of the United States or any foreign jurisdiction: (A) patents, patent applications, any reissues, reexaminations,
divisionals, continuations, continuations-in-part and extensions thereof (collectively, &ldquo;Patents&rdquo;); (B) trademarks,
service marks, trade names (whether registered or unregistered), service names, industrial designs, brand names, brand marks, trade
dress rights, Internet domain names, identifying symbols, logos, emblems, signs or insignia, and including all goodwill associated
with the foregoing (collectively, &ldquo;Marks&rdquo;), (C) copyrights, whether registered or unregistered (including copyrights
in computer software programs), mask work rights and registrations and applications therefor (collectively, &ldquo;Copyrights&rdquo;);
(D) confidential and proprietary information, or non-public processes, designs, specifications, technology, know-how, techniques,
formulas, inventions, concepts, trade secrets, discoveries, ideas and technical data and information, in each case excluding any
rights in respect of any of the foregoing that comprise or are protected by Copyrights or Patents (collectively, &ldquo;Trade Secrets&rdquo;);
(E) all uniform resource locators, e-mail and other internet addresses and domain names and applications and registrations therefor
(&ldquo;Domain Names&rdquo;); and (F) all applications, registrations and permits related to any of the foregoing clauses (A) through
(E).</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;IRS&rdquo; means the Internal
Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Knowledge&rdquo; means with respect
to Paloma, the actual knowledge of Sherris and such knowledge as would reasonably be expected to be known by him in the ordinary
and usual course of the performance of his responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Law&rdquo; means any foreign,
federal, state or local law (including common law), statute, code, ordinance, rule, regulation or other requirement issued, enacted,
adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Legal Proceeding&rdquo; means
any judicial, administrative, arbitral or mediation-related actions, suits, proceedings (public or private) or claims or proceedings
by or before a Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Liability&rdquo; means any debt,
loss, damage, adverse claim, liability or obligation (whether direct or indirect, known or unknown, asserted or unasserted, absolute
or contingent, accrued or unaccrued, liquidated or unliquidated, or due or to become due, and whether in contract, tort, strict
liability or otherwise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Lien&rdquo; shall mean any lien,
mortgage, encumbrance, security interest, claim, lease, charge, or pledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Losses&rdquo; means any and all
Liabilities, Taxes and Tax Losses, costs and expenses, and any and all claims, demands or suits (by any Person, including without
limitation any Governmental Body), including the costs and expenses of any and all actions, suits, proceedings, demands, assessments,
judgments, settlements and compromises relating thereto and including reasonable attorneys&rsquo; and other advisors&rsquo; fees,
costs and expenses in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Merger Consideration&rdquo; means
250,000,000 shares of Stratus Common Stock (as may be adjusted as provided in this Agreement), which shares are to be issued pursuant
to Sections 3.1(b) and 3.3 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Merger Consideration Schedule&rdquo;
has the meaning ascribed to it by Section 3.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Multiple Employer Plan&rdquo;
shall mean: (i) a &ldquo;multiple employer plan&rdquo; within the meaning of Section 413(c) of the Code or Section 3(40) of ERISA
or (ii) a plan which if maintained or administered in or otherwise subject to the laws of the United States would be described
in subpart (A).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Order&rdquo; means any order,
injunction, judgment, decree, ruling, writ, assessment or arbitration award of a Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Ordinary Course of Business&rdquo;
means the ordinary and usual course of day-to-day operations of the business of Stratus or Paloma, as the case may be, consistent
with past practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Paloma Balance Sheet&rdquo; has
the meaning ascribed to it by Section 5.20.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Paloma Common Stock&rdquo; mean
the issued and outstanding shares of the Common Stock of Paloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Paloma Derivative Securities&rdquo;
means: (a) the Paloma Warrants, (b) the Paloma Notes, and (c) the Paloma Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Paloma Financial Statements&rdquo;
has the meaning ascribed to it by Section 5.20.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Paloma Intellectual Property&rdquo;
means all Intellectual Property Rights owned by or licensed to Paloma.</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Paloma Material Adverse Effect&rdquo;
means any condition, change, situation or set of circumstances (any such item, an &ldquo;Effect&rdquo;) that has had or would reasonably
be expected to have a material adverse effect on: (i) the business, assets, properties, liabilities, financial condition, operations,
or results of operations of Paloma or (ii) the ability of Paloma to consummate Merger and the other transactions contemplated by
this Agreement or perform its material obligations under this Agreement or the Paloma Documents, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Paloma Notes&rdquo; means the
18.0% convertible promissory notes of Paloma in the aggregate amount (principal and interest) currently of approximately $1,130,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Paloma Options&rdquo; means the
options to purchase Paloma Common Stock listed on Schedule 5.4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Paloma Stockholders&rdquo; means
the holders of any shares of Paloma Common Stock issued and outstanding immediately prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Paloma Technology&rdquo; means
all Technology owned by or licensed to Paloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Paloma Warrants&rdquo; means the
warrants to purchase Paloma Common Stock listed on Schedule 5.4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Permits&rdquo; means any approvals,
authorizations, consents, licenses, permits or certificates of a Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Person&rdquo; means any individual,
corporation, partnership, firm, joint venture, association, joint-stock Company, trust, unincorporated organization, Governmental
Body or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Post-Closing Amounts&rdquo; means
transactions fees and expenses incurred by Paloma in connection with the transactions contemplated herein for: (1) corporate counsel
up to $50,000 and (2) accountants, patent counsel and other advisors up to $25,000, all of which shall be provided to Stratus (with
appropriate invoices) prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Software&rdquo; means computer
programs, including any and all software implementations of algorithms, models and methodologies whether in source code, object
code or other form, databases and compilations, including any and all data and collections of data, descriptions, flow-charts and
other work product used to design, plan, organize and develop any of the foregoing and all documentation, including user manuals
and training materials related to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Stratus Material Adverse Effect&rdquo;
means, with respect to Stratus, any Effect that has had or would reasonably be expected to have a material adverse effect on: (i)
Stratus or the business, assets, properties, liabilities, financial condition, operations, or results of operations of Stratus,
or (ii) the ability of Stratus to consummate the Merger and the other transactions contemplated by this Agreement or perform its
material obligations under this Agreement or the Stratus Documents, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Stratus Common Stock&rdquo; means
Stratus&rsquo; common stock, $0.001 par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Subsidiary&rdquo; means any Person
of which any other Person directly or indirectly owns voting securities, other voting rights or voting partnership interests which
are sufficient to elect at least a majority of such first Person&rsquo;s board of directors or other governing body (or, if there
are no such voting interests, the second Person directly or indirectly owns 50% or more of the equity interests of such first Person).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Takeover Proposal&rdquo; means
any inquiry, proposal or offer from any Person or &ldquo;group&rdquo; (as defined in Section 13(d) of the Securities Exchange Act
of 1934, as amended, (the &ldquo;Exchange Act&rdquo;)), other than Stratus relating to any: (A) direct or indirect acquisition
(whether in a single transaction or a series of related transactions) of all or any portion of the assets of Paloma, (B) direct
or indirect acquisition (whether in a single transaction or a series of related transactions) of all or any portion of the any
class of equity securities of Paloma, (C) tender offer or exchange offer that if consummated would result in any Person or &ldquo;group&rdquo;
(as defined in Section 13(d) of the Exchange Act) beneficially owning 15% or more of any class of equity securities of Paloma or
(D) merger, consolidation, share exchange, business combination, recapitalization, liquidation, dissolution or similar transaction
involving Paloma ; in each case, other than the transactions contemplated by this Agreement.</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Tax Return&rdquo; means any return,
report or statement required to be filed with respect to any Tax (including any schedules or attachments thereto, and any amendment
thereof), including any information return, claim for refund, amended return or declaration of estimated Tax, and including, where
permitted or required, combined, consolidated or unitary returns for any group of entities that includes Paloma or any of its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Taxes&rdquo; means: (i) all federal,
state, local or foreign taxes, charges, fees, imposts, levies or other assessments, including all net income, gross receipts, capital,
sales, use, ad valorem, value added, transfer, franchise, profits, inventory, capital stock, license, withholding, payroll, employment,
social security, unemployment, national insurance or health, excise, severance, stamp, occupation, property and estimated taxes,
customs duties, fees, assessments and other taxes of any kind whatsoever, (ii) all interest, penalties, fines, additions to tax
or additional amounts imposed by any Taxing Authority in connection with any item described in clause (i), and (iii) any liability
in respect of any items described in clauses (i) and/or (ii) payable by reason of Contract, assumption, transferee liability, operation
of Law, Treasury Regulation Section 1.1502-6(c) (or any predecessor or successor thereof of any analogous or similar provision
under Law) or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Taxing Authority&rdquo; means
the IRS and any other Governmental Body responsible for the administration of any Tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Technology&rdquo; means, collectively,
all designs, formulas, algorithms, procedures, techniques, ideas, know-how, Software (whether in source code, object code or human
readable form), databases and data collections, Internet websites and web content, tools, inventions (whether patentable or unpatentable
and whether or not reduced to practice), invention disclosures, developments, creations, improvements, works of authorship, other
similar materials and all recordings, graphs, drawings, reports, analyses, other writings and any other embodiment of the above,
in any form or media, whether or not specifically listed herein, and all related technology, documentation and other materials
used in, incorporated in, embodied in or displayed by any of the foregoing, or used or useful in the design, development, reproduction,
maintenance or modification of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Transaction Expenses&rdquo; means
the expenses payable by Paloma to its outside professional legal, financial, accounting, other advisors and as well as certain
creditors for services performed by them with respect to the negotiation of this Agreement and the other agreements contemplated
hereby and the transactions contemplated hereby and thereby whether or not billed or accrued or for services provided to either
Paloma prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Treasury Regulations&rdquo; means
the regulations promulgated under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;VasculoMedics&rdquo; means VasculoMedics,
Inc., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;VasculoMedics Letter of Intent&rdquo;
means that certain letter agreement dated January 9, 2014 between Stratus and VasculoMedics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE II<BR>
THE MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Merger. Upon the terms and
subject to the conditions set forth in this Agreement, and in accordance with the DGCL at the Effective Time: (a) Paloma Merger
Sub will merge with and into Paloma, and (b) the separate corporate existence of Paloma Merger Sub will cease and Paloma will continue
its corporate existence under the DGCL as the surviving corporation in the Merger (sometimes referred to herein as the &ldquo;Paloma
Surviving Corporation&rdquo;).</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the terms and subject to
the conditions set forth herein, the closing of the Merger (the &ldquo;Closing&rdquo;) will take place as soon as practicable (but
in any event within five (5) business days after satisfaction or waiver of each of the conditions set forth in Article VIII hereof),
unless another time or date is agreed to in writing by the parties hereto. The Closing may be held by the remote exchange of documents,
and the actual date of the Closing is hereinafter referred to as the &ldquo;Closing Date.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of this
Agreement, at the Closing, Paloma, Stratus and Paloma Merger Sub, as the case may be, will cause a certificate of merger (the &ldquo;Certificate
of Merger&rdquo;) to be executed, acknowledged and filed with the Secretary of State of the State of Delaware in accordance with
the relevant provisions of the DGCL and shall make all other filings or recordings required under the DGCL. The Merger will become
effective at such time as the Certificate of Merger has been duly filed with the Secretary of State of the State of Delaware or
at such later date or time as may be agreed by Paloma and Stratus in writing and specified in the Certificate of Merger in accordance
with the DGCL (the effective time of the Merger being hereinafter referred to as the &ldquo;Effective Time&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of the Merger. The Merger
shall have the effect set forth herein and in the applicable provisions of the DGCL. Without limiting the generality of the foregoing,
and subject thereto, from and after the Effective Time all property, rights, privileges, immunities, powers, franchises, licenses
and authority of Paloma and Paloma Merger Sub shall vest in the Paloma Surviving Corporation, and all debts, liabilities, obligations,
restrictions and duties of each of Paloma and Paloma Merger Sub shall become the debts, liabilities, obligations, restrictions
and duties of the Surviving Paloma Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificate of Incorporation;
By-laws. At the Effective Time: (a) the Paloma Certificate of Merger shall be amended so that such certificate of incorporation
shall contain only the provisions in the certificate of incorporation of Paloma Merger Sub (other than the corporate name) and,
as so amended, shall be the certificate of incorporation of the Paloma Surviving Corporation, and (b) the by-laws of Paloma Merger
Sub as in effect immediately prior to the Effective Time shall be the by-laws of the Paloma Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors and Officers. The directors
and officers of Paloma Merger Sub immediately prior to the Effective Time shall, from and after the Effective Time, be the directors
and officers, respectively, of the Paloma Surviving Corporation until their successors have been duly elected or appointed and
qualified or until their earlier death, resignation or removal in accordance with the certificate of incorporation and by-laws
of the Paloma Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE III<BR>
EFFECT OF THE MERGER ON THE</B><BR>
SECURITIES OF PALOMA AND PALOMA MERGER SUB</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect on Paloma Capital Stock.
As of the Effective Time, by virtue of the Paloma Merger and without any action on the part of Paloma Merger Sub, Paloma or the
holders of: (i) any shares of Paloma Common Stock, (ii) the Paloma Derivative Securities or (iii) any shares of common stock of
Paloma Merger Sub, the following shall occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cancellation of Certain Paloma
Capital Stock. Each share of Paloma, Common Stock that is owned by Stratus, Paloma Merger Sub or Paloma (as treasury stock or otherwise)
or any of their respective direct or indirect wholly-owned Subsidiaries will automatically be cancelled and retired and will cease
to exist, and no consideration will be delivered in exchange therefor.</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion of Paloma Stock. All
Paloma Common Stock and all Paloma Derivative Securities issued and outstanding immediately prior to the Effective Time (other
than Dissenting Securities, and Paloma Notes that are not converting and are to be paid off by Stratus, and shares to be cancelled
and retired in accordance with Section 3.1(a)) will be converted into the Merger Consideration which Merger Consideration shall
be distributed to the Paloma Stockholders and holders of the Paloma Derivative Securities as more particularly set forth in the
Merger Consideration Schedule, but in any event subject to Sections 3.3 and 3.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cancellation of Shares. At the
Effective Time, all shares of Paloma Common Stock and all Paloma Derivative Securities (except for any Paloma Notes that are to
be paid off by Stratus), will no longer be outstanding and all shares of Paloma Common Stock and all Paloma Derivative Securities
(except for any Paloma Notes that are to be paid off by Stratus), will be cancelled and retired and will cease to exist, and each
holder of a certificate or other document formerly representing any such shares of Paloma Common Stock or Derivative Securities
(except for any Paloma Notes that are to be paid off by Stratus), will cease to have any rights with respect thereto, except the
right to receive the Merger Consideration, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion of Paloma Merger Sub
Capital Stock. Each share of common stock of Paloma Merger Sub issued and outstanding immediately prior to the Effective Time shall
be converted into and become one newly issued, fully paid and non-assessable share of common stock of the Paloma Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Escrow Fund. At the Closing, Stratus
shall issue the Escrow Shares and the Escrow Agent shall hold such shares in accordance with the terms of Section 9.4 (the &ldquo;Escrow
Fund&rdquo;). The Paloma Stockholders shall have the sole and exclusive right to exercise any and all voting and consensual rights
and powers, and shall be entitled to receive and retain any and all cash dividends, accruing to an owner of their respective portion
of the Escrow Shares pursuant to the terms of Article IX. For income tax purposes, the Paloma Stockholders shall be deemed the
owners of their pro rata portion of the Escrow Fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of Merger Consideration.
At the Effective Time: (i) Stratus shall issue cerificates in the name of the Paloma Stockholders representing the Paloma Merger
Consideration in accordance with the merger consideration schedule set forth on Schedule 3.3 hereto (the &ldquo;Merger Consideration
Schedule&rdquo;) and (ii) the Paloma Stockholders shall deliver to Stratus certificates representing all of the issued and outstanding
shares of Paloma Common Stock, provided that prior to any issuance of any Merger Consideration, the Paloma Stockhodlers shall have
delivered to Stratus a properly completed Omnibus Consent Agreement. Upon surrender of such certificates for cancellation to Stratus
and delivery of the Omnibus Consent Agreement, the holders of such certificates shall be entitled to receive in exchange therefor,
and Stratus shall cause the transfer agent to deliver the Merger Consideration (or evidence of such Consideration in book-entry
form) into which the securities formerly represented by such certificates shall have been converted pursuant to the terms of this
Article III, and the certificates so surrendered shall forthwith be cancelled. All Merger Consideration paid upon the surrender
or exchange of certificates shall be deemed to have been paid in full satisfaction of all rights pertaining to the shares of Paloma
Common Stock previously represented by such certificates, and at the Effective Time the transfer books of Paloma shall be closed
and there shall be no further registration of transfers on the stock transfer books of the shares of Paloma Common Stock that were
outstanding immediately prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Fractional Shares. No certificates
or scrip representing fractional shares of Stratus Common Stock shall be issued and any fractions shall be rounded up or down to
the nearest whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lost, Stolen or Destroyed Certificate.
If any certificate evidencing Paloma Common Stock shall have been lost, stolen or destroyed, upon the making of an affidavit of
that fact by the person claiming such certificate to be lost, stolen or destroyed and, if required by Stratus, the posting by such
person of a bond, in such reasonable amount as Stratus may direct, as indemnity against any claim that may be made against it with
respect to such certificate, Stratus will issue, in exchange for such lost, stolen or destroyed certificate, the applicable Merger
Consideration and cash in lieu of any fractional shares of Stratus Common Stock to which such holder would be entitled pursuant
to Section 3.3, in each case pursuant to this Agreement.</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withholding Taxes. Stratus shall
be entitled to deduct and withhold from that portion of the Merger Consideration otherwise payable pursuant to this Agreement such
amounts as Stratus is required to deduct and withhold with respect to the making of such payment under the Code or any provision
of state, local, provincial or foreign Tax Law. To the extent that amounts are so withheld and remitted to the appropriate governmental
body, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the holder of such securities
in respect of which such deduction and withholding was made by Stratus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holder Representative Reserve.
Notwithstanding anything herein to the contrary, at the Closing, Stratus shall cause to be deposited, in an account designated
by the Holder Representative, via a single stock certificate, the Holder Representative Reserve. The Holder Representative Reserve
may be applied as the Holder Representative, in such Holder&rsquo;s sole discretion, determines appropriate to pay, settle, defray,
offset, or pay any claims, charges, fees, costs, liabilities or expenses of the Holder Representative incurred in connection with
the transactions contemplated by this Agreement and settlement of any claims. The balance of the Holder Representative Reserve
held pursuant to this Section 3.7, if any, shall be distributed to the Paloma Stockholders who are entitled to receive the Merger
Consideration by depositing such balance with Stratus&rsquo; transfer agent for distribution when so determined by the Holder Representative
in his sole discretion. Stratus shall have no liability or responsibility to the Paloma Stockholders with respect to the Holder
Representative Reserve or the actions and responsibilities of the Holder Representative contemplated by this Section 3.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Appraisal Rights. Notwithstanding
anything in this Agreement to the contrary, shares of Paloma Common Stock that are issued and outstanding immediately prior to
the Effective Time and which are held by a Paloma Stockholder who did not vote in favor of the Merger (or consent thereto in writing)
and who is entitled to demand and properly demands appraisal of Paloma Common Stock pursuant to, and who complies in all respects
with, the provisions of the DGCL (the &ldquo;Dissenting Holders&rdquo;), shall not be converted into or be exchangeable for the
right to receive the applicable Merger Consideration, but instead such Holder shall be entitled to payment of the fair value of
such Paloma Common Stock (the &ldquo;Dissenting Securities&rdquo;) in accordance with the provisions of the DGCL (and at the Effective
Time, such Dissenting Securities shall no longer be outstanding and shall automatically be canceled and shall cease to exist, and
such holder shall cease to have any rights with respect thereto, except the right to receive the fair value of such Dissenting
Securities in accordance with the provisions of the DGCL, unless and until such holder shall have failed to perfect or shall have
effectively withdrawn or lost rights to appraisal under the DGCL. If any Dissenting Holder shall have failed to perfect or shall
have effectively withdrawn or lost such right, such Holder&rsquo;s shares of Paloma Common Stock shall thereupon be treated as
if they had been converted into and become exchangeable for the right to receive, as of the Effective Time, the applicable Merger
Consideration for such Stock without any interest thereon. Paloma shall give Stratus: (i) prompt notice of any written demands
for attempted withdrawals of such demands and any other instruments served pursuant to the DGCL, and (ii) the opportunity to participate
in all negotiations and proceedings with respect to demands for appraisal under the DGCL. Paloma, except with the prior written
consent of Stratus, shall not voluntarily make any payment with respect to, or settle, or offer or agree to settle, any such demand
for payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE IV<BR>
TERMINATION, AMENDMENT AND WAIVER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination of Agreement. This
Agreement may be terminated at any time prior to the Effective Time as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the election of Stratus or
Paloma, on or after March 31, 2014 if the Closing shall not have occurred by the close of business on such date; provided, however,
that the right to terminate this Agreement under this Section 4.1(a) shall not be available to any party who is in material default
of any of its obligations hereunder;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by mutual written consent of Stratus
and Paloma;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by either Stratus or Paloma if:
(i) there shall be in effect a final nonappealable Order of a Governmental Body of competent jurisdiction restraining, enjoining
or otherwise prohibiting the consummation of the transactions contemplated hereby or (ii) there shall be any Law enacted, promulgated
or issued or deemed applicable to the Merger by any Governmental Body that would make consummation of the Merger illegal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by Stratus, so long as Stratus
is not in material breach of its representations, warranties, covenants or agreements under this Agreement, if there shall have
been a material breach of any representation, warranty, covenant or agreement of Paloma set forth in this Agreement, which breach
would give rise to a failure of a condition set forth in Section 8.1 and is incapable of being cured or, if capable of being cured,
shall not have been cured within twenty (20) Business Days following receipt by Paloma, as the case may be, of written notice of
such breach from Stratus ;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by Paloma, so long as such party
is not in material breach of its representations, warranties, covenants or agreements under this Agreement, if there shall have
been a material breach of any representation, warranty, covenant or agreement of Stratus set forth in this Agreement, which breach
would give rise to a failure of a condition set forth in Section 8.2 and is incapable of being cured or, if capable of being cured,
shall not have been cured within twenty (20) Business Days following receipt by Stratus of written notice of such breach from Paloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination. In the
event of the termination of this Agreement as provided in Section 4.1, written notice thereof shall be given to the other party
or parties, specifying the provision hereof pursuant to which such termination is made, and this Agreement shall forthwith become
null and void (other than Section 7.9, all of which shall survive termination of this Agreement); provided, however, that nothing
contained herein shall relieve any party from liability for breach of this Agreement or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE V<BR>
REPRESENTATIONS AND WARRANTIES OF PALOMA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Paloma and Sherris hereby jointly and
severally represent and warrant to Stratus that, except as set forth on the applicable Disclosure Schedule to this Agreement (the
&ldquo;Disclosure Schedule&rdquo;), which exceptions shall be deemed to be part of the representations and warranties made hereunder,
the following representations are true and complete as of the date of the Closing. The Disclosure Schedule shall be arranged in
sections corresponding to the numbered and lettered sections and subsections contained in this Article V and the disclosures in
any section or subsection of the Disclosure Schedule shall qualify other sections and subsections in this Article V to the extent
it is apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Organization and Good Standing.
Paloma is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all
requisite corporate power and authority to own, lease and operate its properties and to carry on its business as now conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorization of Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma has all requisite power,
authority and legal capacity to execute and deliver this Agreement and each other agreement, document, or instrument or certificate
contemplated by this Agreement or to be executed by Paloma in connection with the consummation of the transactions contemplated
by this Agreement (together with this Agreement, the &ldquo;Paloma Documents&rdquo;), and to consummate the transactions contemplated
hereby and thereby. The execution and delivery of this Agreement and each of the Paloma Documents by Paloma, the performance of
its obligations hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby have been duly
authorized by Paloma &rsquo;s Board of Directors and no other action on the part of Paloma is necessary to authorize the execution,
delivery and performance by Paloma of this Agreement and the consummation of the transactions contemplated hereby other than the
consent of the holders of Paloma Common Stock.</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement and each of Paloma
Documents have been duly and validly executed and delivered by Paloma and (assuming the due authorization, execution and delivery
by the other parties hereto and thereto) this Agreement constitutes, and each of Paloma Documents when so executed and delivered
will constitute, legal, valid and binding obligations of Paloma enforceable against Paloma in accordance with their respective
terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditors&rsquo; rights
and remedies generally, and subject, as to enforceability, to general principles of equity (regardless of whether enforcement is
sought in a proceeding at law or in equity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors of Paloma,
at a meeting duly called and held at which all the directors of Paloma were present in person or by telephone (or, in lieu of a
meeting, by the written consent of the directors of Paloma ), duly and by majority vote adopted resolutions: (i) approving and
declaring advisable this Agreement, the Merger and the other transactions contemplated by this Agreement, (ii) directing that the
adoption of this Agreement be submitted to the stockholders of Paloma and (iii) recommending that the stockholders of Paloma adopt
this Agreement, which resolutions have not been subsequently rescinded or modified or withdrawn in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedule 5.2(d) sets forth a true,
correct and complete list of the holders of record of Paloma Common Stock as of the date hereof. Prior to the Effective Time, Paloma
will deliver to Stratus true, correct and complete copies of the irrevocable written consents, which are valid and effective under
the DGCL of the requisite holders of Paloma Common Stock (the &ldquo;Paloma Shareholder Consents&rdquo;) to the Merger. The Paloma
Shareholder Consents are the only approval of holders of any class or series of Paloma Common Stock necessary or required (under
applicable Law, Paloma &rsquo;s certificate of incorporation and bylaws, or otherwise) to approve this Agreement on behalf of Paloma
and the transactions contemplated hereby, including the Merger. From and after the time of such delivery to Stratus, the Paloma
Shareholder Consents shall remain in full force and effect and shall be valid and effective under the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conflicts; Consents of Third Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The execution and delivery by
Paloma of this Agreement or the Paloma Documents, the consummation of the Merger and the transactions contemplated hereby or thereby,
or compliance by Paloma with any of the provisions hereof or thereof will not conflict with, or result in any violation of, default
or breach (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration
of any obligation or to loss of a material benefit under, or give rise to any obligation of Paloma to make any payment under, or
to the increased, additional, accelerated or guaranteed rights or entitlements of any Person under, or result in the creation of
any Liens upon any of the properties or assets of Paloma under, any provision of: (i) the certificate of incorporation and by-laws
of Paloma; (ii) any Intellectual Property, Technology, Contract or Permit to which Paloma is a party or by which any of the properties
or assets of Paloma are bound; (iii) any Order of any Governmental Body applicable to Paloma or any of its properties or assets
or (iv) any applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on Schedule
5.3(b), no consent, waiver, approval, Order, Permit or authorization of, or declaration or filing with, or notification to, any
Person or Governmental Body is required on the part of Paloma in connection with: (i) the execution and delivery of this Agreement
or the Paloma Documents, the compliance by Paloma with any of the provisions hereof or thereof, or the consummation by Paloma of
the Merger or the other transactions contemplated hereby or thereby or (ii) the continuing validity and effectiveness immediately
following the Closing of any Permit or material Contract of Paloma.</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The authorized capital stock of
Paloma consists of: 10,000,000 shares of common stock, of which 7,877,428 shares are issued and outstanding and 5,000,000 shares
of Preferred Stock, of which no shares are issued and outstanding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of the issued and outstanding
shares of Paloma Common Stock have been duly authorized, are validly issued, fully paid, and nonassessable, and are held of record
by the Paloma Stockholders as set forth in Schedule 5.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on Schedule
5.4(c), there is no existing option, warrant, call, right or Contract of any character to which Paloma is a party requiring, and
there are no securities of Paloma outstanding which upon conversion or exchange would require, the issuance, sale or transfer of
any additional shares of capital stock or other equity securities of Paloma or other securities convertible into, exchangeable
for or evidencing the right to subscribe for or purchase shares of capital stock or other equity securities of Paloma. Except as
set forth on Schedule 5.4(c), Paloma is not a party to any voting trust or other Contract with respect to the voting, redemption,
sale, transfer or other disposition of the capital stock of Paloma. Each agreement or instrument set forth on Schedule 5.4(b) will
be terminated effective as of the Closing. Schedule 5.4(c) sets forth an accurate and complete list of all Paloma Derivative Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third-Party Interests: Paloma
does not own, directly or indirectly, any shares of capital stock or equity or ownership interests in, any other Person (collectively,
&ldquo;Paloma Third-Party Interests&rdquo;). Paloma has no rights to, or is bound by any commitment or obligation to, acquire by
any means, directly or indirectly, any Paloma Third-Party Interests or to make any investment in, or contribution or advance to,
any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma has delivered to Stratus
true, correct and complete copies of its certificate of incorporation and by-laws (each certified by the secretary, assistant secretary
or other appropriate officer) or comparable organizational documents of Paloma as currently in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The minute books of Paloma previously
made available to Stratus contain true, correct and complete records in all material respects of all corporate action of the stockholders
and board of directors (including committees thereof) of Paloma. The stock certificate books and stock transfer ledgers of Paloma
previously made available to Stratus are true, correct and complete in all material respects. No stock transfer taxes have been
or payable with respect to all transfers of shares of Paloma prior to the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liabilities. Except as set forth
on Schedule 5.7, Paloma has no Indebtedness, obligations or Liabilities (whether or not required by GAAP to be reflected on a balance
sheet), including but not limited to Transaction Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma has: (i) duly and timely
filed all Tax Returns required to be filed by or on behalf of it in all jurisdictions in which such Tax Returns are required to
be filed (after giving effect to any duly obtained extensions of time in which to make such filings), all such Tax Returns are
true, complete and accurate in all material respects, and Paloma has maintained, to the extent required, all documentation supporting
the positions taken thereon, and (ii) timely paid all Taxes due and payable or claimed or asserted by any Taxing Authority to be
due and payable (except to the extent of any accrual for Taxes established on the Balance Sheet).</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma has complied in all material
respects with all applicable Laws relating to the payment and withholding of Taxes, and has duly and timely withheld and paid over
to the appropriate Taxing Authority all amounts required to be so withheld and paid under all applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma has made available to Stratus
true and complete copies of all Tax Returns of Paloma for all taxable periods since inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma&rsquo;s federal income
tax returns have not been audited, and no action, suit, proceeding, investigation or audit with respect to Taxes of any type is
pending or, to the Knowledge of Paloma, threatened. There are no outstanding assessments, claims or deficiencies for any material
Taxes of Paloma that have been asserted or assessed or, to the Knowledge of Paloma, proposed. No issue has been raised by a Taxing
Authority in any prior examination of Paloma which, by application of the same or similar principles, could reasonably be expected
to result in a material proposed deficiency for any subsequent taxable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the transactions taken
pursuant to this Agreement, other than payments to employees of Paloma, will give rise to any withholding obligation under any
provision of Law (including Section 1445 of the Code).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma is not, nor has ever been,
classified as an entity other than a corporation for US tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and Assets. Paloma has
good and marketable title or license to all of its material properties and assets, free and clear of all Liens. All material licensed
or leased properties of Paloma are held under valid and binding leases and/or licenses. Paloma leases all such properties as are
necessary in all material respects to the operations of Paloma as now conducted. Paloma does not own any real property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedule 5.10(a) sets forth an
accurate and complete list of all Patents and Patent applications, registered marks, and registrations and applications for registrations
of Marks, Copyrights and Domain Names owned or filed by Paloma (collectively, &ldquo;Registered Paloma Intellectual Property&rdquo;).
Schedule 5.10(a) lists the jurisdictions in which each such Registered Paloma Intellectual Property has been issued or registered
or in which any application for such issuance and registration has been filed or in which any other filing or recordation has been
made. Each item of Registered Paloma Intellectual Property is valid and subsisting, all necessary registration, maintenance and
renewal fees currently due in connection with such Registered Paloma Intellectual Property has been paid and all necessary documents
and certificates in connection with such Registered Paloma Intellectual Property have been filed with the relevant patent, copyright,
trademark or other authorities in the United States or foreign jurisdictions, as the case may be, for the purposes of maintaining
such Registered Paloma Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma has full title to and ownership
of, or has valid and continuing rights to use, sell or license, all Paloma Intellectual Property and Paloma Technology, free and
clear of any Liens of any kind. To Paloma&rsquo;s knowledge, Paloma Intellectual Property and Paloma Technology are sufficient
for the operation and conduct of the business of Paloma as presently conducted. To the Knowledge of Paloma, no third Person has
any rights to any Paloma Intellectual Property or Paloma Technology that is owned by Paloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To Paloma&rsquo;s Knowledge, no
Paloma Intellectual Property or Paloma Technology is infringing, misappropriating or violating, and has not infringed, misappropriated
or violated, the Intellectual Property Rights of any third Person, nor will, to Paloma&rsquo;s Knowledge, the use, practice or
other commercial exploitation of Paloma Intellectual Property or Paloma Technology by Paloma, or the licensing, marketing or, to
Paloma&rsquo;s Knowledge, use of the same, or the operation of Paloma &rsquo;s business, infringe, constitute an unauthorized use
of or misappropriate any Intellectual Property Rights of any third Person. Paloma is not a party to or the subject of any pending
or, to the Knowledge of Paloma, threatened suit, action, investigation or proceeding which involves a claim against Paloma, of
infringement, unauthorized use, or violation of any Intellectual Property Rights of any Person, or challenging the ownership, use,
validity or enforceability of any Paloma Intellectual Property or contesting the right of Paloma to use, sell, exercise, license,
transfer or dispose of any Paloma Intellectual Property or Paloma Technology, or any products, processes or materials covered thereby
in any manner, nor has Paloma received any written communications alleging such claims.</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of Paloma, no
Person (including employees and former employees of Paloma ) is infringing, violating, misappropriating or otherwise misusing any
Paloma Intellectual Property or Paloma Technology, and Paloma has not made any such claims against any Person (including employees
and former employees of Paloma).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance. Paloma has made available
to Stratus all material policies of insurance covering Paloma, and its employees, properties or assets, including policies of property,
fire, workers&rsquo; compensation, products liability, and other casualty and liability insurance, and such policies are in a form
and amount which Paloma reasonably believes is adequate for the operation of its business. Each of such insurance policies is in
full force and effect and Paloma is in compliance with the terms thereof. Other than customary end of policy notifications from
insurance carriers, since January 1, 2013, Paloma has not received any written notice regarding any actual or possible: (i) cancellation
or invalidation of any insurance policy; (ii) refusal or denial of any coverage, reservation of rights or rejection of any material
claim under any insurance policy; or (iii) material adjustment in the amount of the premiums payable with respect to any insurance
policy. There is no filed workers&rsquo; compensation or other claim under or based upon any insurance policy of Paloma. All information
provided to insurance carriers (in applications and otherwise) on behalf of Paloma is accurate and complete in all material respects.
The consummation of the transactions contemplated hereby will not, in and of itself, cause the revocation, cancellation or termination
of any such insurance policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Material Contracts and Obligations.
Schedule 5.12 sets forth a list of all material Contracts to which Paloma is a party or by which it is bound. Paloma has made available
to Stratus copies of all of the foregoing Contracts (or written summaries in the case of oral Contracts). All of such Contracts
are valid, binding and in full force and effect on Paloma. Paloma is not in default under any material provision of any of such
Contracts and, to the Knowledge of Paloma, no other party to any such Contracts is in default under any provision thereof. As of
the date hereof, Paloma has not received any written communication from any other party to the Contracts listed on Schedule 5.12
stating that such other party has decided or plans to terminate or otherwise discontinue such Contract. To the Knowledge of Paloma,
no event has occurred that with notice, lapse of time or both would constitute a breach or default thereunder by Paloma, or would
permit the modification or premature termination of such Contract by any other party thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance. Paloma has, in all
material respects, complied with all Laws and Orders applicable to its business, operations or assets and has all material Permits
required thereby wherein the failure to so comply would have a Paloma Material Adverse Effect. There is no term or provision of
any Order or Law applicable to or binding upon Paloma that has had or would reasonably be expected to have a Paloma Material Adverse
Effect. Paloma has not received any written or oral notices or communications from any Governmental Body of: (i) any material pending
violation with respect to any Laws, Orders or material Permits applicable to its business, operations or assets or (ii) threatening
to terminate, revoke or cancel any material Permit held by Paloma. Since its inception, Paloma has not entered into or been subject
to any Order with respect to any material aspect of its business, operations, properties, assets or employees or received any written
notice from any Governmental Body commencing or threatening any inquiry, investigation or Legal Proceeding with respect to any
of the foregoing. To the Knowledge of Paloma, none of the employees of Paloma is in violation of any Contract or covenant (either
with Paloma or with another entity) relating to employment, patent, other proprietary information disclosure, non-competition,
or non-solicitation.</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee Benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma has made available to Stratus
accurate and complete copies of all employee manuals and handbooks, disclosure materials, policy statements and other materials
relating to the employment of Paloma&rsquo;s employees to the extent currently effective and material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedule 5.14(b) lists all written
and describes all non-written employee benefit plans (as defined in Section 3(3) of ERISA) and all bonus, equity-based, incentive,
deferred compensation, retirement or supplemental retirement, profit sharing, severance, golden parachute, vacation, cafeteria,
dependent care, medical care, employee assistance program, education or tuition assistance programs and other similar fringe or
employee benefit plans or programs that may involve annual payments to a Paloma employee in excess of $10,000, and which are currently
in effect relating to any Paloma employee or which is maintained by, administered or contributed to by, or required to be contributed
to by, Paloma or any Paloma Affiliate, or under which Paloma or any Paloma Affiliate has any current or may incur liability after
the date hereof (each, a &ldquo;Paloma Employee Plan&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Paloma Employee Plan that
is intended to be qualified under Section 401(a) of the Code has received a favorable determination letter or opinion letter with
respect to such qualified status from the IRS. To the Knowledge of Paloma, nothing has occurred that could reasonably be expected
to adversely affect the qualified status of any such Paloma Employee Plan or the exempt status of any related trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Paloma Employee Plan has
been maintained in compliance, in all material respects, with its terms and, both as to form and operation, with all applicable
Laws, including without limitation, the Code and ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma has not engaged in any
transaction in violation of Sections 404 or 406 of ERISA or any &ldquo;prohibited transaction,&rdquo; as defined in Section 4975(c)(1)
of the Code, for which no exemption exists under Section 408 of ERISA or Section 4975(c)(2) or (d) of the Code, or has otherwise
violated the provisions of Part 4 of Title I, Subtitle B of ERISA. Paloma has not knowingly participated in a violation of Part
4 of Title I, Subtitle B of ERISA by any plan fiduciary of any Paloma Employee Plan subject to ERISA and has not been assessed
any civil penalty under Section 502(l) of ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Paloma Employee Plan is subject
to Title IV or Section 302 of ERISA or Section 412 of the Code, and neither Paloma nor any Paloma Affiliate has ever maintained,
contributed to or partially or completely withdrawn from, or incurred any obligation or liability with respect to, any such plan.
No Paloma Employee Plan is a Multiemployer Plan, and neither Paloma nor any Paloma Affiliate has ever contributed to or had an
obligation to contribute, or incurred any liability in respect of a contribution, to any Multiemployer Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Paloma Employee Plan provides
for medical or death benefits beyond termination of service or retirement, other than: (i) pursuant to COBRA or an analogous state
law requirement or (ii) death or retirement benefits under a Paloma Employee Plan qualified under Section 401(a) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma is not a party to any contract
that has resulted or could reasonably be expected to result, separately or in the aggregate, in the payment of: (i) any &ldquo;excess
parachute payment&rdquo; within the meaning of Section 280G of the Code and (ii) any amount the deduction for which would be disallowed
under Section 162(m) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of Paloma, no
payment pursuant to any Paloma Employee Plan or other arrangement to any &ldquo;service provider&rdquo; (as such term is defined
in Section 409A of the Code and the United States Treasury Regulations and IRS guidance thereunder) to Paloma, including the grant,
vesting or exercise of any stock option, would subject any Person to tax pursuant to Section 409A(1) of the Code, whether pursuant
to the Merger or the transactions contemplated hereby or otherwise.</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of Paloma, Paloma
has no material liability with respect to any misclassification of: (A) any Person as an independent contractor rather than as
an employee, (B) any employee leased from another employer or (C) any employee currently or formerly classified as exempt from
overtime wages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the execution and delivery
by Paloma of this Agreement, the performance by Paloma of its obligations hereunder, nor the consummation by Paloma of the transactions
contemplated hereby will: (i) result in any payment (including severance, unemployment compensation, golden parachute, bonus or
otherwise) becoming due to any stockholder, director or Paloma employee under any Paloma Employee Plan or otherwise, (ii) materially
increase any benefits otherwise payable under any Paloma Employee Plan, or (iii) result in the acceleration of the time of payment
or vesting of any such benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Labor and Employment Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma is not, or at any time
has been, a party to any collective bargaining agreement or other labor union agreement, nor is any such collective bargaining
agreement being negotiated. To the Knowledge of Paloma, no activities or proceedings are underway by any labor union to organize
any employees of Paloma. Paloma : (i) has no direct or indirect Liability with respect to any misclassification of any Person as
an independent contractor or temporary worker hired through a temporary worker agency rather than as an employee, (ii) is in compliance
in all material respects with all applicable foreign, federal, state and local Laws respecting employment, employment practices,
labor relations, fair employment, employment discrimination, health and safety, terms and conditions of employment, wages and hours,
workers compensation, unemployment Laws, immigration Laws and social security Laws and (iii) has not received any written remedial
order or notice of offense under applicable occupational health and safety Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is no unfair labor practice
charge or complaint against Paloma pending or, to the Knowledge of Paloma, threatened, before the National Labor Relations Board,
any court or any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect to Paloma, there
are no pending or, to the Knowledge of Paloma, threatened actions, charges, citations or consent decrees concerning: (i) wages,
compensation, bonuses, commissions, awards or payroll deductions, equal employment or human rights violations regarding race, color,
religion, sex, national origin, age, disability, veteran&rsquo;s status, marital status, or any other recognized protected class,
status or attribute under any federal, state, local or foreign equal employment Law prohibiting discrimination, (ii) representation
petitions or unfair labor practices, (iii) occupational safety and health, (iv) workers&rsquo; compensation, (v) wrongful termination,
negligent hiring, invasion of privacy or defamation or (vi) immigration or any other claims under state or federal labor Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedule 5.15(d) contains a complete
and correct list setting forth: (i) the names and titles of, and current annual compensation and the two (2) most recent annual
bonuses for and exempt or non-exempt status of, each current employee of Paloma, (ii) the names of each director of Paloma, (iii)
the name of each Person who currently provides, or who has within the prior twelve (12) month period provided, services to Paloma
as an independent contractor, and (iv) the names of each employee or independent contractor of Paloma who is a party to a non-competition
agreement with Paloma. To the Knowledge of Paloma, no person has any plans to terminate employment or service with Paloma. Except
as specifically identified on Schedule 5.15(d), all employees of Paloma are employed at will.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma has never terminated any
employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation. There is no Legal
Proceeding pending or threatened against Paloma or any Affiliate thereof, against any of the officers, directors or employees of
Paloma or any Affiliate thereof with respect to their business activities on behalf of Paloma, or to which Paloma or any Affiliate
thereof is otherwise a party before any Governmental Body nor, to the Knowledge of Paloma, are there any facts, claims or allegations
that could reasonably be expected to result in such a Legal Proceeding or a Paloma Material Adverse Effect. Paloma is not subject
to any Order, nor is any Affiliate of Paloma subject to any Order that relates to Paloma. Paloma is not engaged in (or intends
to engage in) any legal action to recover monies due it or for damages sustained by it. There are no facts, claims or allegations
that could reasonably be expected to result in liability of Paloma under Paloma &rsquo;s organizational documents or in any indemnification
agreements in effect as of the date hereof.</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related Party Transactions. Except
as noted on Schedule 5.17: (i) Paloma is not indebted to any director, officer or employee of Paloma (any such Person, an &ldquo;Paloma
Related Party&rdquo;) (except for amounts due as salaries and bonuses under employment contracts or employee benefits plans and
amounts payable in reimbursement of ordinary expenses); (ii) to the Knowledge of Paloma, no Paloma Related Party owns any direct
or indirect interest of any kind in, or controls or is a director, officer, employee or partner of, or consultant to, or lender
to or borrower from or has the right to participate in the profits of, any Person which is: (A) a competitor, supplier, landlord,
tenant, creditor or debtor of Paloma, (B) engaged in a business related to the business of Paloma, or (C) a participant in any
transaction to which Paloma is a party; (iii) no Paloma Related Party is indebted to Paloma, nor has Paloma made any loans or committed
to make any loan or extend or guarantee credit to or for the benefit of any Paloma Related Party; (iv) no Paloma Related Party
owns or has any interest in any property (real or personal, tangible or intangible), used in or pertaining to the business of,
Paloma other than as a result of his, her or its ownership of or interest in Paloma Stock;or (v) no Paloma Related Party is a party
to any Contract or involved in any business arrangement or other relationship with Paloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Banks. Schedule 5.18 contains
a complete and correct list of the names and locations of all banks in which Paloma has accounts or safe deposit boxes and the
names of all persons authorized to draw thereon or to have access thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Advisors. Except as
set forth on Schedule 5.19, no Person has acted, directly or indirectly, as a broker, finder or financial advisor for Paloma in
connection with the transactions contemplated by this Agreement and no Person is entitled to any fee or commission or like payment
in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements. Paloma
has made available to Stratus true and complete copies of: (i) Paloma&rsquo;s unaudited balance sheet as of December 31, 2013 and
December 31, 2012, and the related unaudited consolidated statements of operations and statements of cash flows of Paloma for the
periods covered therein, (collectively, the &ldquo;Paloma Annual Financial Statements&rdquo;), and (ii) the unaudited balance sheet
of Paloma as of June 30, 2013 and the related consolidated statement of operations and statement of cash flows for the six-month
period then ended (the &ldquo;Paloma Interim Financial Statements&rdquo;, and with Paloma Annual Financial Statements, the &ldquo;Paloma
Financial Statements&rdquo;). The Paloma Financial Statements are consistent with, and have been prepared from, the books and records
of Paloma and fairly present the financial condition and operating results of Paloma at the respective dates thereof and for the
periods indicated. The balance sheet of Paloma as of December 31, 2013 included in the Paloma Interim Financial Statements is referred
to herein as the &ldquo;Paloma Balance Sheet&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Absense of Certain Charges. From
the date of the Paloma Balance Sheet to the date hereof, there has not been any event, occurrence or condition that has had, or
would reasonably be expected to have, a Paloma Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">5.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclaimer. It is the explicit
intent, understanding and agreement of Stratus, that Paloma and Sherris are not making any representation or warranty whatsoever,
oral or written, express or implied, other than those set forth in this Agreement and any certificates furnished in connection
with this Agreement. Stratus acknowledges that it is not relying on any statement, representation or warranty, oral or written,
express or implied made by Paloma or Sherris or their representatives or agents, except for representations and warranties set
forth in this Agreement, and any certificates furnished in connection with this Agreement. Except for the representations and warranties
set forth in this Agreement and any certificates furnished in connection with this Agreement, the Shares are being sold &ldquo;as
is&rdquo; and &ldquo;where is&rdquo; and the Parties expressly disclaim all other representations and warranties of any kind or
nature expressed or implied (including, any relating to the financial condition, prospects, results of operations, assets or liabilities
of Paloma). Specifically, neither Paloma nor Sherris are making any representation, warranty or covenant of any kind with respect
to any projections, estimates or budgets heretofore delivered to or made available to Stratus of future revenues, expenses or expenditures,
future results of operations (or any component thereof), future cash flows or future financial condition (or any component thereof)
of Paloma or the future business and operations of Paloma.</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE VI<BR>
REPRESENTATIONS AND WARRANTIES OF STRATUS<BR>
AND PALOMA MERGER SUB</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Stratus and Paloma Merger Sub represent
and warrant to Paloma on the date hereof, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Organization and Good Standing.
Each of Stratus and Paloma Merger Sub is a corporation, validly existing and in good standing under the laws of its jurisdiction
of organization and has all requisite corporate power and authority to own, lease and operate its properties and carry on its business
as now conducted. Stratus is duly qualified or authorized to do business as a foreign corporation and is in good standing under
the laws of each jurisdiction in which it owns or leases real property and each other jurisdiction in which the conduct of its
business or the ownership of its properties requires such qualification or authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorization of Agreement. Each
of Stratus and Paloma Merger Sub has all requisite power and authority and legal capacity to execute and deliver this Agreement
and each other agreement, document, instrument or certificate contemplated by this Agreement or to be executed by Stratus and Paloma
Merger Sub in connection with the consummation of the transactions contemplated hereby and thereby (the &ldquo;Stratus Documents&rdquo;),
and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance by each of Stratus
and Paloma Merger Sub of this Agreement and each of Stratus Documents, to the extent applicable, have been duly authorized by all
necessary corporate action on behalf of Stratus and Paloma Merger Sub. This Agreement has been, and each Stratus Document will
be at or prior to the Closing, duly executed and delivered by each of Stratus and Paloma Merger Sub, to the extent applicable,
and (assuming the due authorization, execution and delivery by the other parties hereto and thereto) this Agreement constitutes,
and each Stratus Document when so executed and delivered will constitute, the legal, valid and binding obligation of each of Stratus
and Paloma Merger Sub, to the extent applicable, enforceable against it and in accordance with its respective terms, subject to
applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditors&rsquo; rights and remedies generally,
and subject, as to enforceability, to general principles of equity, (regardless of whether enforcement is sought in a proceeding
at law or in equity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conflicts; Consents of Third Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the execution and delivery
by Stratus and Paloma Merger Sub of this Agreement and of Stratus Documents, nor the compliance by Stratus with any of the provisions
hereof or thereof will: (i) conflict with, or result in any violation of, default or breach of, any provision of the articles of
incorporation, certificate of formation or by-laws of Stratus or Paloma Merger Sub, (ii) conflict with, violate, result in the
breach of, or constitute a default under any note, bond, mortgage, indenture, license, agreement or other obligation, in each case
to which Stratus and Paloma Merger Sub is a party or by which Stratus and Paloma Merger Sub or their properties or assets are bound
or (iii) violate any Law or Order of any Governmental Body by which Stratus or Paloma Merger Sub are bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on Schedule
6.3(b), no consent, waiver, approval, Order, Permit or authorization of, or declaration or filing with, or notification to, any
Person or Governmental Body is required on the part of Stratus or Paloma Merger Sub in connection with the execution and delivery
of this Agreement or the Stratus Documents or the compliance by Stratus or Paloma Merger Sub with any of the provisions hereof
or thereof or the consummation by Stratus of the transactions contemplated hereby.</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SEC Filings. As of their respective
filing dates, Stratus&rsquo; SEC filings complied in all material respects with the requirements of the Securities Exchange Act
of 1934 Act and the Securities Act of 1933. Stratus has, to its knowledge, filed with the SEC all filings required by those laws
and has provided all certifications of its officers which are required by Sarbanes-Oxley and the rules and regulations promulgated
in connection therewith, as such rules and regulations have been enacted by the SEC. None of Stratus&rsquo; SEC filings, as of
their respective dates, contained any untrue statement of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not
misleading; provided, however, that Stratus makes no representations or warranties as to the information contained in or omitted
from Stratus&rsquo; SEC filings in reliance upon and in conformity with information furnished to Stratus by or on behalf of counterparties
to the material contracts included in Stratus&rsquo; SEC filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Advisors. Except as
set forth on Schedule 6.5, no Person has acted, directly or indirectly, as a broker, finder or financial advisor for either Stratus
or Merger Sub in connection with the transactions contemplated by this Agreement and no Person is entitled to any fee or commission
or like payment in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The authorized capital stock of
Stratus consists of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One billion (1,000,000,000) shares
of common stock, $0.001 par value, of which 593,311,148 shares are issued and outstanding and of which 90,750,435 shares are subject
to outstanding option grants and warrants (exclusive of an undeterminate number issuable upon conversion of the convertible notes),
all as of February 11, 2014; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ten Million (10,000,000) shares
of preferred stock, $0.001 par value, of which no shares are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of the issued and outstanding
shares of capital stock of Stratus have been duly authorized, are validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on Schedule
6.6, there is no existing option, warrant, call, right or Contract of any character to which Stratus is a party requiring, and
there are no securities of Stratus outstanding which upon conversion or exchange would require, the issuance, sale or transfer
of any additional shares of capital stock or other equity securities of Stratus or other securities convertible into, exchangeable
for or evidencing the right to subscribe for or purchase shares of capital stock or other equity securities of Stratus. Stratus
is not a party to any voting trust or other Contract with respect to the voting, redemption, sale, transfer or other disposition
of the capital stock of Stratus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Records. Stratus has
delivered to Paloma true, correct and complete copies of its articles of incorporation and by-laws (each certified by the secretary,
assistant secretary or other appropriate officer) as currently in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE VII<BR>
COVENANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Board Seat. Effective as of the
Closing, Sherris (the &ldquo;Paloma Designee&rdquo;) will be elected to the Stratus Board of Directors. The term of service for
the Paloma Designee shall be the same as for the other members of the Stratus Board of Directors, which is approximately one (1)
year from the Closing Date. The Paloma Designee shall not be removed from the Stratus Board of Directors except in the event of
his individual commission of an act of fraud or a breach of any agreement pursuant to which he is providing services to Stratus
or Paloma Surviving Corporation.</P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooperation. The parties shall
cooperate fully with each other and their respective employees, legal counsel, accountants and other representatives and advisers
in connection with the steps required to be taken as part of their respective obligations under this Agreement; and each of them
shall, at any time and from time to time after the Closing, upon the request of the other, do, execute, acknowledge and deliver,
or cause to be done, executed, acknowledged and delivered, all such further acts, deeds, assignments, transfers, conveyances, consents,
receipts, acknowledgments, acceptances and assurances as may be reasonably required (without incurring unreimbursed expense) to
satisfy and perform the obligations of such party hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Public Announcements. Without
the prior written consent of the other party, no party hereto will make any press release or other public disclosure with regard
to the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further Assurances. Subject to
the terms and conditions of this Agreement, each party agrees to use all of its reasonable efforts to take, or cause to be taken,
all actions and to do or cause to be done, all things necessary and proper or advisable to consummate and make effective the transactions
contemplated by this Agreement (including the execution and delivery of such further instruments and documents as the other party
may reasonably request).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Access to Information. Prior to
the Effective Time, each party shall be entitled, through its officers, employees and representatives (including its legal advisors
and accountants), to make such investigation of the properties, businesses and operations of the other parties and such examination
of the books, records and financial condition of such other party as it reasonably requests and to make extracts and copies of
such books and records. Each party shall reasonably cooperate, and shall cause such party to reasonably cooperate, with all such
reasonable requests. No investigation by or on behalf of any party prior to or after the date of this Agreement shall diminish
or obviate any of the representations, warranties, covenants or agreements of the other parties contained in this Agreement. In
order that a party may have full opportunity to make such physical, business, accounting and legal review, examination or investigation
as it may reasonably request of the affairs of the other party, each such other party shall use commercially reasonable efforts
to cause the officers, employees, consultants, agents, accountants, attorneys and other representatives of such other party to
cooperate fully in connection with such review and examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conduct of the Business Pending
the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise expressly
contemplated by this Agreement, Paloma shall, given the current financial constraints:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;conduct its business only in the
Ordinary Course of Business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;use commercially reasonable efforts
to: (A) preserve its present business operations, organization, material rights, franchises, Intellectual Property Rights and goodwill
and (B) preserve, to the extent feasible, its present relationship with Persons having material business dealings with such party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;use its commercially reasonable
efforts to maintain: (A) all material assets and properties of such party in their current condition, ordinary wear and tear excepted
and (B) insurance upon all of the properties and assets of such party in such amounts, of such kinds and with such carriers as
are substantially similar to that in effect on the date of this Agreement;</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;maintain its books, accounts
and records in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;give all required notices of the
transactions contemplated by this Agreement and use its commercially reasonable efforts to obtain all third party consents material
to such party&rsquo;s business that are necessary or advisable in order to consummate the transactions contemplated by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not take any action which would
reasonably be expected to adversely affect the ability of the parties to consummate the transactions contemplated by this Agreement;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly notify Stratus in writing
if, prior to the consummation of the Closing, to its Knowledge: (a) any of the representations and warranties contained herein
applicable to Paloma are not accurate and complete in all material respects or (b) Paloma fails to comply with or satisfy any material
covenant, condition or agreement to be complied with or satisfied by it hereunder; provided, however, that the delivery of any
notice pursuant to this Section 7.6 shall not limit or otherwise affect the remedies available hereunder to Stratus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reasonable Best Efforts; Regulatory
Approvals. Upon the terms and subject to the conditions set forth in this Agreement, each of the parties agrees to use its best
efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other
parties in doing, all things reasonably necessary, proper or advisable to consummate and make effective, in the most expeditious
manner practicable, the Merger and the other transactions contemplated by this Agreement and bring about the fulfillment of the
conditions precedent contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">7.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Solicitation by Paloma</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma shall use its reasonable
best efforts to cause its directors, officers, employees, investment bankers, financial advisors, attorneys, accountants, agents
and other representatives (collectively, the &ldquo;Representatives&rdquo;) to, immediately cease and cause to be terminated any
discussions or negotiations with any Person conducted heretofore with respect to a Takeover Proposal, and use best efforts to obtain
the return from all such Persons or cause the destruction of all copies of confidential information previously provided to such
parties by Paloma or Representatives. Paloma shall not, and shall not permit its Representatives to, directly or indirectly: (i)
solicit, initiate, knowingly facilitate or encourage (including by way of furnishing information) any inquiries or proposals that
constitute, or may reasonably be expected to lead to, any Takeover Proposal, (ii) other than informing Persons of the existence
of the provisions contained in this Section 7.8, participate in any discussions or negotiations with any third party regarding
any Takeover Proposal or (iii) enter into any agreement related to any Takeover Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the other obligations
of the Company set forth in this Section 7.8, Paloma shall promptly advise Stratus, in writing, and in no event later than 24 hours
after receipt, if any proposal, offer, inquiry or other contact is received by, any information is requested from, or any discussions
or negotiations are sought to be initiated or continued with, Paloma in respect of any Takeover Proposal, and shall, in any such
notice to Stratus, indicate the identity of the Person making such proposal, offer, inquiry or other contact and the terms and
conditions of any proposals or offers or the nature of any inquiries or contacts (and shall include with such notice copies of
any written materials received from or on behalf of such Person relating to such proposal, offer, inquiry, contact or request),
and thereafter shall promptly keep Stratus informed of all material developments affecting the status and terms of any such proposals,
offers, inquiries, contacts or requests (and Paloma shall provide Stratus with copies of any additional written materials received
that relate to such proposals, offers, inquiries, contacts or requests) and of the status of any such discussions or negotiations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma acknowledges that damages
for any breach of the obligations in this Section 7.8 will be difficult to measure and that Stratus has the right to have the provisions
of this Section 7.8, specifically enforced.</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">7.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality and Non-Disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential Information. The
term &ldquo;Confidential Information&rdquo; means any information disclosed to a party to this Agreement (referred to in this Section
7.9 as the &ldquo;Recipient&rdquo;), either prior to or subsequent to the date of this Agreement, whether orally, in writing, in
any other medium, however documented (or not documented), by or on behalf of any other party to this Agreement (referred to within
this Section 7.9 as the &ldquo;Disclosing Party&rdquo;) including, without limitation, the Disclosing Party&rsquo;s actual and
proposed business(es); historical and protected financial information; budgets; services; products; trade secrets; techniques;
processes; operations; formulae; product specifications; know-how; processes; compositions; inventions; discoveries; designs; formats;
business, marketing and manufacturing plans and materials; analyses; strategies; forecasts; research and development; concepts;
ideas; names, addresses and any other characteristics, identifying information or aspects of the Disclosing Party&rsquo;s existing
or potential customers, employees, vendors or suppliers; or any information derived, summarized or extracted from any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential Information shall
not include any information which: (i) is or becomes available to the public other than as a consequence of a breach by any person
of any fiduciary duty or obligation of confidentiality, including, without limitation, catalogues, product descriptions and sales
literature that the Disclosing Party has distributed to the public generally; or (ii) is or was developed by a Recipient independently
of, and without reliance on or reference to, the confidential information of the Disclosing Party. All of the parties agree that
in the event an order by any court or other government entity is issued requiring a Recipient to turn over any Confidential Information,
Recipient shall give the Disclosing Party written notice of such court order immediately upon knowledge thereof and shall cooperate
with any efforts of Disclosing Party to protect the confidentiality of the information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Disclosure of Confidential
Information. Each party to this Agreement hereby agrees to hold in strict confidence and trust all Confidential Information and
agrees not to disclose or otherwise provide or transfer, directly or indirectly, any Confidential Information or anything related
to the Confidential Information to third parties without the prior written consent of the other party or as permitted by Section
7.9(b) or the next sentence. A Recipient may disclose Confidential Information (without consent of the other party): (i) to its
directors, officers, stockholders, employees, agents and advisors (including without limitation attorneys, accountants, consultants,
bankers, financing sources and financial advisors) (&ldquo;Representatives&rdquo;) who are advised of the terms of this Section
7.9 and who need to know such information to enable Recipient to evaluate and assist with respect to the Merger with a Disclosing
Party, and then only to the extent necessary to carry out the legitimate use of the Confidential Information and (ii) as required
by any final, unappealable court order. Each party further agrees that it may use the Confidential Information only in connection
with the evaluation of this transaction and not for any other purpose or for the benefit of any third party. Each party agrees
to require any of its Representatives who obtain Confidential Information to comply with this Section 7.9 and also agrees to be
responsible for any breach of this Section 7.9 by such persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">7.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment of Merger as a Tax-Free
Reorganization. The parties shall cooperate and take all commercially reasonable actions as may be necessary to qualify the Merger
as a &ldquo;reorganization&rdquo; under Section 368(a) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE VIII<BR>
CONDITIONS TO CLOSING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions Precedent to Obligations
of Stratus and Paloma Merger Sub. The obligations of Stratus and Paloma Merger Sub to consummate the transactions contemplated
by this Agreement are subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions (any or
all of which may be waived by Stratus in whole or in part to the extent permitted by applicable Law):</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the representations and warranties
of Paloma and Sherris contained in Article V, that are qualified as to materiality shall be true and correct in all respects and
those that are not qualified as to materiality shall be true and correct in all material respects as of the Closing as though made
at and as of the Closing, except to the extent such representations and warranties expressly relate to an earlier date (in which
case such representations and warranties that are qualified as to materiality shall be true and correct in all respects on and
as of such earlier date and those that are not qualified as to materiality shall be true and correct in all material respects on
and as of such earlier date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma shall have performed and
complied in all material respects with all obligations and agreements required in this Agreement to be performed or complied with
by it prior to the Closing Date, and received all Paloma Shareholder Consents, and Stratus shall have received copies of such corporate
resolutions and other documents evidencing the performance thereof as Stratus may reasonably request;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there shall not be in effect any
Order by a Governmental Body of competent jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the
transactions contemplated hereby, and there shall not be pending any Legal Proceeding seeking to restrain or prohibit the consummation
of the Merger or seeking a material amount for damages in connection with the transactions contemplated hereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there shall be no Indebtedness
or Liabilities of Paloma (including any Transaction Expenses other than the Post Closing Amounts) outstanding other than (i) Indebtedness
to be paid by Paloma at Closing, or (ii) Liabilities not to exceed $1,300,000 including with respect to all amounts including the
principal amount plus accrued interest payable under the Paloma Notes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there shall not have been any
Paloma Material Adverse Effect since the date of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stratus shall have received a
certificate signed by the Chief Executive Officer of Paloma, in form and substance reasonably satisfactory to Stratus, dated the
Closing Date, to the effect that each of the conditions specified above in Section 8.2 have been satisfied in all respects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma shall have obtained all
consents, waivers and approvals referred to on Schedule 5.3(b), each such consent, waiver and approval being in form and substance
reasonably satisfactory to Stratus and not requiring as a term thereof or condition thereto any adverse condition or requirement
on the conduct of business by Paloma, Stratus;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a non-competition agreement, substantially
in the form attached hereto as Exhibit A, shall have been entered into by Sherris, and such agreement shall remain in full force
and effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an employment agreement, substantially
in the form attached hereto as Exhibit B, shall have been entered into by Sherris on the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the board of directors will be
reconstituted as set forth in Section 7.1, which Stratus represents and warrants that it will accomplish in a timely fashion;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma shall have delivered, or
caused to be delivered, to Stratus certificates of good standing as of a recent date with respect to Paloma issued by the Delaware
Secretary of State;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stratus and the Paloma Stockholders
shall have entered into the Registration Rights Agreement in the form attached hereto as Exhibit C;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of the Paloma Notes
shall have agreed to waive any conversion rights under the Paloma Notes (except to the extent that the holders may have converted
the Notes or any portion thereof to Paloma Common Stock prior to the Closing), and extend the maturity of the Paloma Notes to the
first anniversary of the Closing Date;</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Paloma Derivative Securities
and any other rights to purchase any shares of Paloma capital stock shall have been converted into or exercised for Paloma Common
Stock or shall have been cancelled; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stratus or a subsidiary of Stratus
shall have acquired all of the capital stock of VasculoMedics substantially in accordance with the terms of the VasculoMedics Letter
of Intent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions Precedent to Obligations
of Paloma. The obligations of Paloma to consummate the transactions contemplated by this Agreement are subject to the fulfillment,
prior to or on the Closing Date, of each of the following conditions (any or all of which may be waived by Paloma in whole or in
part to the extent permitted by applicable Law):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the representations and warranties
of Stratus and Paloma Merger Sub contained in Article VI that are qualified as to materiality shall be true and correct in all
respects and those that are not qualified as to materiality shall be true and correct in all material respects as of the Closing
as though made at and as of the Closing, except to the extent such representations and warranties expressly relate to an earlier
date (in which case such representations and warranties that are qualified as to materiality shall be true and correct in all respects
on and as of such earlier date and those that are not qualified as to materiality shall be true and correct in all material respects
on and as of such earlier date); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stratus shall have performed and
complied in all respects with all obligations and agreements required by this Agreement to be performed or complied with by Stratus
on or prior to the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there shall not be in effect any
Order by a Governmental Body of competent jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the
transactions contemplated hereby, and there shall not be pending any Legal Proceeding seeking to restrain or prohibit the consummation
of the Merger or seeking a material amount for damages in connection with the transactions contemplated hereby and the Paloma Stockholders
have approved the Merger and all Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there shall not have been any
Stratus Material Adverse Effect since the date of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paloma shall have received a certificate
signed by the Chief Executive Officer of Stratus, in form and substance reasonably satisfactory to Paloma, dated the Closing Date,
to the effect that each of the conditions specified above in Section 8.1 have been satisfied in all respects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a non-competition agreement, substantially
in the form attached hereto as Exhibit A, shall have been entered into by Sherris and such agreement shall remain in full force
and effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an employment agreement, substantially
in the form attached hereto as Exhibit B, shall have been entered into by Sherris on the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the board of directors of Stratus
shall have been reconstituted as provided in Section 7.1, which Stratus represents and warrants that it will accomplish in a timely
fashion; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stratus and the Paloma Stockholders
shall have entered into the Registration Rights Agreement in substantially the form attached hereto as Exhibit C.</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE IX<BR>
INDEMNIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival of Representations and
Warranties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties
of the parties contained in this Agreement shall survive the Closing until 11:59 p.m. EST on the twelfth (12th) month anniversary
of the Closing Date (the &ldquo;Expiration Date&rdquo;). Any claim for a Loss asserted in good faith on or prior to the Expiration
Date which sets forth in a written notice in reasonable detail (based on the facts then available) the nature and estimated scope
of such claim will be timely made for purposes hereof (the &ldquo;Timely Claim&rdquo;). Any claim for indemnification with respect
to any of such matters that is not asserted by notice to the other party on or prior to the Expiration Date may not be pursued
and is hereby irrevocably waived after such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All covenants and agreements made
by the parties to this Agreement which contemplate performance following the Closing Date shall survive the Closing Date in accordance
with their terms. All covenants and agreements that contemplate performance prior to the Closing Date shall not survive the Closing
Date; provided, however, that if any such covenant or agreement is breached on or prior to the Closing Date, the non-breaching
party shall retain all rights and remedies hereunder with respect to such breach following the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by Paloma Stockholders.
Subject to the limitations set forth in this Article IX, from and after the Closing Date, Stratus, the Surviving Paloma Corporation,
and their respective subsidiaries, shareholders, members, directors, officers, employees, consultants, independent contractors,
agents and representatives (the &ldquo;Stratus Indemnified Parties&rdquo;) shall be entitled to be indemnified, defended and held
harmless by the Paloma Stockholders for all Losses suffered or incurred by such Stratus Indemnified Party (irrespective of whether
or not such Losses arise out of or in connection with a third-party claim) resulting from, or arising out of or relating to the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any failure of the representations
and warranties made by Paloma set forth in this Agreement or in any Paloma Document to be true and correct;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any breach of any covenant or
other agreement on the part of Paloma under this Agreement or any Paloma Document; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any claims by Paloma Stockholders
or the holders of any other security of Paloma with respect to the determination by Paloma to enter into this Agreement or the
allocation of the Merger Consideration as set forth in the Merger Consideration Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by Stratus. Subject
to the limitations set forth in this Article IX, from and after the Closing Date, the Paloma Stockholders and their respective
subsidiaries, shareholders, members, directors, officers, employees, consultants, independent contractors, agents and representatives
(the &ldquo;Target Indemnified Parties&rdquo; and with the Stratus Indemnified Parties, each an &ldquo;Indemnified Party&rdquo;)
shall be entitled to be indemnified, defended and held harmless by Stratus for all Losses suffered or incurred by such Target Indemnified
Party (irrespective of whether or not such Losses arise out of or in connection with a third-party claim) resulting from, or arising
out of or relating to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any failure of the representations
and warranties made by Stratus or Paloma Merger Sub set forth in this Agreement or in any Stratus Document to be true and correct;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any breach of any covenant or
other agreement on the part of Stratus or Paloma Merger Sub under this Agreement or any Stratus Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Escrow Arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Escrow Fund. The Escrow Shares
shall be available to compensate the Stratus Indemnified Parties for any claims by such Parties for any Losses incurred or sustained
by them and for which they are entitled to recovery under this Article IX.</P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Escrow Period; Distribution upon
Termination of Escrow Period. Subject to the following requirements, the Escrow Fund shall be in existence as of the Closing and
shall terminate at 11:59 p.m., local time, on the sixth (6th) month anniversary after the Closing Date with respect to Fifty (50%)
percent of the Escrow Fund, and the balance of the Escrow Fund shall terminate at 11:59 P.M., local time twelve (12) months after
the Closing Date (the &ldquo;Escrow Period&rdquo;); provided, however, that the Escrow Period shall not terminate with respect
to 100% of the amount of any unsatisfied claims specified in any Officer&rsquo;s Certificate delivered in good faith prior to the
respective expiration date with respect to facts and circumstances existing prior to the Expiration Date (each, an &ldquo;Unresolved
Claim&rdquo;). As soon as an Unresolved Claim has been resolved (whether by settlement, other agreement or Order), Stratus shall,
within five (5) days, deliver to the Transfer Agent for distribution, to and in the names of those Persons designated by the Holder
Representative, the portion of the Escrow Shares, if any, not required to satisfy other Unresolved Claims. For the purposes hereof,
&ldquo;Officer&rsquo;s Certificate&rdquo; shall mean a certificate signed by any executive officer of Stratus and delivered to
the Holder Representative: (1) stating that Stratus has paid, incurred, sustained or accrued, or reasonably anticipates that it
will have to pay, incur, sustain or accrue Losses and (2) specifying in as much detail as then exists the individual items of Losses
included in the amount so stated, the date each such item was paid, incurred, sustained or accrued, or the basis for such anticipated
liability, and the nature of the misrepresentation, breach of warranty or covenant to which such item is related.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification Procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Subject to Section 9.4, the following
shall apply to all Claims; provided that the Holder Representative shall be the exclusive person to act on and receive all Notices
on behalf of the Paloma Stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims for Indemnification. In
the event that any Indemnified Party asserts a Timely Claim, it shall provide written notice thereof containing as much detail
as then exists regarding the claim (the &ldquo;Claim Notice&rdquo;) to the party against which such claim is asserted (an &ldquo;Indemnifying
Party&rdquo;) with a copy to the Holder Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resolution of Conflicts; Arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Indemnifying Party shall
object in writing to any claim or claims made in any Claim Notice to recover Losses within thirty (30) days after delivery of such
Claim Notice, then the Indemnifying Party and Indemnified Party shall attempt in good faith to agree upon the rights of the respective
parties with respect to each of such claims. If the Indemnifying Party and Indemnified Party should so agree, a memorandum setting
forth such agreement shall be prepared and signed by both parties, and the Indemnifying Party shall pay the agreed-upon amount
of the Claim to the Indemnified Party or the same shall be deducted from the Escrow Fund; or shall be paid by the Indemnified Party
because the amount is less than the Threshold Amount as set forth in Section 9.6(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If no such agreement can be reached
after good faith negotiation and prior to sixty (60) days after delivery of the Claim Notice, then the matter shall be referred
to arbitration in accordance with Section 11.9 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third-Party Claims With Respect
to Indemnified Parties.</P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event an Indemnified Party
becomes aware of a third-party claim which the Indemnified Party reasonably believes, after investigation, may result in a demand
against an Indemnifying Party, the Indemnified Party shall notify the Indemnifying Party in writing of such claim. The Indemnifying
Party shall have the right to elect to assume the defense of such claim; provided that the Indemnifying Party shall have acknowledged
in writing to the Indemnified Party that to the best of its knowledge, such party is obligated to indemnify the Indemnified Party
with respect to such third-party claim as and to the extent provided hereunder; and provided, further, that in the event the Indemnifying
Party subsequently determines that it is not obligated to indemnify any such Indemnified Person with respect to such third-party
claim, it shall promptly notify the Indemnified Party to such effect and the Indemnifying Party shall cease to have the right to
control the defense of such third-party claim. Notwithstanding the foregoing, the Indemnifying Party shall not have the right to
elect to assume the defense of such third-party claim if: (w) the Indemnified Party determines in good faith that there is a reasonable
probability that such third-party claim seeks material non-monetary relief; (x) the third-party claim is a criminal proceeding
or (y) the claim seeks relief which would limit or otherwise adversely affect the conduct of business by the Indemnified Party.
Failure by the Indemnifing Party to notify the Indemnified Party of its election to assume the defense of any such claim or litigation
by a third party within ten (10) days after notice thereof has been given to the Indemnifying Party shall be deemed a waiver by
the Indemnifying Party of its right to assume the defense of such claim or litigation, and the Indemnified Party shall have the
right to retain its own counsel, without prejudice to its right of indemnification under this Agreement. All claims for legal fees
and expenses or other Losses for which an Indemnified Party is entitled to indemnification pursuant to this Section 9.5(c) shall
be subject to the claims processing and dispute procedures set forth in Section 9.5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Indemnifying Party, if he
or it are entitled to and do assume the defense, shall retain counsel reasonably satisfactory to the Indemnified Party to defend
such claim and shall pay the fees and disbursements of such counsel with regard thereto. If the Indemnifying Party elects to assume
the defense, the obligations under Article IX of this Agreement shall include taking all steps necessary in the investigation,
defense or settlement of such claim or litigation (including the retention of legal counsel) and holding the Indemnified Parties
harmless from and against any and all Losses caused by or arising out of any settlement approved by the Indemnifying Party or any
judgment in connection with such claim or litigation; provided, however, that: (x) the Indemnifying Party shall first consult with
the Indemnified Party regarding such settlement, (y) no settlement may be made by the Indemnifying Party without the consent in
writing of the Indemnified Party, unless such settlement: (i) releases the Indemnified Parties from any liability in respect thereof,
(ii) does not include any admission of culpability on the part of the Indemnified Parties and (iii) does not impose an injunction
or other equitable relief upon the Indemnified Parties or any of their Affiliates or otherwise impose affirmative or negative covenants
on the Indemnified Party, and (z) the Indemnifying Party shall not enter into any settlement with respect to Taxes without the
Indemnified Party&rsquo;s consent, which shall not be unreasonably withheld. If the Indemnifying Party elects to assume the defense,
the Indemnifying Party shall permit the Indemnified Party to participate in such defense or settlement through separate counsel
chosen by the Indemnified Party, with the fees and expenses of such separate counsel borne by the Indemnified Party; provided,
however, that in the event the Indemnified Party shall conclude (upon the advice of counsel) that there may be legal defenses or
rights available to it which are different from, in actual conflict with, or additional to those available to the Indemnifying
Party, the Indemnified Party shall be entitled to select separate counsel to act on its behalf, and the Indemnifying Party shall
pay the reasonable separate counsel fees and other reasonable expenses related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Indemnified Party elects
to assume such third-party claim or litigation, the Indemnified Party shall permit the Indemnifying Party to participate in such
defense or settlement through separate counsel chosen by the the Indemnifying Party, with the fees and expenses of such separate
counsel borne by the Indemnifying Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation on Indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than as set forth below,
resort to indemnification pursuant to this Article IX and the Escrow Fund shall be the sole and exclusive remedy of the Stratus
Indemnified Parties and the Stratus Indemnified Parties hereby waive, to the fullest extent permissible by law, any and all other
rights or remedies that may arise under any applicable statute, rule or regulation.</P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of determining the
amount of Escrow Shares to satisfy any Indemnification Claims, the Escrow Shares shall be valued at the fair market value of such
shares at the time such claim is made based on the average closing price on the exchange on which shares of Stratus are traded
for the twenty (20) day period immediately prior to the date that such claim is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An Indemnifying Party shall not
have any liability under this Article IX unless the aggregate amount of Losses to the indemnified parties as finally determined
exceed One Hundred Thousand ($100,000) Dollars (the &ldquo;Threshold Amount&rdquo;), in which event, subject to Section 9.6(a)
the Indemnifying Party shall be required to pay the full amount of such Losses in excess of the Threshold Amount; provided however,
that the maximum liability of any Paloma Stockholder and the maximum liability of Sherris hereunder shall be limited to the fair
market value of the Escrow Fund of each as held by the Escrow Agent, and the maximum liability of Stratus shall be limited to the
fair market value of the Escrow Fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE X<BR>
HOLDER REPRESENTATIVE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holder Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the adoption of this Agreement
and the approval of the Merger and the transactions contemplated hereby by the Paloma Stockholders, Sherris (the &ldquo;Holder
Representative&rdquo;) shall be appointed as the Holder Representative hereunder to give and receive notices and communications,
to waive any breach or default of Stratus under this Agreement, to receive all notices and services of process on behalf of the
Paloma Stockholders in connection with any claims under this Agreement, including indemnification claims by or against Paloma pursuant
to Article IX and to take all other actions that are either: (i) necessary or appropriate in the judgment of the Holder Representative
for the accomplishment of the foregoing or (ii) specifically mandated by the terms of this Agreement; provided, however that such
agency shall apply only to matters affecting the Paloma Stockholders and any matter that affects only an individual Paloma Stockholder
shall be addressed by Stratus and such Paloma Stockholder. In the event of the death, disability or resignation of the Holder Representative,
the agency may be changed by the Paloma Stockholders as expeditiously as possible; and thereafter, written notice shall be given
to Stratus or the designated successor. No bond shall be required of the Holder Representative, and the Holder Representative shall
not receive any compensation for his services. Notices or communications to or from the Holder Representative shall constitute
notice to or from the Paloma Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except for intentional fraud,
the Holder Representative shall not be liable for any act done or omitted hereunder as Holder Representative. Pursuant to the following
sentence, and to the fullest extent permitted by applicable Law, the Paloma Stockholders shall be, severally based on such Paloma
Stockholders&rsquo; pro rata Portion of the Merger Consideration and not jointly, obligated to indemnify and defend the Holder
Representative and hold the Holder Representative harmless against any loss, liability or expense incurred without gross negligence
or bad faith on the part of the Holder Representative and arising out of or in connection with the acceptance or administration
of the Holder Representative&rsquo;s duties hereunder, including the reasonable fees and expenses of any legal counsel retained
by the Holder Representative. At the time of distribution pursuant to Section 9.4 of any remaining Escrow Shares, the Holder Representative
shall be entitled to deduct and withhold from such Shares to pay and reimburse fees and expenses of third parties incurred or expected
to be incurred in connection with such Holder&rsquo;s role as Holder Representative pursuant to this Agreement to the extent the
Holder Representative Reserve would be insufficient to pay and reimburse fees and expenses of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The grant of authority provided
for in Section 10.1 is coupled with an interest and is being granted, in part, as an inducement to Stratus and Paloma Merger Sub
to enter into this Agreement, shall be irrevocable.</P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the performance
of the Holder Representative&rsquo;s obligations hereunder, the Holder Representative shall have the right at any time and from
time to time to select and engage, at the cost and expense of the Paloma Stockholders, attorneys, accountants, investment bankers,
advisors, consultants and clerical personnel and obtain such other professional and expert assistance, and maintain such records,
as the Holder Representative may deem necessary or desirable and incur other out-of-pocket expenses related to performing its services
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In dealing with this Agreement
and any instruments, agreements or documents relating thereto, and in exercising or failing to exercise all or any of the powers
conferred upon the Holder Representative hereunder or thereunder: (i) the Holder Representative and his agents, counsel, accountants
and other representatives shall not assume any, and shall incur no, responsibility whatsoever (in each case, to the extent permitted
by applicable Law) to the Paloma Stockholders or Stratus by reason of any error in judgment or other act or omission performed
or omitted hereunder or in connection with this Agreement or any such other agreement, instrument or document other than with respect
to intentional fraud of the Holder Representative, and (ii) the Holder Representative shall be entitled to rely in good faith on
the advice of counsel, public accountants or other independent experts experienced in the matter at issue, and any error in judgment
or other act or omission of the Holder Representative pursuant to such advice shall in no event subject the Holder Representative
to liability to the Paloma Stockholders or Stratus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of the immunities and powers
granted to the Holder Representative under this Agreement shall survive the Closing and/or any termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A decision, act, consent or instruction
of the Holder Representative, including an extension or waiver of this Agreement, shall constitute a decision of the Paloma Stockholders
and shall be final, binding and conclusive upon the Paloma Stockholders ; and Stratus may rely upon any such decision, act, consent
or instruction of the Holder Representative as being the decision, act, consent or instruction of the Paloma Stockholders. Stratus
is hereby relieved from any Liability to any Person for any acts done by them in accordance with such decision, act, consent or
instruction of the Holder Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Holder Representative has
all requisite power, authority and legal capacity to execute and deliver this Agreement and each other agreement, document, or
instrument or certificate contemplated by this Agreement or to be executed by the Holder Representative in connection with the
consummation of the transactions contemplated by this Agreement (together with this Agreement, the &ldquo;Holder Representative
Documents&rdquo;), and to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement
and each of the Holder Representative Documents, the performance of such Person&rsquo;s respective obligations hereunder and thereunder
and the consummation of the transactions contemplated hereby and thereby have been duly authorized by all required action on the
part of the Holder Representative. This Agreement has been, and each of the Holder Representative Documents will be at or prior
to the Closing, duly and validly executed and delivered by the Holder Representative and (assuming the due authorization, execution
and delivery by the other parties hereto and thereto) this Agreement constitutes, and each of the Holder Representative Documents
when so executed and delivered will constitute, legal, valid and binding obligations of the Holder Representative enforceable against
it in accordance with their respective terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar
laws affecting creditors&rsquo; rights and remedies generally, and subject, as to enforceability, to general principles of equity
(regardless of whether enforcement is sought in a proceeding at law or in equity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE XI<BR>
RESCISSION RIGHTS; PREEMPTIVE RIGHTS;<BR>
PAYMENT OF POST-CLOSING PAYMENT AMOUNTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rescission Rights. It is the
intention of Stratus to raise at least Ten Million Dollars ($10,000,000) after the Effective Date through the sale by Stratus of
its securities upon usual and customary terms (the &ldquo;Financing&rdquo;). In the event that at least Seven Million Five Hundred
Thousand ($7,500,000) Dollars in gross proceeds from the Financing is not achieved by within sixty (60) days from the Closing Date
or March 31, 2014, whichever is later, Stratus and Paloma will then, at the option of the Holder Representative to be exercised
no later than May 1, 2014, take all necessary steps to unwind the Merger (the &ldquo;Rescission&rdquo;) and return the parties
to the position they were in immediately prior to the closing of the Merger. The Rescission shall be effected by notice to Stratus
from the Holder Representative.</P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preemptive Rights. Each Paloma
Stockholder will be allowed to participate in the Financing on the same terms and conditions and have the right and option for
at least ten (10) calendar days after receipt of all final, fully negotiated offering documents, to purchase the securities being
offered in the Financing sufficient to maintain such Person&rsquo;s pro-rata ownership interest in Stratus post-closing of the
Financing. As soon as practicable, all offering documents will be provided to the Paloma Stockholders. If a Paloma stockholder
declines to purchase his, her or its pro-rata share, then any oversubscription shall be permitted for an additional period of five
(5) days to any Paloma Stockholder who has purchased his, her or its pro-rata ownership interest pursuant to this Section 11.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">11.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of Post-Closing Payment
Amounts. Simultaneously with the Closing of Financing, Status shall pay the Post-Closing Payment Amounts. All payments will be
made to the Client Trust Account of Rubin and Rudman LLP for distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of the Promissory Note
Holders. Stratus acknowledges that Paloma has borrowed monies from three (3) individuals as evidenced by Promissory Note Agreements
attached hereto as Exhibit D, which, as of the Effective Date represent an outstanding indebtedness of Paloma of approximately
$1,130,500. Stratus represents, warrants and agrees that it will assume responsibility for the payments of the Promissory Notes,
and on or before the first anniversary of the Closing Date, will pay the entire original principal balance of each Promissory Note,
together with all accrued and unpaid interest, which in the aggregate are estimated to approximate $1,300,000, and take such and
further steps as is necessary to discharge the three (3) Promissory Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stratus Shares Issued for the
Value of VasculoMedics, Inc. Stock Held by Paloma. Simultaneously with the Closing of the Merger, Stratus is completing a merger
with VasculoMedics, pursuant to which VasculoMedics will become a wholly owned subsidiary of Stratus. Paloma owns Six Hundred Twenty-Five
Thousand (625,000) shares of the Common Stock of VasculoMedics and will, in accordance with the terms and conditions of the VasculoMedics
Agreement and Plan of Merger dated February 25, 2014 receive a total of 2,444,444 shares of the Common Capital Stock of Stratus
(&ldquo;S Shares for V&rdquo;). It is therefore agreed that the number of Stratus shares represented by the S Shares for V will
be included in the consideration going to the Paloma shareholders in the Merger in addition to the Merger Consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>ARTICLE XII<BR>
MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">12.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Submission to Jurisdiction; Consent
to Service of Process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties hereto hereby irrevocably
submit to the non-exclusive jurisdiction of any federal or state court located within the State of California over any dispute
arising out of or relating to this Agreement or any of the transactions contemplated hereby and each party hereby irrevocably agrees
that all claims in respect of such dispute or any suit, action proceeding related thereto may be heard and determined in such courts.
The parties hereby irrevocably waive, to the fullest extent permitted by applicable law, any objection which they may now or hereafter
have to the laying of venue of any such dispute brought in such court or any defense of inconvenient forum for the maintenance
of such dispute. Each of the parties hereto agrees that a judgment in any such dispute may be enforced in other jurisdictions by
suit on the judgment or in any other manner provided by law.</P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the parties hereto hereby
consents to process being served by any party to this Agreement in any suit, action or proceeding by delivery of a copy thereof
in accordance with the provisions of Section 12.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">12.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Law. This Agreement
shall be governed by and construed in accordance with the laws of the State of California applicable to contracts made and performed
in such state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">12.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement; No Third-Party
Beneficiaries. This Agreement: (a) constitutes the entire agreement, and supersedes all prior agreements and understandings, both
written and oral, among the parties with respect to the subject matter of this Agreement and (b) is not intended to confer upon
any Person other than the parties hereto any rights or remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">12.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment and Waivers. This Agreement
may be amended, supplemented or changed by the parties hereto; provided, however, that there shall be made no amendment that by
Law requires further approval by the Paloma Stockholders without such approval having been obtained. This Agreement may not be
amended except by an instrument in writing signed on behalf of each of the parties hereto. No action taken pursuant to this Agreement,
including any investigation by or on behalf of any party, shall be deemed to constitute a waiver by the party taking such action
of compliance with any representation, warranty, covenant or agreement contained herein. The waiver by any party hereto of a breach
of any provision of this Agreement shall not operate or be construed as a further or continuing waiver of such breach or as a waiver
of any other or subsequent breach. No failure on the part of any party to exercise, and no delay in exercising, any right, power
or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy
by such party preclude any other or further exercise thereof or the exercise of any other right, power or remedy. Any agreement
on the part of a party to any extension or waiver shall be valid only if set forth in an instrument in writing signed on behalf
of such party. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">12.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices. All notices and other
communications under this Agreement shall be in writing and shall be deemed given: (i) when delivered personally, (ii) when sent
by facsimile (with confirmation of transmission), (iii) when sent via confirmed email, or (iv) one business day following the day
sent by overnight courier (with written confirmation of receipt), in each case at the following addresses and facsimile numbers
(or to such other address or facsimile number as a party may have specified by notice given to the other party pursuant to this
provision):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If to Paloma or Holder Representative,
to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Paloma Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">37 Neillian Crescent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Jamaica Plain, Massachusetts 02130</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attention: David Sherris, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">E-mail: dsherris@palomapharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">with a copy (which shall not constitute
notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Rubin and Rudman LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">50 Rowes Warf, 3rd Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Boston, Massachusetts 02110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attention: Peter B. Finn, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">E-mail: PFinn@rubinrudman.com</P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If to Stratus or Paloma Merger Sub, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1800 Century Park East</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Los Angeles, CA 90067</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attention: Jerrold Rubinstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Email: jhr@miaminc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">TroyGould PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1801 Century Park East, Suite 1600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Los Angeles, California 90067</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attention: David L. Ficksman, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Email: dficksman@troygould.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">12.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability. If any term or
other provision of this Agreement is invalid, illegal, or incapable of being enforced by any law or public policy, all other terms
or provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of
the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination that
any term or other provision is invalid, illegal, or incapable of being enforced, the parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order
that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">12.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment. Neither this Agreement
nor any of the rights, interests or obligations hereunder shall be assigned, in whole or in part, by operation of Law or otherwise
by any of the parties without the prior written consent of the other parties. Subject to the preceding sentence, this Agreement
will be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">12.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts. This Agreement
may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement and all of which,
when taken together, will be deemed to constitute one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">12.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Arbitration. In the event of
any dispute, controversy, disagreement, breach or claim arising out of or relating to this Agreement or interpretation of any of
the provisions, the same shall be submitted, for resolution, to final and binding arbitration in accordance with the following
procedures: The parties shall first attempt to mediate the matter(s). If the matter(s) has not been satisfactorily resolved (or
waived), within thirty (30) days after written notice by either party to the other requesting mediation, then the matter shall
be referred to arbitration for resolution under the then commercial arbitration rules of the American Arbitration Association (the
&ldquo;A.A.A.&rdquo;) and the decision of the arbitrator shall be final and binding on the parties. The parties shall have the
right to select the arbitrator. If the parties are unable to agree upon an arbitrator within thirty (30) days following a notice
of initiating arbitration to the other party, then the arbitrator shall be appointed by the A.A.A. Each party shall be responsible
for the filing fee and the arbitrator&rsquo;s fee; and otherwise, each party shall be responsible for its own costs and expenses,
including but not limited to, travel, consultants, depositions, witnesses and attorneys&rsquo; fees and disbursements. The arbitrator
shall be authorized to only interpret and apply the provisions of this Agreement or any related agreements entered into under this
Agreement and shall have no power or authority to modify or change any of the above in any manner.</P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The arbitrator shall have no authority
to award punitive or speculative damages or any damages inconsistent with this Agreement. In addition to monetary award, the arbitrator
shall be empowered to award equitable relief, including an injunction and specific performance of any obligation under this Agreement.
The arbitrator shall, within thirty (30) days of the conclusion of the hearing, unless such time is extended by mutual agreement,
notify the parties in writing of his/her decision, stating the reasons for such decision and separately listing the findings of
fact and conclusions of law. The arbitration shall be conducted in Los Angeles, California, and shall be governed by the laws of
the State of California, and the decision of the arbitrator may be entered in any court of competent jurisdiction. Any costs, fees
or taxes incident to enforcing the award shall, to the maximum extent permitted by Law, be charged against the non-prevailing party
or shall be recovered by the prevailing party, as applicable, in any final judgment or arbitration award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">12.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reverse Split. Stratus intends
to effect a reverse split of up to 1-to-100 with respect to shares of its outstanding Common Stock. All share numbers with respect
to the Stratus Common Stock including the Merger Consideration are before giving effect to such reverse split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Signature Page Follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">IN WITNESS WHEREOF, the parties hereto
have caused this Agreement and Plan of Merger to be executed by their respective officers thereunto duly authorized, all as of
the date first written above.</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</td>
    <td style="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">&ldquo;<b>STRATUS</b>&rdquo;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">STRATUS MEDIA GROUP, INC.</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:____________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:__________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:___________________________</P></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&ldquo;<b>PALOMA MERGER SUB</b>&rdquo;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&ldquo;<b>PALOMA</b>&rdquo;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>PALOMA ACQUISITION, INC.</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">PALOMA PHARMACEUTICALS, INC.</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:____________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:__________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:___________________________</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:____________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">David Sherris, Ph.D., President and CEO</P></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><b>&ldquo;HOLDER REPRESENTATIVE&rdquo;</b></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">_______________________________</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">David Sherris, Ph.D.</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><b>&ldquo;SHERRIS&rdquo;</b></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">_______________________________</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">David Sherris, Ph.D.</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">EXHIBIT &ldquo;A&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">NON-COMPETITION AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">EXHIBIT &ldquo;B&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">EMPLOYMENT AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">EXHIBIT &ldquo;C&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">REGISTRATION RIGHTS AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">EXHIBIT &ldquo;D&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">PROMISSORY NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>DISCLOSURE SCHEDULE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>AGREEMENT AND PLAN OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>BY AND AMONG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>STRATUS MEDIA GROUP, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>PALOMA ACQUISITION, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>PALOMA PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: center">February 25, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">This Disclosure Schedule is made and
given by Paloma Pharmaceuticals, Inc. (&ldquo;Paloma&rdquo;) pursuant to the Agreement and Plan of Merger dated as of February
25, 2014 (the &ldquo;Merger Agreement&rdquo;), by and among the Stratus Media Group, Inc. (&ldquo;Stratus&rdquo;), Paloma Pharmaceuticals,
Inc. and Paloma Acquisition, Inc. (&ldquo;Paloma Merger Sub&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Schedule numbers in the Disclosure Schedule
correspond to the Section numbers of the Paloma representations and warranties contained in Article V of the Merger Agreement and
the covenants of Paloma contained in Article VII of the Merger Agreement. If, and to the extent, any item required to be disclosed
in a section of this Disclosure Schedule is disclosed in any other section(s) of the Disclosure Schedule, each item shall be deemed
to be included in such Section where such information is required to be disclosed to the extent such item is described in sufficient
detail to enable a party to reasonably identify that such item belongs to such section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Capitalized terms used by not otherwise
defined herein shall have the meaning ascribed to them in the Merger Agreement.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><U>Schedule 5.2 (d)</U>:</TD>
    <TD STYLE="width: 80%">Attached
hereto and made a part hereof are the following schedules:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedule of Holders of
Paloma Common Stock</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(ii)&nbsp;&nbsp;&nbsp;&nbsp;Schedule of Holders of
Paloma Stock Options</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(iii)&nbsp;&nbsp;&nbsp;Schedule of Holders of
Paloma Stock Warrants</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><U>Schedule 5.3 (b)</U>:</TD>
    <TD>No consents, waivers, or approvals are needed or required in connection with the
Merger.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><U>Schedule 5.4 (c)</U>:</TD>
    <TD>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
pre-emptive rights have been granted to any party. Paloma has not entered into any voting trust or other contract with respect
to the voting or other disposition of the capital stock of Paloma.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See <U>Schedule 5.2(d)(i) and (ii)</U> for a listing
of the of the Holders of the Paloma Stock Options and Warrants. All Stock Options and Warrants will be cancelled in connection
with the closing of the Merger.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>The Company is not a party to any voting trusts or agreements.&nbsp;&nbsp;There are no Company Derivative Securities.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; padding-right: 5.4pt"><U>Schedule 5.5</U>:</TD>
    <TD STYLE="width: 80%">None, except Paloma own Six
Hundred Twenty Five Thousand (625,000) shares of the Common Stock of Vasculo Medics, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><U>Schedule 5.7</U>:</TD>
    <TD>Liabilities
and Indebtedness include:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>(i)&nbsp;&nbsp;&nbsp;&nbsp;Paloma Notes;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>(ii)&nbsp;&nbsp;&nbsp;Transaction Expenses;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>(iii)&nbsp;&nbsp;&nbsp;On-going patent maintenance
fees;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>(iv)&nbsp;&nbsp;&nbsp;Delaware franchise taxes;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>(v)&nbsp;&nbsp;&nbsp;Miscellaneous accrued fees of approximately
$2,000.00; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>(vi)&nbsp;&nbsp;&nbsp;Directors&rsquo; and Officers&rsquo; Liability Policy with policy renewable in October, 2014 with
appropriate tail policy to be purchased.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><U>Schedule
5.9</U>:</TD>
    <TD>Paloma pays Sherris One Thousand ($1,000.00) Dollars per month for the lease of its facilities.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><U>Schedule
5.10</U>:</TD>
    <TD>See
<U>Schedule 5.10(a)</U> annexed hereto and made a part hereof consisting of: (i) description of the four (4) Patent Families consisting
of twenty one (21) pages; (ii) description of the Patent Families consisting of two (2) pages and (iii) spread sheet of the patent
filings of fifteen (15) pages.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><U>Schedule
5.12</U>:</TD>
    <TD>There
are no Material Contracts.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><U>Schedule
5.14(b)</U></TD>
    <TD>There
are no benefit plans except: (i) contribution to a family health plan maintained by a separate, independent entity with payments
of $366.85 made on a bi-weekly basis and (ii) Equity Incentive Plan. David Sherris is the sole employee.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><U>Schedule
5.15(d)</U></TD>
    <TD>(i):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;David
Sherris, President and CEO</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD><U>Annual Compensation</U>: $300,000.00 with 50% of the salary in 2013 to the present deferred.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD><U>Bonuses</U>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2010:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$180,000.00</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2011:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$105,000.00</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$-0-</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$-0-</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>(ii)&nbsp;&nbsp;&nbsp;&nbsp;DavidSherris</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elkan R. Gamzu, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Daniel
L. Menichella</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>(iii)&nbsp;&nbsp;&nbsp;None</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>(iv)&nbsp;&nbsp;David
Sherris</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><U>Schedule
5.16</U>:</TD>
    <TD>There is no pending litigation. Approximately two (2) years ago in 2012, Michael Petrokansky (who owns 1.59% of Paloma&rsquo;s
outstanding Common Stock) made a number of accusations to Paloma and Sherris regarding the management and threatening legal action.
He claimed to represent other stockholders although that was not confirmed. Paloma believes that the focus of his efforts was to
force an exit for his investment. The allegations were completely without merit and the Company&rsquo;s legal counsel responded
to each allegation. There has been no communication from Mr. Petrokansky since October 2, 2013. To date, there is no pending litigation.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><U>Schedule
5.18</U>:</TD>
    <TD>Fidelity
Investments for checking and savings and American Express credit cared for additional purchase.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><U>Schedule
5.19</U>:</TD>
    <TD>There are no financial advisors.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: center; text-indent: -1.5in"><B><U>SCHEDULE
5.2(d)(i)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="sc52d1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B><U>SCHEDULE 5.2(d)(ii)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="sc52d2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B><U>SCHEDULE 5.2(d)(iii)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>WARRANT HOLDERS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="sc52d3.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.5in; text-align: center; text-indent: -1.5in"><B><U>SCHEDULE
5.10</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.5in; text-align: center; text-indent: -1.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="5" style="border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>FAMILY 1: COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS (Hoxie Ref.: PAL-01)</b></font></td></tr>
<tr>
    <TD STYLE="width: 13%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Application No./Country</font></td>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Status</font></td>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Patent Expiration</font></td>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Pending Claim Types</font></td>
    <TD STYLE="width: 41%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Selected Pending Claims</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">13/180,149/U.S.</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Pending</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Expect a Notice of Allowance this year</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- 2026 (plus patent term adjustment that may be available)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Patent term extension and pediatric exclusivity depending on clinical
        trials and product development may extend the patent term up to 5.5 years</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Compound, composition, and method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">34. A method of treating a skin disease, comprising administering
        to a subject a composition comprising a therapeutic amount of benzo(c)chromen-6-one derivative P529.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">46. Compound P529 in free or salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">48. A pharmaceutical composition comprising Compound P529 in free
        or salt form.</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">2011265398/Australia</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2026</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Composition and method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A composition for preventing or treating a skin disease comprising
        a benzo(c)chromen-6-one derivative in an acceptable delivery vehicle.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">6. The composition of claim 1, wherein said composition is one or
        more compositions selected from the group consisting of Table I.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">7. The composition of claim 6, wherein said Table I comprises . . .
        P529.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">34. A method of preventing and/or treating a skin disease, comprising
        administering to a subject a therapeutic amount of one or more benzo(c)chromen-6-one derivative compositions selected from Table
        I.</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">PI0621638-2/Brazil</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2026</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Composition and method of treatment claims </font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Same as pending AU claims.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">2,651,244/Canada</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2026</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Compound, composition, and use claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pursuing claims to bicyclic compounds. </font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">200680055090.8/China</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Issued</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2026</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Composition and Swiss-type use claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A composition for preventing or treating a skin disease comprising
        one or more compositions selected from the group consisting of benzo(c)chromen-6-one derivatives . . . P529.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2. The composition of claim 1, wherein said skin disease is selected
        from the group consisting of psoriasis, atopic dermatitis, and aging skin.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">29. Use of a composition of one of claims 1-28 for the manufacture
        of a medicament for the treatment of a skin disease.</P></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.5in; text-align: center; text-indent: -1.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FAMILY 1: COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS (Hoxie Ref.: PAL-01)</B></FONT></TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; width: 13%"><font style="font: 10pt Times New Roman, Times, Serif">10191108.0/Europe</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; width: 12%"><font style="font: 10pt Times New Roman, Times, Serif">- Allowed</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; width: 17%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- 2026</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- At least 10 years market exclusivity from the date of approval
        in Europe and an additional year could be available on the basis of an additional approval, e.g., for a new indication</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Supplementary protection certificate (SPC) (based on delays in
        getting regulatory approval), for up to five years from the normal expiry date of 2026, so until 2031</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; width: 17%"><font style="font: 10pt Times New Roman, Times, Serif">- Use claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; width: 41%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A benzo(c)chromen-6-one derivative comprising a dibenzo[b,d]pyran-6-one
        moiety for use in preventing or treating a skin disease, wherein said skin disease is selected from the group consisting of psoriasis,
        atopic dermatitis, and aging skin, and wherein said compound is selected from the group consisting of . . . P529 . . . in free
        or pharmaceutically acceptable salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2. A compound for use according to claim 1, wherein said compound
        is P529.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">12167951.8/Europe (divisional application of European Patent Application No. 10191108.0)</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Pending</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Communication from European Patent Office indicated that the claims
        are novel and inventive</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- 2026 (also see above regarding market exclusivity and SPC)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Compound and composition claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A benzo(c)chromen-6-one derivative selected from . . . compound
        P529 in free or salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5. A pharmaceutical composition comprising a benzo(c)chromen-6-one
        derivative of any one of claims 1-4.</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">13105204.6/Hong Kong (based on European Patent Application No. 12167951.8)</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2026</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Compound and composition claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Same as pending EP 12167951.8 claims.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">9616/DELNP/2008/India</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2026</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Composition and method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Same as pending AU claims.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">MX/a/2008/013799/</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mexico</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2026</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Compound, composition, and Swiss-type use claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #1A1A1A">1. A composition for preventing or treating a skin
        disease, wherein&nbsp;said&nbsp;composition comprises one or more compounds selected from the group consisting of . . . P529 . . .
        or pharmaceutically acceptable salts thereof. &nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #1A1A1A">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #1A1A1A">2. Use of one or more compounds selected from the
        group consisting of . . . P529 . . . or pharmaceutically acceptable salts thereof for preparing a medicament for preventing and/or
        treating a skin disease in a subject. &nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #1A1A1A">13. A compound selected from&nbsp;the&nbsp;group
        consisting of . . . P529 . . . or a pharmaceutically acceptable salt thereof.&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #1A1A1A">16. A pharmaceutical composition comprising a compound
        selected from the group consisting of . . . P529 . . . or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable
        excipient. &nbsp;&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">20084974/Norway</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2026</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Composition and method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Same as pending AU claims.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="5" style="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>FAMILY 2: COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS (Hoxie Ref.: PAL-01B)</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 13%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Application No./Country</font></td>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Status</font></td>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Patent Expiration</font></td>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Pending Claim Types</font></td>
    <TD STYLE="width: 41%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Selected Pending Claims</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">11/680,292/U.S.</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Issued as U.S. Patent No. 8,475,776</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- 2030</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Patent term extension and pediatric exclusivity depending on clinical
        trials and product development may extend the patent term up to 5.5 years</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Composition and method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A composition comprising a compound according to Formula I:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="image_009.jpg" alt="" style="height: 145px; width: 185px">
        </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4. A method of treating cancer comprising administering an effective
        amount to a subject a composition of claim 1 . . .</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">13/901,011</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending (continuing application of U.S. Patent Application No. 11/680,292)</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2027</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- To be determined</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- To be determined</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">2007219981/Australia</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Allowed</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2027 </font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Compound, composition, method of treatment, and use claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A compound selected from the group consisting of . . . P529 . . .
        in free or pharmaceutically acceptable salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">6. A compound of formula P529 in free or pharmaceutically acceptable
        salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">10. A pharmaceutical composition comprising one or more compounds
        selected from the group consisting of . . . P529 . . . in free or pharmaceutically acceptable salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">14. A method of treating a disease characterized by unwanted angiogenesis,
        comprising administering to a subject one or more compounds selected from the group consisting of . . . P529 . . . in free or pharmaceutically
        acceptable salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">15. A method of treating a disease, wherein the disease is cancer
        . . . or wherein the disease is selected from the group consisting of hereditary hermorrhagic telangiectasia, solid or blood born
        tumors, acquired immune deficiency syndrome, postmenopausal symptoms, osteoporosis, cardiovascular disease, Alzheimer&rsquo;s disease,
        strokes, vascular malformations, abnormal wound healing, inflammatory and immune disorders, gout, macular degeneration, diabetic
        retinopathy, retinopathy of prematurity, corneal graft rejection, multifocal choroiditis, Best&rsquo;s disease, Stargardt&rsquo;s
        disease, cblC-type cobalamin deficiency, hyperviscosity syndrome, Sorsby&rsquo;s fundus dystrophy, pseudoxanthoma elasticum, rubeosis
        iridis, Osler Weber syndrome, Osler-Weber-Rendu disease, keratoconjunctivitis, Vitamin A deficiency, phylectenulosis, bacterial
        infection, viral infection, parasitic infection, fungal infection, atopic and superior limbic dermatitis, chronic uveitis, chronic
        vitritis, Eales&rsquo; disease, radial keratotomy, uncharacteristic proliferation of fibrovascular or fibrous tissue, proliferative
        vitreoretinopathy, chronic retinal detachment, trauma (including but not limited to abrasion, previous surgery with complications
        such as corneal allograft rejection, alkaline burns, acid burns or hydrocarbon burns, mechanical or thermal damage to Bruch&rsquo;s
        membrane), pterygium, arthritis (rheumatoid and osteoarthritis), psoriasis, atopic dermatitis, dermal photodamage), Sj&ouml;gren&rsquo;s
        syndrome, systemic lupus, polyarteritis, pemphigoid, sickle cell anemia, Paget&rsquo;s disease, vein or artery occlusion, carotid
        obstructive disease, Lyme disease, Behcet&rsquo;s disease, bartonelosis, arteriosclerosis, induction of amenorrhea to block ovulation
        or to prevent implantation by the blastula, surgical adhesions, chronic inflammation, ulcerative colitis and Crohn&rsquo;s disease,
        comprising administering to a subject one or more compounds selected from the group consisting of . . . P529 . . . in free or pharmaceutically
        acceptable salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">19. Use of one or more compounds selected from the group consisting
        of . . . P529 . . . in free or pharmaceutically acceptable salt form, in the manufacture of a medicament for treating a disease
        characterized by unwanted angiogenesis.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">28. The compound of claim 6 in the free form.</P></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FAMILY 2: COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS (Hoxie Ref.: PAL-01B)</B></FONT></TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 13%"><font style="font: 10pt Times New Roman, Times, Serif">PI0708318-1/Brazil</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 17%"><font style="font: 10pt Times New Roman, Times, Serif">-2027 </font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 17%"><font style="font: 10pt Times New Roman, Times, Serif">- Composition and method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 41%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A composition comprising a compound according to Formula I:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="image_009.jpg" alt="" style="height: 145px; width: 185px">       </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5. The composition of any one of claims 1-4, wherein said composition
        is one or more compositions selected from the group consisting of Table I.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">6. The composition of claim 5, wherein said Table I comprises benzo(c)chromen-6-one
        derivatives . . . P529.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">16. A method of preventing or treating a disease characterized by
        unwanted angiogenesis, comprising administering to a subject a therapeutic amount of one or more composition selected from the
        group consisting of Formula I . . .</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">18. The method of claim 16, wherein said subject has or is predisposed
        toward a cancer.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">20. The method of claim 16, wherein said subject has or is predisposed
        toward a disease selected from the group consisting of hereditary hemorrhagic telangiectasia, solid or blood born tumors, acquired
        immune deficiency syndrome, post-menopausal symptoms, osteoporosis, cardiovascular disease, Alzheimer&rsquo;s disease, strokes,
        vascular malformations, abnormal wound healing, inflammatory and immune disorders, gout, macular degeneration, diabetic retinopathy,
        retinopathy of prematurity, corneal graft rejection, multifocal choroiditis, Best&rsquo;s disease, Stargardt&rsquo;s disease, cblC-type
        cobalamin deficiency, hyperviscosity syndrome, Sorsby&rsquo;s fundus dystrophy, pseudoxanthoma elasticum, rubeosis iridis, Osler
        Weber syndrome, Osler-Weber-Rendu disease, keratoconjunctivitis, Vitamin A deficiency, phylectenulosis, bacterial infection, viral
        infection, parasitic infection, fungal infection, atopic and superior limbic dermatitis, chronic uveitis, chronic vitritis, Eales&rsquo;
        disease, radial keratotomy, uncharacteristic proliferation of fibrovascular or fibrous tissue, proliferative vitreoretinopathy,
        chronic retinal detachment, trauma (including but not limited to abrasion, previous surgery with complications such as corneal
        allograft rejection, alkaline burns, acid burns or hydrocarbon burns, mechanical or thermal damage to Bruch&rsquo;s membrane),
        pterygium, arthritis (rheumatoid and osteoarthritis), psoriasis, atopic dermatitis, dermal photodamage), Sj&ouml;gren&rsquo;s syndrome,
        systemic lupus, polyarteritis, pemphigoid, sickle cell anemia, Paget&rsquo;s disease, vein or artery occlusion, carotid obstructive
        disease, Lyme disease, Behcet&rsquo;s disease, bartonelosis, arteriosclerosis, induction of amenorrhea to block ovulation or to
        prevent implantation by the blastula, surgical adhesions, chronic inflammation, ulcerative colitis and Crohn&rsquo;s disease.</P></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FAMILY 2: COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS (Hoxie Ref.: PAL-01B)</B></FONT></TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 13%"><font style="font: 10pt Times New Roman, Times, Serif">2,643,579/Canada</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 17%"><font style="font: 10pt Times New Roman, Times, Serif">- 2027 </font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 17%"><font style="font: 10pt Times New Roman, Times, Serif">- Compound, composition, and use claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 41%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A compound according to Formula I:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="image_009.jpg" alt="" style="height: 145px; width: 185px">
        </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">15. The compound of claim 11, wherein the compound is P529 in free
        or pharmaceutically acceptable salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">16. The compound of claim 15, wherein the compound is in free form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">24. The pharmaceutical composition of claim 22 comprising P529 in
        free or pharmaceutically acceptable salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">25. The pharmaceutical composition of claim 24, wherein P529 is
        in free form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">32. Use of a therapeutic amount of one or more compounds <font style="background-color: white">of
        any one of claims 1-5, in free or pharmaceutically acceptable salt form, for preventing or treating cancer.</font></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">&nbsp;</font></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">38. Use of a therapeutic amount of one or more compounds <font style="background-color: white">of
        any one of claims 1-5, in free or pharmaceutically acceptable salt form, for preventing or treating a disease selected from the
        group consisting of hereditary hemorrhagic telangiectasia, solid or blood born tumors, acquired immune deficiency syndrome, post-menopausal
        symptoms, osteoporosis, cardiovascular disease, Alzheimer&rsquo;s disease, strokes, vascular malformations, abnormal wound healing,
        inflammatory disorders, immune disorders, gout, macular degeneration, diabetic retinopathy, retinopathy of prematurity, corneal
        graft rejection, multifocal choroiditis, Best&rsquo;s disease, Stargardt&rsquo;s disease, cblC-type cobalamin deficiency, hyperviscosity
        syndrome, Sorsby&rsquo;s fundus dystrophy, pseudoxanthoma elasticum, rubeosis iridis, keratoconjunctivitis, Vitamin A deficiency,
        phylectenulosis, bacterial infection, viral infection, parasitic infection, fungal infection, superior limbic dermatitis, chronic
        uveitis, chronic vitritis, Eales&rsquo; disease, radial keratotomy, uncharacteristic proliferation of fibrovascular or fibrous
        tissue, proliferative vitreoretinopathy, chronic retinal detachment, trauma, pterygium, arthritis, psoriasis, atopic dermatitis,
        dermal photodamage, Sj&ouml;gren&rsquo;s syndrome, systemic lupus, polyarteritis, pemphigoid, sickle cell anemia, Paget&rsquo;s
        disease, vein occlusion, artery occlusion, carotid obstructive disease, Lyme disease, Behcet&rsquo;s disease, bartonelosis, arteriosclerosis,
        induction of amenorrhea to block ovulation or to prevent implantation by the blastula, surgical adhesions, chronic inflammation,
        ulcerative colitis and Crohn&rsquo;s disease.</font></P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">200780014874.0/China</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Issued</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2027 </font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Composition claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">1. A composition comprising a compound selected from a group consisting of . . . P529.</font></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FAMILY 2: COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS (Hoxie Ref.: PAL-01B)</B></FONT></TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 13%"><font style="font: 10pt Times New Roman, Times, Serif">07757634.6/Europe</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Pending</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Communication from European Patent Office indicated that P529,
        among others, is novel and inventive</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 17%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- 2027</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- At least 10 years market exclusivity from the date of approval
        in Europe and an additional year could be available on the basis of an additional approval, e.g., for a new indication</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Supplementary protection certificate (SPC) (based on delays in
        getting regulatory approval), for up to five years from the normal expiry date of 2027, so until 2032</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 17%"><font style="font: 10pt Times New Roman, Times, Serif">- Compound, use, and composition claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 41%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A compound selected from the group consisting of . . . P529 . . .
        or a pharmaceutically acceptable salt thereof.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4. A compound of claim 1 or claim 2 or a pharmaceutically acceptable
        salt thereof for use in treating a disease or condition, wherein said disease or condition is a cancer, hereditary hermorrhagic
        telangiectasia, solid or blood born tumors, acquired immune deficiency syndrome, postmenopausal symptoms, osteoporosis, cardiovascular
        disease, Alzheimer&rsquo;s disease, strokes, vascular malformations, abnormal wound healing, inflammatory and immune disorders,
        gout, macular degeneration, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, multifocal choroiditis,
        Best&rsquo;s disease, Stargardt&rsquo;s disease, cblC-type cobalamin deficiency, hyperviscosity syndrome, Sorsby&rsquo;s fundus
        dystrophy, pseudoxanthoma elasticum, rubeosis iridis, keratoconjunctivitis, Vitamin A deficiency, phylectenulosis, bacterial infection,
        viral infection, parasitic infection, fungal infection, atopic and superior limbic dermatitis, chronic uveitis, chronic vitritis,
        Eales&rsquo; disease, radial keratotomy, uncharacteristic proliferation of fibrovascular or fibrous tissue, proliferative vitreoretinopathy,
        chronic retinal detachment, trauma (including but not limited to abrasion, previous surgery with complications such as corneal
        allograft rejection, alkaline burns, acid burns or hydrocarbon burns, mechanical or thermal damage to Bruch&rsquo;s membrane),
        pterygium, arthritis (rheumatoid and osteoarthritis), psoriasis, atopic dermatitis, dermal photodamage), Sj&ouml;gren&rsquo;s syndrome,
        systemic lupus, polyarteritis, pemphigoid, sickle cell anemia, Paget&rsquo;s disease, vein or artery occlusion, carotid obstructive
        disease, Lyme disease, Behcet&rsquo;s disease, bartonelosis, arteriosclerosis, induction of amenorrhea to block ovulation or to
        prevent implantation by the blastula, surgical adhesions, and chronic inflammation (including but not limited to ulcerative colitis
        and Crohn&rsquo;s disease).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5. A pharmaceutical composition comprising a compound of claim 1
        or 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, or excipient.</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">7981/DELNP/2008/India</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2027 </font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Composition and method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Same as pending BR claims.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">2008-557486/Japan</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Pending</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- First Official Action indicated that P529, among others, is novel
        and inventive</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2027 </font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Compound, composition, and use claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A compound according to Formula I:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="image_009.jpg" alt="" style="height: 145px; width: 185px">
        . . .</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">in free or pharmaceutically acceptable salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">7. A compound of formula P529, in free form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">9. A pharmaceutical composition for preventing and/or treating cancer
        comprising a compound according to claims 1-8 in free or pharmaceutically acceptable salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">24. Use of a compound according to claims 1-8, in free or pharmaceutically
        acceptable salt form, for preventing and/or treating cancer.</P></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FAMILY 2: COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS (Hoxie Ref.: PAL-01B)</B></FONT></TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 13%"><font style="font: 10pt Times New Roman, Times, Serif">2013-229579/Japan (divisional application of Japanese Patent Application No. 2008-557486)</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 17%"><font style="font: 10pt Times New Roman, Times, Serif">- 2027</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 17%"><font style="font: 10pt Times New Roman, Times, Serif">- To be determined</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 41%"><font style="font: 10pt Times New Roman, Times, Serif">- To be determined</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">MX/a/2008/011013/</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mexico</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2027 </font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Compound, composition, and use claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A compound in free or pharmaceutically acceptable salt form according
        to Formula I:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="image_009.jpg" alt="" style="height: 145px; width: 185px">&#8232;&#8232;
        . . .</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2. A compound selected from the group consisting of . . . P529 . . .
        in free or pharmaceutically acceptable salt form.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">9. Use of a therapeutic amount of one or more compounds selected
        from the group consisting of Formula I, in free or pharmaceutically acceptable salt form, in the manufacture of a medicament for
        preventing or treating a disease characterized by unwanted angiogenesis.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">11. The use of claim 9, wherein said medicament is for administration
        to a subject who has or is predisposed toward a cancer.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">13. The use of claim 9, wherein said disease is selected from the
        group consisting of hereditary hermorrhagic telangiectasia, solid or blood born tumors, acquired immune deficiency syndrome, postmenopausal
        symptoms, osteoporosis, cardiovascular disease, Alzheimer&rsquo;s disease, strokes, vascular malformations, abnormal wound healing,
        inflammatory and immune disorders, gout, macular degeneration, diabetic retinopathy, retinopathy of prematurity, corneal graft
        rejection, multifocal choroiditis, Best&rsquo;s disease, Stargardt&rsquo;s disease, cblC-type cobalamin deficiency, hyperviscosity
        syndrome, Sorsby&rsquo;s fundus dystrophy, pseudoxanthoma elasticum, rubeosis iridis, Osler Weber syndrome, Osler-Weber-Rendu disease,
        keratoconjunctivitis, Vitamin A deficiency, phylectenulosis, bacterial infection, viral infection, parasitic infection, fungal
        infection, atopic and superior limbic dermatitis, chronic uveitis, chronic vitritis, Eales&rsquo; disease, radial keratotomy, uncharacteristic
        proliferation of fibrovascular or fibrous tissue, proliferative vitreoretinopathy, chronic retinal detachment, trauma (including
        but not limited to abrasion, previous surgery with complications such as corneal allograft rejection, alkaline burns, acid burns
        or hydrocarbon burns, mechanical or thermal damage to Bruch&rsquo;s membrane), pterygium, arthritis (rheumatoid and osteoarthritis),
        psoriasis, atopic dermatitis, dermal photodamage), Sj&ouml;gren&rsquo;s syndrome, systemic lupus, polyarteritis, pemphigoid, sickle
        cell anemia, Paget&rsquo;s disease, vein or artery occlusion, carotid obstructive disease, Lyme disease, Behcet&rsquo;s disease,
        bartonelosis, arteriosclerosis, induction of amenorrhea to block ovulation or to prevent implantation by the blastula, surgical
        adhesions, chronic inflammation, ulcerative colitis and Crohn&rsquo;s disease.</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">20084077/Norway</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2027 </font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Composition and method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Same as pending BR claims.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: -1.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="5" style="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>FAMILY 3: METHODS OF TREATING FIBROTIC DISORDERS (Hoxie Ref.: PAL-03)</b></font></td></tr>
<tr>
    <TD STYLE="width: 13%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Application No./Country</font></td>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Status</font></td>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Patent Expiration</font></td>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Pending Claim Types</font></td>
    <TD STYLE="width: 41%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Selected Pending Claims</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">12/934,010/U.S.</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2029</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">14. A method of treating a disease selected from the group consisting
        of pulmonary fibrosis, cystic fibrosis of the lungs, idiopathic pulmonary fibrosis, progressive massive fibrosis, diffuse parenchymal
        lung disease, and tuberculosis comprising administering to a mammal in need thereof an effective amount of P529 or a pharmaceutically
        acceptable salt thereof.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">15. The method of claim 14 comprising administering to the mammal
        in need thereof an effective amount of P529.</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">2009228303/Australia</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2029</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A method of preventing or treating a disease characterized by
        unwanted extracellular matrix formation, comprising administering to a mammal a therapeutic amount of one or more compositions
        selected from the group consisting of Formula I, Formula II, Formula III and Formula IV.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3. The method of claim, wherein said composition is P529.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5. The method of claim 1, wherein said disease is a fibrotic disorder.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">6. The method of claim 5, wherein said fibrotic disorder is selected
        from the group consisting of pulmonary fibrosis, systemic sclerosis, scleroderma, proliferative vitreoretinopathy, hepatic cirrhosis,
        cystic fibrosis of the pancreas and lungs, endomyocardial fibrosis, idiopathic pulmonary fibrosis of the lung, mediastinal fibrosis,
        myleofibrosis, retroperitoneal fibrosis, nephrogenic systemic fibrosis, progressive massive fibrosis, injection fibrosis, glomerulonephritis,
        diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection, glomerulopathies,
        diffuse parenchymal lung disease, post-vasectomy pain syndrome, tuberculosis, sickle-cell anemia-caused spleen fibrosis and rheumatoid
        arthritis.</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">PI0909374-5/Brazil</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2029</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Same as pending AU claims.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">2,719,853/Canada</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2029</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Same as pending AU claims.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">200980119152.0/China</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2029</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Same as pending AU claims.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">09724901.5/Europe</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending </font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2029</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Swiss-type use claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. The use of a therapeutic amount of one or more compounds of Formula
        I or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the therapeutic and/or prophylactic treatment
        of a disease characterized by unwanted extracellular matrix formation selected from the group consisting of pulmonary fibrosis,
        systemic sclerosis, scleroderma, hepatic cirrhosis, cystic fibrosis of the pancreas and lungs, endomyocardial fibrosis, idiopathic
        pulmonary fibrosis of the lung, mediastinal fibrosis, myleofibrosis, retroperitoneal fibrosis, nephrogenic systemic fibrosis, progressive
        massive fibrosis, injection fibrosis, diffuse parenchymal lung disease, post-vasectomy pain syndrome, tuberculosis, sickle-cell
        anemia-caused spleen fibrosis, and mesangial hyperproliferative cell disorder, said Formula I being as follows:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="image_009.jpg" alt="" style="height: 145px; width: 185px"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">12. The use of claim 1, wherein said compound is P529.</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">2011-502028/Japan</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- 2029</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Method of treatment claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">- Same as pending AU claims.</font></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FAMILY 3: METHODS OF TREATING FIBROTIC DISORDERS (Hoxie Ref.: PAL-03)</B></FONT></TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 13%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">MX/a/2010/010431/</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mexico</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><font style="font: 10pt Times New Roman, Times, Serif">- Pending</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 17%"><font style="font: 10pt Times New Roman, Times, Serif">- 2029</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 17%"><font style="font: 10pt Times New Roman, Times, Serif">- Swiss-type use claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 41%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. The use of a therapeutic amount of one or more compounds of Formula
        I</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="image_009.jpg" alt="" style="height: 145px; width: 185px">
        . . .</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">or pharmaceutically acceptable salts thereof in the manufacture
        of a medicament for the therapeutic and/or prophylactic treatment of a fibrotic disorder selected from the group consisting of
        mesangial hyperproliferative cell disorders, pulmonary fibrosis, systemic sclerosis, scleroderma, hepatic cirrhosis, cystic fibrosis
        of the pancreas and lungs, endomyocardial fibrosis, idiopathic pulmonary fibrosis of the lung, mediastinal fibrosis, myleofibrosis,
        retroperitoneal fibrosis, nephrogenic systemic fibrosis, progressive massive fibrosis, injection fibrosis, diffuse parenchymal
        lung disease, post-vasectomy pain syndrome, tuberculosis, and sickle-cell anemia-caused spleen fibrosis.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4. The use of claim 1, wherein said compound is P529.</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="5" style="border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>FAMILY 4: RADIATION COUNTERMEASURE AGENTS (Hoxie Ref.: PAL-02)</b></font></td></tr>
<tr>
    <TD STYLE="width: 13%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Application No./Country</font></td>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Status</font></td>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Patent Expiration</font></td>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Pending Claim Types</font></td>
    <TD STYLE="width: 41%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Selected Pending Claims</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">13/985,866</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- Pending</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">- 2032</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font: 10pt Times New Roman, Times, Serif">- Method and composition claims</font></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. A method for reducing radiation damage, reducing potential damage
        by exposure to radiation, treating damage caused by exposure to radiation, and/or inhibiting formation of damage caused by radiation
        in a subject comprising administering to the subject an effective amount of an agent which is an analog or derivative of benzo[c]chromen-6-one.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">8. The method of claim 1 wherein the agent is selected from the
        group consisting of compounds presented in Table 1.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">10. The method of claim 8 wherein the agent is P529.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">24. A pharmaceutical composition comprising an effective amount
        of a compound of formula I . . . in combination with an effective amount of a cytoprotective agent in a pharmaceutically acceptable
        carrier.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">25. A pharmaceutical composition for use in reducing radiation damage,
        reducing potential damage by exposure to radiation, treating damage caused by exposure to radiation, and/or inhibiting formation
        of damage caused by radiation comprising a compound of formula I . . . in free or pharmaceutically acceptable salt form.</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Paloma IP </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We use a boutique patent group that focuses
on the life sciences (Hoxie and Associates LLC).&nbsp;Understanding the details of patent law is not easy, so the following may
be confusing. If you need further explanation, please do not hesitate to ask and I will do my best, or ask our patent council,
to help.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Paloma IP portfolio relevant to P529 (the
structure of P529 is provided at the end of this document) comprises four patent families:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Family 1 (Hoxie Ref.: PAL-01) is entitled
&ldquo;Compositions and Methods to Treat Skin Diseases Characterized by Cellular Proliferation and Angiogenesis.&rdquo; Family
1 is directed to, <I>inter alia</I>, specific compounds, including P529, and methods of preventing and/or treating skin diseases
comprising administering compounds of the invention.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">A patent from this family recently issued in China. The patent, which will expire in October 2026,
includes claims directed to a composition for preventing or treating a skin disease comprising P529.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">We expect to receive a Notice of Allowance for the U.S. application from this family this year.
A pending claim in the U.S. application is specifically directed to P529 which, upon the patent issuing, will prevent all unauthorized
uses of P529.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">P529 and other compounds of interest have been found to be novel and inventive by, among others,
the U.S., European, Japanese, and Chinese patent offices.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Family 2 (Hoxie Ref.: PAL-01B) is entitled
&ldquo;Compositions and Methods to Treat Diseases Characterized by Cellular Proliferation and Angiogenesis.&rdquo; Family 2 is
directed to, <I>inter alia</I>, a genus of compounds (Formula I), encompassing P529, and methods of preventing and/or treating
a variety of diseases including cancer, abnormal wound healing, uncharacteristic proliferation of fibrovascular or fibrous tissue,
psoriasis, atopic dermatitis, and photodamage.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">A patent from this family recently issued in the U.S. as U.S. Patent No. 8,475,776, which will
expire in 2030. The issued claims are directed to a composition comprising a compound Formula I and a method of treating cancer
comprising administering an effective amount to a subject a composition of claim 1. A continuing application has been filed.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">A patent from this family recently issued in China. The patent, which will expire in February 2027,
includes claims directed to a composition comprising P529.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Family 3 (Hoxie Ref.: PAL-03) is entitled
&ldquo;Methods of Treating Fibrotic Disorders.&rdquo; Family 3 is directed to, <I>inter alia</I>, methods of preventing and/or
treating fibrotic disorders, such as pulmonary fibrosis, comprising administering P529.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Family 4 (Hoxie Ref: PAL-02) is entitled
&ldquo;Radiation Countermeasure Agents.&rdquo; Family 4 is directed to, <I>inter alia</I>, methods for reducing radiation damage
comprising administering P529. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">U.S. patents that issue from Family 1 and from
Family 2 will expire, at the earliest, in April 2026. U.S. patents that issue from Family 3 will expire, at the earliest, in March
2029. U.S. patents that issue from Family 4 will expire, at the earliest, in February 2032. Patent term extension, based on delays
in obtaining regulatory approval, and pediatric exclusivity could extend the patent term for a selected patent up to 5.5 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">European patents that issue from Family 1 will
expire, at the earliest, in October 2026. European patents that issue from Family 2 will expire, at the earliest, in February 2027.
European patents that issue from Family 3 will expire, at the earliest, in March 2029. A supplementary protection certificate (SPC),
based on delays in obtaining regulatory approval, could extend the patent term for a selected patent up to five years. In addition,
there will be at least 10 years market exclusivity from the date of approval in Europe.&nbsp;No other company can submit an application
for approval based on data Paloma submits for 8 years, and no other company can actually be approved based on data Paloma submits
for 10 years.&nbsp;An additional year could be available on the basis of an additional approval, for example for a new indication.&nbsp;Practically
speaking, this blocks any generic companies from getting approval for 10-11 years, because generic companies do not normally independently
generate the preclinical/phase 1/2/3 data necessary for approval &minus; they normally rely on simple bioequivalence studies referencing
the originator's safety and efficacy data.&nbsp;The market exclusivity is independent of patent protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The attached excel spreadsheet and table
provide a more detailed summary of the status of the applications discussed above, as well as information on other patent families
in Paloma&rsquo;s IP portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The structure of P529 is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt">&nbsp;<IMG SRC="image_013.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 10%; border: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt"><B><U>HOXIE
    REF. NO.</U></B></FONT></td>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt"><B><U>COUNTRY</U></B></FONT></td>
    <TD STYLE="width: 9%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt"><B><U>APPLICATION
    NO.</U></B></FONT></td>
    <TD STYLE="width: 9%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt"><B><U>FILING
    DATE</U></B></FONT></td>
    <TD STYLE="width: 13%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt"><B><U>TITLE</U></B></FONT></td>
    <TD STYLE="width: 9%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt"><B><U>STATUS</U></B></FONT></td>
    <TD STYLE="width: 9%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt"><B><U>PRIORITY
    DATE</U></B></FONT></td>
    <TD STYLE="width: 9%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt"><B><U>PUBLICATION
    NO.</U></B></FONT></td>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt"><B><U>PATENT
    NO.</U></B></FONT></td>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt"><B><U>GRANT
    DATE</U></B></FONT></td>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt"><B><U>PATENT
    EXPIRATION DATE</U></B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-AU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">AU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2006343534</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2006343534</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-AU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">AU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2011265398</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Dec-11</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2011265398</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-BR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">BR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PI06216382</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PI0621638-2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-CA</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">CA</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2651244</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2651244</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-01-CN</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">CN</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">2006800550908</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">101484125</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">ZL
    2006 8 0055090.8</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">13-Feb-13</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">12-Oct-26</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">06825973.8</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2025058</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-EPD</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">10191108.9</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Allowed</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2364700</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-EPDD</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12167951.8</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS,
    COMPOSITIONS, AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2517702</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-01-HKDD</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">HK</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">13105204.6</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">30-Apr-13</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">COMPOSITIONS,
    COMPOSITIONS, AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">1178071</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-IN</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">IN</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">9616/DELNP/2008</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">9616/DELNP/2008</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-JP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">JP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2009507662</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2009-535331</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-MX</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">MX</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">MX/a/2008/013799</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">MX/a/2008/013799</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-01-NO</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">NO</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">2008
    4974</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">20084974</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-NZ</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">NZ</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">572584</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">572584</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">572584</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">7-May-12</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-PCT</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">WO</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PCT/US2006/040242</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12-Oct-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">WO
    2007/133249</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">11/412618</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">27-Apr-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Apr-05</FONT></td>
    <TD NOWRAP COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US-2006-0257337</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-USC</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">13/180149</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">11-Jul-11</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Apr-05</FONT></td>
    <TD NOWRAP COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US-2011-0268679</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-01-USN</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">11/680292</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">28-Apr-05</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">US-2007-0197567</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">8475776</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">2-Jul-13</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">19-Jan-30</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01-USND</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">13/901011</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">23-May-13</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Apr-05</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-AU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">AU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2007219981</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Allowed</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2007219981</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-BR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">BR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PI0708318-1</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PI07083181-1</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-01B-CA</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">CA</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">2643579</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">2643579</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-CN</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">CN</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">200780014874.0</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">101431893</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">ZL
    2007 8 0014874.0</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">4-Sep-13</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-27</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">07757634.6</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1996021</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-EPD2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12171834.0</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2543371</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-EPD3</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12171847.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2543367</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-01B-EPD4</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">EP</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">12171867.0</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">2545913</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-IN</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">IN</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">7981/DELNP/2008</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">7981/DELNP/2008</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-JP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">JP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2008-557486</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2009-528381</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-JPD</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">JP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2013-229579</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-01B-MX</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">MX</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">MX/a/2008/011013</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">MX/a/2008/011013</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%"><FONT STYLE="font-size: 9pt">PAL-01B-NO</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%"><FONT STYLE="font-size: 9pt">NO</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%"><FONT STYLE="font-size: 9pt">2008
    4077</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%"><FONT STYLE="font-size: 9pt">20084077</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-NZ</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">NZ</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">570845</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">570845</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-PCT</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">WO</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PCT/US2007/062971</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-07</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">WO
    2007/101247</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-01B-PROV</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">60/777318</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">COMPOSITIONS
    AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-Feb-06</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-02-PCT</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">WO</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PCT/US2012/025475</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">16-Feb-12</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">RADIATION
    COUNTERMEASURE AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">16-Feb-11</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">WO
    2012/112791</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-02-PROV</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">61/443485</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">16-Feb-11</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">RADIATION
    COUNTERMEASURE AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">16-Feb-11</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-02-US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">13/985866</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">16-Feb-12</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">RADIATION
    COUNTERMEASURE AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">16-Feb-11</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-03-AU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">AU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2009228303</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-09</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">METHODS
    OF TREATING FIBROTIC DISORDERS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2009228303</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-03-BR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">BR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PI09093745</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-09</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">METHODS
    OF TREATING FIBROTIC DISORDERS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-03-CA</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">CA</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2719853</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-09</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">METHODS
    OF TREATING FIBROTIC DISORDERS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2719853</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-03-CN</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">CN</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2009801191520</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-09</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">METHODS
    OF TREATING FIBROTIC DISORDERS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">102046165</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-03-EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">09724901.5</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-09</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">METHODS
    OF TREATING FIBROTIC DISORDERS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2271334</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-03-JP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">JP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2011502028</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-09</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">METHODS
    OF TREATING FIBROTIC DISORDERS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2011-515488</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-03-MX</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">MX</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">MX/a/2010/010431</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-09</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">METHODS
    OF TREATING FIBROTIC DISORDERS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD NOWRAP COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">MX/a/2010/010431</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-03-NZ</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">NZ</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">588769</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-09</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">METHODS
    OF TREATING FIBROTIC DISORDERS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">588769</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-03-PCT</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">WO</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PCT/US2009/038285</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">25-Mar-09</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">METHODS
    OF TREATING FIBROTIC DISORDERS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">WO
    2009/120799</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-03-PROV</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">61/039146</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">METHODS
    OF TREATING FIBROTIC DISORDERS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-03-US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">12/934010</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-09</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">METHODS
    OF TREATING FIBROTIC DISORDERS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Pending</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">25-Mar-08</FONT></td>
    <TD NOWRAP COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US-2011-0021618</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-AT</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">AT</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">396989</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-AU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">AU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2002234466</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2002234466</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2002234466</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">16-Feb-06</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-BE</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">BE</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-CA</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">CA</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2438713</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2438713</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2438713</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">26-Apr-11</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-CH</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">CH</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-04-CY</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">CY</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">20081100872</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-DE</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DE</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">60226851.6-08</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-DK</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DK</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">EP</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-ES</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">ES</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">2307721</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-FI</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">FI</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-FR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">FR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-04-GB</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">GB</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-GR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">GR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">3066326</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-IE</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">IE</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-IT</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">IT</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-LI</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">LI</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-22</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-LU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">LU</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-MC</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">MC</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-04-NL</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">NL</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-PCT</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">WO</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PCT/CA2002/000227</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">WO
    2002/066467</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-PROV</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">60/270198</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-PT</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PT</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-SE</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">SE</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-TR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">TR</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">02701135.2</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1373260</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">28-May-08</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-04-US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">09/934086</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Aug-01</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">DIBENZO[C]CHROMEN-6-ONE
    DERIVATIVES AS ANTI-CANCER AGENTS</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US-2002-0115711</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">6632835</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">14-Oct-03</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-05-PCT</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">WO</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PCT/CA2002/000228</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">NON-STEROIDAL
    ESTROGEN RECEPTOR LIGANDS</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">WO
    2002/066428</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 10%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">PAL-05-PROV</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">60/270145</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 13%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">NON-STEROIDAL
    ESTROGEN RECEPTOR LIGANDS</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 9%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; width: 8%; border-top: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-05-US</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">09/934254</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Aug-01</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">NON-STEROIDAL
    ESTROGEN RECEPTOR LIGANDS</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Issued</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US-2002-0156077</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">6599921</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">29-Jul-03</FONT></td>
    <TD NOWRAP STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Aug-21</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-06-PCT</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">WO</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PCT/CA2002/000226</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Feb-02</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1,2-DIPHENYL-1-NAPHTHYL
    ETHENE DERIVATIVES, ANALOGS AND USE THEREOF</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">WO
    2002/066451</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-06-PROV</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">60/270199</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1,2-DIPHENYL-1-NAPHTHYL
    ETHENE DERIVATIVES, ANALOGS AND USE THEREOF</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Expired</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">PAL-06-US</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">09/934260</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">21-Aug-01</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">1,2-DIPHENYL-1-NAPHTHYL
    ETHENE DERIVATIVES, ANALOGS AND USE THEREOF</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">Abandoned</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">22-Feb-01</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">US-2002-0147187</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B><U>SCHEDULE 6.6</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Options and Warrants Outstanding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">As of February 11, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 83%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outstanding</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">593,311,148</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,943,523</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">51,806,912</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total derivatives</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,750,435</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fully-diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">684,061,583</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">These numbers do not include the dilutive
effect of notes with mandatory conversion features since the number of shares to be issued is dependent on future events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 67; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.2
<SEQUENCE>3
<FILENAME>stratus_8k-ex0202.htm
<DESCRIPTION>AGREEMENT AND PLAN OF MERGER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 2.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">AGREEMENT AND PLAN OF MERGER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">THIS AGREEMENT AND PLAN OF MERGER (the
&ldquo;<U>Agreement</U>&rdquo;), dated as of February&nbsp;25, 2014 (the &ldquo;<U>Effective Date</U>&rdquo;), by and among Stratus
Media Group, Inc., a Nevada corporation (&ldquo;<U>Stratus</U>&rdquo;); VasculoMedics Acquisition, Inc., a Delaware corporation
and a wholly owned subsidiary of Stratus (&ldquo;<U>VasculoMedics Merger Sub</U>&rdquo;); VasculoMedics, Inc., a Delaware corporation
(&ldquo;<U>VasculoMedics</U>&rdquo;), David Sherris, Ph.D (&ldquo;<U>Sherris</U>&rdquo;), and Sherris as Holder Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">WHEREAS, the parties hereto have determined
that it would be advisable and in the best interests of their respective companies and the security holders of their respective
companies that VasculoMedics Merger Sub be merged with and into VasculoMedics in a statutory reverse triangular merger (the &ldquo;<U>Merger</U>&rdquo;),
with VasculoMedics surviving the Merger as the surviving entity and on the terms and subject to the conditions set forth in this
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">WHEREAS, the respective Boards of Directors
of Stratus, VasculoMedics Merger Sub and VasculoMedics have determined that the Merger, in the manner contemplated herein, is advisable
and in the best interests of their respective equity holders and, by resolutions duly adopted, have approved and adopted this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">WHEREAS, Sherris is the majority stockholder,
founder and President of VasculoMedics; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">WHEREAS, Stratus, VasculoMedics Merger
Sub, Sherris and VasculoMedics desire to make certain representations, warranties, covenants and agreements in connection with
the Merger and also to prescribe various conditions to the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">NOW, THEREFORE, in consideration of the
representations, warranties, covenants and agreements contained in this Agreement, the receipt and legal sufficiency of which is
hereby acknowledged, accepted and agreed to, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE I</B><BR>
<B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">1.1<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Certain Definitions</U>. For purposes of this Agreement, the following terms shall have the meanings specified in this
<U>Section 1.1</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo; means,
with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, or is controlled
by, or is under common control with, such Person, and the term &ldquo;control&rdquo; (including the terms &ldquo;controlled by&rdquo;
and &ldquo;under common control with&rdquo;) means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo; has the
meaning ascribed to it in <U>Section 2.2(a</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Closing Date</U>&rdquo; has
the meaning ascribed to it in <U>Section 2.2(a</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Cobra</U>&rdquo; means the
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, or any successor statute thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Code</U>&rdquo; means the Internal
Revenue Code of 1986, as amended from time to time.</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Contract</U>&rdquo; means any
contract, agreement, indenture, note, bond, loan, instrument, lease, commitment or other legally binding arrangement or agreement,
whether written or oral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>DGCL</U>&rdquo; means the Delaware
General Corporation Law in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Dissenting Securities</U>&rdquo;
has the meaning ascribed to it by <U>Section 3.9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Effective Time</U>&rdquo; has
the meaning ascribed to it by <U>Section 2.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>ERISA</U>&rdquo; means the
Employee Retirement Income Security Act of 1974, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Escrow Agent</U>&rdquo; means
the Person who will act as Escrow Agent pursuant to <U>Section 9.4</U>, which Person shall be subject to the approval of the Holder
Representative and Stratus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Escrow Shares</U>&rdquo; means
(a) 2,200,000 shares of Stratus Common Stock representing in the aggregate ten (10%) percent of the Merger Consideration held by
the former VasculoMedics Stockholders except Sherris and (b)&nbsp;14,666,667 shares of Stratus Common Stock representing, in the
aggregate, seventy-five (75%) percent of the shares of Stratus Common Stock issued to Sherris in the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo; means generally
accepted accounting principles in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Governmental Body</U>&rdquo;
means any government or governmental or regulatory body thereof, or political subdivision thereof, whether federal, state, local
or foreign, or any agency, instrumentality or authority thereof, or any court, arbitrator or mediator (public or private).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo; of
any Person means, without duplication: (i) the principal of and premium (if any), prepayment penalties (if any) in respect of:
(A) indebtedness of such Person for money borrowed and (B) indebtedness evidenced by notes, debentures, bonds or other similar
instruments for the payment of which such Person is responsible or liable; (ii) all obligations of such Person issued or assumed
as the deferred purchase price of property, all conditional sale obligations of such Person and all obligations of such Person
under any title retention agreement; (iii) all obligations of such Person under leases required to be capitalized in accordance
with GAAP; (iv) all obligations of such Person for the reimbursement of any obligor on any letter of credit, banker&rsquo;s acceptance
or similar credit transaction and (v) all obligations of the type referred to in clauses (i) through (iv) of any Persons for the
payment of which such Person is responsible or liable or for which any property or asset of such Person is secured by a Lien, under
any legally binding obligation, including as obligor, guarantor, surety or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Intellectual Property</U><B>
</B>or <U>Intellectual Property Rights</U>&rdquo; shall mean all of the rights arising from or in respect of the following, whether
protected, created or arising under the Laws of the United States or any foreign jurisdiction: (A) patents, patent applications,
any reissues, reexaminations, divisionals, continuations, continuations-in-part and extensions thereof (collectively, <B>&ldquo;</B><U>Patents</U><B>&rdquo;</B>);
(B) trademarks, service marks, trade names (whether registered or unregistered), service names, industrial designs, brand names,
brand marks, trade dress rights, Internet domain names, identifying symbols, logos, emblems, signs or insignia, and including all
goodwill associated with the foregoing (collectively, &ldquo;<U>Marks</U>&rdquo;), (C) copyrights, whether registered or unregistered
(including copyrights in computer software programs), mask work rights and registrations and applications therefor (collectively,
&ldquo;<U>Copyrights</U>&rdquo;); (D) confidential and proprietary information, or non-public processes, designs, specifications,
technology, know-how, techniques, formulas, inventions, concepts, trade secrets, discoveries, ideas and technical data and information,
in each case excluding any rights in respect of any of the foregoing that comprise or are protected by Copyrights or Patents (collectively,
&ldquo;<U>Trade Secrets</U>&rdquo;); (E) all uniform resource locators, e-mail and other internet addresses and domain names and
applications and registrations therefor (&ldquo;<U>Domain Names</U>&rdquo;); and (F) all applications, registrations and permits
related to any of the foregoing clauses (A) through (E).</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>IRS</U>&rdquo; means the Internal
Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Knowledge</U>&rdquo; means
with respect to VasculoMedics, the actual knowledge of Sherris and such knowledge as would reasonably be expected to be known by
him in the ordinary and usual course of the performance of his responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Law</U>&rdquo; means any foreign,
federal, state or local law (including common law), statute, code, ordinance, rule, regulation or other requirement issued, enacted,
adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Legal Proceeding</U>&rdquo;
means any judicial, administrative, arbitral or mediation-related actions, suits, proceedings (public or private) or claims or
proceedings by or before a Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Liability</U>&rdquo; means
any debt, loss, damage, adverse claim, liability or obligation (whether direct or indirect, known or unknown, asserted or unasserted,
absolute or contingent, accrued or unaccrued, liquidated or unliquidated, or due or to become due, and whether in contract, tort,
strict liability or otherwise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Lien</U>&rdquo; shall mean
any lien, mortgage, encumbrance, security interest, claim, lease, charge, or pledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Losses</U>&rdquo; means any
and all Liabilities, Taxes and Tax Losses, costs and expenses, and any and all claims, demands or suits (by any Person, including
without limitation any Governmental Body), including the costs and expenses of any and all actions, suits, proceedings, demands,
assessments, judgments, settlements and compromises relating thereto and including reasonable attorneys&rsquo; and other advisors&rsquo;
fees, costs and expenses in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Merger Consideration</U>&rdquo;
means 22,000,000 shares of Stratus Common Stock (as may be adjusted as provided in this Agreement), which shares are to be issued
pursuant to <U>Sections 3.1(b</U>) and <U>3.3</U> of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Merger Consideration Schedule</U>&rdquo;
has the meaning ascribed to it by <U>Section 3.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Multiple Employer Plan</U>&rdquo;
shall mean: (i)&nbsp;a &ldquo;multiple employer plan&rdquo; within the meaning of Section 413(c) of the Code or Section 3(40) of
ERISA or (ii)&nbsp;a plan which if maintained or administered in or otherwise subject to the laws of the United States would be
described in subpart (A).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Order</U>&rdquo; means any
order, injunction, judgment, decree, ruling, writ, assessment or arbitration award of a Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Ordinary Course of Business</U>&rdquo;
means the ordinary and usual course of day-to-day operations of the business of Stratus or VasculoMedics, as the case may be, consistent
with past practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Paloma</U>&rdquo; means Paloma,
Inc., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Paloma Letter of Intent</U>&rdquo;
means that certain letter agreement dated January&nbsp;9, 2014 between Stratus and Paloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Permits</U>&rdquo; means any
approvals, authorizations, consents, licenses, permits or certificates of a Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo; means any
individual, corporation, partnership, firm, joint venture, association, joint-stock Company, trust, unincorporated organization,
Governmental Body or other entity.</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Software</U>&rdquo; means computer
programs, including any and all software implementations of algorithms, models and methodologies whether in source code, object
code or other form, databases and compilations, including any and all data and collections of data, descriptions, flow-charts and
other work product used to design, plan, organize and develop any of the foregoing and all documentation, including user manuals
and training materials related to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Stratus Material Adverse Effect</U>&rdquo;
means, with respect to Stratus, any Effect that has had or would reasonably be expected to have a material adverse effect on: (i)
Stratus or the business, assets, properties, liabilities, financial condition, operations, or results of operations of Stratus,
or (ii) the ability of Stratus to consummate the Merger and the other transactions contemplated by this Agreement or perform its
material obligations under this Agreement or the Stratus Documents, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Stratus Common Stock</U>&rdquo;
means Stratus&rsquo; common stock, $0.001 par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo; means
any Person of which any other Person directly or indirectly owns voting securities, other voting rights or voting partnership interests
which are sufficient to elect at least a majority of such first Person&rsquo;s board of directors or other governing body (or,
if there are no such voting interests, the second Person directly or indirectly owns 50% or more of the equity interests of such
first Person).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Takeover Proposal</U>&rdquo;
means any inquiry, proposal or offer from any Person or &ldquo;group&rdquo; (as defined in Section 13(d) of the Securities Exchange
Act of 1934, as amended, (the &ldquo;<U>Exchange Act</U>&rdquo;)), other than Stratus relating to any: (A)&nbsp;direct or indirect
acquisition (whether in a single transaction or a series of related transactions) of all or any portion of the assets of VasculoMedics,
(B)&nbsp;direct or indirect acquisition (whether in a single transaction or a series of related transactions) of all or any portion
of the any class of equity securities of VasculoMedics, (C)&nbsp;tender offer or exchange offer that if consummated would result
in any Person or &ldquo;group&rdquo; (as defined in Section 13(d) of the Exchange Act) beneficially owning 15% or more of any class
of equity securities of VasculoMedics or (D)&nbsp;merger, consolidation, share exchange, business combination, recapitalization,
liquidation, dissolution or similar transaction involving VasculoMedics ; in each case, other than the transactions contemplated
by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Tax Return</U>&rdquo; means
any return, report or statement required to be filed with respect to any Tax (including any schedules or attachments thereto, and
any amendment thereof), including any information return, claim for refund, amended return or declaration of estimated Tax, and
including, where permitted or required, combined, consolidated or unitary returns for any group of entities that includes VasculoMedics
or any of its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Taxes</U>&rdquo; means: (i)
all federal, state, local or foreign taxes, charges, fees, imposts, levies or other assessments, including all net income, gross
receipts, capital, sales, use, ad valorem, value added, transfer, franchise, profits, inventory, capital stock, license, withholding,
payroll, employment, social security, unemployment, national insurance or health, excise, severance, stamp, occupation, property
and estimated taxes, customs duties, fees, assessments and other taxes of any kind whatsoever, (ii) all interest, penalties, fines,
additions to tax or additional amounts imposed by any Taxing Authority in connection with any item described in clause (i), and
(iii) any liability in respect of any items described in clauses (i) and/or (ii) payable by reason of Contract, assumption, transferee
liability, operation of Law, Treasury Regulation Section 1.1502-6(c) (or any predecessor or successor thereof of any analogous
or similar provision under Law) or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Taxing Authority</U>&rdquo;
means the IRS and any other Governmental Body responsible for the administration of any Tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Technology</U>&rdquo; means,
collectively, all designs, formulas, algorithms, procedures, techniques, ideas, know-how, Software (whether in source code, object
code or human readable form), databases and data collections, Internet websites and web content, tools, inventions (whether patentable
or unpatentable and whether or not reduced to practice), invention disclosures, developments, creations, improvements, works of
authorship, other similar materials and all recordings, graphs, drawings, reports, analyses, other writings and any other embodiment
of the above, in any form or media, whether or not specifically listed herein, and all related technology, documentation and other
materials used in, incorporated in, embodied in or displayed by any of the foregoing, or used or useful in the design, development,
reproduction, maintenance or modification of any of the foregoing.</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Transaction Expenses</U>&rdquo;
means the expenses payable by VasculoMedics to its outside professional legal, financial, accounting, other advisors and as well
as certain creditors for services performed by them with respect to the negotiation of this Agreement and the other agreements
contemplated hereby and the transactions contemplated hereby and thereby whether or not billed or accrued or for services provided
to either VasculoMedics prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>Treasury Regulations</U>&rdquo;
means the regulations promulgated under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>VasculoMedics Balance Sheet</U>&rdquo;
has the meaning ascribed to it by <U>Section 5.20</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>VasculoMedics Common Stock</U>&rdquo;
means the issued and outstanding shares of the Common Stock of VasculoMedics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>VasculoMedics Derivative Securities</U>&rdquo;
means: (a) the VasculoMedics Warrants, (b) the VasculoMedics Notes, and (c) the VasculoMedics Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>VasculoMedics Financial Statements</U>&rdquo;
has the meaning ascribed to it by <U>Section&nbsp;5.20</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<FONT STYLE="font-weight: normal"><U>VasculoMedics
Intellectual Property</U></FONT>&rdquo; means all Intellectual Property Rights owned by or licensed to VasculoMedics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>VasculoMedics Material Adverse
Effect</U>&rdquo; means any condition, change, situation or set of circumstances (any such item, an &ldquo;<U>Effect</U>&rdquo;)
that has had or would reasonably be expected to have a material adverse effect on: (i) the business, assets, properties, liabilities,
financial condition, operations, or results of operations of VasculoMedics or (ii) the ability of VasculoMedics to consummate Merger
and the other transactions contemplated by this Agreement or perform its material obligations under this Agreement or the VasculoMedics
Documents, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>VasculoMedics Options</U>&rdquo;
means the options to purchase VasculoMedics Common Stock listed on Schedule 5.4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>VasculoMedics Stockholders</U>&rdquo;
means the holders of any shares of VasculoMedics Common Stock issued and outstanding immediately prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<FONT STYLE="font-weight: normal"><U>VasculoMedics
Technology</U></FONT>&rdquo; means all Technology owned by or licensed to VasculoMedics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;<U>VasculoMedics Warrants</U>&rdquo;
means the warrants to purchase VasculoMedics Common Stock listed on Schedule &nbsp;5.4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE II</B><BR>
<B>THE MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">2.1<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>The Merger</U>. Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the
DGCL at the Effective Time: (a) VasculoMedics Merger Sub will merge with and into VasculoMedics, and (b)&nbsp;the separate corporate
existence of VasculoMedics Merger Sub will cease and VasculoMedics will continue its corporate existence under the DGCL as the
surviving corporation in the Merger (sometimes referred to herein as the &ldquo;<U>VasculoMedics <FONT STYLE="font-weight: normal">Surviving
Corporation</FONT></U>&rdquo;).</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon the terms and subject to the conditions set forth herein, the closing of the Merger (the &ldquo;<FONT STYLE="font-weight: normal"><U>Closing</U></FONT>&rdquo;)
will take place as soon as practicable (but in any event within five (5) business days after satisfaction or waiver of each of
the conditions set forth in <U>Article&nbsp;VIII</U> hereof), unless another time or date is agreed to in writing by the parties
hereto. The Closing may be held by the remote exchange of documents, and the actual date of the Closing is hereinafter referred
to as the &ldquo;<FONT STYLE="font-weight: normal"><U>Closing Date</U></FONT><U>.</U>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the provisions of this Agreement, at the Closing, VasculoMedics, Stratus and VasculoMedics Merger Sub, as the
case may be, will cause a certificate of merger (the &ldquo;<FONT STYLE="font-weight: normal"><U>Certificate of Merger</U></FONT>&rdquo;)
to be executed, acknowledged and filed with the Secretary of State of the State of Delaware in accordance with the relevant provisions
of the DGCL and shall make all other filings or recordings required under the DGCL. The Merger will become effective at such time
as the Certificate of Merger has been duly filed with the Secretary of State of the State of Delaware or at such later date or
time as may be agreed by VasculoMedics and Stratus in writing and specified in the Certificate of Merger in accordance with the
DGCL (the effective time of the Merger being hereinafter referred to as the &ldquo;<FONT STYLE="font-weight: normal"><U>Effective
Time</U></FONT>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">2.3<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Effect of the Merger</U>. The Merger shall have the effect set forth herein and in the applicable provisions of the DGCL.
Without limiting the generality of the foregoing, and subject thereto, from and after the Effective Time all property, rights,
privileges, immunities, powers, franchises, licenses and authority of VasculoMedics and VasculoMedics Merger Sub shall vest in
the VasculoMedics Surviving Corporation, and all debts, liabilities, obligations, restrictions and duties of each of VasculoMedics
and VasculoMedics Merger Sub shall become the debts, liabilities, obligations, restrictions and duties of the Surviving VasculoMedics
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">2.4<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Certificate of Incorporation; By-laws.</U><B> </B>At the Effective Time: (a) the VasculoMedics Certificate of Merger
shall be amended so that such certificate of incorporation shall contain only the provisions in the certificate of incorporation
of VasculoMedics Merger Sub (other than the corporate name) and, as so amended, shall be the certificate of incorporation of the
VasculoMedics Surviving Corporation, and (b) the by-laws of VasculoMedics Merger Sub as in effect immediately prior to the Effective
Time shall be the by-laws of the VasculoMedics Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">2.5<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Directors and Officers</U>. The directors and officers of VasculoMedics Merger Sub immediately prior to the Effective
Time shall, from and after the Effective Time, be the directors and officers, respectively, of the VasculoMedics Surviving Corporation
until their successors have been duly elected or appointed and qualified or until their earlier death, resignation or removal in
accordance with the certificate of incorporation and by-laws of the VasculoMedics Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE III</B><BR>
<B>EFFECT OF THE MERGER ON THE</B><BR>
<B>SECURITIES OF VASCULOMEDICS AND VASCULOMEDICS MERGER SUB</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">3.1<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Effect on VasculoMedics Capital Stock</U>. As of the Effective Time, by virtue of the VasculoMedics Merger and without
any action on the part of VasculoMedics Merger Sub, VasculoMedics or the holders of: (i)&nbsp;any shares of VasculoMedics Common
Stock, (ii) the VasculoMedics Derivative Securities or (iii)&nbsp;any shares of common stock of VasculoMedics Merger Sub, the following
shall occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cancellation of Certain VasculoMedics Capital Stock</U>. Each share of VasculoMedics, Common Stock that is owned by Stratus,
VasculoMedics Merger Sub or VasculoMedics (as treasury stock or otherwise) or any of their respective direct or indirect wholly-owned
Subsidiaries will automatically be cancelled and retired and will cease to exist, and no consideration will be delivered in exchange
therefor.</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conversion of VasculoMedics Stock</U>. All VasculoMedics Common Stock and all VasculoMedics Derivative Securities issued
and outstanding immediately prior to the Effective Time (other than Dissenting Securities, and shares to be cancelled and retired
in accordance with <U>Section 3.1(a)</U>) will be converted into the Merger Consideration which Merger Consideration shall be distributed
to the VasculoMedics Stockholders and holders of the VasculoMedics Derivative Securities as more particularly set forth in the
Merger Consideration Schedule, but in any event subject to <U>Sections&nbsp;3.3</U> and <U>3.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cancellation of Shares</U>. At the Effective Time, all shares of VasculoMedics Common Stock and all VasculoMedics Derivative
Securities will no longer be outstanding and all shares of VasculoMedics Common Stock and all VasculoMedics Derivative Securities
(except for any VasculoMedics Notes that are to be paid off by Stratus) will be cancelled and retired and will cease to exist,
and each holder of a certificate or other document formerly representing any such shares of VasculoMedics Common Stock or Derivative
Securities will cease to have any rights with respect thereto, except the right to receive the Merger Consideration, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conversion of VasculoMedics Merger Sub Capital Stock</U>. Each share of common stock of VasculoMedics Merger Sub issued
and outstanding immediately prior to the Effective Time shall be converted into and become one newly issued, fully paid and non-assessable
share of common stock of the VasculoMedics Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">3.2<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Escrow Fund</U>. At the Closing, Stratus shall issue the Escrow Shares and the Escrow Agent shall hold such shares in
accordance with the terms of <U>Section 9.4</U> (the &ldquo;<U>Escrow Fund</U>&rdquo;). The VasculoMedics Stockholders shall have
the sole and exclusive right to exercise any and all voting and consensual rights and powers, and shall be entitled to receive
and retain any and all cash dividends, accruing to an owner of their respective portion of the Escrow Shares pursuant to the terms
of <U>Article&nbsp;IX</U>. For income tax purposes, the VasculoMedics Stockholders shall be deemed the owners of their pro rata
portion of the Escrow Fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">3.3<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Payment of Merger Consideration</U>. At the Effective Time: (i) Stratus shall issue cerificates in the name of the VasculoMedics
Stockholders representing the VasculoMedics Merger Consideration in accordance with the merger consideration schedule set forth
on <U>Schedule 3.3</U> hereto (the &ldquo;<U>Merger Consideration Schedule</U>&rdquo;) and (ii)&nbsp;the VasculoMedics Stockholders
shall deliver to Stratus certificates representing all of the issued and outstanding shares of VasculoMedics Common Stock, provided
that prior to any issuance of any Merger Consideration, the VasculoMedics Stockhodlers shall have delivered to Stratus a properly
completed Omnibus Consent Agreement. Upon surrender of such certificates for cancellation to Stratus and delivery of the Omnibus
Consent Agreement, the holders of such certificates shall be entitled to receive in exchange therefor, and Stratus shall cause
the transfer agent to deliver the Merger Consideration (or evidence of such Consideration in book-entry form) into which the securities
formerly represented by such certificates shall have been converted pursuant to the terms of this <U>Article&nbsp;III</U>, and
the certificates so surrendered shall forthwith be cancelled. All Merger Consideration paid upon the surrender or exchange of certificates
shall be deemed to have been paid in full satisfaction of all rights pertaining to the shares of VasculoMedics Common Stock previously
represented by such certificates, and at the Effective Time the transfer books of VasculoMedics shall be closed and there shall
be no further registration of transfers on the stock transfer books of the shares of VasculoMedics Common Stock that were outstanding
immediately prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">3.4<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No Fractional Shares</U>. No certificates or scrip representing fractional shares of Stratus Common Stock shall be issued
and any fractions shall be rounded up or down to the nearest whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">3.5<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Lost, Stolen or Destroyed Certificate</U>. If any certificate evidencing VasculoMedics Common Stock shall have been lost,
stolen or destroyed, upon the making of an affidavit of that fact by the person claiming such certificate to be lost, stolen or
destroyed and, if required by Stratus, the posting by such person of a bond, in such reasonable amount as Stratus may direct, as
indemnity against any claim that may be made against it with respect to such certificate, Stratus will issue, in exchange for such
lost, stolen or destroyed certificate, the applicable Merger Consideration and cash in lieu of any fractional shares of Stratus
Common Stock to which such holder would be entitled pursuant to <U>Section 3.3</U>, in each case pursuant to this Agreement.</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding Taxes</U>. Stratus shall be entitled to deduct and withhold from that portion of the Merger Consideration
otherwise payable pursuant to this Agreement such amounts as Stratus is required to deduct and withhold with respect to the making
of such payment under the Code or any provision of state, local, provincial or foreign Tax Law. To the extent that amounts are
so withheld and remitted to the appropriate governmental body, such withheld amounts shall be treated for all purposes of this
Agreement as having been paid to the holder of such securities in respect of which such deduction and withholding was made by Stratus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">3.7<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Appraisal Rights</U>. Notwithstanding anything in this Agreement to the contrary, shares of VasculoMedics Common Stock
that are issued and outstanding immediately prior to the Effective Time and which are held by a VasculoMedics Stockholder who did
not vote in favor of the Merger (or consent thereto in writing) and who is entitled to demand and properly demands appraisal of
VasculoMedics Common Stock pursuant to, and who complies in all respects with, the provisions of the DGCL (the &ldquo;<U>Dissenting
Holders</U>&rdquo;), shall not be converted into or be exchangeable for the right to receive the applicable Merger Consideration,
but instead such Holder shall be entitled to payment of the fair value of such VasculoMedics Common Stock (the &ldquo;<U>Dissenting
Securities</U>&rdquo;) in accordance with the provisions of the DGCL (and at the Effective Time, such Dissenting Securities shall
no longer be outstanding and shall automatically be canceled and shall cease to exist, and such holder shall cease to have any
rights with respect thereto, except the right to receive the fair value of such Dissenting Securities in accordance with the provisions
of the DGCL, unless and until such holder shall have failed to perfect or shall have effectively withdrawn or lost rights to appraisal
under the DGCL. If any Dissenting Holder shall have failed to perfect or shall have effectively withdrawn or lost such right, such
Holder&rsquo;s shares of VasculoMedics Common Stock shall thereupon be treated as if they had been converted into and become exchangeable
for the right to receive, as of the Effective Time, the applicable Merger Consideration for such Stock without any interest thereon.
VasculoMedics shall give Stratus: (i) prompt notice of any written demands for attempted withdrawals of such demands and any other
instruments served pursuant to the DGCL, and (ii) the opportunity to participate in all negotiations and proceedings with respect
to demands for appraisal under the DGCL. VasculoMedics, except with the prior written consent of Stratus, shall not voluntarily
make any payment with respect to, or settle, or offer or agree to settle, any such demand for payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE IV</B><BR>
<B>TERMINATION, AMENDMENT AND WAIVER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">4.1<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination of Agreement</U>. This Agreement may be terminated at any time prior to the Effective Time as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At the election of Stratus or VasculoMedics, on or after March 31, 2014 if the Closing shall not have occurred by the close
of business on such date; provided, however, that the right to terminate this Agreement under this <U>Section 4.1(a</U>) shall
not be available to any party who is in material default of any of its obligations hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by mutual written consent of Stratus and VasculoMedics;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by either Stratus or VasculoMedics if: (i) there shall be in effect a final nonappealable Order of a Governmental Body of
competent jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the transactions contemplated hereby
or (ii) there shall be any Law enacted, promulgated or issued or deemed applicable to the Merger by any Governmental Body that
would make consummation of the Merger illegal;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by Stratus, so long as Stratus is not in material breach of its representations, warranties, covenants or agreements under
this Agreement, if there shall have been a material breach of any representation, warranty, covenant or agreement of VasculoMedics
set forth in this Agreement, which breach would give rise to a failure of a condition set forth in <U>Section 8.1</U> and is incapable
of being cured or, if capable of being cured, shall not have been cured within twenty (20) Business Days following receipt by VasculoMedics,
as the case may be, of written notice of such breach from Stratus ;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by VasculoMedics, so long as such party is not in material breach of its representations, warranties, covenants or agreements
under this Agreement, if there shall have been a material breach of any representation, warranty, covenant or agreement of Stratus
set forth in this Agreement, which breach would give rise to a failure of a condition set forth in <U>Section 8.2</U> and is incapable
of being cured or, if capable of being cured, shall not have been cured within twenty (20) Business Days following receipt by Stratus
of written notice of such breach from VasculoMedics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">4.2<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Effect of Termination</U>. In the event of the termination of this Agreement as provided in <U>Section 4.1</U>, written
notice thereof shall be given to the other party or parties, specifying the provision hereof pursuant to which such termination
is made, and this Agreement shall forthwith become null and void (other than <U>Section&nbsp;7.8</U>, all of which shall survive
termination of this Agreement); <I>provided, however</I>, that nothing contained herein shall relieve any party from liability
for breach of this Agreement or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE V</B><BR>
<B>REPRESENTATIONS AND WARRANTIES OF VASCULOMEDICS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">VasculoMedics and Sherris hereby jointly
and severally represent and warrant to Stratus that, except as set forth on the applicable Disclosure Schedule to this Agreement
(the &ldquo;Disclosure Schedule&rdquo;), which exceptions shall be deemed to be part of the representations and warranties made
hereunder, the following representations are true and complete as of the date of the Closing. The Disclosure Schedule shall be
arranged in sections corresponding to the numbered and lettered sections and subsections contained in this Article V and the disclosures
in any section or subsection of the Disclosure Schedule shall qualify other sections and subsections in this Article V to the extent
it is apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.1<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Organization and Good Standing</U>. VasculoMedics is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware and has all requisite corporate power and authority to own, lease and operate its properties
and to carry on its business as now conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.2<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Authorization of Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics has all requisite power, authority and legal capacity to execute and deliver this Agreement and each other
agreement, document, or instrument or certificate contemplated by this Agreement or to be executed by VasculoMedics in connection
with the consummation of the transactions contemplated by this Agreement (together with this Agreement, the &ldquo;<U>VasculoMedics
Documents</U>&rdquo;), and to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement
and each of the VasculoMedics Documents by VasculoMedics, the performance of its obligations hereunder and thereunder and the consummation
of the transactions contemplated hereby and thereby have been duly authorized by VasculoMedics &rsquo;s Board of Directors and
no other action on the part of VasculoMedics is necessary to authorize the execution, delivery and performance by VasculoMedics
of this Agreement and the consummation of the transactions contemplated hereby other than the consent of the holders of VasculoMedics
Common Stock.</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement and each of VasculoMedics Documents have been duly and validly executed and delivered by VasculoMedics and
(assuming the due authorization, execution and delivery by the other parties hereto and thereto) this Agreement constitutes, and
each of VasculoMedics Documents when so executed and delivered will constitute, legal, valid and binding obligations of VasculoMedics
enforceable against VasculoMedics in accordance with their respective terms, subject to applicable bankruptcy, insolvency, reorganization,
moratorium and similar laws affecting creditors&rsquo; rights and remedies generally, and subject, as to enforceability, to general
principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Board of Directors of VasculoMedics, at a meeting duly called and held at which all the directors of VasculoMedics were
present in person or by telephone (or, in lieu of a meeting, by the written consent of the directors of VasculoMedics ), duly and
by majority vote adopted resolutions: (i)&nbsp;approving and declaring advisable this Agreement, the Merger and the other transactions
contemplated by this Agreement, (ii) directing that the adoption of this Agreement be submitted to the stockholders of VasculoMedics
and (iii) recommending that the stockholders of VasculoMedics adopt this Agreement, which resolutions have not been subsequently
rescinded or modified or withdrawn in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedule 5.2(d)</U> sets forth a true, correct and complete list of the holders of record of VasculoMedics Common Stock
as of the date hereof. Prior to the Effective Time, VasculoMedics will deliver to Stratus true, correct and complete copies of
the irrevocable written consents, which are valid and effective under the DGCL of the requisite holders of VasculoMedics Common
Stock (the &ldquo;<U>VasculoMedics Shareholder Consents</U>&rdquo;) to the Merger. The VasculoMedics Shareholder Consents are the
only approval of holders of any class or series of VasculoMedics Common Stock necessary or required (under applicable Law, VasculoMedics
&rsquo;s certificate of incorporation and bylaws, or otherwise) to approve this Agreement on behalf of VasculoMedics and the transactions
contemplated hereby, including the Merger. From and after the time of such delivery to Stratus, the VasculoMedics Shareholder Consents
shall remain in full force and effect and shall be valid and effective under the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.3<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Conflicts; Consents of Third Parties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The execution and delivery by VasculoMedics of this Agreement or the VasculoMedics Documents, the consummation of the Merger
and the transactions contemplated hereby or thereby, or compliance by VasculoMedics with any of the provisions hereof or thereof
will not conflict with, or result in any violation of, default or breach (with or without notice or lapse of time, or both) under,
or give rise to a right of termination, cancellation or acceleration of any obligation or to loss of a material benefit under,
or give rise to any obligation of VasculoMedics to make any payment under, or to the increased, additional, accelerated or guaranteed
rights or entitlements of any Person under, or result in the creation of any Liens upon any of the properties or assets of VasculoMedics
under, any provision of: (i) the certificate of incorporation and by-laws of VasculoMedics; (ii)&nbsp;any Intellectual Property,
Technology, Contract or Permit to which VasculoMedics is a party or by which any of the properties or assets of VasculoMedics are
bound; (iii) any Order of any Governmental Body applicable to VasculoMedics or any of its properties or assets or (iv) any applicable
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as set forth on <U>Schedule&nbsp;5.3(b</U>), no consent, waiver, approval, Order, Permit or authorization of, or
declaration or filing with, or notification to, any Person or Governmental Body is required on the part of VasculoMedics in connection
with: (i)&nbsp;the execution and delivery of this Agreement or the VasculoMedics Documents, the compliance by VasculoMedics with
any of the provisions hereof or thereof, or the consummation by VasculoMedics of the Merger or the other transactions contemplated
hereby or thereby or (ii) the continuing validity and effectiveness immediately following the Closing of any Permit or material
Contract of VasculoMedics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.4<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Capitalization</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The authorized capital stock of VasculoMedics consists of: 10,000,000 shares of common stock, of which 5,625,000 shares
are issued and outstanding and 5,000,000 shares of Preferred Stock of which no shares are issued and outstanding;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All of the issued and outstanding shares of VasculoMedics Common Stock have been duly authorized, are validly issued, fully
paid, and nonassessable, and are held of record by the VasculoMedics Stockholders as set forth in <U>Schedule 5.2(d</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as set forth on <U>Schedule 5.4(c</U>), there is no existing option, warrant, call, right or Contract of any character
to which VasculoMedics is a party requiring, and there are no securities of VasculoMedics outstanding which upon conversion or
exchange would require, the issuance, sale or transfer of any additional shares of capital stock or other equity securities of
VasculoMedics or other securities convertible into, exchangeable for or evidencing the right to subscribe for or purchase shares
of capital stock or other equity securities of VasculoMedics. Except as set forth on <U>Schedule 5.4(c</U>), VasculoMedics is not
a party to any voting trust or other Contract with respect to the voting, redemption, sale, transfer or other disposition of the
capital stock of VasculoMedics. Each agreement or instrument set forth on <U>Schedule 5.4(b</U>) will be terminated effective as
of the Closing. <U>Schedule 5.4(c)</U> sets forth an accurate and complete list of all VasculoMedics Derivative Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.5<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Third-Party Interests</U>: VasculoMedics does not own, directly or indirectly, any shares of capital stock or equity
or ownership interests in, any other Person (collectively, &ldquo;<U>VasculoMedics Third-Party Interests</U>&rdquo;). VasculoMedics
has no rights to, or is bound by any commitment or obligation to, acquire by any means, directly or indirectly, any VasculoMedics
Third-Party Interests or to make any investment in, or contribution or advance to, any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.6<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Corporate Records</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics has delivered to Stratus true, correct and complete copies of its certificate of incorporation and by-laws
(each certified by the secretary, assistant secretary or other appropriate officer) or comparable organizational documents of VasculoMedics
as currently in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The minute books of VasculoMedics previously made available to Stratus contain true, correct and complete records in all
material respects of all corporate action of the stockholders and board of directors (including committees thereof) of VasculoMedics.
The stock certificate books and stock transfer ledgers of VasculoMedics previously made available to Stratus are true, correct
and complete in all material respects. No stock transfer taxes have been or payable with respect to all transfers of shares of
VasculoMedics prior to the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.7<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Liabilities</U>. Except as set forth on <U>Schedule 5.7</U>, VasculoMedics has no Indebtedness, obligations or Liabilities
(whether or not required by GAAP to be reflected on a balance sheet), including but not limited to Transaction Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.8<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics has: (i) duly and timely filed all Tax Returns required to be filed by or on behalf of it in all jurisdictions
in which such Tax Returns are required to be filed (after giving effect to any duly obtained extensions of time in which to make
such filings), all such Tax Returns are true, complete and accurate in all material respects, and VasculoMedics has maintained,
to the extent required, all documentation supporting the positions taken thereon, and (ii) timely paid all Taxes due and payable
or claimed or asserted by any Taxing Authority to be due and payable (except to the extent of any accrual for Taxes established
on the Balance Sheet).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics has complied in all material respects with all applicable Laws relating to the payment and withholding of
Taxes, and has duly and timely withheld and paid over to the appropriate Taxing Authority all amounts required to be so withheld
and paid under all applicable Laws.</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics has made available to Stratus true and complete copies of all Tax Returns of VasculoMedics for all taxable
periods since inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics&rsquo;s federal income tax returns have not been audited, and no action, suit, proceeding, investigation or
audit with respect to Taxes of any type is pending or, to the Knowledge of VasculoMedics, threatened. There are no outstanding
assessments, claims or deficiencies for any material Taxes of VasculoMedics that have been asserted or assessed or, to the Knowledge
of VasculoMedics, proposed. No issue has been raised by a Taxing Authority in any prior examination of VasculoMedics which, by
application of the same or similar principles, could reasonably be expected to result in a material proposed deficiency for any
subsequent taxable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>None of the transactions taken pursuant to this Agreement, other than payments to employees of VasculoMedics, will give
rise to any withholding obligation under any provision of Law (including Section 1445 of the Code).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics is not, nor has ever been, classified as an entity other than a corporation for US tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.9<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Property and Assets</U>. VasculoMedics has good and marketable title or license to all of its material properties and
assets, free and clear of all Liens. All material licensed or leased properties of VasculoMedics are held under valid and binding
leases and/or licenses. VasculoMedics leases all such properties as are necessary in all material respects to the operations of
VasculoMedics as now conducted. VasculoMedics does not own any real property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.10<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Intellectual
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedule 5.10(a)</U> sets forth an accurate and complete list of all Patents and Patent applications, registered marks,
and registrations and applications for registrations of Marks, Copyrights and Domain Names owned or filed by VasculoMedics (collectively,
&ldquo;<U>Registered VasculoMedics Intellectual Property</U>&rdquo;). <U>Schedule 5.10(a)</U> lists the jurisdictions in which
each such Registered VasculoMedics Intellectual Property has been issued or registered or in which any application for such issuance
and registration has been filed or in which any other filing or recordation has been made. Each item of Registered VasculoMedics
Intellectual Property is valid and subsisting, all necessary registration, maintenance and renewal fees currently due in connection
with such Registered VasculoMedics Intellectual Property has been paid and all necessary documents and certificates in connection
with such Registered VasculoMedics Intellectual Property have been filed with the relevant patent, copyright, trademark or other
authorities in the United States or foreign jurisdictions, as the case may be, for the purposes of maintaining such Registered
VasculoMedics Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics has full title to and ownership of, or has valid and continuing rights to use, sell or license, all VasculoMedics
Intellectual Property and VasculoMedics Technology, free and clear of any Liens of any kind. To VasculoMedics&rsquo;s knowledge,
VasculoMedics Intellectual Property and VasculoMedics Technology are sufficient for the operation and conduct of the business of
VasculoMedics as presently conducted. To the Knowledge of VasculoMedics, no third Person has any rights to any VasculoMedics Intellectual
Property or VasculoMedics Technology that is owned by VasculoMedics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To VasculoMedics&rsquo;s Knowledge, no VasculoMedics Intellectual Property or VasculoMedics Technology is infringing, misappropriating
or violating, and has not infringed, misappropriated or violated, the Intellectual Property Rights of any third Person, nor will,
to VasculoMedics&rsquo;s Knowledge, the use, practice or other commercial exploitation of VasculoMedics Intellectual Property or
VasculoMedics Technology by VasculoMedics, or the licensing, marketing or, to VasculoMedics&rsquo;s Knowledge, use of the same,
or the operation of VasculoMedics &rsquo;s business, infringe, constitute an unauthorized use of or misappropriate any Intellectual
Property Rights of any third Person. VasculoMedics is not a party to or the subject of any pending or, to the Knowledge of VasculoMedics,
threatened suit, action, investigation or proceeding which involves a claim against VasculoMedics, of infringement, unauthorized
use, or violation of any Intellectual Property Rights of any Person, or challenging the ownership, use, validity or enforceability
of any VasculoMedics Intellectual Property or contesting the right of VasculoMedics to use, sell, exercise, license, transfer or
dispose of any VasculoMedics Intellectual Property or VasculoMedics Technology, or any products, processes or materials covered
thereby in any manner, nor has VasculoMedics received any written communications alleging such claims.</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of VasculoMedics, no Person (including employees and former employees of VasculoMedics ) is infringing,
violating, misappropriating or otherwise misusing any VasculoMedics Intellectual Property or VasculoMedics Technology, and VasculoMedics
has not made any such claims against any Person (including employees and former employees of VasculoMedics ).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.11<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Insurance</U>. VasculoMedics has made available to Stratus all material policies of insurance covering VasculoMedics,
and its employees, properties or assets, including policies of property, fire, workers&rsquo; compensation, products liability,
and other casualty and liability insurance, and such policies are in a form and amount which VasculoMedics reasonably believes
is adequate for the operation of its business. Each of such insurance policies is in full force and effect and VasculoMedics is
in compliance with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January 1,
2013, VasculoMedics has not received any written notice regarding any actual or possible: (i)&nbsp;cancellation or invalidation
of any insurance policy; (ii)&nbsp;refusal or denial of any coverage, reservation of rights or rejection of any material claim
under any insurance policy; or (iii)&nbsp;material adjustment in the amount of the premiums payable with respect to any insurance
policy. There is no filed workers&rsquo; compensation or other claim under or based upon any insurance policy of VasculoMedics.
All information provided to insurance carriers (in applications and otherwise) on behalf of VasculoMedics is accurate and complete
in all material respects. The consummation of the transactions contemplated hereby will not, in and of itself, cause the revocation,
cancellation or termination of any such insurance policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.12<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Material Contracts and Obligations</U>. <U>Schedule 5.12</U> sets forth a list of all material Contracts to which VasculoMedics
is a party or by which it is bound. VasculoMedics has made available to Stratus copies of all of the foregoing Contracts (or written
summaries in the case of oral Contracts). All of such Contracts are valid, binding and in full force and effect on VasculoMedics.
VasculoMedics is not in default under any material provision of any of such Contracts and, to the Knowledge of VasculoMedics, no
other party to any such Contracts is in default under any provision thereof. As of the date hereof, VasculoMedics has not received
any written communication from any other party to the Contracts listed on <U>Schedule 5.12</U> stating that such other party has
decided or plans to terminate or otherwise discontinue such Contract. To the Knowledge of VasculoMedics, no event has occurred
that with notice, lapse of time or both would constitute a breach or default thereunder by VasculoMedics, or would permit the modification
or premature termination of such Contract by any other party thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.13<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliance</U>. VasculoMedics has, in all material respects, complied with all Laws and Orders applicable to its business,
operations or assets and has all material Permits required thereby wherein the failure to so comply would have a VasculoMedics
Material Adverse Effect. There is no term or provision of any Order or Law applicable to or binding upon VasculoMedics that has
had or would reasonably be expected to have a VasculoMedics Material Adverse Effect. VasculoMedics has not received any written
or oral notices or communications from any Governmental Body of: (i) any material pending violation with respect to any Laws, Orders
or material Permits applicable to its business, operations or assets or (ii) threatening to terminate, revoke or cancel any material
Permit held by VasculoMedics. Since its inception, VasculoMedics has not entered into or been subject to any Order with respect
to any material aspect of its business, operations, properties, assets or employees or received any written notice from any Governmental
Body commencing or threatening any inquiry, investigation or Legal Proceeding with respect to any of the foregoing. To the Knowledge
of VasculoMedics, none of the employees of VasculoMedics is in violation of any Contract or covenant (either with VasculoMedics
or with another entity) relating to employment, patent, other proprietary information disclosure, non-competition, or non-solicitation.</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.14<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Employee Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics has made available to Stratus accurate and complete copies of all employee manuals and handbooks, disclosure
materials, policy statements and other materials relating to the employment of VasculoMedics&rsquo; employees to the extent currently
effective and material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedule 5.14(b)</U> lists all written and describes all non-written employee benefit plans (as defined in Section&nbsp;3(3)
of ERISA) and all bonus, equity-based, incentive, deferred compensation, retirement or supplemental retirement, profit sharing,
severance, golden parachute, vacation, cafeteria, dependent care, medical care, employee assistance program, education or tuition
assistance programs and other similar fringe or employee benefit plans or programs that may involve annual payments to a VasculoMedics
employee in excess of $10,000, and which are currently in effect relating to any VasculoMedics employee or which is maintained
by, administered or contributed to by, or required to be contributed to by, VasculoMedics or any VasculoMedics Affiliate, or under
which VasculoMedics or any VasculoMedics Affiliate has any current or may incur liability after the date hereof (each, a &ldquo;<U>VasculoMedics
Employee Plan</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each VasculoMedics Employee Plan that is intended to be qualified under Section&nbsp;401(a) of the Code has received a favorable
determination letter or opinion letter with respect to such qualified status from the IRS. To the Knowledge of VasculoMedics, nothing
has occurred that could reasonably be expected to adversely affect the qualified status of any such VasculoMedics Employee Plan
or the exempt status of any related trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each VasculoMedics Employee Plan has been maintained in compliance, in all material respects, with its terms and, both as
to form and operation, with all applicable Laws, including without limitation, the Code and ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics has not engaged in any transaction in violation of Sections 404 or 406 of ERISA or any &ldquo;prohibited transaction,&rdquo;
as defined in Section 4975(c)(1) of the Code, for which no exemption exists under Section 408 of ERISA or Section 4975(c)(2) or
(d) of the Code, or has otherwise violated the provisions of Part 4 of Title I, Subtitle B of ERISA. VasculoMedics has not knowingly
participated in a violation of Part 4 of Title I, Subtitle B of ERISA by any plan fiduciary of any VasculoMedics Employee Plan
subject to ERISA and has not been assessed any civil penalty under Section 502(l) of ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No VasculoMedics Employee Plan is subject to Title IV or Section 302 of ERISA or Section&nbsp;412 of the Code, and neither
VasculoMedics nor any VasculoMedics Affiliate has ever maintained, contributed to or partially or completely withdrawn from, or
incurred any obligation or liability with respect to, any such plan. No VasculoMedics Employee Plan is a Multiemployer Plan, and
neither VasculoMedics nor any VasculoMedics Affiliate has ever contributed to or had an obligation to contribute, or incurred any
liability in respect of a contribution, to any Multiemployer Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No VasculoMedics Employee Plan provides for medical or death benefits beyond termination of service or retirement, other
than: (i)&nbsp;pursuant to COBRA or an analogous state law requirement or (ii)&nbsp;death or retirement benefits under a VasculoMedics
Employee Plan qualified under Section&nbsp;401(a) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics is not a party to any contract that has resulted or could reasonably be expected to result, separately or
in the aggregate, in the payment of: (i)&nbsp;any &ldquo;excess parachute payment&rdquo; within the meaning of Section&nbsp;280G
of the Code and (ii)&nbsp;any amount the deduction for which would be disallowed under Section&nbsp;162(m) of the Code.</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of VasculoMedics, no payment pursuant to any VasculoMedics Employee Plan or other arrangement to any &ldquo;service
provider&rdquo; (as such term is defined in Section&nbsp;409A of the Code and the United States Treasury Regulations and IRS guidance
thereunder) to VasculoMedics, including the grant, vesting or exercise of any stock option, would subject any Person to tax pursuant
to Section&nbsp;409A(1) of the Code, whether pursuant to the Merger or the transactions contemplated hereby or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of VasculoMedics, VasculoMedics has no material liability with respect to any misclassification of: (A)&nbsp;any
Person as an independent contractor rather than as an employee, (B)&nbsp;any employee leased from another employer or (C)&nbsp;any
employee currently or formerly classified as exempt from overtime wages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the execution and delivery by VasculoMedics of this Agreement, the performance by VasculoMedics of its obligations
hereunder, nor the consummation by VasculoMedics of the transactions contemplated hereby will: (i)&nbsp;result in any payment (including
severance, unemployment compensation, golden parachute, bonus or otherwise) becoming due to any stockholder, director or VasculoMedics
employee under any VasculoMedics Employee Plan or otherwise, (ii)&nbsp;materially increase any benefits otherwise payable under
any VasculoMedics Employee Plan, or (iii)&nbsp;result in the acceleration of the time of payment or vesting of any such benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.15<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Labor and Employment Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics is not, or at any time has been, a party to any collective bargaining agreement or other labor union agreement,
nor is any such collective bargaining agreement being negotiated. To the Knowledge of VasculoMedics, no activities or proceedings
are underway by any labor union to organize any employees of VasculoMedics. VasculoMedics : (i) has no direct or indirect Liability
with respect to any misclassification of any Person as an independent contractor or temporary worker hired through a temporary
worker agency rather than as an employee, (ii) is in compliance in all material respects with all applicable foreign, federal,
state and local Laws respecting employment, employment practices, labor relations, fair employment, employment discrimination,
health and safety, terms and conditions of employment, wages and hours, workers compensation, unemployment Laws, immigration Laws
and social security Laws and (iii) has not received any written remedial order or notice of offense under applicable occupational
health and safety Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There is no unfair labor practice charge or complaint against VasculoMedics pending or, to the Knowledge of VasculoMedics,
threatened, before the National Labor Relations Board, any court or any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to VasculoMedics, there are no pending or, to the Knowledge of VasculoMedics, threatened actions, charges,
citations or consent decrees concerning: (i) wages, compensation, bonuses, commissions, awards or payroll deductions, equal employment
or human rights violations regarding race, color, religion, sex, national origin, age, disability, veteran&rsquo;s status, marital
status, or any other recognized protected class, status or attribute under any federal, state, local or foreign equal employment
Law prohibiting discrimination, (ii)&nbsp;representation petitions or unfair labor practices, (iii) occupational safety and health,
(iv)&nbsp;workers&rsquo; compensation, (v) wrongful termination, negligent hiring, invasion of privacy or defamation or (vi) immigration
or any other claims under state or federal labor Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedule&nbsp;5.15(d)</U> contains a complete and correct list setting forth: (i) the names and titles of, and current
annual compensation and the two (2) most recent annual bonuses for and exempt or non-exempt status of, each current employee of
VasculoMedics, (ii) the names of each director of VasculoMedics, (iii) the name of each Person who currently provides, or who has
within the prior twelve (12) month period provided, services to VasculoMedics as an independent contractor, and (iv) the names
of each employee or independent contractor of VasculoMedics who is a party to a non-competition agreement with VasculoMedics. To
the Knowledge of VasculoMedics, no person has any plans to terminate employment or service with VasculoMedics. Except as specifically
identified on <U>Schedule&nbsp;5.15(d)</U>, all employees of VasculoMedics are employed at will.</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics has never terminated any employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.16<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Litigation</U>. There is no Legal Proceeding pending or threatened against VasculoMedics or any Affiliate thereof, against
any of the officers, directors or employees of VasculoMedics or any Affiliate thereof with respect to their business activities
on behalf of VasculoMedics, or to which VasculoMedics or any Affiliate thereof is otherwise a party before any Governmental Body
nor, to the Knowledge of VasculoMedics, are there any facts, claims or allegations that could reasonably be expected to result
in such a Legal Proceeding or a VasculoMedics Material Adverse Effect. VasculoMedics is not subject to any Order, nor is any Affiliate
of VasculoMedics subject to any Order that relates to VasculoMedics. VasculoMedics is not engaged in (or intends to engage in)
any legal action to recover monies due it or for damages sustained by it. There are no facts, claims or allegations that could
reasonably be expected to result in liability of VasculoMedics under VasculoMedics &rsquo;s organizational documents or in any
indemnification agreements in effect as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.17<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Related Party Transactions</U>. Except as noted on <U>Schedule 5.17</U>: (i) VasculoMedics is not indebted to any director,
officer or employee of VasculoMedics (any such Person, an &ldquo;<U>VasculoMedics Related Party</U>&rdquo;) (except for amounts
due as salaries and bonuses under employment contracts or employee benefits plans and amounts payable in reimbursement of ordinary
expenses); (ii)&nbsp;to the Knowledge of VasculoMedics, no VasculoMedics Related Party owns any direct or indirect interest of
any kind in, or controls or is a director, officer, employee or partner of, or consultant to, or lender to or borrower from or
has the right to participate in the profits of, any Person which is: (A) a competitor, supplier, landlord, tenant, creditor or
debtor of VasculoMedics, (B) engaged in a business related to the business of VasculoMedics, or (C) a participant in any transaction
to which VasculoMedics is a party; (iii) no VasculoMedics Related Party is indebted to VasculoMedics, nor has VasculoMedics made
any loans or committed to make any loan or extend or guarantee credit to or for the benefit of any VasculoMedics Related Party;
(iv) no VasculoMedics Related Party owns or has any interest in any property (real or personal, tangible or intangible), used in
or pertaining to the business of, VasculoMedics other than as a result of his, her or its ownership of or interest in VasculoMedics
Stock;or (v) no VasculoMedics Related Party is a party to any Contract or involved in any business arrangement or other relationship
with VasculoMedics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.18<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Banks</U>. <U>Schedule 5.18</U> contains a complete and correct list of the names and locations of all banks in which
VasculoMedics has accounts or safe deposit boxes and the names of all persons authorized to draw thereon or to have access thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.19<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Financial Advisors</U>. Except as set forth on <U>Schedule 5.19</U>, no Person has acted, directly or indirectly, as
a broker, finder or financial advisor for VasculoMedics in connection with the transactions contemplated by this Agreement and
no Person is entitled to any fee or commission or like payment in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.20<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Financial Statements</U>. VasculoMedics has not prepared any financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclaimer</U>.
It is the explicit intent, understanding and agreement of Stratus, that VasculoMedics and Sherris are not making any representation
or warranty whatsoever, oral or written, express or implied, other than those set forth in this Agreement and any certificates
furnished in connection with this Agreement. Stratus acknowledges that it is not relying on any statement, representation or warranty,
oral or written, express or implied made by VasculoMedics or Sherris or their representatives or agents, except for representations
and warranties set forth in this Agreement, and any certificates furnished in connection with this Agreement. Except for the representations
and warranties set forth in this Agreement and any certificates furnished in connection with this Agreement, the Shares are being
sold &ldquo;as is&rdquo; and &ldquo;where is&rdquo; and the Parties expressly disclaim all other representations and warranties
of any kind or nature expressed or implied (including, any relating to the financial condition, prospects, results of operations,
assets or liabilities of VasculoMedics). Specifically, neither VasculoMedics nor Sherris are making any representation, warranty
or covenant of any kind with respect to any projections, estimates or budgets heretofore delivered to or made available to Stratus
of future revenues, expenses or expenditures, future results of operations (or any component thereof), future cash flows or future
financial condition (or any component thereof) of VasculoMedics or the future business and operations of VasculoMedics.</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE VI</B><BR>
<B>REPRESENTATIONS AND WARRANTIES OF STRATUS</B><BR>
<B>AND VASCULOMEDICS MERGER SUB</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Stratus and VasculoMedics Merger Sub
represent and warrant to VasculoMedics on the date hereof, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">6.1<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Organization and Good Standing</U>. Each of Stratus and VasculoMedics Merger Sub is a corporation, validly existing and
in good standing under the laws of its jurisdiction of organization and has all requisite corporate power and authority to own,
lease and operate its properties and carry on its business as now conducted. Stratus is duly qualified or authorized to do business
as a foreign corporation and is in good standing under the laws of each jurisdiction in which it owns or leases real property and
each other jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification or
authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization
of Agreement</U>. Each of Stratus and VasculoMedics Merger Sub has all requisite power and authority and legal capacity to execute
and deliver this Agreement and each other agreement, document, instrument or certificate contemplated by this Agreement or to
be executed by Stratus and VasculoMedics Merger Sub in connection with the consummation of the transactions contemplated hereby
and thereby (the &ldquo;<U>Stratus Documents</U>&rdquo;), and to consummate the transactions contemplated hereby and thereby.
The execution, delivery and performance by each of Stratus and VasculoMedics Merger Sub of this Agreement and each of Stratus
Documents, to the extent applicable, have been duly authorized by all necessary corporate action on behalf of Stratus and VasculoMedics
Merger Sub. This Agreement has been, and each Stratus Document will be at or prior to the Closing, duly executed and delivered
by each of Stratus and VasculoMedics Merger Sub, to the extent applicable, and (assuming the due authorization, execution and
delivery by the other parties hereto and thereto) this Agreement constitutes, and each Stratus Document when so executed and delivered
will constitute, the legal, valid and binding obligation of each of Stratus and VasculoMedics Merger Sub, to the extent applicable,
enforceable against it and in accordance with its respective terms, subject to applicable bankruptcy, insolvency, reorganization,
moratorium and similar laws affecting creditors&rsquo; rights and remedies generally, and subject, as to enforceability, to general
principles of equity, (regardless of whether enforcement is sought in a proceeding at law or in equity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conflicts;
Consents of Third Parties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the execution and delivery by Stratus and VasculoMedics Merger Sub of this Agreement and of Stratus Documents, nor
the compliance by Stratus with any of the provisions hereof or thereof will: (i) conflict with, or result in any violation of,
default or breach of, any provision of the articles of incorporation, certificate of formation or by-laws of Stratus or VasculoMedics
Merger Sub, (ii) conflict with, violate, result in the breach of, or constitute a default under any note, bond, mortgage, indenture,
license, agreement or other obligation, in each case to which Stratus and VasculoMedics Merger Sub is a party or by which Stratus
and VasculoMedics Merger Sub or their properties or assets are bound or (iii)&nbsp;violate any Law or Order of any Governmental
Body by which Stratus or VasculoMedics Merger Sub are bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as set forth on <U>Schedule 6.3(b</U>), no consent, waiver, approval, Order, Permit or authorization of, or declaration
or filing with, or notification to, any Person or Governmental Body is required on the part of Stratus or VasculoMedics Merger
Sub in connection with the execution and delivery of this Agreement or the Stratus Documents or the compliance by Stratus or VasculoMedics
Merger Sub with any of the provisions hereof or thereof or the consummation by Stratus of the transactions contemplated hereby.</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">6.4<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>SEC Filings</U>. As of their respective filing dates, Stratus&rsquo; SEC filings complied in all material respects with
the requirements of the Securities Exchange Act of 1934 Act and the Securities Act of 1933. Stratus has, to its knowledge, filed
with the SEC all filings required by those laws and has provided all certifications of its officers which are required by Sarbanes-Oxley
and the rules and regulations promulgated in connection therewith, as such rules and regulations have been enacted by the SEC.
None of Stratus&rsquo; SEC filings, as of their respective dates, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements made therein, in light of the
circumstances under which they were made, not misleading; provided, however, that Stratus makes no representations or warranties
as to the information contained in or omitted from Stratus&rsquo; SEC filings in reliance upon and in conformity with information
furnished to Stratus by or on behalf of counterparties to the material contracts included in Stratus&rsquo; SEC filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">6.5<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Financial Advisors</U>. Except as set forth on <U>Schedule&nbsp;6.5</U>, no Person has acted, directly or indirectly,
as a broker, finder or financial advisor for either Stratus or Merger Sub in connection with the transactions contemplated by this
Agreement and no Person is entitled to any fee or commission or like payment in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">6.6<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Capitalization</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
authorized capital stock of Stratus consists of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>One
billion (1,000,000,000) shares of common stock, $0.001 par value, of which 593,311,148 shares are issued and outstanding and of
which 90,750,435 shares are subject to outstanding option grants and warrants (exclusive of an indeterminate number of shares
issuable upon the exercise of convertible notes), all as of February&nbsp;11, 2014; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Ten Million (10,000,000) shares of preferred stock, $0.001 par value, of which no shares are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>All of the issued and outstanding shares of capital stock of Stratus have been duly authorized, are validly issued, fully
paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Except
as set forth on <U>Schedule 6.6</U>, there is no existing option, warrant, call, right or Contract of any character to which Stratus
is a party requiring, and there are no securities of Stratus outstanding which upon conversion or exchange would require, the
issuance, sale or transfer of any additional shares of capital stock or other equity securities of Stratus or other securities
convertible into, exchangeable for or evidencing the right to subscribe for or purchase shares of capital stock or other equity
securities of Stratus. Stratus is not a party to any voting trust or other Contract with respect to the voting, redemption, sale,
transfer or other disposition of the capital stock of Stratus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">6.7<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Corporate Records</U>. Stratus has delivered to VasculoMedics true, correct and complete copies of its articles of incorporation
and by-laws (each certified by the secretary, assistant secretary or other appropriate officer) as currently in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE VII</B><BR>
<B>COVENANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">7.1<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Cooperation</U>. The parties shall cooperate fully with each other and their respective employees, legal counsel, accountants
and other representatives and advisers in connection with the steps required to be taken as part of their respective obligations
under this Agreement; and each of them shall, at any time and from time to time after the Closing, upon the request of the other,
do, execute, acknowledge and deliver, or cause to be done, executed, acknowledged and delivered, all such further acts, deeds,
assignments, transfers, conveyances, consents, receipts, acknowledgments, acceptances and assurances as may be reasonably required
(without incurring unreimbursed expense) to satisfy and perform the obligations of such party hereunder.</P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">7.2<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No Public Announcements</U>. Without the prior written consent of the other party, no party hereto will make any press
release or other public disclosure with regard to the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">7.3<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Further Assurances</U>. Subject to the terms and conditions of this Agreement, each party agrees to use all of its reasonable
efforts to take, or cause to be taken, all actions and to do or cause to be done, all things necessary and proper or advisable
to consummate and make effective the transactions contemplated by this Agreement (including the execution and delivery of such
further instruments and documents as the other party may reasonably request).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">7.4<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Access to Information</U>. Prior to the Effective Time, each party shall be entitled, through its officers, employees
and representatives (including its legal advisors and accountants), to make such investigation of the properties, businesses and
operations of the other parties and such examination of the books, records and financial condition of such other party as it reasonably
requests and to make extracts and copies of such books and records. Each party shall reasonably cooperate, and shall cause such
party to reasonably cooperate, with all such reasonable requests. No investigation by or on behalf of any party prior to or after
the date of this Agreement shall diminish or obviate any of the representations, warranties, covenants or agreements of the other
parties contained in this Agreement. In order that a party may have full opportunity to make such physical, business, accounting
and legal review, examination or investigation as it may reasonably request of the affairs of the other party, each such other
party shall use commercially reasonable efforts to cause the officers, employees, consultants, agents, accountants, attorneys and
other representatives of such other party to cooperate fully in connection with such review and examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">7.5<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Conduct of the Business Pending the Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Except as otherwise expressly contemplated by this Agreement, VasculoMedics shall, given the current financial constraints:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>conduct its business only in the Ordinary Course of Business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use commercially reasonable efforts to: (A) preserve its present business operations, organization, material rights, franchises,
Intellectual Property Rights and goodwill and (B) preserve, to the extent feasible, its present relationship with Persons having
material business dealings with such party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use its commercially reasonable efforts to maintain: (A) all material assets and properties of such party in their current
condition, ordinary wear and tear excepted and (B) insurance upon all of the properties and assets of such party in such amounts,
of such kinds and with such carriers as are substantially similar to that in effect on the date of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>maintain its books, accounts and records in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>give all required notices of the transactions contemplated by this Agreement and use its commercially reasonable efforts
to obtain all third party consents material to such party&rsquo;s business that are necessary or advisable in order to consummate
the transactions contemplated by this Agreement;</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(vi)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>not take any action which would reasonably be expected to adversely affect the ability of the parties to consummate the
transactions contemplated by this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(vii)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>promptly notify Stratus in writing if, prior to the consummation of the Closing, to its Knowledge: (a) any of the representations
and warranties contained herein applicable to VasculoMedics are not accurate and complete in all material respects or (b)&nbsp;VasculoMedics
fails to comply with or satisfy any material covenant, condition or agreement to be complied with or satisfied by it hereunder;
provided, however, that the delivery of any notice pursuant to this <U>Section&nbsp;7.5</U> shall not limit or otherwise affect
the remedies available hereunder to Stratus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">7.6<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Reasonable Best Efforts; Regulatory Approvals</U>. Upon the terms and subject to the conditions set forth in this Agreement,
each of the parties agrees to use its best efforts to take, or cause to be taken, all actions, and to do, or cause to be done,
and to assist and cooperate with the other parties in doing, all things reasonably necessary, proper or advisable to consummate
and make effective, in the most expeditious manner practicable, the Merger and the other transactions contemplated by this Agreement
and bring about the fulfillment of the conditions precedent contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">7.7<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No Solicitation by VasculoMedics </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics shall use its reasonable best efforts to cause its directors, officers, employees, investment bankers, financial
advisors, attorneys, accountants, agents and other representatives (collectively, the &ldquo;<U>Representatives</U>&rdquo;) to,
immediately cease and cause to be terminated any discussions or negotiations with any Person conducted heretofore with respect
to a Takeover Proposal, and use best efforts to obtain the return from all such Persons or cause the destruction of all copies
of confidential information previously provided to such parties by VasculoMedics or Representatives. VasculoMedics shall not, and
shall not permit its Representatives to, directly or indirectly: (i) solicit, initiate, knowingly facilitate or encourage (including
by way of furnishing information) any inquiries or proposals that constitute, or may reasonably be expected to lead to, any Takeover
Proposal, (ii) other than informing Persons of the existence of the provisions contained in this <U>Section 7.7</U>, participate
in any discussions or negotiations with any third party regarding any Takeover Proposal or (iii) enter into any agreement related
to any Takeover Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In addition to the other obligations of the Company set forth in this <U>Section&nbsp;7.8</U>, VasculoMedics shall promptly
advise Stratus, in writing, and in no event later than 24 hours after receipt, if any proposal, offer, inquiry or other contact
is received by, any information is requested from, or any discussions or negotiations are sought to be initiated or continued with,
VasculoMedics in respect of any Takeover Proposal, and shall, in any such notice to Stratus, indicate the identity of the Person
making such proposal, offer, inquiry or other contact and the terms and conditions of any proposals or offers or the nature of
any inquiries or contacts (and shall include with such notice copies of any written materials received from or on behalf of such
Person relating to such proposal, offer, inquiry, contact or request), and thereafter shall promptly keep Stratus informed of all
material developments affecting the status and terms of any such proposals, offers, inquiries, contacts or requests (and VasculoMedics
shall provide Stratus with copies of any additional written materials received that relate to such proposals, offers, inquiries,
contacts or requests) and of the status of any such discussions or negotiations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics acknowledges that damages for any breach of the obligations in this <U>Section&nbsp;7.7</U> will be difficult
to measure and that Stratus has the right to have the provisions of this <U>Section 7.7</U>, specifically enforced.</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">7.8<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Confidentiality and Non-Disclosure</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidential Information</U>. The term &ldquo;<U>Confidential Information</U>&rdquo; means any information disclosed
to a party to this Agreement (referred to in this <U>Section&nbsp;7.8</U> as the &ldquo;<U>Recipient</U>&rdquo;), either prior
to or subsequent to the date of this Agreement, whether orally, in writing, in any other medium, however documented (or not documented),
by or on behalf of any other party to this Agreement (referred to within this <U>Section&nbsp;7.8</U> as the &ldquo;<U>Disclosing
Party</U>&rdquo;) including, without limitation, the Disclosing Party&rsquo;s actual and proposed business(es); historical and
protected financial information; budgets; services; products; trade secrets; techniques; processes; operations; formulae; product
specifications; know-how; processes; compositions; inventions; discoveries; designs; formats; business, marketing and manufacturing
plans and materials; analyses; strategies; forecasts; research and development; concepts; ideas; names, addresses and any other
characteristics, identifying information or aspects of the Disclosing Party&rsquo;s existing or potential customers, employees,
vendors or suppliers; or any information derived, summarized or extracted from any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Confidential Information shall not include any information which: (i) is or becomes available to the public other than as
a consequence of a breach by any person of any fiduciary duty or obligation of confidentiality, including, without limitation,
catalogues, product descriptions and sales literature that the Disclosing Party has distributed to the public generally; or (ii)
is or was developed by a Recipient independently of, and without reliance on or reference to, the confidential information of the
Disclosing Party. All of the parties agree that in the event an order by any court or other government entity is issued requiring
a Recipient to turn over any Confidential Information, Recipient shall give the Disclosing Party written notice of such court order
immediately upon knowledge thereof and shall cooperate with any efforts of Disclosing Party to protect the confidentiality of the
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Disclosure of Confidential Information</U>. Each party to this Agreement hereby agrees to hold in strict confidence
and trust all Confidential Information and agrees not to disclose or otherwise provide or transfer, directly or indirectly, any
Confidential Information or anything related to the Confidential Information to third parties without the prior written consent
of the other party or as permitted by <U>Section 7.8(b</U>) or the next sentence. A Recipient may disclose Confidential Information
(without consent of the other party): (i) to its directors, officers, stockholders, employees, agents and advisors (including without
limitation attorneys, accountants, consultants, bankers, financing sources and financial advisors) (&ldquo;<U>Representatives</U>&rdquo;)
who are advised of the terms of this <U>Section&nbsp;7.8</U> and who need to know such information to enable Recipient to evaluate
and assist with respect to the Merger with a Disclosing Party, and then only to the extent necessary to carry out the legitimate
use of the Confidential Information and (ii) as required by any final, unappealable court order. Each party further agrees that
it may use the Confidential Information only in connection with the evaluation of this transaction and not for any other purpose
or for the benefit of any third party. Each party agrees to require any of its Representatives who obtain Confidential Information
to comply with this <U>Section&nbsp;7.9</U> and also agrees to be responsible for any breach of this <U>Section 7.9</U> by such
persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE VIII</B><BR>
<B>CONDITIONS TO CLOSING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">8.1<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Conditions Precedent to Obligations of Stratus and VasculoMedics Merger Sub</U>. The obligations of Stratus and VasculoMedics
Merger Sub to consummate the transactions contemplated by this Agreement are subject to the satisfaction, on or prior to the Closing
Date, of each of the following conditions (any or all of which may be waived by Stratus in whole or in part to the extent permitted
by applicable Law):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the representations and warranties of VasculoMedics and Sherris contained in <U>Article V</U>, that are qualified as to
materiality shall be true and correct in all respects and those that are not qualified as to materiality shall be true and correct
in all material respects as of the Closing as though made at and as of the Closing, except to the extent such representations and
warranties expressly relate to an earlier date (in which case such representations and warranties that are qualified as to materiality
shall be true and correct in all respects on and as of such earlier date and those that are not qualified as to materiality shall
be true and correct in all material respects on and as of such earlier date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics shall have performed and complied in all material respects with all obligations and agreements required in
this Agreement to be performed or complied with by it prior to the Closing Date, and received all VasculoMedics Shareholder Consents,
and Stratus shall have received copies of such corporate resolutions and other documents evidencing the performance thereof as
Stratus may reasonably request;</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>there shall not be in effect any Order by a Governmental Body of competent jurisdiction restraining, enjoining or otherwise
prohibiting the consummation of the transactions contemplated hereby, and there shall not be pending any Legal Proceeding seeking
to restrain or prohibit the consummation of the Merger or seeking a material amount for damages in connection with the transactions
contemplated hereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>there shall be no Indebtedness or Liabilities of VasculoMedics (including any Transaction Expenses other than the Post Closing
Amounts) outstanding other than Indebtedness to be paid by VasculoMedics at Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>there shall not have been any VasculoMedics Material Adverse Effect since the date of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Stratus shall have received a certificate signed by the Chief Executive Officer of VasculoMedics, in form and substance
reasonably satisfactory to Stratus, dated the Closing Date, to the effect that each of the conditions specified above in <U>Section&nbsp;8.2</U>
have been satisfied in all respects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics shall have obtained all consents, waivers and approvals referred to on <U>Schedule&nbsp;5.3(b</U>), each such
consent, waiver and approval being in form and substance reasonably satisfactory to Stratus and not requiring as a term thereof
or condition thereto any adverse condition or requirement on the conduct of business by VasculoMedics, Stratus;<SUP> </SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a non-competition agreement, substantially in the form attached hereto as <U>Exhibit&nbsp;A</U>, shall have been entered
into by Sherris, and such agreement shall remain in full force and effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>VasculoMedics shall have delivered, or caused to be delivered, to Stratus a certificate of good standing as of a recent
date with respect to VasculoMedics issued by the Delaware Secretary of State;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All VasculoMedics Derivative Securities and any other rights to purchase any shares of VasculoMedics capital stock shall
have been converted into or exercised for VasculoMedics Common Stock or shall have been cancelled; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Stratus or a subsidiary of Stratus shall have acquired all of the capital stock of Paloma substantially in accordance with
the terms of the Paloma Letter of Intent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">8.2<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Conditions Precedent to Obligations of VasculoMedics.</U> The obligations of VasculoMedics to consummate the transactions
contemplated by this Agreement are subject to the fulfillment, prior to or on the Closing Date, of each of the following conditions
(any or all of which may be waived by VasculoMedics in whole or in part to the extent permitted by applicable Law):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the representations and warranties of Stratus and VasculoMedics Merger Sub contained in <U>Article&nbsp;VI</U> that are
qualified as to materiality shall be true and correct in all respects and those that are not qualified as to materiality shall
be true and correct in all material respects as of the Closing as though made at and as of the Closing, except to the extent such
representations and warranties expressly relate to an earlier date (in which case such representations and warranties that are
qualified as to materiality shall be true and correct in all respects on and as of such earlier date and those that are not qualified
as to materiality shall be true and correct in all material respects on and as of such earlier date); and</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Stratus shall have performed and complied in all respects with all obligations and agreements required by this Agreement
to be performed or complied with by Stratus on or prior to the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>there shall not be in effect any Order by a Governmental Body of competent jurisdiction restraining, enjoining or otherwise
prohibiting the consummation of the transactions contemplated hereby, and there shall not be pending any Legal Proceeding seeking
to restrain or prohibit the consummation of the Merger or seeking a material amount for damages in connection with the transactions
contemplated hereby and the VasculoMedics Stockholders have approved the Merger and all Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>there
shall not have been any Stratus Material Adverse Effect since the date of this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VasculoMedics
shall have received a certificate signed by the Chief Executive Officer of Stratus, in form and substance reasonably satisfactory
to VasculoMedics, dated the Closing Date, to the effect that each of the conditions specified above in <U>Section&nbsp;8.1</U>
have been satisfied in all respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE IX</B><BR>
<B>INDEMNIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">9.1<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Survival of Representations and Warranties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The representations and warranties of the parties contained in this Agreement shall survive the Closing until 11:59 p.m.
EST on the twelfth (12<SUP>th</SUP>) month anniversary of the Closing Date (the &ldquo;<U>Expiration Date</U>&rdquo;). Any claim
for a Loss asserted in good faith on or prior to the Expiration Date which sets forth in a written notice in reasonable detail
(based on the facts then available) the nature and estimated scope of such claim will be timely made for purposes hereof (the &ldquo;<U>Timely
Claim</U>&rdquo;). Any claim for indemnification with respect to any of such matters that is not asserted by notice to the other
party on or prior to the Expiration Date may not be pursued and is hereby irrevocably waived after such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>All covenants and agreements made by the parties to this Agreement which contemplate performance following the Closing Date
shall survive the Closing Date in accordance with their terms. All covenants and agreements that contemplate performance prior
to the Closing Date shall not survive the Closing Date; <I>provided</I>, <I>however</I>, that if any such covenant or agreement
is breached on or prior to the Closing Date, the non-breaching party shall retain all rights and remedies hereunder with respect
to such breach following the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">9.2<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Indemnification by VasculoMedics Stockholders</U>. Subject to the limitations set forth in this Article&nbsp;IX, from
and after the Closing Date, Stratus, the Surviving VasculoMedics Corporation, and their respective subsidiaries, shareholders,
members, directors, officers, employees, consultants, independent contractors, agents and representatives (the &ldquo;<U>Stratus
Indemnified Parties</U>&rdquo;) shall be entitled to be indemnified, defended and held harmless by the VasculoMedics Stockholders
for all Losses suffered or incurred by such Stratus Indemnified Party (irrespective of whether or not such Losses arise out of
or in connection with a third-party claim) resulting from, or arising out of or relating to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
failure of the representations and warranties made by VasculoMedics set forth in this Agreement or in any VasculoMedics Document
to be true and correct;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
breach of any covenant or other agreement on the part of VasculoMedics under this Agreement or any VasculoMedics Document; or</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any claims by VasculoMedics Stockholders or the holders of any other security of VasculoMedics with respect to the determination
by VasculoMedics to enter into this Agreement or the allocation of the Merger Consideration as set forth in the Merger Consideration
Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">9.3<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Indemnification by Stratus</U>. Subject to the limitations set forth in this <U>Article&nbsp;IX</U>, from and after the
Closing Date, the VasculoMedics Stockholders and their respective subsidiaries, shareholders, members, directors, officers, employees,
consultants, independent contractors, agents and representatives (the &ldquo;<U>Target Indemnified Parties</U>&rdquo; and with
the Stratus Indemnified Parties, each an &ldquo;Indemnified Party&rdquo;) shall be entitled to be indemnified, defended and held
harmless by Stratus for all Losses suffered or incurred by such Target Indemnified Party (irrespective of whether or not such Losses
arise out of or in connection with a third-party claim) resulting from, or arising out of or relating to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
failure of the representations and warranties made by Stratus or VasculoMedics Merger Sub set forth in this Agreement or in any
Stratus Document to be true and correct; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
breach of any covenant or other agreement on the part of Stratus or VasculoMedics Merger Sub under this Agreement or any Stratus
Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">9.4<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Escrow Arrangements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Escrow
Fund</U>. The Escrow Shares shall be available to compensate the Stratus Indemnified Parties for any claims by such Parties for
any Losses incurred or sustained by them and for which they are entitled to recovery under this <U>Article&nbsp;IX</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Escrow
Period; Distribution upon Termination of Escrow Period</U>. Subject to the following requirements, the Escrow Fund shall be in
existence as of the Closing and shall terminate at 11:59 p.m., local time, on the sixth (6<SUP>th</SUP>) month anniversary after
the Closing Date with respect to Fifty (50%) percent of the Escrow Fund, and the balance of the Escrow Fund shall terminate at
11:59 P.M., local time twelve (12) months after the Closing Date (the &ldquo;<U>Escrow Period</U>&rdquo;); <I>provided, however</I>,
that the Escrow Period shall not terminate with respect to 100% of the amount of any unsatisfied claims specified in any Officer&rsquo;s
Certificate delivered in good faith prior to the respective expiration date with respect to facts and circumstances existing prior
to the Expiration Date (each, an &ldquo;<U>Unresolved Claim</U>&rdquo;). As soon as an Unresolved Claim has been resolved (whether
by settlement, other agreement or Order), Stratus shall, within five (5) days, deliver to the Transfer Agent for distribution,
to and in the names of those Persons designated by the Holder Representative, the portion of the Escrow Shares, if any, not required
to satisfy other Unresolved Claims. For the purposes hereof, &ldquo;<U>Officer&rsquo;s Certificate</U>&rdquo; shall mean a certificate
signed by any executive officer of Stratus and delivered to the Holder Representative: (1) stating that Stratus has paid, incurred,
sustained or accrued, or reasonably anticipates that it will have to pay, incur, sustain or accrue Losses and (2) specifying in
as much detail as then exists the individual items of Losses included in the amount so stated, the date each such item was paid,
incurred, sustained or accrued, or the basis for such anticipated liability, and the nature of the misrepresentation, breach of
warranty or covenant to which such item is related.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification Procedures</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Subject to <U>Section&nbsp;9.4</U>, the
following shall apply to all Claims; provided that the Holder Representative shall be the exclusive person to act on and receive
all Notices on behalf of the VasculoMedics Stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Claims
for Indemnification</U>. In the event that any Indemnified Party asserts a Timely Claim, it shall provide written notice thereof
containing as much detail as then exists regarding the claim (the &ldquo;<U>Claim Notice</U>&rdquo;) to the party against which
such claim is asserted (an &ldquo;<U>Indemnifying Party</U>&rdquo;) with a copy to the Holder Representative.</P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Resolution of Conflicts; Arbitration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If the Indemnifying Party shall object in writing to any claim or claims made in any Claim Notice to recover Losses within
thirty (30) days after delivery of such Claim Notice, then the Indemnifying Party and Indemnified Party shall attempt in good faith
to agree upon the rights of the respective parties with respect to each of such claims. If the Indemnifying Party and Indemnified
Party should so agree, a memorandum setting forth such agreement shall be prepared and signed by both parties, and the Indemnifying
Party shall pay the agreed-upon amount of the Claim to the Indemnified Party or the same shall be deducted from the Escrow Fund;
or shall be paid by the Indemnified Party because the amount is less than the Threshold Amount as set forth in Section 9.6(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If no such agreement can be reached after good faith negotiation and prior to sixty (60) days after delivery of the Claim
Notice, then the matter shall be referred to arbitration in accordance with <U>Section 11.9</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Third-Party Claims With Respect to Indemnified Parties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event an Indemnified Party becomes aware of a third-party claim which the Indemnified Party reasonably believes,
after investigation, may result in a demand against an Indemnifying Party, the Indemnified Party shall notify the Indemnifying
Party in writing of such claim. The Indemnifying Party shall have the right to elect to assume the defense of such claim; provided
that the Indemnifying Party shall have acknowledged in writing to the Indemnified Party that to the best of its knowledge, such
party is obligated to indemnify the Indemnified Party with respect to such third-party claim as and to the extent provided hereunder;
and <U>provided</U><I>, </I><U>further</U>, that in the event the Indemnifying Party subsequently determines that it is not obligated
to indemnify any such Indemnified Person with respect to such third-party claim, it shall promptly notify the Indemnified Party
to such effect and the Indemnifying Party shall cease to have the right to control the defense of such third-party claim. Notwithstanding
the foregoing, the Indemnifying Party shall not have the right to elect to assume the defense of such third-party claim if: (w)
the Indemnified Party determines in good faith that there is a reasonable probability that such third-party claim seeks material
non-monetary relief; (x)&nbsp;the third-party claim is a criminal proceeding or (y) the claim seeks relief which would limit or
otherwise adversely affect the conduct of business by the Indemnified Party. Failure by the Indemnifing Party to notify the Indemnified
Party of its election to assume the defense of any such claim or litigation by a third party within ten (10) days after notice
thereof has been given to the Indemnifying Party shall be deemed a waiver by the Indemnifying Party of its right to assume the
defense of such claim or litigation, and the Indemnified Party shall have the right to retain its own counsel, without prejudice
to its right of indemnification under this Agreement. All claims for legal fees and expenses or other Losses for which an Indemnified
Party is entitled to indemnification pursuant to this <U>Section&nbsp;9.5(c)</U> shall be subject to the claims processing and
dispute procedures set forth in <U>Section&nbsp;9.5(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Indemnifying Party, if he or it are entitled to and do assume the defense, shall retain counsel reasonably satisfactory
to the Indemnified Party to defend such claim and shall pay the fees and disbursements of such counsel with regard thereto. If
the Indemnifying Party elects to assume the defense, the obligations under <U>Article&nbsp;IX</U> of this Agreement shall include
taking all steps necessary in the investigation, defense or settlement of such claim or litigation (including the retention of
legal counsel) and holding the Indemnified Parties harmless from and against any and all Losses caused by or arising out of any
settlement approved by the Indemnifying Party or any judgment in connection with such claim or litigation; <I>provided, however</I>,
that: (x) the Indemnifying Party shall first consult with the Indemnified Party regarding such settlement, (y) no settlement may
be made by the Indemnifying Party without the consent in writing of the Indemnified Party, unless such settlement: (i) releases
the Indemnified Parties from any liability in respect thereof, (ii) does not include any admission of culpability on the part of
the Indemnified Parties and (iii) does not impose an injunction or other equitable relief upon the Indemnified Parties or any of
their Affiliates or otherwise impose affirmative or negative covenants on the Indemnified Party, and (z)&nbsp;the Indemnifying
Party shall not enter into any settlement with respect to Taxes without the Indemnified Party&rsquo;s consent, which shall not
be unreasonably withheld. If the Indemnifying Party elects to assume the defense, the Indemnifying Party shall permit the Indemnified
Party to participate in such defense or settlement through separate counsel chosen by the Indemnified Party, with the fees and
expenses of such separate counsel borne by the Indemnified Party; provided, however, that in the event the Indemnified Party shall
conclude (upon the advice of counsel) that there may be legal defenses or rights available to it which are different from, in actual
conflict with, or additional to those available to the Indemnifying Party, the Indemnified Party shall be entitled to select separate
counsel to act on its behalf, and the Indemnifying Party shall pay the reasonable separate counsel fees and other reasonable expenses
related thereto.</P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If the Indemnified Party elects to assume such third-party claim or litigation, the Indemnified Party shall permit the Indemnifying
Party to participate in such defense or settlement through separate counsel chosen by the the Indemnifying Party, with the fees
and expenses of such separate counsel borne by the Indemnifying Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">9.6<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Limitation on Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Other than as set forth below, resort to indemnification pursuant to this <U>Article&nbsp;IX</U> and the Escrow Fund shall
be the sole and exclusive remedy of the Stratus Indemnified Parties and the Stratus Indemnified Parties hereby waive, to the fullest
extent permissible by law, any and all other rights or remedies that may arise under any applicable statute, rule or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For purposes of determining the amount of Escrow Shares to satisfy any Indemnification Claims, the Escrow Shares shall be
valued at the fair market value of such shares at the time such claim is made based on the average closing price on the exchange
on which shares of Stratus are traded for the twenty (20) day period immediately prior to the date that such claim is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>An Indemnifying Party shall not have any liability under this <U>Article&nbsp;IX</U> unless the aggregate amount of Losses
to the indemnified parties as finally determined exceed <B>[Twenty-Five Thousand ($25,000)]</B> Dollars (the &ldquo;<U>Threshold
Amount</U>&rdquo;), in which event, subject to <U>Section&nbsp;9.6(a</U>) the Indemnifying Party shall be required to pay the full
amount of such Losses in excess of the Threshold Amount; provided however, that the maximum liability of any VasculoMedics Stockholder
and the maximum liability of Sherris hereunder shall be limited to the fair market value of the Escrow Fund of each as held by
the Escrow Agent, and the maximum liability of Stratus shall be limited to the fair market value of the Escrow Fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE X</B><BR>
<B>HOLDER REPRESENTATIVE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder
Representative</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Upon the adoption of this Agreement and the approval of the Merger and the transactions contemplated hereby by the VasculoMedics
Stockholders, Sherris (the &ldquo;<U>Holder Representative</U>&rdquo;) shall be appointed as the Holder Representative hereunder
to give and receive notices and communications, to waive any breach or default of Stratus under this Agreement, to receive all
notices and services of process on behalf of the VasculoMedics Stockholders in connection with any claims under this Agreement,
including indemnification claims by or against VasculoMedics pursuant to <U>Article&nbsp;IX</U> and to take all other actions that
are either: (i) necessary or appropriate in the judgment of the Holder Representative for the accomplishment of the foregoing or
(ii)&nbsp;specifically mandated by the terms of this Agreement; provided, however that such agency shall apply only to matters
affecting the VasculoMedics Stockholders and any matter that affects only an individual VasculoMedics Stockholder shall be addressed
by Stratus and such VasculoMedics Stockholder. In the event of the death, disability or resignation of the Holder Representative,
the agency may be changed by the VasculoMedics Stockholders as expeditiously as possible; and thereafter, written notice shall
be given to Stratus or the designated successor. No bond shall be required of the Holder Representative, and the Holder Representative
shall not receive any compensation for his services. Notices or communications to or from the Holder Representative shall constitute
notice to or from the VasculoMedics Stockholders.</P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Except for intentional fraud, the Holder Representative shall not be liable for any act done or omitted hereunder as Holder
Representative. Pursuant to the following sentence, and to the fullest extent permitted by applicable Law, the VasculoMedics Stockholders
shall be, severally based on such VasculoMedics Stockholders&rsquo; pro rata Portion of the Merger Consideration and not jointly,
obligated to indemnify and defend the Holder Representative and hold the Holder Representative harmless against any loss, liability
or expense incurred without gross negligence or bad faith on the part of the Holder Representative and arising out of or in connection
with the acceptance or administration of the Holder Representative&rsquo;s duties hereunder, including the reasonable fees and
expenses of any legal counsel retained by the Holder Representative. At the time of distribution pursuant to <U>Section&nbsp;9.4</U>
of any remaining Escrow Shares, the Holder Representative shall be entitled to deduct and withhold from such Shares to pay and
reimburse fees and expenses of third parties incurred or expected to be incurred in connection with such Holder&rsquo;s role as
Holder Representative pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The grant of authority provided for in <U>Section 10.1</U> is coupled with an interest and is being granted, in part, as
an inducement to Stratus and VasculoMedics Merger Sub to enter into this Agreement, shall be irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In connection with the performance of the Holder Representative&rsquo;s obligations hereunder, the Holder Representative
shall have the right at any time and from time to time to select and engage, at the cost and expense of the VasculoMedics Stockholders,
attorneys, accountants, investment bankers, advisors, consultants and clerical personnel and obtain such other professional and
expert assistance, and maintain such records, as the Holder Representative may deem necessary or desirable and incur other out-of-pocket
expenses related to performing its services hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In dealing with this Agreement and any instruments, agreements or documents relating thereto, and in exercising or failing
to exercise all or any of the powers conferred upon the Holder Representative hereunder or thereunder: (i) the Holder Representative
and his agents, counsel, accountants and other representatives shall not assume any, and shall incur no, responsibility whatsoever
(in each case, to the extent permitted by applicable Law) to the VasculoMedics Stockholders or Stratus by reason of any error in
judgment or other act or omission performed or omitted hereunder or in connection with this Agreement or any such other agreement,
instrument or document other than with respect to intentional fraud of the Holder Representative, and (ii) the Holder Representative
shall be entitled to rely in good faith on the advice of counsel, public accountants or other independent experts experienced in
the matter at issue, and any error in judgment or other act or omission of the Holder Representative pursuant to such advice shall
in no event subject the Holder Representative to liability to the VasculoMedics Stockholders or Stratus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>All of the immunities and powers granted to the Holder Representative under this Agreement shall survive the Closing and/or
any termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>A decision, act, consent or instruction of the Holder Representative, including an extension or waiver of this Agreement,
shall constitute a decision of the VasculoMedics Stockholders and shall be final, binding and conclusive upon the VasculoMedics
Stockholders ; and Stratus may rely upon any such decision, act, consent or instruction of the Holder Representative as being the
decision, act, consent or instruction of the VasculoMedics Stockholders. Stratus is hereby relieved from any Liability to any Person
for any acts done by them in accordance with such decision, act, consent or instruction of the Holder Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Holder Representative has all requisite power, authority and legal capacity to execute and deliver this Agreement and
each other agreement, document, or instrument or certificate contemplated by this Agreement or to be executed by the Holder Representative
in connection with the consummation of the transactions contemplated by this Agreement (together with this Agreement, the &ldquo;<U>Holder
Representative Documents</U>&rdquo;), and to consummate the transactions contemplated hereby and thereby. The execution and delivery
of this Agreement and each of the Holder Representative Documents, the performance of such Person&rsquo;s respective obligations
hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby have been duly authorized by
all required action on the part of the Holder Representative. This Agreement has been, and each of the Holder Representative Documents
will be at or prior to the Closing, duly and validly executed and delivered by the Holder Representative and (assuming the due
authorization, execution and delivery by the other parties hereto and thereto) this Agreement constitutes, and each of the Holder
Representative Documents when so executed and delivered will constitute, legal, valid and binding obligations of the Holder Representative
enforceable against it in accordance with their respective terms, subject to applicable bankruptcy, insolvency, reorganization,
moratorium and similar laws affecting creditors&rsquo; rights and remedies generally, and subject, as to enforceability, to general
principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).</P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE XI</B><BR>
<B>INTENTIONALLY DELETED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>ARTICLE XII</B><BR>
<B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">12.1<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Submission to Jurisdiction; Consent to Service of Process</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The parties hereto hereby irrevocably submit to the non-exclusive jurisdiction of any federal or state court located within
the State of California over any dispute arising out of or relating to this Agreement or any of the transactions contemplated hereby
and each party hereby irrevocably agrees that all claims in respect of such dispute or any suit, action proceeding related thereto
may be heard and determined in such courts. The parties hereby irrevocably waive, to the fullest extent permitted by applicable
law, any objection which they may now or hereafter have to the laying of venue of any such dispute brought in such court or any
defense of inconvenient forum for the maintenance of such dispute. Each of the parties hereto agrees that a judgment in any such
dispute may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each of the parties hereto hereby consents to process being served by any party to this Agreement in any suit, action or
proceeding by delivery of a copy thereof in accordance with the provisions of <U>Section&nbsp;12.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">12.2<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the State of California
applicable to contracts made and performed in such state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">12.3<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Entire Agreement; No Third-Party Beneficiaries</U>. This Agreement: (a) constitutes the entire agreement, and supersedes
all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter of this Agreement
and (b)&nbsp;is not intended to confer upon any Person other than the parties hereto any rights or remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">12.4<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Amendment and Waivers</U>. This Agreement may be amended, supplemented or changed by the parties hereto; <I>provided</I>,
<I>however</I>, that there shall be made no amendment that by Law requires further approval by the VasculoMedics Stockholders without
such approval having been obtained. This Agreement may not be amended except by an instrument in writing signed on behalf of each
of the parties hereto. No action taken pursuant to this Agreement, including any investigation by or on behalf of any party, shall
be deemed to constitute a waiver by the party taking such action of compliance with any representation, warranty, covenant or agreement
contained herein. The waiver by any party hereto of a breach of any provision of this Agreement shall not operate or be construed
as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach. No failure on the part of any
party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall
any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the
exercise of any other right, power or remedy. Any agreement on the part of a party to any extension or waiver shall be valid only
if set forth in an instrument in writing signed on behalf of such party. All remedies hereunder are cumulative and are not exclusive
of any other remedies provided by law.</P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">12.5<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notices</U>. All notices and other communications under this Agreement shall be in writing and shall be deemed given:
(i) when delivered personally, (ii) when sent by facsimile (with confirmation of transmission), (iii)&nbsp;when sent via confirmed
email, or (iv) one business day following the day sent by overnight courier (with written confirmation of receipt), in each case
at the following addresses and facsimile numbers (or to such other address or facsimile number as a party may have specified by
notice given to the other party pursuant to this provision):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If to VasculoMedics or Holder Representative, to<BR>
        <BR>
        </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">VasculoMedics Pharmaceuticals, Inc.<BR>
        37 Neillian Crescent<BR>
        Jamaica Plain, MA 02130<BR>
        Attention: President</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">with a copy (which shall not constitute notice) to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Rubin and Rudman LLP<BR>
        50 Rowes Warf, 3rd Floor<BR>
        Boston, Massachusetts 02110<BR>
        Attention: Peter B. Finn, Esq.<BR>
        E-mail: PFinn@rubinrudman.com</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If to Stratus or VasculoMedics Merger Sub, to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1800 Century Park East</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">6<SUP>th</SUP> Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Los Angeles, CA 90067</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attention: Jerrold Rubinstein</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Email: jhr@miaminc.com<BR>
        <BR>
        </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">with a copy to:<BR>
        <BR>
        TroyGould PC<BR>
        1801 Century Park East, Suite 1600<BR>
        Los Angeles, California 90067<BR>
        Attention: David L. Ficksman, Esq.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Email: dficksman@troygould.com<BR>
        <BR>
        </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">12.6<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severability</U>. If any term or other provision of this Agreement is invalid, illegal, or incapable of being enforced
by any law or public policy, all other terms or provisions of this Agreement shall nevertheless remain in full force and effect
so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse
to any party. Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced, the
parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely
as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated
to the greatest extent possible.</P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">12.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>.
Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned, in whole or in part, by operation
of Law or otherwise by any of the parties without the prior written consent of the other parties. Subject to the preceding sentence,
this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors
and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">12.8<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original
copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">12.9<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Arbitration</U>. In the event of any dispute, controversy, disagreement, breach or claim arising out of or relating to
this Agreement or interpretation of any of the provisions, the same shall be submitted, for resolution, to final and binding arbitration
in accordance with the following procedures: The parties shall first attempt to mediate the matter(s). If the matter(s) has not
been satisfactorily resolved (or waived), within thirty (30) days after written notice by either party to the other requesting
mediation, then the matter shall be referred to arbitration for resolution under the then commercial arbitration rules of the American
Arbitration Association (the &ldquo;<U>A.A.A.</U>&rdquo;) and the decision of the arbitrator shall be final and binding on the
parties. The parties shall have the right to select the arbitrator. If the parties are unable to agree upon an arbitrator within
thirty (30) days following a notice of initiating arbitration to the other party, then the arbitrator shall be appointed by the
A.A.A. Each party shall be responsible for the filing fee and the arbitrator&rsquo;s fee; and otherwise, each party shall be responsible
for its own costs and expenses, including but not limited to, travel, consultants, depositions, witnesses and attorneys&rsquo;
fees and disbursements. The arbitrator shall be authorized to only interpret and apply the provisions of this Agreement or any
related agreements entered into under this Agreement and shall have no power or authority to modify or change any of the above
in any manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The arbitrator shall have no authority
to award punitive or speculative damages or any damages inconsistent with this Agreement. In addition to monetary award, the arbitrator
shall be empowered to award equitable relief, including an injunction and specific performance of any obligation under this Agreement.
The arbitrator shall, within thirty (30) days of the conclusion of the hearing, unless such time is extended by mutual agreement,
notify the parties in writing of his/her decision, stating the reasons for such decision and separately listing the findings of
fact and conclusions of law. The arbitration shall be conducted in Los Angeles, California, and shall be governed by the laws of
the State of California, and the decision of the arbitrator may be entered in any court of competent jurisdiction. Any costs, fees
or taxes incident to enforcing the award shall, to the maximum extent permitted by Law, be charged against the non-prevailing party
or shall be recovered by the prevailing party, as applicable, in any final judgment or arbitration award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">12.10<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Reverse Split</U>. Stratus intends to effect a reverse split of up to 1-to-100 with respect to shares of its outstanding
Common Stock. All share numbers with respect to the Stratus Common Stock including the Merger Consideration are before giving effect
to such reverse split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><I>Signature Page Follows.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">IN WITNESS WHEREOF, the parties hereto
have caused this Agreement and Plan of Merger to be executed by their respective officers thereunto duly authorized, all as of
the date first written above.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 54%; padding-right: 5.4pt; padding-left: 5.4pt">&ldquo;<B>STRATUS</B>&rdquo;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">STRATUS MEDIA GROUP, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:____________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:__________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:___________________________</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&ldquo;<B>VASCULOMEDICS MERGER SUB</B>&rdquo;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&ldquo;<B>VASCULOMEDICS</B>&rdquo;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">VASCULOMEDICS ACQUISITION, INC.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">VASCULOMEDICS PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:____________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:__________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:___________________________</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:____________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:&nbsp;&nbsp;&nbsp;David Sherris, Ph.D.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President and CEO</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><B>&ldquo;HOLDER REPRESENTATIVE&rdquo;</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">_______________________________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">David Sherris, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><B>&ldquo;SHERRIS&rdquo;</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">_______________________________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">David Sherris, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">EXHIBIT &ldquo;A&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">NON-COMPETITION AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>DISCLOSURE SCHEDULE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>AGREEMENT AND PLAN OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>BY AND AMONG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>STRATUS MEDIA GROUP, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>VASCULOMEDICS ACQUISITION, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>VASCULOMEDICS PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: center">February 25, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">This Disclosure Schedule is made and given by VasculoMedics
Pharmaceuticals, Inc. (&ldquo;VasculoMedics&rdquo;) pursuant to the Agreement and Plan of Merger dated as of February __, 2014
(the &ldquo;Merger Agreement&rdquo;), by and among the Stratus Media Group, Inc. (&ldquo;Stratus&rdquo;), VasculoMedics Pharmaceuticals,
Inc. and VasculoMedics Acquisition, Inc. (&ldquo;VasculoMedics Merger Sub&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The Schedule numbers in the Disclosure Schedule correspond
to the Section numbers of the VasculoMedics representations and warranties contained in Article V of the Merger Agreement and the
covenants of VasculoMedics contained in Article VII of the Merger Agreement. If, and to the extent, any item required to be disclosed
in a section of this Disclosure Schedule is disclosed in any other section(s) of the Disclosure Schedule, each item shall be deemed
to be included in such Section where such information is required to be disclosed to the extent such item is described in sufficient
detail to enable a party to reasonably identify that such item belongs to such section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Capitalized terms used by not otherwise defined herein shall
have the meaning ascribed to them in the Merger Agreement.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.2 (d):</TD>
    <TD STYLE="width: 75%; padding-top: 6pt; padding-bottom: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">David Sherris, Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5,000,000 Shares</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">Paloma Pharmaceuticals, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;625,000 Shares</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">The Company has not issued any Preferred Stock, Stock Options, Warrants or Corporate Notes.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">The Company has not adopted an Equity Stock Option Plan.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.3 (b):&nbsp;&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">There are no consents or approvals required.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.4 (c):&nbsp;&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">There are no options, warrants, calls, rights, notes and no securities outstanding with any conversion rights.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">The Company is not a party to any voting trusts or agreements.&nbsp;&nbsp;There are no Company Derivative Securities.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt; width: 25%">Schedule 5.5:&nbsp;&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; width: 75%">There are Third-Party Interests.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.7:&nbsp;&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">There are no Liabilities and Indemnities.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.10 (a):</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">There are no Patents and/or Patent applications.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.12:&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">There are no Material Contracts.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.14 (b):&nbsp;&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">There are no Company Employee Plans.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.15 (d):</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">(i)&nbsp;&nbsp;The Company entered into an Executive Employment Agreement with Dr. David Sherris dated as of November 1, 2006 that terminated on November 1, 2012 and has not been renewed.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">The Company does not currently have any employees.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">(ii)&nbsp;&nbsp;Dr. David Sherris is the sole director.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">(iii)&nbsp;&nbsp;No person, within the past twelve (12) months has provided any service as an independent contractor.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">(iv)&nbsp;&nbsp;None.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.16:</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">There is no litigation.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.17:</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">There are no third party transactions.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.18:</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">The Company uses Fidelity Investments and Brookline Bank for checking and savings.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.19:</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">There are no financial advisors.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 6pt; padding-bottom: 6pt">Schedule 5.20:</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt">There are no Financial Statements.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><U>SCHEDULE 6.6</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Options and Warrants Outstanding</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Options and Warrants Outstanding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">As of February 11, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 83%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outstanding</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">593,311,148</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,943,523</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">51,806,912</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total derivatives</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,750,435</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fully-diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">684,061,583</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">_______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">These numbers do not include the dilutive effect of notes with mandatory
conversion features since the number of shares to be issued is dependent on future events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 35; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>stratus_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Stratus Media Group Acquires<BR>
Paloma Pharmaceuticals, Inc. and VasculoMedics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">March 6, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">LOS ANGELES--Stratus Media Group, Inc., (OTCBB: SMDI) announced
today the acquisition, through merger, of two biotechnology companies, Paloma Pharmaceuticals, Inc. and VasculoMedics, Inc. With
these acquisitions, Stratus, which will be renamed RestorGenex, plans to create a world-class pharmaceutical company with an initial
focus on dermatology, ocular diseases and women&rsquo;s health. The merger agreements were approved by the boards of directors
of all companies and are expected to close following the satisfaction of certain closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Paloma Pharmaceuticals brings to RestorGenex an integrated
design platform technology to develop drugs that treat a number of indications. In addition, through the merger with VasculoMedics,
RestorGenex will gain an epigenetic platform company utilizing computational design to create small molecule drugs inhibiting or
stimulating the binding of zinc-finger transcription factor to their cognate DNA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">As part of the transaction, Paloma Founder and Chief Executive
Officer, David Sherris, Ph.D., will join the RestorGenex board of directors and will serve as Chief Scientific Officer of RestorGenex,
and President of the Paloma and VasculoMedics divisions of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&ldquo;We are excited to debut RestorGenex as a newly integrated
biotechnology company, combining several impressive platforms and technologies to treat patients in a number of indications with
unmet medical needs. &rdquo; said Sol J. Barer, chairman of the board of RestorGenex.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-indent: -1in">About Paloma Pharmaceuticals</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Paloma Pharmaceuticals, Inc. has developed a non-steroidal,
synthetic, small molecule drug library through computational design, synthetic and medicinal chemistry, resulting in a family of
anti-tumor agents, &ldquo;Palomids&rdquo;. All Palomids are wholly synthetic with a molecular weight ranging from 300 to 500 Daltons.
Through a series of <I>in vitro</I> and <I>in vivo</I> animal models, the Palomids were shown to have activity in several indication
areas. Palomid 529 (P529) is the result of three generations of Palomid design work and is the lead for clinical development. Paloma
Pharmaceuticals is focused on developing its Palomid library for cancer, ocular disease, pulmonary fibrosis, dermatology (psoriasis,
atopic dermatitis, rosacea, actinic keratosis, keloid and hypertrophic scarring, Dupuytren&rsquo;s disease, bullous blistering
diseases), CNS (Huntington&rsquo;s disease and infantile spasm, a form of childhood epilepsy), biodefense and anti-viral application.
P529&rsquo;s activity has been shown to reside in its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway,
specifically as a first-in-class allosteric, dual TORC1/TORC2 dissociative inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">http://www.palomapharma.com</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-indent: -1in">About VasculoMedics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">VasculoMedics Inc. was founded as a platform epigenetic company
to develop orally available small molecular inhibitors of zinc finger transcription factors. Zinc finger transcription factors
are a subset of transcription factors utilizing zinc at its core for activity. Transcription factors are proteins that bind to
specific parts of DNA that control the transfer of genetic information from DNA to RNA. RNA in turn directs the protein making
machinery to manufacture one or more proteins controlled by the transcription factor. Hence, by inhibition of a transcription factor,
one can specifically inhibit the synthesis of one or more proteins controlled by the particular transcription factor. Many diseases
can be linked to the activation of particular proteins whose synthesis is controlled by transcription factors. Inhibition of such
transcription factors could then be able to control disease pathology. Since transcription factors are functionally closer to the
ultimate pathological protein(s), specific inhibition of transcription factors may result in a greater degree of disease fighting
activity along with reduced level of toxicity. This may have advantage over conventional small molecule drugs that directly inhibit
their target protein through a one-toone interaction as transcription factor inhibitors will lite rally turn off pathological protein
manufacturing capability at its source. VasculoMedics disease area of focus includes dermatology, cancer and ophthalmic diseases
of retinal origin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Statements in this press release relating to plans, strategies,
projections of results, and other statements that are not descriptions of historical facts may be forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities Acts of 1933 and 1934. Forward-looking information
is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due
to a number of factors. Although the company's management believes that the expectations reflected in the forward-looking statements
are reasonable, it cannot guarantee future results, performance or achievements. The company has no obligation to update these
forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Stratus Media Group, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tim Boris, 310-526-8700</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">timb@stratusmediagroup.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>sc52d1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sc52d1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`((`7L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]ZM5N[O\`
MM>VM;62WB\V&65FEA,GW#&```R_WS^5'V75_^?W3O_`%_P#X[1=?\C=9?]>=
MQ_Z'!6E0!F_9=7_Y_=._\`7_`/CM'V75_P#G]T[_`,`7_P#CM:5%`&;]EU?_
M`)_=._\``%__`([1]EU?_G]T[_P!?_X[7SU_P6"_:C\?_L8?\$YOB9\2?AEH
M2Z]XP\-6,<MJCVC7<=A$\\<<]X\2D%UMXGDF(^Z/+RP*!J^*M"_X*H^/_P!F
M7_@DM\2?CUHW[0^A_MJ7\$EFNCR67PXM]#;P5-)N60:S:VEW'*EM\H.72.52
MP.71UVYNM&,*E26T+7]7LDM_F[1Z7NFC3V3;A%;SO;Y6OY==M^MK'ZM?9=7_
M`.?W3O\`P!?_`..T?9=7_P"?W3O_``!?_P".U\7:/_P7"\-:1^S;\&_$WB+X
M4?&\?$/XRSR6&A_#ZQ\)!/$>IR6\:M=7L5M+<!$L%#"199)QF)U?H'*V+7_@
MO?\`!F3]E74?B9<^'OBMI^J:9XP7X?R_#VY\,[?&KZ^^#'IR6(D*&9XSYB_O
M=I`*DB0%*VJ1<)2B_L_YI:=]6EIU:6^AE3?/&,E]K_@O7MI&3]$WL?9/V75_
M^?W3O_`%_P#X[1]EU?\`Y_=._P#`%_\`X[7Y0:O_`,%Q$\/?\%-8_&7CFV^,
M7P;^#F@?`S4-;O\`P1X\T,Z)J<^IIK0@CE2R9RLL\RK%%`P<YWE05S(*^O/V
M\_\`@IM<_LD?\$J=?_:'C\"Z]HNM_P!E6TNC>%_%<"07MO>7DR06J7T=O-($
M`:5))(Q*&"@H2CY"S*ZHJK:]^BU=^:44O-RY=%YHN,.:M[!;_P#VL9-^2CS)
M-^3/J/[+J_\`S^Z=_P"`+_\`QVC[+J__`#^Z=_X`O_\`':_*_P#:$^-/[:7_
M``2P^&_@CX]?%CX[>$/B_P"#-6UW3--\9_#R'P)9Z/%X>AU"15<Z=J$#>?</
M;N?+C,P`=3N<,:^@_&G_``7\^!WPY_9HO/BCKMCXZTO2--^),OPLO=-GL;0:
ME9:M$6\QY8_M.Q+=8U,A<R;MF/DR0M6HMOE6]^5KL[P5NSUJ05TVO>WW,E--
M76S7,GW5I._?:$G9I/0^S?LNK_\`/[IW_@"__P`=H^RZO_S^Z=_X`O\`_':^
M6?VB?^"SWPJ_9IOOCK'K.C^.]2MOV>+30KKQ5>Z7I]O+;.VKR1I;0VS/<(9)
M%657D!"@+G:7;Y:Q_P!G[_@NC\)/C?\`$CQSX9UCPQ\6OA+=>!?"LWCB6;X@
M^%VT1-7T.%V634+./S'GDA``8;HT9@PPI(8+FI)KF6UF_DE>_I9-KNDVM#3E
M:MYM+YOELO\`R:/WKN?7WV75_P#G]T[_`,`7_P#CM'V75_\`G]T[_P``7_\`
MCM?''A__`(+J_#BYTV"]\0_#OXQ^!;/6_`FJ?$7PM-X@TFPB7QCI>GPM<7`L
MO)O92MQY"^:L5T(&*,C'`9<Y?@O_`(+_`/PT^(7POT/Q7I/PL^/\MEXSU_2/
M#/@V*Z\*0Z>WCB^U%)'5=-EN;J."2.#R9!-*\L<:%>&<%2:Y97Y;:Z:=;N3@
ME;OS)QMO=,EM)<U]-=>FD5)N_;E:=]K,^V_LNK_\_NG?^`+_`/QVC[+J_P#S
M^Z=_X`O_`/':Q?@C\4+CXR?#>S\07?A+Q9X&NKF6X@FT3Q+;PP:E9/#/)"?,
M$$LT3*QCWH\<KHZ.C*Q#"NLH::=F"U,W[+J__/[IW_@"_P#\=H^RZO\`\_NG
M?^`+_P#QVM*BD,Q;&;5[RYO(_M>G+]DF$6?L3G?F-'S_`*WC[^/PJQ]EU?\`
MY_=._P#`%_\`X[1HG_(3UC_K\7_TGAKSG]LGX2_%#XS_``@&D?"3XN_\*4\5
M+?17#>(?^$5M/$FZW57#V_V6Y98_G)4[\Y&SCJ:FI/DCS6O_`%^F_P"5V.,;
MNU['HWV75_\`G]T[_P``7_\`CM'V75_^?W3O_`%__CM?D[_P2]_;C^-?A/\`
M8U\1_M9?M,_M/3>*?A5X8EU?1KKP=!\.=*LYYKJWOA:6\T5W:A)&DDD4*L)0
M+F8;GPNZNI_;(_X.5[+X,?`CQS_8/P-^./@WXN:1X>MO$6A:)\1/!8MK6]LI
M9%1KZ06]Z6^S0ET67]XCH\JC:2DH15*D80Y[W]U2T[-<R^?+[UNBWMJ5&G)R
M<6K6DX_--1?R4G;UVW5_TY^RZO\`\_NG?^`+_P#QVC[+J_\`S^Z=_P"`+_\`
MQVOD[X8?\%7]3\;?LS_"WQK_`,,X_M)ZOKGQ$BN5DT33?!L-M-IK6L*R2W,[
M75Y'!;VL^2;9I)]\X("J6XKPSQ9_P5)E_:P_;%_8)UOX6ZYXP\.>`/BAK?C&
MT\2^'M2@%C=33Z?8B+[+?PAF&^&8R':'90VU@254CH]E+VZP_6]OPO?TZ7[Z
M/4RC)2I>U6W+*7_@*;:]?=>GEVU/TD^RZO\`\_NG?^`+_P#QVC[+J_\`S^Z=
M_P"`+_\`QVOS[_X+T?M^_$7]CCQ'\$?#OAOX@1?`CP-\1M5OK3Q+\5YO!Z^*
M8_#,D$"R6MK]E?,>;ARX)=<A8V92!&]>)^)?^"G_`,0/V/O^"CWPMTWQ#X[\
M?_M9>$[WX&3:F_\`PJ/PG#=1^+;Z36Y$755L+:X>W4QV\"J\RS",;7V!/,\N
ML:<U)*3=E>4=>\8RD_3X;:V>J:3CJ:SIRBM-7RJ7R<U#YZOI?:SL]#]</LNK
M_P#/[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=KY<\(?\`!7OPQ\7OV=?A?\2?
MAK\*/CC\5-*^*BWQM;/POX?M9KC06L]PG34I9KJ*UM7#JR(IG)E=2(]_&>$\
M1?\`!PQ\&=%^$7PF\66G@_XS>()?C++K-CH7A_1_"ZWFNQ:CI;(EQIT]HL^X
M7)D<(@C+ID$LZ*-U5*\9.#W6EOZW[:==-]"(^\DUL[O[KW^ZSWZ)OHS[>^RZ
MO_S^Z=_X`O\`_':/LNK_`//[IW_@"_\`\=KXMM_^"^/PPETJYU^7X=_&NR\`
MZ+XAL/"?B/QA=Z!:6^E>%-6NA'NL[U'NQ=JUO)*L,[Q6\D<<A"[VW*6]1;_@
MIEH.L_M8>*?A+X6^'/Q4\<WO@+4-'TSQ5K^A:?8R:/X=GU/#0"8RW<=S(J(1
M)*UO;RK$AW,0`<.,7)I+K_\`:_A[T;/9\T;/5$N22;?3_@K[[IIK=---:,^@
M?LNK_P#/[IW_`(`O_P#':KZ5-J^IVS2?:].3;-+%C[$YSLD9,_ZWOMS^-;5>
M7?M!_M`Z?^RC^RG\0_B9JMM+>Z?X"TO5]=FMHCA[H6YFE\I3@X+E0N<$#=D]
M*RJU8TH.I/9*[^1I3IRJ35..[T._^RZO_P`_NG?^`+__`!VC[+J__/[IW_@"
M_P#\=K\C==^/?[>/A+_@GK;?MJ7GQT^'DVD-H<'CB;X-)X!MDT8:3+M98%U;
MS#?>9]F=9L$Y$N4WE1S]F^%O^"R_PNU?4M:L=3TWQ9H=UH'PCM?C//)<VT!M
M[S19H1(ZVK"7S)9HB=C*8T7=C#'-:U%[/F5324/B75>[*7H](3V;^%^5XB^>
M453U4OA?1^]&.G7>4=TOB5NMOJ7[+J__`#^Z=_X`O_\`':/LNK_\_NG?^`+_
M`/QVOC34?^"^?P7M?V?OA1\1;31OB%J^E_&#1?$&OZ38V&GVDM]86NB6TMQ?
MF[4W0CC91"R`+(^7(&0,L(OV6_\`@OI\)OVJ?CYX'\!V?@;XU^#/^%F:7-JO
MA+Q%XO\`"JZ3H7B1(;=;B:.TN&F9IF1&8%E0QY0X<AD+G*U.4'O&]_E>_P"3
M^YKHPNN2-3H]5Z?TS[0^RZO_`,_NG?\`@"__`,=H^RZO_P`_NG?^`+__`!VO
MDGX6_P#!;?X9?%;QMX%@MO"'Q1TSP-\4?$EWX2\'_$#4=*M8O#?B'48"ZB.(
MK=->1K,T;K"\UM&LA5L'Y6QY_P#%;_@Y(^#'PD\7?$#2[KX=_'[5H/ACXCOO
M"GB#5M)\'+>:59ZC;RB&&`W2W'EJUW+\EN'*DG_6"($$S&\FE'=[=^FEN_O1
MTW]Z.FJ&U:[?31_C^'NRUV]V79GWM]EU?_G]T[_P!?\`^.T?9=7_`.?W3O\`
MP!?_`..U^</_``5^_P""C7CSX8?LR?"?QCI/A;XQ?!V[MOCKX>T#7M'OK2U?
M5M=T[R9+N6&W%A<745U#,`D>V*4[W1XF&0RT?M"?\%S?#WQA_8(^/WB'PC-\
M</V<_'WP6FT9-8@\1_#_`$ZZ\3:0E]=P+#*FE7EV()8Y4=T_>RQLH)<`_)N%
MK%R6Z=K>34&GZ>^O/0N--N<(?SI6>N[E*-OOC\[Z'Z/?9=7_`.?W3O\`P!?_
M`..T?9=7_P"?W3O_``!?_P".U\-_'K_@OO\`#K]E_P"('C+P+>?#C]H/XD>(
MOA=I>FZEXGN_"/@V'4;>UL[K3UO?[0FD6X2*WA5#B0R&/#$[0R*S#O?V_/\`
M@HQIGPV_X(Z>-/VBOAW?27MKJ7@Z+4O"UXL6UUGU#RX+.1D/*E);B,LIZ%"#
MTJ:[=.G*I%<RCVZMWLEZV:7G=;IBPT?:U*=/9SM:_G;]))^C7<^I_LNK_P#/
M[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=K\P?VU_VZOC%_P`$O?@-\%O`^G>,
MO#@U:U^%U]XBOO$GQ%L[W7+OQUK]@EF5T.*8W<+?:;MIYC]Z:7`0(@QS]'?L
MI?M<^+_V\OVEVUG0M4_X1'X,>$M*N-.^QK]EDNOB!KN(5OS$[HTR6.ENX@,E
MN4\VYE.7*1[6VE#WY0@[\KDOE%M7]'*-EUUBVE&46\(U$X0G+3F2?WI.WK9W
M[:2UO&27UA]EU?\`Y_=._P#`%_\`X[4^@W[ZIH5E<R!0]Q`DK!1P"R@G'YU\
M9?\`!$CXY>)_&?PS^+_PR\9Z_KGBSQ#\!_B9K7@U=<UB\>\O=4L%F\^SDFG=
MF>1Q%+L)8EL1KFOL;P=_R*.E_P#7G%_Z`*C1QC..TE&2]))27SL]3752E![Q
M<HOUBW%_*ZT"Z_Y&ZR_Z\[C_`-#@K2K'UBP34?%%@DAF4"UN&S%,\1^_!W4@
M_A4W_"+6W_/74?\`P87'_P`72`TJ*S?^$6MO^>NH_P#@PN/_`(NC_A%K;_GK
MJ/\`X,+C_P"+H`XK]JY/BZWP3U'_`(4=)\.$^(PEA-@/'4=ZVB/'YB^<)39L
M)E;R]Q4KD;@`1@Y'YQ>#/^"$?Q>^(GPY_:WU?XCZM\"_!_Q%_:-\-PZ'9Z1\
M-=.O;3PO:SP'SQ?7)G3SC-/<?ZU@CD;I'R[/L7]4O^$6MO\`GKJ/_@PN/_BZ
M/^$6MO\`GKJ/_@PN/_BZSE1A)24OM)Q]%)<KMZK^KEQJ23BUT:?JXOF5_1K]
M-C\YO$O_``3D_:MU6']F#XHPZY^S_P#\+V_9[&HZ#<:29=6C\(ZUH=W;K;`B
M?RGNTO%BBCY\ORR[EL;4V/POB/\`X(9?'?Q#\)IOB"?''PHA_:=N?C3:_&22
MW6&_/@CS;9&MXM/#E/MGE>2WF&39N+$Q\<35^J?_``BUM_SUU'_P87'_`,71
M_P`(M;?\]=1_\&%Q_P#%UNYMS]I]J]T^WOQJ.WK.*D_/R;1DH145"VEK6[KE
ME!7](R<5Y6[(_*']H+_@AS^T#_P49^/_`/PL;]H+Q)\$M$\36?PWF\-Z'?\`
MP[DU:)_#FN0:J;[3;^`7:%R$'$CB5'Q(Z*F/G/UU^T-^P=XV_P""@7_!*"[^
M"GQOUOPU9_$O6]%MX-2U[P[YMUIJ:K:RI+!>QI)'`Y5GBC=X]J8WNJG`#5]2
M?\(M;?\`/74?_!A<?_%T?\(M;?\`/74?_!A<?_%U$DG2]BM%OIT=W+F7:5WJ
M_P"['^5&BG)5E7^TORM%6?E:.B\WW9^:7C#_`()S_MJ?MY>'?`7PT_:<\9_L
MXVGP?\,ZMIVLZY)\/X-8E\0^*&L,&.WF-VB6\:3.-TCQJI5@"J8^6LC]H'_@
MWS\3_'S]NGXS^(;_`,1>#/\`A1OQ'T[5-9TO0'$O]H:;XKO='33/MSH+?R_+
MC/FS*RR[P[+\IP37ZB?\(M;?\]=1_P#!A<?_`!='_"+6W_/74?\`P87'_P`7
M2J)333^US7\^=13?K[L6NSBFNMYI?NW%Q^SRV\N5MI?^323[J33T/RYT7_@A
MU\9M4_X(Y?'#X0^*_&'@#7/CW\;O$5MKFJ>(3>WG]DNMM<V!@B>8VWGD);V;
M`8@P&DQTRU>L_M6?\$?_`!-^U9^V'JOBG4/$FA:/X&\0?L_7GPANWMY)9=6M
MK^>Y>7[3'"T0B>!58=95<D8VC[U?=O\`PBUM_P`]=1_\&%Q_\71_PBUM_P`]
M=1_\&%Q_\7557[1-2V:M_P"4W2_](?WZCHMTHJ,.C;^;G&?_`*5!?+0_';]E
MC_@W'\6?`OX?ZEIY^%O[-.@>,=0^'/B7PC=^-M)\;^+-2O=2OK^QDM+2X2RN
MXOLMDFV1A<%1,6W,85B'[NOJOQW_`,$U?%^O?\$M_@G\`=8\!?`WXNQ^#M*L
M=*\6:;XLUG4],LY/L^GR0K<:5J%K:R7%M<+.4Q(8%8PF9/D+Y'V]_P`(M;?\
M]=1_\&%Q_P#%T?\`"+6W_/74?_!A<?\`Q=%5^UA*$]I6O_VZYM6Z+XY;6\K6
M%#W&I0TMS6_[>44]=WI%6NSPO_@E=^RGXV_8G_88\$_#;XA>,$\:^)O#L4R2
MWD,\]Q;643S.\5E;RW'[Z2"WC98HVD`;9&HVJ`%'T-6;_P`(M;?\]=1_\&%Q
M_P#%T?\`"+6W_/74?_!A<?\`Q=74J2J2<Y;O^OZ>[ZZDP@HJR_K_`"]%HNFA
MI45F_P#"+6W_`#UU'_P87'_Q='_"+6W_`#UU'_P87'_Q=9E!HG_(3UC_`*_%
M_P#2>&M%UW(1ZC%<_H_ANWDU'509+_Y+I5&+Z<9_<1'GY^>O4^P["K__``BU
MM_SUU'_P87'_`,71)*2LP/S@T#_@B!XXU3_@B3XN_9IUOQ;X8T[QQJ/B.^\3
MZ1JNG237.F)<?VK_`&C9QS&2%)-A*HDA6,E-Q*A\8;E_V@?^".7[2/\`P41U
M7QWXG^/'B;X(^'_%"?"RX\!>"K/P+)JD^GO>7+I-/=W\EW$LB1F6)55(ED*I
M,>K19E_4?_A%K;_GKJ/_`(,+C_XNC_A%K;_GKJ/_`(,+C_XNLY4HRI^REM:W
MI^[]DVO-P]UOY[E^T?/[3K?F_P#)U4MZ<ZNOGW/S(_:0_P""4O[2W[7O[/WP
M*\,?%&?X(>,M.^'EIJ6F>+/A_8^+?$OAOPMXG3R8H])O&NK:)[J2XMFA1V22
M,(2TFPIOR*?[$_\`P0L^*'[,&M_LDMJ&N_#B6P_9_P#%7C/6=9CTV\O\7-KJ
MZ!;-+-98"S,@'[Q9I!M'224\G]0_^$6MO^>NH_\`@PN/_BZ/^$6MO^>NH_\`
M@PN/_BZZ(591K.NOB?YWNV^[OU=WT5DDECR+D5/HDTO).+C9=M)/;KJ];L^=
MO^"C'@7]I;XE:'8:#\#M,_9EU_PKK5E=67BS2OB[8ZK=0WB/M")$EGNCDB93
M()$E3^[@D$@?)_\`P2;_`."$/Q!_X)W_`+5W@SQWK7BOP1K6DZ=\-]2\.ZM:
MZ6;F$VNJWNKO?M%9Q/%M-C&C!%=Y%D9@3Y2@X'Z<_P#"+6W_`#UU'_P87'_Q
M='_"+6W_`#UU'_P87'_Q=8P@HW:W:DK^4DTUZ>]IVT-*DG.'(]M'\TTT_P`/
MF?D-9_\`!O\`?&F#]BWX'?"C7]4^&7Q!\+^`K[Q-=>+_``)>>,M?T#P_XFDO
M[EKC3KHW=C;"XDDM)-C>7)"%Y<*PW;J[;]B?_@A9\4/V8-;_`&26U#7?AQ+8
M?L_^*O&>LZS'IMY?XN;75T"V:6:RP%F9`/WBS2#:.DDIY/ZA_P#"+6W_`#UU
M'_P87'_Q='_"+6W_`#UU'_P87'_Q=;4ZCA5]K'?^OO\`5W=M%HDD5FZK;GUY
MO_)U).W;XGMUU>MV?CSK_P#P;0ZAI/[5?Q*\6K\.?@!\5+#Q;XY3Q;H'B'QA
MXP\4:3JVAPSW0N;VUN-.T]?L=X%+2+`?,BY^:7S%;RD^@/VL?^"4WQ,_:,_X
M*(>%/BWH6D?!SX;7_A/QC8:C%\1_#NN:O:^+M2\/06T:S:5>Z<ENMG=2S2*\
M1GDN"!:E(_+P&#?H-_PBUM_SUU'_`,&%Q_\`%T?\(M;?\]=1_P#!A<?_`!=9
MT?W2IJ'_`"[M;Y<J_**3_F3:E>[%5_>.HY;ST?X_J[KHFDXVLC2KSGXR?`W1
M_P!IS]F[QS\.O$'FC1?'%AJNAWK1?ZR.*X::)F7_`&ANR/<"NT_X1:V_YZZC
M_P"#"X_^+JAX;\-V\VG2$R7_`/Q]7"_+?3KTG<=G]NO?J:BI3C4@Z<]FK/YE
M4ZDJ<U..ZU/R\3_@E]^W;XQ_8YLOV5?$OQ*_9JMO@5#8P^%;CQ5IEAK#^-)M
M"@D'EJ()`+(3-`B1,N["J3^\9AO;T'_@IU_P1&\2_M/^)/@:OPA\0^&_"6@>
M!_#[?#OQ=!K$D@N-5\*/)9DV\#)!*&F"6\H`DV*3+G<O-?HC_P`(M;?\]=1_
M\&%Q_P#%T?\`"+6W_/74?_!A<?\`Q=;.;<_:2UES<S?=V:U[JTI*VWO2[F2@
MDN6.BM9+MJGIYWC%WWO&/8_+;X=?\$"OB#X%^,?[1]W_`,)+X$E\!^*/!?BO
MPO\`!_14FNE_X1-M?EDGN/M"^1MAC61]@\DRDQD\#&T^E:/_`,$A_B`LO[",
M=[K?@[[+^S+X=U31?%Y@O+GS+]KO28;)6T_-OB0!XV),WE84@X)XK[__`.$6
MMO\`GKJ/_@PN/_BZ/^$6MO\`GKJ/_@PN/_BZS@E&G&ENHI+_`,!Y[7_\&2OW
M->>2G*HM&^?_`,G48NW;2*MV/R$_8"_X-N-3_8L^.W@75[WX;?L^>+9?`WC1
M]4@^(-QXO\4)X@N=(3>;?.C!1IRZBKF-O,\TP!5V^4SCSC]#?#O_`()??$CX
M8_!;]J/P_=:%\$/B4OQW^+MWXTMO#_BJ[OO['N=$N;BW:6"YDCM6DM[X11N8
MI(XYEBF$3Y;;BOO7_A%K;_GKJ/\`X,+C_P"+H_X1:V_YZZC_`.#"X_\`BZIM
MN/++72WR;@WIMJZ<;Z:ZWW$G:7-'35/T:4TM=].>5M=-+;'Y9>"O^"%/Q<\,
M_LK>!/`<7B?P1IUEX1_:`T_XHZ9X7'B#5=3TCP;X?MC+_P`2JPO+F`W-Q*=_
MF?O(X8S(\ARI)9NA_;J_X(K?%/\`:=\6?MK7^@Z_X`M(?VC].\'6?AH:A?7<
M;6+Z.]NUR;S9;.$#")O+\HRYR-P3M^EG_"+6W_/74?\`P87'_P`71_PBUM_S
MUU'_`,&%Q_\`%T^9W3[?/[,(ZO=Z4XZO=W?4JG4E3ES1\OPJ.HM/\3?RT/Q?
MUKX.?M)_$'_@K1^VUX)_9_U?X-:=>ZQX/\(^'_$TGCF/4"L=O-H)A$]C):JV
M)D)?`FB9#N!(^7:WU'^W1_P36U#P/_P;I>(_V>_#-RWB;6O`W@>U-M<"(1-J
MEUITT5]*8T);9YK0R!5R2-X7=WK[]_X1:V_YZZC_`.#"X_\`BZ/^$6MO^>NH
M_P#@PN/_`(NLZJE*A[*#M*T?>ZWCS.+7HY-I7_X#HS5/$0K):0M9>2C"+^_D
M1\O:MX@\;_\`!1[_`()U?#6Z^%'B?3O"6E_%O1].D\2>)%O)+?5M%TN:%#>K
MIR)#(AOF_>0*TCQK"6+@LR!3\^>)/^"&NJ>$_P!NS1_&G@NT^%NA?#K0-=\(
M:SI&KRR3IXG\&Z?H5E);3Z-9Q_9G22VO<1M)(UU%C?*6BD8!C^DG_"+6W_/7
M4?\`P87'_P`71_PBUM_SUU'_`,&%Q_\`%UM4FO;NO27*^;F76S33BNEU%JZV
MWDMI23YJ5+EH*A/5*+A\GI)^KLON78^&/^"">E7GCOP9^T!\:)%N$T7XY_%O
M6O$'ASS5Q]HTJ%EM+><9).'\E\9QPH(&"*^Y_!W_`"*.E_\`7G%_Z`*/^$6M
MO^>NH_\`@PN/_BZ/!W_(HZ7_`-><7_H`K/11C".T8QBO2,5%?.RU--7.4WO*
M4I?^!2<OU"Z_Y&ZR_P"O.X_]#@K\^[O]ISQY9?\`!1?3_B\WBC5S\"]1\>2?
M`;^P?M;_`-DK*(3Y>M"+.S[2=;62P,O_`#RVK7WCX]FECF\NVU2TT:]N-,O(
M;2]N8Q)';3-Y6QRA9=X4X;;N7(!&1UKXTO?^")OP"D_8WC\!VUE\.;;XJP:5
M$L?Q;/AJP?Q-_;:,LW]LM/GSVF-ROFLIGR02A?!S2@W&K[1K2-M.KN_>MTOR
M*4=;*\TU=QTJ24J;IK1RZ]%9:7Z_$XRT3^!I[Z^C_`K6[[1_^"@?[6D]E8W6
MLW-CIOA2YM=-AF2)KR8:;=D1HTC+&C.55=S,%Z9(`K`^'7_!52\OOB]\3_A]
MXK\/?#$>,OAQX+O/&,MIX'^(_P#PE,49LW,=QI]^7L+26PNE9H=JM#(&61SD
M&,J>IUW]C/3O&D?Q[_MKXF0F?X]>%M/\-W]SID$=E-I3V^GSV<ES$3*X)D,Y
M<(0-F-N7SFN#^&7_``3MU+0=4DN/$?Q:^',MK:?"_4?A;H^D^$O`Z>'=*TJT
MNG@=;I8#J%RQE5HFW(KI&P,>Q8BKF7&K&JO:*G_+*WG+EGRV_P"WU#XE9J72
MSNZ3ARP<M^97\H\\+W_[=<]M5;JW&W6?L\?\%$?&OQ/^)?PET_QG\(K7P+X<
M^..A7>L>$[Z'Q<FK:A&UO;Q77D7]JEM'';F2W=Y$:&XN!A`KB-FVB'_@J?>^
M-?BWIW@CX%?#/QAK?@/QG\4+B\U";Q!HMVUKJ&B:9ID'VF26.13E1)>-I]LW
M]Z.YD'>NI\/?LI:1H.M?LZ7?_"=Z=+_PH'2+C2MGV=%_M[S=+33_`#,^<?(Q
ML\S'[S.=N1]ZJ'Q+_8)^%7[0_P"U9K7Q(^+,/P_^*>G-X?LM`\-^&_$FAV>H
M67AE8I9YKJXC^T-(K37+RQAG6.,A+>-<MUKIQ<(RJN%'X$W9ZWLKN+^_E5K+
M3?K?'!3J1I<];X[+32UVDI?=JUY[=#PCXY_M9ZW^T+_P3Y_9;^)UGH%SJ?C*
M]^)OAF+4]!LKF*UD.L07$]K?60DF=40+=13QDNW"@YST/I'C'_@JGKWP4\!_
M'(?$+X5P:9X^^"%EI6LSZ%H/BC^U;'Q'IFHR&*WN+.\EM+9]_F17,;1RVZ8>
M%?F*N&&+<_\`!+;3/"O@'6?"GP_^*^A_#_PS%\3K/XF^#]-T_P`.VCVW@Z>&
M)3)8Q1><(I+:2Z!FVA(]@DD11R'6_P"*O^"=EQ\8/!WQKN/'WQ@\-:O\0?C1
M9Z1I$VL:1X>_LW2M"T[3)/-M[:WL9+Z>4EI9+F21WNB6:88"J@4D7S1JW]US
MDY6[.5.DK1WUC*,HZZ<J;6KB*47&4>77EBHK7?EJ5'[U^\))Z:\S5]$S7_:(
M_;Z^+O[,?P./CGQG\+?@SX,L(+5[N=/%?QG72$>1E=[?3H9O[+DCEU%ECD#Q
M$K"K&,17%P#(T=[5_P#@HWXJ\?\`C[P'X=^$?PIM_&MUX_\`AW#\2+6ZU[Q4
MGA^ST^RD=5$-R4MKJ42GS(U7RHI07?#&-`9*B_::_8JN_C#^TOJ'Q*\)?%'P
M3X6U+7O!1\":@VL^%8]?O--LFEGD>72KC[9`+*>07#!_,CN(I#%`6B(CVMO?
MLY?L>Z1^S_\`$+X?:]_PG^G:M_P@OPJM?AEY'V5(/MWD302_;MWG-LW>3CRL
M-C=GS#CG**G*/O::O[N2K;RUFJ3Z?%9Z*3-*UXO]WKHOOYJ5_NC[5?*_6*7`
M?`;_`(*R>*/BW:_!7Q-K/P5N_"'PY^.%^VA:1J,_B:.\UJRU);*XN2L^GQ6Y
MC%L[6ES''*+HS'8K/;Q;MJ^C_P#!/?\`;AU[]N_P?-XPC\+>"M'\$W!ECLI=
M,\:-J^M6%S'(`;+5;'[%"EA=B-E9X5GGV-E2?NLW->%OV#--\*_`/X"^"H?B
M;I_G?`[Q/_PDD>HBPC!U9OLVHP"+RC.1#@W^[<6D'[G&WYLK<_9W_9'O?A_^
MUUK/QI\<_$'X9Z[XPU;PXOAN=_"'A%O"R:M&)8G%SJ1DU&\:]N(U@BCA;,8A
M0RJ%(<;=J;3J2YU97E;TY4XOS?->/2VCU5[E1<L%R.[M&_KS--=%;EM+KU2M
M?3ZHHK-_X3'2/^@IIW_@2G^-'_"8Z1_T%-._\"4_QJ!FE16;_P`)CI'_`$%-
M._\``E/\:/\`A,=(_P"@IIW_`($I_C0!I45F_P#"8Z1_T%-._P#`E/\`&C_A
M,=(_Z"FG?^!*?XT`:5%9O_"8Z1_T%-._\"4_QH_X3'2/^@IIW_@2G^-`!HG_
M`"$]8_Z_%_\`2>&M*N>T?Q7I<6HZJ6U*P4272LA-P@W#R(AD<\\@C\#5_P#X
M3'2/^@IIW_@2G^-`&E16;_PF.D?]!33O_`E/\:/^$QTC_H*:=_X$I_C0!\B_
M\%L9_B!X2_99'B[PC\3?$7@6P\/:WH*7-AH,:6UUK,EQKVG6Y6>].Z5+80R2
M@Q0")G9AOE:/=$_UKX_\>Z/\*_`VL>)?$.HVND:#H%E+J&HWUR^R&TMXD+R2
M,>P55)_"OGO_`(*,?LY>)_VV_A(/`WAOXK?#[P+X>O+FROM2;4_"TNN7L\]G
M?6][!Y,D>IVB1)OMU5U:.0LK'#(>:S_$WPO\9?M)>.]6\!_&'7/"/B+X*W_@
M&?1?$MKIUO'I%GXRU6[N@?-MHUO+B_LDM;6(QMNNOG>Z#)_J\K"4_8RA#23E
M)J^WP*UWKHW&R\VM+7M=X*:E/5:7MVNEIYZW?HWZ_*ND?'O]HM/VFOC/XYL[
M_P`7R^(O%_P`O_'7@7X:7)EN+3PQ(E\8=-B^P*")-1DB19)AM9C+.T`+*BEF
M?"C]IJWTWXQ?#[2/V>_VB-=^*&M_%7X>Z_'XC'BSQ'=>(++1/$-MIQO;"_FC
MGS'H]SYQG2;3T%NGEXS;+Y`(]+^`_P#P0+_9S_8]_:_M?C%\'(?#_@S5]!\-
M76G>'["]O]2U>VTW6)A+'_:<IEU(-.GD2M"UKE%()99$?##T?XC?L$WO[59\
M4S?'+XP>'?$\^J^#-3\$Z)!X/T'_`(1NR\/PZDH6]O1'<7U_)->2*D,8=I1&
MD<;*(LR.Q*D?]GY*5T^6:\U[U7E5];MJ4-7:[49-\T;15-_[1SU+6YHMZ76U
M+F]WLG%VUNKRBDTTY>&?\$N/CM-\2_VJ_A]8:#XX^*S7D_P[N-9^(^F^/_&H
MUFV\37SW"16U]H<37$T,UN)DNW:[T@)IWE2P1Y,G[J+VW_@MC/\`$#PE^RR/
M%WA'XF^(O`MAX>UO04N;#08TMKK69+C7M.MRL]Z=TJ6PADE!B@$3.S#?*T>Z
M)^$^/_[(7QWU;2/`NOV7QF^'?B#QY\,;*;1O!%QX<\$VN@+H]S?Q0V,^KZ@U
M_J5\MQ#;6@FD^RV\<?F.5^5MJ!?:?^"B/[-_BG]M?X.Q^!/#WQ9^'W@K0;J>
MQO=4DU/PK+K=[<W%G?6][`89(]3M$B0R6ZAU:.0LK':R'FNFJX^TIRAM&=]-
M%;G<MNW*[)*Z2LKW3MST$U&U3=I7ZO9+?N^^C>MTDUS<3_P5[^-7B_6OA5XI
M^%7PN\2:OX3\40^#M2\:>*/$VCW!@O?"NCVD,CPI%(O,=U?7$?D1-P5BBO)%
M.Z)0WRGH?[>5I\3-:TZR^*-Y^U7KO@[X>>$_"NDSK\+;'Q''%:7=[H5MJ6H>
M(M;U72VCFD6)9HHQ!Y[L!YLIMYBX=/I/]K__`((K?`/_`(*%Z;<>)?C7:>$?
M$GQJG\//HB>,M&N=4T:RM77SOLTT>F+J;H1$90=LDLA?;@MM(5>?^!7_``1]
M3]B_X6ZYX$^!'QF\+?#[P9XZ\.VVE>+;._\`#4FM75QJ"PR076K:?</J49M+
MB>.3[DRW44;1Q[4VJ5/'&,XQJIV;=K=FTZEG?=+E<4TEI)J4=;RCTR<93IR6
MB2:?=7]FWY-W4K:V<;QET4_NWX3^)-)\8_"WPWJV@:K+KVAZGI=M=Z=J<LAD
M?4+=XE:.=F(!)="&)(!)/(%7O"W_`"#)?^ORZ_\`2B2N9^"WA7PA\`_@_P"%
M?`WA[4+.'0?!VD6NBZ<DMW&SK;V\*PQAB,`MM09.!SVK7\-^*]+@TZ0/J5@A
M-U<,`UP@X,[D'KW!!_&NS$.+JR=/57=K[V\SGH<RIQ4]'97MM?R.AHK-_P"$
MQTC_`*"FG?\`@2G^-'_"8Z1_T%-._P#`E/\`&L34TJ*S?^$QTC_H*:=_X$I_
MC1_PF.D?]!33O_`E/\:`/D7XKS_$#P3_`,%B?@?#>_$WQ%?^$/&NB>+7C\(V
ML:6.BV4=I;Z;Y+2(F9+JYWRRL99I"J[E$44/SF3Y1^./[95Q\/=(^)GCW7_C
M5XR\/?M+_#WXG36^E_#9];O;;3IO#L6I+!!;_P!@`"&[L+G2Y?M!U,PNRR2A
MQ=)Y05?L3XX_LQ_$KXI?MG>"/BOI7QK^$FBV?PYAU2RT/1KOP#=7TK6VHI;)
M<K<W*ZY$)9!]F7RW2*)5W'<CUM?&7]GOQE^TIXNMM+\=_&#X?R_"2U\0V^N/
MX9T+PE)I^J:K%:SBXM+*\U&;4[B.2$3)`\WDVD+3>5M!C1V4F']WV3?2Z?E^
M\YK];OETZW3E%NS=RMK3G&.[U]?=DK6TTU3MIJHM;:'_``4>\;Z_+K/P3^&6
MA>(]9\(P_&3QQ_PC^M:MH]P+74H=-@TR_OYX;:XR'MY9OLB1>=&1*BNYC*OM
M8>;_``4^&FK>)_VBOCM^SC??$_XN)X'\%R>&_%VD7T?BNX?Q!'9:B+QKC2)-
M8EWWYMO/LF(=9UN5CDV+<!?E'<?%/]DGQ+\7/@UX!AU?X[:7>?%WX8^,'\7Z
M!XUF\.6JVNXRW*"SN=-AGC66`Z?=/:,4GBD;"RAU?BN%^*?_``3O\8?%+X<?
M$/S_`-H7PY9?$#XMZQIDOB[5K;PQ)%H]YH=A&\<>A6]DFJ+=6UM*';SI!?M*
M_G7`#()`$F-^22MJWUV:_=VOY)W=NRE:_/:5SLY*ST2MIT:E-MK_`!1:BGH[
MN+=N6ZZ?_@CIXK\2>*/A5\3%N/%GBCQ[\-M+^(&I:?\`#?Q)XBOVU+4-8T6-
M8@TGVUOWEW`MX;N.&>0LS1QK\[J%-?7]>2?LSZ1XD^%7@[^Q?&/C/X3:M8Z=
M%!::):^#O"DOA>TTNVC38(3#+J5Z&4`(%V&,(%QM.1CTG_A,=(_Z"FG?^!*?
MXUM.VB3O915^KLDKOS>[\VS&'5M6NV[=%=MV7DMEY6T1I45F_P#"8Z1_T%-.
M_P#`E/\`&C_A,=(_Z"FG?^!*?XUF6:59O@[_`)%'2_\`KSB_]`%'_"8Z1_T%
M-._\"4_QH\'?\BCI?_7G%_Z`*`(=8TVWU3Q181W-O#<(+6X8+*@<`[X.<'ZF
MN*\3?'7X-^"OC!IGP]UGQC\,M)\?:TB2:=X9O=6L8-8OU<L$:*T=Q-(&*/@J
MISL;'0UVFNR30ZW$UL@DN%T^Z,2GHS[H<#\\5\:_\$=OV??AW\8O^";WA/Q-
MXH\)>$/%_B?XCWDOBGQM>ZKI,%[<:EX@CO[AW:Y,JLS36D^^*,.<P^4%7;BB
M&LG?96O\V]ODF[][*WO71+2-UN_NV_X;3M=WTL_M'_A#](_Z!>G?^`R?X4?\
M(?I'_0+T[_P&3_"O@+XN_MG^.O#'[2OAC6_`WCOXJ>./!=Q\5[3P+XB@E\+:
M%I_@/3%GO7T^6PAFGBBUFXNH&*,;FVFN;8SQNK&-288\+XV_M%?M#6/PT^.W
MQ0\._&.'3(_A3\6(_"F@^%I_">GSZ3>V!O["&5-1D*"[GPEX?+^S3VK#R_G>
M0MN6:4O:)./6_P`K.FO_`'+!IJZ:NUI:Y6M2FX2WNEZM^T_^523O:SLG9WM^
MC7_"'Z1_T"]._P#`9/\`"C_A#](_Z!>G?^`R?X5^=/[3W[87QR_81U_XP>#1
MX\NOBQK">%/"6J>%=1U?1-*M;K2M1UG7)]&F1(H%L[:2%"BS0I<29#`+).5)
M8>D?"3XF?M'?#SPU\9I_&.F_%2+PGI'@2XUOPYXA^(:>#?[9L]9ABG\RW6/P
M_,]O+;%!#*AF@#*R2JSNK(!$ZT8498C[,5)W[\E^9*]M5;K9.ZLW<T5&3J*E
M]IN*_P#`N6S]'S+TL[VL?9W_``A^D?\`0+T[_P`!D_PH_P"$/TC_`*!>G?\`
M@,G^%?"%K\7_`(YZ+^RO^SY]O^,;W?Q!_::UW1[.YUO_`(1W3(++P5:RZ7<Z
MG<+I=MY!WSM%;B)6O6N5\QRX15Q$,SX^_M7?&7]E+PM^T[X+B^)1\;:W\-?#
MWAOQ7X4\5ZQHNG_VE8+J=Y-:RV5_#:0V]I-M:T=XRD,3F.X()W*KUTU:<J<Y
MP>\&UZN*3:7HGULM'KM?FA5C*E&M]F24O2,I.*;]6K65WJKK>WZ!?\(?I'_0
M+T[_`,!D_P`*\V\>_M-?`GX5?%*Q\#^*/B#\)?#?C74VA6S\/ZIKNGV>J79F
M;9"([:1UE<R-\JX4[CP,UYC\`?$WQ,^$_P"WY??"OQC\3M2^*&C:S\/(_%\4
M^IZ)IVFRZ1?1:A]EGCMOL4,6;602H5CG\Z6/R@#-)N)KP']J_P"'GQ,^-/[6
M'[7_`((\`_#SX6>/[?Q3\.?#5G=P^-/$$UC';SF'5OL[16JV%Q'=,'^<"2:V
M"O&GSC.Y>:K5Y**KQU7O.VU^5R35^FL6KO3[S:FE*HZ4G:SBF^W-RN_GI).Q
M^BO_``A^D?\`0+T[_P`!D_PKE=8^(7PXT,^+DFU#PJ]SX"LAJ/B.SM_*N+S1
M;=HGF1YX(PTJ;XT=D!7+A3M!KX#/[7%[XS_8T^&\/P1^)7QZ&N:/\);/6++P
M]X:\*^'KN_CBCBGMQJ.N7VLQ262IYMF4%O!<PS2&.X:/SP08NH^`?[2&N_M*
M_"#]IC7=;MM%M)-5^$'AG7VBL--@MRMQ?^&KF><-,J^=,H;`03.^Q1M4@9R\
MRF\/1Q%2D[^ROOU^.S]&X/9Z;;IAA%[2M0HU59U+?+X&T[];35M//:U_NOP6
M?"WQ$\':3X@T:UTN^T?7;*'4+"Y2T55N()4$D;@,H(#*P/(!YZ5I_P#"'Z1_
MT"]._P#`9/\`"OS4\/\`[1_QB\1R_"#X2_#:+XJVNC>&?@9X:\3:A<_#NV\(
MRZM<7E[&]O`L[>(YU@6TC2S<[;>)I7>4;I(U4"3V,?M<_%O]G2Y_9Z\7?'J;
M3_!'ASQAH>I>&_'^ER)9F#1_$,4)N[*^6:!I@J3Q6=Y&8EN'0-/`H#-S75BH
MPI5)J]HJ4HIO^ZYK\X<OK*/1MKGPTYU*4&U>3C&32Z7C&7_I,N;T3ZV3^R/^
M$/TC_H%Z=_X#)_A1_P`(?I'_`$"]._\``9/\*\H_X)]>//&WQ<_90\-^-?'\
MUQ_;GCAKKQ';V4]G':OHVG7=Q)/I]BR(JG=#9O;HQ?+EU<L2:]IK.<90ERRT
M:W79]O5;&R<9*\=5T?==UY/=&;_PA^D?]`O3O_`9/\*/^$/TC_H%Z=_X#)_A
M6E14C,W_`(0_2/\`H%Z=_P"`R?X4?\(?I'_0+T[_`,!D_P`*TJ*`.>T?PKI<
MNHZJ&TVP81W2J@-NAVCR(C@<<<DG\35__A#](_Z!>G?^`R?X4:)_R$]8_P"O
MQ?\`TGAK2H`S?^$/TC_H%Z=_X#)_A1_PA^D?]`O3O_`9/\*TJ*`,W_A#](_Z
M!>G?^`R?X4?\(?I'_0+T[_P&3_"M*O(_V_?'NO?"S]A?XR>)?"QF7Q)H'@G6
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MTG6[*R2UL_&-[,Z`M;>4H\W3=.$(@23!0R-,L65C+-MBHSHRE3C[SC&7WQ3>
MJZ7DHPMWE>]EKCAYPJI3>B;C_P"`R:7S:7-+_MQK7=?5?P4_:F^`G[2OB*YT
MCX<_$;X0^/\`5K*W-W<67AO7].U6X@A#*IE>."1V5-S*-Q&,L!GFMKXV?%WX
M3?LU:!::K\1O$_P[\`:7?W'V.UO/$FI6>E6]S/M9_*1YV16?:K':#G"DXXKX
MF_X)C?#/7_\`@G1\9/AS\'OB;\$/V:_#7C;Q_P"'M1MM-\=?"*W>WFU6#2H[
M1GAU2*>SAG+N'\QIQ-(CRX!CC)4GV#P]X<TCXG?\%FOBG;^)]-L=7'ASX1:#
M9Z/#?6ZS1P6NH7^K#4`BN2H$WV>V23"_.L:*QP`*TJQ2E%4G=/FU_P`*D_5?
M#9WVUEJDKQ2DW3E4JJUN73_$XQWVTYK^=K:.]O=OC%\9_A#^SOX7L-;^('BO
MX;^!=%U69;:RO_$.IV6F6MY*4+B..2=E5V**S`*2<`GH*C^(GQP^#OP@\1>&
M]'\6>+_AIX7U;QDXBT"RU?5;&RN-<<LB!;6.5E:<EI(QB,-RZCN*_.#_`((6
M^'[#XE_'[Q%IGBJQL=<T[P-\-O\`A'_!Z7T:W4$&A3^*O$MNZP[B4\N6VL[&
M-MJX:.&-3A5"UPG_``11^''@_P"+'[!/[:J>+HM/U^RT[6=8\&6MUJ:Q3+9^
M&=/L=^FVT<CY5;:'?))'@!%;YQD\CGJU53A.KNHQE/\`[=C+DM_B;<7?9>\K
M>ZN;HITG.JJ/7FC"_G**E=?W4N9>?NO12=OV4_X0_2/^@7IW_@,G^%4/#?A7
M2Y].D+Z;8.1=7"@M;H>!.X`Z=@`/PKSK_@G/X@USQ9_P3]^"&I^)9)Y?$.H>
M`M$N=2DG8M))</80M(S$DDL6))))))KU3PM_R#)?^ORZ_P#2B2NO$T71K3HW
MORMK[G8Y,/5]K2C5M;F2?WA_PA^D?]`O3O\`P&3_``H_X0_2/^@7IW_@,G^%
M:5%8&YF_\(?I'_0+T[_P&3_"C_A#](_Z!>G?^`R?X5I44`>6?'+]H/X*?LPO
MIJ_$KQO\+?AXVL"0V`\3:S8:2;X1[?,\K[0Z;]N]-VW.-RYZBM3X,_$WX6_M
M'>%)->^'GB#P!X\T.*X:T?4?#M_::I:),H5FB,L#.@<!E)7.0&''-<#_`,%&
M?"_P7T[]G#Q!\1/C/\,O`WQ+TSX;:7=ZE8VGB#P_9ZM+YK*H%O:BXC<)+<2+
M#$`N-[&,<X%8G_!+C]C/_ACO]@[0/"3:5I7A;Q;XBBN/$7B2+2+.*TM[+5[\
MF:>.**,!%2W+K!&%`4);H``!BI4FH5)-7<5I;JW>RU\D[]GR]QR2O!)[O6_9
M;O3S<=]];;'J'AGXS_"'QI\7=6^'VC^*_AOJWCW0(C/JGAJRU.RGU?38P4!>
M:U5C-&H,D>2R@?O$_O"F^"OC;\'OB3\4-:\#^'?%WPUU_P`:>&PYU?P_INJV
M5UJFE!'"/]HMD8RQ;795.]1@L`>37YS^'_A-X]_9U\%_L:?#'Q!\&O\`A%O&
M'PW^*5I8OXYM-=TVYM/$WFQWHU*YLO*8W\OVZV\ZXNEN[>UQAMS2LB[O8/CI
MX$O/A5_P4#_9AN_$_P`.?`WP]^&GAGQ7K6@>!KSP+>B\N;O4-1LKCR(-0@:V
MLQI]K-$ES,\=M]L#7$<6]T5=[ZP2E**O?WG#U?+%IJ^UW)147[S?8FK>+DK;
M1YOE>::TWTA=R7NJ_6UW]X?\(?I'_0+T[_P&3_"C_A#](_Z!>G?^`R?X5I45
M`S-_X0_2/^@7IW_@,G^%'_"'Z1_T"]._\!D_PK2HH`S?^$/TC_H%Z=_X#)_A
M1X._Y%'2_P#KSB_]`%:59O@[_D4=+_Z\XO\`T`4`0ZQJ":=XHL'D69@;6X7$
M4+RG[\'903^-?/\`JG_!-7X!:MXYUW76\'>*+;_A*=;3Q'KFC6>M^(+/PYK>
MHJ8F^TW6CQ3KIUP[-#$SF2W;S&0,^XY-?0UU_P`C=9?]>=Q_Z'!7AW[.O[>E
M[^TYJEK-X>^"7Q;@\'W6J7VE+XMOKGPY'I:M9W$UM+*85U9K[R_.@=1BU+'(
M.T`Y!'XTX[]_FNO36WW7Z"E\#4MNWR?3KI<IW/\`P3M^!=W\1E\3R>$_%+7L
M7B1/&,%C_;6O_P!C66LK.)_[0@TWS_L4-PT@9GDCA5G\V8,6$L@;K]6_9@^%
MVN>`O%_ABZ\+ZC+H?CS7_P#A)]=MO^)DOV[4?-@E\_>"'3Y[:$[(RJ?)C;@L
M#V_QI^)TGP<^&>I>(XO#/BGQC)IWE[='\.6B76IWF^5(\11N\:MMW[FRXPJL
M>U=0IW*.,>Q[41M%*,=$M/E[OX>['_P&/9#E[TN:6KW^>NO_`)-+_P`"?=GD
M?Q3_`&9/A7\;M9\5W_BSP?+KUQXW\-1>$-;%U:WK17VEQ333QP&/[B%9;B5Q
M(BK("P._Y5Q2^'G[*GP]^&GAOQ'I%J?BAK.G>*M/;2M0@\2^+_$WB,&V961X
MX3J%S.;?<KD,82A.%R3M7%S]J']KJ#]F?Q!X%T2'P-XV^(/B'XB:A<Z;I&E>
M&FTU)F>WM9+J5I'O[RTA51%$Y_UA)(P!S6/\)/V_?#WQS^&.B>)/#'@[XDZA
M/>^*8_!^MZ&^A_9]6\&7Y`,_]J0RR*(8K<%3))&TBX=#&9`P)E1C).FEY->4
MGV[.4]7M>6NK'*<DU.3VUOZ+\[0TZVCIHC:^('[-7PR^*'P&T;X::UX:U.X\
M(>'%L!I%O#_:5M=Z2]CL-G-;7D16ZAGB\M-LT<JR#!^;DYY[1?V&/@SHOPO\
M8^$3X7\1ZGIGQ"G@N/$UUJ^I:WJNK:X\`C$'VC4;F62]D6(1(J*9MJ*"%`!(
M.)XQ_P""C4'A']G7XT?$!O"4TZ?!SQ?<>%)K$:D%.J>3-:H9UD\K]WE;H-L*
MMRA&[G</;O"GQ/D\4_$WQ7X;/ACQ3ID?A86>W6;ZT2/3-;-Q$9"+.02%I?*Q
MMDW(H5F`&[G%*IS?O+_Q$I7_`)E)*2;]59ZZZ*^QG:*_=)?`W&W9IN+2]'=:
M:?(H-X#\(O\`&=/B$=)U'_A+X]%;PZM_]GO>+!IUN##Y>/+_`-:JMNV[N,;L
M<5YE\;OV"O@_^T+X_P!?\3>(].^(\>K>*]-AT?6_[$\7>)]!MM8M(5D6.&YM
MK&ZA@F4+-*OSH<B1@<@U]#44K*RC;17MY7;;^]MM^;?<M-IN2W=OPLE]UE;T
M78^=_B!_P3[^!?Q'NM->Z\%:OI$&F:%'X76R\.WFL>'["\TB,L4TZZM;"2&"
M[M%WR`07"21A99%VX=@>B^'W[*/PH^%GACQ!H^@^%=1L=-\4Z!8^&-4ASJ4O
MVK3K*T:SMH-SLS+LMW9-ZD.V<LQ;FMK]L3]HU/V2?V;_`!-\0Y=(?78O#<<$
MCV*7/V=IUDN(H3A]K8(\S=]WG;CC.1Z91*THRIRU3W71WOOWWE][[L4=)*4=
MX[>6RT[:12^2['@?CK]A_P"$/C^+P<9M#\9Z+>>`M$'AO0]2\-Z]X@\/:G:Z
M8!$/L;WEA/!<309@B;9+(Z[D#8W9-<A_P4!_8IL/VN?V+=.^">FP&;P_-KFB
M-J5QXD.IZA=QZ9:7\-S<M'<2I-//>211-&'F?+&9B\G7/U715<S<E)_S*7JU
M+FN^^N_JPBN56CII9>2M;3M;I\C)M->L;"TB@AM[^*&%!'&BZ=.%10,``;.@
M%2?\)3;?\\M1_P#!?<?_`!%:5%%[ZL$DE9&;_P`)3;?\\M1_\%]Q_P#$4?\`
M"4VW_/+4?_!?<?\`Q%:5%(9F_P#"4VW_`#RU'_P7W'_Q%'_"4VW_`#RU'_P7
MW'_Q%:5%`'/:/XDMX]1U4F._^>Z5ABQG./W$0Y^3CIT/L>XJ_P#\)3;?\\M1
M_P#!?<?_`!%&B?\`(3UC_K\7_P!)X:TJ`,W_`(2FV_YY:C_X+[C_`.(H_P"$
MIMO^>6H_^"^X_P#B*TJ*`,W_`(2FV_YY:C_X+[C_`.(J'4M7T[6-.GM+NSN[
MJUNHVAFAETR=XYD8$,K*4P002"#US6Q12:35GL";3NCYG^'_`/P36^`OPRTV
MXL]+\)^+I+5]`N_"UI%J/B#Q%J2Z%IET@CN+731<W$G]FHZ!5/V/R3M1`"`J
MX?\`#G_@G3\&_A1X1_X1[18?C#%X;71I/#\6BW7Q#\8WNF6UB\!@\F*UGOGA
MBV1G$;(BM$0K1E&4$?2M<_\`%;QZ?A7\,?$/B8:)K_B4^']-N-1_LG0K47>I
MZGY4;2>1:PEE$D[[=J)N&YB!GFB4E&+;VMKZ:O\`67WONQQC*4E%;WT]=-?7
M1?<NQ\N_&/\`X)4?"KXE>!/$6DV4GCB/4O&-C!X?UG7?$VJ^(/&&JC0OM*3W
M>G64^IW4SV0N`I5GB.`2K%'9$V^G_'G]C;X4?M(^,M)\1^)=%\86WB/1=+GT
M.VU?P]K.N^&]0;3YG1Y+.6XTZ:WDF@+QHWE2LR!@2`"Q)\A_9E_X+6:%^TC^
MU!X9^$]U^S_^U)\+_$/BRTO;ZPN_'W@:/1+!X;2,/,Y<W+N5!:-,JA`>:,$C
M<*]@_;1_X*$?#_\`85T?2YO%P\1:I?ZS<VT%MIF@Z6]_=)'->068NIR-L5M;
M+-<Q*99Y(U+,$0O(RHU.%U",M>9^[ZN\;+\5;SEW=Y4[2<D]5O\`A_DONBNB
M,7QQ_P`$]?@9XYB\*@>#_$'AA_!6A2>&-'G\(:GKGA2XMM*=HV:P:73)K=Y;
M;=$C>5*S(&RP`+,3E>(?^"7G[.GB"\WK\/=6T6TET>R\/WVEZ!J&MZ'I.M:?
M9[Q;6M_8V<T5K?Q(LCIMNHI048HV4^6O2OVU/VQ_"/[!O[/&M?$GQJFL76DZ
M/LCCL-(M1=:EJD[G"6]M"64/(W)P650JLS,JJ2/,OB9_P58\+_"OX>:;XXO_
M`(;?&*?X<2:/I.NZSXO@T*W_`+*\-6NHJCQ//ON5GN1$DBM.UA%=)",[V!!%
M*,N=NVNJO_BE=J[[N\GKW_O:NW*HP\G9?W4XWLNR?+HNR[:?1EAK6GZ580VM
MK:7EM;6T:Q0PQ:9.D<2*,*JJ$P````!TQ57PWXDMX=.D!CO_`/CZN&^6QG;K
M.Y[)[].W0UNVEW'?VD4\+K+#,@DC=3E74C((/H15'PM_R#)?^ORZ_P#2B2G*
M]_>W)C:RY=@_X2FV_P">6H_^"^X_^(H_X2FV_P">6H_^"^X_^(K2HI%&;_PE
M-M_SRU'_`,%]Q_\`$4?\)3;?\\M1_P#!?<?_`!%:5%`'GWQI^%W@G]HCP[IN
MD>,]#OM<TO2=7LM=M[62VO8XOMEG,L]M(ZH%$JI*JOY<FY"57*G`J/X@_"7P
M/\5/B7X'\8:]HFI7WB+X;W5U>^'+SR;Z+^SIKFV>UG;8FU)-T+LN)%8#.0`0
M#6=^TK^UQHW[-VI^%M$_L'Q1XV\:>.+B6W\/>%O#<$$FI:H(%5[F8-<S06T,
M,*.K22SSQH-R*"7=$;0_9?\`VGO#O[6/PL_X2CP_!K&F?9;VXTK5M(UFU^R:
MGH&H6[;+BRNXLL$FC;KM9D8%61W1E8I6<7;9.[]=$W_Z2F^GNI]`E=-<W56^
M3YM/G[VG7WGW./\`AM^QA\*OA?\`$VV\96^G>/\`Q!XFL+6YLK"^\6^)?$7B
MI]*BN-HN!:+J=Q<+;&4(JNT(0LJA22O%9?PM_P""?GP6^$'Q!\->)]*T+QU>
MZGX*CEB\.1Z[XE\1Z]8^'%DC$3?8;2^N9K>U/E#RP88T*IE%(4D5F_#_`/X*
ML^`OB#XZ\-VT7AOQ_IO@;QQJD^A^%?B%?Z=;Q>&/$M]$#^X@<3FZC$A280RW
M%M%#.86\J23*;W_"O_@JAX&^*_Q!\(:?!X7^(>D>$/B1>W.F>"O'6IZ9!#X<
M\6W<*L_D6[+.UU$94CG>![JW@CN%@<Q/)E-]0NW'E^7YV\F^:Z6[YKI:A4NN
M;G]7^-WYI<KN]E9W>C/H?_A*;;_GEJ/_`(+[C_XBC_A*;;_GEJ/_`(+[C_XB
MM*BD!F_\)3;?\\M1_P#!?<?_`!%'_"4VW_/+4?\`P7W'_P`16E10!F_\)3;?
M\\M1_P#!?<?_`!%'@[_D4=+_`.O.+_T`5I5F^#O^11TO_KSB_P#0!0`77_(W
M67_7G<?^AP5^=_\`P1V^,_@/2M.T_P`/W'[5-K-XIG\5^*;:/X1SZUX87RI6
MUG4&55MULUU8OM_?`-<G.<X*86OT*UB2XC\46!MHH9G^RW&1+*8P!O@[A6]N
MU3?:M7_Y\=._\#G_`/C5$=)\W3_AOZV%)7CR^=_S_P`^Y^4'A;]G7P9X'_X(
M*>//']EH-HWCGQ:+N/5/$%R#<ZE/;IXE*16BSR$O':QK%'LMT*Q*06"[F9CZ
M9\0=4_9YU7_@H;\=;/\`:??PTOC&SU#P^_PRA\2.ZZDND&RA,+^&P#Y_VAM4
M2]\PZ?\`Z095C#=(Q7Z)_:M7_P"?'3O_``.?_P"-4?:M7_Y\=._\#G_^-4J4
M>2<9=(JR\M4[KL^E^SDNHK7C-/>5K^?KW7EIJD[Z6/B__@KGXIT7P9\>_P!E
MW4/$'Q8_X4EI4/BO61+XO^V:5:?V<3H5X%7S-4@GM!YA(C_>1DG?\N&P1\V?
M!S6$NO#%M::%K\OQ'\`K^U9H.H:!\2IK=$F\?27+>;?3--$J6UU]FNO,M%N+
M6-(&2W1$4>6:_6/[5J__`#XZ=_X'/_\`&J/M6K_\^.G?^!S_`/QJG27)557L
MXOY1G3G;Y^SMIWO9V"LO:4I4^\9+[XSC?IMS]?-=;K\UOC3_`,HX?VW_`/LK
MVI?^E&DUZOXE_P"2[_M\_P#8BZ)_Z8]0K[2^U:O_`,^.G?\`@<__`,:H^U:O
M_P`^.G?^!S__`!JN7$X;VN%6&O;]W&%_\,%"]O/>WROU-,/+V6)^L[^^YV]9
M.5OQM?\``_.#]FO]GKP9^SG\4?V(_$W@O0(]!\2?$+P-JL7BO5[,O+J?BE6T
M&"]'VV>1FDO&6X1'C\]G\O:%3:GRU\<?LBW?P0_:6U?P=/XVUSX-_!KQYHWP
M]\17^H^.KFVU"S\=^+KS4(F@;69#J.DVL+W-I+#>3R7%I?WK0R02JDJQ>8]?
MNUXBTF[\6>'[[2[_`$S3I[#4K>2UN8O[0E7S(I%*NN5B!&02,@@U\Z_";_@F
ME'\-]2^'<>K>._'OCSPQ\(Y(Y_!?AGQ!J.F#3?#\T-L]K;3*]II=O=7#PV\D
MD:&ZGF^^78-(%D'97Y:^(J2FK0E>R_E3Y[I-6:^)-)64G?F<;)F6$C+#4(P@
M[R5M>[BHI73NFG9IWUBME+5'Q#IOBCP9;?\`!,+]ICP5X+\,?`LV?@R#0[>;
MQW\'A"GA?QOOO1Y3R11;E@U**%8S<1>=<;?/B/G,K*JW/VWOA[X<^*?[>_Q]
MTSXR_%S]G[X2W4]OI,'P_P!0^*OAE[O4=,TMM/3%_P"&[^36;&.TF34!=M(;
M>-IEFCC:1MODJ/UH^U:O_P`^.G?^!S__`!JC[5J__/CIW_@<_P#\:I5KU:OM
M9;VM\^ZM:S[6T2;275502I1E".SM;Y.]G>]UZZWL[]'^=7[=OCCQ=_P3_P#B
MCH'C;PM->^+?$G[17@:T^%<>IPVK0VMUXRA'_$EU&9%WF)94N;XO\S86WB7/
M&ZOO']FSX':9^S-^S[X*^'NC9.F>"M$M-&MW/WIA!$L9D;U9RI9CW+$U@?&;
M]G*'X[?$/X;^(==24GX7ZY)XBTS3X-3"V5U?-:36L<MPIMBS^4EQ*T85DPY!
M.[`%>A_:M7_Y\=._\#G_`/C55S^[*^[E^%W)?-2G/:RY>56T)Y$G&VR7XZ1?
MRY80M?6_,^II45F_:M7_`.?'3O\`P.?_`.-4?:M7_P"?'3O_``.?_P"-5!9I
M45F_:M7_`.?'3O\`P.?_`.-4?:M7_P"?'3O_``.?_P"-4`:5%9OVK5_^?'3O
M_`Y__C5'VK5_^?'3O_`Y_P#XU0`:)_R$]8_Z_%_])X:TJY[1[G5!J.J[;.P)
M-TN\&\<;3Y$73]USQCTZGTR;_P!JU?\`Y\=._P#`Y_\`XU0!I45F_:M7_P"?
M'3O_``.?_P"-4?:M7_Y\=._\#G_^-4`:5%9OVK5_^?'3O_`Y_P#XU1]JU?\`
MY\=._P#`Y_\`XU0!I45F_:M7_P"?'3O_``.?_P"-4?:M7_Y\=._\#G_^-4`?
M%OP!^./AO5?B?\?OVP?'FJ_V9\-?#$3^!?"=\UE/+]DT+2IW_M&^6.)6>076
MI&;!1"3%9P8IG_!?']HKX?\`P[_8/O\`0/$/CGPAH&O>(-9\.7VEZ9J>L6]I
M>ZC;P>(--EGEAAD=7D2.-69V4$(JDM@"OJ[XM?"6R^.OA6+0_%>@:=J^CQ7U
MKJ)LVU:XBAGFMIDGA\U411+&)$1C')NC;:`RL.*Z?[5J_P#SXZ=_X'/_`/&J
M(W4::_D<?GRVDWY.4[M^K?71W]]S[W_RBO2,4HWW>FUM?RX_X*S?%/XR?%7Q
M!J_Q"^&'P9T+]H+X":9\+=77P]XNT;XE:19:;HU]>V]U;ZEJGDN9&O)8;5/*
MB\K;M26Z4,S3,$\^^)/[5/ASXM_\$DO#VC>-_BQ!\+_B5X6\#:59CX"7FK:7
MJD'CZ:"."?3(I8(8(M6NXM4@:T!CL;M(U$YB<.8IU;]B/M6K_P#/CIW_`('/
M_P#&J/M6K_\`/CIW_@<__P`:I0CRQE%/=II]59S:\G;G=KQZ:WTLW.\X5'O&
M_H[J"?FK\EW9[NZ:O+FA^'FIW^M^`-#O-5TX:/JEWI]O->6`.18S-&I>'/\`
ML,2OX5-X6_Y!DO\`U^77_I1)1]JU?_GQT[_P.?\`^-50\-W.J#3I-EG8,/M5
MQDM>..?/?/\`RR/?/U]NE:5)*4G)*U^AC3CR046[V1T-%9OVK5_^?'3O_`Y_
M_C5'VK5_^?'3O_`Y_P#XU4&AI45F_:M7_P"?'3O_``.?_P"-4?:M7_Y\=._\
M#G_^-4`?(G[:/Q:T#]F'_@IS\!_B'\0M:TWPC\.[SPAXH\)GQ%K%S]DTG3]5
MGETR\@AGN'*PP--!8W.PRL`YB*CYL"N3_86^.?A6RN_BO(-9GM1^U!\4_$5W
M\+PUC<"'Q)#:Z/:I)=02HK1K;R&RN)HYF95E4AD+;QG[G^U:O_SXZ=_X'/\`
M_&J/M6K_`//CIW_@<_\`\:K-TTZ4J,MG"</E.HJC^=U9>71V+]H^=5([IQE_
MV]&#@OE9IM;MIZJ^GY._"SXN^#?VA?\`@GM^R)^S[H^L65_\8/!_B[PK8^*_
M"$#;];\*?V%<C^UYM0M2WGVD*BUFC,LBJCF>,*2)5!TOA[X8T_Q-X\_9M^!7
MPJ_:0\!_'?P9\+O&]IK]EIWAC2+*[U+PSHFEB5U;6]4M;F6WQ&'AM(=EM9R3
M22*3YNR4']4/M6K_`//CIW_@<_\`\:H^U:O_`,^.G?\`@<__`,:KJ]M)U76E
MNZGM7VYERVTUT3BGU>LDFKW6$Z<73=);<G(NZB^>^NCNU/7:+:3<7:QI45F_
M:M7_`.?'3O\`P.?_`.-4?:M7_P"?'3O_``.?_P"-5B:&E16;]JU?_GQT[_P.
M?_XU1]JU?_GQT[_P.?\`^-4`:59O@[_D4=+_`.O.+_T`4?:M7_Y\=._\#G_^
M-4>#O^11TO\`Z\XO_0!0!7\1"[;5T%@T"7QTZ[^S-.A>)9,P[2Z@J2N<9`()
M'<=:^!_CA_P63\9_"S_@E7\._C'8^$]`U3XH:[J_]C>(?#BQR_9K&?3?M<OB
M$)'YPE7[/;Z;?LF7D*E8\B7HWZ`77_(W67_7G<?^AP5\,_"?]@;QY%_P4A^(
ML?B;P_;C]GM/[?\`$GAF\&IQROJ&K>(K:PAU"!K<2>9$(3%J;!F3:W]HM@Y!
MK.\^=J/;F5]N:'O*+[*:NGWM%*S9:Y.6\N]G;=*2:YEW<9<K2[7>R9ZW\>/V
MU=>TCX\:1X7\"R^$CH?_``K#6_B-K&MZO:7=U!9Q1"&/2\?9V!\N65YI'PKN
MT5LX0!B#3?@;^T]XK^(O[7O@;P[=:YH^J>'/$OP6MO&L_P#9FGO;6=SJ#WL$
M?VFW$X^TQPM'*=L<K9`V[AN!KP[]@3]B#XQ^!?V9/CA!\3M"CM_'=YX2B^%G
M@^%=6M[S^U-!TG3IX-/NVE60JDEU/=W$C"4HRC8&`Q7K'[*/[,7CCX:_M%?"
MG7=;T3[%I7AKX"V'@O4I_MEO)]FU>.YM7>VVHY9L+&Y\Q08SMX;D5K3Y?K*2
MUCNF^JE#$M771Q_=1:Z3M?WK'-7]HJ5E\6E[='&>'4K>3_>M/K"]M+E+]C/]
MLKQK\4/`/[/3>(_$WA.2_P#B1=>*+?58[W2;D:EJ_P#9\UR(!9M;!;6`HD0:
M4S@!E&$&\UZ]<_M__"ZQ^,UGX$N-5\16NL:CK+>';.^N/"6KQ:#=ZDJN391:
MNUJ-.>?,4D?EK<%O-C:+'F`I7SU^RO\`L:_$GX;_`/#)_P#;7AS['_PK34?&
MD_B3_B86LG]FIJ'VO[(?DD/F>9YL?^KW;=WS;<''"_%W]FO]H+XX?'70Y?%O
MA'XDZ_?^%OC%I^OV&N+XWTW3_!-CX5MM66:&.VTNWNXY;J[2W*%VU"S>4,DY
MCN"%AB>,/>5>%*7PMJ[[)RBF[[:<S=GT3=]+.VVL/.HOB2=EW?+)K3S:2NNK
M2MK=?0X_X++_`+-HDMF;XC^58WMU/IUMJDOA_5(]*N;^%'>33H[UK86SW^$;
M%DLAN6)55B+,H/KW[/'[4?@G]J?0-6U#P7J5_=CP_J3Z1JMGJ6CWNC:CI5VB
M)(8;BSO8H;B%]DB,!)&NY74C(.:^4OAE^Q=\1-#_`&2OV9/#5_X81-?^'/Q6
M/B;6[=KZU<Z;8FZU9_/#B0JY\NZB^6-F?$A&WA@/<_V7/@CXB^&G[5W[2/B7
M5=*6PT3X@>)M(U+0[A9XG_M"*'0K&UFDV(Q9")X95Q(%)VY`((),.W*,G4T:
MNNUVO9N_H^>2MW@]=T7+=<O9/[W)<OJK1=^SVV9\^_&'_@H;\</A:_Q?\?VL
M7PHUKX;_``B^(T7@RX\)R:1?V?B/6;:2"QV26NI"\E@>\,]]&J6YL0)`I7S%
M9@:^B_CO_P`%'?A!^S;XRU'P_P"*_$.L)JNA:9'K.MQ:3X7U77(_#EE)NV7&
MHRV-M-'8QL$=@URT8*HS9V@FOB/]H/\`X)]:_P"-O$G[2%M#^RC%XH^)7Q*\
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M8O+;2K"_)%G=:C+%:LFFQ3`%D>]:$,@+_=!:OC+]L']C_P`=?LL_![]ECP)X
M-UK3#XS\>>&+?]G/Q;?6CM'-+IL]H+B;4+3<F3]B6SOFBWCY5NFX!-?0_P`+
M?A[\3?V'?VE/BU8^$/@KJ'C_`,$?$.ZT/4/#&K:3K^EZ?::$+?2[;2GL=12[
MN([F.*!;*.59+6"ZW1S$"/>NT]?)'VDDG>*DTGW:;TOTO"5.:EM?FCO8Q;DJ
M=WNXJ7HG97MU]]5%9.Z2C+:Y[%K_`/P47^#_`(:^+L_@JZ\3WW]JV6LP>';R
M^A\/ZE/H6G:I,$\JPN=62W;3[>Z8RQ*(9;A9-TT:[=SJ#[=7YL>#O^">=SX6
M^(7C[PG\0_@U\=/B/HOBGXBZAXGLO$'ACXNS:;X4N;6^OQJ$4E[I+Z]:&.6V
MED*R+%93;_LRR*9&?:/TGK&GK0A.7Q.S?E[L7:V]T[K[O,NII6E&/PK;SU>O
M;56=MUU"BBB@`HHHH`****`,W1/^0GK'_7XO_I/#6E6;HG_(3UC_`*_%_P#2
M>&M*@`HHHH`****`.8^-7Q!N/A+\'/%GBJTT6]\1W?AK1KO58=)LSBXU1X(7
ME6WC.#\\A4*.#RPXKXA^#'_!4'XDZ]'H>IW^K?!/XBZ3XX^%FK_$FSA\$17D
M<O@W[$JF."_E>ZG6[ADE9K83A+-O/M9U$/#"/[(_:ET#QQXJ_9L\>:;\,]5M
M-#^(=_H-Y!X;U"Z`\FRU!H6$$C95@`)"IR58#K@]*^'?@M^S=\0/`GQH\*>+
M?!/[.WQ#^'D6G^$M2C^)MCXD\;:->)\6KH6F+2WE$.HWJWFH-=22,=2OO(D$
M8*/(R/L3%QG/VD4[/ET?9N-3[]>1]U9**]\UO&/LVU?5W7>SIV]+KF2Z.[;:
MY4>C?\$A_P!J#]H[]L7PM'X]^)OB+]E+Q!\.-7TB.333\*KS5+S4K+4F$,C6
MM\UQ(\$;11NPDC4EUD*CIU]`^//[1/Q6\9?M5:A\'?@L?AYI&M>%_"<'BW7=
M=\8V-UJEH/M<UU!8V$5I:W%M(&D>UE>2X:4K$BJ!%*S_`"?*OC;P0W[('QTT
MCXY_#C]DVQ^`VD>!_#]]HC^'(KCP]HFH_%C6-5GM;?3M)2+1)KV(I'+'YGFW
M'S*[IL3:)&'T5\2_#'Q1_9X_X*!^(OBOX7^%OB'XK>%_B-X"T[0;ZQ\/ZUI5
MG?Z%J>F75W+#YB:C=6L4EO/'J$@\R.1W1K<YC(<&NFM*$N24=%[VVMFE-J[_
M`/`6KKK%--/7"C&<8RC)WE[MKZ?:A?R7N\W7=2:M)-1X;X*?\%*/BK^WQ<Z3
MX=^#6E?#OP3XITOPFWB'QA=>,(;K6[/3K_[??Z8FDP06T]I*VZZTZZ9KIW'E
MQ(G[AWD(3E?@9_P5=^-G[<'PB^(/CWX4>$/AYX<TWX(Q-9>*]$\3I>W][XDU
MNVC6?4--L;B"2$644489([J6"Y,LDJY@C5#NI?L9?LE?&O\`X)G?$@>*4^%]
M]\6%^(_@PQ^)=/\`!VOZ;!)X=UY-:U/5/+`U2YM$FM'&LS1B5'9U:U.8]L@-
M<M^Q3^R+^TC_`,$\_@I\</`'_"J5^(VJ?'*YN/%]AK6A^(].@T/PUK.J6[0W
MEE?K>7$%U]GMI$B<36L-PTL;'"!UVG&M[10FZ?Q*,VMOXG.U%=N7EN_Y7RP;
M=Y/FVI*FZBYO@O'U]GRQYF^O/S6OU5YVTBG'])?@+\8=-_:%^!W@[Q[HRR)I
M/C71+/7;)9""Z0W,"3(K8R,@.`<'&16WX6_Y!DO_`%^77_I1)7)?LI?!)?V:
M?V7_`(=?#M;A+O\`X07PUIV@&=,[9S:VT<)<9YP2A(SSS76^%O\`D&2_]?EU
M_P"E$E=>*5-5YJC\-W;TOI^!R89U'1@ZOQ65_6VII4445SFX4444`>$?\%&_
MVB?B#^RW^RAXP\:?#?P=HOBO6_#FB:CK$LNMZG]BTO2H;2SFN6FF"!IYR3&$
M2&)1O9@&E@7,@](^$7Q&D\:?`;PQXMU86UK-JV@6FKWHA4K#"TENDLFT$DA0
M2<9).!U->7_\%-[+QAXP_8K^(O@OP/\`#OQ/\0M?^(/AC5O#EK#I%[I5HFG2
MW-E-%'/</?WEL/)WNH/E>8X_N&LOX)^*?B=-\$/A1X)OO@IXD\/6E[ILGAGQ
M9>:QXAT=9_"\5OI@6*]2*TN;I+N.>X`B54E61,[W15&#DW/V5?DUDN3EOWM.
MZ7E?DO\`G9::-0YJ/,]/?YK=ER-?.W/9==DKO7R7X<?\%&?BW?>$_@]\8O$V
MC?#V#X)_''Q#9:%IFB6,%U_PDGAN'4F$>E7UQ?-.UK=><^T2P);P^3]I0++,
M8SOR_P!G'_@J)\2?C+XZ^%6K3O\`"6ZT#XJ^,=5\(S?#[3([H^,O!)L4F::>
M\NC</%,UN(8S<P_8[<0_;(`)7RAEYWX9_LP?'7Q=^RY\`?V>O$'PPN?#$/P4
M\1:1=:KX[O->TV[T/5[/09B]C)8107+WYEN6AM&,=S:PK$C3`L2JA\SX&?LD
M?&2T\;_!C5+OX4^//"GQRT'Q)&_Q-^+UUXQTJ;2O&6E!G:_@:.&^EO+VVN/+
MB%G:7%E"EEO3R_LPC(;K@J?MK1?N*=E?=T_<LW\^?G;M-)^XKI)<]5SY&VO>
MY6W;I->TTC_Y)RVO%VU>K;_3:BBBL30****`"LWP=_R*.E_]><7_`*`*TJS?
M!W_(HZ7_`-><7_H`H`AUBU>[\46"QW,UJ1:W!WQ!"3\\''S*P_3M4W]B7/\`
MT&-1_P"^+?\`^-477_(W67_7G<?^AP5\[_`C]J/Q3=>)/VFYM8L]?\<0_#CX
MB1Z!X;T31-/MS?M;OHVCSI:Q9,2,3<WDK&6YE54#DR2I$F5(^\Y172+E\E*,
M?OO-?C\RUDGWDH_-J3^[W6?1']B7/_08U'_OBW_^-4?V)<_]!C4?^^+?_P"-
M5\\7/_!43PMX7\!_$74?%O@?XB>"/$7PTNM+L[_PIJT6F2ZM?R:HZ1:;]EDM
M;V>RD6YF<PJS7*A'C?S3$J[JT?&?_!0E/A_9^$=.U7X0_%J#XB>.M1N['1/`
M4::--K5Y':Q)-<7AG343IL=M&DD>9'O%^9U3&\[:/)>7XV_'5-K=)W>@+:_K
M^']?,]V_L2Y_Z#&H_P#?%O\`_&J/[$N?^@QJ/_?%O_\`&J^<KO\`X*N^`M-^
M")\8W7A?XDPW]IXU7X=ZGX331$N?$.D:XW*6DD$,KQR;U:)EDMY98V2>-@Q4
ML5]%_9D_:YL?VDM=\::%-X1\9>`/%WP_O;>TUOP_XFCL_M=NMQ`L]O.DEE<W
M-M+#(A;:T<S8:-U8*5HC[UVME]VT7H^NDHO2^DD]F)M)I/?\=VM5TUC):]4U
MN>D?V)<_]!C4?^^+?_XU1_8ES_T&-1_[XM__`(U7Y>?M`?\`!2#QA\+?BS\8
M;K2_VD]#C^('@?XI6WACPM\%M5MM!DB\6:?<0V$<=ND20Q:LLCSWDC+="Y:-
M/)^=&0-7ZIQL6C!8;21R,YP:(>]2C66TDG]\8R]+VDKJ]UUZ7)>[4E2ZIM?=
M)Q?GNM'U6W6V?_8ES_T&-1_[XM__`(U1_8ES_P!!C4?^^+?_`.-5\I>*?B#\
M5_VR?VPOB3\//A]\2Y_@YX)^#`L++5M7TKP_9:GK?B#5[RQ>Z$"OJ$4UM#:0
M1RVCN%@:65F*B6(<GO\`XB_M+^,_V3OAKI]MXC\`_$3XWZSH'A\ZGXF\1^"=
M%TS2;`+$'W2BWU#4XLRN(I&,%J]PZ[1E4$D2LN=<G/)V6^O;5WOLE97NVM&O
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M7]B7/_08U'_OBW_^-4?V)<_]!C4?^^+?_P"-5\D?LJ_\%3]1\9_L?>-/BO\`
M%OX=>)_`>F>$-<U73(YX(;*[36FAUJZTVVLK2WM;Z[N'O=\<$$@=4CDN)#Y+
M/&0PP/VW/V_]2US]D;XPZ3:>'/B7\%?BAX0T?2]=@LM;EL8KZ2QN-1CA2[M[
MC3KRZ@9"\<L3IYPD4\.@5U+-WO9;[_A?[[:M;I:O0J;Y4V]DVOFG;\VEZM+?
M0^UO[$N?^@QJ/_?%O_\`&J/[$N?^@QJ/_?%O_P#&JTJ*0S-_L2Y_Z#&H_P#?
M%O\`_&J/[$N?^@QJ/_?%O_\`&JTJ*`,W^Q+G_H,:C_WQ;_\`QJC^Q+G_`*#&
MH_\`?%O_`/&JTJ*`.>T?1[A]1U4#5;]=MTH)"0?/^XB.3^[]\<8Z#W-7_P"Q
M+G_H,:C_`-\6_P#\:HT3_D)ZQ_U^+_Z3PUI4`9O]B7/_`$&-1_[XM_\`XU1_
M8ES_`-!C4?\`OBW_`/C5:5%`&;_8ES_T&-1_[XM__C5']B7/_08U'_OBW_\`
MC5:5%`&;_8ES_P!!C4?^^+?_`.-4?V)<_P#08U'_`+XM_P#XU6E7/_%;PYKG
MC#X8^(=*\,>(V\'^(]2TVXMM+UU;"*_.CW3QLL5S]GE_=S>6Y5_+?Y6VX)&<
MTI-I-I7'%)R2;L7O[$N?^@QJ/_?%O_\`&J/[$N?^@QJ/_?%O_P#&J_/S]E/P
M[^U9\._^"HNG?#KQO^U=_P`+N\&^&_",OB;QA8_\*RT?P['9M<N]MIEMY]L7
MD\V1X[F?&Y,):CAA)Q[!_P`%>?C7\8_V>_V?(?%OPSU_POX7TK2M6T:+5[R[
MTXZEJEZ+K6;&S^RVT<F+>!#%/*7GD$S<!$C1F$R7:_L[/XW9>7O..OS7S6UV
MTB=>:46M8V^=TFK>J:_6RNSZC_L2Y_Z#&H_]\6__`,:H_L2Y_P"@QJ/_`'Q;
M_P#QJOES_@K+^U=XW^"WP7U#PI\']0M=-^+.KZ!JGB.'5+BRCO8/"^D:;#YU
MYJ,L4@*.Q8PVT*."'FN5)4I'*5\(_:9_;)^(WP__`&:OA_XRT?\`:/T.#XR>
M(_!_A?5O"?PBAT/2)+KQ[>W0A%PES`RO?RK=3-(BRV+6<5LJLS!O+9JFD_:-
MJ/>*_P#`N9*W5V<))V3=U9)NXYKE:3ZJ3].7EO=[+XD]7MJ[)J_Z-?V)<_\`
M08U'_OBW_P#C54/#>CW$FG2$:K?I_I5P,*D'.)W&>8SUZ_CQCI6W8232V,+7
M$:Q7#1J945MRHV.0#QD`]\53\+?\@R7_`*_+K_THDIO1V)B[I,/[$N?^@QJ/
M_?%O_P#&J/[$N?\`H,:C_P!\6_\`\:K2HI%&;_8ES_T&-1_[XM__`(U1_8ES
M_P!!C4?^^+?_`.-5I44`9O\`8ES_`-!C4?\`OBW_`/C5']B7/_08U'_OBW_^
M-5\^?M;?%+QSXH_:K^%_P2\"^*Y_A^WC#2-7\5:_XEL=.MK[5+.PTZ2RB6WL
MUNXIK5))IKU`TDT,H6-'"IO=71W[`?[1WBCQO\-/B?HGQ$U2#Q#XH^"7B_4/
M".I:[!9)9G7X;>WM[N"\>"/]W'-);W,7F+%A-ZL55`0BSSKD=1Z)*4O^W8R4
M)/Y2?+;>Z;2MJ-P:E&*U;:7SDG)+YQ5^VJUNSZ!_L2Y_Z#&H_P#?%O\`_&J/
M[$N?^@QJ/_?%O_\`&J_/7PC^U_\`&[PC\"?@7^TCXA\<?V]X9^-7B#2K#4?A
MO'H=E!IFAZ?K3)%IS6-T(EOC=0LT'F/<32Q3>=+MBA4(4I_`3]NSXFWO@O\`
M9E^-6L_%W0O%.B_M&>*8_#6I_#R*QTR'3_#XO%E$0TRXC47SW5A+`L5R+B>X
M5]\Y\N`J@76-.;ER-6:DH._2<K6B_-W2NKQ762(G*,8N=[KE<K]XKF;:_P#`
M7H[2?1;V_1;^Q+G_`*#&H_\`?%O_`/&J/[$N?^@QJ/\`WQ;_`/QJM*BH*,W^
MQ+G_`*#&H_\`?%O_`/&J/[$N?^@QJ/\`WQ;_`/QJM*B@#-_L2Y_Z#&H_]\6_
M_P`:H\'?\BCI?_7G%_Z`*TJS?!W_`"*.E_\`7G%_Z`*`*7B^74H+LOH\%E=:
MNFEWC64-[.T%M-.##Y:R2*CLB%L`LJ,0"2%;&#\DK^P_\:=5_9G^.*+XA\->
M#/BE\8/'<'C'[/X=\2ZE%I]E;0)IMO\`V:-6BM[>]C^T6NG&.2YAMU>,W+E$
M;:`?KW6+!-1\46"2&90+6X;,4SQ'[\'=2#^%3?\`"+6W_/74?_!A<?\`Q=+E
M5V^ZM\N:,MMG=QC>]U96M9N[YGHNSO\`.S7Y2>UN_16^&O@9_P`$WO%_P>;X
MVZC%\&_V8XM+^*EGH%FGPX@U&Z;P]<+9-=+=F^O&TK,\THF283&Q8LXV.AV>
M>]+X&?\`!.7XW?LUZQX%\;^&KWP5J6M>"KW6],T_P!KOC;5K_1-$\-:A!8K'
MIUIKDUC)>EH)].AF3S;,H$GEA545(WK[R_X1:V_YZZC_`.#"X_\`BZSM-FT#
M6=>U+2K/6/M6J:,8AJ%G#K,KSV'FKOC\U!)NCWK\R[@-PY&15*34W..C:M\N
MVOE=:ZI.5FN9DVTY7M>_X6_7YM)N]D?)ND_\$\OB+K]FGB3Q+JW@Y/''B7XV
MZ5\4M?L[&YN)--TJPL8H;6+3[6=H$DN95MK:+,LD,`DD=\K&`*]R^#G[/>M?
M#W]K[XT>/[VYTR71OB+!H,6FPP2.;F`V%M/%-YRE`JY:5=NUFR`<[>E>H_\`
M"+6W_/74?_!A<?\`Q='_``BUM_SUU'_P87'_`,725E#V<=KW^Z$8+[HPBM=>
MK=V)QYI^TEJ[6_\`)I2_.<MM-DDDCX<^,?["OQT\:^#?VCOAKI>B_!.Y\"_M
M!^);G4&\1ZUXBU"?4-`L[NSLK25QI"Z;Y4]S"ML\L0^WQKYGE$LNTY^J_@KX
M5^(7@3Q=J>AZY>>%M0^'6C:-I-CX7NH3<GQ!<W$4+I?2:@7_`')#,L!B\KGF
M3?\`PUW'_"+6W_/74?\`P87'_P`71_PBUM_SUU'_`,&%Q_\`%T0]V"@NBBOE
M"/+%?)7];ZW*E[S;?>3]'.2E+[VE\M%;4^:/$/[.OQE^`7[9/CKXD?!^V^&W
MBWPM\6;.SG\3>&O%FNWF@3:?K%G#':PWUI=VUC>AXY;5526&2%<-!&ZR?,ZG
MS;]J#]@OXW_M.:]:WOC;3_@A\3K36/!*:)=^']>U35K3PQX/UHRW+-J]II30
M7<.IR+'<1(KW!MIA]E_=RP"=E3[@_P"$6MO^>NH_^#"X_P#BZ/\`A%K;_GKJ
M/_@PN/\`XNLY4HR@J<M4ORLU;Y)Z=596:LC2-649<\=]/P:=_P#R77H];IW9
M^>_@+X:_%S]FS]M?X,>#_!FG?#GQ3XG\%?L[6NA:W9ZUK5[I5A>"WO[:%Y+:
M]BM+B1,2HI`>U.]"1F,\UZ;^S1_P3=\7?!"^_9]O]2UWPYJFI>`=8\6^)O&4
MUOYT,=UJ&O"XED2Q0H<PQ3W#(#(R$QH&QN)4?7?_``BUM_SUU'_P87'_`,76
M=X4FT#QYX?M]6T/6/[9TN[#&"\L=9EN+>;:Q5MLB2%6PRD'!X(([5NZDI1M/
M5MR;?^*I*I9>5Y?.R?DN54(QTC\/NV7^"$8)^MD^V]O,^+K[_@FC\2/'W["_
MQ1^!7B1/AD-.NO&&H>,/!^K->7.JV^L/+XBGUR&UU?3I;.-(H-S1P2K%//O1
MI,8P`QKO_!,_5/&/[-'Q.\)Z%^S_`/LM_`?Q+XMTVTL+34_`M^\_]H!+R&XD
MCNI$T2Q>.("$%5`FW,1D)MR?N+_A%K;_`)ZZC_X,+C_XNL[Q#-H'A(V/]JZQ
M_9G]J7::?9?:]9EA^UW+YV01[I!OD;:V$7).#@<5$?=T773U=E&_JU9=MM#:
MK^\3YN[?WOF?RO=^6NIT=%9O_"+6W_/74?\`P87'_P`71_PBUM_SUU'_`,&%
MQ_\`%T`:5%9O_"+6W_/74?\`P87'_P`71_PBUM_SUU'_`,&%Q_\`%T`:5%9O
M_"+6W_/74?\`P87'_P`71_PBUM_SUU'_`,&%Q_\`%T`&B?\`(3UC_K\7_P!)
MX:TJY[1_#=O)J.J@R7_R72J,7TXS^XB//S\]>I]AV%7_`/A%K;_GKJ/_`(,+
MC_XN@#2HK-_X1:V_YZZC_P"#"X_^+H_X1:V_YZZC_P"#"X_^+H`TJ*S?^$6M
MO^>NH_\`@PN/_BZ/^$6MO^>NH_\`@PN/_BZ`-*BLW_A%K;_GKJ/_`(,+C_XN
MC_A%K;_GKJ/_`(,+C_XN@#Y)T[X5_%3]C/\`9_\`C)X^TS2-`\=?M%?%_P`6
MM?6T5E97E]I2,\L=CI-K.ZB*5;*TLDB,LK>6J'SWS\WS=+_P5)^`7Q?_`&K/
MV>?^%>_#O1?AO<0ZM>:9J.H:GXC\57NE-9RV.I6E\L<4$&FW0F606Y0NTD93
M<#M?&*^D?^$6MO\`GKJ/_@PN/_BZ/^$6MO\`GKJ/_@PN/_BZ%HH*_P`'+;T@
MDHKY6O?KI?K<O[SEWN_G)W?_``%TU\K?"_[:O_!&K5OV\SXA^(>I?%'XL?!W
MXK>)?!O_``C-]X?\!?$61?"%Z8?M1MHKMWTZ.XN;<M<-Y@,2</(%3)+-D1?\
M$]?VA_#W_!.2\_9;S\*OB%X4U3P['H`\9^-O&&IWNKZ2D\49N"+'^S&CNOLD
M[3FR/VJWVQQ6BLJ-$S-]_P#_``BUM_SUU'_P87'_`,71_P`(M;?\]=1_\&%Q
M_P#%TN6/+.G;W9;KIO)^JUD]G?SW*4Y\\*E_>AL^M[15^SLHKI;RVM%X`\*_
M\()X$T30_MESJ']C6$%C]JN3F:Y\J-4\QSW9MN3[DU+X6_Y!DO\`U^77_I1)
M1_PBUM_SUU'_`,&%Q_\`%U0\-^&[>;3I"9+_`/X^KA?EOIUZ3N.S^W7OU-:3
MFYR<Y;O4RA!0BH1V6AT-%9O_``BUM_SUU'_P87'_`,71_P`(M;?\]=1_\&%Q
M_P#%U!9I45F_\(M;?\]=1_\`!A<?_%T?\(M;?\]=1_\`!A<?_%T`>!_M8_LY
M?$/5_P!J'X7?&7X6)X+U;Q%X'T_5O#FJ:#XHU.YTJSU73-0%O(SQ7EO;73PS
MQ7%G;D`V[JZ/*"4(4U@_LY_LK?%WX.O.^HWGPSO/^%M^,=:\5?%18OMADL8[
MJQ6WLK31Y0B"8P^1:QR37,<?F(LCA$9@H^FO^$6MO^>NH_\`@PN/_BZ/^$6M
MO^>NH_\`@PN/_BZGDCR.#V:<?^W924I+T<E=]>S2;0W)N2ELU9_-)Q3]5%M+
MY=E;X=^#?_!/?XU:?\)O@I\%_&5S\+O^%6?`WQ'8ZM;>(-+U*\N-:\56FDS/
M)I-M-I\MFD-E)D6SSRI>7'S0,$3$F4Z#1/V`/$'Q2_:Q\,^/?%?PD_9[^%-K
MH&N-XJUC4/!-[)K'B'QQJ4:L+-+R[DTK3S'!%+(UP^3<-)+%"/D"L6^PO^$6
MMO\`GKJ/_@PN/_BZ/^$6MO\`GKJ/_@PN/_BZU4Y<_M&[RNY7_O-)<WK[L?*\
M4[7N1**<7"UDURVZ<OO>[;:WO2\[.R=K&E16;_PBUM_SUU'_`,&%Q_\`%T?\
M(M;?\]=1_P#!A<?_`!=04:5%9O\`PBUM_P`]=1_\&%Q_\71_PBUM_P`]=1_\
M&%Q_\70!I5F^#O\`D4=+_P"O.+_T`4?\(M;?\]=1_P#!A<?_`!='@[_D4=+_
M`.O.+_T`4`%U_P`C=9?]>=Q_Z'!7XR_LK>#-#M/B-^S]<^%OA5J_PI^*'B'X
MM^(XG^+.ZTL-(\9Z7!K5[<ZCI%P]C<27%Y//;VZQ00:G!$N8)'B?]T0_[*:Q
MJ5OI?BBPDN9X;=#:W"AI7"`G?!QD_0UX+=?L(?#"X_9RT'X;)XJUNVL?"WBX
M>-M'U>#5;5-5T[4AJDFI;TD\KR]ADFEA*F,YAD9223OHI^[7IU?Y6ONYE?\`
M!;;2^%Z,F?O4I4^Z?W\LDOQ:UW6ZU/(?B)^WS\=4^#WQ?^.'A;3?AA_PJKX0
M^(=5T[_A%]0T^\DU_P`3:?H]RUOJ5VFI+=I!9RLT-T886LILB)-S_O/ER)_$
MWQD/[<W[5&N_!JZ^&=F++PWX6UACXNT^^OCJDJZ9=/#9I';SV_V97&2URSS%
M"`/L[Y++ZCXZ_P"":'PZ\<S>,-)/Q0\=Z5\,_B%KA\0>)OAW8:IIB>']7N9)
M(Y;E2[VC:A!#<RQ!YHK>\B1VDE^4"5PVC\9?V`O"?Q4^*'COQ7I7QF^)?P]O
MOB9I=OHGB2W\,ZSIB6FH64%NT"1+'=6D_D.$>3$\!CG!D.V51@#&<:CP\8PT
MGIOTER6;?>//JEVO[MGR&W[MXCF?PW?_`(#S>ZEVDHW3?5M>]=<QXGXF_P""
MPWBKXOZC\.K/X:Z9_P`(O'XJ^&.F_$?4;^[^&'B;XC&V?46D2VTT6VB>4T.T
MP7!>ZFD`.U`D3DN4[W7?VZ_C9X[\,?LS6/A3P1X;\#>-?CE'J,>O6?CG3M13
M_A$WLK7SII5M<VUQ,!LEV0R>2TH>+,D/+5W?B#]A#P%I_B7PGK/PW^(?B?X+
M:OX1\+0^"8+GPA=Z7*M]HT!5K:TN(=2M+R&00,K&.3RQ*OFRC?AV![>Z^!/A
MC6_'/PL\3ZUXYU?7O$7PH2^^Q7]W>6*/J\EY:_9IY;M(88X]Q4E@(%A16Z+M
MPM=57V<E/D32<G_X#S2:7_@#BGJG=:7=YOFC[1<MWKRI?/EBF_\`P)2DM&K/
M73W5XI_P31U;XV:Y^T9^T=!\0OB3X5\7:%X:\?'24L;/PS?V3V\QT31YU-F\
M^J7*6MF!,V;7RW)E>27SAO,8\%_:+U>X_9T_X+4>+?CS#<WD6B>#[/P;X2\9
MQ+<,MN="UC^TK?[3(@X8VU^FGRYQQ&)NW(^V?A1^SIX<^#/[17C_`,?Z+\1_
M$2VGQ*O4U;6/"L]UILFBC4%M+6T^V1'[-]L20PVD0*_:C%DL?+Z8J?$C]D'X
M8?%K4_C#/KVJR7T'QN\-VGA?Q!:/?6_D0VMM%=1QO;C9N27%W(VYF?#)&5"X
M.8<FHT9Q7O0C"Z[M149J_:?O*_2,NFRU<8RE4@W:,Y/7LG*Z=N\=';;F77=_
M%GQTU:Z_:%_X+)?`GXJ)=W8\,>"?B9?_``M\+HDQ%O=M#X>U6XUJ[4`E6W78
MAM-W_4-D&.3G[X_;D^,FJ_L[_L8?%?Q[H4"W&M>#/".J:U8QN,J9[>TDE0D8
M.0&4$\=!7!>"_P!A'X6^`_!7P,T.P\1ZM]G^`6I2:QHL\NJ6TEQK%Y+9W5K/
M/J#F/]])+]LGF=D\LM,V[.,J?0OA#\+_``Y\+O@M)X'U'QKK7Q!T^Y>^^U7O
MC#68]4OKR*[GEE>"64A0T2+,8D7;\L2(O.,G/$TV\)+#4GK[UGMJTM>ZO+FE
M;I<THU5]9AB*JNO=NM]%*;MYVCRQOI?<\5_8G_X)C_"7P/X/^&_Q-N=)N]?^
M,!L;;7M4^(-QK5Z^N^(+VXLHDG:ZNQ*'N+5P!MM)"UL@"[8EP*\`_P""??Q]
M^,7[//[+_P`";^[/PTO/A9XS^(EWX+&D0V%\?$$,=YJ>HK%?_;C.MN&%R`&M
M?LA`B&1<%C@?27P"_8(T#]G-?"ND:)\?/C%<_#WP1>M=Z'X)O/$FG?V791@R
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M7=Y=ZKY`BEENGBWRO)<.#@B,*F$7"*`37TO+_P`$UO`4GBR"9?BW\1(O"=EX
M[7XCV7@^/5M+71[/6?MWVYY0_P!C^VR1/.TI,,US)&/.8HJ,D31]=-^Q/\-)
MQ.&\3ZKBX^)T?Q7<?VC:_P#(439B#_5?\>O[L93[_)_>5S48S7LYM^\G'Y6J
M8>=O.W)5>K=_=\E'HQ5IN<(ZQ:EIM>\*\?E?GIK;37?5R\A^(WQK\2?%WX`_
M`;QW\0?"WPWU.+QS\8/#M]X6TZTGFOT\/Z;=,WV*=[N"Z,%UJ"QDR&2+-J&E
M"JDPC$KZO[0'[6OQ[_X7/\?M$^''_"H=+T/X'>'++Q`L_B72]1U"[UN6>QEN
M?L16"Z@2!3Y$G^DYD*Y5?L[\N.W\*_L`?##P3X4TWPYIGB[7K7PIX?\`'UO\
M0M`T)-2L_L/AVZBD:;[#:+Y.Z.P:5Y)/(+,4,C"-HTPH[.^_9Q\!W_BWXNZR
M_B*[%U\:-)M='UM5O[?R[6&WM9K5&MALRKE)W)+EQN"X`&09Q"G]7FL/I+F<
MHK_N%3C&_=J47=OXK*]T[%4K?682JZQLD_\`P94;MV3C)672[MKJ=[\#/B:G
MQK^"?@_QE':-8)XMT.RUI;5GWFV%S`DPC+8&=N_&<#.*ZJN-^$FC^&O@U\*O
M#/A#3-:AGTWPII-KH]I+=7<33R0V\*0HTA4*I<J@)(4#.<`=*Z#_`(3'2/\`
MH*:=_P"!*?XUV8CV;JR='X;NWI?0Y\-[148*K\5E?UMJ:5%9O_"8Z1_T%-._
M\"4_QH_X3'2/^@IIW_@2G^-8FX:)_P`A/6/^OQ?_`$GAK2KGM'\5Z7%J.JEM
M2L%$ETK(3<(-P\B(9'//((_`U?\`^$QTC_H*:=_X$I_C0!I45F_\)CI'_04T
M[_P)3_&C_A,=(_Z"FG?^!*?XT`:5%9O_``F.D?\`04T[_P`"4_QH_P"$QTC_
M`*"FG?\`@2G^-`$WB#1(?$V@WNG7+W<=O?P/;2M:W4MI.JNI4F.:)EDC?!X=
M&5E."""`:_-OX;?LC>'-*_;?^,FD?LR^'X/"W@30OA5?>!_&3:9=20Z7KWBZ
M0(;")B[E)[^UMVE-Q=9,BM>!99&D+A?T'^(,FE^/?`6MZ''XKET!]9L)[%=3
MTJ^ABO\`3C+&R>?;NX=5E3=N1F5@&4$@]*^>_P!GO]@FS_9J^$]MX$\/_M(?
M%G_A#M/TBXTFQTUSX5MS9&5'`NUN+;2(KEKI)',WFR2OYDN6E$NY@V,Z*J<Z
MELXR6G7FC*.OHI-Q7\S3NE%J6D:CCRM:OF3UZ6E&5_FTK]>5-6NU;Y7_`."(
MW[-GP]_8"^*_ACPMXJ_97\1?LZ?'?Q_X:NM/CU>7QLGBW2?%\-@MK+=F.6*]
MF6UN'8B<PF"-0J$)*^"H]Z^*7P-\'?MV?\%1/'O@'XL:'8^-_!'P[^&^BWNC
M^'-5!GTV&^U2ZU6*YU#R"-GVI8;6**.<_O(E9_+*EW-/^.__``3SU/Q]97FM
M67[0/CKQ/\2KC3?^$8T?Q1XBUO3M+F\"Z9=W$3:G=:9'HUA:(;Z2&)55Y023
M'&OF(FX-Z?\`'']C[PW\6/C3:?$7P_\`%OQQ\+?&J>'V\+:AJGA34-*8ZWI_
MF^=%'<Q:A:7<)>&0RM'+&B2IY\HWX;`Z:U1U>2<TG;F37353M9=O>C>RLFY.
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M.D?]!33O_`E/\:YS<TJ*S?\`A,=(_P"@IIW_`($I_C1_PF.D?]!33O\`P)3_
M`!H`^3_VS?!NC_M*_P#!1?X)_"'QQ90>(/AQ-X3\1^,=1\-WP\W2]?OK.XTN
MWM!>6Y!CN8X?M<TBQRYC\S8Y4LB8O_\`!)VVE\"Z)\;_`(;6QO!X2^%/Q/O_
M``YX4MYYI)1INE-96-Y%9Q,Y+>3`]W)'&NX[$55&%4*/0/VF?V9O"O[1_C7P
M5XLMOB%XB^'GCCX?RW9T?Q'X7O[`7B6]U%Y5S:2Q7MO<VLT$FV)RLD+%7@B9
M2I7G&^%'[%G@CX,_\(DVB?$KQY#+X?US5?$NLO\`\)-%'_PG>HZC"\=Q<:ND
M:*D^&<21I$L,<3QQ[%54504?<BTU]F2?G*52,HR_[=@N2[UV2T"O[[5NC3]$
MH23C_P!O3?-VU=]4K_,VK_!_PM\`/^"I?P2O]!^%_B;X$V][K?B#2M3\<:E=
MQ7S_`!>GN+>22'39[BUNKN:8R2*;R.76&@D468CA7>2J;-Q^RKX#\`?\%<_A
M9;?`?0WT?Q5X1AU76_C'KUMJ%U<27NEZA#,;.RU6YED=KV[N+TI/$L[/+%%:
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MT`:59O@[_D4=+_Z\XO\`T`4?\)CI'_04T[_P)3_&CP=_R*.E_P#7G%_Z`*`"
MZ_Y&ZR_Z\[C_`-#@K@Y_VQ_AO;?LV:[\7G\1X^'?AJ'4)]2U;^S[K_1DL9I8
M+H^3Y?G-Y<D$J_*A+;<KN!!/>77_`"-UE_UYW'_H<%?D7XS\*?&:;_@@M\<+
MZQ\>_#&V^'PL?'3OHL_@*^FUEK<:OJ?FQC41K"0B1CNVO]B(4$`H^"3$Y-)O
MR;_KJ:48*=2,7UDEYZWV_P""?K_IFHPZQIMO=V[^9;W4:S1/@C<K`$'!Y'![
MU/7Y:^)]&^/?[7O[27QI\-^"=8CT^[^&^F:!IOA`2?&'6_!7_"->?I$-TFJ/
MI=AIMQ!JL<MV\PS?.\3"S:$1J%D+^T>+[?5/VE?VZ4^%?Q,^(?BGPK:>&?A!
MIWBB.R\$>,+_`,,Q:KJES=W,&H:BEU:/;W%Q#:^1;JB.QA7[5NDB+,FW6HK2
MLO.U^RC*7W\L7?1)-K6W,XX46Y4U*7:+=N\G!?G-6UO9-VVYOLVQ\<Z+J?B_
M4/#UMK&EW&OZ3;07E]ID5W&]Y903F18998@=Z)(89@C,`&,3X)VG&K7Y;^,?
M"UM\&_VJ_P!JKXH>!/%'CKQ?XO\`!OP+\/>*_#5\?&>IW]MK=VUOX@"7,ME#
M.+.[A;RXI$@\@VZ,[-#'&9&)]"^'6G-^SM\</V1+WP7\8OB-\0I?C7%>6_B6
MWU[QA>^(;'Q98#19;]]8@@N)I8+'R;E+;!LEACVW?E[2&0"E3O/D[6OZOGM\
MO<=V[6\[2Y7-V5UVNO10A*7SM-6M>^J[7_0:OG7Q]_P5?^`OPI^(NI>&O%/C
M2]\-2Z-K@\-ZAK&K>&M6LO#ECJ1A$XM9=9DMETY)#$RMAK@?>`ZG%<3_`,$<
M?!6JZ_\`LSV'Q,\5>//B)XW\5^++G5+:1M=\1W5S8:?:0:G<0PP6]GO%NI58
M%S.T;7#;F#2E=J+2_9H\;>"?AWX<_;'U?XCZCH.E>!;;XHZDFMW&M2QQV`MG
MT?2HW24O\I5]VS:?O%@H!)`KE]K92D]HTW-_*=-6OTTF[NSL]KI:WNHV^U-1
M7SC-WMUUBK*ZNM[-Z?25C^T/H&I_M$-\-+=;V;75\,1^+/M*(ALFLY+EK9`)
M-VXN71C@+MV\[N<57^''[5OP^^+?QP\??#?P[XEM=3\;?#`V:^)]+CAE5]+-
MW%YUOEV0))N09/ELVT\-M/%?,'_!.'2=%_9#_P""5O@GXN_$;3-0T/5_!'PV
MF6[GU)IQ>6&@6\UQ>VEFT+$[62`Q*%V[\A4).T"OG']F/6O&O[+GQQ_9Q^*/
MC?X1?$#X?S?$*]U;PW\1O$NMW^AOIFHW7B2Z_M*QVK:ZC/=`1:@L4$9G@BVQ
MS$-L8A#U*FU7^KRZ-I]/>E.2I+MJDHM;J6NJWSE+]RZRZV:[<L8Q=1_)MM>3
M1^N%%?E9\>+'QQJ?P6_:-^*=A\9?C#H?BWX??&>/1/"RV7B>9=*T.Q&HZ8DL
M`T\YM+I9$NY1MO8KA$PFQ44,K=E\5_&-M^PW\??C!X'UCQS\=?$OP]U'P-X1
MU.*RA\8W%]XB;5M0UV[TITLM0OKE#9"[*0*_ESV\<.YWB:!@&&%*?/"F^LTF
ME_BIJHEIY:;7YM$FG<UY=:EMH-IOTJ>S?XV>_P`-V[-6?Z'>,_&NC_#CPGJ.
MO>(=6TS0=#TBW>[O]1U&Z2UM+*%!EY)97(1$4<EF(`%:,<@EC#*0RL,@@Y!%
M?CQ^T!8>)]0_9#_;[^&GC.^\0V&F^`O!FF>)-,T2/XMZWXNN-#N;G3KQGAGU
M*Y\FZ9)%@@DDL96EMP7)!=9*^E=/^#MAX_\`VZ++X*7WQ#^+FC?#WPI\,+;Q
M5H6F67Q)UZUU'Q%>WFH7,5W>2ZH+P7]U':)':HL+7#0Q_:URG,8&C6R775>G
M(YO\(NV_G97:EZ14GYW_`/`H15OG45_*]KV5_O2BOFS_`()*_%;7?C'^P]H.
MJ:]XDN_&K66KZUHVF^)KL+]H\2:;9:K=VEE?2%0`[R6\,1,@'[PY?G?FOI.G
M./+*R_K_`"].@E?5/=-I^J=GZKL^H4445(PHHHH`S=$_Y">L?]?B_P#I/#6E
M6;HG_(3UC_K\7_TGAK2H`****`"BBB@`JGX@\06'A/0;W5-4O;33=,TV![J[
MN[J988+6%%+/)([$*J*H)+$@``DU<JMK.LVGAS1[K4-0NK>QL+&%[BYN;B01
MQ6\2*6=W8X"JJ@DDG``-3-VBW>WKL.*NTMSQ[]FO_@H;\(?VM_&VI>&O`OBJ
M>^\0Z7IMOK4FFZEHFH:-=7&GSDB&^MX[V"%KFU?`Q/"'B.Y/F^=<Z7[27[;O
MPT_9+NM/M?&VN7UOJ6J6]Q?6^F:1H>H:]J36MNNZ>[:TL()YTMHAC?.R")"R
MAG!90?`O@GXBT_\`:$_:CU#]KWQ'?V7@?X-^$?!UQX7\#W^M3K8+KFGW%Q#<
MWFOW#2E1;6DC011VRR$%XE:9MHEC%;7@+Q+8:3_P6J^*T>L7-I!<7GP?\.76
MBM<2(IELH=2U?[:T61DQI)-;&0@X4O'D?,M5):03]UM2;3Z64Y+MO&*DT]8W
M:>J:$M%.6Z7+:W6[A%]]G)I/K96T=STWXK?\%&O@U\'?"GAK6=2\9#5;+QCI
MCZWHR^&M*OO$ES?Z;'&))+]8-.AGF%FBE=]P4$2EE#."P!S/B%_P5,^`?PR?
M2CJ/Q#LKNTU73+77/M^CZ?>:QI^FZ=<NJ6]]?W5I#+!86LK,-D]V\4;!7(8A
M&(^%_P#@@?K5GH/[1WB;^U;NTBM-:^&R:QX,DF=8Q/X?_P"$N\2R^9!N`8PK
M'<6+,<X`DB)SN4UPG_!#;Q?X,\,?L!?MPR:]>6-EI+:[K6NEKV7;O\,76F$Z
M;<`,/,^RR1+-Y1Y!`8*,@YSKU/9TYU;:1A.=O\,W#EO;>^M[?8FN7JM*5/GJ
MJC?[48W[\T8RYDOY=;+77F@[]'^T%M=1WMM'-#(DL,JAT=&#*ZD9!!'!!%4?
M"W_(,E_Z_+K_`-*)*\I_X)PZ+K/AS_@GQ\#=/\0B5==LO`.AP7ZRC#K,MA`'
M##`(((((Q7JWA;_D&2_]?EU_Z425V8NBJ->=%._*VON=CDPU5U:,*K^TD_O1
MI4445SFX4444`<!^T#^U#X(_9?T/3+WQGJUQ9OKEZNG:5I]AIEUJVJ:Q<D%O
M)M+&TBENKEPH9V$43%45G;"J2-#X%?'GPC^TQ\+]-\9^!M;MO$'AS5@WD742
M/$RNC%)(I8I%62&6-U9'BD59$965E5@17SS\?=6M](_X+)?L[C5GBAM-0\!>
M,;+1FG95634C-H\K1Q9&3*;6*=MJD'8CGHK5R?[`OQ)T71=2_:7@M/$NAV[>
M//C'XD3P3:F^CBFUJYMM,LUOELT<AIV2Z@NR_EAL>6YZ#C/VEJ,JKU:A.:7^
M"I&GR^KOS7[65GN6X>_&"=KRC%M[>]"4^:_96L_-2UTL>Y^"?^"C7P9^(OQK
MB^'^C^,A=^(+N[N].L9CI5]%I&K7=H`;JTL]3>$6-W<0@GS(8)Y)$V2!E!C?
M:OPO_P""B_P<^,GQAM/`GA_Q=)<^(-62]DT<W&C7]EI_B-;-PET=-OIX$M-1
M$3'Y_LDLN`&/121\*^`_$&C:[_P1\_8,L=%OM.CUX^.O!$-M%'*OF+?65R7U
M=<*/EDBBAU#S<CY-LFXY&:]A_:3U?7K/]O?]ESQIXL\5>`_B7X%\1>+-1LO`
M.E>&+%]*O-,EO-,N&AU::5KF\75H8;-9HV:'['&ANDFV2?(B=7LN6JZ<G>TW
M3;6S?+!Q:WMS.=DM=M9+=8RG>+E%6]SGL]TKSNG_`(5#5[[VBW9/[VHHHK$L
M****`"LWP=_R*.E_]><7_H`K2K-\'?\`(HZ7_P!><7_H`H`AUBZ>T\46#1VT
MUT3:W`V1%`1\\'/S,H_7O7/2?"[PM+\-;[P8WPYTIO!^J)<1WNA'3K`Z;=K<
M.\DZR6^[RW$KR.SAE.\NQ.236YXIFO[;4/,TNVM+S4TTR\:TM[JY:V@GF!AV
M))*L<C1H6P"XC<J"2%;&#\W?"K]L/X^?$']I_P`3_#6]^#GP@TV7P/!I%]KF
MH0?%74;E5M=0,^UK:,^'XS-*BVTI*.T2DE!OY)47O/D_K_(&^5<YZ=\8OV0O
MA'^T3JUA?_$#X%^`_'5]I5L+*QN/$/AG2=3ELX`2PBC:?<40$D[5(&2>*N_&
MC]F7X9_M(6FD6_Q#^#7@_P`>P>'PXTN/Q'H&F:HFFAP@<0"<N(]PC3.W&=BY
MZ"O//V%/^"CG@[]I[X?>%+#Q#XT^'&F?%KQ`+^1O!]GK4$>I/%;W=S$LL=D\
MK7&PQ6_F$X(QN.<"O4O$O[7?PG\&?&*R^'>L?$_X>:5\0-2>)+3PQ>>([.#6
M+II?]4([1I!,Q?\`A`4[NV:(N]K=7IYO7;SW_$+V][LON5ORM89K'P'\!^(?
MBGHGCF_^%/AR^\;>&K;[%I'B"XT;3I=5TJ##CR;>Y8F6),2R?*C`?O'X^8UG
M?!_]EGX6_L]>*=1USP!\%?!?@?6]8C,-_J'A_P`/:7IEU?(7#E998=K."X#8
M8D9`/6M/XG_M??";X(ZRNG>-/BA\._".H/<QV:VNM>)+.PF:>1`\<02616WL
MA#*N,D$$#%7O"/[3/PW^('CGQ'X8T'X@>"-;\2^#@QU_2;#7;6YOM#VDJWVJ
M%'+P8((/F!<$4*2O=/O_`)R_.[]=0<;JS\O\H_DTOP-+P;HFG_#KPY!H_A_P
M@NA:3:EVAL=.@M+6VA+NTCE8T<*-SLS'`Y9B3R37GFL_L5?!CQ'\6QX_U#X`
M_#J_\=B]BU(>)+CPKI$NKBZB*F.X^U,#+YJ%$*ONW#:,'@5TGP7_`&O?A-^T
MA;ZO+\._BA\._'L7A]$DU1_#GB2SU1=-5]Y1IS!(_EAO+DP6QG8V.AJY\$/V
MF_AM^TUI5]??#?X@^!_B#9:9*L%Y<>&M=M=6BM)&&Y4D:!W",1R`2"132:E=
M;K7T3%IR\KV?]?D:/CCP]IGQ.\*7F@^)?!T?B'0]101W>G:G;VEW:72@A@)(
MI'*,,@'!!Y`J/QWX3T?XH^&CHWB;P3;^(M'::&X-CJEK9W=L9(9%EB?RY'*[
MDD1'4XRK*I&"`:^:]=_X*(_%>+QI\2KGPW^S\GCSP#\*_%<_AG6;C0?&L?\`
MPE,JPV,-Y)=V^E7-I#;S*!/&@B&H>:Q)VHQX/K:?\%"?@A:?`OP9\2=8^*G@
M3PIX+^(-HEYH&I>(];MM&CU%60.47[2\9\Q0?GC^\A!#`$5,6G!55M[K_P#`
MES0??5;>=TM4[-IJ?)U]Y?\`@+M)?)[_`.31U=W\+O"U_H.KZ5/\.=*FTOQ!
M?_VKJEG)IU@T&I7FY'^TSH6VRS;HHF\QP6S&ASE1AGC7X2^$OB5)K#>(OAKH
M^OMXBTQ=$U4ZEIEA='4[!7>1;2?S&/FP!Y)&$;Y0-(QQEC3_`(N_M/\`PU_9
M]\(Z=X@\>_$/P-X(T'6)%AL-2U_7K73;2^=D,BI%+,ZH[%%+`*22H)Z"D\2_
MM0_#/P9X"TSQ5K'Q$\"Z3X8UJQ.J:=K%YKUK!87]H$60W$4[2".2((Z-O5BN
M'4YP11))1?-M'1^6EK>6FGIY!%MM<O77UUO?SUU]3%\"?LP_#'X7>"M5\-^&
M?@SX.\.^'=>LCIFIZ5I?A_2[2RU&T)F)MYH8\))$3<3G8P*_OY./G;.'K?["
MOP.\2_#S1?".H_L\_#._\*>&Y9I](T6Y\(Z/+IVER3'=,\$#`QQ-(>6**"QZ
MYKU+X:?%+PS\:?!%CXF\'>(M"\6>&]45FL]5T:_BO[&["L48QS1,R.`RLIP3
M@J1U%;U5-.[YM_\`+_(47I[NW^>_WF%H*1>%=#LM,TSPU-IVFZ=`EK:6EJMM
M#!:PHH5(XT60*J*H`"@````5;_MNY_Z`^H_]]V__`,=K2HH;;=V"22LC-_MN
MY_Z`^H_]]V__`,=H_MNY_P"@/J/_`'W;_P#QVM*BD,S?[;N?^@/J/_?=O_\`
M':/[;N?^@/J/_?=O_P#':TJ*`.>T?6+A-1U4C2K]MUTI(#P?)^XB&#^\]L\9
MZCW%7_[;N?\`H#ZC_P!]V_\`\=HT3_D)ZQ_U^+_Z3PUI4`9O]MW/_0'U'_ON
MW_\`CM']MW/_`$!]1_[[M_\`X[6E10!F_P!MW/\`T!]1_P"^[?\`^.T?VW<_
M]`?4?^^[?_X[6E10!F_VW<_]`?4?^^[?_P".U1\465MXX\-:AHNM>%GU?1]6
MMI+*^L+V.UN+:]@D4I)%+&\A5T92596!!!((KH*Y_P"*WB#7O"?PQ\0ZIX6\
M/+XN\2Z=IMQ<Z5H;:@FGC6+I(V:*U^T.&2'S'`3S&!5=V3P*F;2BW):??^'4
MJ";DE%Z_=^/0^=O'/_!)C]G?Q9X<?3=,^`G@CP0+J6(7UUX6\+:'I=YJ%HLB
MO+8R3I'Y@MIU7RYE1D9XV9=P#&O6/C=^S3\-?VF8-+B^)'P<\(_$&/0_,_LY
M/$N@Z9JRZ?YFT2>2)R_E[MB9VXSL7/05\T_LT?\`!3G]H/XA_ML^%?@[\5?V
M2?\`A4?_``DNC7^O/JT?Q1TWQ(UA9VNU/-DM[6`%5>>2&%2[KDN2H;8V.Q_;
MA_;^^+WP&_:.\/\`PR^#/[.K?'C7]3\-S>)]0'_">6/A==,MDNEMEP;J)EE)
M=A]U@1QP>2*D]()Z\U^7KMS7]+<LK[6L^Y$=')K3EM?I\5DO6_-%=WHNB/8/
MC'^R]\,/VB=-T:S^('P7\&^.K/PZCQZ3!XA\/Z7J<>EJX0,L"S[A$"(XP0F,
MA%]!47C_`/9.^%/Q7\9:)XB\4_!'P/XE\0>&88;?1]4U7PYI5Y>:5%"YDA2W
MFDW/$L;DLH0@*Q)&#7G_`,0OVV_B/;>-M%\`>"/@Y8^)OBL/!UOXR\4Z-J?C
M%-+TKPS%-YD<=F-02UN/M-W)<PS11JL"Q,L+R/+$NT-Y;X,_X+27_P"T-\.O
M$GC;X-_![4/&_@_X:6"7?CV;5/$46BZAI-R$$MUIEA`(9X[Z]MH1(\JO-;0Y
M$:I,Y<[1R4&Y-[-N]]-&TY7VLFFN;:[2O>2NXQ<DH);I*UM;.S2MOK=/EWM=
MVT=OMO\`MNY_Z`^H_P#?=O\`_':H>&]8N(].D`TJ_?\`TJX.5>#C,[G',@Z=
M/PXSUJ7X9?$32OB]\.-`\6:#<&[T3Q/IMOJNGSE2IFMYXUEC8@\C*L#@]*M>
M%O\`D&2_]?EU_P"E$E5.$H2<)*S1$)QG%3B[IA_;=S_T!]1_[[M__CM']MW/
M_0'U'_ONW_\`CM:5%269O]MW/_0'U'_ONW_^.T?VW<_]`?4?^^[?_P".UI44
M`>?_`!H^#/@S]I#PK%H7Q$^&&A>/=$@N5O8M.\1Z5I^J6L<ZJRK*L4[.@<*[
M@,!D!V&>32:-\&/!?ARU\)0Z?\,-"L(?`"NOA>.WTK3XE\-AXC"XL@K`6P:)
MF0^5MRK%3P<5RW[4/[5>K_![XA>"/`'@CP=%X[^)'Q!^V7.FZ?>ZN='TNQL;
M/R3=WM[>+#</%&GGPHHCMY7DDE10H7<Z7_V-?VJ!^U?\--4U"\\/7/A#Q5X3
MUN[\,>*-`FNTO/[(U2U*^=%'<(`L\)5XY(Y0J[TD4E$;<BE/WD^7U^YI7\TF
MU&^R?NWOH$_=MS]=%\[NWS2;MU6NQ+X-_9=^&'PZ^+.I>/O#_P`%_!NA>.M9
M:=]0\1Z=X?TNUU:^:=M\QENDQ*YD;YGW,=QY.35/X5?L=_"#X%>/)?%7@CX$
M>`/!OB>XCDBEUC0_#&DZ=?R)(0TBM/#MD(8@%@6Y(&:Y;X-?M^R_%S]M;QC\
M)9_AUXG\):=X8\+1>)[37]>DCM9-;B:_N+)GBLN98H-]LY62<QR..1"$*2/Q
M'PW_`."IFL>,=0^'7BK5/A7+H/P1^+^N+X>\(^+7\0K+JTL\^18SWNE_9U%M
M:WC)((G2ZFD`,)EBB\P["E[W(X=59?.3AR^3<DTH[MIV3LPJ>[S\_367_@//
M?S2C9\VRNM3ZP_MNY_Z`^H_]]V__`,=H_MNY_P"@/J/_`'W;_P#QVM*B@#-_
MMNY_Z`^H_P#?=O\`_':/[;N?^@/J/_?=O_\`':TJ*`,W^V[G_H#ZC_WW;_\`
MQVCP=_R*.E_]><7_`*`*TJS?!W_(HZ7_`-><7_H`H`+K_D;K+_KSN/\`T."O
M!_@;X)UG2/\`@I+\?M=NM(U.VT36?#OA*#3]0EM72UOI(5U/SDBE(V.T?F1[
M@I)7>N<9%>Y:PEQ)XHL!;2PPO]EN,M+$9`1O@[!E]N]3?9=7_P"?W3O_``!?
M_P".T":NK?UT9^='P<_97UCP=^PC^S1:6WPXU+2O$VE?'&W\2:U#%X?>"_LU
M?5K]9K^Y41B1`UJT8>9\9B906VD5R_Q9^'NI6/[(7[3GP)U#X._$'7_C%\4_
M'>MZCHM]:>$M0N=&UV74+U)M)U8ZVD!L;9;*%K;=Y\\4D)T]E"_ZO?\`I_\`
M9=7_`.?W3O\`P!?_`..T?9=7_P"?W3O_``!?_P".U-"/LDTMFW]S5)63Z6]E
M&WJ]+I-5S.\9+=<MO6+J.[[W]K*ZZV6N]_A+XL?LJWWB_P`:_MRWFJ^!KK7=
M2\6_"_3/#VDZH=$=YM?QHUX)[:TEV;I<W`A+1QDXD\O(W;:Q/BA\`/$OPB/[
M/VI?#[X.1:U>>$_@+XNT>70#HAATN:\>STB2VTJ]0!(T$]PLX\ERI<B7'(8C
M]"/LNK_\_NG?^`+_`/QVC[+J_P#S^Z=_X`O_`/':7([SE%V<OPTJK3_P:W\O
M,*%J;IZ74+[];\F_I[-6_P"`C\Q_!?A;6?VBOVCO%OB+XA6WQ]\7>#/$_P`"
MM9\.>*9W^%=WX1BT^:>\M&ETK2+-[./4)=D,DKQK-)>N^6$4LS+*@^F?^"8O
MC;Q_K%QXW\/>(#XB\2>!?"0L;'PAXQ\3^`KSP5X@UB`_:':RO+*YA@,QM$,"
M"[AMX(IC*^(PZR$_3_V75_\`G]T[_P``7_\`CM'V75_^?W3O_`%__CM;*24>
M6*LK6_\`)YS_``YVEU[MW=\N1[MZW3^Z,(?BH*_3LE96^(OA%^TG>?LG?$G]
MH_2[CX6?&OQ7XI\3_$Z?4O#6G:+X`U:2RUV*>PTVWBD75G@73(8O-CDWRS72
M+&L;LQX`/SY\,?V*/'?[$OQ-^'+>//$?QD\-V`^$J^'3KGPJ\#V_C:*RU-]7
MN[_4M.GADT;4YX89/MEN8Y4BC286;"1R4C6OU@^RZO\`\_NG?^`+_P#QVC[+
MJ_\`S^Z=_P"`+_\`QVLHP2C!/5QC&/E:--T_Q4FWK9M+2UT];ZSMM)N7G=S5
M3\)+339O6]FOA+Q'9:M^R-\(/V>_!7P^'Q7L/A?#X>U+3[CQ^OPNN?$WCS0(
M-UK+:6$=A#8'^S_/4,&:XTV2)%LXHWA238R\+^Q9^R_XD70_V*[;Q=\/O%#)
MX%\2^.]0O4\1^'T$V@.TMZUA<7"QQBWMI&)C:)HPD>XJ8?EVU^D_V75_^?W3
MO_`%_P#X[1]EU?\`Y_=._P#`%_\`X[6C=^9O=N]^N]_ZM9:)VO=O)PO&,5LE
M;]/N?G?UMH>!?\$Y_AUJ?PU_X7M;7VA7V@6FH_%W7=3TR*>R>UCNK6=+5Q<0
M@J`T4DAE;>N59BYR3FOH^LW[+J__`#^Z=_X`O_\`':/LNK_\_NG?^`+_`/QV
MIBK4X4_Y8QC_`.`Q4;_.UR_M3E_-*4O_``*3E^%S2HK-^RZO_P`_NG?^`+__
M`!VC[+J__/[IW_@"_P#\=H&:5%9OV75_^?W3O_`%_P#X[1]EU?\`Y_=._P#`
M%_\`X[0!I45F_9=7_P"?W3O_``!?_P".T?9=7_Y_=._\`7_^.T`&B?\`(3UC
M_K\7_P!)X:TJY[1[?5#J.J[;RP!%TN\FS<[CY$73][QQCUZ'UP+_`-EU?_G]
MT[_P!?\`^.T`:5%9OV75_P#G]T[_`,`7_P#CM'V75_\`G]T[_P``7_\`CM`&
ME16;]EU?_G]T[_P!?_X[1]EU?_G]T[_P!?\`^.T`:5%9OV75_P#G]T[_`,`7
M_P#CM'V75_\`G]T[_P``7_\`CM`'QA\+_B3/\#+3]HC]KOXJ>&?&=F;^[7P_
MX;\.R:<J:U:^'-+F:VM(K>WF:-A+?WLUQ<B-F4N+BW'.%IW_``4B^$7[/'Q2
M^-GAOQ+\5_A1\=O$GQ`\!Z.+_P`)Z[X$\/\`BZ:>V,CR,(8+S0_W45TLD0.+
MEXRGF(P.UB:^NO%7P_7QU;6D.MVWAK6(;"\AU&UCOM'^T+;74+AX9T#R$++&
MX#*X^92`00:T_LNK_P#/[IW_`(`O_P#':B4.:$8MV<;)-;Z1MS)])-MMNV[;
MZE<WO2;UYKW[/56B^\8I)+RMV5_S=_8UU3XJ_L,_&/1_&'Q\\*_%/Q1??$#X
M/Z'I5WJ^@>%[[QA>V6JZ5>Z@YL-0.FPSRK<M;:C;_OV413/#.3)N%>9?\$Z=
M(^)'_!/C]GS]HSP3X_\`@U\5)?&7QHU.]\>^$K'0/"]WK5G=R:Q:F)=+N=1M
M(I;:RN;>:(),;R2*)!(L@8H21^M_V75_^?W3O_`%_P#X[1]EU?\`Y_=._P#`
M%_\`X[5UTJRFI_;4HNW\LI<[2\[\J3UTBM+MME.3IRC..Z<7Y<T8J*?IRIW5
M]Y-WT5N!_8D^"][^SC^QM\*?A_J3*^I>"?"&E:'=E7#J9K:TBBDPPX(W(<$=
M:[[PM_R#)?\`K\NO_2B2C[+J_P#S^Z=_X`O_`/':H>&[?5#ITFR\L%'VJXR&
MLW//GOG_`):COGZ>_6MJ]:5:K*K+>3;^_4PHTE2IQIQV2M]QT-%9OV75_P#G
M]T[_`,`7_P#CM'V75_\`G]T[_P``7_\`CM8FII45F_9=7_Y_=._\`7_^.T?9
M=7_Y_=._\`7_`/CM`'RQ^V+/JGP-_P""A7P5^,%QX6\8^)/`UGX8\1>#-9G\
M,>'+OQ#>Z)/>/87EM/):6<4MT8'_`+/EB,D43;'>,-A7S61^P3XGUOX8>./%
M>KZU\-?B=8Q_M+?%+6?$.E,^B,$\-Z=!IEM#;7.KJY233Q=)89CCE3S`\\<;
MJC9`^OOLNK_\_NG?^`+_`/QVC[+J_P#S^Z=_X`O_`/':=)N"LNTHKTE-5'\^
M9:/HFU9Z,*OOZ^:?S4'!/T47JNK2?>_PO%\5H/'?_!7GQ??V_A/XOVV@^)/A
M7:>`;36[OX7>);;3/[635K^22-KF2Q6)(5CFC?[0SB`AN)#7FGP<T/Q;\4_V
M-_V6_P!G.?X9_$_0_'/PG\6>&_\`A,;G4O"E[IVB:3:^';H22W<6IR0BQO4N
M&M8A"MK-))(+E6(&V0K^F?V75_\`G]T[_P``7_\`CM'V75_^?W3O_`%__CM%
M!NDH)?9E&7JX5)5(_+FG*_>-E=-797?M7-O[2:]$X1IOYN,8ORDF]G8TJ*S?
MLNK_`//[IW_@"_\`\=H^RZO_`,_NG?\`@"__`,=I`:5%9OV75_\`G]T[_P``
M7_\`CM'V75_^?W3O_`%__CM`&E6;X._Y%'2_^O.+_P!`%'V75_\`G]T[_P``
M7_\`CM'@[_D4=+_Z\XO_`$`4`%U_R-UE_P!>=Q_Z'!7R1_P2K_X*-^+?VS/$
M?Q)\-?$;1/#7A_Q'X7U.XOO#YT<RI#K7A\ZA>Z?#<E)7=A-'<:?<QRX;;DQD
M*H<`_6]U_P`C=9?]>=Q_Z'!7YJ>*O^">'QY\)_L]?#/4?ASI]OH'Q4M]9\6^
M#_$F_4+4&U\,>(-4O)O[0\P2%)7LV:TO(X06<_O$`#DBI]Y2]U7NFOF_A]/>
MLFWHHN3"R:LW;5/Y).^G72]DMY<J.@\!?\%@?B!\4?%W[2<D4/PU\(>"/A[9
M:3J_@#7]8L-2O4U#3I]5O--FN[Z.V<RR+,]C*\"P(A"21%RP)(]X'[<]K\'/
MVEOV@+;XD>)8[#P-X"/A6#18H].:>Y^TZG!*#;P16\;W%U+-.L82)5D<EB%&
M.*\&_:/_`.";/C6WO/CGH7PZ\'(WA+5?A/X)\%>#HTU&UB%Q)I6HWCS6^))5
M9/+MY(3ODVJV["LQ!`U?C_\`L+_%*R_X*)>-/VCO!OAR/Q%JWA6Z\/S^'_#U
M]J%I]C\8V2V%Q::G#`)I-ECJ$0E5H+QQ&>'B+F&:3%3Y8^SC%W6S=M6DVN9K
MNTDWZW2>SSO.56;:MLTNEW!-Q3[*5TF^N[6K7T[\;/\`@HC\(_V>?&][X>\4
M^(]3@U+1[*#4M9.G^'-4U6V\-6LY817&IW%I;RPZ=$P1V#W;Q+LC=\[5)$_[
M?/[0^L?LS_L2_$+XD>$TT:^UKPSHCZCIHU")[BQF?*[3(L4D;.GS9PLBD^HK
MY/\`B]^Q+J__``U=\:-?\4_!_P".OQ1\'_&3^SM2@7P!\5CX92R5=,BT^ZTS
M4[`Z]IT$Q`MU99D^T!TG9"5$8#?1'[>/[-FI_%/_`()C^-_A7X&\/&ZU"_\`
M"2:'I&BSWR,2$2-$@:>XDVMA%VEY'^;&2QS2LW1;E\7KZW7?31<RNGJU96OM
MHJT4OA__`&?EKKH[-:)ZWMU7A?QCXZ^`'P]U_P`4?&SQUX'\1:1:QV[VG_"(
M^`=2TNXA=F*>5Y!U'49KR65WA2**!%D+G:%D9U`I:1_P4<^#^I?"_P`;^,+G
MQ+J7A[1?AM+!%XI7Q'X;U30;[0O/6-H9)[.]MH;E(G612LOE>60'(;Y'V\E\
M;/V3)/V:/V5_%4'[*GP]\%?#?QWJLVG2W`\(:#HVD7FHV\5U&;E8C-"+-[O[
M*URL!NP8EDD&X@$FOEO4OV"/BEXV^%W[5,=A\./B!I2_%/1/"UIX=L/'7CRV
M\0ZWJ4UE<W#7GVB9K^ZAMQ\X=84N#"$==FQB\,=.\G.W1:>NGWKING?7N8IN
M-.,FKM[^GZ/KU6_S^M;;_@J_\#+W5_#^FP>)/$D^K^+H3=:!ID7@G77U#7[8
M-@W5E;"S\ZZM<?/]HA1XO+!DW[/FK>U__@HO\'_#7Q=G\%77B>^_M6RUF#P[
M>7T/A_4I]"T[5)@GE6%SJR6[:?;W3&6)1#+<+)NFC7;N=0:<_P`$?$#_`/!3
MFR^(@TI/^$2M_A?/X<&H^=#F.^?58K@0"/=YO,2%MP79QC.<"OE+P=_P3SN?
M"WQ"\?>$_B'\&OCI\1]%\4_$74/$]EX@\,?%V;3?"ES:WU^-0BDO=)?7K0QR
MVTLA618K*;?]F613(S[0J#YW3Y]+\S?RJ<J79-PO*[TVZ;U4NE4Y=URI?.GS
M-^:4K1LM=_EZ!^UI^VG\1?A5_P`-:_V)K<5M_P`*KLO"5UX;W6$$GV)K[_CZ
M#;D/F!]O\>2NX[2.,?<]?"?[77[&OQ)^*'_#77]A^'/MW_"T-/\`"4'AG_B8
M6L7]IO8Y^U#YY!Y6S/\`RUV;OX=U?=E3&]Q1O=W_`*W"BBBJ+"BBB@`HHHH`
M****`,W1/^0GK'_7XO\`Z3PUI5FZ)_R$]8_Z_%_])X:TJ`"BBB@`HHHH`*AU
M&Z>RT^>:.WFO)(HV=((2@DG(&0BEV5<GH-S`9/)`YJ:H=1NGLM/GFCMYKR2*
M-G2"$H))R!D(I=E7)Z#<P&3R0.:4OA8X[GS;^PE^UK\2?VA?C?\`'/PI\1_"
M?A?P;<_#35M)M=/T[2=0DU&:&"]TN&]VW=RP6.2=3*`WDQK&ARJO,%$KN_X*
M@?MLZ]^QO\`KJ;X?Z1I'B?XJ:Q9WMUX>TC4S)]B2"R@-S?7]WY1#BUMX%^8A
MEWR2P1!@\RU\\:-^T1\4?V.?C#^TK\6->_9P^(EG;?%35="D\(6.I>(_#:'4
MK^'3;;38=.E^QZC=S)/<7*[8_*@F4*P9R@#;=S_@IO\`\$QOCS^TO\1?&GQ$
M^$_[0+>!9M:^'<OA%_!<W@?3M:_M)")Y);6&_NIE^QBZ>2-'=%4YCC9F81H$
MPQ?/]7BZ>_*KVUM)0O9K5ZRLI)>]:5UT-L-[/VMIZ^NG5+T5DVU>R;BXWT=O
M3OB1\=/VB?%W[(OA/XF?#AO@CHT<GP\A\8:P?%5MJ=TM]?/:Q7#6<,<$L7V2
MW"&4_:7EN6!V+Y!`,A\<^'7_``59^,_[6_P&\9?%OX3^#O`FA>$_A=X>TS7-
M7\.^*HKVZU;Q7//I5KK%U9V=U!)%'8JEI<K'%<2070FE8$Q1(OS8FH?`/]I'
MP_\`LJ_!#X!^._!OCWXN?#ZS\*Q2?$C6/"%QX;T;4]79)`+;PN8KC4[58[..
M%5BN;F%G:YCB5`5\Z5AM_M:_LI']IC2_$D'A3]D?XC^#/''CS0K7PW<:WJ'C
M'1M%\*I"L9@ADUFQTK7)?[22QBD?RXI+*YSY:1*50[E[,8K5:SP]G[S5/R:<
MM7?1Q>B2;2M%3O9WERX&WLZ2Q&ZBN;?5>[VU3^)NR<O>Y;)IJ'WO\*?B+8_&
M#X7>&_%NF+,FF^*-*M=7M%F7;(L-Q"LJ!AV;:XS[U=\+?\@R7_K\NO\`THDJ
MA\(_AS:?![X4>&/".GR22V'A;2;72+9Y/OO%;PI$A;W(09J_X6_Y!DO_`%^7
M7_I1)58CV?M9>R^&[MZ=#/#^T]E#VWQ65_7K^)I4445B;A1110!\_?M6_M&^
M-O#OQX^'7PA^&$?A2V\:^/[34=:GUKQ);37VG>']+T]K99Y39P302W4TDEW#
M%&@GA5=SNSD)L>S^P_\`M5ZS\=_ACXS3QY8Z+I'C?X5>)+[PEXK_`+(:0Z9/
M<VL<4PN[99294AF@GAE6.0LR;RI9]H=N4_:Y^'7Q`\%_MJ?"/XT^"?!&J_$K
M3O#NAZYX0\1:!I&IV%CJD5M?FSN8;R#[=/;VTP2>P2-XVG1L3JZAMA%<W^RM
M\*_BO\,I_$<NM_#**W_X:*\=ZYXD\5/'XDM?-^'5B^FQ6VGB:,%UO+B1;2".
M5;61DCDE8AW1=QRO/V,W'XN2;U_G]I%02\O9W;Z7;OJE;22CSQO\-X[?R<DG
M-OSY[)+XFE&RL]>:^&W_``48^+E_X5^#WQB\2Z/\/+?X)_''Q#9:%IFBV4-U
M_P`)'X;AU)A'I5]<WQG:VNO-DV^;`EM#Y/VE`LLQC._J]0_:J^._P(_;-^$O
M@_XG6/PCU+PC\;=1U?2--L_"J:@-6\+W%K;S7D#RW-P_EZA"UM`1*ZVUH4DE
M7"NJY;R3X/\`[,OQM\3_`+-_[/'[/OBSX5WOA_3O@CXGT:\USQO<:_IMSHVM
MZ?H$YDLGTZ.&Z:^,UT8+1MES:PK$K3!F)50_;?LKQ_%GQC^UO<_$_P"-'[/7
MQ/L_&%[+/X?\.31ZSX6N_#7P[T-IC\T6S6&NI;FX58Y+JX6V,C;4AC01Q#?U
MI4_:VA\*E)*_6GRPY;_WG)RU=G&S>R47A4Y^1N2UY5>W2?-.]N\5%1T5U+1;
MR<C[FHHHK$L****`"LWP=_R*.E_]><7_`*`*TJS?!W_(HZ7_`-><7_H`H`AU
MBU>[\46"QW,UJ1:W!WQ!"3\\''S*P_3M4W]B7/\`T&-1_P"^+?\`^-5#KE^N
MEZY#<N&*6^GW4K!>I"M"3C\J^*/V%/@GXH_;O^"/A/\`:'\8?&3XSZ%XJ\<W
M,?B+1M*\.>)/[.T'PYIBW4[VVG#3`CV5VLEN\:SRWD4\S$?))'M7!'WI6Z*U
MWVN]/R;]$];V3):1OUZ?)?\`#+U:TM=K[=_L2Y_Z#&H_]\6__P`:H_L2Y_Z#
M&H_]\6__`,:KY^^"_P"VOX^^/'Q:^*.EZ'\((_\`A$_A7K>H^'+C6+CQ7%%=
MZ_?VT0DBBL+3R-I#;XED>YGMUC,HVF;:^WS:R_X*677Q&\5?&;X2>+=-\#:3
MXP\(?#[4O$DS?#7XH'7Y]/\`(WP7-I<3&PM9M,OXV>%HR89!\S,#F/:V,Z\8
MTO:K^3G7G'E<K_\`@*OWM;35%PIWGR/I+D?E+F4;?^!.W:]]=';[*_L2Y_Z#
M&H_]\6__`,:H_L2Y_P"@QJ/_`'Q;_P#QJOC.]_X**^*/AY\$/#]G\._A[;>.
M]1\*_!S3_B9XA'C'Q]-IMRFGRV[^1%'>?8+EK^\D-K<^9)*L$8*HS.#)A>U_
M:J_;/\9_#_\`X)D6OQ1T?3-#T#Q[XQM-&L](A%Q+JFGZ1>:Q=VUI;S.TL-M)
M,D/VI)&5H4)*%2OKTUH.$IQBKN+Y;=6W*44M>\H22=[:;VU,:,U.,)/3F7-\
MK1D_N4HO:]GL?2_]B7/_`$&-1_[XM_\`XU1_8ES_`-!C4?\`OBW_`/C5?%]C
MX8\`?LB?M-_#[3?%?QX_:EN/B)K&J/:SW^M?VW>^$O&]W>))<?8Y%>RDT&T"
MK'(8X[#[+)"D17=@-G4\$?\`!4_Q9XA\(^`OB5JGP=BTCX%?$KQ):Z!H_B)?
M%1GU^UBO;C[+I^HWFE&S6*&UN)FA&4O99$2XC9H_O!9BN>7+!WUY=-KW223\
MV]$[2>NFA3O%.4E;2_G;75I7[.[5UYW/KS^Q+G_H,:C_`-\6_P#\:H_L2Y_Z
M#&H_]\6__P`:K\[_`/@HU^W+\0OC%^R#\:9_!?PS_P"+9^&?$C>#W\8)XL6U
MUC[597T$=S>PZ>8%1K)+I7M_,6\\\E&98"M>O_M2?\%:(?V6/AU\?]3U'P#=
M:SXA^"FL:3I]AX?T[5?-N_%=OJ45L]K<QX@S"2TETIC"RD?8I#N.<#/VD5%2
M;LFDU?31VM]_,K=7KV=J49.HZ26J=GZZW^ZSOVZ[GUC_`&)<_P#08U'_`+XM
M_P#XU1_8ES_T&-1_[XM__C5?&O[;7[?NF^(?A-\3-)T.P\3SZ#X8\">'O&=W
MXA\-^*VT+4-VJ:CMM+2WGCAD*%H;>22252?D=4V_O-R]/\>O^"A7Q#\!?%;X
MO>&?`GP9T[QI:_!30[7Q!K6IZGXV31H[R">T>Y%O;(+2X=[O$4N%D$<)"9:=
M"0E56DJ/\72U]^EFT[]MGOTL]FB:355\M/5Z?/F2:MWNFMMNNSM]1_V)<_\`
M08U'_OBW_P#C5']B7/\`T&-1_P"^+?\`^-52^%?Q%L/B_P#"_P`-^+=+6==,
M\4:7:ZO9K.NV40W$2RH&`)`;:XR,GFM^M)PE"3A-6:T)ISC."G!W3U1F_P!B
M7/\`T&-1_P"^+?\`^-4?V)<_]!C4?^^+?_XU6E14%F;_`&)<_P#08U'_`+XM
M_P#XU1_8ES_T&-1_[XM__C5:5%`&;_8ES_T&-1_[XM__`(U1_8ES_P!!C4?^
M^+?_`.-5I44`<]H^CW#ZCJH&JWZ[;I02$@^?]Q$<G]W[XXQT'N:O_P!B7/\`
MT&-1_P"^+?\`^-4:)_R$]8_Z_%_])X:TJ`,W^Q+G_H,:C_WQ;_\`QJC^Q+G_
M`*#&H_\`?%O_`/&JTJ*`,W^Q+G_H,:C_`-\6_P#\:H_L2Y_Z#&H_]\6__P`:
MK2HH`S?[$N?^@QJ/_?%O_P#&J/[$N?\`H,:C_P!\6_\`\:J;Q!ILVM:#>V=O
MJ%WI,]U`\,5]:+$T]FS*0)8Q*CQEU)W#>C+D#*L,@_F+\9/B?XO_`.">'QV^
M.8^&7Q%^)7Q%\-_#?X'7OB/Q;%XU\1S^)K;0_$Z;6TIEDN&)MI[F+[3/+:Q,
MD)C$;+%&ICJ>>TN6W1O_`,!BY?E&R_O.*ZMJX4W.RCO=+[Y1C^<K^B;[)_II
M_8ES_P!!C4?^^+?_`.-4?V)<_P#08U'_`+XM_P#XU7Q+X6\,^)?V*OVL_P!F
MZUB^)7Q(\<VOQQCU/0_&4'BCQ%/J]M>:C#ID^J1:C:0R,T6GG?#-&8;,16YC
MD11%\BLO4?%_P]J?[97_``4.\7?"G4O''Q!\(>"/AUX!TO6X[7P=XDN?#MY?
MZIJESJ,*W4MU:21W#I;Q68V0%O(+R%I$DP@&E2,HRY%J];_]NIM_>E[NVZOR
MZVRISC.'M-E:+7>TFHK\7KZ-J^E_K+^Q+G_H,:C_`-\6_P#\:H_L2Y_Z#&H_
M]\6__P`:K\QOV#?BEXX_X*G>,)O`OQ#^)'Q"TC3_`(5>#FAOI_"&OS>&+[Q#
MK+:YKFDC4Y[BQ>*9A'#I2NL`Q;F6=V>)L1JO)?L'^/?BQ_P4E_9M^/'C/QM\
M7OB#HGC#X":C?>"O"<WA?7I-&M#?:5`D[:M?VMOLAOY+F41B2*[BDMQ&KK'$
MN]R<ZE2-.,IRVC&4_P#MR+Y6_6_+9=I)W^)1TA3E*I[+[7,H_P#;[2=O1*]W
MWBUK>-_UF_L2Y_Z#&H_]\6__`,:JAX;T>XDTZ0C5;]/]*N!A4@YQ.XSS&>O7
M\>,=*Y+]BKXUWG[27['GPK^(6HQ1P:AXX\):7KMU'&NU$FN;2*9PHR<#<YP,
MG`[UWGA;_D&2_P#7Y=?^E$E;UZ4J-25*>\6T_EH84:JJTXU([-7^\/[$N?\`
MH,:C_P!\6_\`\:H_L2Y_Z#&H_P#?%O\`_&JTJ*R-3-_L2Y_Z#&H_]\6__P`:
MH_L2Y_Z#&H_]\6__`,:K2HH`S?[$N?\`H,:C_P!\6_\`\:H_L2Y_Z#&H_P#?
M%O\`_&J^9?VP=2U?XS?MP_"'X(CQ1XI\+>#M=\/:[XQ\1'PYJ\VC:CK(T^;3
MH+:S6^MY([J"+S+UI)/L[H[B)5+;"ZM<_P""8'Q`\0ZGX;^+?P_\1>(=9\6/
M\&?B'?>#M,UG5Y_M.I7NG+:V=Y:_:9R`T\T<=X(FE<;W\L,Q9BSLZ5YJZ[2D
MO-1FJ;_\G=DNR;TTN5/<MZI/R<HN:_\`)5?YI=[?1W]B7/\`T&-1_P"^+?\`
M^-4?V)<_]!C4?^^+?_XU7P]XA\">(OV>?^"HGP3\/>!_BO\`%SQUJ_B^+7-5
M^)>C^(_$CZKID.A&.5K>_:RVK;:<POOL]M;FTB@5U21"KXD:O!/^"6&IGPK^
MUM::C\:OB3^W;X6^)E_XDU;1M.\-_$J?4(/AKXIN96O6B33"T!@<);1AXHY9
MT)=08D<`85+WW%=U+[XM*R[W>E^Z::T8JON<WE;[G=Z]K)7L^C3ZH_5S^Q+G
M_H,:C_WQ;_\`QJC^Q+G_`*#&H_\`?%O_`/&JTJ*!F;_8ES_T&-1_[XM__C5'
M]B7/_08U'_OBW_\`C5:5%`&;_8ES_P!!C4?^^+?_`.-4>#O^11TO_KSB_P#0
M!6E6;X._Y%'2_P#KSB_]`%`!=C=XLL@>0;.XR/\`@<%?+?P;_8#^+7[,^B7?
M@?X<?'C3-!^$7]N-J.D:5?>`TU+Q#X8L99UGFTRRU%[U;;R-YF$1N;"=H8YM
MF7$:$?3VL:;;ZIXHL([FWAN$%K<,%E0.`=\'.#]35'P]<>#O%VH:O::2_AG4
M[KP_>?V?JD-H8)I--N?*CF\B=5R8Y/*EB?8V&VR(V,,"2.DN9;_I==-M[??;
MJ[CUCRO:_P"-GU]+_P!(\CL_V#(3\"?CWX%N?%FH+;_'36-;U26^L;46USHB
MZE:QVYCC)=Q(T83<'.W=NQM&.?./AE_P2]\4Z#JDEQXC^(O@N6UM/A?J/PMT
M?2?"7P^_X1W2M*M+IX'6Z6`W]RQE5HFW(KI&P,>Q8BKF7ZW_`.$/TC_H%Z=_
MX#)_A1_PA^D?]`O3O_`9/\*S]E!PY&M.50_[=4)4TO\`P"4E??7>Y7/)._\`
M><O^WG*,V_\`P**=MM+6MH?DK^W+^P;=)\>]%TOQ#-XJ_LKX>_"[PUX<\*:I
M_P`,^I\6]&\175G-<?;"UJ+*[DTPF,*CQK<6S2F>&3SG%OMK[^L_@IK/[='_
M``3QT[P?\>M!C\)>)_&OAZV_X2.P\/71A?0-0&R5);23=+Y4T$R1RI\\H1XP
M-T@&6]L_X0_2/^@7IW_@,G^%'_"'Z1_T"]._\!D_PK:4G.$HU->:3E\VVW;K
MJWWLK*R1G"*A.,J>G*DEZ144ON4?7NV?*4O_``3]^,/Q0U[X10_%CXY^%O'7
MAOX2^(H_$L8L?AY)H^N>(+F&SNK6'[7>#4Y;<<71:3R;./>5X\O.14\#_P#!
M+KQ=H7@CP!\,M8^+MCJ_P.^&7B*TUS1M!A\)M:^(+J"PN3=:;I][JAOGAGMH
M)1!G98Q22K;1AG!+LWUQ_P`(?I'_`$"]._\``9/\*\[\&?M&?!#XC?%K4?`/
MA[QW\*M>\=Z.TR7_`(<T[6K"ZU:Q:%MDPEM4<RH8V.UMRC:>#@T0DU.\=[\W
MS5O>\VK*S>W2UV5)7C[VUN7Y:Z>5^9Z=?DK?/_Q6_P""5?CCQMX!^(_PZT/X
MU67AOX3?$+Q-=^*VTD^"DO-9L+FZN%O)[5;]KQ86LGO/,EV"T6<+)L%P,;J[
MWXW?\$V=,^-/[??@3XVS>(OLECX:T\6NM^&&TM)X/$TT"7JZ=</.7!C-J=1O
M"%V.)/,3./+4U]#_`/"'Z1_T"]._\!D_PH_X0_2/^@7IW_@,G^%1RQM%?RZ+
M_P`!Y?G9;7V>JUU!W;FW]OXO/7F_%ZOOUT/C#X,_\$7X/A#^PG\2/@R?B3?:
MW>^/[ZW,?B.\T<>9I>G68M8M.T]8!/\`/';6UJD0;S%W%G?:"2*]OU+]C'^T
M?'GQ\UO_`(239_PO'0K+1?)_L_/]B_9K&XM/-W>;^_W>?OVXCQLQDYR/8/\`
MA#](_P"@7IW_`(#)_A7'P?$WX;R^)_&FCM=Z!;7WP[MX+OQ(+JW%O%I$$\+3
MQRR2R*L>PQ([%@Q"A6W$8J,3&%6FX5]4U9W[6MJ_3=[]6[CI7A552G\5[KUO
M?1?/1;=$K&M\!OAA_P`*2^!O@SP9]N_M/_A$="L=%^V>3Y/VO[-;I#YNS<VS
M=LSMW'&<9/6NLK`\-6GA?QIX=L-7T>+0-6TG5+>.[LKVS6*>WO(9%#)+'(N5
M=&4@AE)!!!!K(\,^+O`WC'XB>)_">FKI=SXA\&BT.LV8L2K60NHVEMR69`K!
MT5B-A.-I!P>*Z*TYSJ.=3XFW?UZF-&$(4XPI_"DDO3H=M16;_P`(?I'_`$"]
M._\``9/\*/\`A#](_P"@7IW_`(#)_A69J:5%9O\`PA^D?]`O3O\`P&3_``H_
MX0_2/^@7IW_@,G^%`&E16;_PA^D?]`O3O_`9/\*/^$/TC_H%Z=_X#)_A0`:)
M_P`A/6/^OQ?_`$GAK2KGM'\*Z7+J.JAM-L&$=TJH#;H=H\B(X'''))_$U?\`
M^$/TC_H%Z=_X#)_A0!I45F_\(?I'_0+T[_P&3_"C_A#](_Z!>G?^`R?X4`:5
M%9O_``A^D?\`0+T[_P`!D_PH_P"$/TC_`*!>G?\`@,G^%`$/Q!TG5]?\!:W8
M^']7B\/:]>V$\&FZI+9"]33;EHV6*X:`L@E$;E6\LLH;;C(SFODKX&_\$Q?&
MW@_]G#Q'\'?'GQ&^'WC'X?\`CG2]1L_%EUIO@*^TOQ3XDO+V%HYM2N-2GUF[
MC:Z9B'9C;%<*J(L:*JK]=_\`"'Z1_P!`O3O_``&3_"L[Q</"7P_\+:CKFO?\
M([HFB:1;O>7^H7_DVUK90(I9Y997PJ(J@DLQ``!)-1*,+2YMI*S]-?NWZ=D^
MBM<92O'EW3NO7^MO5]W?XP^+7["?[1MOX,\(ZM%\7]+\<_$;X<Z7_P`(]X%O
MM*\'6^@P:1=7JQ6=UX@U5+N]NXKV6"T$I$<$<2DR2A86+KY?LGQE_8S\=WG[
M3S_%OX5?$O0?`WB?6?"L?A/Q';>(/"#^(=/U:*WG>>SN8XXKZRD@N(6GNESY
MDD;K.`8\H#6_\*OVTOV;_CMXWM?#/@CXL_!'QEXDOE=K;2M#\4:7J-]<!%+N
M4AAE9V"JI8X'`!)X%>B>/=5\$?"OPXVL>)[CPKX<TE)H;=K[5)+>SMEEED6*
M)#))M7<\CHBC.69E`R2!6M3FDTY[W=GU]ZZ?K>[\];=(I9PM&ZC:VFG32S6G
MERIKHK76KDW\M?#K_@E/XF_99\0Z#KGP1^+5GX;UQ/")\*>)Y_&'A,^)(O$[
M"]GOHM2*07EBT-VMQ>7Q)#O$RW(!C^0&N9^$_P#P1C\4_LN^"?''@[X2_'*7
MP]X.^*]E&/&(UWPH-8UN?4WB>"_U6PO8[RVCM;BZC9"1-;W,<<D8=4P2A^SO
M'=[X,^%W@_4?$/B:7PQX=T#2(&N;_4]4:"TL[*)?O22RR81%'<L0*Y+7?VB_
M@AX7\6>%M!U/QW\*M.UWQS##<^&].NM:L(;OQ!%,=L,EG$SA[A9#PIC#!CTS
M4M*=X-7YKJW^)N35NS=WR[.RT]U6:DX6DM+=?\/*KW[I)+FW2=KVD[]O\+/A
MOI?P<^&7AWPCH<3P:+X6TRVTBPC=MS)!!$L48)[G:@R>]7/"W_(,E_Z_+K_T
MHDH_X0_2/^@7IW_@,G^%4/#?A72Y].D+Z;8.1=7"@M;H>!.X`Z=@`/PJYSE.
M3G-W;U(A",(J$59+0Z&BLW_A#](_Z!>G?^`R?X4?\(?I'_0+T[_P&3_"H+-*
MBLW_`(0_2/\`H%Z=_P"`R?X4?\(?I'_0+T[_`,!D_P`*`/&?VI?V1O$7Q:^-
M?P\^)_P^\;Z;X$^('P^AU#34GU;P\VO:5J^F7R1_:+2XMDNK67(FM[:5)([A
M"K0D$.KD#+^`'[%?C/X`WVAW=G\6IKRXU3Q5JWB_XC!_#<'E^-[J]M_*CAAW
M2/)IUO;,D!B5'E<QVZQN[Y9SZO\`%CQE\.O@-X(N?$WCG5?!7@SPW9NB7&JZ
M[<VVG6,#.P1`\TQ5%+,0H!/)(`Y-:'@R3PA\1_">G:]X>/AO7M"UBW2[L-1T
MXPW5I?0N-R2Q2IE'1@00RD@@\&B"LGR^GI=J37E=KFMU>H3]ZRE_6CC?U2;2
M>Z6B>B/FW]DW]AKXU?LU^.=>UC4OC%\,O&5UXVUIM5\5ZS=?#*]@\1:S'N;R
M;9+O^W'@@BMXF$4"+:F*)5SY;,SLVM+^Q3\4_B_\2_AMJ?QA^+GA+Q;X=^%^
ML)XEL-*\->`I?#TVJZK%"\-M<7L\NI7BND0EED\J"*`-*48G:@2O6="^,_PA
M\4?&/4_AWIGBOX;ZC\0-%A^T:AX8M=3LIM9L(\(=\MHK&:-<21G+*!B1?[PH
M\,_&?X0^-/B[JWP^T?Q7\-]6\>Z!$9]4\-66IV4^KZ;&"@+S6JL9HU!DCR64
M#]XG]X4Z>G+R]+./I'9K_#;?I9=@GKS\WVKJ7_;U[KYW>G5:'I%%9O\`PA^D
M?]`O3O\`P&3_``H_X0_2/^@7IW_@,G^%(#2HK-_X0_2/^@7IW_@,G^%'_"'Z
M1_T"]._\!D_PH`TJS?!W_(HZ7_UYQ?\`H`H_X0_2/^@7IW_@,G^%'@[_`)%'
M2_\`KSB_]`%`!=?\C=9?]>=Q_P"AP5\/_#OXI6/P<MOVUM;U#QI?_#Z#_A<-
MG9+KFGZ&VMZA:R7&A^'($6TLQ%,9[J1I!'$IAF`D="T4J@HWV9X^TZSUR7^S
MM0%^;+4],O+.;[$\\4X20PJVR2`B6-L$X=&5E."&!P:\KTS]B#X-Z7\!->^&
MG_"+>(+OPKXHU-M;U4W]_K-[JE]J!DCE%Z^I32O>_:5>*)DF\_S(S%'L9=JX
M4>92G)=8<OWSIR?X0?S:T*NFHI])J3]%&2_.7W'R#J/[<GQQ^%_P,_:GLKG6
M/'EKK_PSL?#>M>$M3^(FC>'CK<$>I2-%(EQ!H^VSDMR;=F0,D5PHFD5]I5"/
M2!X;_:)E_;2U[X.G]I;71HQ^']IXU76T\&Z$NL6NHM=75H]K;9M&MH]/++%(
M4G@N;G"!1<K\SO[/HG_!/OX(:)X6\;Z1_P`(MXIU.'XDPV5OXHNM7UG7M5U#
M7%LW=[7S[RYGDN&:/>55O,W;%1,[(T5?4!X"\(K\8I_'W]DZC_PEMQHJ>'I+
M_P"SWOS6*S-.L/EX\OB1V;=MW<XW8XJ<1!RDG3=E9I_^`247IU4W%MZ72>G0
MSAS)2OO=->7O1<ODX\R2=[77J?G1\-/^"@W[0/[8$/PNT3P]%\2;>ZD^$.E>
M-?$=Y\,;'PC_`&A>:K?7%S;(9!XCG6".S464C^7;QM(SS8,D:H!)[!\<?C/^
MTGX;_9W^"GB/QK8_$'X=645A<M\6KWX;Z3HNO^(-$NPT,-M.MG/'J$<E@=T\
M\XLH[F>,"/'R)(3[%??\$\O@A/X>\%:=8^&_&?AP?#S2)/#^@WOAOQ#XBT'4
M[33G=':S>]LKB*YF@+QH_ES2.NY0V,\UM?$G]CKX:_%CPMH>CZQ_PM46F@:?
M)I<+Z=XU\4Z9=7EM)MWI>7%M=QS7V[;DM=/*V6<YR[$W5;DI<F[DWY6O-I:6
MLK2BFE;:]]%?5>S51/7E22MUVBF];W>C:;O9O;6YY-_P4_\`B_\`VG_P2'OO
M$OA[QC-J7AWQ39^'H=2\66,GV-[C0[^^LH;Z_1X]H@#6<\SEE`$88G`"\+\9
MKOP]^R'\3_V>?"6E_L_?!F^^%-YXNM/#/@G6+35%34_"5]=6MU</=6U@=,:*
M,$029EBO1)(9,D<FOIN'PEX/A^%R^"/^$:@?P<NE_P!B?V))HDCV#6/E>3]E
M,+1E&B\OY"A!!7@C%>*?"_\`X)H?`CX/>(_!VH:)X=\?&/X>79OO#&EZCXL\
M3ZIHN@3^5)"KVNFW5U)9Q%(YI%3;"/+W?)M(&+]U5W*/P.<9=+N*?PNUME=Q
M:MRRDVC%7=#EE\?+)>2DUNK^?Q76J2/G_P""G[0/Q/\`$G['WAOXB_$3]H7Q
MW8:U\3/$=YX>\.Z#X(\!Z1>7TYM[F]6&VLTELK@?;95LV:6YN?\`0XX?,S%`
M1]J6AX:_;*^/.M_LY?V'_P`)1K7A;QW8_'^U^&7]L^*]"T6]U=-,NHXIE^VV
M^FO_`&<]Q&MT%#VK(C"&,D9,BM]:Z[^Q7\']?^"OA_X?OX9\0V7AOPEJ;ZSH
M?]FW^LZ=J.CWCR32//;W]O(EW"[&XG!*3#*RLGW#MIG@;]B#X,_#GPS!I.E>
M$M92TA\70>/"US=ZO=W$^NPI&JZA-/-(\LTK>6K.9&82ON=P[NS'+#QY6O:Z
MI./W*=.3UWNXJI%ZV=X[>\QXB\J=J>DK2U\W"HE\E*4&M+JS>MHH^2_BG\0?
MVC_A]H7[62VG[0VKW,'[-NFKXB\.7%SX2T,ZAXBWZ/'J)M=6D2S6!K=6CEC4
M6=O:S8EW-.V%5>X\">.[G6?B7^VAXF\BS2\NOAUX:U3R9;=+FW61M`OI=K1R
MADD3)P5<%6'!!!(KZ?\`$?[/7PW\6VWQ,AU#PYJ-Q'\8K$:=XO&S4$_M>W%H
M;,)\I'D_Z.2F8=A[YW<T:3^SU\-]#/C'[+X<U&+_`(3_`$FUT/7OEU!OM]G;
M6SVL$7)/E[89'7='M8YR22`:Y\32J5,+4HI^\XI1?9\LE)M[ZMQ?79[==Z4H
M1KT:O2,FY>:]VUEMI[W;=?+YA^#'Q0^)W[5?BWP'\-_#WQ0OOA+::!\$O#?C
M._O_``YH&D37VKZEJ8FAC7RKRUGMH;*`6;L8H(8V9IU`DC5-K<;XT\&_%BU_
M:D_:YU[PS\9KWP-J_@CP/X<U*XFT;POITZZ]J<&D74B/,E\ER([,F.3,$.R7
M]X/])`7#?4/Q#_8'^"_Q,/A*2\\.^,-+O?!'A\^%-(U#P]KOB#P_J$>D8B_T
M&6ZL)X9KB#]S&?+G>1=P+8RS$]9H/[.'PQ\+0>+8=-\*W5C!XYT>TT#6H8(+
MY(KFQM;9[2W@1!\L*I!(Z#R@AP<DD@$=68<U6-1T/=DW)Q^;GRW[63BK6:T\
ME?FP<%3E1576,5%2^48*5N_,TW=V:O;JSI?V;OB5=_&;]G?P%XPOX8+:^\5^
M'-/UBXA@SY44EQ;1S,JY).T%R!DYP*[2N8\!V&A?#+P-HWAO0['4;+1?#UC!
MIFGVWV.ZD^SV\,:QQ)N=2S815&6))QR2:U?^$IMO^>6H_P#@ON/_`(BML1*$
MJLI4E:+;LO*^A.&C.-&,:KO))7?=VU-*BLW_`(2FV_YY:C_X+[C_`.(H_P"$
MIMO^>6H_^"^X_P#B*Q-C2HK-_P"$IMO^>6H_^"^X_P#B*/\`A*;;_GEJ/_@O
MN/\`XB@`T3_D)ZQ_U^+_`.D\-:5<]H_B2WCU'528[_Y[I6&+&<X_<1#GY..G
M0^Q[BK__``E-M_SRU'_P7W'_`,10!I45F_\`"4VW_/+4?_!?<?\`Q%'_``E-
MM_SRU'_P7W'_`,10!I45F_\`"4VW_/+4?_!?<?\`Q%'_``E-M_SRU'_P7W'_
M`,10!I50\4>%],\<>&M0T76M.L=7T?5K:2ROK"]MTN+:]@D4I)%+&X*NC*2K
M*P(()!%,_P"$IMO^>6H_^"^X_P#B*/\`A*;;_GEJ/_@ON/\`XBAJZLP3:=T?
M"?['?['_`,)?$'_!4[X@>/OAW\)_AYX$\*?`G3AX$TJZ\.>&K'3%U?Q!=*MQ
MJL^ZWC0O]EMVM;4;L[7EN@,?-G>_X+R_`_PIXR_8TF\::MHMMJ?B3PGKOAR+
M1;NZ9YETDS^(M,666")B8XYF3,9F51)Y;,F[8S*?3?BW^POX%\9_L?Z[\$O"
M\5]X-\&>+]1DNO$`33+V_NM1@NKW[7J*B:5_,6>Y+2KY[LYC\S(4[5`Z+]J'
M]C[X8?MD:)8Z7X_LOB#J&DV"QA-.TSQ+XBT2RF,<J31O-!8W$,<SQR11NCRJ
MS(R`J11%M*C_`''%_-/FDUY.3DDGLM-DKFG/)])7^Y644_/E2<NE]5>[M\$_
M\'`W_!0SX.:3XYU;X`?%CQ:?#.A6'@:[\6'2YM&OKL>,]9FCGBT>SW00R(MM
M;SQ/<RF4HK2K9C)5)EJ+XH:C9?M/_P#!#*R\2_#KP/\`#_Q!\+->^'>D?\+`
M\902O:^+XUT,+!?-::=<6<,5W<6:6DWV>:?4(0KIF-7"H)?TI@^%_A(?`^Z^
M'5U!XLUCPM?Z;<:1=1ZO>ZMJ=[=VTZNLJ27MP\ETY*NPWM*6`P`1@8\C\4?\
M$Q_@'XQL7L+[PSX[.A7$-C;W>@0>*O$UOH6II9P06\`N]-CNEL[K$-M;HQGB
M<R")?,WU-.+A&I%;R<6GWY7-KFCZ2BM):J*6EM:<E*I2JO[*:MY/DO9^;BWJ
MG:[T=UR_0WPZ\16'C#X?:%JVER3S:9JFG6]W9R3Y\V2&2-70MGG<5(SGG-3^
M%O\`D&2_]?EU_P"E$E,MO$%C96T<,-O?10Q*$1$TV=510,``!,``53\-^)+>
M'3I`8[__`(^KAOEL9VZSN>R>_3MT-:U&I3<H[7,*,7&$8O=(Z&BLW_A*;;_G
MEJ/_`(+[C_XBC_A*;;_GEJ/_`(+[C_XBH-32HK-_X2FV_P">6H_^"^X_^(H_
MX2FV_P">6H_^"^X_^(H`^7/VA;2T\7_\%@/V>-)UJWBO--T;P3XM\1:5#/'O
MBBU6.?2+=+A03M\U+>XN55L%E$KXQN)K*_X)M1O\/?#O[56DZ!!;VWAWPM\6
M==7PW:VJK]FM`]A974\42)\JJ+V:YRB@88MQG)/MW[1/[-OPX_:H;PY-XRT;
MQ)+J/@^]DO\`0]5T>\U?0M6TF:2%X)3!>V#P7,:R1.RNBR!7&-P.T8R/!W[%
MOP:\`3_#V72?!E[:W'PMO[_5?#L^=3DFM[V_BDAO;J>1F+7D\Z2R;Y;HRNS.
M7)W_`#5G[-NC*GLW"<;^<ZD9\WK%+E\TEJMC24USQE:Z4HRL_P"["4>7TDWS
M-]+RT?7X2\,>!--L_P#@D7^PYXE\-0VEAXZO?&_@_48=6B1$U":_U><)K,OF
M$EWDFCGNVE^8EPA+@A<!OA_X3>/OV=/!?[&?PR\0?!K_`(17QA\-_BE:6+^.
M;37M-N;3Q-YL=Z-2N;'RF-_(;ZV\ZYNEN[>UQAMS2LB[OM?X8_\`!/3X&?!W
MXA6'B3P_X/\`$-K<Z-J-YK&D:=/J>N7>AZ#>W;2//<V&ES3/8V4K&:;#V\$9
M432!2H=@=?X7_L;?"WX3?%.S\;6=C\0==\4Z9;W%KIVH>*_$WB/Q3)I$=QL\
M\6@U.XN%M3($17:$(S*H4DKQ74JB]JZEK)U%4MV45"T%MI[MGLK/6+Y4C"I%
MRING>_N.%^KO[2\GNKOG3MJ[IVDKMGNE%9O_``E-M_SRU'_P7W'_`,11_P`)
M3;?\\M1_\%]Q_P#$5B6:5%9O_"4VW_/+4?\`P7W'_P`11_PE-M_SRU'_`,%]
MQ_\`$4`:59O@[_D4=+_Z\XO_`$`4?\)3;?\`/+4?_!?<?_$4>#O^11TO_KSB
M_P#0!0`77_(W67_7G<?^AP5XY=_\%!/!MG^Q%XK^/;:9XG/@_P`'VVL75[9B
MW@_M*5=,N;BVG$:>=Y9+/;.4W2+D%<[22!['=?\`(W67_7G<?^AP5^1?C/X"
M>*M2_P"""WQP\3P_&SXG6&B+8^.K@^$8+'PZ=&=$U?4PT!DDTMK_`,M\$L1=
MAP7.UU&`(J2:BVNS-*$5*K"+ZR2^^Y^OFAZO'K^BV=_"'6&]@2X0.`&"NH89
MQD9P?6K5?E!\68_V=KWXU_'_`/X:OD\,+KR>'-'7X;P^*IHEO%T3^Q8SO\-"
M4[_MK:DM[N^Q?Z1YRP`@9BS@_'2Z^)WP-^'/P@C\20ZM!X]_:Y^#VD?![Q!=
MW*R)J=MXG#PI!/<R8.VX6SU+5I'9L?/9D$D[0=IQ;DXTUK=)=KR4W&+?\UXJ
M$E;W9R2UW.>C+]W&51_93?>WN<SMV2DY)WUC&^E]/U]HK\C?V5?%^HBV\7Z'
MK_A[Q5XSM/V"?AQXD\$3V$$D]M=^)=0FEDBLWMIHP)!.^B:?`?,C!*?VFVP9
M%8'[-NO^"I/CE\4YOAC<_L^V'A?Q;^SUKNH:GH?P;TSR=$TZZ@FA\BWO;V.3
MR-0OX([J4&46UI*B3C?"JRIGGK5HQA*I3U2A*:Z:*-24;KISQIW3UT:OTOO"
MG)M0GI+F4'U5W*G&5GUY74L]KM:75VOV1KSCX;_M%6OQ&_:'^)?P]CTRXM;O
MX;1Z3+/>-*&CO1?P23)M7&5*>4P.<YR"*_/KQO\`L\?##X#?\$X?V7;G6-)T
M_2/A?XT\0>%=3^,NLWQ,@\06[Z9/+!)KMY+N::R.I/9(_P!I<Q*C)'\L7RCU
MG_@DG9?"JR_:[_:<_P"%*+IX^&TK^&I-).DF8Z*Y-O?><=.+?N39^<)`GV7_
M`$8$.(^AKKJT>2I4IWOR2<?N46WY+WK+T\SDIU^>G2J+_EY%2^3YK+U]V[71
M/J>Y>./^"D?@'P%X0\<:G=V7B:>[\&>,U^']OH]K:0RZGXIUMX+>:&TTV+S<
M3-(MPN/,:,*(Y7?9&C/7JG@OXJ3>,/B+XG\/2>$_%NBKX92R8:IJ-K%'IVKF
MXB,A6TE21C*8<;)<JH5R`"W6OS%T.WO?V8?V]_BU^TQK:3^*?AEX(^)^L^&_
M$EA+#YS>`8;W3=%W>)+-$3<VT1B&[+;F2V<M&559EDZ3]N^\AUO2_P!O6>TN
MV:WN]$\`R0W5G<LA*,&*R12QD$'!!5T((X(/>N>+;PM.LOBE&+:[-PC+\;\U
M]K/EM>,C6I-1KSIO92DD^Z4I+\+<MM'>\MI1/U#HK\SOVC/A#X;_`&&/CE\<
MK+X/Z7/\-K>^_9KU77+K_A%8"+FYU.SNI([?4F7<#/?(LTF;AV\Y]Q+2$X(Y
M;_@BM:?!+XD?MJZMXJ\+>&_V?OAYXR\.?#_3M"3PMX6M+^WUV^\QOM4FM21Z
MIH^EW2K)!/;KYL*3"99U,LS;8A58>U;6.UF_-6E5CMVYJ=O^WKVLF56?LT[[
MW2];JE+\%4O_`-NM=4?JU1110,****`"BBB@`HHHH`S=$_Y">L?]?B_^D\-:
M59NB?\A/6/\`K\7_`-)X:TJ`"BBB@`JGX@UN'PUH-[J-PEW+;V$#W,J6EI+=
MSNJ*6(CAB5I)'P.$169C@`$D"KE8OQ&\?Z3\*/`&M^)]>NGL=$\/6,VHZA<K
M!).;>WB0O))LC5G;:JDX52>.E34=HME05Y)6N>,?!;_@HCX?^)_QAN?`?B3P
M5\0_A+XG'AS_`(2_3[7QK9V=JNKZ2K^7+=126US<)&86:/S8+AHIX_-0M$.<
M2?!']ORS^/L"ZWHGPO\`BXOPYO;.YU#2?&\^DVITS78(06$EM9QW+ZJ5F56:
M`O8H)AM*%A)'O^"OBQJ4'[0/Q^^)&A_!?XU0_M4:[XW^!'BC1KSQ"MQINHW7
M@!MH-C:P7&CQV]A$NH3R,K1/;FZ9K.-_-*($%_\`8\_:;T7X6?&#X8:_X`_:
M<^(WQF\&ZSX5NM8^+/A_5YM/U2R^&^FZ=H_[B06=A812:1.MR$B-MM1IR)"R
M.\9:G!\T6]FHW7;XJJOT?NQIIMJT>;FO:-K*HK6Y=4Y=-](TW;K\3F^5/WG%
M*UVV?='P$_;_`-'^-'QQ/PXUGP'\2?A?XRN=`7Q3I.G^,+"T@;7=,\T123P-
M:W-PJO$[Q"2"<Q7$?G)NB'..E_;4_;'\(_L&_L\:U\2?&J:Q=:3H^R..PTBU
M%UJ6J3N<);VT)90\C<G!95"JS,RJI(^%?!?[7GPS^#?_``4)D^(MI\?K/]HS
MP;IOPRU.?QIXQ?[%K$WPRL8+N"2WBBDT*"*S5+V5V#P&U:[<V4;^:8T"@_X+
M2:A^T*OQ/\1^(O#7[/:?%OX2>&OA?JL6E:TOCS3M$C\-ZA?VMS#J&I26=P&F
MN9X;,+'%L5-L<]RJLQG(3'&5'3PT:L-&U+T]USMKLKJ*3;]U3;?PZ&N&IQG7
M<).ZNK6W=U"]ENTG*]OBY+;MZ_77Q,_X*'67@7X3^'O&6C_"GXR>/=(USPFG
MC6Y/AW1K5_[&TUHDE!FDN;J&&6XVN?\`1;62>X.QB(RNUFI:W_P5=^#]KXQ^
M$>BZ-J&N^+9OC/<:?%HESHNDRS65C%?V\]Q:37T[A([82QV\I6)V^T-M8K$5
M1V7Y0TC]IWPMXR_X)>_#+PA\8OCQ+^QYXL?X81//H`\0:+*?$&ER6[VMI<K/
M<6QFG$D5KYIATV>&YB^T^6SK(8F'._%7]L_P'X9_9G_8%L/'^L_#+X/>*]$\
M:>&];U;P;-K$.E'POI:Z1J<,4[6MS,9[:TP8@#,3MWJK.6Z]]:G"&*E2^RJL
M(_\`;LISB_N45;KI.]M+<5"4YX95'\7LIR?^*,$U;O=WV]VSA:]]?UDK-\+?
M\@R7_K\NO_2B2I]!UZQ\5:'9:GIEY::CINHP)=6EW:S+-!=0NH9)(W4E61E(
M(8$@@@BH/"W_`"#)?^ORZ_\`2B2L&FG9FR:>J-*BBBD,****`.4^.?QI\/\`
M[.?P?\1^.?%5T]GX?\+V,E_>R1QF60H@X2-!R\CG"H@Y9F4#DUSW['?[4VA_
MMK_LU^%OBAX:TS7]&T7Q;!+/;6.N6\=OJ%KY<TD+)-'')(JL'C;@.>W?BOG#
M_@JX/C]<_%SX/3?#'X")\>?`?AB]N/$FM:./'&G^&-VK6^P:8T[78830PL\M
MPL:H?W\-NY93$H?SS_@A1^UK-I7_``3Y^$'@KXC:!_PK;Q-XYUC7M&\!P?;A
MK'_"4);M<7T]SN@CV6OEDW,>R=E+?9=P)\Q5J(R;I5*B5VMEL]+KKNY/9*^B
M33=WRE1<LXQZ6;;W\^E[**5V^[::T5_J;X=_MYV'QD^)UQI/@OX=?$KQ9X0L
M=;E\.W?CVQMM/C\.0WL+&.=4\Z\CO;B**8&%Y[>UEA$BNOF'RW*S_!?_`(*$
M?#_]H']J/Q1\*/"H\17^K>$]'36KG5Y-+>WT:\C-Y-9LEI<2;3=%)H)%:2%6
MARK*)2Z.J_FA^PIXEU;X*:1^S]HW@O\`:-^)/BCXW6/B&R\`>-_@Q=WVF3:;
MH6FP7TQUBXFTN.R2YMA$J22IJ,KF20-$IF=95%?4/@7]L[X/>(O^"\'B"UT_
MXK_#6^N;_P"%&F>&+6&W\3V4LESJT>NZ@TFGHJRDM=J&4F`?O`&&5YK6C%2G
M3BG=2<UZVI\Z:[Q;:M;J^6[M>17]Q57MR\C]+U%!I_WDKW\ES65[1^_Z***D
M`HHHH`*S?!W_`"*.E_\`7G%_Z`*TJS?!W_(HZ7_UYQ?^@"@"'6)+B/Q18&VB
MAF?[+<9$LIC`&^#N%;V[5-]JU?\`Y\=._P#`Y_\`XU1=''BVR_Z\[C_T."OE
MS0O^"@_Q/^/-GK'B;X)_`7_A8'PUT:[:R@UO6/&<'AR_\620W<MO=/HUH]O+
M'-#'Y1*RWMQ8K*Q(3Y1YA5U?E^?]?>%M+GU']JU?_GQT[_P.?_XU1]JU?_GQ
MT[_P.?\`^-5RE_\`M/?#_P`.^)M(\/Z]XR\)^&O%FM3P65OX>U37;*'5&O)H
MQ+':"$2DO.5.0L9;<.5+#!I/#7[5OPN\9_&'4?AYH_Q)\`ZMX_T@2&_\,V?B
M&TGUBR$>W>9;19#,FW<N=RC&X9ZT^O*M]?PW^ZZ^\5]+OR_';\F=9]JU?_GQ
MT[_P.?\`^-4?:M7_`.?'3O\`P.?_`.-5YUX]_;P^!_PJ^)K>"O%'QE^%/AOQ
MDDD,+:#JGBVPL]35YE5HE-M)*LNYU="HVY8.I&<BM/Q+^UW\)_!GQBLOAWK'
MQ/\`AYI7Q`U)XDM/#%YXCLX-8NFE_P!4([1I!,Q?^$!3N[9H6MK==%Y^@WI>
M_35^G<[+[5J__/CIW_@<_P#\:H^U:O\`\^.G?^!S_P#QJN'\6?MG?!_P%XAE
MTG7/BO\`#71=5@%P9;*_\3V5M<1BW8+/NC>4,/+8@/D?*2`<5VM]XZT32_%6
MF:%<ZQI5OK>M0SW.G:=+=QI=7\4'E^=)%$3OD6/S8MY4$+YB9QN&1.Z377;S
M_JP=6NJ'_:M7_P"?'3O_``.?_P"-4?:M7_Y\=._\#G_^-5P'B+]I/^P/VS/"
MGPC_`+%\W_A)_"&K>*O[6^U[?LWV&[T^V\CR=AW;_M^[?O&WRL;6W96[H7[7
M?PG\4?&>Y^'&F_$_X>:C\0[)Y$N/"]KXCLYM:@:-=T@>S60S*57E@4X')IK5
M1DOM7:_[=;B_N::_':P2]UM/I:_S2:^]-"_M!_!2W_:;^"7BCX?^*=-AD\/^
M+=/ETV^%KJTMO.L;C&Z.18LJZG#`],@9!&17GWPH_8GO_!'QGTKX@>+/'7C+
MXL>*?#>FW.DZ!<^*;O2X$T""Z,1NO(BTS2[.-GF\B`,\RR,%B`0H&?=F_`/_
M`(*.>#O%?Q*\:^#?'OC3X<>$/%FG?$+4?!_AG1KG6H+'4/$$$'V<1/%;S2^9
M-*SS%#Y0P6`PH)Q7I^N?MB_"/PS\0=.\):E\4_AQI_BK5[UM,L-%N?$ME%J%
M[=JXC:WB@:02/*'(4HJE@Q`QFE2=^2K#[<4UZ2CT\[2L[:ZV8I_:A+[#:?JG
M9_*\?1VN=K]JU?\`Y\=._P#`Y_\`XU1]JU?_`)\=._\``Y__`(U7*^)OVI?A
MEX*^,&F?#W6?B-X$TGQ]K2))IWAF]U^T@UB_5RP1HK1Y!-(&*/@JISL;'0UY
M]\`_^"G7P1_:1^)'Q$\*>&OB#X4FUKX9WT]KJ<#Z[8,UQ!!;V\\]_`L<[LUG
M&;@1/,RJ%EAE0XVY(FGMT3?R5D_NNK]KC::W[I?-WM]]G8]K^U:O_P`^.G?^
M!S__`!JC[5J__/CIW_@<_P#\:KC?A/\`M=_"?X]>&]:UGP-\3_AYXTTCPTN_
M5[[0O$=GJ-MI2[6?-Q)#(RQ#:CMER.%8]`:F^'7[5OPN^+_C_4/"GA+XD^`?
M%'BG2+<75]HVD>(;2]U"RA.S$DL$4C2(G[Q/F90/G7U%/[7+UW^7<5U;FZ;?
M,ZS[5J__`#XZ=_X'/_\`&J/M6K_\^.G?^!S_`/QJM*BD,S?M6K_\^.G?^!S_
M`/QJC[5J_P#SXZ=_X'/_`/&JTJ*`.>T>YU0:CJNVSL"3=+O!O'&T^1%T_=<\
M8].I],F_]JU?_GQT[_P.?_XU1HG_`"$]8_Z_%_\`2>&M*@#-^U:O_P`^.G?^
M!S__`!JC[5J__/CIW_@<_P#\:K2HH`S?M6K_`//CIW_@<_\`\:H^U:O_`,^.
MG?\`@<__`,:K2HH`S?M6K_\`/CIW_@<__P`:H^U:O_SXZ=_X'/\`_&J^2M"_
MX+%>&=2_:@^,7A&Z\+7UG\//A!X.OO%DWC@7RS1:Y_9]P;;4(;6U5-S)!,LL
M/F^9\\L$J!/EW5/IG_!3CQ9X+U;3$^*/P=;P#9^-O"VJ>*?!;P>*$U6XOQ86
MSWDNGZC$+>(6-Z;4)*%B>ZA_UB^=N0!X=6"I>W?PV<K^2YO_`)"5EN[:="E"
M3J>R^U?EMY^[I\N>-^U];6=OH?XM?"6R^.OA6+0_%>@:=J^CQ7UKJ)LVU:XB
MAGFMIDGA\U411+&)$1C')NC;:`RL.*Z?[5J__/CIW_@<_P#\:KYC_P""=7[;
M'QY_;!FCU3XD?LRK\%_`^JZ##K6AZ^?B-I_B(ZN9O+>*(6UO"DD6Z)S)NDQC
M;M(R>.K_`&A?VPO&'A3XZ'X8?"?X;6?Q*\<:?X>'BO6$U7Q)_P`([I>F6+R3
M0VT?VD6URSW=Q-!*L<7E!`L;M)+&`N_6I%TGR25F[Z=;I:W71VCK?6R[6,Z4
ME53G!W2MKTLVK:[--R5K:7?<]Q^U:O\`\^.G?^!S_P#QJC[5J_\`SXZ=_P"!
MS_\`QJODSPQ_P54U7]H^Q\-V?P(^%K^//$^I^%F\6ZS8>(_$2^&[7P[`+BYL
MULI;E+>[WWSWEI<PI&L?E8@D=IT787Y?P9_P6DO_`-H;X=>)/&WP;^#VH>-_
M!_PTL$N_'LVJ>(HM%U#2;D();K3+"`0SQWU[;0B1Y5>:VAR(U29RYVQ*2C=M
MZ*^O2R;3=]N5-6<MKV5[M7J*<FDEJ[:==;-*V]VFG;>UW:R=OMO[5J__`#XZ
M=_X'/_\`&JH>&[G5!ITFRSL&'VJXR6O''/GOG_ED>^?K[=*E^&7Q$TKXO?#C
M0/%F@W!N]$\3Z;;ZKI\Y4J9K>>-98V(/(RK`X/2K7A;_`)!DO_7Y=?\`I1)5
MSA*$G"2LT1"<9Q4XNZ8?:M7_`.?'3O\`P.?_`.-4?:M7_P"?'3O_``.?_P"-
M5I45)9F_:M7_`.?'3O\`P.?_`.-4?:M7_P"?'3O_``.?_P"-5I44`9OVK5_^
M?'3O_`Y__C5'VK5_^?'3O_`Y_P#XU7SW_P`%"OVW/B#^RCK/PX\/?"WX,-\;
M_&WQ'OKZVM-%_P"$MM?#2P16EM]HFE-Q<QO&2%_A.W/."3@'U[]F[QWXU^)G
MP3T'7/B)X#7X8^,M0B=]2\,+KD.M_P!DL)'54^UPJL<I*!7R@P-^.<9HC[R;
M71V_"^G?U6BVW$]&EW_K7MZ/7KL=-]JU?_GQT[_P.?\`^-4?:M7_`.?'3O\`
MP.?_`.-5X3\$_P!O:X^,W[;OB[X0O\./%'A:R\.>&(?$MEKNNR):RZ[&]_<6
M1:*QP9HH-]NY22<QR..1"$*2/BZ]_P`%,+2#_@I;X8_9ZT?P?=:S9ZI:WRZO
MXO745CL]'U*WLA??V:L.QC//]G>&23YT$2W,.=Q?`(>\HN/VDVO^W;I^EG%K
M6VMENU<G[CDI?9LG_P!O)-6[W33TZ7>R=OI#[5J__/CIW_@<_P#\:H^U:O\`
M\^.G?^!S_P#QJM*B@9F_:M7_`.?'3O\`P.?_`.-4?:M7_P"?'3O_``.?_P"-
M5I44`9OVK5_^?'3O_`Y__C5'@[_D4=+_`.O.+_T`5I5F^#O^11TO_KSB_P#0
M!0!!KMBNJ:Y%;.2J7&GW43%>H#-"./SK\M;^;Q#\%?\`@F%K'P#\4>!OVG/#
M_P`9/@KX>U/0_!.K?#FP\6MI7BRX6WE&F:A#?Z$/L[QR9@9K>_=?)DWJZ8!)
M_4O6$N)/%%@+:6&%_LMQEI8C("-\'8,OMWJ;[+J__/[IW_@"_P#\=K.=)34H
MMZ223MOI>S3Z-7=MUKM=*VM*KR24K7L[^7FGW3Z]=%K:Z?R%^PS^SWK_`(;_
M`&POC%XR\4^&+NU\87O@CP;HEKXEU.T,DUU)'ILGVV&*\8-YH%RL9EV,P+JA
M;)"U\^_\$Z_V78]"T+X'>!OB+XF_:DTGQY\)/$$NICPY+\-;:+PI!J\9NDNK
ME->@T`)-:72S7$GF/J9>9;G#L96VU^G_`-EU?_G]T[_P!?\`^.T?9=7_`.?W
M3O\`P!?_`..UT.=Z[K=W>W9J3DK=M6WMV['+"GRX?V%[Z6OW]WEU[Z:;[:;'
MY!?"?XW7>E_'W3E^(-MXU\*_`_2?CYXA\4Z5XLM_AVVJZ=<ZJ-3N;2WBE\26
MNJ2F*VFFOHXA)-I<2%1):_:&$4DE=]\6?A[J5C^R%^TY\"=0^#OQ!U_XQ?%/
MQWK>HZ+?6GA+4+G1M=EU"]2;2=6.MI`;&V6RA:VW>?/%)"=/90O^KW_8VG?\
M$QOAEI?C2/68M-O/)AUEO$46@OX@UR3PQ#J#3M<_:5T1M0.FK(+AC."+8;9O
MWHQ(`U>\_9=7_P"?W3O_``!?_P".UG02ITH0>Z7*_-?N];[\W[M*_P#*EIS*
MZZ*M1RK2JKK+F7K>H[-;6_>-M7NVWK;1_'W['O[$>F>+/AU^U?X=\>>$7M9?
MB_XZUK3M6U&YTUK2Y\1::]E;P13+(55Y(07G,3*2JLSE2#FN/_X([W7CG]HG
MXE>)_B#\2[-K;6_@OI@^!M@6*R"^N]/G#:SJ:."05NIX[)<#&/LA!S7WC]EU
M?_G]T[_P!?\`^.UR7P3^`6F_LZ^!!X:\'0Z;I&C?;;O4FA,5S<O+<W=Q)<W$
MKRS7#R.\DTLCDLQ^]@8``#I-P:\H1C\XQY$__`'--+^;R1BX+D<.\W+7M*7.
MUZ\T:>O:-NIX0U[JGQH_X*P:=K.A>'?&=AI'PZ^&_B#PYJ6LZQX;OM+TZ34;
MW4]+>WCM+BXA2.]&RQF<R6YDC"E,MEL5\P_"WX<:GJG[&?[//P#L?A#\0](^
M,?PY^(>BZIKFJ7GA'4+72-%N+#5#<ZKKB:U)"+&Z6ZA2YVB&X>6?[>JE,EU7
M]0OLNK_\_NG?^`+_`/QVC[+J_P#S^Z=_X`O_`/':*+=-4UOR-/YJI*JO1<TG
M=;M):W5RZCY^?^]I\N14_F[+?:]]&FT?G1\5_P!E?6+S]BK]LHVGPXU*7Q?X
MQ^*TVJZ:8?#[MJ6N0P7.FR6ES#B/S)TC(F:*1=P7$A4C!H^*_P"ROK%Y^Q5^
MV4;3X<:E+XO\8_%:;5=-,/A]VU+7(8+G39+2YAQ'YDZ1D3-%(NX+B0J1@U^B
M_P!EU?\`Y_=._P#`%_\`X[1]EU?_`)_=._\``%__`([44H^SY;?9IJG]WL_>
M]?W:_I(SJ0Y^:_6;G]_M-/3]X_N/B#XCW?B+X/\`_!1&YOOA19?$76+OXC^*
M]*@^(7A7Q#\.M2G\,3PQ0VD0US3_`!"+=+6TEMK2WSY3W,Z2NHC6&*;D^9?M
M&_#GQ3XH\.?MC_#Q/AWX_P!=O?$OQ*T;QY%IT?AJ^_L[QGX=M;3PX;ZUM=0,
M0LIKB6.SNH1:F=9'8,FW&:_2S[+J_P#S^Z=_X`O_`/':/LNK_P#/[IW_`(`O
M_P#':JC^[BDM[-:^M.27HG36COHW%67*H[2E>?,]KI_-<R_*;5][J+U=[_!/
MQ,L9_P!JK]IWQ=X\^'?PZ\?Z-H&B_`KQ!X2U34M;\&:GX:N?$%[=RPR:=ID%
MG?6\%Q<FW$%R_F1QM&ANE16W.5K=^#G[-]Y\.?$W[!7]D^`KG0K?P9X2U.RU
MW[)HC6J:$UQH43217.U`(#+=KEE?;OF'(+BOMG[+J_\`S^Z=_P"`+_\`QVC[
M+J__`#^Z=_X`O_\`':<?=BXKK;\)59/[W5DO1+=W;QG#GE&3Z7_%4U^"IKYM
MVLK):5%9OV75_P#G]T[_`,`7_P#CM'V75_\`G]T[_P``7_\`CM(T-*BLW[+J
M_P#S^Z=_X`O_`/':/LNK_P#/[IW_`(`O_P#':`#1/^0GK'_7XO\`Z3PUI5SV
MCV^J'4=5VWE@"+I=Y-FYW'R(NG[WCC'KT/K@7_LNK_\`/[IW_@"__P`=H`TJ
M*S?LNK_\_NG?^`+_`/QVC[+J_P#S^Z=_X`O_`/':`-*O/OVK_"GCOQW^S1X[
MT7X8:UIGASXAZMHEU:>'M4U'>+73[UXRL4KE$=@%8YR$8@@':V,'K_LNK_\`
M/[IW_@"__P`=H^RZO_S^Z=_X`O\`_':BK352#IRV:M]Y5.;A-36ZU/Q3UG_@
MGO\`MMZQ\0_%'PTU?PE^SS9^&Y?V>-1\"6<_@V'7ETUK8--]CLH;J^_=_P!I
M->"%I/.?;]G:1S\W-?5?C[XAM^VQXY^`^M/\(?C/;>&?A#H6M>)?'5CK/@74
MM&N8WN-!FTX:/:PW$,1U"YD-U/Q8M*H$'#_O(PWZ`_9=7_Y_=._\`7_^.T?9
M=7_Y_=._\`7_`/CM:RDY0]G.S6NZW;E4EKWUJ:KKRK:[O%DI<T;I[:/IRPB_
MG:"2?1-[Z6_+?X4K\-_^":GQ.M/%O[/_`,/_`-H3P=^SYX&\-:OJ?Q"T76--
M\2V-AK=]=26L.F6^F:?XB>(RZDTR/F2V"C85C=R9$4?17C[QQ??LD?\`!3CQ
MC\0_$'@KXCZWX(^)OPXTC3[#4O"G@W4/$KV6HZ7>7SR6=S%I\,\\#2QZC&T;
MNBQ-Y<H+ADQ7U7XJ^'Z^.K:TAUNV\-:Q#87D.HVL=]H_VA;:ZA</#.@>0A98
MW`97'S*0""#6G]EU?_G]T[_P!?\`^.TG*34==8W7?1J7Y<VBZ<L;WU!**YHV
MTE:_35.+_..O>[VLF?EW_P`$[_!7C#_@F7\7[SQ3\2_AM\31I?Q=\$G40/#/
MA2]\63^']33Q#K.I/I5VNF0SR0RF'68=KLHA9H9AORE<I_P3ITCXD?\`!/C]
MGS]HSP3X_P#@U\5)?&7QHU.]\>^$K'0/"]WK5G=R:Q:F)=+N=1M(I;:RN;>:
M(),;R2*)!(L@8H21^M_V75_^?W3O_`%__CM'V75_^?W3O_`%_P#X[45*<:D)
M4Y;2C*'GRRES->J:BD^T5I=MO2%249JK]JZGZS24;^C5[KO)M-627`_L2?!>
M]_9Q_8V^%/P_U)E?4O!/A#2M#NRKAU,UM:11288<$;D.".M=]X6_Y!DO_7Y=
M?^E$E'V75_\`G]T[_P``7_\`CM4/#=OJATZ39>6"C[5<9#6;GGSWS_RU'?/T
M]^M=%>M*M5E5EO)M_?J<]&DJ5.-..R5ON.AHK-^RZO\`\_NG?^`+_P#QVC[+
MJ_\`S^Z=_P"`+_\`QVL34TJ*S?LNK_\`/[IW_@"__P`=H^RZO_S^Z=_X`O\`
M_':`/F#_`(*B_!/X!?M`6O@C1?CW\,_B5X\TW3;FXU?0[OPIX>\2ZI_95W&(
MD;S'T%6GA=ED!3S0$;RF(.Y*R_\`@G=\3_'OPN^%WA/P]XY\*?&O5(/B/XR\
M0OX3NM>MYM3U#PAX?0RW6GKK]U/*UQ`[Q+LC^T%Y@TL4,F&4X^L_LNK_`//[
MIW_@"_\`\=H^RZO_`,_NG?\`@"__`,=HI^Y?S^[=:V_F2BHJ7\MUU"I[R7EU
MZ[25O\-Y<SCUDDSX=TOXUOKW_!8?Q3KND>%?BS9V&K_"^R\$:7KFH_"SQ+!I
M"ZU#J]_*4DN'L5B6!5EB<W#.(&5N)#7S5\$_V/\`]NWX"_MF?LP6?BK2_P!G
M/7-$\/:WXAU'5_$7AV#Q%<O*-059=7O-3N)(UB2]N0\IML*D1G.TJ(U"C]=_
MLNK_`//[IW_@"_\`\=H^RZO_`,_NG?\`@"__`,=HH?NU#JXW]'>4I/3UD[]T
MHIZJX5_WLI-Z7M^$8P7X17S<NCL:5%9OV75_^?W3O_`%_P#X[1]EU?\`Y_=.
M_P#`%_\`X[0!I45F_9=7_P"?W3O_``!?_P".T?9=7_Y_=._\`7_^.T`:59O@
M[_D4=+_Z\XO_`$`4?9=7_P"?W3O_``!?_P".T>#O^11TO_KSB_\`0!0!'JTL
MD/B*W>&/SI5L+HI'NV[VW08&>V3WKXA_X)I?M1^.?VD]9N->\3?&J74/B-H%
MOJ:^/?@/+X<TS3KKPS<!T-K%9"007\2Q@QH+JZN+FWN?/)4Q9!C^WM565O$=
ML(&C2<V-T(VD0NBMN@P2`02,]1D?45\E6G[*7QM_:$_:Z^!WQ'^+'A_X)^#I
MO@S'J%U/JW@W7=0U;5/$EQ<V9M/LBK<V%K]BL"999WC,URQ>.!0>&D)35ZNK
MTM;TT>JOH_--7^'E:UN3_AZ;IW];=--=>ZT7VELT[]E7_@J?J/C/]C[QI\5_
MBW\.O$_@/3/"&N:KID<\$-E=IK30ZU=:;;65I;VM]=W#WN^.""0.J1R7$A\E
MGC(8=CJG_!3K1/!?@OXE7_C'X9_%3P3KOPN\-IXQU/PUJ=OI=QJ=[HY,@:]M
M6L[Z>UE1##,'0W"RIY?S(-\>_P`COO\`@FC\2/'W["_Q1^!7B1/AD-.NO&&H
M>,/!^K->7.JV^L/+XBGUR&UU?3I;.-(H-S1P2K%//O1I,8P`WJW[(/[&.F?#
M27Q2FK_LV_LU?""+7M+_`+*N)?AQ<B\FUNWDSYT%RW]CZ<4BP%(7,NXMSMV@
MLFY24G&U[:?^`Z>CYM)+71:*[N6U&,]=N=[?R\RV_P"W-5YO5V5CH?V@?^"D
M?PW_`&<;[3H]8;7=3AU/PI-XPBN-'L1>H+-;FSM+:/:K>8\]Y<WT,-O&B-YC
MA\E0N:=X(_;]TK6Y/'=AXH\`_$/X<>)O`'AW_A+;S0/$,>FR7M_I96;%S;26
M-Y<VL@WP2QE#.KHX7>JAT9OECP[_`,$4/&.N?LG_`!-\&>,_$W@[7?$MQ#HG
MAWP'+=P3:GI<7A[P_>&]TBRU.*:-6?SY7D6[5-P*,NUG*\^R_!?]AB;PO\,O
MB=IEI^SU^S-\#=;\6^%KK0;34/AY>&YDU!IXG79=.-&L&CA5_+;`\[/7"E!N
MC$MJE4E1NW:3C?T;A_V]\,9*[V=DKIHHI<U-5>Z3_P#)5+Y?&XM6TY6]FGUG
MP`_X*8>'?CY\1?!&A?\`"O\`XI^#K+XG:1<ZSX-UKQ+I=K:6/B2*W2.25(TC
MN9+J"01R>8JW4$/F(C.A=<$[>N_&7Q)9_P#!2WPU\/X]1V^$=0^&VIZ_<6'V
M>(^9>PZG801R^9M\P8CFD7:&VG=D@D`CG/"W[&7BC0_$'[*-U+?Z"T?P+T*Z
MTO7@D\I-W++HR6"FU_=?.OFJ23)Y9V8.,_+4G[0?P7^+=C^VSX7^+/PVT'X<
M^*;73?!5_P"%+W3O$OBR]\/R(]Q>VERLT;V^FWP<`6Q4JP0Y8'/%=-7V<,7&
M,=8)S5^ZY*BBW\W'RO9Z''1=6>%;FK3:@[=O>@Y)?+F^5UJ=P?VT/"X\9_&?
M0_L&O_:_@9IUKJ>O/Y$/EW<=Q927J"U/FY=A'&P/F",;B`"1S7SYXA_;LUB/
M]NOP+J'AGPO\5/'?ASQ]\%H_$^G>$="CM_,$LFH0R+<S_:;F&QMY$MW92TEP
MI<XC0R,54S?$S]D7X^7?Q+^,>L>$+'X.647[0GA+2-,\03:MXAU*X?PCJ-O:
M7-G<&VACL4&I0&&6/RV>2R;<C%EP=M6]`_9!^-WP'^*7PJ\8^!X?A7XGF\%_
M"2R^'.L:1KFN7^E+>W$<D4CW%O=PV5P4C5H5P'MV,@8@B(C)Y8*2K*4]HZ=]
M72KJ7JN;V=GMK=/JMZUW3Y(;O5_*I1:^?+[2Z\K-=_4?"O[?]A\6/@1X-\>?
M#CX:_%#XE6_C);D_V7I%II]C?:(]M(8;J*^;4;RUMX9H;@-"T7G-(SHY171'
M=><U7_@J[X'A^'/PGUS2?!_Q,\3ZA\9IKVP\/^']*TB!]5CO[/(NK*Z62=(;
M>2)TE5Y7E^SIY,C-,$PY\9M_^"77Q.\&_!OX6Z'+_P`*\^+%IIMWXCUKX@>"
M-?\`$&HZ!X5\2:IK%\-0\XK#:W8O(+25IHXK:\MFC<2"4[)$`KK_`-D?_@FS
MXR_9\TK]FVUU"]\"K%\&M3\77>JPZ*L]M:/%JS71M8[*%H_D5!.@:-V`0*0K
M28!.\U=2Z:KSLNMG^3L^C>MXH;<>7EUW_6S:^ZZ]WJE_,>Q?L[?MSQ_M,>.+
MW3]#^&/Q(M/#^FZE>:)=>*;UM'.DP:E9Y2ZLRL-_)=[HIDEA,GV?R&>([)71
MHW?W:OCWP!^Q;\0+#_@H':_%2/PY\./A?I?FWW_"4WG@WQ9J,\OQ-B,<\=E_
M:>DO8V]G'/&T_G&Z,UQ.IB$0D:-LC["I+6G!O>ROZ]?3R3U2WONZ>E245M?3
MTZ+U[M:/=6V11112`****`"BBB@#-T3_`)">L?\`7XO_`*3PUI5FZ)_R$]8_
MZ_%_])X:TJ`"BBB@`HHHH`*I^((+^YT&]CTNYM++4Y('6TN+JV:Y@@F*G8\D
M2O&TB!L$H)$+`$!ESD7*Q_B"^O1^`M;/A6/2)?$XL)SI":K))'8/>>6WDBX:
M-6D6+S-N\HI8+G`)J*GP/?;IO\O,J&LDOSV/DG]G_P"(7Q>^#?\`P4MC^#'B
MWXJW'QHT#6OAP?%^H75[X<T_2KKPG?17D5LJQM91QK]ENS).8XIQ)*GV7B:3
M#DTO^"C_`.U'XH^"W[0VB:+KOQ3UW]G_`.$5UX4NM1MO&^C^&+;5Y-5\0)(^
MW2I9;NTN[>'_`$=1+%`(EGO)"8X9-R>6_)?#GP;^U%^Q'\"?%>J+\,/A3XV^
M,?C^YAEU?Q;:>,=7UZ[\1Z[*4M[:2XL5T:S2UTN!2%""[2.TMXR07;<9/4_V
MA_V3_B3K/[8%[\2M$\*_"7XLZ'KW@0>#+CPYX[UVZTF'00T\KW;6C1Z=J"2Q
M7T<J1W$;1Q%A:0`M(ORJZT9.--7O;F3:TNW&;2TUT;C%-VVC-K7E%!I.HUI?
MELM[6<$WKIJE*5O\44[KF/.O@]\8_P!HK]L?Q=H/PXU+QG<_`GQ1X7^&.E>+
M_%U]H_ANRN-2NM7U.6^AM+9H-0CN8+>WC2S:::$*9C(XC66(1L6\P_9._;:_
M:-_X*+_`7XM^/](\=V/PLU+X!3W/AI=&TSP]97VG>,]=TZ%)[Z6^:[666.RE
M^6*.&TF@EC$KLT[G8%]!_98_X)R_'3]@#5?#>O?#^X^%?C[4[_P##X2\3:3K
M^NZEH=EI5Q:ZA=WE@=-N$M+Z22T@34+BU$,L<;&.WMV#K\R#"_9G_P""7'[0
M7["OPQ^*O@3X?>(/A3XOTWXW(=8UGQ)KUY>Z3>^&=?O('@U*YM[&*TN8KZV_
MU4L,+W%L0RLC/@AP\3S-5'1^*T^7;^)SOD_N\O)?^YK"_O+2J/(IQ]I\-X7W
M^#ECS_WN;GUU]ZRG;1Z_='[+'QNC_:7_`&9?A[\18;7[%'X[\-Z?KZVP8L+?
M[5;1S;`2`3MWXR0,XKJ_"W_(,E_Z_+K_`-*)*POV?_@[8?L\?`GP9X!TIVET
MSP5H=EH5K(R!&DBMH$A5B!P"0@)`]:W?"W_(,E_Z_+K_`-*)*Z<6Z;KS='X;
MNWI?3\#EPWM%1@JOQ65_6VII4445SFX4444`?-7[6WQ2\<^*/VJ_A?\`!+P+
MXKG^'[>,-(U?Q5K_`(EL=.MK[5+.PTZ2RB6WLUNXIK5))IKU`TDT,H6-'"IO
M=71W[`?[1WBCQO\`#3XGZ)\1-4@\0^*/@EXOU#PCJ6NP6269U^&WM[>[@O'@
MC_=QS26]S%YBQ83>K%50$(LO[6/[.7Q#U?\`:A^%WQE^%B>"]6\1>!]/U;PY
MJF@^*-3N=*L]5TS4!;R,\5Y;VUT\,\5Q9VY`-NZNCR@E"%-8/[.?[*WQ=^#K
MSOJ-Y\,[S_A;?C'6O%7Q46+[89+&.ZL5M[*TT>4(@F,/D6L<DUS''YB+(X1&
M8*,_?]C-1^+DGO\`\_/:1Y+>7L][>[>]_>>NDN3GA?X;Q>F_(H2YT^E^>UNK
M7+T3MXQ\.?VLOC7HGP?^`/[1'B7Q^NJ>%?CEXFT?2]3^'HT*SATKP]IVN2)#
MITEE<K$M^US`SP&5IYI8YO.FVQ0@(4W=/_;F^)?Q7_X*L?#'2_#>LVMA^SYK
M\_B;PQ%:?V="\_BS4=)M2]UJ"W#*9([:*Z)MXA&5\UK:=SNC:,FK\._^";GQ
MFU3X$?"+X#>.;WX;0?";X.:W:WL/B31-6O9/$'B:RTR21M*@>QDLTAL)A_HS
MS3)>3_/;L$7$F4XKP!_P;L3?`K]J'X#>)O"/[1?[1FJ>"?A/=7$\^E>(_'QG
M-G"L48M[.PABLUB2UF*>5<Q$H'@^5:ZH^S]J[:0YI<M]7R.$4N;JVGS?%>3;
MOHU%G/5Y^7^]9<UMN92DWR]D_=VTY5R]9(_36BBBL30****`"LWP=_R*.E_]
M><7_`*`*TJS?!W_(HZ7_`-><7_H`H`AUBP34?%%@DAF4"UN&S%,\1^_!W4@_
MA4W_``BUM_SUU'_P87'_`,71=?\`(W67_7G<?^AP5^,O[*W@S0[3XC?L_7/A
M;X5:O\*?BAXA^+?B.)_BSNM+#2/&>EP:U>W.HZ1</8W$EQ>3SV]NL4$&IP1+
MF"1XG_=$.0]ZK"F_M.U^UVE^MWK>R=DWH*?NTY3[7?W1;_3T[V1^S7_"+6W_
M`#UU'_P87'_Q='_"+6W_`#UU'_P87'_Q=?'^F?\`!1;QS)X5L_!]WI?A&'XW
MS?&-OAF^G+#.;!K))?M[ZDL/GF7:=`'VD9DP)G4'CY*ROC#_`,%(_%OPE_:P
M\.Z%:^+?ACXV\,ZK\0+/P7JGA[PYX/UF^O/#*74S6T1O?$4=R^G6]\KF&9[&
MXMH9"CM&A;"S.4_?<%'[;27FY*#7GKSQUV6MVK,=7]W&<I?93;]$YI^6\)>M
ME;=7^U?^$6MO^>NH_P#@PN/_`(NC_A%K;_GKJ/\`X,+C_P"+KX7^)G_!0+X\
M>&/"_P`9OB)86GPCC^'GP3^(!\+W&D7&G:C/K7B2R2YM4G=+E;E(;*9(KD;,
MPW*RN#D0@8/6_P#!<[X-V'[0_P"R+X4\":I<7EII_B_XE>%])GN+24Q7%LLV
MI1IYD;CE77.X'U`J.=N%.<5?VCA9=;5.7E?W23W\G8/=3J)OX%._K#FNN^\6
MMO-7/KO_`(1:V_YZZC_X,+C_`.+H_P"$6MO^>NH_^#"X_P#BZ_-_XA_M%:_^
MVM_P3Y\#?`K6+JYM_B=XRN=1\&?$\VT["?3[7P^I_MZ<N/F5;OR[>%&Y&-6C
MYYW5A_\`!*W]ICX^?&']@OP[H_P@_P"%7:5I'P3^'?AW3G_X2[2[[4[GQ;JL
MFB6]^UM')!>6RV$"0SV\0E>.Y)9V(3:F&T;A:K/F]V'*[]'%J3Y^_+HDK7;;
MM;3449>Y&WO2YM--))Q7+?;FNW?:R5WH]/T\_P"$6MO^>NH_^#"X_P#BZSM-
MFT#6=>U+2K/6/M6J:,8AJ%G#K,KSV'FKOC\U!)NCWK\R[@-PY&17Q7K7_!5#
MQ3XUU[X+:G8W_@?X+>`/BQX.TSQ!8:]X\\.WVKZ;K&KWGF2-H":C!=VEK87,
M<4)*O<>8;@S#RHCY95\[XU_M6W7[%GQ]_;*\?Z=HW_"0ZS9P^`=-TG3C'<2K
M<WMZDMG;[TMXY)W19)U9DAC:1U4JBEBHI55*FO>WYG&WFGRV[:O;7L]FF*'O
M35./5)_)JZ_#?L[K=-+[V_X1:V_YZZC_`.#"X_\`BZ/^$6MO^>NH_P#@PN/_
M`(NOB;X>?MT?'[Q=X2^+^F:9X5B\6^)O"O@[_A)_".NWWPC\4^`='U:^0R"7
M1IK75Y?,>8[(V2:&YVL)^47RCO\`6/@9^W:W[4/[1O@[0_`RZ1>>"KOX:V_C
MWQ%>2(\EW9R:E+&NDVJ%7"1LZ0ZA)('5FQ#'C;DDTHMNR_K2;_\`<<K=[*VZ
MNN9)<S_K6"_]OCZ7UM9V^@?^$6MO^>NH_P#@PN/_`(NC_A%K;_GKJ/\`X,+C
M_P"+K2HJ2C-_X1:V_P">NH_^#"X_^+H_X1:V_P">NH_^#"X_^+K2HH`S?^$6
MMO\`GKJ/_@PN/_BZ/^$6MO\`GKJ/_@PN/_BZTJ*`,W_A%K;_`)ZZC_X,+C_X
MNC_A%K;_`)ZZC_X,+C_XNM*B@#GM'\-V\FHZJ#)?_)=*HQ?3C/[B(\_/SUZG
MV'85?_X1:V_YZZC_`.#"X_\`BZ-$_P"0GK'_`%^+_P"D\-:5`&;_`,(M;?\`
M/74?_!A<?_%T?\(M;?\`/74?_!A<?_%UI44`9O\`PBUM_P`]=1_\&%Q_\71_
MPBUM_P`]=1_\&%Q_\76E10!F_P#"+6W_`#UU'_P87'_Q='_"+6W_`#UU'_P8
M7'_Q=:5>7?MO?&/4OV>/V-/BOX\T:+SM7\&>$-5UJQ0IO!GM[266/*]P&4$^
MP-95ZRI4I59;13?W&M"BZM2-*.\FE]YW_P#PBUM_SUU'_P`&%Q_\71_PBUM_
MSUU'_P`&%Q_\77YR?\$Y-1\,_!'X^_#O2_'/[,'B#X?>._B'8R)X;^+NOZOH
MNM>(/B'>G3S?:F=3GM+F6Y@9]LCQ1.\L12-0H@\M(E]M_P""O_P)^!WB[]GS
M6O%GQ:\'_P#";ZZNE2^&/!VF/<7-Q=7&K7C`6L.F6RR!8]0EG6("YA59E1&W
M2+$C8VQ:EA]&KM=%NWT26[;=DDU%Z[7T,<,XUGH[)ZIOMW?1*U[M-K1ZGU=_
MPBUM_P`]=1_\&%Q_\71_PBUM_P`]=1_\&%Q_\77Y)_M??\$Q?'WQI\1_LSW/
MQM_9VUO]J_2_"/POM_#OC.;3_B/#H6H:'K`DA>YO8_,N[4ZA*RJZX,JK(1N9
MP<9O_LJ>`_@O_P`%1_@E^T+X^L]'N[O0OAI;6OA+X5+J+SIJ'PRMM/\`#]A<
MH;'+;K.^2^+^;-%(97:V56D9$7,U9*G"K-N_L^=NW\L).-U>WQ>ZX_9<6WS7
MC9NC&52<(6MS\J5_YI)2MI?9<R=];QMRV=U^KO\`PBUM_P`]=1_\&%Q_\75#
MPWX;MYM.D)DO_P#CZN%^6^G7I.X[/[=>_4UPO[`OQ/UKXV?L-?!SQAXC:1_$
M'BGP5H^JZD\B[6>YFLHI)6(P,$NQ/0=>E>D^%O\`D&2_]?EU_P"E$E;XBC*C
M5E1EO%M?<[&-"JJM.-5?:2?WA_PBUM_SUU'_`,&%Q_\`%T?\(M;?\]=1_P#!
MA<?_`!=:5%8FQF_\(M;?\]=1_P#!A<?_`!='_"+6W_/74?\`P87'_P`76E10
M!F_\(M;?\]=1_P#!A<?_`!='_"+6W_/74?\`P87'_P`77R?^V;X-T?\`:5_X
M*+_!/X0^.+*#Q!\.)O"?B/QCJ/AN^'FZ7K]]9W&EV]H+RW(,=S'#]KFD6.7,
M?F;'*ED3#/\`@F=J%Q\(?AO^T)X'L1=-X6^#/Q#U71?"-K<S22KI^F#3[*^A
MLHV<EO(A>ZDBC7<=B*JC"J%$>T2I2K2V49S_`.W835-_/F;LMK*][NQ?LWSQ
MIQU;E&/SE%S7RY4OF[6TN?6?_"+6W_/74?\`P87'_P`71_PBUM_SUU'_`,&%
MQ_\`%U^5?PV^&&C_``R_8I_9+_:9T>*3_A=OC_Q;X4G\8>,3*[:KXGMM>GAA
MU"TOIC@S6J)*GEPN#%`+6+R@FP,.6_9'T31_#'QZ^`6JZGHMGI&KZCX_U@O^
MT1$U])_PN6)A,EOI;W#0)*3=M*@"7K+8E=/3[!)=!D\KH]C-5O82W4N1_P")
M<C=NZ7/IM*35HQ;=C%SCR>TAJG'G7FO?W[/W-?LI.[DDF?K[_P`(M;?\]=1_
M\&%Q_P#%T?\`"+6W_/74?_!A<?\`Q=:5%9%F;_PBUM_SUU'_`,&%Q_\`%T?\
M(M;?\]=1_P#!A<?_`!=:5%`&;_PBUM_SUU'_`,&%Q_\`%T>#O^11TO\`Z\XO
M_0!6E6;X._Y%'2_^O.+_`-`%`$.L:E;Z7XHL)+F>&W0VMPH:5P@)WP<9/T->
M"W7["'PPN/V<M!^&R>*M;MK'PMXN'C;1]7@U6U35=.U(:I)J6])/*\O89)I8
M2IC.89&4DD[Z^@+K_D;K+_KSN/\`T."N$_9E_;&^&O[8^D>)+WX;>*K7Q-!X
M0UNX\.:R([>:WET^_@($L+QS(C\9X<#8PY5F%"^)6W5I>EFK/Y2MKWL)[:[/
M3UNGI\U?3JKGA'@_]E.RE_X+'^,_CQ=VUEI>AV_@+3O#^EW)UB"2/6]3>:8W
M=X+=9"T3PVL=I;!W52RLP&0,U>E_X)K>`I/%D$R_%OXB1>$[+QVOQ'LO!\>K
M:6NCV>L_;OMSRA_L?VV2)YVE)AFN9(QYS%%1DB:/T#4?^"E_P1T[Q-\5=&/C
M=;G5/@G)8Q>-+:STF^NY-'>];9;H!%"WGLS_`"L(/,,9X?::]U5MR@^O/(Q1
M3?(H3ATUB_)RYT_/WK->BML.I[SG3GUW7I#D^7NO7OS.^Y\\>)_V*/AKXL^"
MGQ3\!W'B?5DTCXN^(Y_$^L31ZE:BYMKF5[=V2W8Q%5CS;1X#J[<M\QR,=W\?
M?A9X/_:,T3P]8:WKS6L/AKQ+IGBFU-C>P(TEU87"W$*/O5P8RZ`,``Q&<,IY
MK5^"7Q_T3X]R>,%T6+486\$>);OPKJ(NXE3==VPC9VCVLVZ,B5"I.#R<@8KN
M*(64:<H[)0<?1).#7HDFB6DW-/JY*7JVU-/YMW/GKP3^Q)\)OA_^T]\4OBUI
MVHRQ^*/BUI\.GZK&VH0&SL0L2132VD>W,4MPL5L9F+-YAM83@;3GR_P3_P`$
ME?AW\(?`+^&/`'QH^*7P_P!#U3PQ8>%?$5MHNK:,?^$H@L[4V<5S<-<6$K07
M9MB(GGLC;.RQQ\AHT9?M6N'\"_'_`$3X@_&KQYX#LHM136_AXNG/J;S1*L$J
MWT+S0F)@Q+?+&P;<%P1QD<TK14>3I9*W2RYK*VUO>EIMJ6Y/FYKZ]^M_=UOW
M]V.N^AXO\7/V!O!'Q4^'5E\/[?XH>,?"OPCM]$LO#ES\/](N](;1=0T^U`18
M'DNK*>^C#Q*D;FWNHF*J""')<Z_Q3_8=^%'QC;XL?VWK%](OQ>MM)@U'[/JT
M4#:1+I:L+*ZL9$420SQ.5E#LSXDC0@``@Z'QU_X*8_!C]FGXDZAX6\;^)]4T
M.^T9-/EU:^;PQJT^C:''?RF&TDOM3BMFL;-))`5#7$\:C!)(`S7N.DZM:Z_I
M5M?6-S;WME>Q)/;W$$@DBGC8!E=&&0RD$$$'!!JI-U8N3UU=WY^N]_GIT)BE
M3E&VC2T79:;+TMZZ7/+_`(%_#Z[^$=S?2:]\<O&GQ/6ZB2*"/Q/_`&!`EAM)
MW-'_`&;I]F69N,F4R8VC;MRV[Q/_`()&_LIV7[&GPK^(<NJVUEX9U;X@^/=9
M\01Z1)K$-\=&TQKJ2/3;-94D=-B6RHX16(0SN.N:^K]=\<Z+X7UG1].U/6-+
MT[4/$5R]GI5K=7<<,VISI$\S10(Q!E=8HI)"J`D)&[8PI-:M%[2YO*WRNG]]
MTM?7N%O=4/-/\''[M7IM=+L9O_"8Z1_T%-._\"4_QH_X3'2/^@IIW_@2G^-:
M5</^SA\?]$_:B^#6D>.?#L6HP:1K+7"0QWT2QW"-!<2V\@959E_UD3XPQR,&
MD,Z;_A,=(_Z"FG?^!*?XT?\`"8Z1_P!!33O_``)3_&M*B@#-_P"$QTC_`*"F
MG?\`@2G^-'_"8Z1_T%-._P#`E/\`&JWQ)\=VGPM^'6O^)M0CN9K#P[IMQJES
M';J&F>*")I7"!B`6(4X!(&<9(IGPL^(EA\7_`(8^'/%FDBX72_%&EVVKV8G0
M)*(;B)98]Z@D!MKC(R<'O0M;VZ6O\[V^_E?W`]+7ZWM\K7^ZZ^\N?\)CI'_0
M4T[_`,"4_P`:/^$QTC_H*:=_X$I_C6E10!SVC^*]+BU'52VI6"B2Z5D)N$&X
M>1$,CGGD$?@:O_\`"8Z1_P!!33O_``)3_&C1/^0GK'_7XO\`Z3PUI4`9O_"8
MZ1_T%-._\"4_QH_X3'2/^@IIW_@2G^-:5%`&;_PF.D?]!33O_`E/\:/^$QTC
M_H*:=_X$I_C6E10!F_\`"8Z1_P!!33O_``)3_&L[QBWA;X@>$=4T'6;G2;_2
M-;M);"^M9;E-ES!*A21&YZ,K$'ZUQGPC_;B^$?QY?Q^W@_Q_X<U^T^%MS]D\
M4W]M<9T_2)/)\]@UT0('"1@EV1V$95E<JRD#G/@K_P`%-/@E^T#?^([3PUXS
ME:^\*:&GB?4+35-#U'1[DZ2ZLR:C!%>01/<VC*N1/`)(SN3YOG7.<_9R@U.S
MC:[[<K5[^C5W?:Q4>>,DX[WLO6]K>M].]SPCXG_\$N#+\,M%TSPS\??B%K.O
M>%M/'AOPCJWB7Q-9VTWP^TZX,4-[=V$NG64$]Q?BRC:**2\ED89YD7<Y;UO]
MH7]B[1?CU^T3X2^)UM\;?B!X(\1^"=&GT;28]%FT"\LK43MF>Z6'4M.O`EU(
M@6)IDVMY:[!A6<,S]B;_`(+"_LZ?\%%O'^J^%_@W\0F\8ZYHEA_:E];CP_JF
MGB"W\Q(]YDNK:)#\[J-H8MSTP#CT#]I+]MWX:?LEW6GVOC;7+ZWU+5+>XOK?
M3-(T/4->U)K6W7=/=M:6$$\Z6T0QOG9!$A90S@LH.M1N/+.IOJTWN[W3UZ_:
MN]=W=]HA:5XT^FC2Z;/;I]FR]++5WXKQO^R_J_C+38K>/]JKXTZ*SZ2-*U"?
M3IO"R2:H0\S?:6WZ0ZV]QMFV%[00#;%$=N]=Y\XLO^"0_P`(O!&BZUH'@#XC
M_$#X8>"/%VAV6@>*/"WAS7+`Z=XEM[:%K?S)I+NVN+J&XEMV$,L]I/!)(J(2
MV]0]>S?%;_@HU\&O@[X4\-:SJ7C(:K9>,=,?6]&7PUI5]XDN;_38XQ))?K!I
MT,\PLT4KON"@B4LH9P6`.9\0O^"IGP#^&3Z4=1^(=E=VFJZ9:ZY]OT?3[S6-
M/TW3KEU2WOK^ZM(98+"UE9ALGNWBC8*Y#$(Q"<4W*+6[LUW?O>ZUU7Q>Z]%9
MZ:#C-J*<7I;3_P`EU3[WY?>WNUKJ>O\`A&7POX#\*:9H>CW.D6&DZ-:16-C:
MQ7*;+:")`D<:\]%50!]*7PWXKTN#3I`^I6"$W5PP#7"#@SN0>O<$'\:W;:ZC
MO;:.:&1)895#HZ,&5U(R"".""*H^%O\`D&2_]?EU_P"E$E5.4I2;GOU(@HJ*
M4-N@?\)CI'_04T[_`,"4_P`:/^$QTC_H*:=_X$I_C6E14EF;_P`)CI'_`$%-
M._\``E/\:/\`A,=(_P"@IIW_`($I_C6E10!X9^TS^S-X5_:/\:^"O%EM\0O$
M7P\\<?#^6[.C^(_"]_8"\2WNHO*N;26*]M[FUF@DVQ.5DA8J\$3*5*\XWPH_
M8K\#?!K_`(1(Z/\`$?QP'T#7-5\2ZWYGB.$)X^U#4H7CN9]9C2-8[@`N)(XX
MUBCB>./8BJ@2O4OVCOVF?`/[(GPDU/QU\2_%>D>#?"FD(6N-0U";8I;!811H
M,O+*VT[8HU:1R,*I/%=5X3\4V/CGPKIFMZ7/]JTS6+2*^LYMC)YT,J!T;:P#
M#*L#@@$9Y%**34E';9^5];>2;5[;-J^Z";?N\W9V^5TW\N9J^ZO;J?*GPU_X
M)A?#/X=W'A339_B7X[\3?#SX?ZM/K7A/P'K&KZ=)H7AVXD,WE>4\5K'?31VZ
MW$J01W-U,D:E<*3&A5?AM_P34\$?#RV\`Z')\9?B3K_PZ^%VK0:SX7\#:EJ>
MCC1],EMC(;*-IH+&+4+B*U+@QI<7<@S%$7\S8*T_V?\`_@M9^S+^U+^TPWP>
M\!?$O_A(?B*DUY;G2H_#VJPJ'M`YN/\`2);98,*(W^;S,-@;2<C/<_#C_@HW
M\&?BU\9K;P%X?\9"^U_49;VWTR5M*OH=*UV:RQ]K@L-2DA6ROIH,GS([::1T
MV294>6^VJ3?NRI_:]Y?WK;3\W'I+5KHQ5=7-3Z7B_*]VX^2>K<=GK='KG_"8
MZ1_T%-._\"4_QH_X3'2/^@IIW_@2G^-:5%(9F_\`"8Z1_P!!33O_``)3_&C_
M`(3'2/\`H*:=_P"!*?XUI44`9O\`PF.D?]!33O\`P)3_`!H\'?\`(HZ7_P!>
M<7_H`K2K-\'?\BCI?_7G%_Z`*`"Z_P"1NLO^O.X_]#@K\A/V:OCJ/^"8_AO2
M_C`-/N+[PS\:$\7>%[VPMHN;OQ5IFNZQ<Z*H(ZS7D,ES:`9!8PVXYP`/UUUB
MZ>T\46#1VTUT3:W`V1%`1\\'/S,H_7O7,2_!WP=/X7T[1'^&6B/HNCZHNN6&
MGMI>GFUL=06=KA;R*/=M2<3NTHE4!P[%L[B34N-VG>W33L]'\TG>-]I)/H%U
M:S5^OS6JOUM>U[;QNNI^4FM_#7Q)^Q%)^TS:VNO7UA\1(/A#X(UK7]>TNZDM
M;FZUN^\0:O<:C<)*A$@#SSS`<Y\O:I)Q7UO#'8_M*_MC_M&?\)U\6_'W@.'X
M*:CHEMH-IHOC2X\.66@6#Z=;WQU*Y@1TM[P7%S)<1EK^.>'9:^6JC$F[ZG\3
M?"7PCXUO]9NM9^&NC:M=>([2WT_5IKW3+">35+:WD:2""=G8F6..1W=$?*JS
ML0`2:R/B/^S+\,_C'\1](\8^+O@UX/\`%7B[P^(AI>N:QH&F7VI::(I#+%Y%
MQ*6DCV2,SKM8;6)(P3FM>:]2,FK))K3[-Y73CZ+W4NS?8CE=JEW=RY=^MHQ3
MO_B:NW_P3\\_'G@/4O`/P5_:S^,VA>/OB7H?BOP/\9KFYT6STSQ-<V.BVYCN
M=,\U9["%E@O5N%D*2"[2;Y0!'Y?.>A_X*H?';5;.7XV>,/AO>_$2P\0_`NZT
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M<^%X-+DTZ5)[%=YDGD::3[:LPECQ$$^K?V8/^4F'[4W_`%Z>#O\`T@NZ[[QG
M^R!\(OB/\58/'?B'X%>`M>\;VLL$T'B'4?#.DW6JPR0;?(=;I\RAH]J["&RN
MT8QBN[TO1-/T/Q-JNM67A!;36==$*ZE?P06D=SJ`A4K")I`^Z3RU9@NXG:&(
M&,TX*U&%/JM_-\J3?SM=^;;;DVV*:<JKJ=_PU;M\KV7DM$EH?$/Q.\-?%SXC
M?\%!OVG/"'PPTSX;^5XL\%>$]*U;6_%6K7:'0XIDU2-IH-/@M)%OF$3RD1R7
M5JNY4!8@G''_`!'^#?Q"T7]J;P/^S-X'O+G4/!'PJ^#.EOI&GS?%K6OAM<ZO
M.MQ)8S:A]ITBRN)[TP1V]JIA9UAB-V&9)&D39^AVGZ)I^D>*M2UVU\(+;:WK
M,4,&H:A%!:)=7T<._P`E)90^]UC\R3:&)"[VQC)KE_CC^SM\._VG+/3[?XD_
M"'PM\0K?27>2QB\3:'INK)9,X`=HA<%PA8*H)7&=HSTJ.3[GOYV4U'R7*YMK
M2]^MU&4=%+?\/+6#E_X$H)/I9[6NG\5_M`?LU^(?%7BO]A/2OC;XIUK4OB!#
MXHU'0->U3PEXZUC2[:]>/P]K+K-'):/9$7+F*,/.D,4AW2Q_ZMV0V_"VH^-?
M"'PO_;(^,EKXV^)7B?Q9\+-<\5Z;X&T&YUZ\N-&T9+73DEC`L%;R[QC++N_T
MI9MFQ1%Y?S%OL/QI^S-\-/B1\*M(\">(O@WX0U[P/X?,3:7X>U'0-,NM*TTQ
M(T<1@M7)BBV(S*NU1M5B!@&NJ\(^&M*^'\%]%H/@R'1(]3NWO[Q+"VL[9;NX
M<*KS2!'&^1@B`L<DA1SP*NM>;J.+MS1FETLYN#YM'H_=DM'>TM]R863HMJZ@
MX73ZJ//I\^:/3[.VUOB+X=:<W[.WQP_9$O?!?QB^(WQ"E^-<5Y;^);?7O&%[
MXAL?%E@-%EOWUB""XFE@L?)N4ML&R6&/;=^7M(9`/,_^"-GQ0UO7?&_A+PS\
M0-?USP=I/A/1]<UKX>:%IMW+#I7CF%]6OH]0OKJ567[7=6A(3[`R;(%ECN,S
MM(C6_P!]?!_]EGX6_L]>*=1USP!\%?!?@?6]8C,-_J'A_P`/:7IEU?(7#E99
M8=K."X#88D9`/6M>V^"_@NSM_#<47POT&*+P=>2ZAH")I.GJNAW,N_S)[4!O
MW$C^;)N>/:S>8^2=QS55\TE*"LO>TZ1YKVM:R:CNM%UMR^ZXY0A:/*W=V2OU
ME9W;>]G)>Z]7HEO[R?YBZI^T1XET_P`6_#7QYX#U7XF:!X)^,WA'QA<6EQXM
M^+=_K6M>)8X-"GODU`:)NEL-*$=S%"\4EC/&\:RB-H(`_E+[5^SA8>(?@Q\3
MOV1-?;XH?$[Q#=_&;P;J<WC,^*O%-SJ>G7\JZ-!J,5PMG(XM;1X9%VAK6.'=
M&7$F]F+U]6>&?V-/@YX*\1:EJ^C_``%^'VDZMK,LL^H7MEX7TB"XOI)8YHI7
MED4!I&>.XN$8L266>4'(=L]FO@#P\A\/X\`V`_X1*![70\6-E_Q)H7B$#1VW
MS_N4,0$95,`H-O3BL^6T9<N[44M=K>TNKJV_.MDMKV6EKJ)SJ1ET3;?G=PL_
MERO=O??<^"/A%<^)/@QX'^,'PS^+#^/]3^+-_P#"_7?$"^)V\?W_`(E\(^.;
M!8T$E_9VEQ-LTF=9KE8S:QVL,:J2(GGC`*X7_!/VS\=?M=?LV^-_!VO_`!"\
M9?#3XNZ1\+=)T/P=X?T;5KBRTO1-*FTZ"73O$%JT<B'4)9YT"RW#JA@,,EH$
M0!Y+C[J^%/[)GPG^!%EKMOX'^"'@;P;;^*(!:ZS%H7AO2M.35X0''EW`AVB9
M,2.-KY'SMZFNDT_X7^%M)\1Z'K%K\.M*MM7\,::VC:-?1:=8I<Z38MLW6EO(
M&W10'RX\QH0IV+QP*<8V4U?XHJ-UI9KVNJ6R=IJ.EE\325TE4I-SC-6]V3?K
M?V>C\KP;[_"KNSO\I?\`!.S]L#6_^"BWQ]T_QE:7VL:;X6^%W@:'0O$FE173
MPVEQXRO9(WU"VFA!Q(^GQVB(I<?*;]]OK7W+7AW[%O[-#?LA_#OQ%IC+>>(-
M;\8^+=8\8ZWJD=G;6(O;S4+N2<XA%P^U8XS%"/G.1"#QG%>O_P!MW/\`T!]1
M_P"^[?\`^.UI*7,HZ6TN[=')N4DO)2;4?[J2Z$1CRMI;7LO1)13]6DI2_O-A
MHG_(3UC_`*_%_P#2>&M*N>T?6+A-1U4C2K]MUTI(#P?)^XB&#^\]L\9ZCW%7
M_P"V[G_H#ZC_`-]V_P#\=J"S2HK-_MNY_P"@/J/_`'W;_P#QVC^V[G_H#ZC_
M`-]V_P#\=H`TJAU'3K?6-/GM+N"&ZM;J-H9H9D#QS(PPRLIX(()!!X(-4_[;
MN?\`H#ZC_P!]V_\`\=J'4;HZQI\]I=Z!=W5K=1M#-#-]F>.9&&&5E,F"""00
M>"#2DKQ:W'%V=SY._8<BT7X9?MT_MFHBZ9X?\.^']6\+*JJ$M;+3;6'PQ9X`
M'"1Q1HOLJJO8"N>\'>`D_P""@WQG\7?M!ZG='P;\)V^'>I?#[P%>WJB&;7+#
M4&CEO/$,J2;?)MG,42VR.09(D:9MHEC`]O\`!W_!/?\`9_\`AUJ%S=^'_P!F
MOX4:%=7EG/IUQ-I_@O1+62>UGC:*>!V106BDC9D=#\K*Q!!!Q1X._P"">_[/
M_P`.M0N;OP_^S7\*-"NKRSGTZXFT_P`%Z):R3VL\;13P.R*"T4D;,CH?E96(
M((.*4Z<9JU36T.7YN#A)_P#;T7;RYI:-J+3C-QMR::I_*+C)?=)7MULE=)M'
MSK^SK\2/B1_P2\^+GPS^!GQB^-_@#XJ^"+OPCJVJ?\)#=^&X?"&H^"-/TN.S
MBMWNW6[DMI+%MYA$DB1R>81F23#!?2O`7B6PTG_@M5\5H]8N;2"XO/@_X<NM
M%:XD13+90ZEJ_P!M:+(R8TDFMC(0<*7CR/F6NJ\1?\$VO@M=_"_7/!WASX0:
M!\.M`\6369\1V_@[0M'T8^([:VF$PLKMHDS);N=RNHPQ1W"LNXY]`^-W[-/P
MU_:9@TN+XD?!SPC\08]#\S^SD\2Z#IFK+I_F;1)Y(G+^7NV)G;C.Q<]!6LZD
MY.-23O)<UV^MU))_+F2=]9<KO;F,X0A"$J45:+M\N64)67_@+\E=6O9H_.?_
M`(('ZU9Z#^T=XF_M6[M(K36OALFL>#))G6,3^'_^$N\2R^9!N`8PK'<6+,<X
M`DB)SN4UPG_!#;Q?X,\,?L!?MPR:]>6-EI+:[K6NEKV7;O\`#%UIA.FW`##S
M/LLD2S>4>00&"C(.?U.^,?[+WPP_:)TW1K/X@?!?P;XZL_#J/'I,'B'P_I>I
MQZ6KA`RP+/N$0(CC!"8R$7T%1>/_`-D[X4_%?QEHGB+Q3\$?`_B7Q!X9AAM]
M'U35?#FE7EYI44+F2%+>:3<\2QN2RA"`K$D8-85J2J4YTME*$J?HI3Y[V[JT
M5;2_O.^MEM3JN-55^O-&=O.,5'E7]VUWY>ZK/EUI?\$X=%UGPY_P3X^!NG^(
M1*NNV7@'0X+]91AUF6P@#AA@$$$$$8KU;PM_R#)?^ORZ_P#2B2C^V[G_`*`^
MH_\`?=O_`/':H>&]8N(].D`TJ_?_`$JX.5>#C,[G',@Z=/PXSUKKQ5;VU:=:
MUN9M_>[G)AZ7LJ4*6_*DON.AHK-_MNY_Z`^H_P#?=O\`_':/[;N?^@/J/_?=
MO_\`':P-S2HK-_MNY_Z`^H_]]V__`,=H_MNY_P"@/J/_`'W;_P#QV@#PO_@J
MMX0TG7/^">'QOU.]TO3KS4M$^'7B633KN>V22?3VDTFYCD:%R"T99&9&*D94
MD'@UU7[.?Q,\-^"OV>/@UI.L>(-$TG5?$GABQBTBRO;Z*"XU1X=/CFE6"-V#
M2E(E9V"`[54L<`9K4^-WP%\!?M,Z+9Z;\2/A1X;^(&G:=.;FTM?$NC:=JT-K
M*5*F2-)RZJVTD9`!P<51^'W[+GPO^$EKHD'A7X+>#/#,'AJ\N-1T>/2?#VEV
M2Z5<W$7DSSVXCVB*26+]V[IAG3Y22.*4+Q53O+DM_P!N\^_KS_AYZ.HU)4TO
ML\__`)-R6^[D7W^6OQK\+?!_Q4_X)D^(?A;X!?XT^%/C1\*OC?XWGT'0?#A\
M)QZ3K7AW3[R&_OY+JQO[>[<7<4)99)6GA;*$%)(LJIYO6?@-\6/V=[7]CG]G
M[7V^$^HV'@7XC6$OAO5-%O[XZ]XBTW2X;EY;N73I(ECL/*LWQ<2"ZNT>295`
MC\Y<?</P@_8Y^#W[/?C";Q#X!^!'@#P/K]Q`]K+J?A_PQI.F7DL+E6>-I8=K
ME&*J2I."5&>E6?@O^RA\*OV;O$-]J_P[^"7@CP%JVIP_9[R]\.>'-*TNXNXM
MP?9))!L9UW`-@DC(!JJ*5.47T4HR_P#!=G!-[NSNW+=\[3O9$UO?A."^TG'_
M`,"4E)KM=-+E6GNK5'K5%9O]MW/_`$!]1_[[M_\`X[1_;=S_`-`?4?\`ONW_
M`/CM(9I45F_VW<_]`?4?^^[?_P".T?VW<_\`0'U'_ONW_P#CM`&E6;X._P"1
M1TO_`*\XO_0!1_;=S_T!]1_[[M__`([1X._Y%'2_^O.+_P!`%`!=?\C=9?\`
M7G<?^AP5\R?#7_@K?X0\=>-/"]EJ?P\^+/@WPUXYUV]\,^'?&&KZ;8SZ!JNI
MVMXUF;0RV5W<2VCRS)((?MD4"R^6VTY&*^F[K_D;K+_KSN/_`$."OR1^%/@+
M5_AU\!/@/\2_%WC;Q'XK^">G_&S5!X@\&7]I9Q:;X<NY?$6H0:5JT-Q:V\5T
MT=MJ#0M)#=S7$3&X5\)Y*"BGK7IQ>S:3^<DM/[VON_9O\5HW:F;M2E);I-KY
M1D_NNE?JUI'6Q^P%%?C5\?H_A#=_"3]I"7QI)I__``VX/'NK?\(/%),G_"P8
M+D7J?\(TFA@G[7]@^SM9,/LN8"K7/F=)<>R_'3]E+P-^T;\>_P!M'4?B3X5T
MKQ7J_A?P!HLNF_;]\\&C7;Z+=N]U:1EMD%R'ACVW,:K,H7"N`2#A5KJGA/K<
MMK7=NW+S:=Y+9K2VFNINJ5\2L,GJY.*]5*UWVB]XO6]GHK'Z85YF_P"T:D?[
M8T?PC.D/YLO@Q_%ZZH+GY=JWRVAMS%MZ_.&#[O4;>Y_-+]LOXH>!/C/\)/`'
MA?XF:/\`!*/Q9?\`P+TO7K'QG\6+*77[S6;BYMI5ET_P_IOF0-+J3RA'DGMK
ME9PTMH/(G_=[.KTSQ?\`$#Q;X<T37?"][K.I_$[4?V+7O=,NX6>;4;K5':W>
M.1",L]PTI!4\DN16]9.E4E?50<T^TN6G7:UZ6E2U_6+UYZ<_:4X<NCJ*#U^S
MS3H7OWO&KO\`E*ZC^@_Q._:*M?AE\?OACX"FTRXNKCXFR:I%;W:2A4L396GV
MEMZD98.N0,'@XKB_VH?V](?V;/BA9^#K'X6_%3XH:_<^&KWQ;):>#;;3)Y;>
MPM)8HI6\N[O;:2:4O,@2&!99')PJD\5\-_LH:?\`LOQ_MP?LC3_L[2^&[N^&
MA:K'XHN?#LLDJ22?V'(8CJS1?N/[59O/+FX_TP@/N^4<>_?MA?"CQC\7_P#@
MJ'X8TWP)\3_$7PH\2I\&]>DLM8TK3-,U%3-_:FG+&EQ#?6TZO`'*NRQF*0[,
M"5<FBO&5.NJ2U^/Y\M.<E;NKQ5^NZ6HJ%53I2J/2W)OTYIP3OV=I/O9V/J_]
MG_X^>%_VG_A!HOCKP9?RZCX<UZ-Y+66:UEM9E*2-%)')#*JR1R)(CHR.H*LA
M!%=E7Y,?`3XM>!/@KHO[$7C'Q)/HWPN\.^`=8\;>#?&]UKFJ216FC^*7M+@7
MBW-W=M\K7-Y;W<JM-)\WFJ`22!5;Q%J7P_\`V@_V5?BCKFI?$KX8>#/#]Y^T
M%JWB/0H?BM9&#P9XY9--A>WL-2BN6@)MI@ZW$;'<<PQ3)',$"ES<?;2A'X4K
MWZ6YZ<4_.\9\ZZM*R3N5'F4(\^DFVK/1W4:DO1>]#D?2+;N]#]<**_);]H?Q
MU\)_B;^Q_P#`7X@ZI8_LX?#K2/"UIK=[HWP:^)MU;'P1XPM?MB0RSZ5</&B"
M411/)8W"6<P$5^H^SHLV1YQ\2=$\+_M$?&[X@R_%[QO\#?V<I-;\+>&G^'=A
M\8_##W6M>$-)ET:%ED\/W\FLV,=I<6]_]K$IMXS,L\$;2-CRE"UO)6^%VZ>>
MVMG)V>B;LE)MJVMI)Q3;M=7_`!BGYV7,M;6;:2O?3]9'_:-2/]L:/X1G2'\V
M7P8_B]=4%S\NU;Y;0VYBV]?G#!]WJ-O<G['W[1J?M9_L[Z#X^CTA]"76Y+N,
MV+7/VDP-;W<UL?WFU=P)A+#Y1PPKQ+X=V=WIW_!5/PE;W^L#Q#?0?`01W.JB
M#R/[3D&KVP>X\O<VSS#E]NXXW8R<9K;_`."-_P#RCI\"?]?>M?\`IYOJ$K4X
M-N[?M->_+5G%?^2Q2_/4P51RK2C:R]S3M>G3D]?63_30^GJ***#8****`"BB
MB@#-T3_D)ZQ_U^+_`.D\-:59NB?\A/6/^OQ?_2>&M*@`HHHH`****`"OG/1O
M^"HWPLUC]J?XG_"GS]:M+SX/^')/$WB7Q#<VB1Z#:P1%/M$27&_?)+`'4R`1
M[4Y7=N!4>E_M7ZO\0-!_9H\=WGPITBSU[XE0:)=-X9T^[GC@ANK_`,L^2K/(
MRH!OP?G95.,%E!R/Q'U7PY^T=>>//'?PB;]E/5/`NK7W[-6N:%,/^%DZ;XBU
M*[$ES<W3:O(UM&INKJ]U$F)XE_>-)=-*3MR*RYW[1QO9*,GKW5.I)/SLX+FB
MM;-/1)FJ@N12?645Z+G@I?-J7N]+IK=Q3_7/X`?\%'?#?QV^*&A^%KGP5\2?
M`-QXUTN;7/!MYXKTNWM+;QE91',DMIY5Q+)$ZQF.8V]XEO<>5*K>5@/MU_VC
M_P!N72?@%\0[7P9I7@GX@_%+QS/I$OB&?P]X-L[6:\T_2XRR&\F>[N+:!5:1
M#''&)3-,X81QOL<K\>_%7_@H5\%OC1\6?V8?B)X5\>Z3K/A/X-Z;J_CCQUJ&
MBI)J0\'Z8^A26:0ZA'`'GMIY+BYC5;>1/-8V\GR?NF(]-\:_M+>!OV.?^"M/
MCSQ#\5_%N@^`/"_Q$^%VA?\`",ZUXAOAI^GZC+IM]J1O;6*>5EB-P@O[5_)S
MYC+(&4$!JZ,1!0FHWLKSU?7E4VO+>-I6WM*W*VK<]"4I4^:2]ZT7;LW*"DK;
MZ*7-Y<T;W2=_2=:_X*J>!-4T7PK-\.O#/Q!^,NJ>+/#S^+8=&\':;;F_L-)1
MGC:YN1?3VL<)\^-X!`9/M#RHZ)$QC?;@WO\`P6=^%^K^'[C7?!7AWXD?$[PO
MH6DVVN>+-;\,:+'+;>"K2?#*;Z.XFAG:98]\DEM:Q7%Q$D3%XERF[XX_X)7?
M%OPY_P`$^OC7J6M_'#7+3X4>'_BWX!_M[PC=^,9/[%ADAC\3Z_>R6(,[+&ER
MEMJU@YML^;ME!"X#8XG_`()5?M`>#OV)/V5OVJ?"'Q99/A[XI^)VM:GX]\'>
M%=<@-EK'BW2=8LREA'86<F&NIWDB>$V\*M(DA",`2M8UI2A"<XJ[C&<K:_%&
M;BJ??57?\SY)6T?N[TH1E44&_=O%<W>+C%NIVM=\O9<\4]5[W[4>%_$VG^-?
M#6G:SI-Y!J&E:M;1WME=0/OBN89%#QR(>ZLK`@^AJ/PM_P`@R7_K\NO_`$HD
MKS3_`()__#76/@U^PI\&O"7B%9H]>\,^"-'TO44FSYD=Q#90QR*V2>0RD'GM
M7I?A;_D&2_\`7Y=?^E$E=>*IQIUYTX.Z3:3\DSDPU252C"I/=I-_-&E1117.
M;A1110!Y3^TK^UQHW[-VI^%M$_L'Q1XV\:>.+B6W\/>%O#<$$FI:H(%5[F8-
M<S06T,,*.K22SSQH-R*"7=$;1_9>_:=\._M9_"X>)_#T&L::;:]GTG5=(UBT
M^R:IH.H6[;+BRNHLL$FC;KM9D8%61G1E8_._[:/Q:T#]F'_@IS\!_B'\0M:T
MWPC\.[SPAXH\)GQ%K%S]DTG3]5GETR\@AGN'*PP--!8W.PRL`YB*CYL"L/\`
MX)S_`+17@OPEXW^(>IWFL7%M8_M)?%[7=3^&X.G7#Q>)+6STJT6>ZMW1&3R)
M/L-S-'*Q59E(9"Q<9*+3BY3?V92]'&I&"C_V]%N>NMK6T3NZZ<6N7NOFG"4G
M+TBURWV5G?5JW7?LF_\`!7[1OVQ?CM%X-\-_`S]I/2]&N+B_@@\<ZUX+2U\(
M3_9&E1W2_%PP97>)D3"9+$`A3G'I7P7_`."A'P__`&@?VH_%'PH\*CQ%?ZMX
M3T=-:N=7DTM[?1KR,WDUFR6EQ)M-T4F@D5I(5:'*LHE+HZK\.?LS^(?`G[.'
M[1?PP\.?LK_M1^+/C?IWQ(\:27?B?X=W?B+3?%&E>%]"DAN[B[NT6&W6ZT=8
M)YH=JM*BR2R+&Z.Q)7U7P+^V=\'O$7_!>#Q!:Z?\5_AK?7-_\*-,\,6L-OXG
MLI9+G5H]=U!I-/15E):[4,I,`_>`,,KS104I2HPGN^9/NY1IN5_3FM'3=Z;W
M0JWN1K2_EY6NUG44+>MN9Z[+7;4^_P"BBB@`HHHH`*S?!W_(HZ7_`-><7_H`
MK2K-\'?\BCI?_7G%_P"@"@"'6)+B/Q18&VBAF?[+<9$LIC`&^#N%;V[5-]JU
M?_GQT[_P.?\`^-477_(W67_7G<?^AP5\)>%_V[_VE=-_9OOOCY=:#\)O'_PQ
MT2\U\Z[X5T73M0T/Q/INGZ=J4UK]IM+F6[N[:_E6"WEE:!XK3<0%60$XI.<8
MZRT7=[+U[>NRW;2'&+D[1U;=DN_]??VNS[M^U:O_`,^.G?\`@<__`,:H^U:O
M_P`^.G?^!S__`!JO%O%7_!3+X.>"YM-.H:]X@33M2ATZ<ZS;^$-8N]#T]=0$
M36@O-3AM7LK-G6>!B+B:,HDT;-M5U)/CE_P4W^"G[.7CKQ#X9\5>*M1AU[PC
M91ZIKMEIOAK5=7DT6Q>,2"]N?L=M*(;4*1FX?$2GY6<-Q537([2TU:^:W7JN
MQ,&IJ\==$_D]G\^A[3]JU?\`Y\=._P#`Y_\`XU1]JU?_`)\=._\``Y__`(U7
METG[2,:?M2QZ`?%?@5/!;_#]O&/EM#=?V@46[6,WWVS/V(6(B8<$^:6.[A!F
MF?`']O\`^%7[3?BZ#0_"&NZO/J-_IAUK3%U3PUJFC1:[8!D5KS3Y;VWACO[<
M&2+,MJTJ`31$G$B$J/O6MN[Z=?=<D_N<9?<^S"Z5W?16UZ:J+7W\R^_S1ZI]
MJU?_`)\=._\``Y__`(U1]JU?_GQT[_P.?_XU7CW_``3:^-7B/]H7]C'PEXN\
M67J:EK^I3:E%<W*P1P"40:E=6\9V1A4!\N)`<`9()[UY3_P2K_X*-^+?VS/$
M?Q)\-?$;1/#7A_Q'X7U.XOO#YT<RI#K7A\ZA>Z?#<E)7=A-'<:?<QRX;;DQD
M*H<`D7S.R[7^ZWXZW]$WT"]H\_2Z7W[?Y>K2ZGUO]JU?_GQT[_P.?_XU1]JU
M?_GQT[_P.?\`^-5\B_\`!//_`(*0>+_VSOVQ?C9X5U#0?#VG?#KPO:V&J>!-
M0M!-]OUBPEO-1L7NKDLY0K+-ISR0A$3$3INW%LCZ6^.>D_$#5O#5O_PKSQ7X
M*\(ZC#/YEY=^)O#%SK]M)`%;*K%!J%BT;;MIWF1A@$;.=P&[0C4Z-)_\/V:Z
MK=695K5)4NL7;\$].][Z/8Z3[5J__/CIW_@<_P#\:H^U:O\`\^.G?^!S_P#Q
MJOB[]G#]NWXK?$7X6:5XMU_Q+\(G\+^)_BM9^#_"OB"+PEJ^FQ^+](8F&6>V
MM!>WABEFNDE6VGDG\AHD$CJH=0>V^%/_``5A\+?$S7OC?8GP9\3+$_!O5)[+
M>O@;Q#.-7ABLK.X+\:<!#,9+LH+;+S-'&)U4Q.&"<XJ$IO:*<GY)*$GIW2J1
MNMUKI9`HR<U!;MI?-N<5][A*SV\SZ;^U:O\`\^.G?^!S_P#QJC[5J_\`SXZ=
M_P"!S_\`QJOFKX%?\%;OAM\4?V5_AU\2->L_&/A2]^(EO;"Q\-_\(AKE_JE[
M>262WDL.G0)8BXU."*,L3=VD#P%4+;@.G=^(_P#@HM\%_!_[/.F_%75O'5EI
M?@+5=0.D1:G>6=U`8;X/)&UI/`T0FMYUDADC:*9$=)%V,`^%JZL'2DX3W3L_
M5VLOG=6[W5MR(24XJ4=FKKTUN_E9W[6?8]:^U:O_`,^.G?\`@<__`,:H^U:O
M_P`^.G?^!S__`!JJOPW^(-A\5?!&G^(-+AUJWL-3C,L,>KZ/=Z/>J`Q7]Y:W
M<45Q$<@\21J2,'&""=RDTT[,:::NMC-^U:O_`,^.G?\`@<__`,:H^U:O_P`^
M.G?^!S__`!JM*BD,S?M6K_\`/CIW_@<__P`:H^U:O_SXZ=_X'/\`_&JTJ*`.
M>T>YU0:CJNVSL"3=+O!O'&T^1%T_=<\8].I],F_]JU?_`)\=._\``Y__`(U1
MHG_(3UC_`*_%_P#2>&M*@#-^U:O_`,^.G?\`@<__`,:H^U:O_P`^.G?^!S__
M`!JM*B@#-^U:O_SXZ=_X'/\`_&J/M6K_`//CIW_@<_\`\:K2HH`S?M6K_P#/
MCIW_`('/_P#&J/M6K_\`/CIW_@<__P`:JYJ-T]EI\\T=O->211LZ00E!).0,
MA%+LJY/0;F`R>2!S7S9^PG^UO\2/V@_C=\<_"OQ(\)^%_!ES\,]6TFUT_3])
MU"349H(+W2X;W;=W+!(Y)U\T!O)C6-#E5>8*)7$TVUV5_E=+]0Z7/8/BU\);
M+XZ^%8M#\5Z!IVKZ/%?6NHFS;5KB*&>:VF2>'S51%$L8D1&,<FZ-MH#*PXKI
M_M6K_P#/CIW_`('/_P#&J^1OV2/^"D'BW]J;_@H;XK\$V^A>';7X,_\`"'OX
MB\&:V@F.J>(Q#J(L);TDOY0LY)1-Y&(\R)&DH<I(HKT_]M_Q9\>_!'A/5-=^
M$D_P<T[2?#.@7>L7LOC2#4;V74KF'#K:HEM)`MK%Y2R,;EI)SN*K]GP"]1*I
M&%%5I:1=Y>EFTVUNFN1W6^B5KV148.5:5%?%%J/S:327_@7IJWM=GM7VK5_^
M?'3O_`Y__C5'VK5_^?'3O_`Y_P#XU7POJ'_!5+QC\9C\*+;PA>?"SX++\1?A
M/_PM7^V/B6D^HV<ZA`\NFVT<-U9;C;QG[1/<F7]W`4;R&!9DA^$7_!4+XC?M
M:0>&+7P[>?"'X'7,FE:0FKW_`(_BN-535?$&J6_VJST72[-;O3Y9"UKMN3*\
MF\K<0JL#GS&36491DXM:IVMZ2E%_^30E'NVERWO&^<91DDT]+7^349+\)Q?D
MF[VL[?=WVK5_^?'3O_`Y_P#XU5#PW<ZH-.DV6=@P^U7&2UXXY\]\_P#+(]\_
M7VZ5K:%]M&B6?]I?93J/D)]K-J&$!EVC?LW?-LW9QGG&,U!X6_Y!DO\`U^77
M_I1)1)6=@3NKA]JU?_GQT[_P.?\`^-4?:M7_`.?'3O\`P.?_`.-5I45)1F_:
MM7_Y\=._\#G_`/C5'VK5_P#GQT[_`,#G_P#C5:5%`&;]JU?_`)\=._\``Y__
M`(U1]JU?_GQT[_P.?_XU7B'[5O[1OC;P[\>/AU\(?AA'X4MO&OC^TU'6I]:\
M26TU]IWA_2]/:V6>4V<$T$MU-))=PQ1H)X57<[LY";'O_L'?M-Z_^T;X!\5V
M7C/3M'TSQ_\`#/Q1>>#?$R:.TATVZN[=(I5NK59294AF@GAE6.0LR;RI9]H=
MB'OIM=F_5)J+?HI-1]=MG8G[EK];+YM-I?-)OT]5?V#[5J__`#XZ=_X'/_\`
M&J/M6K_\^.G?^!S_`/QJOG+X(_M@?$SQS_P45\:?"CQ=X)\/>$?"VD^";?Q5
MH:QZBU_K5TLFIW=D)+MD(MH0ZV^]8(C*5#*6FW,T4?CO[./_``5$^)/QE\=?
M"K5IW^$MUH'Q5\8ZKX1F^'VF1W1\9>"38I,TT]Y=&X>*9K<0QFYA^QVXA^V0
M`2OE#*4_?Y.7[6W_`(%R:]O>7RWE9!/W.9/[-K_^`<^G?W=?/97=C[O^U:O_
M`,^.G?\`@<__`,:H^U:O_P`^.G?^!S__`!JM*B@#-^U:O_SXZ=_X'/\`_&J/
MM6K_`//CIW_@<_\`\:K2HH`S?M6K_P#/CIW_`('/_P#&J/!W_(HZ7_UYQ?\`
MH`K2K-\'?\BCI?\`UYQ?^@"@`NO^1NLO^O.X_P#0X*_/SP#\./V@K/\`8=U[
M]G;3/@EK?A[5_%^H>)M+N_'>OZ_H;>'-'T[4[[4)_M\<-K?3W]Q,(;B,1V[6
ML0:1@'DC12U??NL6KW?BBP6.YFM2+6X.^((2?G@X^96'Z=JF_L2Y_P"@QJ/_
M`'Q;_P#QJHG3C-.,]8M6:[I_C]S*A.4&I0T:=T^S[]NM]4S\SOVUOV*?CKXY
M^&GQ`^$NF^%OB=XX\*Z=H.EZ-\+I=&\;Z;X=\,:=:V]C:Q7']JQ+=V]]>7;R
MP38BN(KJT.^`#R,RR+]*:A^S5XVG^)_[6VHKHN;/XF^$=*TOPU)]L@_XF5S#
MI5Y;RIC?F/;++&N90@.[()`)'T[_`&)<_P#08U'_`+XM_P#XU1_8ES_T&-1_
M[XM__C5&*A]8HRHU7\5[OJ^96;[7\[?H30M1J4ZE-6Y+6732UEZ:=^_<^#]=
M_P"">GQ'^)OA*V\,SVD/AR/5/V7'^%MQJ<UW#-%IVMR^2I@=(I#(ZJ%<ET!0
M@'#$D`]+^P;^S##X?^)'@C6?%7P)^/7@SQGX,T.6VCUWQ9\7Y/%OA^QFE@CA
MN8;"%]>O)"DN!L9[*'Y(P3Y;!4K[+_L2Y_Z#&H_]\6__`,:H_L2Y_P"@QJ/_
M`'Q;_P#QJM_:/GE/K*__`)-.I/UWJ2^5KWUOC"C&-.-/I&UOE&G#\J<?G>UC
MQO\`X)I_!KQ)^S_^Q=X3\)^+M-_LGQ!IEQJDES:_:(I_+6;4[J>,[XF9#F.1
M&X8XW8.""*^./%7_``3P^//A/]GKX9ZC\.=/M]`^*EOK/BWP?XDWZA:@VOAC
MQ!JEY-_:'F"0I*]FS6EY'""SG]X@`<D5^E?]B7/_`$&-1_[XM_\`XU1_8ES_
M`-!C4?\`OBW_`/C58^SB[*6J_-;->DE>+MK9NS1M%N*]WI^?1^J>J\TCXW\#
M_LZ?$#]CS]MO5]9^''PH3Q+\.;OP=X$^'VFA/$5GIPTNQLKO4TO;G;(S22?9
M+>>"3R]H,V[:C%@V._\`^"J&B_$[X@?`?3/!/P]\$^)?%VC^-]6CTOQQ)X>U
M33;'5[#P^49KM;0W]U;1&:X`%MN$H:-)Y)%^95KZ)_L2Y_Z#&H_]\6__`,:H
M_L2Y_P"@QJ/_`'Q;_P#QJKJ-U%:H[^]S:]=>9Q?1Q;O?2[4FF[6LJ:5.7-3T
MT2TZ6CRIKJFDE\TG;>_R?\3?!/C#X_\`PY^$.B^'_@;XP^%VF?#+XD>&=173
M-<O]`5(M(LV?S)+<:?J-TFR%`B^62KG(V(V#C5_9Y^%OCWX?_M$?M.:%JG@3
M5X?#OQ/\2/XF\/\`BY-0TY])G1]"TNQ^S21"Y^W1S":VEZVOE[5SYG*@_3?]
MB7/_`$&-1_[XM_\`XU1_8ES_`-!C4?\`OBW_`/C53*/-&K"7_+SFYO\`M]4T
M_P#TU%^M^CLG3]R4)Q^QRV\N5S:_].27I;KJ?F/X1_8T^*U[\&OV4KWQ3\&?
MBT+CX"^$;CX?^(O#7AOXC6?AW7+PRV-@JZMIU]I^LP1RVPFL1$\%S<V[LLV_
MRV,:@^W7_P"QC-<?`;X66'@3X6^-?!RVGQGTOQWX@T?QCXLBUW6(4BN&:[OY
M[J34;U96;:L@2.YD8Y!VARRC[*_L2Y_Z#&H_]\6__P`:H_L2Y_Z#&H_]\6__
M`,:K:55RJ^V>_,I_-353YIS5VGZ*UHVS=-.E['IRN/R<90TOU4963^^]W?2H
MK-_L2Y_Z#&H_]\6__P`:H_L2Y_Z#&H_]\6__`,:K(T-*BLW^Q+G_`*#&H_\`
M?%O_`/&J/[$N?^@QJ/\`WQ;_`/QJ@#2HK-_L2Y_Z#&H_]\6__P`:H_L2Y_Z#
M&H_]\6__`,:H`-$_Y">L?]?B_P#I/#6E7/:/H]P^HZJ!JM^NVZ4$A(/G_<1'
M)_=^^.,=![FK_P#8ES_T&-1_[XM__C5`&E16;_8ES_T&-1_[XM__`(U1_8ES
M_P!!C4?^^+?_`.-4`:5%9O\`8ES_`-!C4?\`OBW_`/C5']B7/_08U'_OBW_^
M-4`7-1NGLM/GFCMYKR2*-G2"$H))R!D(I=E7)Z#<P&3R0.:_/GP3\$?C'\<_
MBC^UII5_\./BC\#M/_:,M[.+0O&=S?>'-0;PS]GT.*P=YX++5Y9O,:6-M@AW
M`A@3)$>5^^O[$N?^@QJ/_?%O_P#&J/[$N?\`H,:C_P!\6_\`\:J73C+F4M5*
M+BUY.S>VM]%UZ%PJ2@U*&C33OZ'Y*Q_LJ?M0_P#!+S]J?3OB]XC^,-K\;?!W
MA#X?0^#]&T2S\$Z+X3_X2NYFO/(T[PO;I;O+);D320W"W*0MQ%Y1PNXCZU_X
M*2Z7\6/C3XR\,_#FR^$OCWQ;\#=5L#J'CNY\(:UH=MJ>NR+*!'H)&H:C9M%9
MR!2US+'N:6,K"NT22L/K7^Q+G_H,:C_WQ;__`!JC^Q+G_H,:C_WQ;_\`QJK<
MG*,5/7E;?K=N6O?WI-WZV5[^\Y91BHR<H*UTEZ62BK=M%9=5=V=E!0^%OVB/
M@GXL^-_Q<T^\\=?LW>/OB)\%+SP/%INB?#S3]<\/6<_@?5TN)DGN+F!M6@M&
MG:V-M]ENK6YGDM/*D\LP-(Q;YP^%G_!+;XA^!?!OQ&_X6]^S'H7[1_Q`^+&@
MV]UI7BK6M0\/ZQ>^#+_[(]C'I^HW^HRQ73K;Q16<CW=FMPTC^<P5G"E_UX_L
M2Y_Z#&H_]\6__P`:H_L2Y_Z#&H_]\6__`,:J)4XRBX2ZWOZ2;;5_5K7XO=2O
M:]](SE&2FMU;_P`E22TVZ:K:[;M>UN5_9;^%FI_`W]FCX>^"]:U7^W=8\(^&
M]/T:^U')/VZ>WMHXI)<D`_,R$\@'FNJ\+?\`(,E_Z_+K_P!*)*/[$N?^@QJ/
M_?%O_P#&JH>&]'N)-.D(U6_3_2K@85(.<3N,\QGKU_'C'2MZU656I*K/=MM_
M,QI4XTX1IQV2M]QT-%9O]B7/_08U'_OBW_\`C5']B7/_`$&-1_[XM_\`XU61
MH:5%9O\`8ES_`-!C4?\`OBW_`/C5']B7/_08U'_OBW_^-4`?-W[7/PZ^('@O
M]M3X1_&GP3X(U7XE:=X=T/7/"'B+0-(U.PL=4BMK\V=S#>0?;I[>VF"3V"1O
M&TZ-B=74-L(K)_8P\"_%GX'>*M3U;6?A?"C?'OXBZQXL\4[/$EKYGP\LO[/A
M@T])T!=;RXD%G!'*MK(R1R3,0[HNX_4_]B7/_08U'_OBW_\`C5']B7/_`$&-
M1_[XM_\`XU13]Q679KY2FIM?.2OWZ+0*GO[^3^:BX)^JB[6VT5T];_&^B1_%
MJ_\`^"J^O_$(?`CXC:-X1UGP!:>`[77+S5?#,D-K=0:I>7/VZ2"+5GG-H4GC
M(VQM,<$&$5Y'\#/V2/C):>-_@QJEW\*?'GA3XY:#XDC?XF_%ZZ\8Z5-I7C+2
M@SM?P-'#?2WE[;7'EQ"SM+BRA2RWIY?V81D-^DG]B7/_`$&-1_[XM_\`XU1_
M8ES_`-!C4?\`OBW_`/C5%']UR6^SM_X$Y/Y-R?,E926DKI(*W[QSO]I6?_@*
MA]Z25F[V>JLV[Z5%9O\`8ES_`-!C4?\`OBW_`/C5']B7/_08U'_OBW_^-4`:
M5%9O]B7/_08U'_OBW_\`C5']B7/_`$&-1_[XM_\`XU0!I5F^#O\`D4=+_P"O
M.+_T`4?V)<_]!C4?^^+?_P"-4>#O^11TO_KSB_\`0!0`77_(W67_`%YW'_H<
M%?E'^R[^U[\3/A7^SW\9O#OCSQKXMUN+XF:!X[\4_#3Q+?7\LEUI%[IEUJ5O
M=Z.ER6WJ88H;:[M@#E4-P%P(17ZN77_(W67_`%YW'_H<%?(_QC_X(_Z9\8_^
M"=EQ\#+GQO=Z=K=IK.IZ_H/C&STTQW.AWEY?7=R66#SOWB>3>36LB&4"6*23
M.W=A>7%PG*E-4]W%Q^4OU3M);7:M=)LVP\HQJP<ME)/[OT?PO>R=TFTCEOB1
M_P`%<]/_`&:--^%W@"2^^%\WC34OAOIWB_5-1^)?Q-@\%V#Q2HL4<<5S);W4
MMU>321SL5$0153<\JET#>G_![_@J-X;^,4WP3U.WTA-.\&?&SPGJVOV.L7.J
MQE]/OM.$+SZ<\:*T<A\IKI_.2;;_`*(^%(8,);S]A#QK\._B3X8\:?"SXE:!
MX9\2Z?X'L?`FOQ^(_"4VO:5KUK9,7M+A;>'4+.6WGC>2YY$[HRW!#(2JL%_;
MT_X)[:O^WS^R[X>\'ZUX_MO#7CG0[Y+_`/X2O2?#^(=TEM/9WT<-G)<LT45Q
M:75S"`;AVC\Q6WNR`GOQ4N><Y4[7E-VOLHN4TG9=%%QDUO>-K:M/DPL.6$(S
MO905^K<E&+:UTNY*45TL[MZ*W)_LN?\`!7NS_:H^#?P=\0Z5X`U'2]?^+'CB
M\\(-X?O]1\N?0HK2"ZNYKV9_)Y'V.WBF6/8NXW42A\'>?)OAM^VCXZ_8_P!&
M_:>\9I\+E\5?"_P/\7=7OO$VL/XH2SU"TLF%E]HDT^Q$$HN?LT9>:1)IK3.0
M(S*2VWZ`^$'_``3#T?X.?\%`-?\`C5I_B6<Z'?Z.EEI/@Q=/6.RT._:UL;*Y
MU".4/EGEM-.M(MOEC:$<[CO(KCOB3_P2O\;>/-"^+G@R'XT65C\+?CEXFN->
M\4Z,W@P2ZM!!</"+FSL+];Q$A$T$(B>2>WN"-S,@CX`SARJNIQV<&G?H^>EH
M[:\K4)3]WWDI6O>R5RO*"4^DT].W+5UC?JN>,/>T;C>UG=Z:?MT>+?V@]!^/
MEMIGPZFT;X>_"]-=T*^\70^-/L6IZC<6]BTR/I<45I(RMM>(M-*\7DLZF,7&
MU@(?`O[<WC&ZT7X:^!/A3\-)_B/XB_X59I?CS6W\3^.&LGL;.X18K2V-\UI.
M;W4;AXKD@RK;QMY#.\L>\"O4/AY^Q)%\/?@_\:O",'B!7A^+NM:QJT<RZ=L&
MBK?VD=L(0GFGSO*$>=V4W9QA<9KA[;_@GKXX^%WB7P?KWPO^*^D>%-<TKX=:
M=\.-?EU?P<=9M]8MK`EK2]MXEO;<VMU&TMU@R/<1$3*&C;9EHHZ64[ZQI7VO
MS*%7GOTTFX+32VVEV)\[U=KIU+=K.=/E\]8*;5];_%T1Y/\`L$?MA>,/#'['
M'P%\&^%_"-GXL^)'Q#C\3ZI%:^*_$SZ+96%CI^J3+/YUY#;7S-,C7-K&D443
MJ07;S%5`6NW?_!;H>'?V??@YXB\2^&?AAX'\7?&A]3GTVQ\4?$]-(\.:19Z>
M0L\MWJ\U@K>:9&CC2*WM)A(S[E<QAI!XA^VO_P`$V+KP)X=^!GPUUG7?'&K^
M"?`_A[Q6P\7VWP<MOB5!<ZO?7T,]JEUH0L+Y874,[FZ2*,.D4T2/;^=Q[]^S
M=^S#\6_C%\&/@]X^;4/#'P@^)WPJ_M?P[H`D\!2V^BZYX6F9(8!=^'Q>P2Z?
M)+':V5P($N8WMWC",J@M"I33E%R[/\+R6E]OLW4O><&YQZ6M6A&,9;V_'EO\
M^NJ]U32C*VM_?/V%/VT]+_;Q_9YG\9:`FBPWNGZI?:!?Q:;K,>M:8E]:2&-F
MMKV%56YMG!22.4(A:.1241LJ/EW_`()N?$&/2?CAH^A_&OX@?&_PG^T[%;:N
M_B'PQXKUJZ'A;QQ'O21KO1[=PVEO:VZ[#%_9ODW$:)()PP\PM]S_``QT+QCI
MOP_6T\:^)-"USQ.YD\W4M!T*31[-02?+\JUGN;ME*KC.^:0,V3@`A1\^Z+^P
M;\3/B/\`&CX6^)_C3\7O#'C^Q^$0O+O2;/0?`;>&[G5-1N+,V7VR^N&U"Z#[
M8)+C]U;16T9DF#$8C1!6JJ.4++W;=;7L]NJUW5K--*^G,EJZ7*^]U\GHG\NM
M]'[UOLORS]GG_@O=X,^/GQ=\`Z9`OPOB\-?$_79=`T&+3_B;9ZEXRLY#YWV6
M;4M"2`&TAG\G'R74TD1G@$D:%G\OW#X9?MF?$#XY?%'57\&_"?3M5^%6@^+K
MKP=?>)+GQ<MIJ\DUI(UO=WMOIIM6BELXKE7C+->1S.(I&2%OD#I^R9^R/\4O
MV2M&\.^!M-^*G@_6OA#X3:2UTO2[_P`#7'_"20Z<&<VUFVJ+J8MW\E3'&)38
M;GCC&?G)DJ#X+?L5_$;]GKXFZ[#X4^+NEVWPG\0>,KOQE+X<N_!WVK6[1[R3
M[3=V,.J&\$*VLMTTLGSV3S(D[HLJD)(KBDVETL]7ZPMS)7Z<[?*_);*[J[3<
M>^GI:=^5OK?DMS+O?=I9_P`._P#@I=_PGW[*?P:^)W_"%?9/^%M^-+7PA_9O
M]L;_`.RO/OKBT^T>;Y`\W;]GW[-B9WXW#&3Y3X]_X*`>+_VBO^"=GQ#^)VI_
M#?7?A]X"LA]GTV^T7XB-8>)=5GM]6BM96@:"S86MJS)(!*TGG.%=3`BNLAZ?
MP3_P2J\:^%-.\`>%'^,NFGX7_"SQY_PFWAW0;3P2L%_,HU*:]CLKZ]:\D69(
MEGDC1X(+8YVLXDP4/</_`,$XM_\`P3<O/V>_^$R_X^_/_P")_P#V3]SS=4?4
M/^/;SN<;O+_UO.-W^S41NX.4M^:5EVCRPY?FI<_7UNK&=3G]IRPV45KWDI3O
M:_1QY-TOD[F7\+?VA/C;XA_X*I?%+X<WFC>"9OA=X9\.>']1MS_PDDHO].CN
MY-67[5'$-,!GFG:UC22"2Z6.%859))#(ZCR+P?\`\%7/#W[,O[)OP3M6N--;
MQ#\3KO7Q8W?Q9^*::;8V=OIU],EQ-?:W/;/(S%FA2&&*U=CYBKA4B:0?3T'[
M+'B?PW^WAJ_Q>T'QIHMKH'B[P[IGA_Q'X<O_``Y)=W5P-/DU"2":TO4O(EMR
M3?D.LEO."(^"I;*^9>%O^"8GB#X1>#?A)/X"^)MAH_Q`^$K:Y:V^KZKX8?4M
M)UG3M6NGN;FTN;!+V"0;9!;.DD=TC!K;G*NR42O:%O._?K;RUTO;7E;M[UD:
MNWMIO[-E;M?E2];IW\F[7T;9S_\`P^DT'5_V/_#GQ)TC2O!<^H:YXZD^'ER]
MYXXCA\(:5J$1F+W$NO16TR?872$&"86VZ5KBW0QQEVV?8/PSU;Q#KO@;3[KQ
M7H^EZ!XAE1OMMAINJ-JEG`X8@>5<M#`TJ$`,&:&,X;E01BO,/B!\&OB_\0/@
M9#X>O/'OPFO?$%\]Q;:^^I_#2XOO#>M:?,CQFU.F-JXE7Y2NYFO)%?\`>`QX
M<!-?]B;]EZW_`&,_V9/#7PYMM4_MB/0!<,;B.U^QVX>>XEN'CMK??)]GMHVE
M*0P;W\J)(TW-MR=%:TK[W5O_``%72\N9-ZZZVVC=P[WBUYW_`/`G9^MK+332
M^[LO0]$_Y">L?]?B_P#I/#6E6;HG_(3UC_K\7_TGAK2J2@HHHH`*AU%+B73Y
MUM)(8;IHV$,DT1ECC?'RLR!E+`'&0&4D<9'6IJAU%+B73YUM)(8;IHV$,DT1
MECC?'RLR!E+`'&0&4D<9'6E+X6..Y\(?LO77Q2T7QU^V]X3U'XD>-/B3XG\+
MC3ET&[NRD+6EW<>&HKCR["UA58K6/[1)\D:`MPI=Y9-TC?.?_!.7]H31OV0O
M@/XW\?>,OB#^V]<?&'3/AKJFMO\`#_\`:"GU&.POI-.MX;BZNM*26!8I5\XJ
M@Q.\Z1.2Z(#NK[+^"?[#_P`<?A1\9OB]XUG^-7PVN=2^+Z07-Y_9_P`,+NU_
MLN^M=-2QLYH/-UN=3$OEQR212*QDPP62+<"MK7/^"=_B?]HKXH#Q%\>OB#X;
M\<6FG>%M7\+:/HWA7PA+X:L;2/5HA!?W,WVB_OY9YV@58H\/&D:F3Y&+Y&4X
MU%"3IOWI4E'M:4826GK)J^EK6U3U6D?9N5/VB]V,[M=TW!N_I9VU771JR?C7
M_!-7]H?PAXF^-GAO3O%VO?M4'XO>(M.:Z76/'UAXBT+PAX^N);7[7>II&FW.
MW3X8K3.U%6V@E"1J5:<&25]?]N[XIZ)<?MU77@CXS_%[QC\%/A:?`$>H^#;S
M1?$]YX2CU_7)+FYAO,:C;F,W-W:Q"S,5@97#_:"YMYL`JGQ>_P""?G[0MGX#
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M=9/,A>3:T?NZ?LC?%+X+_#;0O`OP1^*?@WP1X*T'PY!H=M!XG\!S>)=2AN(_
M-#WZ7,6I62&63>CLLL,JF1"W1RE>:>+O^"5'CC1_AY\$/!7PZ^*_A#P[X0^!
M&K6?B+1T\0^`[G7-4U34X8;N.6:\N8=6M(WCF-Y+(R1P1L'QB3'%$&HR2W2J
MQEZQ]I*4KK:R3M%:;K33W4X74F]W2E'TE[-15NUWJ]]GK_-]N5F^%O\`D&2_
M]?EU_P"E$E3Z##?6^AV4>IW%I>:DD"+=SVMLUM!/,%&]XXF>1HT+9(0R.5!`
M+-C)@\+?\@R7_K\NO_2B2D]'8I.^II4444AA1110!\U_\%:]/\;']@;XHZMX
M*^(>M?#BX\,>$M9UJXO=$MXO[4N_L^G7$D4,-S)N%J#*J%Y$C,NU2(Y(6(D'
MJ?[/>N:GJ_[*W@?4FEEU/6;KPI87)DNI6=[NX:SC;=(YRQ+.>6/)R37/?MS_
M```\9_M2_LZ^)/A[X2\8^&/!4'C/2KW0]9O=7\,3ZZYL[JVD@?[.D5]:"*8>
M82'<RKQ@H:R_@W^SY\7?AYX<^%FE:G\7?#ESIW@(RVNM6FC>!OL$'BNP6Q%O
M9P.;B]NI;:6&4+.TL4F)=H38BYS$8MPK1O;FY+?+G3MV^*/W/YU-J]*2UY>>
M_P`^1Q7SY9+YJ[2V_/OX&?ME7&C+^SYXOLOC5XR\2?M$^,_&$7AKXK?#K6=;
MO7M--^V^;#-:SZ$X\K1?L=U'`MO.L-NTJJP,EQYY+6?V=?VQ/[.U3]G+Q8/C
M?XUU[X_>-O&T'AGXN?#[5M:O9;;2DOFEAN+:;07'E:-]BN8X%MIEAMVE52&D
MN//);[GM?V2OB3\3_C/X,\2_%WXE^$/%&B?#R^FUK1-`\+>"9_#]O-J;0O!#
M=7LEQJ5\\X@CEF\N./R5\R3>V_8@4L_V2OB3\3OC3X+\2_%[XE^$?%.A_#R_
MEUK1/#_A;P5/X>@GU-HF@ANKV6XU*^>?R(Y9O+CC\E?,DWMOV(%VHM*<7+1<
MR?\`A@N6\%OI*TM-?BC[R]ZT8A.2J*#^RTO.3Y[3>UVN:-I>ZU9V@[1/HJBB
MBH&%%%%`!6;X._Y%'2_^O.+_`-`%:59O@[_D4=+_`.O.+_T`4`0ZQIMOJGBB
MPCN;>&X06MPP65`X!WP<X/U-<5XF^.OP;\%?&#3/A[K/C'X9:3X^UI$DT[PS
M>ZM8P:Q?JY8(T5H[B:0,4?!53G8V.AKM-=DFAUN)K9!)<+I]T8E/1GW0X'YX
MKXU_X([?L^_#OXQ?\$WO"?B;Q1X2\(>+_$_Q'O)?%/C:]U728+VXU+Q!'?W#
MNUR959FFM)]\48<YA\H*NW%$-9.^RM?YM[?)-W[V5O>NB6D;K=_=M_PVG:[O
MI9_5OPX\7>!OBX=?'AY=+U$^%]8N-`U0+8F,VE]!M,L)WH,E0Z'<N5(88)KI
M#X/T@#_D%Z=_X#)_A7YBW/B/XI_`/X=?M4_%[PA\4KW0].\#_&B[GB\(1:!I
M\^G:XIGTU+M+Z>>*2Z/FQ2!(S:RVWE;2Q\TGCZ@\#>*?BE\8?^"E_P`5/#G_
M``LN[\/?#/X6V_A^\M_#^G:+8/<:O/>VTDDL5Q=SPR.MK^Y)*Q!)BTF5G15V
M--.7-1HS>CG&#?ES0C*_^&[:6[TU74B4DJE2'\LI)>?+.44O6RUV78^@O`.J
M>"/BMX5M]=\+W'A7Q)HEXTBP:CI4D%Y:SF-VC<++'N1BKJRG!X92#R#6Q_PA
M^D?]`O3O_`9/\*_.#PE\>_B]:_L._!+Q7IU[XV\.?#9;KQ"/'FM_"[PKHEWK
M>CA-5DM[&1=,FLYXVL47SGN#9VDMS^Z1]NWS2W5^(M)O/BM_P5)^!'C7P_\`
M&OQI>:!J7P5UC7[:ZTFQT7[+K%I'?:`[A1-82.L-Z'623#"12J"%X!N#%*<9
MN[T6MWVM"<[M=FH/S>Z3LT6U:',NR:\[SC&WJN9/[KVNC[T_X0_2/^@7IW_@
M,G^%'_"'Z1_T"]._\!D_PK\\O`7[3GQOL/V5_@I^TGJGQ:_MBU^*7BS0H-2^
M'?\`8NF)H-OI>M7Z6<5K8S);KJ/VRV2XBD\R6[E61X908PK`+%\;_P!I/X\:
M!\!OVG/C)IGQ@_LRS_9_\:ZI!HGA0>&=-;3M;L+$6T\MEJ$\D37+F5)&BBDM
MI+9XRV7,YQMT2?.X2T:OS?W>5TU*]KWM[2/PWZVO;4:=THZ\S2C_`'K\]K7M
MOR/>W2_E]W>&?%W@;QC\1/$_A/35TNY\0^#1:'6;,6)5K(74;2VY+,@5@Z*Q
M&PG&T@X/%=)_PA^D?]`O3O\`P&3_``K\\/B#I7Q(U_\`:Q_:^\8^`_BIK'PM
M;PSX*\/:W';6.@:=J$M_>II%W-"ETU[%,OV90C*T4*12L7R)U"[3/\0/VV/C
M;^T1\8/!/A7P+9_$[3+27X1Z+X_UB3X:6WA*74GU#56E6..0^)9UA6SB%M)A
M8(VE=I!NDC50),N=WE"WO1=FOE-KRVIRZ]NY,)1E%5$_=:;3]'"/KO4CT[]C
M]"/^$/TC_H%Z=_X#)_A3+KPSHEC:R3SZ?I4,,*EY)'@C544#)))&``.]?%GC
M/XM_M'^*X_V4/!6KZ_%\&/'GQ,75[?Q^;72]-U6X@-E9>>7M`S7-M%-)Y>Y#
MNGBC\\[TEV!:W/\`@K!H2ZOX%_9Y\`>*+]]7\!^,_BIH>@>,YM32,)KMLL%S
M/#!=K$L<)2ZO;>U1T"+&YD"!`&"U<TU4]E%J[G&"?1\TE&_HK^38Z<E*+FT[
M*,I/NN6+E;ULO0^@O@A\:OA!^TUI5]??#?Q;\-OB#9:9*L%Y<>&M4LM6BM)&
M&Y4D:!G",1R`2"17<?\`"'Z1_P!`O3O_``&3_"O&?VG-`^'?[+_P?U[QO9R:
M-\)-3:PTWPO_`,)9H'@Z'4]:MK3[3%;VMC:V\<$KSN#*([>$Q31I)(A\F108
MV^)[W]M#]HK2/%?B3X;67BWQMX>UEO'_`(*TO1M:^)/ASPY<ZU;:?K:7D5P)
MK?1REG)&&M!-$"L-PK.R2\`"CF4IJ$.KC'YRDHI?BFUT5[7M=I^Y3=2ILDW\
MHQN_RMZVO:Y^GW_"'Z1_T"]._P#`9/\`"C_A#](_Z!>G?^`R?X5\C^,9?B\W
M[=?@[X/:?\=/$>F>$],^'<WBSQ!K<^@:)-KVM7$6IB!`LGV);.W5EE59"MJ0
M8X@$".QF'GOP!_;)\>:Q^V1\&1I7CCXK?$?X4?&!M7M&UCQ-X5T+0O#EW+%8
M27T4NBQ110:RD:-`\:M>K-#+#)N6>9@LK%+]XDX[/F_\EE*-_*\HM1OOUL$I
M<O-=?#RW_P"WHJ5O-I--V^5[,^^O^$/TC_H%Z=_X#)_A1_PA^D?]`O3O_`9/
M\*TJ*"C-_P"$/TC_`*!>G?\`@,G^%'_"'Z1_T"]._P#`9/\`"M*B@#GM'\*Z
M7+J.JAM-L&$=TJH#;H=H\B(X'''))_$U?_X0_2/^@7IW_@,G^%&B?\A/6/\`
MK\7_`-)X:TJ`,W_A#](_Z!>G?^`R?X4?\(?I'_0+T[_P&3_"M*B@#-_X0_2/
M^@7IW_@,G^%'_"'Z1_T"]._\!D_PK2J'4;%-4T^>VD,RQW$;1.89GAD`88.U
MT(93SPRD$'D$&AWMH"M?4YKP]JO@CQ;XCUO1]*N/"NIZMX9FCM]8L;22WFN=
M)EDC$L:7$:Y:)FC974.`2K`C@YK"^&'QH^$/QM\3^(-$\&>*_AOXNUGPG-]G
MURPT74[*_NM&EWNFRYCB9FA;?'(N'`.48=0:_.KQ1X*TS]DCX1?\%/-,^&6E
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M"S0]:\"_\%@?!-W\1O`WA+X=:GK/PLU#POX'L_`NIG5M)O[2RO+:>ZCO;F2V
MLIHWMXS;?9[=;,PHLLY$Y8A%]6_X*9:EX$\-_"O5+*?X?^'/B#\6_BKHUSX#
M\*:))IEO<:EX@$WSM`\CJ633H&(N;AW/E1)&7(+E`TU9.-*-2"NW?3JVI2BD
MO.5E_AYK.[CK5."=64)NR5M>B5DV_2-WK]KEOHGIZU\:OB_\)?V;/#UGJWQ%
M\4?#KP#I6H7`M+6]\1ZE9Z5;W,Q4N(DDG9%9]JLVT$G"DXXJO\9OCM\&OV<=
M$TW4_B'XR^&7@/3=:<II]WXBU:QTN"_8*&(B>=T60A2#A2>"#7R'^P?^S1;_
M``O_`&X9_ACXZDL?&NH_"/\`9[\(^%[&[O;?SH98KB?4X=3:)92<).UK;H_R
MY9(XU8X4"OBW_@DKXP^/>@V'QD\<>`?!_P`%?%NE?!W5)?"EI?>.O$E_;7L/
M@>S-U=IIFDK!:30PK/N#"Y:3RB8(U:!EB1DK$2A2<ES:+F?-TY8S<;_/1^2<
MM&X)3FDI3:CR^][JMUO*$9_A=KS:CJE)N/[BV'A[0=5L(;JUL=(N;:YC66&:
M*&-XY4895E8#!!!!!'7-5?#?A72Y].D+Z;8.1=7"@M;H>!.X`Z=@`/PK'_9D
M^+-A\>OV</`/C?2],DT73?%_AVPUFTTYUVM817%O'*D)``'R!PO0=.@KI_"W
M_(,E_P"ORZ_]*)*UKTW3J2IO1IM?<94:BJ0C-:IJX?\`"'Z1_P!`O3O_``&3
M_"C_`(0_2/\`H%Z=_P"`R?X5I45D:F;_`,(?I'_0+T[_`,!D_P`*/^$/TC_H
M%Z=_X#)_A6E10!SGBX>$OA_X6U'7->_X1W1-$TBW>\O]0O\`R;:ULH$4L\LL
MKX5$50268@``DFK.DZ+X>U_2K:^L;31KVRO8DGM[B"*.2*>-@&5T8`AE((((
M."#7SS_P6-^!_A3XR_\`!.3XPW'BG1;;7?\`A%/!.O:QI<%XSR6MO>QZ7<B*
MX:#/E221$[HVD5C$X#IM<!A[!^R<,_LK_#3_`+%32_\`TCBHIWDJE_L\G_DW
M/_\`(!47+[-_S<__`)+R?_)E7P5\;?@]\2?BAK7@?P[XN^&NO^-/#8<ZOX?T
MW5;*ZU32@CA'^T6R,98MKLJG>HP6`/)K?@U7P1=>/KCPI'<>%9/%%I8IJ<^C
MK);F_@M'=HTN&@_UBQ,Z.H<KM+*P!R#7Q1\=/`EY\*O^"@?[,-WXG^'/@;X>
M_#3PSXKUK0/`UYX%O1>7-WJ&HV5QY$&H0-;68T^UFB2YF>.V^V!KB.+>Z*N]
M^B^`OP/\*?`W_@N%\0;?PMHMMI7]O?![3M8U6<,\UUJM[-K^HF2XN)Y"TLTA
M`50TC,51$081%4%'WW37\W.GZQA*:TZ723L]4FN^A53@IO\`E4'\I5%#?K9W
MU6CL^VOV=_PA^D?]`O3O_`9/\*/^$/TC_H%Z=_X#)_A6E10!F_\`"'Z1_P!`
MO3O_``&3_"C_`(0_2/\`H%Z=_P"`R?X5I44`9O\`PA^D?]`O3O\`P&3_``H\
M'?\`(HZ7_P!><7_H`K2K-\'?\BCI?_7G%_Z`*`*7B?Q%9^&O$6GSWLWDQ-;7
M$8;8S98M"<<`^AKYUU3]@;]FS5O'.NZZVAZM;?\`"4ZVGB/7-&L_$FN6?AS6
M]14Q-]INM'BN%TZX=FAB9S);MYC(&?<<FOI>Z_Y&ZR_Z\[C_`-#@KP3PK_P5
MH^`'BOXA:3X:_P"$XN=%O_$.H76DZ-=>(?#FJZ#I>NWEM<?9IK:RO[VVAM+N
M99OD$<$KLS?=!HC_`!%R_%T[[K;YI?.PI?`U+X>O;9_I?\3;UKX'_!;Q%\./
M&_A&\TSSO#WQ'UB37O$5I]IOE_M&]D:%GEWA@\>3!%\L;*HV<#DYZ?PO:?#O
MP9\3/%/C#35^S>(_&J6<>M7>;E_MBVD;QVXV-E$V([#Y%7.?FR0*]+HHT22[
M))>22LEZ):+L@MJWU;;^;U;]6VVSYGUW]CCX#ZY\/]&\+1_\)GH>@Z##>6UM
M:^'_`!MXCT/S8KN=I[B.=K.[B>Y1I7=@LY<+O8*%!(K<\6?L\?!/Q=XI^'NM
M-9ZAH^I?"RS;3?#,V@:OJNA?V?9L;<M9LME+"L]L?LMOF"</$1&`5P3GU+PI
M\:?#GC;XF^*_!^FWMQ/X@\$"S.LV[6-Q%':_:HC+!MF=!%*6122(W;;P&VD@
M56;X[Z"G[0J?#$F[_P"$GD\.MXH4>3_HYLUN1;'Y\_?$C+\N.ASFBFU&48T]
M&VVK=TI-M?+F?I?N$]G*6RT^3<4E\WRK[CQ;P=^Q/^SOX"^(6G>(],T?4TET
M769_$6EZ3/K^M7/A[2-2F:5WO+32)9VT^VGWSS,KQ6ZLC2NRE22:\V^&/_!.
M3X47_P`0_BCXC^)48U^?QO\`$.?Q=!8V&O:U!I.H6JM;262:GI\;Q6=[+#+"
MS`7$4ZK\H#$<#Z&_:1_;Q^%W[)NLP:;XUU_4(=6GTV?6VTW1M`U'7[ZVTZ`@
M37\]O803RP6B,0IN)56(-QNSQ6U\(_VH?"OQO^)7BWPQX=GGO9_!]KI5]/>I
MY;V-];ZE;M<6LMO*KMYB&-3DD#MC((-%*T9*I3Z+E7EK%Z=G>"^YA6][W:F\
MGS>MDU\U[[;]4S(N?`_PJO->\?:G):[K[XH6,&F>)I/,O!_:=O#!);QIC.(L
M12R+F((3NR22`1QOCK]D_P"!7C^+P<9H/$6BWG@+1!X;T/4O#?B?7/#VIVNF
M`1#[&]Y87$%Q-!F")MDLCKN0-C=DU]'44K13NEV_"]ONYG;U?=CU_/\`&U_O
MLK][+L>/V?@'X6VFK^`M0?\`M"]U+X9QW,?AZ]O]1U&]NK7[1!Y$[2RS.SW+
MO'D,]P9&));.XYJY\?\`PO\`"S]J;X0:WX"^(.G6'BGPCXC@^SZAIUW;S;)5
MR&5E90'CD5@&21&5T9596#`$>@>./&>G?#CP7J_B'6)VM=(T*RFU&^F6%YC#
M!"C22,$0,[852=JJ6.,`$TWP)XVT[XE>"-'\1:/++<:1KUE#J-C++;R6[RP3
M()(V:.15D0E6!VNH89P0#Q3=IMWUVO\`.]K^MG;O9]@BW3:<=.W3:U[>EUZ7
M1\X1?L*?LZR:%XAL=1L/$OB1O$UE;:==W_B/Q=X@UW5+>WMYQ<P1VM]>74MS
M9B.X"S+]FEB(D1'^\BD6O!O[%?[/7@;7I-7M=+UB]UJ?5]+UVXU35_$6MZMJ
M%[?:89C8SSW-U<22S-")Y%7S&8%`B$%(XU7Z;HIIM.Z\OP=U]S5UYZD\J<7%
MK1_Y6_+3TT/,KC3OAQ=_&'_A/I8UD\6?V&_AO[:WVD@Z>TXG:`Q?ZHYD4-NV
M;N,9QQ7EWPH_8C_9W^"?C_PUXE\/:7K4.I^"Y+A_#:7GB37-1L_#:W$4D,T-
MA:W%Q);VD#QR%3#!&D9V1?+F*/9]/44H^[\.EK_BVW][;;\V^XWK>_7?Y))?
M@DO1)'.?\+:\/_\`00_\@2?_`!-'_"VO#_\`T$/_`"!)_P#$UT=%`SG/^%M>
M'_\`H(?^0)/_`(FC_A;7A_\`Z"'_`)`D_P#B:Z.B@#C]*^)VAVU]J3O?86XN
M1)&?)D^9?)C7/W?53^57?^%M>'_^@A_Y`D_^)K1T3_D)ZQ_U^+_Z3PUI4P.<
M_P"%M>'_`/H(?^0)/_B:/^%M>'_^@A_Y`D_^)KHZ*0'.?\+:\/\`_00_\@2?
M_$U#J/Q+\.:II\]M)J,RQW$;1.81/#(`PP=KH`RGGAE((/((-4?VC?VC_!'[
M)'P7USXA_$;Q!:>%_!WAN$3ZAJ-PDDBPJS!%"I&K22.S,JJB*S,6``)-:NA_
M%CPYXA^%%GXY@U>TB\)7VDIKL>J71-K`MB\(G$\AE"F-/*(8[PNT9SC!I/E<
M9-[+?LKWW];/[F-<RDDMWMYVMMZ77WH\!^%7[$GP!^#GCKQ!XCTH^.;[4O%T
M#6^OKK_COQ-K]IX@0V_V7%[:W]Y-!=8@_=J9HW*J`%Q@55^'?[`O[-GPPT6Y
MTZPT/5[^RF\.3>$;>'7/$NNZXND:1,@26RL/MMQ-]@A=50%;7RLB*/\`YYIC
MJ/"'_!4CX'>-M&\7WUKXMU&T3P-X:/C+58-4\,:MI=VVB!7;^T[:WN;:.:\M
M,1MB:U25#\H!RRY\W_9^_P"#@3]D3]J3XCIX2\"_%Q=:U][*[U$6S>&=9LU%
MO:P/<3R&2>T2,!(HW;!;)VX`)(%-M*]^D=?\*4E_X#;F\K<WF)7M=;77_@7N
MM?/X;=?A\BE\8O\`@FA\$?B1X)\0:98ZQXHBU+Q?I\'AS6-<\2^(->\7ZD-"
M^U)/=Z=93:G>3-9?:`FTR1="0Q1RBX])^-/[*?P1^/GQ>TWQ]KLWC6R\8:/H
MI\.VFJ^'?&OB+PY/%IYE\YK?_B774`96D"LVX$L43).Q<5?V)O\`@L+^SI_P
M46\?ZKX7^#?Q";QCKFB6']J7UN/#^J:>(+?S$CWF2ZMHD/SNHVABW/3`./0/
MVDOVW?AI^R7=:?:^-M<OK?4M4M[B^M],TC0]0U[4FM;==T]VUI803SI;1#&^
M=D$2%E#."R@N7N*//HM6K^=T[?\`DU[::R[L4/>;4->CM\M_NC]T>R/._'?[
M%_P%^)$GAVXU5_'+:QX7TJYT*RUVU\=^)K/79M/N)5FEM+K4H;Q+R\A,B*P2
MYFD52/E`R:H>+/\`@G[^S+XN>V4^&+G1;.#0;;PO-I_A[6]9T'3M3TJW+F&R
MO;2RGA@O8%\V0;+E)`5D=3E6(/>_%;_@HU\&O@[X4\-:SJ7C(:K9>,=,?6]&
M7PUI5]XDN;_38XQ))?K!IT,\PLT4KON"@B4LH9P6`.9\0O\`@J9\`_AD^E'4
M?B'97=IJNF6NN?;]'T^\UC3]-TZY=4M[Z_NK2&6"PM968;)[MXHV"N0Q",06
MUY>M_P#R;WOQ^/S^+S!.\4UM;3T]W\+\GE\/D>K:3\0_"N@:5;6-C-;V5E91
M)!;V\%H\<4$:@*J(H4!5````&`!46@?$[0[*Q=);[:QN9Y`/)D/RM,[*?N]P
M1766UU'>VT<T,B2PRJ'1T8,KJ1D$$<$$51\+?\@R7_K\NO\`THDIRO?WMQ1M
M9<NQG?\`"VO#_P#T$/\`R!)_\31_PMKP_P#]!#_R!)_\371T5)1SG_"VO#__
M`$$/_($G_P`31_PMKP__`-!#_P`@2?\`Q-='10!XO^TM\,?A?^USX`D\+>.+
MWQ/<:!<++%=6>D>(]9T%+^*6-HI(;@V$\!N(61F!BE+(<_=KG/!O[*OP,\#M
MX!:"#Q#J4OPNN[N\\+2ZWXFUS6I=(>ZM#93(KWEQ*S1&W)C6)RT:`DHJGFL/
M5O\`@M9^S+HG[8`^`EQ\2_\`B[+:S%X?&A1^'M5E_P!.DVA8?M"VQM_XAEO,
MVKSDC!P:M_P6L_9ET3]L`?`2X^)?_%V6UF+P^-"C\/:K+_ITFT+#]H6V-O\`
MQ#+>9M7G)&#@II325/7VFUOM6M]]KK[UW05'RW]IIR7O?[-[WOVO9W[V?8M_
M"W]BS]G_`.$'Q!\->)]*MO%%[J?@J.6+PY'KOB[Q!KUCX<62,1-]AM+ZZFM[
M4^4/+!AC0JF44A213O#W[&_P-\+_`+0?_"T[74/B4?'.%C?4+CXC^*KF.6!9
MGG6U>WDOF@>U661V%LT9A!8X09KTO]KO]LKX;?L'_!FX^(/Q7\2KX4\(VMU#
M927YL;F](FE;;&@BMXY)6)(/13@`DX`JI^QY^W/\+/V^?@_/X^^$_BC_`(2C
MPC;7TNFR:B^FWFG*L\2H\B[+J*)R%61?F"[>>O!P0E=N<=X;O^6]ONO=?>A3
MVY9_;[_:M?[]G]S.W_X6UX?_`.@A_P"0)/\`XFC_`(6UX?\`^@A_Y`D_^)KE
M_P!EC]L'X;_ML_#V^\5_"WQ1;^+O#FG:M<Z)-?V]M/#";NW*B5$,J)YBC<N)
M$RC`@JQ%>ET[6WZV?R>J?S6J"][^5U\UHU\GHSG/^%M>'_\`H(?^0)/_`(FC
M_A;7A_\`Z"'_`)`D_P#B:Z.BD,YS_A;7A_\`Z"'_`)`D_P#B:T?!W_(HZ7_U
MYQ?^@"M*LWP=_P`BCI?_`%YQ?^@"@`NO^1NLO^O.X_\`0X*_.&W\1>"=)_X-
M^OB)I_CHZ=-9>))?&NCZ7IUSAYM9U6;6]5^PVEK']Z6[>X6/RDCR^]01C;D?
MHQK%T]IXHL&CMIKHFUN!LB*`CYX.?F91^O>O+_!?[%7P8^&WQ27QSX=^`/PZ
MT#QJD\UTOB#3O"ND6NJ++,'6:07*`2[Y!(X9MV6#MG.365:E[6#IR=DTU=;_
M`"_SZ;V9=*HZ<XU8[Q::[:7W/SS_`&O/C'XT\,?L\^+O$>A:C\2[7XD_`#1O
M#%IXM\2:M\6;[P_H>E:M]BTZ<6=GHUJ9+?5Y97G_`'RZC;QK*UT8UN)`%CB]
M6_:B^.GQ#^#/QC^,_P`#K+Q3XF'B+]H&]T*Y^%=__:4KW6B1:GLT_6A9N6+P
MKIRVT]^H3`C$X*XK[#^(?[)WPI^+OQ!_X2WQ9\$?`_B?Q5]D-A_;6K>'-*O=
M0^SE'0P^?)ND\LI(Z[=V,.PQ@FNJUOP)H'B7QQH7B;4?`5EJ'B3PND\>C:M<
MV5E+?:0LZA)EMYF<O")%`5PA&X``Y%=3GSU%.:T;;DNC3LVEVO)+6UTM+MZO
M"$/9TU"F]8Q2B^S6B;[V5^MG>]D?"/[8OQW\;?"J_P#VLM.T?QYXC\/Z?HY^
M'>A6NK2ZB\[>$;+4IEM-0O[?S6*QS"&5Y#*,'>BR,25S79?L\?"GP[\$O^"T
M6L>'/#_COQ=XK2#X0&YN--\1^+9_$EYH#2:K;803W;RWBI,%\T)/,Z@LQC"*
M<5]<ZI\._#FN'Q+]M^'^GWG_``F=JMCX@\^PL9/[=MUC:)8;O+'SXQ&[H%DW
M`*[#&"16-\'_`-G3X=_L](B^`/A#X5\#K''+"@\/Z'INF!4E9'E4>25P':.-
MF'1C&A.2HK*E>-959;IR?F^:G*%O1-\WS:'4@GA_8Q[KY6G&5_6T>7^G?PC]
MM?X5:YX&^-WB?X\_!WXG>"/#?Q+\#^"5M_%_AGQ8J76A:WHT)N[FU-X4ECN-
M-99/M31W:L4.QPT<BJV/F+P'_P`9X:M^TG\:!KWQ8^&5Y>?"KPMXJTO2/#WB
MVZT5M+O9M"N;J*::2U\I[IH2NU4GW6[*S%H"2"/T"^-/[(?PC_:2\3VVM_$3
MX&>`_'NLV5L+.WO_`!'X:TG5+J"`,SB)))][*@9W8*#C+,<9)KKSX'T(W>NW
M'_""6?G^*;>.TUJ3['9;]7ACC:-(K@[\S(L;N@5\@*S`#!-85:4I8>5*#M+7
ME_NM\[;^;DI?W7&\=7<VC**Q$*LE=?:_O)**2^237]Y.ST1^>/BCXB?&7]LW
M]H3X:^$;6Z^VV<_P-T7QLVFQ_%?6?AFVJZG?2.EY?I<:18SSW8M]ENGD,Z0Q
M&Z#,CM(FST#XB>`_BWKFN?L=_"[XD?%'Q%INO:S_`&[9^/+[P)XBGLQXF6RL
M/-2-KM(K>52YB3?+%'!*K-+Y;1D[J^IOBG^RQ\+?CGX7T+0_&WP5\%^,-%\+
MQ^3HVGZYX>TO4+72$V*FVWBFW+"NQ$7"`#"*.@%=!H7PO\+>%[;PQ#IGPZTK
M3H?!,#6WAV.UTZQA70(FC\IH[0*P%NIC^0K'M!7CIQ775<)\Z2LG)OY<TI)/
MT4E&VMTDM(I17-"$XJ%WJHI?-1C%M==7%ROI9MO?WCXN^('@G6]=_:7_`&I9
M7^)/Q8M="^"_@;2;CPKH5EXRU"UL[6]?1[ES>3O'*)[J3_1T^2>1XF9GD='D
M(<3?&C3_`(D_$+]DC]G3QI:7WBWQOX9\.>!K76_'OA;P_P#$6]\(>*=>6>RL
M@-3AOH)X&N7MA]KD:VGN8(YS)DR&1(Q7VK+X+T.:_P!?NG\#6C77BN!+76YF
ML[(R:Q"B-&D=RV_,R*CNH5\@*S`<$UR'Q2_9)^$WQRT?0-.\;?`_P-XPT_PI
M;_9-$M=;\-Z5J$.CP[47R[9)MPA3;'&-J`#"*.PKFY)>_K\3B]==5[2[?>_/
M'JG:*LTU%K:/*I0D_LJ2T[/DLEVLHOYRO9WE?JOV=/'^C_%?]G_P/XG\/7&K
MW>@^(=`L=2TZ?5M_V^:WFMTDC:XW_-YI5@7W<[B<UV=95MJ4ME;1PPZ'?10Q
M*$1$-NJHH&``!)@`"G_VW<_]`?4?^^[?_P".UTUI*524H[-LSI)Q@HRWL:5%
M9O\`;=S_`-`?4?\`ONW_`/CM']MW/_0'U'_ONW_^.UF:&E16;_;=S_T!]1_[
M[M__`([1_;=S_P!`?4?^^[?_`..T`:5%9O\`;=S_`-`?4?\`ONW_`/CM']MW
M/_0'U'_ONW_^.T`&B?\`(3UC_K\7_P!)X:TJY[1]8N$U'52-*OVW72D@/!\G
M[B(8/[SVSQGJ/<5?_MNY_P"@/J/_`'W;_P#QV@#2HK-_MNY_Z`^H_P#?=O\`
M_':/[;N?^@/J/_?=O_\`':`/S`_X+I_M,:WHGQ4U?PGXA^!WQ_\`'/PW\+?#
M[4=8TK4_!W@]]6T"7Q!=VUS;1WFHW/F(D,>G0AW5?G(>Z,Q53!"Q^JO^":G[
M77A#Q1_P3Z^#UUKD\WPYU&'P!!>/HWC)X=(U1+#3TCM)M2,#R%A9%A'(L^=A
MCGA8E=X%?16OQQ>+-"O=+U3PU-J6F:E`]K=V=TEK-!=0NI5XY$:0JR,I(*D$
M$$@UYM:_LH^#H_BY>>+;GPG=Z@TOA*/P-9:/<PZ>=(T?1PQ::TM[=<`1SD1"
M57+AEMXE`55P517)"<'KS6=]GI[5K\9Q5]U%>205K5)PJ;<MU\G[._\`Z3*5
MOYGYL^?/"EMXM^'_`/P63\#K\4=<\(?$3Q-XL^&VL6WAR[\+:9+H,7A*SM[V
MUFNS<Z?-<7LDOVMFME2Z-VJAK9HU@!9G:7P7H=A^W9^TQ^T!\2=8U6RT[X>^
M"M"OO@YX0U1YE:"&1E+:_J0WX5?]),%J&#`$:?)SAJ^C?@?^RU\+OV8[_4+K
MX;?!;P7\/;G5HTBOIO#7A[2])DO$0DHLK6^PN%))`;.,G'6N@L/AIX8TKX;7
M7@RU^'FF6W@^^AN+>YT*+3[%--N(K@NUPCVX;RV64R2%P5PY=MV<FIG3C*DJ
M<U=*,X]M9R>NG]R4HONY.6Y4:DE-S6C<HMO?X4O_`&Z,6NEER[,^,?V=?B1\
M2/\`@EY\7/AG\#/C%\;_``!\5?!%WX1U;5/^$AN_#</A#4?!&GZ7'9Q6[W;K
M=R6TEBV\PB21(Y/,(S))A@OI7@+Q+8:3_P`%JOBM'K%S:07%Y\'_``Y=:*UQ
M(BF6RAU+5_MK19&3&DDUL9"#A2\>1\RUU7B+_@FU\%KOX7ZYX.\.?"#0/AUH
M'BR:S/B.W\':%H^C'Q';6TPF%E=M$F9+=SN5U&&*.X5EW'/H'QN_9I^&O[3,
M&EQ?$CX.>$?B#'H?F?V<GB70=,U9=/\`,VB3R1.7\O=L3.W&=BYZ"MIU)R<:
MDG>2YKM];J23^7,D[ZRY7>W,9PA"$)4HJT7;Y<LH2LO_``%^2NK7LT?G/_P0
M/UJST']H[Q-_:MW:16FM?#9-8\&23.L8G\/_`/"7>)9?,@W`,85CN+%F.<`2
M1$YW*:X3_@AMXO\`!GAC]@+]N&37KRQLM);7=:UTM>R[=_ABZTPG3;@!AYGV
M62)9O*/((#!1D'/ZG?&/]E[X8?M$Z;HUG\0/@OX-\=6?AU'CTF#Q#X?TO4X]
M+5P@98%GW"($1Q@A,9"+Z"HO'_[)WPI^*_C+1/$7BGX(^!_$OB#PS##;Z/JF
MJ^'-*O+S2HH7,D*6\TFYXEC<EE"$!6)(P:PK4E4ISI;*4)4_12GSWMW5HJVE
M_>=];+:G5<:JK]>:,[><8J/*O[MKOR]U6?+K2_X)PZ+K/AS_`()\?`W3_$(E
M77;+P#H<%^LHPZS+80!PPP""""",5ZMX6_Y!DO\`U^77_I1)1_;=S_T!]1_[
M[M__`([5#PWK%Q'IT@&E7[_Z5<'*O!QF=SCF0=.GX<9ZUUXJM[:M.M:W,V_O
M=SDP]+V5*%+?E27W'0T5F_VW<_\`0'U'_ONW_P#CM']MW/\`T!]1_P"^[?\`
M^.U@;FE16;_;=S_T!]1_[[M__CM']MW/_0'U'_ONW_\`CM`'Y\?&C2/BI_P3
M+\3?$+XV>#OC5X.\=_#/XC_$&SE3X7ZCX2C6>;4-1U"TL;F+3]7@NQ*UY\C[
M4DADC'EL&C4JS@^-&D?%3_@F7XF^(7QL\'?&KP=X[^&?Q'^(-G*GPOU'PE&L
M\VH:CJ%I8W,6GZO!=B5KSY'VI)#)&/+8-&I5G'UMHG['/P>\,_&%_B'IOP(\
M`:?X_DNYK]_$UMX8TF+6&N9MPEF-VN)C(^]]S[LMO;).31HG['/P>\,_&%_B
M'IOP(\`:?X_DNYK]_$UMX8TF+6&N9MPEF-VN)C(^]]S[LMO;).31AU[/V?\`
M=]WO[GN>YK\7P:-_#I9:"K)3Y_[SYNWO>][VGP_%JEO=W.)_;8^$UK_P4/\`
MV?/#-G\+OC;X?\$:[9>+;;7/#/B[3;2S\2P+J&F2R^9$ENTJQ3LACF#KN.PQ
M-N4[6%?'O[3/[>7QGA^$OQ#^#OB'POXV^.B>%O&^E>!_%WC+X*>#IVU.^TB;
M2TOM0B-@MU(+:]<@VDLD=PL<0O=Z".1%B/Z`^*OV4_A7XZ^%]KX(UOX)^"=8
M\%V5\^J6V@7WAW2[C2[>[=I'>X2V?,2RLTTS%PNXF5R3ECGI?A3\.O#?P(\$
M6OAGP/\`#[3O!OANR9WMM*T*PL=.L;=G8NY2&%E12S,6.!R22>34PA9271M.
MVZ;]S779.,>5I:23UVL6Y+G4UNDTGLTO>MMNTY<R;V=['Q#_`,&^'[0EA\6_
M#O[06CZ5\+?B5\,],TKXG:CJ5G;>)O#8T>"VAN51$T^-0[!;FU6W`FA`Q$)8
M>3NX_1.N7\)^'-,\!#4O[#\&QZ+_`&S?RZIJ'V"WL[;[==RX\VXEV.-\K[5W
M.V6;`R3BM;^V[G_H#ZC_`-]V_P#\=K1RO&$?Y8PC_P"`Q4?T,H0493:V<I/T
MYI-_J:5%9O\`;=S_`-`?4?\`ONW_`/CM']MW/_0'U'_ONW_^.U)9I5F^#O\`
MD4=+_P"O.+_T`4?VW<_]`?4?^^[?_P".T>#O^11TO_KSB_\`0!0!D_$G6-5\
M/65Y?Z%HW_"1:W8Z+?W&GZ5]K2T_M.X01-';^<X*1>8X5=[#"[LG@5^??P6_
MX+0_M-_%S]K[5_@U)^P]_9?B7PA_9MUXL'_"Y-*G_P"$?L+UAY=U_P`>RI<8
MCW/Y<4C/\N#M)%?HU=?\C=9?]>=Q_P"AP5\._L__``9\:Z=_P6W_`&MO%!\/
M:_I6@^)_`_AJRT+7[G3YH=-O[F*WD5UAN"GER-&Q&X(6*]Q67/*%=.W,K2=O
M\,)22[^\TD]?2SU+Y5*E))\KO'7_`!3A%_<FWMZW6A]2Z9^VS\&=:^,C?#JS
M^+GPQN_B#'<R63>&(?%-C)K*SQJS21&T$OG;U56++LR`I)'%>9_LO?\`!7CX
M%_M;?%[XF^"?#'C+2(=8^%M[-;7QO=6T]8M6MX8P\]_9>7<.TMG%G#S,J!#P
M<5^1GP-_9'\7:I^S#\`_V?[;]ECXE^%/VC_`GQ>76?$/Q2O/`XM]%ABM=2>Z
MN-2&OX_TA)8%A1,,?,-LJ+D"#?\`0'P.^!FI_LC_`+8G[=VF:1^R->^*?%?B
MJWU77_A[K5QX!@D\(:K8R:<C-HQOOD!%S+(`]I$<2%)%8JXJI-P4I-W2C4:?
M23BJ;4EUL^::L]?=?78M>:@E;WHIWW2<JD7?I?W8ZK2\ET=W]=_M[?\`!9?X
M=?!#]@_XI?%#X+>/?A+\7O%'P^L[*X.E:7XHMM4BA%S?06BR7"VDK2+&#,3U
M7<5QN&<U]B^&-8/B'PUI]^8_*-];1W!0'.S>H;&>^,U_,9^U1^R/^T9\<M-\
M0ZT/`'Q8\7'5/A';:1%I^G_L_3>!;;PS,NL:1<CP];P01^;>QVB;PDKJ5*PO
MY;.$D*_TT_#VVDLO`.APS1O%-%I\".CJ59&$:@@@\@@UT1@O8RE+?FMZ)77H
M[VO=76NC:LWDY7<.7^]\_=I->EG*2Z/NDU9;%%%%9%!1110`4444`%%%%`!1
M110`4444`%%%%`&;HG_(3UC_`*_%_P#2>&M*LW1/^0GK'_7XO_I/#6E0`444
M4`?(?_!0W]NWX_\`['^MZEJ'@']EM/BU\.=`\/OKFL>+)OB=I?AJ+3_*$KW$
M9MKB-Y6$<4:N7'!WX`)6NF_9K_X*-VOQ9_X)@6/[3?C3P=J?@/2)/#%YXLO=
M#CN?[2NK>RM_.=3&YCA\TRQ1+(F40$2+SCYJ\D_X+L>&/B/^TU\,/A]^SC\/
M/#_C"2V^.'B2"P\9>)]-T^<Z?X8\/6[I->-<78C:*%Y0%1$=@9`)%P<X/3_M
MD?M3?\*4T7Q!^S%\&?A[J/B'XHP_""_\0>%=/&FVMQX>MK2W5K*WMK@22J<N
MZA$B:(QR<*6P2*YYU)1PM62UE=\G?W82G+31-;)=?<E=FT81EB*47I'1R[6E
M*,(ZZM-OF;_Q1:T=CRGX`_\`!=3XD_&#QOH'AS5?V5]:\.:Q\5O!=_XT^$D"
M?$#3+_\`X3F&WMQ<)%<,J*-+\V)X\//N"LQ4CY<U'X3_`."S_P"T=)^UK:?!
M3Q7^Q5+X:\?:OX1U+Q;I>G0?%S2]4:[BMHY1"LCPVWDVR3W*+;B6:10K/G#8
MP?E/_@CA^RKK7[,?[>GP:\1?"SX6_'KP_8^)/`6I-\<;GXC_``Z_L*PTNXWO
M-';Z1(UM%Y;F\92+2RW1-!]G)!>.;R_LO_@D-\(_&?Q+_:#_`&@?VK_BMX3\
M5>$O$?Q-U?\`L#PCH?B#39K75-#\+Z=E8%^RR1K+$UPX\QH\?,8U8`[LMW3I
MQC))O11J<S])3A!IV5V[QE>RC*,)-16J.2,Y.+:6KE#E^:C*2:Z62GI\492B
MFWHR7]F__@KM\;?'7_!0OPC^S[\5_P!E)OA'J_BK0;SQ(;^+XEV/B4V%A`'4
M3R16EMM5'G00@O(GS-P&Z5ZY_P`%8_\`@ISIO_!+W]GJW\5CPK<?$'Q7J]S)
M!HWA6UO_`+%/J,<$+W-[<&7RI3'!;6T<DLDGEL!A0<;LCY0_9.^*6H_LV67[
M4O[?_P"T!X'^(.A3>)=5@T'PQX9O-*^S^(-+\,6MQ':VD4=I=&`Q27,\J.T;
M,NXQAADL"V/_`,%?_P!BK]JOX[^/?B-\9OAMIWPM\0>#M5^#MSX4TWPQXF36
M+CQ9HEO=P-+J4>FV5FAM_P"T;ABD>YWD+>5&G"Y!XL3.:P\'%6E:\O)M2G%.
M_6RC"5OA;;[7Z\-"#Q$E)WC>T?.W+&37=*3<H_S126E[KVS]H/\`X+'_`!4^
M'/[(O@GXP^`_V6-?^(OAC5?AU9_$;Q9?-XTL]'T_PM:W$!G%M#-+"TNH31K'
M*TBQ0*47R6P3*%7R_7?^#F9O'GAK7?%?P:_9Z\3_`!+\`?#KPSIGBGXAZUJ'
MBS3_``[-X5@O86G2.*VF$C7TBQI("(F`+IM&0RN?FW]H#XL?M-Z+_P`$X/V;
MOV8?%GP/^-K>$-=\$V`^)>N_"OP!?ZOJEMH:*8[;0XTN=B0:D\,,:7IE8")I
M#LC=<HWD7[3W[-B?M8:Y\3/%&L_LN?M3_#X^#/!FE:9^S_H.C?"`7"SQ6C11
MQPZ\$AN//D$]NK-#>S;%M?-*@R/$'[,3%1KU53^!3DH]79<UU;3FULHQ3C.7
M+*7/RI<^-'WJ=-3^)Q5^UVXV=^FG,W+6,>:-XMW2_H=^$OQ+T[XS_"OPUXPT
M=;I-)\5:5:ZQ9+=1>5.(+B)98]Z?PMM<9&>#5_PM_P`@R7_K\NO_`$HDKE?V
M7+GQO>?LU^`9?B7:6-A\0Y/#UBWB6VLRGD0:CY"?:%39E,"3=PI*CH"1@UU7
MA;_D&2_]?EU_Z424\3&,*TXPV3=M;]>_7U,,-.4Z4)2W:7ET[=#2HHHK$W"B
MBB@#E?C?\5X/@9\)-?\`%UQH?BKQ+'H%F]W_`&3X:TB75M7U)A]V"VMH@6DD
M=B%'11G+,JAF'Q7\&?\`@OCX;\:_\$Y_BG^T5XO^'/B+P7IOPU\6W7A%?#BW
MJ7^JZE<I);PP(1LC2*:26X1&CRXCVM\[XK[,_:"^,/\`PH#X,^(/&7_"+>,?
M&W_"/VWVG^P_"FF_VEK.I?,%\NVM]R^9)SG;N'`/I7X(?#;X;?&3XU_\$M_V
MBOA;IW[.WQ^\/>-/^%FW'QGTE/$W@JXTNSUJP74;.7^SH'<[Y-0\M7<0(C;A
M&0K,2!44WS5I4Y.RY5K_`"_O()R\VH<[L[KW=F5.ZIPG%7?,]/YO<E:/DG/D
M5_[VY]^I_P`'"S_`S1/B58_M&?`GQ/\`!;X@^!?#EGXKTWPO:^(;3Q*WB>PN
M[J.R@,%S"L<:2_:I4C:-A\H;=DD,H]@_8*_X*B^*?VDOVCO$7P:^+_P3U3X"
M_%;2/#\'BZQT:;Q+:^(K;5M'DD$/VA+JW1%1UF(5HBN1D<YW*OYC_P#!2KX!
M_&O_`(+"_%CQY\??!7P%^,/@/3OA9\/](TG3/#OCOPX^C:[XJOK?7%U*XCL[
M0/(TRK;A]I4Y=]J`%CBOM;]B+4/&O[=__!8O4_VC[SX0?%KX/>!/"'PJC\!6
MMK\1-`_L+5-6U&;46NY'AMR[EX$CX\P$?,RCJ#73AXJ7*ZBLWSW7:,5-TY>L
MVHK>SZ15S&J[)\CNK0L[;R;ASQMV@G)]^[?*S])J***Q-`HHHH`*S?!W_(HZ
M7_UYQ?\`H`K2K-\'?\BCI?\`UYQ?^@"@!VIZ9<7&HV]S;7$,+PQR1$2PF0,'
M*'LRX^X/SIOV75_^?W3O_`%__CM%%`!]EU?_`)_=._\``%__`([1]EU?_G]T
M[_P!?_X[110`?9=7_P"?W3O_``!?_P".T?9=7_Y_=._\`7_^.T44`'V75_\`
MG]T[_P``7_\`CM'V75_^?W3O_`%__CM%%`!]EU?_`)_=._\``%__`([1]EU?
M_G]T[_P!?_X[110`?9=7_P"?W3O_``!?_P".T?9=7_Y_=._\`7_^.T44`'V7
M5_\`G]T[_P``7_\`CM'V75_^?W3O_`%__CM%%`!]EU?_`)_=._\``%__`([1
M]EU?_G]T[_P!?_X[110`?9=7_P"?W3O_``!?_P".T?9=7_Y_=._\`7_^.T44
M`'V75_\`G]T[_P``7_\`CM'V75_^?W3O_`%__CM%%`$-KH^J6<]S(M_8$W4@
ME?-D_!"*G'[WT4?K4WV75_\`G]T[_P``7_\`CM%%`!]EU?\`Y_=._P#`%_\`
MX[1]EU?_`)_=._\``%__`([110`?9=7_`.?W3O\`P!?_`..UB:5\*;+0_'>J
M^*;+3/"5GXFUZ""VU/5X-#6._P!1B@W"&.:<2"218][;%8D+N.,9-%%'F'D;
M?V75_P#G]T[_`,`7_P#CM'V75_\`G]T[_P``7_\`CM%%`&)X\^%-E\4]/L[3
MQ/IGA+Q':Z=?0:G:0ZIH:WD=K=P-OAN(UDD(66-OF1QAE/((K;^RZO\`\_NG
M?^`+_P#QVBBC;3^OZT0!]EU?_G]T[_P!?_X[1]EU?_G]T[_P!?\`^.T44`'V
M75_^?W3O_`%__CM0V&CZIIT#1I?V!#222G=9/U=RY_Y:^K&BB@";[+J__/[I
MW_@"_P#\=H^RZO\`\_NG?^`+_P#QVBB@`^RZO_S^Z=_X`O\`_':/LNK_`//[
MIW_@"_\`\=HHH`/LNK_\_NG?^`+_`/QVC[+J_P#S^Z=_X`O_`/':**`#[+J_
M_/[IW_@"_P#\=H^RZO\`\_NG?^`+_P#QVBB@`^RZO_S^Z=_X`O\`_':/LNK_
M`//[IW_@"_\`\=HHH`/LNK_\_NG?^`+_`/QVC[+J_P#S^Z=_X`O_`/':**`#
I[+J__/[IW_@"_P#\=JSH^G_V3I%K:[O,^S0I%NQC=M`&<?A110!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>sc52d2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sc52d2.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`%:`<L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]Z+JZOKC7
M9K:VFM(4A@CE)E@:0L7:0=G7'W!^=.^RZO\`\_NG?^`+_P#QVBU_Y&Z]_P"O
M.W_]#GK2H`S?LNK_`//[IW_@"_\`\=H^RZO_`,_NG?\`@"__`,=KR+_@I7>^
M/-._X)^?&2X^%YU-?B!!X0U&30CIBEKX7(@<C[.%^8SXSY>WG?MQSBOS`^)'
MQ;^'GP#T^W^(_P"Q-JWA&P;P7\!O$&L_$2_\*16][9F[2WM6T8ZR$W12:I]I
M^VN!=!KDJESD8W$3&:<I)[15_P#R6<ON]RU[]47[-ODY=Y.WEO!;^?/IWL?L
MY]EU?_G]T[_P!?\`^.UD^"_&L/Q(TB34/#OBCPOKUA#=3V,ESIRBZACN()6B
MGA+I.0)(Y$='7.5964@$$5^1>N_ML_$OXG:WHNIS?M,^)H?A-X=^.'AO1E^(
M>DMHFE65Q:WWAQ[J_LKJ06GV9H;2^V1*DZL`USLF\V6.-HVZ_P#\%!?B!\*?
M!WBW2X/B9IOP/T#3K_XG:GH&KZ9X6T6*'Q;KUAKS16&B;);-H9)71GD=(5%Y
M=-(6\W<&+5>S:EV;^Z-.?WVJ))+=JRNVDX7O0C..TN7_`,F=2/YT[N^R>MK.
MW[&?9=7_`.?W3O\`P!?_`..T?9=7_P"?W3O_``!?_P".U^9W[3?[>'QZ\#?&
MZ[G7Q7<^#H_"OAWX7ZKJ'A"/1]/FM)KW7=;FL-4MKB6:![D1A!A1%-&RM$I#
MXW!O4/\`@IMJ/@B']O3X#VOQ^F\+1_LZ7&A^('G3Q@UNOA27Q*HM?L8O_M/^
MC-(+4WIMUF_C$I0;ER*E%QDHZ?%*/E>"N]?/:/=V6E[DPDI)M)_#&7G[UK:>
M5[R[)-ZV/N'[+J__`#^Z=_X`O_\`':/LNK_\_NG?^`+_`/QVOQ\^$G[0GQK_
M`&9_@MX2T?X=>*9M*^'7QIUOQ=X.^#D6K:8DR:*9M8M_^$<O8C<1M)):BP:]
MDAA8^4UO%"51D`-<OKG_``5=_:0^,6O>,O%F@_$C4?`_@W2?A)KGB+3-+M=#
MT:Z,FNZ#I^BR7^Z6>SE8PG4+V\MI%##_`(]G">4P##-5$U?:T7)IZ.*47*2:
M[Q27,E=KGAW=M53DY.*U][E6NC;DHJWE)MV;M?EEV5_VK^RZO_S^Z=_X`O\`
M_':/LNK_`//[IW_@"_\`\=K\VOVFOV\OC=)^W%X1\&:'\3?A/\(=(N/#/A;Q
M!IT7C/7K71K+QM+>W<@U&VBCN--NIKYU2-(4AM;RRDB:=&9IMX"<-\2?V[?C
M5X!_9!O_`(LZ[\>7TS3O^%K>)-&NM-1?#>@7RZ'I>H:E:I9Z1<7^FSVD^HE4
MCE,-V5:Y2S6.%HI/->;2I%P3<NCDO_`9*#_\F?X._GG3?/;EZ\O_`)-!S7X+
M7S/U>^RZO_S^Z=_X`O\`_':/LNK_`//[IW_@"_\`\=J+X?ZV?$O@/1-1,>J1
M&_L(+DIJ<*0WJ;XU;$Z(`J2C/S*H`#9`XK7ISBX2<'T)IS4XJ<=GJ8MC-J]Y
M<WD?VO3E^R3"+/V)SOS&CY_UO'W\?A5C[+J__/[IW_@"_P#\=HT3_D)ZQ_U^
M+_Z3PUI5!9F_9=7_`.?W3O\`P!?_`..T?9=7_P"?W3O_``!?_P".U^6OQ@GT
M'X3_`/!7#6]0TBZ^%_Q<U[X@ZO=VFHZ?<0W%E\3_`(6&/0O+$D;@DS>'3%"[
ME9(XHF>^B97F)#'R3]D;]N7XA?LF?L-:!X8N/B!K\WA\_"#X=:OHFHR'1=(C
M\#7&K:G-I\C27\NF7,4.FHD41EEN[:\D0;BI!8;9H352FIKKRI>LE.5ONAHU
M>+OH]-;JTW"?+ZOY<T(W^^>JW5MM3]I?LNK_`//[IW_@"_\`\=H^RZO_`,_N
MG?\`@"__`,=K\J_V)_V]?C_^TYX\^%>CR?$X7L"Z;X_U74'T6PTK4!XV&BZQ
M9PZ;&MW]@A0Q313A&GMK:W\Z)]R)"[)(G)_!?_@HM^T/\1OV-_&'CVZ_:,^`
M]KJ4NDZ%?W.DS>,=)AUKP5?O>,;ZQF:30H[;11/&#:0KJL=^(IU4-<ONWU5U
MRQF]I)->C;BG]\7IOMIJB+>]*/9V^:2;_P#2EJ_/L?L!]EU?_G]T[_P!?_X[
M1]EU?_G]T[_P!?\`^.UYY^P]\84_:`_9%^'OC6.X\67D7B718+^.Y\30V,6J
MW2N.)9Q8HEH2XPP:!5C965E&#7JM74@X3<);K0BG-3BIKJ8NE3:OJ=LTGVO3
MDVS2Q8^Q.<[)&3/^M[[<_C5C[+J__/[IW_@"_P#\=H\+?\@R7_K\NO\`THDK
MYS_X+4?\HD?VC?\`LGVK_P#I*]<V)K>RHRJVORIO[D=&'I>UJ1IWM=I?>?1G
MV75_^?W3O_`%_P#X[63X<\:P^,=6UFPTCQ1X7U2^\.78L-6M[-1/+I=P8TE$
M,ZK.3%(8Y(WVN`=LBG&&!K\S/#/P:^*O_!.?]A?Q!XL\':KX*^$E_P#&'Q]X
M$M]&\/\`A&V35]$\*VUU)IFF7<Z)<VMO&]Q=AGEF"P(%;;AV;+T>-OVJ/&GP
M`_::^(/@VZ^*%I\./!,_Q=TOP]XJ^*,^A>'[+4+"`>#(+Q9[NX>R6Q-S>7<4
M<)GN8'"AQ%$J#RE3KJ4U"I*#?PZ=O>_=7^2]JD^K:T70YJ4^>DJEMUS?]NVJ
M?B^33IYGZD_9=7_Y_=._\`7_`/CM'V75_P#G]T[_`,`7_P#CM?F]\'_VXOC7
M\3_^"FS>#+OXN?"SPSX>T'Q#86"^#_$.HP:'JOC;19M%AN3?V&CS::U_)/)<
M3/(LBZFL48MVA>V)1G?],ZCE]Q3Z/_@/Y;[/5;,J_ON'5?YM?IZ=C%EFU>/5
MX+7[7IQ\Z&27=]B?C84&,>;WW_I5C[+J_P#S^Z=_X`O_`/':+K_D;K+_`*\[
MC_T."OG?_@KIX'T#XC_L3:QH_B7Q_H/PVTF?5M+FDUCQ'9-=>&Y6AO(ITL]7
M7?&HT^Y:,02F26-#YRJ6)8(^52?(K^:7WM+^DM7LM32G#FERGT1]EU?_`)_=
M._\``%__`([1]EU?_G]T[_P!?_X[7Y(?L[?M&:YI/Q"_9-U%M??X*^`[B3QO
MI,WAGX=ZC;_\()XZOK*XMFMFT>*]M\R6VHN\_P!E@4[E3_CV:,EY'\U_9L_X
M*L_'W]IW]M+X5_#C0OCH\'@[XH3:7>SW]I)X=\3:UH,4^FZU<SZ=+-%HEE:V
MU\@M;7S('@N&MY`N9)4=HSO3A[2<:<-W_P`&WI=)NSU2W29G)\M*5:6T5=_+
M1V]'I?9]&UJ?MS]EU?\`Y_=._P#`%_\`X[1]EU?_`)_=._\``%__`([7Q?\`
M\$IO&6N:WX8_:3T7Q5\7O%7Q'\1^%?B1XBTQM*\0WMC->>'K)+F<6C^7!!%+
M#'<1#<B-^YVQCR$C3(/YI?`?XR_#K]G']@O]FKX@_`"TL+KXW^#]#UK4OBK_
M`,*T2Q;6XO#Z6%VUR^N$12PJRW(L'A;48I")$RD<@$BG&$T[-[.-.6FKM4BY
M7MVC:\GT5WTL]?92<I06ZE./S@[6]9?975Z'[^_9=7_Y_=._\`7_`/CM'V75
M_P#G]T[_`,`7_P#CM?C+HO[=?Q5^+6A>'KOQ)^TG=Z1X4\'?'_2/#USXT\*^
M(]$O-+NM(O-!>X87.III%E974,=V#&-UFD7F2LCK,\<3K](?\$W_`-L_XS?M
M&_MQ>([#Q?\`%#X66VDZ9J7B72]3^&$WB"T_X2C2UM+_`,FPN;?3$TR"[@C\
MF-7DEGO[R.9;I718<JBZ0BY/EZZ_<H4Y_P#N1+U,9348J?1V_&4X_P#N-OYH
M_0+59M7TRV63[7IS[IHHL?8G&-\BIG_6]MV?PJQ]EU?_`)_=._\``%__`([1
MXI_Y!D7_`%^6O_I1'6E4EF;]EU?_`)_=._\``%__`([1]EU?_G]T[_P!?_X[
M7YP_\%G-*\":S_P4-_9NB^(NO?`3PYX;'AGQ8SW7Q?T"WUKPZT@DTG:@@GO+
M1!<D;MC^:2N'^1L\9'C#]O#XQ>!/VMM<C\+>+3K_`(/TGXM?\(!H?@FUTC31
MIE[IS>"AJT*QS1V_VKS/M:KY;+/MVR%2KC:%SC53I\[\_/:HJ:^;DU9>M]%K
M<J;3LO\`+[+G]R47=^B]/TU^RZO_`,_NG?\`@"__`,=H^RZO_P`_NG?^`+__
M`!VOS(_X(J_&[4?VBOVY_%/C#6OB<_Q2U[6O@MX4N=9O#I]G9#1-0>]U%[K2
MQ':Q1(OV:5F79(&F3.V1V89KYMT34_AMH7@CQYJ7PWLO#NH?MBZ9^TOK%WH=
MOX5BMY?'$VG)KCF\6Y6+_2#IIT[[8'%R1;$%0?F*5H_=E&-3JI-VUMRU52^:
MUYF]K)VON0]82E#HXK73XJ3J:]MN6SUN];/0_<G[+J__`#^Z=_X`O_\`':/L
MNK_\_NG?^`+_`/QVOPYO?^"E_P`8_P!HO]FGXO75G\=->L]"T;0O`_C*RU;0
M_$.BWVK^&4O-=$-_8W]Y9:+I\-M)%;-&]S;-'*T)B`>X>*22-OJ+X,_MO?%S
MXD_\%,CX)MOCC\++?P9X>\0V.G66@^(?$FF6^J_$70)=%BN%U6PLH=)$MY//
M-,TJW-KJ$5J!`T?V0!2S73@Y24=FVU]S2_.Z\[-JZ3LJK4%)[\O^7-^37I=)
MVN?I)]EU?_G]T[_P!?\`^.U7BFU>35Y[7[7IP\F&.7=]B?G>7&,>;VV?K6U6
M;:_\C=>_]>=O_P"ASU`P^RZO_P`_NG?^`+__`!VC[+J__/[IW_@"_P#\=K2H
MH`S?LNK_`//[IW_@"_\`\=H^RZO_`,_NG?\`@"__`,=K2K\P?^"F4^@_##_@
MI=X/\=PW?PO^)WBUW\-Z&GPS\40W%KXRTV,ZA*8]6\(W*'=N\R=7NMD31M'8
MRJ\R[2BB=ZD*?\SM]^WK=V7E>[T3!JU.<U]E7_%7UZ::_*V[/TL^RZO_`,_N
MG?\`@"__`,=H^RZO_P`_NG?^`+__`!VOR$;]N?QG^SW\,/B3H5[^T1XO;QI<
M_';Q#X;6_P#%'BKP]I-EX*L8$U&ZM%O+FZT2_-K#>Q0?N(?LVV1XHUMS!'O#
M>>?LC?\`!2;XRVOPS\?_`!$\8?'O7QXGFU/X;:G?:#K(TI-.TW0K]]*CU?48
MK62U5K6U3S9X7FC,<*%W9_WP$@,.U5<4G9-4W=[?O%%K[E*\GT2;V*K0=*4H
MO5KG^:A)Q?WM:+K==S]OOLNK_P#/[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=
MK\L_BE_P4Y^(R_L'I\4H?BW8:-H]I\7/%%A<WMO<:+HNK:YX=L[N\CM;/29M
M2L9].DNUA$4J0SHDMTENRI,'))_4?X?ZV?$O@/1-1,>J1&_L(+DIJ<*0WJ;X
MU;$Z(`J2C/S*H`#9`XHA>4/:>47Y^]%27X/7SN3.T9\GG)>7N2Y7^.WDUZ$O
MV75_^?W3O_`%_P#X[1]EU?\`Y_=._P#`%_\`X[6E10!CW\^J:7'%+)<V$J&>
M&)D6T="0\BH<'S#C[WI6Q6;XI_Y!D7_7Y:_^E$=:5`&+-%=R>+KO[+/;PXLX
M-WFP&7/SS8QAUQW]:L?9=7_Y_=._\`7_`/CM?.?_``55_P"$=_X9)\8?\)?_
M`&+_`,(I]M\+_P!M?VQY7]G?8O[>M_/^T>;^[\GR]V_?\NW.>,U\ZR_%#P!\
M$=!^-?B#]F76=/\`#OP<31M`B.L>`K[2;/P=H_B*6_DAGN8+F:UO-.M8H[1K
M9M1FCM9EBB".8VG!J>=7:?\`6E]>R>R?65EU*Y+I-=_U2T[VO=KI%-]+'Z+?
M9=7_`.?W3O\`P!?_`..US/QH^"=G^T+\)O$7@;Q@FG:OX6\6:?-I>JV7DW%O
M]JMI5*2)YD5PLB94D91@1V(K\Z/V&/\`@H?\:/B7\:+[X7ZSX^TGQO)XL\7V
M4'@[Q9H]Q8:[:'2["""]UX"^MM+T^VN5\B:VCCF%FF&O<+O\L2-WOCO]IB^\
M'?&WQ!X6U/XMZ?\`L_\`A.]\6>)YXO$-GHVC0MK^IP?V6MKI1:[M9(II91=7
M,S(JF]N?)`CE41OE3;MM>\)27FH\OY\UO.47%7=KRI\OO+=22T\^9IZ?X?DF
MF[*]OOK3-$U#1]-M[2WNM.CM[6-88D^QR':J@`#)FR>!WJ;[+J__`#^Z=_X`
MO_\`':_.SQ%X5\!ZY_P2/_9-/Q-\8?##PC9:1H&BWD-C\4M,$O@SQ%=+HC)]
M@U".>2*..3:[R0F1RT<L(<13&,H<>]^)'BZ2S^('Q7\#:WJWPE7P'^SSX<\4
M0>'K!;36+?55L[GQ-+;VDMU?VKRR6#I"</%';W$B2QL'B(*GJJP:K5*;=^65
MK_)N[];;:OJ]U>J=&\5&DNBLN]YQA9=/M)WVZ=VOTK^RZO\`\_NG?^`+_P#Q
MVC[+J_\`S^Z=_P"`+_\`QVOSP^"/[:'QD^(/[;^H:3J_Q7^$6A)#XAUNPE^&
M>H>-K"+7DTRV%T+6:VT0Z&FH&=X8K>[$KZK+!)&\DBH(W1(O2/V6/'WQ8^)7
MB']GJ#7?B]XBNXO'?P_N/B'X@6+1-'A^USHVBA+"/%H?*L_]+N-V,SGS.)UV
MKMRI1=1JVE[?BI2_*$ORW,Y24;];?YI?FU]Y]C_9=7_Y_=._\`7_`/CM'V75
M_P#G]T[_`,`7_P#CM?FOX!_;,U3P!X\^$NDW?Q;T'0M`O[B*QC^'_@;4/"]C
MXEO+J77;N'?<:)=V#33Z>T0BW2:;<0W*A9BL$S$RI^G53!\U-5%W:^X;TER>
M2?WF;]EU?_G]T[_P!?\`^.T?9=7_`.?W3O\`P!?_`..UI44#,W[+J_\`S^Z=
M_P"`+_\`QVC[+J__`#^Z=_X`O_\`':TJ*`.>T>WU0ZCJNV\L`1=+O)LW.X^1
M%T_>\<8]>A]<"_\`9=7_`.?W3O\`P!?_`..T:)_R$]8_Z_%_])X:/&.JWVA>
M$=4O=+TN77-3L[26>TTV*>.!]0F5"R0K)(0B%V`4,Y"C=DD"E.7+%R?3YCC'
MF:B@^RZO_P`_NG?^`+__`!VC[+J__/[IW_@"_P#\=K\O=/\`#L7BWP3\>=!^
M-VD:;\$+CQ-_PB/B/Q3XF^+@\.ZEX8U#58]0>Y^RW%O:ZQB:WE$"VT,32H1;
MVZ*S;E4/YUX*\6_#3QS;:]#J>@?"K1_B+I$^AV?P$_X1?1AI-GK$4.NW2_VI
MX6LRSM##<SIYUQ]G>13$0TTLMJ8Y&N$;RY'O=+37M>W=W=E%V<E[VB(E)*G[
M1>>^GI?LFKW>J4O=;NT?L/\`9=7_`.?W3O\`P!?_`..T?9=7_P"?W3O_``!?
M_P".U\&_\%._&'P1\?\`Q-4?%C5/!FM>#D\!^);#PL-1N4N;9?%4%U!#-#9;
M2?\`B=1X$<21_P"EJPF6$!O-%?*G[9,]DWPS\32WKH?VOK#Q;8/JCVQ/_"96
MWA'^Q+?^U#&8OWZZ9_9S7V?)_<_:6;9_IA6LZ,O:>7KM\?)^%N>7:FU+78TJ
M1<':S>^RN](J7Z\B[U%R^9^SOV75_P#G]T[_`,`7_P#CM'V75_\`G]T[_P``
M7_\`CM?,'_!,VW^&</C3XPM\#$\)+\%Y=4TQ]'/A%81X=?4?[/C%\;/R?W!X
M%J)?)^3S1)N_>^;7UC6DE;[E^*O]W9]5J90ES1N<]X;M]4.G2;+RP4?:KC(:
MS<\^>^?^6H[Y^GOUJ_\`9=7_`.?W3O\`P!?_`..T>%O^09+_`-?EU_Z425Q7
M[8`T:7]ECX@Q>(?$\_@G0[G0+RWOO$$*L6T2*2)D:Z.WD+&&WL<@!5)+*`6&
M=27+%R[&M.*E)1?4ZG0]8G\3V;W&FZYH6H6\<\UJ\MM`942:&1HI8R5F(#I(
MCHR]59&!P015S[+J_P#S^Z=_X`O_`/':_(/QK\5?V6-6^`.I?"S7-)_9/\+Z
MOJ>J7>D^!_'OA*73]'\%SRRVUJ;SQ/9F5A!:7]DAMU98KBXG\Z*.&.Y8&3RO
MK_\`X*4ZM\%OC=\%?"=OXI^,_P"S=I=CX-\2P7SGXG6MCXDT'5+@Z3<!+:>S
M:^M`TS6]]'=1XDR`(W",K`TYRBJ;J+96^YVU_'MOIO=*8+FDHO1M/SVV7S[K
MUV:;^O?LNK_\_NG?^`+_`/QVC[+J_P#S^Z=_X`O_`/':_*SQIXO\$?$I--U'
MQEX6\,>#?C1>>$_`MU\&O#K6AM;[2)?M;^8F@02(DL2"=!YZQHK+;K$+H"%5
M`_66M90Y;KM)K[OU[KIIJ[D1E=_)/[U?[NSZK70YZXM]4_X2BS!O+#?]EGPW
MV-\`;X<\>;]._8]<\7_LNK_\_NG?^`+_`/QVBZ_Y&ZR_Z\[C_P!#@K2K,LS?
MLNK_`//[IW_@"_\`\=H^RZO_`,_NG?\`@"__`,=I_BCQ3IG@?PUJ&M:UJ-CI
M&CZ3;27M]?WMPEO;64$:EY)99'(5$5069F(``))K\TOC%^USJW@7]G?P;??#
M_P"*MKX!L/&?B?QSK>G>(KOQ5HF@^'-?MO[>N'MXH[R_T35VNKJ99EDMH+6*
M/SHA<.9#LC!B=115W_6_^3+C3NOZ[7_R^]'Z5?9=7_Y_=._\`7_^.T?9=7_Y
M_=._\`7_`/CM?GI_P3@_:\^,GQR^&GP!^*OC7XB7NK1_&3QKKGA2_P#"46B:
M=9Z/I=O;6^M3PS0NMN+TW"MID:DO<&,I(08MX\PT_'<_@Y_VW-7DL4T6Y_:C
ML/BNK::NT/XEC\,?V,O"C_6#2#;-+G_EV^T,<_Z4:TKJ5&I[.:U5]M=I1C;_
M`,FYG_=4GTL2E>+?K^'/KY*\''_$X][GZ+_9=7_Y_=._\`7_`/CM'V75_P#G
M]T[_`,`7_P#CM?GY_P`$/?$=BVMZE86DWP7\7ZYJ?@[2M;\9^*?!_A:32?$-
MIKDLLWVC3O$5Q)>74EUJ.\S2-YI@EC9)MT*AUQ^BM74I\EM;^GDVG;RNG9]5
MJM&F\XS4F[=.^^J3U71ZZKH[IZIG/>)+?5!IT>^\L&'VJWP%LW'/GIC_`):G
MOCZ^W6K_`-EU?_G]T[_P!?\`^.T>*?\`D&1?]?EK_P"E$=:59EF;]EU?_G]T
M[_P!?_X[1]EU?_G]T[_P!?\`^.UI44`9OV75_P#G]T[_`,`7_P#CM'V75_\`
MG]T[_P``7_\`CM?'W[=/QC^)_A7XG_&>\\*_$C5O".B?!GX3V/C^UTBQTC3+
MA-=OS-K9>&[ENK::06SIIT2,L!BDYRDJ$'=S_P`8_P!LCQ/I?[3'B#2K?XN_
M\(YXZTGQ1HFE>$_A`EEIDG_";:3<I8O<:@R2V[:C.I%Q?_Z1:7$5O;"Q_>J?
M)GWN"<I*/?\`S2^>^RO*R>FA5:#I?%_7NQE\K*2NW:-W:]S[A^RZO_S^Z=_X
M`O\`_':/LNK_`//[IW_@"_\`\=K2HI$F;]EU?_G]T[_P!?\`^.U0M[?5/^$H
MO`+RPW_98,M]C?!&^;''F_7OW'3'/0UFVO\`R-U[_P!>=O\`^AST`'V75_\`
MG]T[_P``7_\`CM'V75_^?W3O_`%__CM:5%`&;]EU?_G]T[_P!?\`^.T?9=7_
M`.?W3O\`P!?_`..UI5\,6'[7_P`9)X_C;HNDJ^O^+_V>O#.NB^MI-(#)XGU:
M>1[C0#MAC#L?[-BCEDBMMNY[Q5`)``ES2=GT3E\H[_HEYM(N%-RM;JTOFW9>
M?KV6Y]J_9=7_`.?W3O\`P!?_`..T?9=7_P"?W3O_``!?_P".U^4^B?MY?$V+
MX=W]Y??MB?LZ3Z%'J-@]U=V/QD\*W7B6%##>--:VMQ-X:L]-BEDV0F.WN[5F
M<PS@W=N/G7>\-?M=>//"WPP^-OBGPY\;/''B#Q%=6_A;5-(T+XB7&A6,_AG0
MK^'2DN]>>.QTV1;>*`2W>ZZCAN-/1HGE:&X"N7IZ-I^7XV_X?R6KTU(A[S45
MU_S2_5>;V2;/TZ^RZO\`\_NG?^`+_P#QVC[+J_\`S^Z=_P"`+_\`QVOSK\#_
M`+9OCE/V?]#G\7?M,_#&V\':UX_;1M0^*WA+Q=H7BC_A&;--*ENA:W=^VC66
MDV\\UW'%$K2V&!'<HGS2R1R5]'?\$D[J6^_8^EN)M8F\1O<^./&$PU>6S%F^
MK*_B34F6Z,0553S5(DPJA?G^4!<"M/9NSOTM^*3_`%_I:B;2C&7=V_\`2_O^
M#I=:[W31]#?9=7_Y_=._\`7_`/CM'V75_P#G]T[_`,`7_P#CM:5%9C,#7H-1
M2T@,]U921?;+;<L=JR,?W\?0F0X_*M^LWQ3_`,@R+_K\M?\`THCK2H`Q9HKN
M3Q==_99[>'%G!N\V`RY^>;&,.N._K5C[+J__`#^Z=_X`O_\`':^<_P#@JK_P
MCO\`PR3XP_X2_P#L7_A%/MOA?^VO[8\K^SOL7]O6_G_:/-_=^3Y>[?O^7;G/
M&:^=9?BAX`^".@_&OQ!^S+K.G^'?@XFC:!$=8\!7VDV?@[1_$4M_)#/<P7,U
MK>:=:Q1VC6S:C-':S+%$$<QM.#4\ZNT_ZTOKV3V3ZRLNI7)=)KO^J6G>U[M=
M(IOI8_1;[+J__/[IW_@"_P#\=H^RZO\`\_NG?^`+_P#QVOS"_88_X*'_`!H^
M)?QHOOA?K/C[2?&\GBSQ?90>#O%FCW%AKMH=+L((+W7@+ZVTO3[:Y7R)K:..
M86:8:]PN_P`L2-WOCO\`:8OO!WQM\0>%M3^+>G_L_P#A.]\6>)YXO$-GHVC0
MMK^IP?V6MKI1:[M9(II91=7,S(JF]N?)`CE41ODE)I:+>,I+S4>3_P"2MYRB
MXJ[M>&TE?S2[[J36W^'Y)IRLKV_0#[+J_P#S^Z=_X`O_`/':/LNK_P#/[IW_
M`(`O_P#':_.SQ%X5\!ZY_P`$C_V33\3?&'PP\(V6D:!HMY#8_%+3!+X,\172
MZ(R?8-0CGDBCCDVN\D)D<M'+"'$4QC*''O?B1XNDL_B!\5_`VMZM\)5\!_L\
M^'/%$'AZP6TUBWU5;.Y\32V]I+=7]J\LE@Z0G#Q1V]Q(DL;!XB"IZ)TN6K4I
M7^&7+?Y7N_NV5WU>ZOI&FYKW-6TFO-N<86_\F3OMT[M?I7]EU?\`Y_=._P#`
M%_\`X[1]EU?_`)_=._\``%__`([7YX?!']M#XR?$']M_4-)U?XK_``BT)(?$
M.MV$OPSU#QM81:\FF6PNA:S6VB'0TU`SO#%;W8E?598)(WDD5!&Z)%Z1^RQX
M^^+'Q*\0_L]0:[\7O$5W%X[^']Q\0_$"Q:)H\/VN=&T4)81XM#Y5G_I=QNQF
M<^9Q.NU=N=*+J-6TO;\5*7Y0E^6YE*2C?K;_`#2_-K[S['^RZO\`\_NG?^`+
M_P#QVC[+J_\`S^Z=_P"`+_\`QVOS7\`_MF:IX`\>?"72;OXMZ#H6@7]Q%8Q_
M#_P-J'A>Q\2WEU+KMW#ON-$N[!II]/:(1;I--N(;E0LQ6"9B94_3JI@^:FJB
M[M?<-Z2Y/)/[S-^RZO\`\_NG?^`+_P#QVC[+J_\`S^Z=_P"`+_\`QVM*B@9F
M_9=7_P"?W3O_``!?_P".T?9=7_Y_=._\`7_^.UI44`<]H]OJAU'5=MY8`BZ7
M>39N=Q\B+I^]XXQZ]#ZX%_[+J_\`S^Z=_P"`+_\`QVC1/^0GK'_7XO\`Z3PT
MGC/3Y]6\'ZK:VVH'2+FYLYHHKX#)LG9"%EQD?<)#=1TZBHJS<(.25[(J$5*2
MBW87[+J__/[IW_@"_P#\=H^RZO\`\_NG?^`+_P#QVOQX^$VC>%]%\,:T?LWP
M*C^`NDCP9H?Q+UOX>^*)=>\+^*YDU.3[5>ZO.;.V@$[H\+7JL]RWD7$7VJ8Q
M=<GX;V_PH;X@?&&VMD\*'4D\6Z3<?LO11*GF+IQU5FE?PP!_R['4Q>&4VW[O
M[,(S)_H8AK:DE.5O-K;5V<4K+O)2YH)V<HJ5[-6,JC<(MM;6]%=-V;V]UKEE
M:Z4G%*_-<_8/X>_#)?A7X4@T30/[+T_3;>2698Q:S2,\DLC2RR.[SEWD>1W=
MW8EF9V))))K:^RZO_P`_NG?^`+__`!VO@W_@IWXP^"/C_P")JCXL:IX,UKP<
MG@/Q+8>%AJ-RES;+XJ@NH(9H;+:3_P`3J/`CB2/_`$M6$RP@-YHKY4_;)GLF
M^&?B:6]=#^U]8>+;!]4>V)_X3*V\(_V);_VH8S%^_73/[.:^SY/[G[2S;/\`
M3"M949>T\O7;X^3\+<\NU-J6NQK4BX2M9O?97>D5+\;\B[U/=\S]G?LNK_\`
M/[IW_@"__P`=H^RZO_S^Z=_X`O\`_':^8/\`@F;;_#.'QI\86^!B>$E^"\NJ
M:8^CGPBL(\.OJ/\`9\8OC9^3^X/`M1+Y/R>:)-W[WS:^L:TDK?<OQ5_N[/JM
M3*$N:-SGO#=OJATZ39>6"C[5<9#6;GGSWS_RU'?/T]^M7S::LPP;W32#U'V%
M_P#X[1X6_P"09+_U^77_`*425Q7[8`T:7]ECX@Q>(?$\_@G0[G0+RWOO$$*L
M6T2*2)D:Z.WD+&&WL<@!5)+*`6&525H-[Z&M./-)1?4WO`=O;Q>%K:T\,7WA
M9=$TDOI=O!I=B!:V7V9S`]NBQR[4\IXVC*#&PH5P",5K_9=7_P"?W3O_``!?
M_P".U^//Q.UOX&>+_P!FKQ!X5MK3]CWPZ_A:ZOY/#.I^$]#6/2/BC<FTM6DD
M\+/%,(]/\0*PMK<O"NK3P2&$+YO,=?97[=OQ-^$GC?4OA);_`!?U#P2?A=IN
MOS6OC?3/%-[;3Z/I&J/HLMQ86VL+(3"C#S-\:W("&1H&`\PPFKG+W'43OMOI
M=.VM_6ZMNG9.UT2KZ76ZEYVY>C\NM]K7:O9GUY]EU?\`Y_=._P#`%_\`X[1]
MEU?_`)_=._\``%__`([7Y%Z%;^"_^$,TNS\9)9_\+<M_#_A%O@1!K2O_`&_%
M:#5;C[,=(67]^'"I!]JV_O/)6/[7^Z`K]AJMJR>^C:V[?KW73NR4];>2?WJ_
MW=GU6NASUQ;ZI_PE%F#>6&_[+/AOL;X`WPYX\WZ=^QZYXO\`V75_^?W3O_`%
M_P#X[1=?\C=9?]>=Q_Z'!6E4%&;]EU?_`)_=._\``%__`([1]EU?_G]T[_P!
M?_X[3_%'BG3/`_AK4-:UK4;'2-'TFVDO;Z_O;A+>VLH(U+R2RR.0J(J@LS,0
M``237YI?&+]KG5O`O[._@V^^'_Q5M?`-AXS\3^.=;T[Q%=^*M$T'PYK]M_;U
MP]O%'>7^B:NUU=3+,LEM!:Q1^=$+AS(=D8,3J**N_P"M_P#)EQIW7]=K_P"7
MWH_2K[+J_P#S^Z=_X`O_`/':/LNK_P#/[IW_`(`O_P#':_/3_@G!^UY\9/CE
M\-/@#\5?&OQ$O=6C^,GC77/"E_X2BT33K/1]+M[:WUJ>&:%UMQ>FX5M,C4E[
M@QE)"#%O'F'N_C=\3OAOX0_X*K#3?#_C?PK'\8=<^&7B#3FTN7Q/%-JRWQ;2
M)=/LX[6:8F#=''+/'!&B*^9YMI+R.=,2I4)\DE=VGHM7>,7*WG>UOFO04(\S
MMMMOM9SY&WV2:?W=G<^T/LNK_P#/[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=
MKX5_X),?\*NN/BO;W7P8_L!],G^&.D?\+!FT7D2>)!.Y7^TVZG5MK7AG\[_2
ML,GG]8J^_*TJ4^3K??\`"3C?T=KQ?6+3ZF,)\S:LU:V_G%2^]7LUT::.>\26
M^J#3H]]Y8,/M5O@+9N.?/3'_`"U/?'U]NM7_`++J_P#S^Z=_X`O_`/':/%/_
M`"#(O^ORU_\`2B.M*LC0S?LNK_\`/[IW_@"__P`=H^RZO_S^Z=_X`O\`_':T
MJ*`,W[+J_P#S^Z=_X`O_`/':/LNK_P#/[IW_`(`O_P#':^/OVZ?C'\3_``K\
M3_C/>>%?B1JWA'1/@S\)['Q_:Z18Z1IEPFNWYFULO#=RW5M-(+9TTZ)&6`Q2
M<Y25"#NY_P",?[9'B?2_VF/$&E6_Q=_X1SQUI/BC1-*\)_"!++3)/^$VTFY2
MQ>XU!DEMVU&=2+B__P!(M+B*WMA8_O5/DS[W!.4E'O\`YI?/?97E9/30JM!T
MOB_KW8R^5E)7;M&[M>Y]P_9=7_Y_=._\`7_^.T?9=7_Y_=._\`7_`/CM:5%(
MDS?LNK_\_NG?^`+_`/QVJ%O;ZI_PE%X!>6&_[+!EOL;X(WS8X\WZ]^XZ8YZ&
MLVU_Y&Z]_P"O.W_]#GH`/LNK_P#/[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=
MKQ'_`(*4>&/A_J_[,]_?>./AWX#^)>H6D\-CX3TKQ5H5OJUK)KE[(EE8J$FC
M?8'GGC5W496,N>@-?%W[5?P(^'G[$GC3P#9>!]2_9Z\9_%/P5X1\/^$?#'P[
MUKPM:ZAX[DEBO+DKJ6BS)="2P<F\EN6;[%)%_H>YGB0,\><JG+%R:ZI*VMW9
MMI>:]W3M)/N:1I\UDGK:^NG5+5]%JW?^ZT?I_P#9=7_Y_=._\`7_`/CM'V75
M_P#G]T[_`,`7_P#CM?`?_!,+QA\%_!OQ`M]:^&FJ>#M*\.W'PXT*U^(-_9W*
M00R^*9KPQ6\>IR.1G67>:Y219C]K9I8A-DM"#X9XOG\(GP[X@O/`[VW_``O*
MWTOQVGQFGT0O_P`)+%IPO3N&IM%^_&-D7V/=\_E*?LG[H-6U6/([7OI/_P`D
M;7_@+MS7_D:E;6QE3?/]E[Q6W\R3M_B5[<O=25]#];_LNK_\_NG?^`+_`/QV
MC[+J_P#S^Z=_X`O_`/':_+0_\,VV?Q5'D?\`"J(OV,;KQI#Y^W[(OP[FUL>'
M9?O?\N)3>D.<_N/M:KG_`$H5[=I'[1WB/]B[_@G%\%?B'LU>X\%Z'&^G:EI,
M]HTEW<:9<QW$.A$>8IN%D$_]EP@,0VRZ<R99>)D^6+=F]8K;K):+YOX?YEKI
ML%.\VDNJ;W[-[=UIOWNK,^W?LNK_`//[IW_@"_\`\=H^RZO_`,_NG?\`@"__
M`,=K\W+O]JK]H+PO^V!I'@3Q+\:/A#X1U?1;[P]ID>@>*?&.F^'IO'*3VME)
M>7,&F/H4]S>F6YFO;>%[+4K:,20)&8]\4IEY;X__`+8/BGQ+XE^)&B#]J35H
MKG1=935?M?PS\2>$M2\/>%-%AU^R@D74MVF_VGI=S';2L9%N9;BU;RIMUPP+
M6ZOMV=_N5KO\?SO8=O\`VW_R;8_4S[+J_P#S^Z=_X`O_`/':/LNK_P#/[IW_
M`(`O_P#':_.+XJ_MJ_%W3_VRF\/^'_C3\)-,TC2[W0[;PMHGBKQYI6C7/Q-T
M^>SLYGO8;+^P9IM0DNY9KF&*73]0M8/-C1!"IBD\W7_8,^-MS\?_`-MWX3^(
M;SXT-\5=:N_A=XBNO$>C)I^GP0_#[5)[SP])-I0^R01R0,A#1_9KYY;I/L^7
M<[C54H.HTEMK^$92V^5G_*WK9M)DK1M?K;\;==NO?7[/-9V^^=>@U%+2`SW5
ME)%]LMMRQVK(Q_?Q]"9#C\JWZS?%/_(,B_Z_+7_THCK2J`,6:*[D\77?V6>W
MAQ9P;O-@,N?GFQC#KCOZU8^RZO\`\_NG?^`+_P#QVO!_^"E7Q1\-_#+]DGXL
M)XCU_1]"?Q+X2N=!T=+^\CMWU;4;BVO5@L[=6(,UQ(00D29=L'`.*\7^,_[7
MOB?PW^TYXAT*W^+I\.>.M"\4Z)HWA/X0+8Z9)_PFVDW"6+7&H.DMNVHS`B>_
MS<6EQ%;VWV']ZI\F?>X>]-07]:I>K?O+17=M4@FN6/,_/\/R6^KLKJU[M(^X
M/LNK_P#/[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=KX!\8?M1?%;X=>&)/B)J
M/Q%\<:YI.O>/_'?@J/PIH6A:*&TRRTN+Q#):7%DTEHTLFH(=(B`-Q*]NP<AX
M&(+'Q?X>?MD?$3XD^-]%@\2_M26]GX+\+^,M"DO/&'A+QEX=US3)8=1LM81K
M2[U)?#^GV3(MQ96R+#]F;$ET=TLCF!8'3BYR4>_+\N:2BOSO_P`$>(C[!2Y^
MBG\^3FO^,6E?UV/UF^RZO_S^Z=_X`O\`_':/LNK_`//[IW_@"_\`\=K\X]'^
M*GCK]E_X;WGB^Q\<>.+[P[XI^*7Q+T)_"6AZ1I$CV*0S^)]12\LWGM7F?4!/
M8#;YTK6I63:UN=NX\W^S=^VG\9OC?\3-(^&]K\>-"UFSUWQ;I5F?&?A/6-#\
M9RP6MSHOB*ZN+6&\BT+3K#S%DTFW(!LIC$SOODE5O*0C%R^'=)/[W;^O+ST*
MKT_8RE&6RY_FH.2;^?*]._EJ?J!]EU?_`)_=._\``%__`([1]EU?_G]T[_P!
M?_X[7QE\2]?L/CO_`,$T-9M?B_\`$G1-!L]$\<7WAZ]\5>+-*@GT74QI/B6>
MTM_[:MHC:VS6MT+2*.X3=;0N9BH,>Y5KSGX:_M:Z+I_AOX9^&%^)7@S]F'X5
M2Q:ZNDZUX0U'29O#?C.\M=0MXH[;2KS5;22VBLI$GFD6VAB$A.4@E,=LS292
MG;F2U:OZ:1OOTW5E\3NK)D5$Z:O+HVGZIM->>JU?PKJT?HG]EU?_`)_=._\`
M`%__`([1]EU?_G]T[_P!?_X[7YK?LW_%;XF_LT_L-_#U;#XCZEK$?B/]F[5O
M%VCVE]H^G"S\)7NDV6DBT^RB.!9I4*WQ,JW<T^]HE*^6I*5W_B[QY\;/@U\5
MO$OVCXY^(O$ND^"_%W@>V33[[PWHD*ZK!K^HVME>VUS)#9H_DPJ[/;>28ID9
MV\Z:Y7:J=4Z+C5C3_FERKUYW#7?JO/3N5.#CIOO;SM;_`#ZVV?S^ZOLNK_\`
M/[IW_@"__P`=H^RZO_S^Z=_X`O\`_':_/^/]IB^\+_"WX/Z'JOQ;T_\`9]\+
MZYI_B6\77=/T;1K:+6=3M=42"ST>*.YM7M09(YII3!!&MU<&']VZ[92S/^""
M^L:KIOA:;PYXB^+GB?7=0M/!7A6^TOP-J\NGQ+I-A+H6FL;NVMEMTO(X5N#+
M`"TC1EE;?OFWR'&A^]BY;6_SDG_Z3]VNBLW,K16OE^-OOW6U]=/BNC]`_LNK
M_P#/[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=K2HI`<]H]OJAU'5=MY8`BZ7>
M39N=Q\B+I^]XXQZ]#ZX%_P"RZO\`\_NG?^`+_P#QVC1/^0GK'_7XO_I/#6E0
M!F_9=7_Y_=._\`7_`/CM'V75_P#G]T[_`,`7_P#CM<3^UW>>!;#]G'Q5+\2]
M;TOP]X(6U7^T[W4M:.CV04R($BFN/,C'E22;(VC9MDRR&)U=9&1OB[2_CW\*
MOB5_P2,^!NGS^-/!&O\`@;2;+P5'\0+:WU>WNK2RT?SH;:<:BD;G99_:(6BG
M$H$>V*=)?D64!0?,Y+LX+_P-M7?91M=^3N-QLE+I:3_\!2=EW<KV2[V[Z?=O
MP]^&2_"OPI!HF@?V7I^FV\DLRQBUFD9Y)9&EED=WG+O(\CN[NQ+,SL22236U
M]EU?_G]T[_P!?_X[7Y(>([?X#_V!K%GXX3P;_P`*(N-+\;-\&8+Q1_8LMZ;V
MWVG0U'RFZ,CR_8OLW[WRV?['^[)KT'X1_P#".7G[4'A?_A)O[+E_:VM?B/IG
MVOS]K>*8?#QT*'[3T^<:5Y#W&['^B_:&;_EY-50_>N*U7,HO5:KFERV?G'XI
MK[,-=2*S=-2>]N;;9\L>:Z?:7PQ?6?N^9^EWV75_^?W3O_`%_P#X[1]EU?\`
MY_=._P#`%_\`X[6E12*.>\-V^J'3I-EY8*/M5QD-9N>?/?/_`"U'?/T]^M7S
M::LPP;W32#U'V%__`([1X6_Y!DO_`%^77_I1)7%?M@#1I?V6/B#%XA\3S^"=
M#N=`O+>^\00JQ;1(I(F1KH[>0L8;>QR`%4DLH!814E:#>^A5./-)1?4WO`=O
M;Q>%K:T\,7WA9=$TDOI=O!I=B!:V7V9S`]NBQR[4\IXVC*#&PH5P",5K_9=7
M_P"?W3O_``!?_P".U^//Q.UOX&>+_P!FKQ!X5MK3]CWPZ_A:ZOY/#.I^$]#6
M/2/BC<FTM6DD\+/%,(]/\0*PMK<O"NK3P2&$+YO,=?97[=OQ-^$GC?4OA);_
M`!?U#P2?A=INOS6OC?3/%-[;3Z/I&J/HLMQ86VL+(3"C#S-\:W("&1H&`\PP
MFKG+W'43OMOI=.VM_6ZMNG9.UT2KZ76ZEYVY>C\NM]K7:O9GUY]EU?\`Y_=.
M_P#`%_\`X[1]EU?_`)_=._\``%__`([7Y%Z%;^"_^$,TNS\9)9_\+<M_#_A%
MO@1!K2O_`&_%:#5;C[,=(67]^'"I!]JV_O/)6/[7^Z`K]AJMJR>^C:V[?KW7
M3NR4];>2?WJ_W=GU6NASUQ;ZI_PE%F#>6&_[+/AOL;X`WPYX\WZ=^QZYXO\`
MV75_^?W3O_`%_P#X[1=?\C=9?]>=Q_Z'!6E4%&;]EU?_`)_=._\``%__`([1
M]EU?_G]T[_P!?_X[3/')U,>"=8_L3R_[9^PS?8/,QM^T>6WEYSQC?MK\SOV=
MY_A+(GP&U7X10:!J/[4M@?M7Q,ATZ1$\7W!&EW)U:W\3E?\`2%5M0$*;;[A;
MD6_E@,J8CVB3=]ER^;]Z^J751M>;Z)K1W&XNUUUYO31)V;Z.5[175I[6/TT^
MRZO_`,_NG?\`@"__`,=H^RZO_P`_NG?^`+__`!VOS?@_:,/Q*^#_`,&O&R?M
MJ^(9//\`&6F)X];3;GPMIUCX0EN],O&_LVZA.GF2UC^U*D"P:@\DNXJK,TJH
MR^V?MQ?$[X1?#'_@H#^S9=^*/&_A'0O';:[<6\%EJ_B>.WGAL)M(U>&.2&TE
MF"QB>[>.$RI&&F=((V9S'&J[\C3Y7_-R]]>6,M._Q+;U5U:\<RLVOY>;_P`F
ME'7JOA>ZZI-)W/K3[+J__/[IW_@"_P#\=H^RZO\`\_NG?^`+_P#QVOAS]EU/
MA]!_P5:\0:AX#U7X8>*-0U;2M>MO$?\`PAEA)I^M>')TO[1C'XG+3W#WET\J
M2);23?9&A6.Y6."5'9H?O6LXZTH5/YE?\6M^NV__``Y4E:<H=G^B^XY[Q);Z
MH-.CWWE@P^U6^`MFXY\],?\`+4]\?7VZU?\`LNK_`//[IW_@"_\`\=H\4_\`
M(,B_Z_+7_P!*(ZTJ`,W[+J__`#^Z=_X`O_\`':/LNK_\_NG?^`+_`/QVM*OR
M5U*RNOV?/"5_?00ZI=^$_CC^T?Y%Z(HVFAT?7[+XD#RIVP#Y<=U8V_E,Q^42
M6,`^],<U37/5A3_F:5_-R27Y_?9=;JG&U/VGFE\K2;?R4=?*[OI9_JQ]EU?_
M`)_=._\``%__`([1]EU?_G]T[_P!?_X[7YV>/OVO_BKXI\7ZMI_P^^,RWWQM
M/B?7-,N?@V=-TB6'PUIEB+UK6ZD3[,=1A69+:P)O+BX:WE&HD0QJ9K?9]"?!
M']J;P]^T-^QG\1OC%X_U;['\%/$"W]]IZWL#6@L?#EO;+!,\AC43-YTD-U-R
M2Q29%4=!6:G>G*ILDKN^BUM;79WUU5U[LM?=8.#514WNW96WZIZ;IZ;.SU7<
M^C_LNK_\_NG?^`+_`/QVC[+J_P#S^Z=_X`O_`/':_,#PI<?LS^.OV+_%ESI7
MC[]E7P=\/O&?CW^UM$\.^*+;3]?\$^#W.FI#%:7%G:WUM:6][<16TMZ(Y)?W
M4T\FV.21"Y^]?V!KF2Y_8E^%'F:9K6CF+PKI\*VFKW;W=]$J6Z(OG2R10O(Y
M50Q9HHV.[)1#\HT47:3>C7)I_BC=I]FGIY[Z+>+K2VJ?-^#M\[_=TU/2OLNK
M_P#/[IW_`(`O_P#':H6]OJG_``E%X!>6&_[+!EOL;X(WS8X\WZ]^XZ8YZ&LV
MU_Y&Z]_Z\[?_`-#GJ1A]EU?_`)_=._\``%__`([1]EU?_G]T[_P!?_X[6E10
M!R?C;X9+\1H--BUO^R]0ATG48-5MHI+681K<P-OAD91.%?8^'4."`Z(X&Y%(
MVOLNK_\`/[IW_@"__P`=K2KX8L/VO_C)/'\;=%TE7U_Q?^SUX9UT7UM)I`9/
M$^K3R/<:`=L,8=C_`&;%'+)%;;=SWBJ`2`!+FHWCY2D_DE=O_P`ECYNR+C3<
MVO-J/WO1=[;OLM6?:OV75_\`G]T[_P``7_\`CM'V75_^?W3O_`%__CM?E/HG
M[>7Q-B^'=_>7W[8G[.D^A1ZC8/=7=C\9/"MUXEA0PWC36MK<3>&K/38I9-D)
MCM[NU9G,,X-W;CYUWO#7[77CSPM\,/C;XI\.?&SQQX@\175OX6U32-"^(EQH
M5C/X9T*_ATI+O7GCL=-D6WB@$MWNNHX;C3T:)Y6AN`KEZ>C:?E^-O^'\EJ]-
M2(>\U%=?\TOU7F]DFS].OLNK_P#/[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=
MK\Z_`_[9OCE/V?\`0Y_%W[3/PQMO!VM>/VT;4/BMX2\7:%XH_P"$9LTTJ6Z%
MK=W[:-9:3;SS7<<42M+88$=RB?-+)')7T=_P23NI;[]CZ6XFUB;Q&]SXX\83
M#5Y;,6;ZLK^)-29;HQ!55/-4B3"J%^?Y0%P*T]F[._2WXI/]?Z6HFTHQEW=O
M_2_O^#I=:[W31]#?9=7_`.?W3O\`P!?_`..T?9=7_P"?W3O_``!?_P".UI45
MF,P->@U%+2`SW5E)%]LMMRQVK(Q_?Q]"9#C\JWZS?%/_`"#(O^ORU_\`2B.M
M*@#%FBNY/%UW]EGMX<6<&[S8#+GYYL8PZX[^M6/LNK_\_NG?^`+_`/QVOF?_
M`(*U>'?^$O\`V4]9TK^P=!\4_P!I^)/!%K_8VN2>7IFK;_%-DOV:Z;R9ML$F
M=CGR9<*S?NW^Z?)/CI:_$G_@G7^Q)X7T?PYJGP[^%D'B3QY<MJEU;:['I7A?
MX::9<QW=U%:6NHWFE7=O;P?:8X(5EGTT1,UTT:10-+$T:4O=<I;)\OJ_<T_\
MF\_AULW%/3V3:3CUO\DDW?\`"WSTNKV^\_LNK_\`/[IW_@"__P`=H^RZO_S^
MZ=_X`O\`_':_,?X0?M,_%S0O$GB[Q3=?'_1/BAXJD^%%_K/@/PMX<\0Z5XA\
M->-;RSN-53]RUMI=G/>W,"Q6[7/V&.$F0[2HC\N)=7X%_M=?%_QE\*O$+67[
M1'PI\=B[\1>$=(@U+PMXRT;QKK'APZCK$=I="9+;0=+MX$DMW/E+/!,XDCD)
M8@;!<8RE*,%N[?C-P7XK]-S.5HIM[+_Y&,ORDC](_LNK_P#/[IW_`(`O_P#'
M:/LNK_\`/[IW_@"__P`=KXE_X*8?!2X^('Q9^"^A7/PS\$?M#W6D>$_%$\NF
M>/9;>W^WO%'I:F[B$=A+`;XDX1%CMHR96`EA%>,_&3]K[XF?"[P[\)?#GA+X
M]?#[P/X4@^%VAZEHOBOXB^+K+P?_`,)WJ#B:*<SC4-&U4W/EK#:M-;6]Q:W$
M7VIM\K^;$\<P?-==;I+SOSZ]_L=M;]T[5R.RDNS;\M8JW5?:UU5OFC]0/LNK
M_P#/[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=K\VM`_:,\0?&/]JOX.76N?%>
M+Q%X]T?XG>((]7^$MC:6'V?P=';:+XAM[*4,ENNH1">-(W66\E>.X^UAX41=
MH'EGBO\`;+\<WFO>#/B+X3^-MC\2/&[?#;4F\2P7=KIUC8?"2YO=:\+IJ,,D
MMK82M9"T@>=BFI0WDUL+/SIUEC61&J*O)+O_`)2:]=8V;7NJZ;>JN*-YQ@NJ
M_P#;FM>VRLG:3NTHNS/UX^RZO_S^Z=_X`O\`_':/LNK_`//[IW_@"_\`\=K\
MZ?V8/C=\:_VD_B/X:\%1_M->#]2T+4K#Q+JA\3_#;7/#_C74";'^P5BM+B\.
MAVMC'(DFH3-M2PW&&5`S%]LH^V_V+?BWJ?Q\_9`^%WC?6A`-8\7>%-,UB^\E
M=L?GSVL<DFT=AN8X':J5.7)SOR_%R7YP?X$]$UMK^#L=W]EU?_G]T[_P!?\`
M^.T?9=7_`.?W3O\`P!?_`..UI45F!F_9=7_Y_=._\`7_`/CM'V75_P#G]T[_
M`,`7_P#CM:5%`'/:/;ZH=1U7;>6`(NEWDV;G<?(BZ?O>.,>O0^N!?^RZO_S^
MZ=_X`O\`_':-$_Y">L?]?B_^D\-:5`&;]EU?_G]T[_P!?_X[6+H_PR70/&NM
M>(K7^RTUOQ"EO#?WC6LSR31P*RPQC=.0D:;Y"$7"[I9&QN=B</\`:[O/`MA^
MSCXJE^)>MZ7X>\$+:K_:=[J6M'1[(*9$"137'F1CRI)-D;1LVR99#$ZNLC(W
MQ=I?Q[^%7Q*_X)&?`W3Y_&G@C7_`VDV7@J/X@6UOJ]O=6EEH_G0VTXU%(W.R
MS^T0M%.)0(]L4Z2_(LH"@^9R79P7_@;:N^RC:[\G<;C:*ETM)_\`@*327=N]
MDN]N^GZ#_9=7_P"?W3O_``!?_P".T?9=7_Y_=._\`7_^.U^2'B.W^`_]@:Q9
M^.$\&_\`"B+C2_&S?!F"\4?V++>F]M]IT-1\INC(\OV+[-^]\MG^Q_NR:]!^
M$?\`PCEY^U!X7_X2;^RY?VMK7XCZ9]K\_:WBF'P\="A^T]/G&E>0]QNQ_HOV
MAF_Y>358?]ZXK5<RB]5JN:7+9^<?BFOLPUU(K/V:EUY>;;9\L>:Z\I?#%]9^
M[YGZ7?9=7_Y_=._\`7_^.T?9=7_Y_=._\`7_`/CM:5%(HY[PW;ZH=.DV7E@H
M^U7&0UFYY\]\_P#+4=\_3WZU?-IJS#!O=-(/4?87_P#CM'A;_D&2_P#7Y=?^
ME$E<5^V`-&E_98^(,7B'Q//X)T.YT"\M[[Q!"K%M$BDB9&NCMY"QAM['(`52
M2R@%A%25H-[Z%4X\TE%]3>\!V]O%X6MK3PQ?>%ET322^EV\&EV(%K9?9G,#V
MZ+'+M3RGC:,H,;"A7`(Q6O\`9=7_`.?W3O\`P!?_`..U^//Q.UOX&>+_`-FK
MQ!X5MK3]CWPZ_A:ZOY/#.I^$]#6/2/BC<FTM6DD\+/%,(]/\0*PMK<O"NK3P
M2&$+YO,=?97[=OQ-^$GC?4OA);_%_4/!)^%VFZ_-:^-],\4WMM/H^D:H^BRW
M%A;:PLA,*,/,WQK<@(9&@8#S#":N<O<=1.^V^ET[:W];JVZ=D[71*OI=;J7G
M;EZ/RZWVM=J]F?7GV75_^?W3O_`%_P#X[1]EU?\`Y_=._P#`%_\`X[7Y%Z%;
M^"_^$,TNS\9)9_\`"W+?P_X1;X$0:TK_`-OQ6@U6X^S'2%E_?APJ0?:MO[SR
M5C^U_N@*_8:K:LGOHVMNWZ]UT[LE/6WDG]ZO]W9]5KH<]<6^J?\`"468-Y8;
M_LL^&^QO@#?#GCS?IW['KGB_]EU?_G]T[_P!?_X[1=?\C=9?]>=Q_P"AP5I5
M!1F_9=7_`.?W3O\`P!?_`..T?9=7_P"?W3O_``!?_P".TSQR=3'@G6/[$\O^
MV?L,WV#S,;?M'EMY><\8W[:_,[]G>?X2R)\!M5^$4&@:C^U+8'[5\3(=.D1/
M%]P1I=R=6M_$Y7_2%5M0$*;;[A;D6_E@,J8CVB3=]ER^;]Z^J751M>;Z)K1W
M&XNUUUYO31)V;Z.5[175I[6/TT^RZO\`\_NG?^`+_P#QVC[+J_\`S^Z=_P"`
M+_\`QVOS?@_:,/Q*^#_P:\;)^VKXAD\_QEIB>/6TVY\+:=8^$);O3+QO[-NH
M3IYDM8_M2I`L&H/)+N*JS-*J,OMG[<7Q.^$7PQ_X*`_LV7?BCQOX1T+QVVNW
M%O!9:OXGCMYX;";2-7ACDAM)9@L8GNWCA,J1AIG2"-F<QQJN_(T^5_S<O?7E
MC+3O\2V]5=6O',K-K^7F_P#)I1UZKX7NNJ32=SZT^RZO_P`_NG?^`+__`!VC
M[+J__/[IW_@"_P#\=KX<_9=3X?0?\%6O$&H>`]5^&'BC4-6TK7K;Q'_PAEA)
MI^M>')TO[1C'XG+3W#WET\J2);23?9&A6.Y6."5'9H?O6LXZTH5/YE?\6M^N
MV_\`PY4E:<H=G^B^XY[Q);ZH-.CWWE@P^U6^`MFXY\],?\M3WQ]?;K5_[+J_
M_/[IW_@"_P#\=H\4_P#(,B_Z_+7_`-*(ZTJ`,W[+J_\`S^Z=_P"`+_\`QVC[
M+J__`#^Z=_X`O_\`':TJ_)74K*Z_9\\)7]]!#JEWX3^./[1_D7HBC::'1]?L
MOB0/*G;`/EQW5C;^4S'Y1)8P#[TQS5-<]6%/^9I7\W))?G]]EUNJ<;4_:>:7
MRM)M_)1U\KN^EG^K'V75_P#G]T[_`,`7_P#CM'V75_\`G]T[_P``7_\`CM?G
M9X^_:_\`BKXI\7ZMI_P^^,RWWQM/B?7-,N?@V=-TB6'PUIEB+UK6ZD3[,=1A
M69+:P)O+BX:WE&HD0QJ9K?9]"?!']J;P]^T-^QG\1OC%X_U;['\%/$"W]]IZ
MWL#6@L?#EO;+!,\AC43-YTD-U-R2Q29%4=!6:G>G*ILDKN^BUM;79WUU5U[L
MM?=8.#514WNW96WZIZ;IZ;.SU7<^C_LNK_\`/[IW_@"__P`=H^RZO_S^Z=_X
M`O\`_':_,#PI<?LS^.OV+_%ESI7C[]E7P=\/O&?CW^UM$\.^*+;3]?\`!/@]
MSIJ0Q6EQ9VM];6EO>W$5M+>B.27]U-/)MCDD0N?O7]@:YDN?V)?A1YFF:UHY
MB\*Z?"MIJ]V]W?1*ENB+YTLD4+R.54,6:*-CNR40_*-%%VDWHUR:?XHW:?9I
MZ>>^BWBZTMJGS?@[?._W=-3TK[+J_P#S^Z=_X`O_`/':H6]OJG_"47@%Y8;_
M`++!EOL;X(WS8X\WZ]^XZ8YZ&LVU_P"1NO?^O.W_`/0YZD8?9=7_`.?W3O\`
MP!?_`..T?9=7_P"?W3O_``!?_P".UI44`9OV75_^?W3O_`%__CM'V75_^?W3
MO_`%_P#X[6E7PQ8?M?\`QDGC^-NBZ2KZ_P"+_P!GKPSKHOK:32`R>)]6GD>X
MT`[88P['^S8HY9(K;;N>\50"0`)<TG9]$Y?*._Z)>;2+A3<K6ZM+YMV7GZ]E
MN?:OV75_^?W3O_`%_P#X[1]EU?\`Y_=._P#`%_\`X[7Y3Z)^WE\38OAW?WE]
M^V)^SI/H4>HV#W5W8_&3PK=>)84,-XTUK:W$WAJSTV*639"8[>[M69S#.#=V
MX^==[PU^UUX\\+?##XV^*?#GQL\<>(/$5U;^%M4TC0OB)<:%8S^&="OX=*2[
MUYX['39%MXH!+=[KJ.&XT]&B>5H;@*Y>GHVGY?C;_A_):O34B'O-177_`#2_
M5>;V2;/TZ^RZO_S^Z=_X`O\`_':/LNK_`//[IW_@"_\`\=K\Z_`_[9OCE/V?
M]#G\7?M,_#&V\':UX_;1M0^*WA+Q=H7BC_A&;--*ENA:W=^VC66DV\\UW'%$
MK2V&!'<HGS2R1R5]'?\`!).ZEOOV/I;B;6)O$;W/CCQA,-7ELQ9OJROXDU)E
MNC$%54\U2),*H7Y_E`7`K3V;L[]+?BD_U_I:B;2C&7=V_P#2_O\`@Z76N]TT
M?0WV75_^?W3O_`%__CM'V75_^?W3O_`%_P#X[6E168S`UZ#44M(#/=64D7VR
MVW+':LC']_'T)D./RK?K-\4_\@R+_K\M?_2B.M*@#%FBNY/%UW]EGMX<6<&[
MS8#+GYYL8PZX[^M6/LNK_P#/[IW_`(`O_P#':^9O^"MOPXT_XQ?LH:WX2U8.
M=+\4>(_!.DW>PX;RI_%-E$^#V.UCBOGOP-XYU[]I3]KW]GGQ+XLT^^MM5^#7
MCR[^&4L\\4D*7^LIX<UYM8NXE8`/!)]GTXQN-PYE`/6JI+VGWV^2C%M^B<HQ
M?G)>=JE"U-U.RD_G%<R7S2D_2+WV/T=^RZO_`,_NG?\`@"__`,=H^RZO_P`_
MNG?^`+__`!VOS(_9S^-GB3PM^UIX=E^W67@KP3K7ASP[8>(=>TK2+*-;-QXF
M\516&G_9_*$%M!>S;8)+H(S*Q5%5)+D74'8^)OVA/^%3_&/Q;H7B+XT_\,\>
M`M:\<^)[VX\9#^R8GO=2MX]*6WTL7&JV]Q:1;X9KF;88O.E^S_NV41RAHA+F
M=E_+)_.+@FNRNI75W?;3WHME6/)*V^L%U^W!SVWTM9VTL[MJTDOT&^RZO_S^
MZ=_X`O\`_':/LNK_`//[IW_@"_\`\=K\]KC]NSQOIWQ1^!Y\=?%>S\/S^)M&
MT'[=X`\*ZCH%EXNU#4+NZ96GN]"U6TFO7L)8C$S"QNHKN$>:JP2L#)'<^*'P
M=\1Z)^UM^T_\;O!WA?X/^(_%OPXMUFT2/5_AW)J_BJ6]3PM;O!'9:K'=K);P
MF21=T"6TCR`RJK`R@JY-13E+X5S7[^[Y.SU;TV?>P4X>TE[./Q-1:\^;;4^_
M?LNK_P#/[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=K\N]$^.7Q%_:"_9I\5VM
M_P#'GX2_$VVB\8?#XZ?>>&O&^E^,=4\-WLWBJP&ZY2QT32(HH2%0I'-')(7A
ME!DQ\JZ?[2O[8/QI^"GQ(U3X;'XTZ-H'A[PMXFOM.G^)'CGQ!H?@^>^D&DZ%
MJ%KI\MZWA^^TP2'^T[XK$MC#+*EFK+*/)F$M<KMKOK^"A^/OK?Y-WL%.'M(\
MT>F_W7_X'YZ79^F/V75_^?W3O_`%_P#X[1]EU?\`Y_=._P#`%_\`X[7S%^R!
M\2OB7\8?CK91>)_B3HFIZ7X>^'?AO7+FV\'"SOM!\37NH'5(Y;M+U[83R6[+
M;02Q^1Y`)YY1ME?5].I!PDXOI?\`!V,XR4M5Y?BD_P!3-^RZO_S^Z=_X`O\`
M_':/LNK_`//[IW_@"_\`\=K2HJ"C-^RZO_S^Z=_X`O\`_':/LNK_`//[IW_@
M"_\`\=K2HH`Y[1[?5#J.J[;RP!%TN\FS<[CY$73][QQCUZ'UP+_V75_^?W3O
M_`%__CM&B?\`(3UC_K\7_P!)X:TJ`,W[+J__`#^Z=_X`O_\`':Q='^&2Z!XU
MUKQ%:_V6FM^(4MX;^\:UF>2:.!66&,;IR$C3?(0BX7=+(V-SL3A_M=WG@6P_
M9Q\52_$O6]+\/>"%M5_M.]U+6CH]D%,B!(IKCS(QY4DFR-HV;9,LAB=761D;
MXNTOX]_"KXE?\$C/@;I\_C3P1K_@;2;+P5'\0+:WU>WNK2RT?SH;:<:BD;G9
M9_:(6BG$H$>V*=)?D64!0?,Y+LX+_P`#;5WV4;7?D[C<;14NEI/_`,!2:2[M
MWLEWMWT_0?[+J_\`S^Z=_P"`+_\`QVC[+J__`#^Z=_X`O_\`':_)#Q';_`?^
MP-8L_'">#?\`A1%QI?C9O@S!>*/[%EO3>V^TZ&H^4W1D>7[%]F_>^6S_`&/]
MV37H/PC_`.$<O/VH/"__``DW]ER_M;6OQ'TS[7Y^UO%,/AXZ%#]IZ?.-*\A[
MC=C_`$7[0S?\O)JL/^]<5JN91>JU7-+EL_./Q37V8:ZD5G[-2Z\O-ML^6/-=
M>4OAB^L_=\S]+OLNK_\`/[IW_@"__P`=H^RZO_S^Z=_X`O\`_':TJ*11SWAN
MWU0Z=)LO+!1]JN,AK-SSY[Y_Y:COGZ>_6KYM-688-[II!ZC["_\`\=H\+?\`
M(,E_Z_+K_P!*)*XK]L`:-+^RQ\08O$/B>?P3H=SH%Y;WWB"%6+:)%)$R-=';
MR%C#;V.0`JDEE`+"*DK0;WT*IQYI*+ZF]X#M[>+PM;6GAB^\++HFDE]+MX-+
ML0+6R^S.8'MT6.7:GE/&T908V%"N`1BM?[+J_P#S^Z=_X`O_`/':_'GXG:W\
M#/%_[-7B#PK;6G['OAU_"UU?R>&=3\)Z&L>D?%&Y-I:M))X6>*81Z?X@5A;6
MY>%=6G@D,(7S>8Z^ROV[?B;\)/&^I?"2W^+^H>"3\+M-U^:U\;Z9XIO;:?1]
M(U1]%EN+"VUA9"848>9OC6Y`0R-`P'F&$U<Y>XZB=]M]+IVUOZW5MT[)VNB5
M?2ZW4O.W+T?EUOM:[5[,^O/LNK_\_NG?^`+_`/QVC[+J_P#S^Z=_X`O_`/':
M_(O0K?P7_P`(9I=GXR2S_P"%N6_A_P`(M\"(-:5_[?BM!JMQ]F.D++^_#A4@
M^U;?WGDK']K_`'0%?L-5M63WT;6W;]>ZZ=V2GK;R3^]7^[L^JUT.>N+?5/\`
MA*+,&\L-_P!EGPWV-\`;X<\>;]._8]<\7_LNK_\`/[IW_@"__P`=HNO^1NLO
M^O.X_P#0X*TJ@HS?LNK_`//[IW_@"_\`\=H^RZO_`,_NG?\`@"__`,=IGCDZ
MF/!.L?V)Y?\`;/V&;[!YF-OVCRV\O.>,;]M?F=^SO/\`"61/@-JOPB@T#4?V
MI;`_:OB9#ITB)XON"-+N3JUOXG*_Z0JMJ`A3;?<+<BW\L!E3$>T2;OLN7S?O
M7U2ZJ-KS?1-:.XW%VNNO-Z:).S?1RO:*ZM/:Q^FGV75_^?W3O_`%_P#X[1]E
MU?\`Y_=._P#`%_\`X[7YOP?M&'XE?!_X->-D_;5\0R>?XRTQ/'K:;<^%M.L?
M"$MWIEXW]FW4)T\R6L?VI4@6#4'DEW%59FE5&7VS]N+XG?"+X8_\%`?V;+OQ
M1XW\(Z%X[;7;BW@LM7\3QV\\-A-I&KPQR0VDLP6,3W;QPF5(PTSI!&S.8XU7
M?D:?*_YN7OKRQEIW^);>JNK7CF5FU_+S?^32CKU7PO==4FD[GUI]EU?_`)_=
M._\``%__`([1]EU?_G]T[_P!?_X[7PY^RZGP^@_X*M>(-0\!ZK\,/%&H:MI6
MO6WB/_A#+"33]:\.3I?VC&/Q.6GN'O+IY4D2VDF^R-"L=RL<$J.S0_>M9QUI
M0J?S*_XM;]=M_P#ARI*TY0[/]%]QSWB2WU0:='OO+!A]JM\!;-QSYZ8_Y:GO
MCZ^W6K_V75_^?W3O_`%__CM'BG_D&1?]?EK_`.E$=:5`&;]EU?\`Y_=._P#`
M%_\`X[1]EU?_`)_=._\``%__`([6E7Y*ZE977[/GA*_OH(=4N_"?QQ_:/\B]
M$4;30Z/K]E\2!Y4[8!\N.ZL;?RF8_*)+&`?>F.:IKGJPI_S-*_FY)+\_OLNM
MU3C:G[3S2^5I-OY*.OE=WTL_U8^RZO\`\_NG?^`+_P#QVC[+J_\`S^Z=_P"`
M+_\`QVOSL\??M?\`Q5\4^+]6T_X??&9;[XVGQ/KFF7/P;.FZ1+#X:TRQ%ZUK
M=2)]F.HPK,EM8$WEQ<-;RC42(8U,UOL^A/@C^U-X>_:&_8S^(WQB\?ZM]C^"
MGB!;^^T];V!K06/ARWME@F>0QJ)F\Z2&ZFY)8I,BJ.@K-3O3E4V25W?1:VMK
ML[ZZJZ]V6ONL'!JHJ;W;LK;]4]-T]-G9ZKN?1_V75_\`G]T[_P``7_\`CM'V
M75_^?W3O_`%__CM?F!X4N/V9_'7[%_BRYTKQ]^RKX.^'WC/Q[_:VB>'?%%MI
M^O\`@GP>YTU(8K2XL[6^MK2WO;B*VEO1')+^ZFGDVQR2(7/WK^P-<R7/[$OP
MH\S3-:T<Q>%=/A6TU>[>[OHE2W1%\Z62*%Y'*J&+-%&QW9*(?E&BB[2;T:Y-
M/\4;M/LT]//?1;Q=:6U3YOP=OG?[NFIZ5]EU?_G]T[_P!?\`^.U0M[?5/^$H
MO`+RPW_98,M]C?!&^;''F_7OW'3'/0UFVO\`R-U[_P!>=O\`^ASU(P^RZO\`
M\_NG?^`+_P#QVC[+J_\`S^Z=_P"`+_\`QVM*B@#-^RZO_P`_NG?^`+__`!VC
M[+J__/[IW_@"_P#\=K2KX8L/VO\`XR3Q_&W1=)5]?\7_`+/7AG71?6TFD!D\
M3ZM/(]QH!VPQAV/]FQ1RR16VW<]XJ@$@`2YI.SZ)R^4=_P!$O-I%PIN5K=6E
M\V[+S]>RW/M7[+J__/[IW_@"_P#\=H^RZO\`\_NG?^`+_P#QVORGT3]O+XFQ
M?#N_O+[]L3]G2?0H]1L'NKNQ^,GA6Z\2PH8;QIK6UN)O#5GIL4LFR$QV]W:L
MSF&<&[MQ\Z[WAK]KKQYX6^&'QM\4^'/C9XX\0>(KJW\+:II&A?$2XT*QG\,Z
M%?PZ4EWKSQV.FR+;Q0"6[W74<-QIZ-$\K0W`5R]/1M/R_&W_``_DM7IJ1#WF
MHKK_`)I?JO-[)-GZ=?9=7_Y_=._\`7_^.T?9=7_Y_=._\`7_`/CM?G7X'_;-
M\<I^S_H<_B[]IGX8VW@[6O'[:-J'Q6\)>+M"\4?\(S9II4MT+6[OVT:RTFWG
MFNXXHE:6PP([E$^:62.2OH[_`())W4M]^Q]+<3:Q-XC>Y\<>,)AJ\MF+-]65
M_$FI,MT8@JJGFJ1)A5"_/\H"X%:>S=G?I;\4G^O]+43:48R[NW_I?W_!TNM=
M[IH^AOLNK_\`/[IW_@"__P`=H^RZO_S^Z=_X`O\`_':TJ*S&8&O0:BEI`9[J
MRDB^V6VY8[5D8_OX^A,AQ^5;]9OBG_D&1?\`7Y:_^E$=:5`&+-%=R>+KO[+/
M;PXLX-WFP&7/SS8QAUQW]:L?9=7_`.?W3O\`P!?_`..U\Y_\%5="_P"$H_9)
M\8:;_8VB^(_[0O?"]M_9.L/LT[4]^O6Z_9[AO*EQ#)G:Y\J3"L?D?[I^>/!/
MCV3]E#X5:QX=;7M"_9@\-7OQ9FTOQ6^B0V/]B?"FW.BQSV\6G7%];?8EMM0N
M(K>874]G''OU.6/R$G96!"7-*2?3\=8+_P!N\]K;M7;C:*DNK?W*+=]+]NME
MUO9,_1/[+J__`#^Z=_X`O_\`':/LNK_\_NG?^`+_`/QVOR7D_:^UO2?B]\1_
M%>H_M#W'A'4A\/[2/P#K7]BZ5YOQ>^QZSXE33%$<MJT5R;A6B_=:;'!+=B59
M;8QQL!7I_P`;/VT_CC9?MIWGAUOB=\(?A2VFW^C6VE>#?%7C>PT:?Q/;SVEI
M-<20V$^B7-WJ#O<37=M%)::G;Q^;;I&8]T4IE3DDK^5_ZOU76/Q1^TD5*G:<
MH=O\HW^5Y63V=M'T/T9^RZO_`,_NG?\`@"__`,=H^RZO_P`_NG?^`+__`!VO
M@SX/>-O'5S\1OV2/%GCW]HSQI9P?%'PQ<:A>Z5,F@Z7HNM:I-!IDT.F1Q?80
M\AD#W&Q/-:YPC^7(OSYO?MO0_LQW'[?FMI^TA_PJ40O\,M.7P^?%[6:ZAYG]
MH:IYW]EF7%P+G'E8-I^]W>5M^;;55DZ4U"6]Y)^L4W\[V_&_:\1LZ<JBZ*+]
M>:2C^M_EZV^Y?LNK_P#/[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=K\X/@]^W
MYX]^$/P1@\!?$+QW+I?QFG\6^!++P]X?UV.U?Q/=>'[T:#'>S36^PR2Y,FJK
M/<NI\N83#S$9$"VO#G[6GQH^'/[)^E^.=5^*&I>+=<^(7[/7B+XEPQ7VAZ5;
MV7AK5=/M=,EMS:);VT<CQM_:#>8MS),&:)2OEJ2E6J;E?EV7Y\CG;ULFGVDF
MF^IK1H2J.,(M-NW7OU].OFMD?HK]EU?_`)_=._\``%__`([1]EU?_G]T[_P!
M?_X[7R[\*/'7QP\`?M):_P##V#6],^,L$&A>'O$][J/B_4;?PU-HT6H7&J07
M,=FFFZ5(L\:?8$:**XP_[Q@]TW!'S+:1?!&3Q=XH;P1_P@'_``UW'\;-0;3_
M`/A'6LQXV,'_``D+B?[<(O\`23IO]G&;SA<?N?(Y^\(JRD^6?*^S>F^CBK)=
M?B]-#!M>R]IYQWVM*#FFWTT2\]=3]//LNK_\_NG?^`+_`/QVC[+J_P#S^Z=_
MX`O_`/':_.E/V[M=_:3^`^B^#=.^*X/C2W^`_B;5/B,WA^/3WU#0?$MHFDH(
M[C]Q)'9W2O)J*&WVH0&8[`4C9?/?CY\</$7_``3?^#'P[\'_``O^(=CX,M_"
M/@"T\11:)K6H>&?#5AXTGFFN)Y(K#3K?P[-/J-P"&%S':S6&U)+=O,\R:2<:
M1C>HZ=UO%)]'S.JK^G[IM;W4D:58\D5+_%?RY7!?>W->B5S]6/LNK_\`/[IW
M_@"__P`=H^RZO_S^Z=_X`O\`_':^`_B'^W]J&OZ5:_#2Y\=:3<_$2X\>>-M*
M\4>'(8[5]1LO#L-AXBGTS[3"B;[:)HHM*>.9@C3#;\[[WW=?_P`$JM=U"T^*
MOC;P_K7Q>\1^(+FWT#P[?Z/X(U6ZTWR]+TZ;1=.;[9:PQVZ72P"<RP!_,:(L
MK;M\VZ0S37.Y+HE%I]^;F?\`[;Y]=K:S7M3E&.[?-\N62A^+=_2V[=E]?:/;
MZH=1U7;>6`(NEWDV;G<?(BZ?O>.,>O0^N!?^RZO_`,_NG?\`@"__`,=HT3_D
M)ZQ_U^+_`.D\-:5(#-^RZO\`\_NG?^`+_P#QVL71_ADN@>-=:\16O]EIK?B%
M+>&_O&M9GDFC@5EAC&Z<A(TWR$(N%W2R-C<[$X?[7=YX%L/V<?%4OQ+UO2_#
MW@A;5?[3O=2UHZ/9!3(@2*:X\R,>5))LC:-FV3+(8G5UD9&^+M+^/?PJ^)7_
M``2,^!NGS^-/!&O^!M)LO!4?Q`MK?5[>ZM++1_.AMIQJ*1N=EG]HA:*<2@1[
M8ITE^190%!\SDNS@O_`VU=]E&UWY.XW&T5+I:3_\!2:2[MWLEWMWT_0?[+J_
M_/[IW_@"_P#\=H^RZO\`\_NG?^`+_P#QVOR0\1V_P'_L#6+/QPG@W_A1%QI?
MC9O@S!>*/[%EO3>V^TZ&H^4W1D>7[%]F_>^6S_8_W9->@_"/_A'+S]J#PO\`
M\)-_9<O[6UK\1],^U^?M;Q3#X>.A0_:>GSC2O(>XW8_T7[0S?\O)JL/^]<5J
MN91>JU7-+EL_./Q37V8:ZD5G[-2Z\O-ML^6/-=>4OAB^L_=\S]+OLNK_`//[
MIW_@"_\`\=H^RZO_`,_NG?\`@"__`,=K2HI%'/>&[?5#ITFR\L%'VJXR&LW/
M/GOG_EJ.^?I[]:OFTU9A@WNFD'J/L+__`!VCPM_R#)?^ORZ_]*)*XK]L`:-+
M^RQ\08O$/B>?P3H=SH%Y;WWB"%6+:)%)$R-=';R%C#;V.0`JDEE`+"*DK0;W
MT*IQYI*+ZF]X#M[>+PM;6GAB^\++HFDE]+MX-+L0+6R^S.8'MT6.7:GE/&T9
M08V%"N`1BM?[+J__`#^Z=_X`O_\`':_'GXG:W\#/%_[-7B#PK;6G['OAU_"U
MU?R>&=3\)Z&L>D?%&Y-I:M))X6>*81Z?X@5A;6Y>%=6G@D,(7S>8Z^ROV[?B
M;\)/&^I?"2W^+^H>"3\+M-U^:U\;Z9XIO;:?1](U1]%EN+"VUA9"848>9OC6
MY`0R-`P'F&$U<Y>XZB=]M]+IVUOZW5MT[)VNB5?2ZW4O.W+T?EUOM:[5[,^O
M/LNK_P#/[IW_`(`O_P#':/LNK_\`/[IW_@"__P`=K\B]"M_!?_"&:79^,DL_
M^%N6_A_PBWP(@UI7_M^*T&JW'V8Z0LO[\.%2#[5M_>>2L?VO]T!7[#5;5D]]
M&UMV_7NNG=DIZV\D_O5_N[/JM=#GKBWU3_A*+,&\L-_V6?#?8WP!OASQYOT[
M]CUSQ?\`LNK_`//[IW_@"_\`\=HNO^1NLO\`KSN/_0X*TJ@HS?LNK_\`/[IW
M_@"__P`=H^RZO_S^Z=_X`O\`_':9XY.ICP3K']B>7_;/V&;[!YF-OVCRV\O.
M>,;]M?F=^SO/\)9$^`VJ_"*#0-1_:EL#]J^)D.G2(GB^X(TNY.K6_B<K_I"J
MVH"%-M]PMR+?RP&5,1[1)N^RY?-^]?5+JHVO-]$UH[C<7:ZZ\WIHD[-]'*]H
MKJT]K'Z:?9=7_P"?W3O_``!?_P".T?9=7_Y_=._\`7_^.U^;\'[1A^)7P?\`
M@UXV3]M7Q#)Y_C+3$\>MIMSX6TZQ\(2W>F7C?V;=0G3S):Q_:E2!8-0>27<5
M5F:549?;/VXOB=\(OAC_`,%`?V;+OQ1XW\(Z%X[;7;BW@LM7\3QV\\-A-I&K
MPQR0VDLP6,3W;QPF5(PTSI!&S.8XU7?D:?*_YN7OKRQEIW^);>JNK7CF5FU_
M+S?^32CKU7PO==4FD[GUI]EU?_G]T[_P!?\`^.T?9=7_`.?W3O\`P!?_`..U
M\.?LNI\/H/\`@JUX@U#P'JOPP\4:AJVE:];>(_\`A#+"33]:\.3I?VC&/Q.6
MGN'O+IY4D2VDF^R-"L=RL<$J.S0_>M9QUI0J?S*_XM;]=M_^'*DK3E#L_P!%
M]QSWB2WU0:='OO+!A]JM\!;-QSYZ8_Y:GOCZ^W6K_P!EU?\`Y_=._P#`%_\`
MX[1XI_Y!D7_7Y:_^E$=:5`&;]EU?_G]T[_P!?_X[1]EU?_G]T[_P!?\`^.UI
M5^2NI65U^SYX2O[Z"'5+OPG\<?VC_(O1%&TT.CZ_9?$@>5.V`?+CNK&W\IF/
MRB2Q@'WICFJ:YZL*?\S2OYN22_/[[+K=4XVI^T\TOE:3;^2CKY7=]+/]6/LN
MK_\`/[IW_@"__P`=H^RZO_S^Z=_X`O\`_':_.SQ]^U_\5?%/B_5M/^'WQF6^
M^-I\3ZYIES\&SIND2P^&M,L1>M:W4B?9CJ,*S);6!-Y<7#6\HU$B&-3-;[/H
M3X(_M3>'OVAOV,_B-\8O'^K?8_@IX@6_OM/6]@:T%CX<M[98)GD,:B9O.DAN
MIN26*3(JCH*S4[TY5-DE=WT6MK:[.^NJNO=EK[K!P:J*F]V[*V_5/3=/39V>
MJ[GT?]EU?_G]T[_P!?\`^.T?9=7_`.?W3O\`P!?_`..U^8'A2X_9G\=?L7^+
M+G2O'W[*O@[X?>,_'O\`:VB>'?%%MI^O^"?![G34ABM+BSM;ZVM+>]N(K:6]
M$<DO[J:>3;')(A<_>O[`US)<_L2_"CS-,UK1S%X5T^%;35[M[N^B5+=$7SI9
M(H7D<JH8LT4;'=DHA^4:*+M)O1KDT_Q1NT^S3T\]]%O%UI;5/F_!V^=_NZ:G
MI7V75_\`G]T[_P``7_\`CM4+>WU3_A*+P"\L-_V6#+?8WP1OFQQYOU[]QTQS
MT-9MK_R-U[_UYV__`*'/4C#[+J__`#^Z=_X`O_\`':/LNK_\_NG?^`+_`/QV
MM*B@#-^RZO\`\_NG?^`+_P#QVC[+J_\`S^Z=_P"`+_\`QVM*OABP_:_^,D\?
MQMT725?7_%_[/7AG71?6TFD!D\3ZM/(]QH!VPQAV/]FQ1RR16VW<]XJ@$@`2
MYI.SZ)R^4=_T2\VD7"FY6MU:7S;LO/U[+<^U?LNK_P#/[IW_`(`O_P#':/LN
MK_\`/[IW_@"__P`=K\I]$_;R^)L7P[O[R^_;$_9TGT*/4;![J[L?C)X5NO$L
M*&&\::UM;B;PU9Z;%+)LA,=O=VK,YAG!N[<?.N]X:_:Z\>>%OAA\;?%/ASXV
M>./$'B*ZM_"VJ:1H7Q$N-"L9_#.A7\.E)=Z\\=CILBV\4`EN]UU'#<:>C1/*
MT-P%<O3T;3\OQM_P_DM7IJ1#WFHKK_FE^J\WLDV?IU]EU?\`Y_=._P#`%_\`
MX[1]EU?_`)_=._\``%__`([7YU^!_P!LWQRG[/\`H<_B[]IGX8VW@[6O'[:-
MJ'Q6\)>+M"\4?\(S9II4MT+6[OVT:RTFWGFNXXHE:6PP([E$^:62.2OH[_@D
MG=2WW['TMQ-K$WB-[GQQXPF&KRV8LWU97\2:DRW1B"JJ>:I$F%4+\_R@+@5I
M[-V=^EOQ2?Z_TM1-I1C+N[?^E_?\'2ZUWNFCZ&^RZO\`\_NG?^`+_P#QVC[+
MJ_\`S^Z=_P"`+_\`QVM*BLQF!KT&HI:0&>ZLI(OMEMN6.U9&/[^/H3(<?E6_
M6;XI_P"09%_U^6O_`*41UI4`8LT5W)XNN_LL]O#BS@W>;`9<_/-C&'7'?UJQ
M]EU?_G]T[_P!?_X[7SG_`,%5?"G_``GG[)/C#1/*T6?^V+WPO9>7K&G?VCIT
MGF:];IBXMM\?GPG/SQ;TWKE=RYR.77Q_IW_!,S7_`(2^%?&'B+X1?#GX:WF@
M^)5OF\/>&;?P;X:N]:^UZ=-I\%M:R3W#QW#P/J!$*3L9V65MI(55GG24G+IM
MYVCS?\!=VTBN2Z5O/Y)=3ZT^RZO_`,_NG?\`@"__`,=H^RZO_P`_NG?^`+__
M`!VOS'US_@HCXT;X=^&I/%'[0#_#'Q+<_`KPSXXT;3SH6E"Y\;>)KL:F)+(Q
M7-J[2^<]O;*;*T6*X8G]RT>'SS/C/_@HG^T-IVK_`!0U6[^*WP>\&>*?#&G^
M*IO^%9:EXSTXZW80V%C?26DUOH3Z&M\\Q6"VNA))JLUO-$TDBH(Y$2/9TY*I
M*DM6K_@VM'MTU[:<UKJ^CH/F4.]O_)HJ2_!KUUM>S/U>^RZO_P`_NG?^`+__
M`!VC[+J__/[IW_@"_P#\=KX`_:>_:I^)'['/AWX@Z)K7Q<U_75L[#P7K?_"2
MWEOX8TB_T:/5M5O[6_@LY+J&WTJ)1%89@;42^UI2KRR$I4OQ6TR^_:L_X(OZ
M):>.O'9^)(^(GC+P[:W6LQ7NCW;&RN?&%C#'`9]'1+%YH8"D<C6Y9/-23#N`
M#4*,I?"K^]&'SER_ES>2TW,8<KJ0IRTYDG\GJG]W3?\`$^^OLNK_`//[IW_@
M"_\`\=H^RZO_`,_NG?\`@"__`,=K\W?"?Q!U[]HK]K#]G_Q5XLTS4XM6^"OC
MB]^&LLCP21?VEK,?AO7GUBZ@1@%DAE^S:<8G&X<RJ#UKJ/\`@E_^VUXZ^-O[
M6%SX8U?XCV7CWPUJ_A2\UY;&Y\2:/K&N^%;B"[LXTL]1BTO1--BTZ\\NZ<36
MLDMZRO%A9$"%I;A%3DH0=[IM=FDG)-?XHKF7JA5+TXIS[1TZW<G%K_MV46G\
M]+'WU]EU?_G]T[_P!?\`^.T?9=7_`.?W3O\`P!?_`..UI45F,S?LNK_\_NG?
M^`+_`/QVC[+J_P#S^Z=_X`O_`/':TJ*`,W[+J_\`S^Z=_P"`+_\`QVC[+J__
M`#^Z=_X`O_\`':TJ*`.>T>WU0ZCJNV\L`1=+O)LW.X^1%T_>\<8]>A]<"_\`
M9=7_`.?W3O\`P!?_`..T:)_R$]8_Z_%_])X:TJ`,W[+J_P#S^Z=_X`O_`/':
MQ='^&2Z!XUUKQ%:_V6FM^(4MX;^\:UF>2:.!66&,;IR$C3?(0BX7=+(V-SL3
MA_M=WG@6P_9Q\52_$O6]+\/>"%M5_M.]U+6CH]D%,B!(IKCS(QY4DFR-HV;9
M,LAB=761D;XNTOX]_"KXE?\`!(SX&Z?/XT\$:_X&TFR\%1_$"VM]7M[JTLM'
M\Z&VG&HI&YV6?VB%HIQ*!'MBG27Y%E`4'S.2[."_\#;5WV4;7?D[C<;14NEI
M/_P%)I+NW>R7>W?3]!_LNK_\_NG?^`+_`/QVC[+J_P#S^Z=_X`O_`/':_)#Q
M';_`?^P-8L_'">#?^%$7&E^-F^#,%XH_L66]-[;[3H:CY3=&1Y?L7V;][Y;/
M]C_=DUZ#\(_^$<O/VH/"_P#PDW]ER_M;6OQ'TS[7Y^UO%,/AXZ%#]IZ?.-*\
MA[C=C_1?M#-_R\FJP_[UQ6JYE%ZK5<TN6S\X_%-?9AKJ16?LU+KR\VVSY8\U
MUY2^&+ZS]WS/TN^RZO\`\_NG?^`+_P#QVC[+J_\`S^Z=_P"`+_\`QVM*BD4<
M]X;M]4.G2;+RP4?:KC(:S<\^>^?^6H[Y^GOUJ^;35F&#>Z:0>H^PO_\`':/"
MW_(,E_Z_+K_THDKBOVP!HTO[+'Q!B\0^)Y_!.AW.@7EO?>((58MHD4D3(UT=
MO(6,-O8Y`"J264`L(J2M!O?0JG'FDHOJ;W@.WMXO"UM:>&+[PLNB:27TNW@T
MNQ`M;+[,Y@>W18Y=J>4\;1E!C84*X!&*U_LNK_\`/[IW_@"__P`=K\>?B=K?
MP,\7_LU>(/"MM:?L>^'7\+75_)X9U/PGH:QZ1\4;DVEJTDGA9XIA'I_B!6%M
M;EX5U:>"0PA?-YCK[*_;M^)OPD\;ZE\)+?XOZAX)/PNTW7YK7QOIGBF]MI]'
MTC5'T66XL+;6%D)A1AYF^-;D!#(T#`>8835SE[CJ)WVWTNG;6_K=6W3LG:Z)
M5]+K=2\[<O1^76^UKM7LSZ\^RZO_`,_NG?\`@"__`,=H^RZO_P`_NG?^`+__
M`!VOR+T*W\%_\(9I=GXR2S_X6Y;^'_"+?`B#6E?^WXK0:K<?9CI"R_OPX5(/
MM6W]YY*Q_:_W0%?L-5M63WT;6W;]>ZZ=V2GK;R3^]7^[L^JUT.>N+?5/^$HL
MP;RPW_99\-]C?`&^'/'F_3OV/7/%_P"RZO\`\_NG?^`+_P#QVBZ_Y&ZR_P"O
M.X_]#@K2J"C-^RZO_P`_NG?^`+__`!VC[+J__/[IW_@"_P#\=IGCDZF/!.L?
MV)Y?]L_89OL'F8V_:/+;R\YXQOVU^9W[.\_PED3X#:K\(H-`U']J6P/VKXF0
MZ=(B>+[@C2[DZM;^)RO^D*K:@(4VWW"W(M_+`94Q'M$F[[+E\W[U]4NJC:\W
MT36CN-Q=KKKS>FB3LWT<KVBNK3VL?II]EU?_`)_=._\``%__`([1]EU?_G]T
M[_P!?_X[7YOP?M&'XE?!_P"#7C9/VU?$,GG^,M,3QZVFW/A;3K'PA+=Z9>-_
M9MU"=/,EK']J5(%@U!Y)=Q569I51E]L_;B^)WPB^&/\`P4!_9LN_%'C?PCH7
MCMM=N+>"RU?Q/';SPV$VD:O#')#:2S!8Q/=O'"94C#3.D$;,YCC5=^1I\K_F
MY>^O+&6G?XEMZJZM>.96;7\O-_Y-*.O5?"]UU2:3N?6GV75_^?W3O_`%_P#X
M[1]EU?\`Y_=._P#`%_\`X[7PY^RZGP^@_P""K7B#4/`>J_##Q1J&K:5KUMXC
M_P"$,L)-/UKPY.E_:,8_$Y:>X>\NGE21+:2;[(T*QW*QP2H[-#]ZUG'6E"I_
M,K_BUOUVW_X<J2M.4.S_`$7W'/>)+?5!IT>^\L&'VJWP%LW'/GIC_EJ>^/K[
M=:O_`&75_P#G]T[_`,`7_P#CM'BG_D&1?]?EK_Z41UI4`9OV75_^?W3O_`%_
M_CM'V75_^?W3O_`%_P#X[6E7Y*ZE977[/GA*_OH(=4N_"?QQ_:/\B]$4;30Z
M/K]E\2!Y4[8!\N.ZL;?RF8_*)+&`?>F.:IKGJPI_S-*_FY)+\_OLNMU3C:G[
M3S2^5I-OY*.OE=WTL_U8^RZO_P`_NG?^`+__`!VC[+J__/[IW_@"_P#\=K\[
M/'W[7_Q5\4^+]6T_X??&9;[XVGQ/KFF7/P;.FZ1+#X:TRQ%ZUK=2)]F.HPK,
MEM8$WEQ<-;RC42(8U,UOL^A/@C^U-X>_:&_8S^(WQB\?ZM]C^"GB!;^^T];V
M!K06/ARWME@F>0QJ)F\Z2&ZFY)8I,BJ.@K-3O3E4V25W?1:VMKL[ZZJZ]V6O
MNL'!JHJ;W;LK;]4]-T]-G9ZKN?1_V75_^?W3O_`%_P#X[1]EU?\`Y_=._P#`
M%_\`X[7Y@>%+C]F?QU^Q?XLN=*\??LJ^#OA]XS\>_P!K:)X=\46VGZ_X)\'N
M=-2&*TN+.UOK:TM[VXBMI;T1R2_NIIY-L<DB%S]Z_L#7,ES^Q+\*/,TS6M',
M7A73X5M-7NWN[Z)4MT1?.EDBA>1RJABS11L=V2B'Y1HHNTF]&N33_%&[3[-/
M3SWT6\76EM4^;\';YW^[IJ>E?9=7_P"?W3O_``!?_P".U0M[?5/^$HO`+RPW
M_98,M]C?!&^;''F_7OW'3'/0UFVO_(W7O_7G;_\`H<]2,/LNK_\`/[IW_@"_
M_P`=H^RZO_S^Z=_X`O\`_':TJ*`,W[+J_P#S^Z=_X`O_`/':/LNK_P#/[IW_
M`(`O_P#':TJ^&+#]K_XR3Q_&W1=)5]?\7_L]>&==%];2:0&3Q/JT\CW&@';#
M&'8_V;%'+)%;;=SWBJ`2`!+FD[/HG+Y1W_1+S:1<*;E:W5I?-NR\_7LMS[5^
MRZO_`,_NG?\`@"__`,=H^RZO_P`_NG?^`+__`!VORGT3]O+XFQ?#N_O+[]L3
M]G2?0H]1L'NKNQ^,GA6Z\2PH8;QIK6UN)O#5GIL4LFR$QV]W:LSF&<&[MQ\Z
M[WAK]KKQYX6^&'QM\4^'/C9XX\0>(KJW\+:II&A?$2XT*QG\,Z%?PZ4EWKSQ
MV.FR+;Q0"6[W74<-QIZ-$\K0W`5R]/1M/R_&W_#^2U>FI$/>:BNO^:7ZKS>R
M39^G7V75_P#G]T[_`,`7_P#CM'V75_\`G]T[_P``7_\`CM?G7X'_`&S?'*?L
M_P"AS^+OVF?AC;>#M:\?MHVH?%;PEXNT+Q1_PC-FFE2W0M;N_;1K+2;>>:[C
MBB5I;#`CN43YI9(Y*^CO^"2=U+??L?2W$VL3>(WN?''C"8:O+9BS?5E?Q)J3
M+=&(*JIYJD2850OS_*`N!6GLW9WZ6_%)_K_2U$VE&,N[M_Z7]_P=+K7>Z:/H
M;[+J_P#S^Z=_X`O_`/':/LNK_P#/[IW_`(`O_P#':TJ*S&8&O0:BEI`9[JRD
MB^V6VY8[5D8_OX^A,AQ^5;]9OBG_`)!D7_7Y:_\`I1'6E0!BS17<GBZ[^RSV
M\.+.#=YL!ES\\V,8=<=_6K'V75_^?W3O_`%__CM?,W_!6WX<:?\`&+]E#6_"
M6K!SI?BCQ'X)TF[V'#>5/XILHGP>QVL<5\[>$_B#KW[17[6'[/\`XJ\6:9J<
M6K?!7QQ>_#661X)(O[2UF/PWKSZQ=0(P"R0R_9M.,3C<.95!ZT0]Y.3Z-KY*
M*;?HG*,?62\[6Z;]FYKM)_.*NE\TI/TB]]C]!+#X41:9\3M4\90?V<GB36M,
MM-'O+S[/.?.M;66YE@CV&?8-CWEP=P4,?,P20J@;WV75_P#G]T[_`,`7_P#C
MM?D[\//^"C7QC\2>(KK1-$^,=AK,?BB+1VMI;K5]"\2:[X)EN/%&BZ:]KJ%I
M8:)IUO8WOV;4IUEM)I;UDDB&V1/++2^TVGQ0\66G[6'CCX>^*/$"?$-?A[X5
M\:VEIKOB/P_H[ZK>Q'3/"-\B3-;V<,(0-J<\;1Q11QS(D7FI(R*U*;:I.MT4
M9R_\%J[7Y?>:4J+JUO9IZ\RBW\E9^EK+OTM8^ROC;\`++]H;P6N@^*)C)9Q7
M45];S:9<W^D7]E<1'*2P7=G=17$#C)&Z.1259E.59@9O@U\#[7X!>`;?PUX8
MDBM]+MYI[DM>R7FI7=S--*TTTT]U<W,D\\KR.S-)+(S$GDU\7_$WXZ_%/3_A
MYXEUGPW\1K[P=I7PD^`.@?$6'1M)T'23;:WJ+QZN\D%P9[60QVCII\2&*V\E
ME!S')'@AO(OC]^U_XV\4^-/#'BG0_B5_PF'Q7\)>-?%UU%\'!I-G-'X3:RT#
MQ)#IDDD=M`-3'GI'"^;B9UNOM6;=$&P#:K2]A4G3>EG*_GRZ7MYVT]-;:&%-
M.K"$WUC=?^`*I:_322OUU?*I69^JWV75_P#G]T[_`,`7_P#CM'V75_\`G]T[
M_P``7_\`CM?FY\"_VNOB_P",OA5XA:R_:(^%/CL7?B+PCI$&I>%O&6C>-=8\
M.'4=8CM+H3);:#I=O`DENY\I9X)G$D<A+$#8/7?^"AL/A3PC\0/AK:_&ZZT+
MQ/\`"BT\+ZO"LOQ#NK>P\(:SXI3[&;`Z[*MN;2(R1+>&)GMS"DI<QQ&40)6<
MDXKF>FK6OE%2_%-*/\TFDM[BC:3LNU_O=O\`@OLDV]M?L;[+J_\`S^Z=_P"`
M+_\`QVC[+J__`#^Z=_X`O_\`':_/?X=?%/0_&/[//PUD\(^#_`/A+PU<I\0-
M.L[/PSJ4?B31HH;>UNU\S2-0DMH6CLY7CW(MM'#'LP@78H%>T_\`!-W_`)'7
MQ7_V)7@?_P!-4E%GS3C_`"\GSYU-_AR?CTL0YI.*[N:_\`Y?OOS?AUN?3_V7
M5_\`G]T[_P``7_\`CM'V75_^?W3O_`%__CM:5%(T,W[+J_\`S^Z=_P"`+_\`
MQVC[+J__`#^Z=_X`O_\`':TJ*`.>T>WU0ZCJNV\L`1=+O)LW.X^1%T_>\<8]
M>A]<"_\`9=7_`.?W3O\`P!?_`..T:)_R$]8_Z_%_])X:TJ`,W[+J_P#S^Z=_
MX`O_`/':Q='^&2Z!XUUKQ%:_V6FM^(4MX;^\:UF>2:.!66&,;IR$C3?(0BX7
M=+(V-SL3A_M=WG@6P_9Q\52_$O6]+\/>"%M5_M.]U+6CH]D%,B!(IKCS(QY4
MDFR-HV;9,LAB=761D;XNTOX]_"KXE?\`!(SX&Z?/XT\$:_X&TFR\%1_$"VM]
M7M[JTLM'\Z&VG&HI&YV6?VB%HIQ*!'MBG27Y%E`4'S.2[."_\#;5WV4;7?D[
MC<;14NEI/_P%)I+NW>R7>W?3]!_LNK_\_NG?^`+_`/QVC[+J_P#S^Z=_X`O_
M`/':_)#Q';_`?^P-8L_'">#?^%$7&E^-F^#,%XH_L66]-[;[3H:CY3=&1Y?L
M7V;][Y;/]C_=DUZ#\(_^$<O/VH/"_P#PDW]ER_M;6OQ'TS[7Y^UO%,/AXZ%#
M]IZ?.-*\A[C=C_1?M#-_R\FJP_[UQ6JYE%ZK5<TN6S\X_%-?9AKJ16?LU+KR
M\VVSY8\UUY2^&+ZS]WS/TN^RZO\`\_NG?^`+_P#QVC[+J_\`S^Z=_P"`+_\`
MQVM*BD4<]X;M]4.G2;+RP4?:KC(:S<\^>^?^6H[Y^GOUJ^;35F&#>Z:0>H^P
MO_\`':/"W_(,E_Z_+K_THDKBOVP!HTO[+'Q!B\0^)Y_!.AW.@7EO?>((58MH
MD4D3(UT=O(6,-O8Y`"J264`L(J2M!O?0JG'FDHOJ;W@.WMXO"UM:>&+[PLNB
M:27TNW@TNQ`M;+[,Y@>W18Y=J>4\;1E!C84*X!&*U_LNK_\`/[IW_@"__P`=
MK\>?B=K?P,\7_LU>(/"MM:?L>^'7\+75_)X9U/PGH:QZ1\4;DVEJTDGA9XIA
M'I_B!6%M;EX5U:>"0PA?-YCK[*_;M^)OPD\;ZE\)+?XOZAX)/PNTW7YK7QOI
MGBF]MI]'TC5'T66XL+;6%D)A1AYF^-;D!#(T#`>8835SE[CJ)WVWTNG;6_K=
M6W3LG:Z)5]+K=2\[<O1^76^UKM7LSZ\^RZO_`,_NG?\`@"__`,=H^RZO_P`_
MNG?^`+__`!VOR+T*W\%_\(9I=GXR2S_X6Y;^'_"+?`B#6E?^WXK0:K<?9CI"
MR_OPX5(/M6W]YY*Q_:_W0%?L-5M63WT;6W;]>ZZ=V2GK;R3^]7^[L^JUT.>N
M+?5/^$HLP;RPW_99\-]C?`&^'/'F_3OV/7/%_P"RZO\`\_NG?^`+_P#QVBZ_
MY&ZR_P"O.X_]#@K2J"C-^RZO_P`_NG?^`+__`!VC[+J__/[IW_@"_P#\=IGC
MDZF/!.L?V)Y?]L_89OL'F8V_:/+;R\YXQOVU^9W[.\_PED3X#:K\(H-`U']J
M6P/VKXF0Z=(B>+[@C2[DZM;^)RO^D*K:@(4VWW"W(M_+`94Q'M$F[[+E\W[U
M]4NJC:\WT36CN-Q=KKKS>FB3LWT<KVBNK3VL?II]EU?_`)_=._\``%__`([1
M]EU?_G]T[_P!?_X[7YOP?M&'XE?!_P"#7C9/VU?$,GG^,M,3QZVFW/A;3K'P
MA+=Z9>-_9MU"=/,EK']J5(%@U!Y)=Q569I51E]L_;B^)WPB^&/\`P4!_9LN_
M%'C?PCH7CMM=N+>"RU?Q/';SPV$VD:O#')#:2S!8Q/=O'"94C#3.D$;,YCC5
M=^1I\K_FY>^O+&6G?XEMZJZM>.96;7\O-_Y-*.O5?"]UU2:3N?6GV75_^?W3
MO_`%_P#X[1]EU?\`Y_=._P#`%_\`X[7PY^RZGP^@_P""K7B#4/`>J_##Q1J&
MK:5KUMXC_P"$,L)-/UKPY.E_:,8_$Y:>X>\NGE21+:2;[(T*QW*QP2H[-#]Z
MUG'6E"I_,K_BUOUVW_X<J2M.4.S_`$7W'/>)+?5!IT>^\L&'VJWP%LW'/GIC
M_EJ>^/K[=:O_`&75_P#G]T[_`,`7_P#CM'BG_D&1?]?EK_Z41UI4`9OV75_^
M?W3O_`%__CM'V75_^?W3O_`%_P#X[6E7Y*ZE977[/GA*_OH(=4N_"?QQ_:/\
MB]$4;30Z/K]E\2!Y4[8!\N.ZL;?RF8_*)+&`?>F.:IKGJPI_S-*_FY)+\_OL
MNMU3C:G[3S2^5I-OY*.OE=WTL_U8^RZO_P`_NG?^`+__`!VC[+J__/[IW_@"
M_P#\=K\[/'W[7_Q5\4^+]6T_X??&9;[XVGQ/KFF7/P;.FZ1+#X:TRQ%ZUK=2
M)]F.HPK,EM8$WEQ<-;RC42(8U,UOL^A/@C^U-X>_:&_8S^(WQB\?ZM]C^"GB
M!;^^T];V!K06/ARWME@F>0QJ)F\Z2&ZFY)8I,BJ.@K-3O3E4V25W?1:VMKL[
MZZJZ]V6ONL'!JHJ;W;LK;]4]-T]-G9ZKN?1_V75_^?W3O_`%_P#X[1]EU?\`
MY_=._P#`%_\`X[7Y@>%+C]F?QU^Q?XLN=*\??LJ^#OA]XS\>_P!K:)X=\46V
MGZ_X)\'N=-2&*TN+.UOK:TM[VXBMI;T1R2_NIIY-L<DB%S]Z_L#7,ES^Q+\*
M/,TS6M',7A73X5M-7NWN[Z)4MT1?.EDBA>1RJABS11L=V2B'Y1HHNTF]&N33
M_%&[3[-/3SWT6\76EM4^;\';YW^[IJ>E?9=7_P"?W3O_``!?_P".U0M[?5/^
M$HO`+RPW_98,M]C?!&^;''F_7OW'3'/0UFVO_(W7O_7G;_\`H<]2,/LNK_\`
M/[IW_@"__P`=H^RZO_S^Z=_X`O\`_':TJ*`,W[+J_P#S^Z=_X`O_`/':/LNK
M_P#/[IW_`(`O_P#':TJ^&+#]K_XR3Q_&W1=)5]?\7_L]>&==%];2:0&3Q/JT
M\CW&@';#&'8_V;%'+)%;;=SWBJ`2`!+FD[/HG+Y1W_1+S:1<*;E:W5I?-NR\
M_7LMS[5^RZO_`,_NG?\`@"__`,=H^RZO_P`_NG?^`+__`!VORGT3]O+XFQ?#
MN_O+[]L3]G2?0H]1L'NKNQ^,GA6Z\2PH8;QIK6UN)O#5GIL4LFR$QV]W:LSF
M&<&[MQ\Z[WAK]KKQYX6^&'QM\4^'/C9XX\0>(KJW\+:II&A?$2XT*QG\,Z%?
MPZ4EWKSQV.FR+;Q0"6[W74<-QIZ-$\K0W`5R]/1M/R_&W_#^2U>FI$/>:BNO
M^:7ZKS>R39^G7V75_P#G]T[_`,`7_P#CM'V75_\`G]T[_P``7_\`CM?G7X'_
M`&S?'*?L_P"AS^+OVF?AC;>#M:\?MHVH?%;PEXNT+Q1_PC-FFE2W0M;N_;1K
M+2;>>:[CBB5I;#`CN43YI9(Y*^CO^"2=U+??L?2W$VL3>(WN?''C"8:O+9BS
M?5E?Q)J3+=&(*JIYJD2850OS_*`N!6GLW9WZ6_%)_K_2U$VE&,N[M_Z7]_P=
M+K7>Z:/H;[+J_P#S^Z=_X`O_`/':/LNK_P#/[IW_`(`O_P#':TJ*S&8&O0:B
MEI`9[JRDB^V6VY8[5D8_OX^A,AQ^5;]9OBG_`)!D7_7Y:_\`I1'6E0!BS17<
MGBZ[^RSV\.+.#=YL!ES\\V,8=<=_6K'V75_^?W3O_`%__CM?+'_!92WTN\_8
ML\51:W>>$=/T:36_!B7]UXJLTO-"MH#XGLQ))?P/+$LMJJY,J-+&&0,"ZYW#
MD/A3^U3\.?V2]*^#L5A\2_V?]+^".JZ'XGM[K5_`6GV&@^#M1U^.\TZ2SM[.
M-+FY$=R8GU']Q'<NTSK*Q4L%54I+DE-]&U]T5+Y7ORKO)I==+<-(M=;_`(?G
M^A]K?9=7_P"?W3O_``!?_P".URDGP*LYOC7#\0Y'BF\5VVCR:#;W$LEY);VE
MG)-'-*D5J;DV\;R/%"7E2,2.(8U9BJ*!^<GAO_@H3\4OB5\4_@)X5NOC!<^#
M_$/BOPAX*UF[M&O?!VDPZ]->"6;5$N+/4XSJ<D\Z)'#;C3(/*620J^PJQ1OP
M-_X*`?'37OA!\6/%FJ?&3X0:CXCT+X7:]XFO?!5KXPT_4_$'@O5[>V$D2C1D
MT.RNK*.WGW0S0W]W>LI,2%V8,[Z^SDIR2W@Y+_P%-.WDU=?G9,<:;E-4HZ\W
M)Z>\]/N:O]S5^GZD?9=7_P"?W3O_``!?_P".T?9=7_Y_=._\`7_^.U^<_P"U
ME^TY\;_V6_%-[X'A^+T%]97L7AS6=4\=^+Y]'\,0>$(-037EEB6\CT>ZL[6V
M:YTJSBC>]LKILW;1&7?+%+'TGQLAU;]K/_@CU8Z7\0/&G@;XC)XP\;^'-&F\
M0^#?$$.N6&I6,GB[3[=3]MM[2S@EN$0E)&AMH4\R-L(O02HR;M%7]Z,?G)I?
MK_2U(@DY0C)VYK/T35T_NU_X)]Z?9=7_`.?W3O\`P!?_`..T?9=7_P"?W3O_
M``!?_P".U^;OA/X@Z]^T5^UA^S_XJ\6:9J<6K?!7QQ>_#661X)(O[2UF/PWK
MSZQ=0(P"R0R_9M.,3C<.95!ZUY=\(/\`@H'\;/C#^V9\)/A?HOQYW>'_`(L7
M=\=1N(M4\-^)/%/@^.VL+JY%C=06WA^RM-,U`X42V\YU`QR0X!VHWGN,>>2A
M#5N[79K5IJ_245S+R:%-.$>:>EHW?=.\E)>L7%I^=^FI^N?V75_^?W3O_`%_
M_CM'V75_^?W3O_`%_P#X[7P9IO[8FNOJW@/PW\1_V@)/A#HD6H^+=)/C"XBT
M&QN?&U_H_B$Z9;VDLM[9O8PR/;*9GBMX(I)7<F(QI"ZG3^%'BOX@_%&S^"/@
M7PO\0;OX5Z9X@\.>--9U*X\+^'-&$\CZ=K%A;VJ0QW-I-;0J!>2;\0'>">CD
M2+E.7+%3W3YO_)$V_P`(NW79VLT/E?M947HX[^O;S[76E]+W3M]P?9=7_P"?
MW3O_``!?_P".T?9=7_Y_=._\`7_^.U^:_P`(?^"C/CKXMZ1X5US4?B[#X<^*
M.I'PG_8'P@MM/TQH_&]A?V>FS7>HF.2W;494)NM0/GVEQ%;VPL?WJGR9]_Z=
M5O4I.&_?]$_UVW75(3NI<KW7]?INM'O%M:F;]EU?_G]T[_P!?_X[1]EU?_G]
MT[_P!?\`^.UI45D!SVCV^J'4=5VWE@"+I=Y-FYW'R(NG[WCC'KT/K@7_`++J
M_P#S^Z=_X`O_`/':-$_Y">L?]?B_^D\-:5`&;]EU?_G]T[_P!?\`^.UBZ/\`
M#)=`\:ZUXBM?[+36_$*6\-_>-:S/)-'`K+#&-TY"1IOD(1<+NED;&YV)^"O^
M"E7@^%_VWM)_LV3X+^*/B;XFD\+Q^#K?5/$TMOX\\%+;:F[W-QI.GQ6D\DMK
M+'YKW$JS6B>5#,LS/&G%7]D3QA\*_!_[57@[5[35/"6E_%]-2\66'Q>O6N8X
M-543:FL%E#J\C$-^\O#8QV23'YD(6U!BW"BE[]O-R6FOPVVV_P"WNRU7,%3W
M=/\`#_Y-?_+1=;/:Q^C/V75_^?W3O_`%_P#X[1]EU?\`Y_=._P#`%_\`X[7Y
M$_\`!36?PPVM?%.727MC^TY8?$='WV!;_A+K;P-_9<7V\PF/_2%TK^RVO/\`
M5?NOM#';_IA6NK/_``S;9_%4>1_PJB+]C&Z\:0^?M^R+\.YM;'AV7[W_`"XE
M-Z0YS^X^UJN?]*%1"?-1]KY)V]5!Z]E[W+?^>+C;J.HN2I[.S^UK_A<EI_X#
MS/M!QEK>Q^I?V75_^?W3O_`%_P#X[1]EU?\`Y_=._P#`%_\`X[7D?_!."WN;
M3]AWX;Q3I?QV\>E!--2]603IIPD<6(82?O!_HGD?ZSY\8W?-FO;JVJ1Y9./;
MNK/YKHR(N\4SGO#=OJATZ39>6"C[5<9#6;GGSWS_`,M1WS]/?K5\VFK,,&]T
MT@]1]A?_`..T>%O^09+_`-?EU_Z425Q7[8`T:7]ECX@Q>(?$\_@G0[G0+RWO
MO$$*L6T2*2)D:Z.WD+&&WL<@!5)+*`6&-25H-[Z&E./-)1?4WO`=O;Q>%K:T
M\,7WA9=$TDOI=O!I=B!:V7V9S`]NBQR[4\IXVC*#&PH5P",5K_9=7_Y_=._\
M`7_^.U^0?C7XJ_LL:M\`=2^%FN:3^R?X7U?4]4N])\#^/?"4NGZ/X+GEEMK4
MWGB>S,K""TO[)#;JRQ7%Q/YT4<,=RP,GE?7_`/P4IU;X+?&[X*^$[?Q3\9_V
M;M+L?!OB6"^<_$ZUL?$F@ZI<'2;@);3V;7UH&F:WOH[J/$F0!&X1E8&KJ32@
MZJ=U=:^3MKWZ_?IO=*::YFHO1M/SVV7S[KUV:;^O?LNK_P#/[IW_`(`O_P#'
M:/LNK_\`/[IW_@"__P`=K\K/&GB_P1\2DTW4?&7A;PQX-^-%YX3\"W7P:\.M
M:&UOM(E^UOYB:!!(B2Q()T'GK&BLMNL0N@(54#]9:TE#ENNTFON_7NNFFKN1
M&5W\D_O5_N[/JM=#GKBWU3_A*+,&\L-_V6?#?8WP!OASQYOT[]CUSQ?^RZO_
M`,_NG?\`@"__`,=HNO\`D;K+_KSN/_0X*TJS+,W[+J__`#^Z=_X`O_\`':/L
MNK_\_NG?^`+_`/QVO!/^"K__``CO_##?B+_A+_[%_P"$4_MC0/[:_MCRO[.^
MQ?VW8>?]H\W]WY/E[M^_Y=N<\9KXK^+/QTTK]G[Q;K5W^R+XA^'7@GX#:_<Z
M/I_B3Q7I6MV&C^`_#FJF'4Y)9;*^.GZCIMG/(L.FP7+_`&.6$M/;QMLN)1*L
MJ:YK/O;\+Z]D]D];RLNI?LVX\R\_G;MW:W:Z139^I_V75_\`G]T[_P``7_\`
MCM'V75_^?W3O_`%__CM?`/@K]L'Q+>:/\(K#XF?M0>`/`_AWQ%9:Q>6WCWPC
MX@T'5K#QK=6^HP06^FG5+W3(K`S)!(_FI;6<$DLBDQ>6L,JFM_P4"_X0*[_:
MP\:0>*_[$E^,D=IX1E^#4=[@ZPLW]HRF5M&!^8-]H7_2C#SY*I]I_<!:TY7>
M"?VG;STTT7?LM&]]FKY<RM+^ZD_+5]7V\]5?W=[V_0?[+J__`#^Z=_X`O_\`
M':/LNK_\_NG?^`+_`/QVOSL_X)Z>*E3_`(*":T=1?X,>+OB-XDU3Q<OBE[3P
MI);_`!#\%6EMJ>RP34M1>\F9K&2!;:."$V]LC1FW:+>J$M^DM2M:<9]U?_AG
MU7F4[<\HKH[?\.NGH]3GO$EOJ@TZ/?>6##[5;X"V;CGSTQ_RU/?'U]NM7_LN
MK_\`/[IW_@"__P`=H\4_\@R+_K\M?_2B.M*@#-^RZO\`\_NG?^`+_P#QVC[+
MJ_\`S^Z=_P"`+_\`QVM*ODO]JG]H70M&_:BU1-`UR[U;Q1\-/A/XJOM:TWPI
M+:7NOZ$TTFC36G[B99(HIY5B=X5N8RC["2KH"*7,E))]I/\`\!BY?I;YETZ;
MG)17DOO:2_%GU%]EU?\`Y_=._P#`%_\`X[1]EU?_`)_=._\``%__`([7Y?\`
M[-W[:?QF^-_Q,TCX;VOQXT+6;/7?%NE69\9^$]8T/QG+!:W.B^(KJXM8;R+0
MM.L/,632;<@&RF,3.^^256\I/JGPG\4-#\<_\$]_%US\<?&-DN@^'M<U[PSK
M'B'6M4AT&+4HM-URZT^W>\E@-O`OVC[/"LL2A(9C*\9C,<AC)BN:A2E4:V5_
M71/];>HJ45.4%TDTOO<K?^D2^[6USZ7^RZO_`,_NG?\`@"__`,=H^RZO_P`_
MNG?^`+__`!VOS:^#'PA^`W[:7P0_9#TK3/"?PE\<>,-0\/:1J.K>*K?2;#4M
M2TG2_#\%JUQ;K?*CO%)]O>SM&B+J0D]R!@H17Z;UO6I>SE*+Z2DEYI:<R]7=
M>33]3&$^9)]TGZ-]/E^31F_9=7_Y_=._\`7_`/CM4+>WU3_A*+P"\L-_V6#+
M?8WP1OFQQYOU[]QTQST-9MK_`,C=>_\`7G;_`/H<]8F@?9=7_P"?W3O_``!?
M_P".T?9=7_Y_=._\`7_^.U<U'3K?6-/GM+N"&ZM;J-H9H9D#QS(PPRLIX(()
M!!X(-?FOX@_9$_9^U+X2_'7QCI]G^SU\!?A[K/B'2O!^FZAK7A73[7POJ$>A
M:JDUR;^U\VSCN5N=2CNK;:9UWQ6T#*><&>9\UNG_``4OS:TO=ZV6A2BFD_.W
MZ_DF_EYGZ.?9=7_Y_=._\`7_`/CM'V75_P#G]T[_`,`7_P#CM?#.E_&32-1_
MX)%>*=*\/0^!?#!&E>((M%MOA]8MH>G^(]$LKTQW6KZ-8H[3);2V\HES`\N#
M<*8Y9-\<C^-'_AFVS^*H\C_A5$7[&-UXTA\_;]D7X=S:V/#LOWO^7$IO2'.?
MW'VM5S_I0JJCY6[;))KIN[:]OSYO=:3VE7LKK7WE_P"`KH^MNK6B7O*Z/U+^
MRZO_`,_NG?\`@"__`,=H^RZO_P`_NG?^`+__`!VOR#_X)O6_A(ZW\/HM12S_
M`.&D+#XHHNAI?*W_``EEM\/_`+"PL1B3_2%TC^QV3/F?NO/8[_\`3":^X=._
M:*^(4_[>>H_!O[=-,VBW5QXY>X^PPJ+SPO+8K#:61?R]JR?VL\Z!A^\,5CEF
MRQ)&TH<[NM&[-:Z1C)JVKNE)W71PJ+=*Z=U-Q[?=O**UVLW%6?53@]$W;Z;^
MRZO_`,_NG?\`@"__`,=H^RZO_P`_NG?^`+__`!VOR<^&W_!0+XX^+/!.L:GK
M7[3O[-/@W6+O28KG6M!\0?%'1[+4O!5VU[:K+;I:R>&XY=)>,/<6Y74FU0I*
MT",)&#2-UWPG_:^\87WB?Q;XS\,?&KXF^-M6?X4:AJG@GP9XNE\,W-KXTU2Q
MN=6CE>U31;-$OXH_*MY!)ITF]XY(Q(Q^6-!Z:OS?W1E+_P!M_%&CIM2Y>MU'
MYN48^OVNWEN?IK]EU?\`Y_=._P#`%_\`X[1]EU?_`)_=._\``%__`([7YL?"
M']MWXG-\`O'^L7?[1/PD\8Z);WGAVSNO$_ASQMH_C'4OAW!>Z@(+[4+I;70=
M+M+:".V+2)]K@F$;PR/*S1(T=?0/_!*C78/%&L_M`ZC9_$&;XK:9>?$*W>Q\
M7206D?\`;L`\-Z(JRAK.**UF`VE!+;QI&_EY`Y-:1IMN5_LJ_P",%;[IWOL[
M-*^MLE)?U_7X;K=I)IOZ9UZ#44M(#/=64D7VRVW+':LC']_'T)D./RK?K-\4
M_P#(,B_Z_+7_`-*(ZTJS*,6:6[C\77?V6"WFS9P;O-G,6/GFQC"-GOZ58^U:
MO_SXZ=_X'/\`_&J^;/\`@J]#X@N?V7M5C\)SZ5:^*7\3>!UT>;5(GEL8KP^*
M;+R&G1"':(2;2P4@E<X.:X'X<^*[^/X6?!7PCX`\5>)O`>M^+O'FJ:-\1KVY
MM;"^\1#5X=,U&]O_`#FN()+<3R75O$ZR+#Y1@>+R46%H@*IKG4GV=OPB[^BY
MM>WN[\VCFN6"GWO^"O\`>^BZI2?0]Y^(7[%OA#XH_%R+QMK&@7LFM)-9W,\%
MKXVUBRTK4I;-Q);27FG0.EE=O&RIM:XAD.(XQG"*!ZQ]JU?_`)\=._\``Y__
M`(U7YO?M*?M>ZM\!_$GB<K\7O#7PTT*R\<>(3?Z+H&J>%="\:^(RB6'D-I]M
MK%C-:ZD^YYA(K/;SLSQD3RL%@;)U;]J3XC_![]GSQ/#H_P`?;S4=9;XN7^B>
M)M7\?Z[H^B2?#72F.HSV33S_`-BW4>FB[,5HB&^LIHB)ECA6#S(V3*C-2HQG
M'9Q4K?XN3]9K7K9CG%J;3W4I1_\``%-_^V.R\^VI^F_VK5_^?'3O_`Y__C5'
MVK5_^?'3O_`Y_P#XU7YI>'?VI/CKXF^$WQ*\3?\`"_O#.K6OPB^%Z^/+"[\!
M7&B^)M+\7SK?:^%BO-1?2X4D4Q:9%#.+.WM#YBL8VB(8'TK_`(*F?VYJW[1G
MPBN+1=0D\*?\(+XJN/'=GI"N=7O?#OVWPX;Z&R9?F$I4KO"#S6@$Z0E)VB==
MG!QG&$M+WWZ6BW=]EIKU2NVM+-Q@W/D]=M;V4962[VE&W=NU]S[C^U:O_P`^
M.G?^!S__`!JC[5J__/CIW_@<_P#\:KX?_;(_:['PS\:7>F:#\:['X0Z+I7@&
MQUWX8:1I=CI-S!\4KV7[4%LH4N;>:2\B3R;");336AN"+T'S/WL!3R=/^"C/
MC;2/%/C.SU3XX:;JFKR3!]0G\&:OX9\1^%_A=H[ZO9VMS>7L$=DFI6&H6=M-
M*<7LMY8J8Y9'ED"&!)6L^1=[:Z=;;[;[Z^[]JUT9[14V][;:[I/:UWOI9>]]
MFY^G'VK5_P#GQT[_`,#G_P#C5'VK5_\`GQT[_P`#G_\`C5?FAH$<G[6/[9GP
MUN-3^-4_Q:^%GP[UK5M7\+>*-0TGPW>:5K=S9Z?87+W,DT6GI;RM:W$\\(N[
M+R#&J-&LBS1S2-Y]>?MG?$/Q]<^`%T'XB0_'7XE>&/&\-Z;OP]K'A[Q/X.LC
M-X;\3"0Z5)I=I8W4L\<2O+_9^H[))#%%%'<,K/=%1DFVI:-6>O9VUUT[^5E>
M]BU&Z<NB3^])NW?IK9-J^VU_UP^U:O\`\^.G?^!S_P#QJC[5J_\`SXZ=_P"!
MS_\`QJOCZ[_:K\76WQJ^&7@+PQX\O/&FD?&;3-#UGPEXLETVS,D]E8EY=?EE
M\JWC@!FM5LRO[M=LNHN$5`BJOVG5N+2;?=K_`,!=F]=;7NO5/L9IZV>]D_OU
M6JTO;S,W[5J__/CIW_@<_P#\:H^U:O\`\^.G?^!S_P#QJM*BH*.>T>YU0:CJ
MNVSL"3=+O!O'&T^1%T_=<\8].I],F_\`:M7_`.?'3O\`P.?_`.-4:)_R$]8_
MZ_%_])X:TJ`,W[5J_P#SXZ=_X'/_`/&JQ?&W@5?B-!IL6MZ)I>H0Z3J,&JVT
M4FHS"-;F!M\,C*(PK['PZAP0'1'`W(I'P5_P4J\'PO\`MO:3_9LGP7\4?$WQ
M-)X7C\'6^J>)I;?QYX*6VU-WN;C2=/BM)Y);66/S7N)5FM$\J&99F>-.*O[(
MGC#X5^#_`-JKP=J]IJGA+2_B^FI>++#XO7K7,<&JJ)M36"RAU>1B&_>7AL8[
M))C\R$+:@Q;A12]]Q=NLK6UUC:UMGH]_Y=&FPJ7C>/I]TK_G9V757O:UC]&?
MM6K_`//CIW_@<_\`\:H^U:O_`,^.G?\`@<__`,:K\B?^"FL_AAM:^*<NDO;'
M]IRP^(Z/OL"W_"76W@;^RXOMYA,?^D+I7]EM>?ZK]U]H8[?],*UU9_X9ML_B
MJ/(_X51%^QC=>-(?/V_9%^'<VMCP[+][_EQ*;TASG]Q]K5<_Z4*B$^:C[7R3
MMZJ#U[+WN6_\Z<;=1U$X5/9Z_:U]'):?^`\S[0<9:WL?J7]JU?\`Y\=._P#`
MY_\`XU1]JU?_`)\=._\``Y__`(U7D?\`P3@M[FT_8=^&\4Z7\=O'I0334O5D
M$Z:<)'%B&$G[P?Z)Y'^L^?&-WS9KVZMJD>63CV[Z/YKHR(N\4SGO#=SJ@TZ3
M99V##[5<9+7CCGSWS_RR/?/U]NE7S<:LPP;'32#U'VU__C5'A;_D&2_]?EU_
MZ425Q7[8`T:7]ECX@Q>(?$\_@G0[G0+RWOO$$*L6T2*2)D:Z.WD+&&WL<@!5
M)+*`6&-25H-VZ&E./-)1?4WO`=W;Q>%K:T\,67A9=$TDOI=O!I=\!:V7V9S`
M]NBQQ;4\IXVC*#&PH5P",5K_`&K5_P#GQT[_`,#G_P#C5?D'XU^*O[+&K?`'
M4OA9KFD_LG^%]7U/5+O2?`_CWPE+I^C^"YY9;:U-YXGLS*P@M+^R0VZLL5Q<
M3^=%'#'<L#)Y7U__`,%*=6^"WQN^"OA.W\4_&?\`9NTNQ\&^)8+YS\3K6Q\2
M:#JEP=)N`EM/9M?6@:9K>^CNH\29`$;A&5@:NI-*#JWNKK7R=M>_7[]-[I33
M3DU%Z-I^>VR^?=>NS3?U[]JU?_GQT[_P.?\`^-4?:M7_`.?'3O\`P.?_`.-5
M^5GC3Q?X(^)2:;J/C+PMX8\&_&B\\)^!;KX->'6M#:WVD2_:W\Q-`@D1)8D$
MZ#SUC166W6(70$*J!^LM:2ARW7:37W?KW7335D1E=_)/[U?[NSZK70YZXN=4
M_P"$HLR;.PW_`&6?`^V/@C?#GGROIV[GICF_]JU?_GQT[_P.?_XU1=?\C=9?
M]>=Q_P"AP5I5F69OVK5_^?'3O_`Y_P#XU1]JU?\`Y\=._P#`Y_\`XU7@G_!5
M_P#X1W_AAOQ%_P`)?_8O_"*?VQH']M?VQY7]G?8O[;L//^T>;^[\GR]V_?\`
M+MSGC-?%?Q9^.FE?L_>+=:N_V1?$/PZ\$_`;7[G1]/\`$GBO2M;L-'\!^'-5
M,.IR2RV5\=/U'3;.>18=-@N7^QRPEI[>-MEQ*)5E37-9][?A?7LGLGK>5EU+
M]FW'F7G\[=N[ZM:6BF^A^I_VK5_^?'3O_`Y__C5'VK5_^?'3O_`Y_P#XU7P#
MX*_;!\2WFC_"*P^)G[4'@#P/X=\166L7EMX]\(^(-!U:P\:W5OJ,$%OIIU2]
MTR*P,R02/YJ6UG!)+(I,7EK#*IK?\%`O^$"N_P!K#QI!XK_L27XR1VGA&7X-
M1WN#K"S?VC*96T8'Y@WVA?\`2C#SY*I]I_<!:TY7>"?VG;STT=EW[+1]=FKY
M<VDO[J3\M7U?;SU5_=WO;]!_M6K_`//CIW_@<_\`\:H^U:O_`,^.G?\`@<__
M`,:K\[/^">GBI4_X*":T=1?X,>+OB-XDU3Q<OBE[3PI);_$/P5:6VI[+!-2U
M%[R9FL9(%MHX(3;VR-&;=HMZH2WZ2U*UIQGW5_\`AGU7FBG\<HKH[?\`#KIZ
M/4Y[Q)<ZH=.CWV=@H^U6^"MXYY\],?\`+(=\?3WZ5?\`M6K_`//CIW_@<_\`
M\:H\4_\`(,B_Z_+7_P!*(ZTJ`,W[5J__`#XZ=_X'/_\`&J/M6K_\^.G?^!S_
M`/QJM*ODO]JG]H70M&_:BU1-`UR[U;Q1\-/A/XJOM:TWPI+:7NOZ$TTFC36G
M[B99(HIY5B=X5N8RC["2KH"*7,E))]I/_P`!BY?I;YETZ;G)17DOO:2_%GU%
M]JU?_GQT[_P.?_XU1]JU?_GQT[_P.?\`^-5^7_[-W[:?QF^-_P`3-(^&]K\>
M-"UFSUWQ;I5F?&?A/6-#\9RP6MSHOB*ZN+6&\BT+3K#S%DTFW(!LIC$SOODE
M5O*3ZI\)_%#0_'/_``3W\77/QQ\8V2Z#X>US7O#.L>(=:U2'08M2BTW7+K3[
M=[R6`V\"_:/L\*RQ*$AF,KQF,QR&,F*YJ%*51K97]=$_UMZBI14Y07232^]R
MM_Z1+[M;7/I?[5J__/CIW_@<_P#\:H^U:O\`\^.G?^!S_P#QJOS:^#'PA^`W
M[:7P0_9#TK3/"?PE\<>,-0\/:1J.K>*K?2;#4M2TG2_#\%JUQ;K?*CO%)]O>
MSM&B+J0D]R!@H17Z;UO6I>SE*+Z2DEYI:<R]7=>33\F8PGS)/ND_1OI\OR:,
MW[5J_P#SXZ=_X'/_`/&JH6]SJG_"47A%G8;_`++!D?;'P!OFQSY7U[=AUSQT
M-9MK_P`C=>_]>=O_`.ASUB:!]JU?_GQT[_P.?_XU1]JU?_GQT[_P.?\`^-5<
MU'3K?6-/GM+N"&ZM;J-H9H9D#QS(PPRLIX(()!!X(-?FOX@_9$_9^U+X2_'7
MQCI]G^SU\!?A[K/B'2O!^FZAK7A73[7POJ$>A:JDUR;^U\VSCN5N=2CNK;:9
MUWQ6T#*><&>;WK/;_@I?FUI>[ULM"E&Z3\[?K^2;^7F?H%)X%6;XB1^*WT32
MY/$$&G-I4-X^HS,8+9Y%E>.-3'M3>Z1ERH!?RH]Q(C3&U]JU?_GQT[_P.?\`
M^-5\,Z7\9-(U'_@D5XITKP]#X%\,$:5X@BT6V^'UBVAZ?XCT2RO3'=:OHUBC
MM,EM+;RB7,#RX-PICEDWQR/XT?\`AFVS^*H\C_A5$7[&-UXTA\_;]D7X=S:V
M/#LOWO\`EQ*;TASG]Q]K5<_Z4*J;4+I;))KIO+JOLZM^?-[K2=R5=ZM:OF3Z
M_"NCZVMJ]E&S5U8_4O[5J_\`SXZ=_P"!S_\`QJC[5J__`#XZ=_X'/_\`&J_(
M/_@F];^$CK?P^BU%+/\`X:0L/BBBZ&E\K?\`"66WP_\`L+"Q&)/](72/['9,
M^9^Z\]CO_P!,)K[AT[]HKXA3_MYZC\&_MTTS:+=7'CE[C[#"HO/"\MBL-I9%
M_+VK)_:SSH&'[PQ6.6;+$D;2ASM-:-V:UTC&35M7=*3NNCA46Z5T[J;CV^[>
M45KM9N*MW4X/1-V^F_M6K_\`/CIW_@<__P`:H^U:O_SXZ=_X'/\`_&J_)SX;
M?\%`OCCXL\$ZQJ>M?M._LT^#=8N])BN=:T'Q!\4='LM2\%7;7MJLMNEK)X;C
METEXP]Q;E=2;5"DK0(PD8-(W7?"?]K[QA?>)_%OC/PQ\:OB;XVU9_A1J&J>"
M?!GBZ7PS<VOC35+&YU:.5[5-%LT2_BC\JWD$FG2;WCDC$C'Y8T'IJ_-_=&4O
M_;?Q1HX-2Y>MU'YN48^OVNWEN?IK]JU?_GQT[_P.?_XU1]JU?_GQT[_P.?\`
M^-5^;'PA_;=^)S?`+Q_K%W^T3\)/&.B6]YX=L[KQ/X<\;:/XQU+X=P7NH""^
MU"Z6UT'2[2V@CMBTB?:X)A&\,CRLT2-'7T#_`,$J-=@\4:S^T#J-G\09OBMI
MEY\0K=['Q=)!:1_V[`/#>B*LH:SBBM9@-I02V\:1OY>0.36D:;;E?[*O^,%;
M[IWOL[-*^MLE)?U_7X;K=I)IOZ9UZ?47M(!/:V4<7VRVW-'=,[#]_'T!C&?S
MK?K-\4_\@R+_`*_+7_THCK2K,HQ9I;N/Q==_98+>;-G!N\V<Q8^>;&,(V>_I
M5C[5J_\`SXZ=_P"!S_\`QJOG;_@J!XKTOP+^SU<:WK>I6&C:-I'BWP)>W]_?
M7"6]K901^*[%Y)99'(5$5069F(``))K@_P!I3]KZRN#\1OB-\)O%/@OQ%:Z9
M\"M?U_1/$NC)8:M%)=V5RXCVW:!_-BCE1@8?,,>]6RNX&B/O62[R7_@-/VGX
MZI>AK&BY)-=7%+UE.,?PYKOR/L7[5J__`#XZ=_X'/_\`&J/M6K_\^.G?^!S_
M`/QJOS_^-/[27Q!_9Q^.,'PW\9_M"ZMX?\'ZO#H.MZS\3-6TSP_8R^$DO8=?
M+6<+O9"P@@FN=)M8HY+V*=U^T/'YCR21,OS9+^W-X_\`V=/@Y+)X2^+JV%WI
M6I>*_$4</B35M&\/VGQ&9O%>LLKV&GR:'>7VH3.D0:XAMKJP2..>V,;IYID3
M2,.:2AU;M\[7_KKV5M3%M*G[3_"_E)-I^>EMM-=6FFC]D_M6K_\`/CIW_@<_
M_P`:H^U:O_SXZ=_X'/\`_&J^$OVHOV7=2_:C_P""GFIKI?A3X=S:AHG@7P;?
MQ^--8N)$U[P/LUO6YS+I"):R&2680E'!NK90`F[SES'73?'K]OF_^$GQ;\?>
M`;KQUI6F>.;CXG^#K'P=X>>.U;4[KPY>OH4=_-%;[#));%Y-75KEE/EL'`D0
MH@6:<7.48;.3LO\`P*,?7K?;9-INQ3C:;BGHE%W_`,45+\+VW^[0^Q_M6K_\
M^.G?^!S_`/QJC[5J_P#SXZ=_X'/_`/&J_/BU\;3?#;]GCX(^(+=?$;3Z+:^/
M[V+^P(;>;50T<%^P-JEPCP-,",H)4:/<!N5ER#YC^QU^U]\<?VJ_VW'^#<7[
M1^GW7A>/P5>>+F\5>"-4\.>,[F:=+FT@6T34!X?L;$+&78O&+&5QYC@S$L@A
MQ51-R5MDW\DFW^$6+[,9/J[?E_FC]5?M6K_\^.G?^!S_`/QJC[5J_P#SXZ=_
MX'/_`/&JX3]BWXMZG\?/V0/A=XWUH0#6/%WA33-8OO)7;'Y\]K'))M'8;F.!
MVKTVNBM3=*I*G+=-K[A*]M=#C=0^&UOJWQ/TOQE<Z#I<_B71-.NM*L+Q]2F/
MV2VN9())T1/+V`NUM!EMN[$8&<9!Z#[5J_\`SXZ=_P"!S_\`QJM*BL^B71?Y
MW_-M^K'UN9OVK5_^?'3O_`Y__C5'VK5_^?'3O_`Y_P#XU6E10!SVCW.J#4=5
MVV=@2;I=X-XXVGR(NG[KGC'IU/IDW_M6K_\`/CIW_@<__P`:HT3_`)">L?\`
M7XO_`*3PUI4`9OVK5_\`GQT[_P`#G_\`C58OC;P*OQ&@TV+6]$TO4(=)U&#5
M;:*349A&MS`V^&1E$85]CX=0X(#HC@;D4CX*_P""E7@^%_VWM)_LV3X+^*/B
M;XFD\+Q^#K?5/$TMOX\\%+;:F[W-QI.GQ6D\DMK+'YKW$JS6B>5#,LS/&G%7
M]D3QA\*_!_[57@[5[35/"6E_%]-2\66'Q>O6N8X-543:FL%E#J\C$-^\O#8Q
MV23'YD(6U!BW"BE[[B[=96MKK&UK;/1[_P`NC385+QO'T^Z5_P`[.RZJ][6L
M?HS]JU?_`)\=._\``Y__`(U1]JU?_GQT[_P.?_XU7Y$_\%-9_##:U\4Y=)>V
M/[3EA\1T??8%O^$NMO`W]EQ?;S"8_P#2%TK^RVO/]5^Z^T,=O^F%:ZL_\,VV
M?Q5'D?\`"J(OV,;KQI#Y^W[(OP[FUL>'9?O?\N)3>D.<_N/M:KG_`$H5$)\U
M'VODG;U4'KV7O<M_YTXVZCJ)PJ>SU^UKZ.2T_P#`>9]H.,M;V/U+^U:O_P`^
M.G?^!S__`!JC[5J__/CIW_@<_P#\:KR/_@G!;W-I^P[\-XITOX[>/2@FFI>K
M()TTX2.+$,)/W@_T3R/]9\^,;OFS7MU;5(\LG'MWT?S71D1=XIG/>&[G5!IT
MFRSL&'VJXR6O''/GOG_ED>^?K[=*OFXU9A@V.FD'J/MK_P#QJCPM_P`@R7_K
M\NO_`$HDKBOVP!HTO[+'Q!B\0^)Y_!.AW.@7EO?>((58MHD4D3(UT=O(6,-O
M8Y`"J264`L,:DK0;MT-*<>:2B^IO>`[NWB\+6UIX8LO"RZ)I)?2[>#2[X"UL
MOLSF![=%CBVIY3QM&4&-A0K@$8K7^U:O_P`^.G?^!S__`!JOQY^)VM_`SQ?^
MS5X@\*VUI^Q[X=?PM=7\GAG4_">AK'I'Q1N3:6K22>%GBF$>G^(%86UN7A75
MIX)#"%\WF.OLK]NWXF_"3QOJ7PDM_B_J'@D_"[3=?FM?&^F>*;VVGT?2-4?1
M9;BPMM860F%&'F;XUN0$,C0,!YAA-7.7N.HG?;?2Z=M;^MU;=.R=KHE7TNMU
M+SMR]'Y=;[6NU>S/KS[5J_\`SXZ=_P"!S_\`QJC[5J__`#XZ=_X'/_\`&J_(
MO0K?P7_PAFEV?C)+/_A;EOX?\(M\"(-:5_[?BM!JMQ]F.D++^_#A4@^U;?WG
MDK']K_=`5^PU6U9/?1M;=OU[KIW9*>MO)/[U?[NSZK70YZXN=4_X2BS)L[#?
M]EGP/MCX(WPYY\KZ=NYZ8YO_`&K5_P#GQT[_`,#G_P#C5%U_R-UE_P!>=Q_Z
M'!6E4%&;]JU?_GQT[_P.?_XU1]JU?_GQT[_P.?\`^-5HEMHR>`.IKX4L/VTO
M#WA#QQK?Q*T/XB>$H/@[K?QLBL/$GBT:C:/H+Z>O@R*$;KYR840:K#:0^8CC
M]ZHC+?,RDA:4W#LK_P#DT8I?-R_"Q7*^5R[)O[HN5O6T79'VU]JU?_GQT[_P
M.?\`^-4?:M7_`.?'3O\`P.?_`.-5\:_L%_'6^_:0_:H'BV\U3^VH+W0?%EMI
M=X+9;=9M-@\83P6)551<K]EC@VN1EQAB6+%C\<_&#PQ\,O%^I^%[JSUWX.Z7
M\2M&\3>(+SX[P^,]832;37M.BUE#%I?B:\*2M#;SW*V2VGVB*56C0)!$]LT@
MI7LJ;E]KF]5RS<+VW:5N:5M4MDWNI*U2I3CKR2Y;]&^7FT?=O2-]'NW$_9#[
M5J__`#XZ=_X'/_\`&J/M6K_\^.G?^!S_`/QJOG7_`()(6-[;?LA+</I7AW0?
M#^I>(]8OO#&F>'[R:\T:QTB6]D:V6PFE@MVDLB"SP,L$49ADC\M?+V$_3E7*
M/+:_9.W572=GYK9^9$97O;HVO6SM=>3W7D<]XDN=4.G1[[.P4?:K?!6\<\^>
MF/\`ED.^/I[]*O\`VK5_^?'3O_`Y_P#XU1XI_P"09%_U^6O_`*41UI5)1F_:
MM7_Y\=._\#G_`/C5'VK5_P#GQT[_`,#G_P#C5:5?G+^TI\:M?TG_`(*`R_&"
MW\#>.K[P5\(->TKP3-XKL[O2TT&RT^X#QZZ;B.2]2]95FU"R9S%:R()-$C^8
M;7*D/>JQI]_P6BN_+F<4VVK)WU=DR7NTY5.WXO>R\[)M+K;HKM?H1]JU?_GQ
MT[_P.?\`^-4?:M7_`.?'3O\`P.?_`.-5^;_[6?\`P55\2_!_X4WFA:5\1]!@
M^+NA^/O&=IK.CLE@U[I.AV]KK\^DR7<3KY=I#LCTF2.XN/+20!6DD9&E)]R_
MX)X_&?\`X7E^R/\`$?Q;XY^,E[XP\&7&IW\46K7_`(I\,I>^&-)BLXA*MUJ/
MA@QV=O.I,\QDBN"\4;PMOC8$*+5.2V4>:_1IM+?Y^EDRJL?9U52EJW)QTUV<
ME_[8[>L>^GU=]JU?_GQT[_P.?_XU1]JU?_GQT[_P.?\`^-5^6&G>-/@IXS_8
M%\&WMGXN_9@\5?#CX??$WQ5'=^$_'7C6VT_PMJPGO=6:QB:9(+Q#/'#*ES!"
M]M)YBD.NTA'K[X_X)TZ'XC\-?L+_``KL?%L%S:Z];^';5;BVN'G>:T7;F*%V
MG59BT<11"955\J=RJ<J&E?F\FE]ZOK^EKKS1FW9I/K?_`,E=G;^EZ=3U?[5J
M_P#SXZ=_X'/_`/&JH6]SJG_"47A%G8;_`++!D?;'P!OFQSY7U[=AUSQT-9MK
M_P`C=>_]>=O_`.ASTB@^U:O_`,^.G?\`@<__`,:H^U:O_P`^.G?^!S__`!JK
MFHS0V^GSR7$H@MTC9I9#)Y8C4#EMV1MP.^>*_(?5_'O[.?Q$^!/QK\0?!;Q%
M\%])\%^)[KPOI8T!KZRDT)C::F[MX@\46D;^=%97<LXM[@W(66:&WC,KJ91Y
M<<_O<JWT_%V_KY]$VJM:/._Z_I?Y;M)_JE)X%6;XB1^*WT32Y/$$&G-I4-X^
MHS,8+9Y%E>.-3'M3>Z1ERH!?RH]Q(C3&U]JU?_GQT[_P.?\`^-5\>_\`!-7Q
MO\-_#W[!UUX>U+Q3X%\/Z--<^)[F2Z\+:]_8_ARXL8KEGOK_`$"9)(Y+?2H/
MM"[9(7_T9B1YS$"5_$?!W[2_[)^C_P#!,%+3Q7J'P9\?>$[+XB>(M&\.^']0
MUK3YM!DU&;5=3EL8[EI'-K#']E?SQ+/\J1E9$RQCW56?)"\-=$TMOB>WJY.R
M[R=M&3!<SN^K:;_PIZW\E'7LNZ/TP^U:O_SXZ=_X'/\`_&J/M6K_`//CIW_@
M<_\`\:K\Q?V*M-^%'P?_`&NOALW@+XG_`+-/[2/BKQ`+#0K_`%#1=(M=5\?>
M';>T\.QV4NH?VQ;WLY2QW6*!HY;>(?Z<5\]G*K+]/Z=^T5\0I_V\]1^#?VZ:
M9M%NKCQR]Q]AA47GA>6Q6&TLB_E[5D_M9YT##]X8K'+-EB3=7EAMKH^G\MFT
MNK]UN6FEHRUNK"5_P3^^_P!WO+EUL[M.RB[GTW]JU?\`Y\=._P#`Y_\`XU1]
MJU?_`)\=._\``Y__`(U7Y.?#;_@H%\<?%G@G6-3UK]IW]FGP;K%WI,5SK6@^
M(/BCH]EJ7@J[:]M5EMTM9/#<<NDO&'N+<KJ3:H4E:!&$C!I&Z[X3_M?>,+[Q
M/XM\9^&/C5\3?&VK/\*-0U3P3X,\72^&;FU\::I8W.K1RO:IHMFB7\4?E6\@
MDTZ3>\<D8D8_+&DO35^;^Z,I?^V_BC1P:ER];J/S<HQ]?M=O+<_37[5J_P#S
MXZ=_X'/_`/&J/M6K_P#/CIW_`('/_P#&J_-CX0_MN_$YO@%X_P!8N_VB?A)X
MQT2WO/#MG=>)_#GC;1_&.I?#N"]U`07VH72VN@Z7:6T$=L6D3[7!,(WAD>5F
MB1HZ^@?^"5&NP>*-9_:!U&S^(,WQ6TR\^(5N]CXND@M(_P"W8!X;T15E#6<4
M5K,!M*"6WC2-_+R!R:TC3;<K_95_Q@K?=.]]G9I7UMDI+^OZ_#=;M)--_3.O
M3ZB]I`)[6RCB^V6VYH[IG8?OX^@,8S^=;]9OBG_D&1?]?EK_`.E$=:59E&+-
M+=Q^+KO[+!;S9LX-WFSF+'SS8QA&SW]*L?:M7_Y\=._\#G_^-5X/_P`%*OBC
MX;^&7[)/Q83Q'K^CZ$_B7PE<Z#HZ7]Y';OJVHW%M>K!9VZL09KB0@A(DR[8.
M`<5XO\9_VO?$_AO]ISQ#H5O\73X<\=:%XIT31O"?P@6QTR3_`(3;2;A+%KC4
M'26W;49@1/?YN+2XBM[;[#^]4^3/O</>FH+^M4O5OWEHKNVJ037+'F?G^'Y+
M?5V5U:]VD?<'VK5_^?'3O_`Y_P#XU1]JU?\`Y\=._P#`Y_\`XU7YD>,_C1\3
M?V0OV;O%WC[PO\1-2^S:UX^^*NF6?AN;2=.?2]+DM3XJU2"^5VMS=R7(N=.3
M(>?R#'(5\G(WGZS_`&?O$?C/PK\;/B1\/O&?Q#\2^/K2P\%Z+XKAU6XTNQM;
M[3Y+^75H+BWMH["VBS$G]GH\0=9IP78&23Y:4[QINIV5]=.E[?=K?;SZ&U6B
MZ=1PEM>2OY1FJ=[><FE;?Y:GT)]JU?\`Y\=._P#`Y_\`XU1]JU?_`)\=._\`
M`Y__`(U7Y?\`[./QH\*?LP?`SQOHWP>\2_!W5-'TVU\._P#"0_&'X?Q1$:?9
MSZ@+6YO]<L29[=-8M[9Y[A[J:23S-K37$$44/E-Z5^SQ\>?B/^T3^U2W@+PG
M^T+K'BKX86FFZMJ6C>/M/TC0+JY\526XT4&(W$5D+&>"WGOKJ)I+2"/.WRB_
MFPR.7JW:*;^+_P`E5WIOW2;LF]$S!?WM-OQM;7:^NJ3;75(^]OM6K_\`/CIW
M_@<__P`:H^U:O_SXZ=_X'/\`_&J^$-/_`&KO''[0_P"QK\6O%&NI8)'X'L]*
M\(WNEWNBVUS:'Q/93J=:G"3Q,)(UGDBAC#`H#;,R@$YK6^'US/9_M?V$UK;_
M`&NYB^*'C5X8-X3SG&B6Y5-QX&3@9[9J)S4)26Z4'.ZOJE*"5O53YEY=-=#6
MT=-7)1UMHW&3=WY./*_.^MEK]L_:M7_Y\=._\#G_`/C5'VK5_P#GQT[_`,#G
M_P#C5?%G[`'[6VO_`!J^,?@^UB^,W_"UKOQ#X8N]5^(?A@:?ID,?PLU-&MO+
ML0+6".YLSYTMU;_9M2EGN'%L6#`PS,WW+6LX.._]:M;[/;=-KSO<$TWI_E^#
MLUZ-)^1F_:M7_P"?'3O_``.?_P"-4?:M7_Y\=._\#G_^-5I45`S-^U:O_P`^
M.G?^!S__`!JC[5J__/CIW_@<_P#\:K2HH`Y[1[G5!J.J[;.P)-TN\&\<;3Y$
M73]USQCTZGTR;_VK5_\`GQT[_P`#G_\`C5&B?\A/6/\`K\7_`-)X:TJ`,W[5
MJ_\`SXZ=_P"!S_\`QJL7QMX%7XC0:;%K>B:7J$.DZC!JMM%)J,PC6Y@;?#(R
MB,*^Q\.H<$!T1P-R*1\%?\%*O!\+_MO:3_9LGP7\4?$WQ-)X7C\'6^J>)I;?
MQYX*6VU-WN;C2=/BM)Y);66/S7N)5FM$\J&99F>-.*O[(GC#X5^#_P!JKP=J
M]IJGA+2_B^FI>++#XO7K7,<&JJ)M36"RAU>1B&_>7AL8[))C\R$+:@Q;A12]
M]Q=NLK6UUC:UMGH]_P"71IL*EXWCZ?=*_P"=G9=5>]K6/T9^U:O_`,^.G?\`
M@<__`,:H^U:O_P`^.G?^!S__`!JOR)_X*:S^&&UKXIRZ2]L?VG+#XCH^^P+?
M\)=;>!O[+B^WF$Q_Z0NE?V6UY_JOW7VACM_TPK75G_AFVS^*H\C_`(51%^QC
M=>-(?/V_9%^'<VMCP[+][_EQ*;TASG]Q]K5<_P"E"HA/FH^U\D[>J@]>R][E
MO_.G&W4=1.%3V>OVM?1R6G_@/,^T'&6M['ZE_:M7_P"?'3O_``.?_P"-4?:M
M7_Y\=._\#G_^-5Y'_P`$X+>YM/V'?AO%.E_';QZ4$TU+U9!.FG"1Q8AA)^\'
M^B>1_K/GQC=\V:]NK:I'EDX]N^C^:Z,B+O%,Y[PW<ZH-.DV6=@P^U7&2UXXY
M\]\_\LCWS]?;I5\W&K,,&QTT@]1]M?\`^-4>%O\`D&2_]?EU_P"E$E<5^V`-
M&E_98^(,7B'Q//X)T.YT"\M[[Q!"K%M$BDB9&NCMY"QAM['(`522R@%AC4E:
M#=NAI3CS247U-[P'=V\7A:VM/#%EX671-)+Z7;P:7?`6ME]F<P/;HL<6U/*>
M-HR@QL*%<`C%:_VK5_\`GQT[_P`#G_\`C5?CS\3M;^!GB_\`9J\0>%;:T_8]
M\.OX6NK^3PSJ?A/0UCTCXHW)M+5I)/"SQ3"/3_$"L+:W+PKJT\$AA"^;S'7V
M5^W;\3?A)XWU+X26_P`7]0\$GX7:;K\UKXWTSQ3>VT^CZ1JCZ++<6%MK"R$P
MHP\S?&MR`AD:!@/,,)JYR]QU$[[;Z73MK?UNK;IV3M=$J^EUNI>=N7H_+K?:
MUVKV9]>?:M7_`.?'3O\`P.?_`.-4?:M7_P"?'3O_``.?_P"-5^1>A6_@O_A#
M-+L_&26?_"W+?P_X1;X$0:TK_P!OQ6@U6X^S'2%E_?APJ0?:MO[SR5C^U_N@
M*_8:K:LGOHVMNWZ]UT[LE/6WDG]ZO]W9]5KH<]<7.J?\)19DV=AO^RSX'VQ\
M$;X<\^5].W<],<W_`+5J_P#SXZ=_X'/_`/&J+K_D;K+_`*\[C_T."M*H*,W[
M5J__`#XZ=_X'/_\`&J/M6K_\^.G?^!S_`/QJOE/_`(*Y_">^^-5C\!]"TB=;
M7Q`/B0VI:)._W8-2L_#FN7=D[=/E%Q!$2.XS7SYX2_:`F^,W[24?[3$>B^-M
M%?Q%\'_&MMH-E86J?V[:Z?I<V@8\FWNXVA^T?VA+J+(98VC=?)+!TXHBTVT^
MBDWZ*+DK;7;::LME[WD:^Q?/""^VE;U<I*S[:1;3>[T\S]+_`+5J_P#SXZ=_
MX'/_`/&J/M6K_P#/CIW_`('/_P#&J_+;X+_\%0?B=\,[;Q5XH\0?$;PY\8?`
M/@2?3&U*Z\-Z_IOBQ;K^U8-1M[:%+_3]%TJ(O'J5KI\7EI`Q3[;,9)G^1(OH
MG_@IV^@^$?\`@DAK,?QT\8Z)%XAA\,,GVO4M6CT:TUKQ!]@E*Q+"KQ0W#&42
M216[*XWQ1R*F^)'6I1Y;M[)Q7WJ^G=I-7]5W,J3522BNMW]W?M\];7=C[`^U
M:O\`\^.G?^!S_P#QJC[5J_\`SXZ=_P"!S_\`QJOS>\$>.?A/\6?VR=-\0>'=
M8\'^)?CM>?%>UN=(U+3;N*\UF?P<VD)F2"6,L6T4VCS?,I^RFX8_\O1K],Z4
M5>DJCTOT_P"W8R_#FY7VE&2Z$<WO\OE?\9+\>6Z[Q<7U.>\27.J'3H]]G8*/
MM5O@K>.>?/3'_+(=\?3WZ5?^U:O_`,^.G?\`@<__`,:H\4_\@R+_`*_+7_TH
MCK2I%F;]JU?_`)\=._\``Y__`(U1]JU?_GQT[_P.?_XU6E7Q'\>/VI[+0/C3
M\9_%_@/QCH4]OX#@\`Z-XLU2SN;:\M=`AB\2W_\`;,%VYW1P/!I\TK3!\/"C
M;SL(#`5G)1>E[?*[2N_)7U?0I1;6GE][?_#OY'U7\4OAS%\:?A]JOA;Q)HMA
M?Z)K,/D74*:M<6TF,AE:.6)%EBD5@K))&RNC*K*P8`C%^!/[/FF?LX:)J5CX
M8TR[;^V;S^T-0O-;\7:GKVHWTWE1Q!I;R_,]PX6.*-%5I"JJH"@"OE>7]LGQ
M5^TY\1I-*^&GQ96R\'^)/C1%X/TKQ-H.GZ=J`&CIX).ISBREG@E@FS?PRE;A
MEF4'(&]%V5V%_P#M$>!;/_@F[XI\0?M*ZGI_B?P?X5\3:QX8U>YURVMDC\2_
MV?X@N-.LQ<P1K%:N]PT$&]-B6Y9V+*D>=I.].'M6K74?5II22T[76G\VW<J5
M-^XGJGJO)OG7_MDK]DM3ZQ^U:O\`\^.G?^!S_P#QJC[5J_\`SXZ=_P"!S_\`
MQJOQP^&ME\&8=%UFR@\2_#/Q/\1A-H>H_!.UT+5K35O^$:FN=>N[N32O#LMN
MS(5LIY%@N/LV`(((_/"VWEJ/VAJW&ROYM>6ENO?NMEI9NYCS7DXK^OET3Z=;
M;I;&;]JU?_GQT[_P.?\`^-50M[G5/^$HO"+.PW_98,C[8^`-\V.?*^O;L.N>
M.AK-M?\`D;KW_KSM_P#T.>H*#[5J_P#SXZ=_X'/_`/&J/M6K_P#/CIW_`('/
M_P#&JN:C-#;Z?/)<2B"W2-FED,GEB-0.6W9&W`[YXK\O_@O\=?V*;7X?_';X
MB66M_"&+X'WMGHUC?^"].O[&7^W7MKN94U;4K!7W"6^NKJ.W_P!-`,L=K&]P
M=K$1PYI-KLK_`->O2UV^UDVJY?=OYV_KTW?3SNTG^C4G@59OB)'XK?1-+D\0
M0:<VE0WCZC,Q@MGD65XXU,>U-[I&7*@%_*CW$B-,;7VK5_\`GQT[_P`#G_\`
MC5?%WP*D^$5Y_P`$J?$'@./XP_"#1?#GC30O%+17%EXAT[4=!\)6EU-*\]I"
MT<Z0RVFF#4((&VNB!1&,Q*Z`>#>"/%'P5?P?X3T+QQ9?LV2?LV:%\0KRUO\`
MQ)X4\-V_A_X9^+;Q]!\ZVEN+>2>XM'>&X,L!D>XFA:XMX<,LZI''<_<<H=(I
M-?.5GM>VKWV;>G<G=*:UNY+_`,!6CUMT6O6*5VM+'ZE?:M7_`.?'3O\`P.?_
M`.-4?:M7_P"?'3O_``.?_P"-5^0?_!-ZW\)'6_A]%J*6?_#2%A\4470TOE;_
M`(2RV^'_`-A86(Q)_I"Z1_8[)GS/W7GL=_\`IA-?<.G?M%?$*?\`;SU'X-_;
MIIFT6ZN/'+W'V&%1>>%Y;%8;2R+^7M63^UGG0,/WABL<LV6)(VE#G::T;LUK
MI&,FK:NZ4G=='"HMTKIW4W'M]V\HK7:S<5;NIP>B;M]-_:M7_P"?'3O_``.?
M_P"-4?:M7_Y\=._\#G_^-5^3GPV_X*!?''Q9X)UC4]:_:=_9I\&ZQ=Z3%<ZU
MH/B#XHZ/9:EX*NVO;59;=+63PW'+I+QA[BW*ZDVJ%)6@1A(P:1NN^$_[7WC"
M^\3^+?&?ACXU?$WQMJS_``HU#5/!/@SQ=+X9N;7QIJEC<ZM'*]JFBV:)?Q1^
M5;R"33I-[QR1B1C\L:#TU?F_NC*7_MOXHT<&I<O6ZC\W*,?7[7;RW/TU^U:O
M_P`^.G?^!S__`!JC[5J__/CIW_@<_P#\:K\V/A#^V[\3F^`7C_6+O]HGX2>,
M=$M[SP[9W7B?PYXVT?QCJ7P[@O=0$%]J%TMKH.EVEM!';%I$^UP3"-X9'E9H
MD:.OH'_@E1KL'BC6?V@=1L_B#-\5M,O/B%;O8^+I(+2/^W8!X;T15E#6<45K
M,!M*"6WC2-_+R!R:TC3;<K_95_Q@K?=.]]G9I7UMDI+^OZ_#=;M)--_3.O3Z
MB]I`)[6RCB^V6VYH[IG8?OX^@,8S^=;]9OBG_D&1?]?EK_Z41UI5F48LTMW'
MXNN_LL%O-FS@W>;.8L?/-C&$;/?TJQ]JU?\`Y\=._P#`Y_\`XU7@_P#P4J^*
M/AOX9?LD_%A/$>OZ/H3^)?"5SH.CI?WD=N^K:C<6UZL%G;JQ!FN)""$B3+M@
MX!Q7SC^TE^W%X\^&'_!0C3O#F@_$2WT_2X/%/A[P_=^!=>\0Z/#>:C;WOV2*
M>]L-)CT1]1GLE%R2+N35H56YAG7RS'$(Y$Y*ZCWT_+_-?>$URP<WT3?W6_/7
M[F?H-]JU?_GQT[_P.?\`^-4?:M7_`.?'3O\`P.?_`.-5^;&M?&G]H/0_@)+X
MQ/[0'B":Z7X&-\7'MO\`A%-!6$:E;1!Q9(?L99;"82?OD8O<%D0Q7$"[D?9^
M/_[:GQ>T;]O'5/#T7Q?^"_PKTG2-7TBVT7PWXT\;V.A_\)1I\UM:33W2V$^B
MSWE]OEFNX(Y+35;9/,MUC*!XI6EN47%I/KS?^2R<'_Y,G]S>Q4H.+?E_E"7K
MM./WVWT/T.^U:O\`\^.G?^!S_P#QJC[5J_\`SXZ=_P"!S_\`QJOS7\,?M2ZE
M\<_^"?'[6.D^(/BRGQ<U_0_ACJ5W?:IX>U[P[K_@RT::PO\`]WIUWIEE:7,;
MX0%[?44,B`)Y<DZAYG]"_;;_`&E-#_:&^$'A_4/@E\3M`UFXB\/^*[:/Q+X'
MNM,UF_TN]M]#-R(+>Z\NX-M,V(@XB*R%'7D'8PBN_94I5-[*_P`OZT]2J=/G
MG3IW^.3CZ-<GWWY_P/N;[5J__/CIW_@<_P#\:H^U:O\`\^.G?^!S_P#QJOBS
M1_B$T_QL_91U:#]I[Q/JW@SQ5H6J6@O?[4\/MIGCW4DELFAMI)([)8I[B0-<
M1A;<I+MMF\O:_GN_S?KG[6WQ5^$OAGP?X9\._%;X6_!;P[!H=WJFDW_C;QII
M_A:T\2ZC)K>JI/"7O=$U(7D<"PVF^&UFLYHQ=9:1O.B:*ZD>2I[/KS2C\X_Y
MK7OY&%"7M::J+;E4ODVE^;]-[,_6/[5J_P#SXZ=_X'/_`/&J/M6K_P#/CIW_
M`('/_P#&JGT*6ZGT2S>]^R_;7@1KC[*Q:#S"HW;"0"4SG!(SC%6Z4E9V'&7-
M%274S?M6K_\`/CIW_@<__P`:H^U:O_SXZ=_X'/\`_&JTJ*11F_:M7_Y\=._\
M#G_^-4?:M7_Y\=._\#G_`/C5:5%`'/:/<ZH-1U7;9V!)NEW@WCC:?(BZ?NN>
M,>G4^F3?^U:O_P`^.G?^!S__`!JC1/\`D)ZQ_P!?B_\`I/#6E0!F_:M7_P"?
M'3O_``.?_P"-5B^-O`J_$:#38M;T32]0ATG48-5MHI-1F$:W,#;X9&41A7V/
MAU#@@.B.!N12/@K_`(*5>#X7_;>TG^S9/@OXH^)OB:3PO'X.M]4\32V_CSP4
MMMJ;O<W&DZ?%:3R2VLL?FO<2K-:)Y4,RS,\:<5?V1/&'PK\'_M5>#M7M-4\)
M:7\7TU+Q98?%Z]:YC@U51-J:P64.KR,0W[R\-C'9),?F0A;4&+<**7ON+MUE
M:VNL;6ML]'O_`"Z--A4O&\?3[I7_`#L[+JKWM:Q^C/VK5_\`GQT[_P`#G_\`
MC5'VK5_^?'3O_`Y__C5?D3_P4UG\,-K7Q3ETE[8_M.6'Q'1]]@6_X2ZV\#?V
M7%]O,)C_`-(72O[+:\_U7[K[0QV_Z85KJS_PS;9_%4>1_P`*HB_8QNO&D/G[
M?LB_#N;6QX=E^]_RXE-Z0YS^X^UJN?\`2A40GS4?:^2=O50>O9>]RW_G3C;J
M.HG"I[/7[6OHY+3_`,!YGV@XRUO8_4O[5J__`#XZ=_X'/_\`&J/M6K_\^.G?
M^!S_`/QJO(_^"<%O<VG[#OPWBG2_CMX]*"::EZL@G33A(XL0PD_>#_1/(_UG
MSXQN^;->W5M4CRR<>W?1_-=&1%WBF<]X;N=4&G2;+.P8?:KC):\<<^>^?^61
M[Y^OMTJ^;C5F&#8Z:0>H^VO_`/&J/"W_`"#)?^ORZ_\`2B2N*_;`&C2_LL?$
M&+Q#XGG\$Z'<Z!>6]]X@A5BVB121,C71V\A8PV]CD`*I)90"PQJ2M!NW0TIQ
MYI*+ZF]X#N[>+PM;6GABR\++HFDE]+MX-+O@+6R^S.8'MT6.+:GE/&T908V%
M"N`1BM?[5J__`#XZ=_X'/_\`&J_'GXG:W\#/%_[-7B#PK;6G['OAU_"UU?R>
M&=3\)Z&L>D?%&Y-I:M))X6>*81Z?X@5A;6Y>%=6G@D,(7S>8Z^ROV[?B;\)/
M&^I?"2W^+^H>"3\+M-U^:U\;Z9XIO;:?1](U1]%EN+"VUA9"848>9OC6Y`0R
M-`P'F&$U<Y>XZB=]M]+IVUOZW5MT[)VNB5?2ZW4O.W+T?EUOM:[5[,^O/M6K
M_P#/CIW_`('/_P#&J/M6K_\`/CIW_@<__P`:K\B]"M_!?_"&:79^,DL_^%N6
M_A_PBWP(@UI7_M^*T&JW'V8Z0LO[\.%2#[5M_>>2L?VO]T!7[#5;5D]]&UMV
M_7NNG=DIZV\D_O5_N[/JM=#GKBYU3_A*+,FSL-_V6?`^V/@C?#GGROIV[GIC
MF_\`:M7_`.?'3O\`P.?_`.-477_(W67_`%YW'_H<%:5049OVK5_^?'3O_`Y_
M_C5'VK5_^?'3O_`Y_P#XU6B6VC)X`ZFOA2P_;2\/>$/'&M_$K0_B)X2@^#NM
M_&R*P\2>+1J-H^@OIZ^#(H1NOG)A1!JL-I#YB./WJB,M\S*2%I3<.RO_`.31
MBE\W+\+%<KY7+LF_NBY6];1=D?77Q*^&UO\`&#0+?2_$F@Z7JFG6NHV>JI;R
M:E,D9N;2XCN;=V"QC>$FBC?:V5)09!%=!]JU?_GQT[_P.?\`^-5\:_L%_'6^
M_:0_:H'BV\U3^VH+W0?%EMI=X+9;=9M-@\83P6)551<K]EC@VN1EQAB6+%C\
M<_&#PQ\,O%^I^%[JSUWX.Z7\2M&\3>(+SX[P^,]832;37M.BUE#%I?B:\*2M
M#;SW*V2VGVB*56C0)!$]LT@I)VC"^G-S-KM:;@W;KI%.5M4M$I61,E^\J4UJ
MX-1OT?N\UD_-NT;Z/5MQU/V0^U:O_P`^.G?^!S__`!JC[5J__/CIW_@<_P#\
M:KYU_P""2%C>VW[(2W#Z5X=T'P_J7B/6+[PQIGA^\FO-&L=(EO9&MEL)I8+=
MI+(@L\#+!%&89(_+7R]A/TY5RCRVOV3MU5TG9^:V?F3&5[VZ-KUL[77D]UY'
M/>)+G5#IT>^SL%'VJWP5O'//GIC_`)9#OCZ>_2K_`-JU?_GQT[_P.?\`^-4>
M*?\`D&1?]?EK_P"E$=:5249OVK5_^?'3O_`Y_P#XU1]JU?\`Y\=._P#`Y_\`
MXU6E7YR_M*?&K7])_P""@,OQ@M_`WCJ^\%?"#7M*\$S>*[.[TM-!LM/N`\>N
MFXCDO4O659M0LF<Q6LB"31(_F&URI#WJL:??\%HKORYG%-MJR=]79,E[M.53
MM^+WLO.R;2ZVZ*[7Z$?:M7_Y\=._\#G_`/C5'VK5_P#GQT[_`,#G_P#C5?F_
M^UG_`,%5?$OP?^%-YH6E?$?08/B[H?C[QG::SH[)8->Z3H=O:Z_/I,EW$Z^7
M:0[(])DCN+CRTD`5I)&1I2?<O^">/QG_`.%Y?LC_`!'\6^.?C)>^,/!EQJ=_
M%%JU_P"*?#*7OAC28K.(2K=:CX8,=G;SJ3/,9(K@O%&\+;XV!"BU3DME'FOT
M:;2W^?I9,JK'V=54I:MR<=-=G)?^V.WK'OI]7?:M7_Y\=._\#G_^-4?:M7_Y
M\=._\#G_`/C5?EAIWC3X*>,_V!?!M[9^+OV8/%7PX^'WQ-\51W?A/QUXUMM/
M\+:L)[W5FL8FF2"\0SQPRI<P0O;2>8I#KM(1Z^^/^"=.A^(_#7["_P`*['Q;
M!<VNO6_AVU6XMKAYWFM%VYBA=IU68M'$40F55?*G<JG*AI7YO)I?>KZ_I:Z\
MT9MV:3ZW_P#)79V_I>G4]7^U:O\`\^.G?^!S_P#QJJ%O<ZI_PE%X19V&_P"R
MP9'VQ\`;YL<^5]>W8=<\=#6;:_\`(W7O_7G;_P#H<](H/M6K_P#/CIW_`('/
M_P#&J/M6K_\`/CIW_@<__P`:JUJ]];Z9I5S<7=Q#:6MO$\DT\SA(X4`)9V8X
M```))/``K\?_``LOA7X6_LD_$#X=?##Q1^S3KW@>S/@ZW\5?%3P%X+^R:'/9
MR:I]FO[;Q$;7472]*VBF6Y<7L/[B\F\U(48.\J5Y\BW]VW;5VU?V4MVWZ+70
MKEM!S>R^^WDNKV22UU[79^KDG@59OB)'XK?1-+D\00:<VE0WCZC,Q@MGD65X
MXU,>U-[I&7*@%_*CW$B-,;7VK5_^?'3O_`Y__C5?('[(GQS^$WAG]@;Q!9>+
M;OX+>&OAYIX\2-%/X%T[_A'?#GB?0;*4B[U33[".::3[/B8+(T,LRL[;E<B5
M!7S58:+^S-\5/V4KG6-*^*_[(WP_^'UY\33XNTCP=XLM]'\1>$=&']BO81Z?
M+IT&H6L,=W,F[4&B27,4TC#8[!G+E)1O_*HJ2_[>DMUTO>3UU;4DTI"@N;5[
MMR7>_*GL^NR5]DFG>UC]5/M6K_\`/CIW_@<__P`:H^U:O_SXZ=_X'/\`_&J_
M*O\`8^\8>"?B9\4?A]K-UX5\,>#/VF9?B!IDEMH-K:&VUO1?")T2(&*WA=$F
MAT+[&TFU&18%E<!E%WQ7USIW[17Q"G_;SU'X-_;IIFT6ZN/'+W'V&%1>>%Y;
M%8;2R+^7M63^UGG0,/WABL<LV6)-3M&/,[]>FND8R:MO=*3OV<)K=*\:\SC_
M`%O**UVLW%6=]5.#V;M]-_:M7_Y\=._\#G_^-4?:M7_Y\=._\#G_`/C5?DY\
M-O\`@H%\<?%G@G6-3UK]IW]FGP;K%WI,5SK6@^(/BCH]EJ7@J[:]M5EMTM9/
M#<<NDO&'N+<KJ3:H4E:!&$C!I&Z[X3_M?>,+[Q/XM\9^&/C5\3?&VK/\*-0U
M3P3X,\72^&;FU\::I8W.K1RO:IHMFB7\4?E6\@DTZ3>\<D8D8_+&B>FK\W]T
M92_]M_%&K@U+EZW4?FY1CZ_:[>6Y^FOVK5_^?'3O_`Y__C5'VK5_^?'3O_`Y
M_P#XU7YL?"']MWXG-\`O'^L7?[1/PD\8Z);WGAVSNO$_ASQMH_C'4OAW!>Z@
M(+[4+I;70=+M+:".V+2)]K@F$;PR/*S1(T=?0/\`P2HUV#Q1K/[0.HV?Q!F^
M*VF7GQ"MWL?%TD%I'_;L`\-Z(JRAK.**UF`VE!+;QI&_EY`Y-:1IMN5_LJ_X
MP5ONG>^SLTKZVR4E_7]?ANMVDFF_IG7I]1>T@$]K91Q?;+;<T=TSL/W\?0&,
M9_.M^LWQ3_R#(O\`K\M?_2B.M*LRC%FENX_%UW]E@MYLV<&[S9S%CYYL8PC9
M[^E6/M6K_P#/CIW_`('/_P#&J^9O^"MOPXT_XQ?LH:WX2U8.=+\4>(_!.DW>
MPX;RI_%-E$^#V.UCBOG;PG\0=>_:*_:P_9_\5>+-,U.+5O@KXXO?AK+(\$D7
M]I:S'X;UY]8NH$8!9(9?LVG&)QN',J@]:(6DG)]&U\E%-OT3E&/K):[VMTW[
M-S7:3^<5=*_FE)^D7OH?I%]JU?\`Y\=._P#`Y_\`XU1]JU?_`)\=._\``Y__
M`(U7Y0?"O_@HG\8?&/Q$M_#FD_&6UU>S\7G2BLDNL:#XB\0^"S-XBTFPDM+Z
MVLM"L+;3[_[-J$RR6LSWQ26)<,!&3-Z_X^\0ZW\-=6_:GT#7_C3X@^(6L:#'
MHM[I/A3Q?!H%VD-D\&F$ZDEC'81'R_M/FQ[@OV?S%8[/.!>JC%N"J='S6]8V
MO^?](SFU&4H[\MOQT/T`^U:O_P`^.G?^!S__`!JC[5J__/CIW_@<_P#\:KXX
M^#7QL^*$GQ@\%>(]:^(^JZUH7CGXN^+OA[_PBC:1IEOIFG6&GMKS6LZ2QVPO
M&NE_LF)2S7!C9)&S%O'F'R_]MSP7K^L?M%?$'X/>%UO#J.IW=O\`'S2E)E\@
MRZ=I[0Q0*RJ1_P`AJPTZ9DS_`,O#$A@VRI<E&TJFD;7?=6LWIUM#FEOTMI=M
M:3I3C.5-?$ON?O2@M>EZB4=;;W[)_HO]JU?_`)\=._\``Y__`(U1]JU?_GQT
M[_P.?_XU7Q#^R?X\MOBS\:?AS\6]/M;)K;X[^*_$>M6EQ=Z;$]Y'I=KI4=C8
MB*62/S85DAL8YCY14.)SNW`\^3Z?K4GAWX.F^A@TZYEM?AOJ<B1WUA!?0%AX
MQ&"T,R/&V#R-RG!`(Y`-#4HUH49JS:=_)JG*;7JG'E?WG/[6+I2JQU2M\[SC
M"Z\O>YEW7;I^FWVK5_\`GQT[_P`#G_\`C5'VK5_^?'3O_`Y__C5?ES\8_P#@
MHU\4_!7[0WQ`LO#/Q1LY;8)XPLX/"VM:WHNH:[X3ET_2]1NK6[ET>UT2WGM(
M#/9QM;O=ZG<^?;2H6C+R[HO4OB7\3/C5\!?'?C&ZN_C[K&KZ+X"\3^"XQ;ZO
MX;T.&VO;?7=0MK2]BO)(;6)Q;0([26_DO#,A9_.GN5VA!/W83Z3M;YNRN;N%
MJCI+62;7W6_I'WI]JU?_`)\=._\``Y__`(U1]JU?_GQT[_P.?_XU7R/_`,$I
M?VH]3^.VJ^--(U_XL)\7O$&BVUC=7VI^'==\/>(/!EJTS7`\K3KO3+*TN8W.
MP%[?44,B`)Y<DZAYG^RJJ4;6\S-.[:[&;]JU?_GQT[_P.?\`^-4?:M7_`.?'
M3O\`P.?_`.-5I45)1SVCW.J#4=5VV=@2;I=X-XXVGR(NG[KGC'IU/IDW_M6K
M_P#/CIW_`('/_P#&J-$_Y">L?]?B_P#I/#6E0!F_:M7_`.?'3O\`P.?_`.-5
MB^-O`J_$:#38M;T32]0ATG48-5MHI-1F$:W,#;X9&41A7V/AU#@@.B.!N12/
MC;_@I6GP^F_:Y^&UY+JOPPOOB?H>J^'[G3_"]U82)\0-2@.K*5DT2^,[&"U&
M)FNHX;*19H89TEG@4^;%G?`CQ=\)_A]_P5#\0>(/#WBGX/7YU:QUC3/$=SX;
MA_L?5/#EX^J6,<5OXGDEN)VO+R>Z/D6;3&T=")XXH)ED)A*'[QQ[WEYZP2:M
MYM_^`][Z#J)Q3MKI'_R:Z:^[_P`"Z'WI]JU?_GQT[_P.?_XU1]JU?_GQT[_P
M.?\`^-5\'?\`!0']C[X%_'W]H?Q)9ZCX>^$?@'4?#G@W4?%/C?XBZCX>L8KF
MQFU&UN=*TPW=XPB:6+;]NGD1YT/^A6P+`/FO)O!'BCX*OX/\)Z%XXLOV;)/V
M;-"^(5Y:W_B3PIX;M_#_`,,_%MX^@^=;2W%O)/<6CO#<&6`R/<30M<6\.&6=
M4CCE2O!R>C2O_P"3*/JM;VNM=+;CG&SLM=_E[O,OPLW9Z*[MIK^I7VK5_P#G
MQT[_`,#G_P#C5'VK5_\`GQT[_P`#G_\`C5>1_P#!."WN;3]AWX;Q3I?QV\>E
M!--2]603IIPD<6(82?O!_HGD?ZSY\8W?-FO;JUJ1Y9./;OH_FNC,XN\4SGO#
M=SJ@TZ399V##[5<9+7CCGSWS_P`LCWS]?;I5\W&K,,&QTT@]1]M?_P"-4>%O
M^09+_P!?EU_Z425Q7[8`T:7]ECX@Q>(?$\_@G0[G0+RWOO$$*L6T2*2)D:Z.
MWD+&&WL<@!5)+*`6&-25H-VZ&E./-)1?4WO`=W;Q>%K:T\,67A9=$TDOI=O!
MI=\!:V7V9S`]NBQQ;4\IXVC*#&PH5P",5K_:M7_Y\=._\#G_`/C5?CS\3M;^
M!GB_]FKQ!X5MK3]CWPZ_A:ZOY/#.I^$]#6/2/BC<FTM6DD\+/%,(]/\`$"L+
M:W+PKJT\$AA"^;S'7V1_P4FU?X2?&_X)^$K?QY\3OV>O!$G@[Q+!?WVE?%FR
ML_$.DF^.DW`_LZ[LI+ZT)N5AODG4>9O&U'"$,#5U)I0=7=::^3MK]]TUNGH[
M-H4(MM)Z74O/5=-/EKMU5TG;Z^^U:O\`\^.G?^!S_P#QJC[5J_\`SXZ=_P"!
MS_\`QJORL\:>+_!'Q*33=1\9>%O#'@WXT7GA/P+=?!KPZUH;6^TB7[6_F)H$
M$B)+$@G0>>L:*RVZQ"Z`A50/UEK24.6Z[2:^[]>ZZ::LSC*[^2?WJ_W=GU6N
MASUQ<ZI_PE%F39V&_P"RSX'VQ\$;X<\^5].W<],<W_M6K_\`/CIW_@<__P`:
MHNO^1NLO^O.X_P#0X*TJS+,W[5J__/CIW_@<_P#\:H^U:O\`\^.G?^!S_P#Q
MJN8_:8^,:_L^_L_^+_&?V5]0G\/:7-=6EBA^?4;H*1;VR?[<LQCC4=V<5^<'
MPP^.WCG]@7]G?Q_X)U.P\8_"'6X;WP?XH@U+Q;'I.K22KJ6K6&E^([R&*QN[
MR%HFN/-NF4NL@DU-CM7*DJ#4I^SZZ6\VWT]$G*796=K-M/E=HM=7;TV6MN[:
M2[ZZW5G^HWVK5_\`GQT[_P`#G_\`C5'VK5_^?'3O_`Y__C5?"7PS_:-\=?%G
MQ7X?\*>#/CYJ?C3P-K7Q(?P_8?$FRTW0KN\UFR3PU<:A<6\,T-F-.F,-[$(_
MM$5MM`#Q-NDC=J[G]N'XF_"/X8?M_P#[-=WXH\<>$M$\>'7;BWAL]8\3QV\\
M5A-I&KPQR16DLP6,3W;1PF6.-3,Z01LSF.-5OEUBN]OQ5U;OO^;5U:\MVC)]
MDW]S:U[;/\CZT^U:O_SXZ=_X'/\`_&J/M6K_`//CIW_@<_\`\:KY+_94^)WP
MBM?^"IOQX\->$/&_A'5/%.IZ%HMQJFGP^)X]2U22_@O-8%[&ZM,\P-L)+>,Q
M<+;H8(PL:!%'V-2^RI=T-Z3E#L_T3^3U.>\27.J'3H]]G8*/M5O@K>.>?/3'
M_+(=\?3WZ5?^U:O_`,^.G?\`@<__`,:H\4_\@R+_`*_+7_THCK2I`9OVK5_^
M?'3O_`Y__C5'VK5_^?'3O_`Y_P#XU6E7Y7_".#4?"6O^._A39V&I7FD?M7_$
MCQBLL]NDOE:8;'Q)?V^N-+*H(B\[2$@6(DKF6(@')K.I/E3:6MG;U\WLE:]V
M]OF4XI4O:O9-)][-2;:76W+LN]^A^C_Q2^',7QI^'VJ^%O$FBV%_HFLP^1=0
MIJUQ;28R&5HY8D66*16"LDD;*Z,JLK!@",7X$_L^:9^SAHFI6/AC3+MO[9O/
M[0U"\UOQ=J>O:C?3>5'$&EO+\SW#A8XHT56D*JJ@*`*_+CXF?MB_$#]G/]A+
MX(Z9\.OBDGPVU+1O@?H6J66G:QKVAZ?:>(YS:LJ)IME<Z'J%YJL\?E#[1#%=
M6:(CVV'!E>1/N[_@GE^T_P"+?VJ-!\4^(?%<_P#9>G>$;2S\(ZM9>0MO''XC
MLHY#KEPDNU7\I9I(X4.0H^S.0!G-=-6FJ<ZO*_A;5WI=1;3?71.U^SE'Y3-.
M,HTIZO3;75I;;:M-_*+\D_I+[5J__/CIW_@<_P#\:H^U:O\`\^.G?^!S_P#Q
MJOSE_9;\>_LD>._#/Q[\6^#O'/PD\(?"'5M)TRRO]$TSQ7::2MTMI<7`.M:J
MD4Z2PM?3W26K+=X>YB@19PXG\H?5_P#P2S^(?AWXE?\`!.SX,7OAC7-%U_3[
M3P?I>GRSZ7>174,-Q!:11S0,T9(62-U*,AY5E((!%1!<T92[*#_\"YONMR_C
MK9Z"E[LDO-K[E%_J_NNKIW/:_M6K_P#/CIW_`('/_P#&JH6]SJG_``E%X19V
M&_[+!D?;'P!OFQSY7U[=AUSQT-9MK_R-U[_UYV__`*'/4C#[5J__`#XZ=_X'
M/_\`&J/M6K_\^.G?^!S_`/QJK>I2QP:=.\OF^4D;,_E!B^T`YVA/FSZ;>?3F
MORU^"</P0TWPY\>(;#Q?^S;=_#'Q!I7A^:]\6:7H,@^'=G=F^NEAM-=T\7Y2
M?4"7C:ZFGU!&G62U6:&$*IGGFU<5O;\>B\KZVOHVN7=HKE]WF\U_E?SM?6W3
M7:]OTED\"K-\1(_%;Z)I<GB"#3FTJ&\?49F,%L\BRO'&ICVIO=(RY4`OY4>X
MD1IC:^U:O_SXZ=_X'/\`_&J^4_\`@G?#\-_$/[#=A\.]>A\!ZKX7U2Y\1)8Z
M9(89]!\5Z3#J4C2WNFV4P*_V/^_B,,2^=%!#)`@FG79-)\X:U^S#\`[7]CK2
M/'6H7W[+_P`"_"GQ(\?/X]T/2/'_`(.L)/"FJ:>FFW-AIT#:8UU8*T[V4D=Z
M<.62:63Y6'2JC5._\J2:>WQ2VMT;]Z5N\9)VD*$>;5[W:[_"G]ZT4;[*Z>J/
MT[^U:O\`\^.G?^!S_P#QJC[5J_\`SXZ=_P"!S_\`QJORK_8^\8>"?B9\4?A]
MK-UX5\,>#/VF9?B!IDEMH-K:&VUO1?")T2(&*WA=$FAT+[&TFU&18%E<!E%W
MQ7USIW[17Q"G_;SU'X-_;IIFT6ZN/'+W'V&%1>>%Y;%8;2R+^7M63^UGG0,/
MWABL<LV6)+G:,>9WZ]-=(QDU;>Z4G?LX36Z5XUYG'^MY16NUFXJSOJIP>S=O
MIO[5J_\`SXZ=_P"!S_\`QJC[5J__`#XZ=_X'/_\`&J_)SX;?\%`OCCXL\$ZQ
MJ>M?M._LT^#=8N])BN=:T'Q!\4='LM2\%7;7MJLMNEK)X;CETEXP]Q;E=2;5
M"DK0(PD8-(W7?"?]K[QA?>)_%OC/PQ\:OB;XVU9_A1J&J>"?!GBZ7PS<VOC3
M5+&YU:.5[5-%LT2_BC\JWD$FG2;WCDC$C'Y8T3TU?F_NC*7_`+;^*-7!J7+U
MNH_-RC'U^UV\MS]-?M6K_P#/CIW_`('/_P#&J/M6K_\`/CIW_@<__P`:K\V/
MA#^V[\3F^`7C_6+O]HGX2>,=$M[SP[9W7B?PYXVT?QCJ7P[@O=0$%]J%TMKH
M.EVEM!';%I$^UP3"-X9'E9HD:.OH'_@E1KL'BC6?V@=1L_B#-\5M,O/B%;O8
M^+I(+2/^W8!X;T15E#6<45K,!M*"6WC2-_+R!R:TC3;<K_95_P`8*WW3O?9V
M:5];9*2_K^OPW6[233?TSKT^HO:0">ULHXOMEMN:.Z9V'[^/H#&,_G6_6;XI
M_P"09%_U^6O_`*41UI5F48LTMW'XNN_LL%O-FS@W>;.8L?/-C&$;/?TJQ]JU
M?_GQT[_P.?\`^-5\L?\`!92WTN\_8L\51:W>>$=/T:36_!B7]UXJLTO-"MH#
MXGLQ))?P/+$LMJJY,J-+&&0,"ZYW#YR_:WM_!%A^P+X>M_AYK/P9\0^'K?P1
M\1D2]^%FE0:3X6EF_L&]:06UM!<W21$,<.//<E]S'&=H$[PG-_9=N_2+O^-O
M/IY;TJ//4I0O\<N7TV^_?8_33[5J_P#SXZ=_X'/_`/&J/M6K_P#/CIW_`('/
M_P#&J^!?BG^V'XW\._LAB]U;XEW/P\^(DGCK^Q=<:ZU30_#6@?#MA9O-%I]W
MJ5_I6I(+&2!89(;MK:2:[GNX"OV:.;R(.`^'7[:7QR^+WP"\?>-#\6+C2&^#
M_P`,)/&"P:+INE7UMXMO;75O$EL#<W-QIZ%[:>#2+?>;6"S+ER\0MP?+K10;
MO;96_&/-?S5NJO?I=:F%%2J1BTM9)67K+D7;=][66]MC].?M6K_\^.G?^!S_
M`/QJC[5J_P#SXZ=_X'/_`/&J^$/V]_$7PYM/VDM9N?CMI/PEUS1I/!VE3?#?
M3/B_K46D>!+B^^U70U;%S/;74$>HK$UF03`\QBPL>U&G8>._M-_\%#_%_P`(
MO@E\-]:^'?BF'X3Q6GPRT[Q/8^#M?\;:8;#Q`&\YH[/31=Z'>:GK4B)$%G$5
MU8;8I+4JZ-*TB8N:47)]';3_`+>?_MO2^NGJDU*//':R?GKR]/\`MY?U>WZH
M_:M7_P"?'3O_``.?_P"-4?:M7_Y\=._\#G_^-5^:E_\`&[]H32OV>O\`A-7^
M/_B"6[_X42?B[):CPIH*PC4[:$.+*/\`T,LNGS"3]\C%[@LB&*Y@7<C]_P#$
MG]K#Q)JGQX_:(TSX>?M`?VMXC\"_#S4IM,^'$P\/W%_;^(?L*7,4UE:I:+?M
M;VRF($W#SI++>%./((;64.5VEI\=_+D;3OY<T6K[7M=I-,TA!RE&,?M.*7K)
M0?Y3BWUM>UVFC[L^U:O_`,^.G?\`@<__`,:H^U:O_P`^.G?^!S__`!JOG[]D
M_P#;5T?]K#]J;QS9>"?'.A^.?A_H7@SP[=V]UHLL%W8QZI<W6KB["W40(D?R
MH+,/'O81E0-JLS9^DZ)P<':1C&:EMY?C%2^]7L_.YF_:M7_Y\=._\#G_`/C5
M'VK5_P#GQT[_`,#G_P#C5:5%069OVK5_^?'3O_`Y_P#XU1]JU?\`Y\=._P#`
MY_\`XU6E10!SVCW.J#4=5VV=@2;I=X-XXVGR(NG[KGC'IU/IDW_M6K_\^.G?
M^!S_`/QJC1/^0GK'_7XO_I/#6E0!F_:M7_Y\=._\#G_^-5B^-O`J_$:#38M;
MT32]0ATG48-5MHI-1F$:W,#;X9&41A7V/AU#@@.B.!N12/@K_@I5X/A?]M[2
M?[-D^"_BCXF^)I/"\?@ZWU3Q-+;^//!2VVIN]S<:3I\5I/)+:RQ^:]Q*LUHG
ME0S+,SQIQ5_9$\8?"OP?^U5X.U>TU3PEI?Q?34O%EA\7KUKF.#55$VIK!90Z
MO(Q#?O+PV,=DDQ^9"%M08MPHI>^XNW65K:ZQM:VST>_\NC385+QO'T^Z5_SL
M[+JKWM:Q^C/VK5_^?'3O_`Y__C5'VK5_^?'3O_`Y_P#XU7Y$_P#!36?PPVM?
M%.727MC^TY8?$='WV!;_`(2ZV\#?V7%]O,)C_P!(72O[+:\_U7[K[0QV_P"F
M%:ZL_P##-MG\51Y'_"J(OV,;KQI#Y^W[(OP[FUL>'9?O?\N)3>D.<_N/M:KG
M_2A40GS4?:^2=O50>O9>]RW_`)TXVZCJ)PJ>SU^UKZ.2T_\``>9]H.,M;V/U
M+^U:O_SXZ=_X'/\`_&J/M6K_`//CIW_@<_\`\:KR/_@G!;W-I^P[\-XITOX[
M>/2@FFI>K()TTX2.+$,)/W@_T3R/]9\^,;OFS7MU;5(\LG'MWT?S71D1=XIG
M/>&[G5!ITFRSL&'VJXR6O''/GOG_`)9'OGZ^W2KYN-688-CII!ZC[:__`,:H
M\+?\@R7_`*_+K_THDKBOVP!HTO[+'Q!B\0^)Y_!.AW.@7EO?>((58MHD4D3(
MUT=O(6,-O8Y`"J264`L,:DK0;MT-*<>:2B^IO>`[NWB\+6UIX8LO"RZ)I)?2
M[>#2[X"ULOLSF![=%CBVIY3QM&4&-A0K@$8K7^U:O_SXZ=_X'/\`_&J_'GXG
M:W\#/%_[-7B#PK;6G['OAU_"UU?R>&=3\)Z&L>D?%&Y-I:M))X6>*81Z?X@5
MA;6Y>%=6G@D,(7S>8Z^ROV[?B;\)/&^I?"2W^+^H>"3\+M-U^:U\;Z9XIO;:
M?1](U1]%EN+"VUA9"848>9OC6Y`0R-`P'F&$U<Y>XZB=]M]+IVUOZW5MT[)V
MNB5?2ZW4O.W+T?EUOM:[5[,^O/M6K_\`/CIW_@<__P`:H^U:O_SXZ=_X'/\`
M_&J_(O0K?P7_`,(9I=GXR2S_`.%N6_A_PBWP(@UI7_M^*T&JW'V8Z0LO[\.%
M2#[5M_>>2L?VO]T!7[#5;5D]]&UMV_7NNG=DIZV\D_O5_N[/JM=#GKBYU3_A
M*+,FSL-_V6?`^V/@C?#GGROIV[GICF_]JU?_`)\=._\``Y__`(U1=?\`(W67
M_7G<?^AP5I5!1F_:M7_Y\=._\#G_`/C58/Q(^'<7Q<\.1:3XAT33M0T^#4;'
M54B_M2>+;<V5W%>6TFY(U/R3P1/C.UMN&!4D'KRVT9/`'4U\*6'[:7A[PAXX
MUOXE:'\1/"4'P=UOXV16'B3Q:-1M'T%]/7P9%"-U\Y,*(-5AM(?,1Q^]41EO
MF92Z=G4Y;V:7-\^:,5^,M'W6A2B^5S71-_=%RLO.T78^VOM6K_\`/CIW_@<_
M_P`:H^U:O_SXZ=_X'/\`_&J^-?V"_CK??M(?M4#Q;>:I_;4%[H/BRVTN\%LM
MNLVFP>,)X+$JJHN5^RQP;7(RXPQ+%BQ\S^)GQ0_9PM_VIOVF_"M]\4?@I9-K
MNB>'#KG_``F6K#Q'IJ:E%JFJ+/'JEJ;Z*1X('DM87MY9XH8%>WB(2/9&9U]G
M&=M9<VG^&;A;YVOZM+S$TE4J4[_!)1OT=TG?\=.Z5]-C]%OM6K_\^.G?^!S_
M`/QJC[5J_P#SXZ=_X'/_`/&J^?\`_@DY%86'[%VDV.CQ:;_8>G:SK-OI=YI)
M(T75K;^TKAX[O3$(Q#IL@;-M"K2)%#Y:)-.BK,_TE6DXJ+LO\M_+IZ/5=2(N
M][]&U]SM_5M.QSWB2YU0Z='OL[!1]JM\%;QSSYZ8_P"60[X^GOTJ_P#:M7_Y
M\=._\#G_`/C5'BG_`)!D7_7Y:_\`I1'6E4%&;]JU?_GQT[_P.?\`^-4?:M7_
M`.?'3O\`P.?_`.-5I5^<O[2GQJU_2?\`@H#+\8+?P-XZOO!7P@U[2O!,WBNS
MN]+30;+3[@/'KIN(Y+U+UE6;4+)G,5K(@DT2/YAM<J0]ZK&GW_!:*[\N9Q3;
M:LG?5V3)>[3E4[?B][+SLFTNMNBNU^A'VK5_^?'3O_`Y_P#XU7/_``T^&UO\
M'_#LVE>'-!TO3;&YU"\U69!J4TK375W<27-Q,[O&S,SS2R,22?O8&``!^?\`
M^UG_`,%5?$OP?^%-YH6E?$?08/B[H?C[QG::SH[)8->Z3H=O:Z_/I,EW$Z^7
M:0[(])DCN+CRTD`5I)&1I2?7OV)_VA-)^)G[#7Q7\>_%;XMS>//AK'>:CY]Y
MJNL>&K^YT/18;.+SH+R?PPOV,S,?/D*122/Y<L(X8E`7]V4TU91YKMV35UU_
M'M9,JK!PJQHO5N36FNJ<UM_VZ[?XEWT^POM6K_\`/CIW_@<__P`:H^U:O_SX
MZ=_X'/\`_&J_,#PI<?LS^.OV+_%ESI7C[]E7P=\/O&?CW^UM$\.^*+;3]?\`
M!/@]SIJ0Q6EQ9VM];6EO>W$5M+>B.27]U-/)MCDD0N?O7]@:YDN?V)?A1YFF
M:UHYB\*Z?"MIJ]V]W?1*ENB+YTLD4+R.54,6:*-CNR40_**4=)-Z-<FG^*-V
MGV:>GGOHK$7VMJGS?@[?._W=#TK[5J__`#XZ=_X'/_\`&JH6]SJG_"47A%G8
M;_LL&1]L?`&^;'/E?7MV'7/'0UFVO_(W7O\`UYV__H<]2,/M6K_\^.G?^!S_
M`/QJC[5J_P#SXZ=_X'/_`/&JMZE+'!IT[R^;Y21LS^4&+[0#G:$^;/IMY].:
M_+7X)P_!#3?#GQXAL/%_[-MW\,?$&E>'YKWQ9I>@R#X=V=V;ZZ6&TUW3Q?E)
M]0)>-KJ:?4$:=9+59H80JF>>;5Q6]OQZ+ROK:^C:Y=VBN7W>;S7^5_.U];=-
M=KV_263P*LWQ$C\5OHFER>((-.;2H;Q]1F8P6SR+*\<:F/:F]TC+E0"_E1[B
M1&F-K[5J_P#SXZ=_X'/_`/&J^4_^"=\/PW\0_L-V'P[UZ'P'JOA?5+GQ$ECI
MDAAGT'Q7I,.I2-+>Z;93`K_8_P"_B,,2^=%!#)`@FG79-)\X:U^S#\`[7]CK
M2/'6H7W[+_P+\*?$CQ\_CW0](\?^#K"3PIJFGIIMS8:=`VF-=6"M.]E)'>G#
MEDFED^5ATJHU3O\`RI)I[?%+:W1OWI6[QDG:0H1YM7O=KO\`"G]ZT4;[*Z>J
M/T[^U:O_`,^.G?\`@<__`,:H^U:O_P`^.G?^!S__`!JORK_8^\8>"?B9\4?A
M]K-UX5\,>#/VF9?B!IDEMH-K:&VUO1?")T2(&*WA=$FAT+[&TFU&18%E<!E%
MWQ7USIW[17Q"G_;SU'X-_;IIFT6ZN/'+W'V&%1>>%Y;%8;2R+^7M63^UGG0,
M/WABL<LV6)+G:,>9WZ]-=(QDU;>Z4G?LX36Z5XUYG'^MY16NUFXJSOJIP>S=
MOIO[5J__`#XZ=_X'/_\`&J/M6K_\^.G?^!S_`/QJOR<^&W_!0+XX^+/!.L:G
MK7[3O[-/@W6+O28KG6M!\0?%'1[+4O!5VU[:K+;I:R>&XY=)>,/<6Y74FU0I
M*T",)&#2-UWPG_:^\87WB?Q;XS\,?&KXF^-M6?X4:AJG@GP9XNE\,W-KXTU2
MQN=6CE>U31;-$OXH_*MY!)ITF]XY(Q(Q^6-$]-7YO[HRE_[;^*-7!J7+UNH_
M-RC'U^UV\MS]-?M6K_\`/CIW_@<__P`:H^U:O_SXZ=_X'/\`_&J_-CX0_MN_
M$YO@%X_UB[_:)^$GC'1+>\\.V=UXG\.>-M'\8ZE\.X+W4!!?:A=+:Z#I=I;0
M1VQ:1/M<$PC>&1Y6:)&CKZ!_X)4:[!XHUG]H'4;/X@S?%;3+SXA6[V/BZ2"T
MC_MV`>&]$590UG%%:S`;2@EMXTC?R\@<FM(TVW*_V5?\8*WW3O?9V:5];9*2
M_K^OPW6[233?TSKT^HO:0">ULHXOMEMN:.Z9V'[^/H#&,_G6_6;XI_Y!D7_7
MY:_^E$=:59E&+-+=Q^+KO[+!;S9LX-WFSF+'SS8QA&SW]*L?:M7_`.?'3O\`
MP.?_`.-5X=_P4.N;N']G_P`0Q66J:WHTFH:AX9T^6[T?4[C3+U(+C78()ECN
M;=TFB+12.NZ-U8!C@BO&_%OQ-UG]BKX@_%GP;X!\:>)?$5CI^C>'+W2++Q0;
M[QY=:+KVIZA+91:<LUWJ-O/(+U$A9([G4(X[=F\TR1POMI*5Y<MMW9>;M>WS
M6W=^ZM6KUR^[S??Y*Z5_O>O97?0^U?M6K_\`/CIW_@<__P`:H^U:O_SXZ=_X
M'/\`_&J_-GX<_P#!4S]HWQC>?'^UU+1OAIX8N?V9-`A\0>);?5/#LC7_`(AW
M1WERUG%#9:Y=VU@Y@M@@E^V7FUQN:/YS%%ZW^U%^VM\0_A!\:_$/AOX<^%SX
MB\3^*M<T'1])663^T5M#-I&H7\KBRO-6T^T9MEB4$<5U:$^8TC&9D$;U).,8
MR6JE:UNJE:S^?_!VM=6?,X2TMS7O_=2<ON33^=M[I?9?VK5_^?'3O_`Y_P#X
MU1]JU?\`Y\=._P#`Y_\`XU7S%^R=\7?BQX]_:3T6U^*NAWO@S7/^$%OIKS0U
MG@2TN'CU=(H+[[-;WU]##))!M.P74[1[F7S&%?/WPS_:/\9^&[_XD?#'5/&G
MBJ[U[X^^/_$MA\/[Z75));W1([;Q#>Z;JD5F[L3"EAI\,%Y$B<*6?:!BHE*U
M-5%KS*5EW<92C;RORMZ[;/46RG*6B@XI^7-#GOYVVTWW6A^CWVK5_P#GQT[_
M`,#G_P#C5'VK5_\`GQT[_P`#G_\`C5?G)\*?VY/VC)?@K\&_"?PK\%WGQ)US
M3O@_X9\6Z_J.J1V.J7FNSWT4\:I+/>Z]IDEN6:R<M=".^+-,Q:-3$!-[3\#/
MVROBYXP^)/@[4?%5OX`L?!7CGXB>(_AY:Z%8Z7='6=,ETS^UVCNYK\W;02;A
MI+QO"EL!F0.LV/W8Z9T7&I*FOLMKML[7^;5M/G9:CG"4%>73>VOV>?\`"*;_
M``6NA]9?:M7_`.?'3O\`P.?_`.-4?:M7_P"?'3O_``.?_P"-5\B_L9?M(?$K
MX_\`BB'0=%U3P7X<\/>"K&&^UV#5[+4]=UG7DN=0U*)?LMQ-J*M:QJEEM$TP
MN]TAD4)&L(#>*?#G_@H1\<OV</V._@[<Z[_PC/Q(U7XE_#K3+_PT(;.8:I97
MC7NA:;YNHW=[J4<6HO*=9CGP6L!OB:)I@)//7"E>;Y4M;I)=V^:WW\CM^-BH
MTV]%Y?BK_@M7^%S])?M6K_\`/CIW_@<__P`:H^U:O_SXZ=_X'/\`_&J^0O@?
M\;?CMXK^.?PJT_XN^&KWP/=SZUK4"1P)::=!XCM%TE98Y);&TU?58XS%,74!
M[MRVQ7"IG:/&]>_X*+_&#X(?`^PU;PJ%\>6/@O1;GQ%XTAU+P\EW/:6S:OJ,
M4!DU:ZUZQ\L31VLD:+;V5_)%]G+-&P>*)G]N,._7HM+Z_KYF47=2?;_-+\6]
M#](?M6K_`//CIW_@<_\`\:H^U:O_`,^.G?\`@<__`,:J_;R^?`CXQO4-CTS3
MZ0TTU='/:/<ZH-1U7;9V!)NEW@WCC:?(BZ?NN>,>G4^F3?\`M6K_`//CIW_@
M<_\`\:HT3_D)ZQ_U^+_Z3PUI4#,W[5J__/CIW_@<_P#\:K%\;>!5^(T&FQ:W
MHFEZA#I.HP:K;12:C,(UN8&WPR,HC"OL?#J'!`=$<#<BD?'?_!1*[^*'PW^/
MJ^+M/L/BA>:<UYX6T[P9?^'O&MMIGA[2[J751%?6^JZ9+?0&^:Z66.,?Z+>D
M(1Y8A=2QL?LF>)M4G^/?PP\4OXX\8ZUKWQ0NO&=KXHT6^\275[I=O'87I2+[
M/IKR&"Q-G)'#:[H(XS^_99C)*X>BG[UI/N_OC9K_`#\MU=:A/2Z7E]SO?\FK
M==;V/M;[5J__`#XZ=_X'/_\`&J/M6K_\^.G?^!S_`/QJOS"_X*/?&KQ=\+?!
M7Q(^*6@?$GQOHGCK1/BO#X"@L+?Q)<+I6F:'-IT(N#_91<VGFPVDT^IBZDA:
M5#"LID^SQ^77H?\`PCC6?[7'_"AH_B-\47^%UUXIADDF;XA:L^LBZ/AR6\_L
MM=9-S_:"QDQ1WOD+<!_F//D,8RHOFHJLMFD_OC"?_I,XZ[<UX]$V5%R5/9O^
M]_Y*Y1_]*B_+ELV];'WU]JU?_GQT[_P.?_XU1]JU?_GQT[_P.?\`^-5Y7_P3
MV\9:EX^_8Q\`:GJNKW?B&YDT]H(]6NI1-/J\$4LD4%W)*.)7FA2.0R#B0N6'
M#5[-5R24FD)7MJ<]X;N=4&G2;+.P8?:KC):\<<^>^?\`ED>^?K[=*OFXU9A@
MV.FD'J/MK_\`QJCPM_R#)?\`K\NO_2B2N;_:2AU*\^`/C"VT7Q-8^#-;O=)N
M+73=<O)1%!IEW*AC@E9S]W$C)S@G)&`3@5G-VBW8J"NTF[&SX?TFX\)Z%9Z7
MI6B:%INF:=`EM:6EI<&&"UB10J1QHL(5550`%`````JW]JU?_GQT[_P.?_XU
M7YD^.]"N/"O[/'Q%\+>$;#Q_\-_&'P6DU'Q#XQM6^/NM7;Z:UQ;1WK:[IDLD
MC-K*$!I5LM3DT^W:660SQQM,9#];_M5WH^+WBWX%>$[GQ#XL\.>$_B#J-W-J
M#Z-K=UX=U'46ATJ>ZM[7[7:217$665I6CAD1F^S$$F,2*U2E>+J1UV_'_AI?
M=9M/F49VMS:73_\`);?HU]]]K.7O_P!JU?\`Y\=._P#`Y_\`XU1]JU?_`)\=
M._\``Y__`(U7YA^"/BQXF^(/P8U/QEJ?Q/\`'C^(OA3HOA-_!_V;Q5<VEMX@
M2XU6X@CNKVVAD2'53J(AC@+SI(LG/D".1F8_J=5-)7]6ON_K;H&M[/R_*_\`
M7?L<]<7.J?\`"469-G8;_LL^!]L?!&^'//E?3MW/3'-_[5J__/CIW_@<_P#\
M:HNO^1NLO^O.X_\`0X*TJD9F_:M7_P"?'3O_``.?_P"-4?:M7_Y\=._\#G_^
M-5Y9_P`%`OCC>?L]?LA>-/$&DF^_X2*:T72-"%C83ZA<_P!I7LB6EH8[:W1Y
MIBLTR.8XD9R$;`)KP+]C7]LW5K3PKX"\!PWOBCQ`^F_%&]^'^IZGXYT;4]-U
M^;23HVH:OIMS+%?)!="<QI90--<1GSF29@"75PZ?ORE%;JWYI/YJ\=-VI76B
M837+%2_Q/Y1BY7^:C+T:L]T?:'VK5_\`GQT[_P`#G_\`C5'VK5_^?'3O_`Y_
M_C5?!'Q2_P""F7QB\3Z3IUI\+=/\+:AKVI:EXOM;%X/`FL^+K/4CIGB%])T^
M"1K"[B73EFB1I'OKJ46^Z)\!`#M^@OV\[#7M+\&_#?7+7QAXET>YTKQSX:M+
MNTT6Z_L^RUC[5K-A;R_:`N9GC\IIT$!F\IA.WF+*RQLA33G[-K:<E%/UERO[
MGTWZ[.X5/<J5*3WA>_R5_G?NKKOJK'NOVK5_^?'3O_`Y_P#XU1]JU?\`Y\=.
M_P#`Y_\`XU7RA\'TUWX?_P#!2$"^UW6[KPY\1-%UVYT=8/B#>>*-/UIK6\LF
M:>6QN%B@T9[99?)CCT^.6*43.)I5DCC$OV#2CK3C/NMNVK7Z7[ZZI/0'I)Q[
M?CI_2Z^ISWB2YU0Z='OL[!1]JM\%;QSSYZ8_Y9#OCZ>_2K_VK5_^?'3O_`Y_
M_C5'BG_D&1?]?EK_`.E$=:5`&;]JU?\`Y\=._P#`Y_\`XU1]JU?_`)\=._\`
M`Y__`(U6E7QQJUWK7P>_;CN/&7B+5_%GB[POXK\2C0?#]UX<\<W$EAH$O]G!
M#H^H^'W=;3'G12RK>6ZS77F2*)1#$A9I=2,7:6B_X*27JVUY=+\SC&0T^5R7
M3_)MO[E_45*2^EOBE\.8OC3\/M5\+>)-%L+_`$368?(NH4U:XMI,9#*T<L2+
M+%(K!622-E=&565@P!&+\"?V?-,_9PT34K'PQIEVW]LWG]H:A>:WXNU/7M1O
MIO*CB#2WE^9[APL<4:*K2%550%`%?'WPI_X*1?M'^(OV<_&?Q@U_X4Z9I_P_
M7X;ZKXYT"\FMM.M[:QGAM/M5I:R3V^OWMQ?QR+N5I39:>P\O<8T+^6GMOPR^
M.OB[Q;XL\>^"OB5XQ\"+I'_"#6?C"'Q/X,6;1AX=L;U[R,QS37%S<*2B6YDC
MO081(%D80Q^7DW*+@VGI*VM]-N9V;_[=D^VG=J]2BTDY:J^G7K&+:^<XKY]D
MVOHW[5J__/CIW_@<_P#\:H^U:O\`\^.G?^!S_P#QJOB;PW\&O%OC;]F[Q)9>
M%=<\9ZOH'B;Q?)JOP^TCQ/\`%WQ#X9UBYTB.PBB=GUE%NM5>)[E+B\A@+#,4
ML7F,B?NU^E/V%?'A^)O[&?PNUU]7UGQ#+J/AFP>75=6BBBOM2D$"J]Q,L4DD
M6^1@6)CD=#NRKL"&+2NF^W+Z^]&[7K%Z/SZWNE':VM[_`(.WX[K\+JS/1?M6
MK_\`/CIW_@<__P`:JA;W.J?\)1>$6=AO^RP9'VQ\`;YL<^5]>W8=<\=#6;:_
M\C=>_P#7G;_^ASU(P^U:O_SXZ=_X'/\`_&J/M6K_`//CIW_@<_\`\:JYJ$Z6
MMA/)+.+6*.-F>9F"B%0,EB6X&.O/''-?`WPM\*>+-)\5_%SX<ZAXAUW^U/$.
MAZ%K?A_3I?C;J][8:G'+>7L8GCU]X/[0TR:],6Q[6RM%AC6!3;2,9)?*F]Y<
MJW_-]ON3>EV[:)ZV=K1YWLORNE^;6]EW:T3^TY/`JS?$2/Q6^B:7)X@@TYM*
MAO'U&9C!;/(LKQQJ8]J;W2,N5`+^5'N)$:8VOM6K_P#/CIW_`('/_P#&J^?O
MV$M+E^*_[%E[X3\5:SXQN[O2]9USPUJUR?%-XVHV;V^I7$;6]OK$,ZWDZ6X`
M@CO&DCN9%A#RK%*7C3PGPA^S/XQ^+O[.TGB7X:^(O&FM^%-=^($VNZ;I?B3X
MZ>+=(-YX;MK"ZL(&BUJ%[V^2.YN-FHB,8C9)(U;&P54VH77V4KI]+-I]+[W<
ME:]]7Y@HMMWWNT_6*:ZV_EY=;6T6]D?>_P!JU?\`Y\=._P#`Y_\`XU1]JU?_
M`)\=._\``Y__`(U7YP_LG_'L_'6'P'\7]'\7?$6PU+4?B=IW@NQ\+7_C:]U"
MP317T:-C:36;3O!>2^2\E_\`;G5[F3:LWG&'"5],V7[9WB6;]KF[^$+:=HK:
M]I.LW>IW@CAEWR>%%TV.>"\C7S.)FOKB.SW'Y&:"X(0<`.5HPYWHK7^7+"?2
M]WRS3:5]IVNHW<ZJ7(]_^#./E]J#2]8[7LOH7[5J_P#SXZ=_X'/_`/&J/M6K
M_P#/CIW_`('/_P#&J^!/@W^W9^V)\<_A<GC+P_\``^PO=!\7Z+!K'A^4VFC1
MKI:S3VQ55/\`PE#-JQ%M+.W[U-(W-;C/EF3RED\(?M\?%W1M<^*7C._\;>"/
M'O@[X9?#6Y\2WOAJU^&VH>#K^74[:XU6&2W9K[49YK-U>R19&E25&0*T:H#Y
MCDDXOEDK-7NNJY4V]/E:^UVE?>VGLV_AUU2\O>:BM=MWZV3=M#[W^U:O_P`^
M.G?^!S__`!JC[5J__/CIW_@<_P#\:KXM\*_MF?M+>&/A=K5U\0/`&A>'+[6=
M2T#1?"/B#5-+L=/TQ;O5-02R8W%G8^(=5DGBA$L4H87-L9BWE`1Y\VO4/^"?
M/C3QOXG\>_M!:?X\\5:+XLU?PS\08=*2XT5+BWTNWC'A_1Y#';VLT]PUJ-\K
ML\/G.!*\IW$L:N$'+F\D_O3@FO5<\?OTN9*2:O\`UK>S^=GZ6:=GH>ZZ]/J+
MVD`GM;*.+[9;;FCNF=A^_CZ`QC/YUOUF^*?^09%_U^6O_I1'6E691Q/Q-^'&
MC_%ZWUKPUXD\,>&_&'AS5K"VCU#2M=MTN;*[42RLJR0R1R)(-P!PPX*@_3"\
M+_LJ^`O`_P`(-2^'NB_"7X6Z1X!U@R&_\-66EV]OH]\9`!)YMHEL(7W!5#;E
M.=HSTKEOV\O%6J>#?AG%>:1J5_I5W)XN\#6;3V=P\$C03^*+.&:(LI!V2122
M1NO1D=E(()%>5?\`!1G]N_XF_LO>/-4E^'VFZ?XGT'P)X=M_$?C#3YO"\,AL
M+>6>X6)GU.XUVP$0G6WF15M[&_DB,+,T;>9%$SC%27^*7*_E&,M?+WB^5\O/
M_+JO6Z6GF[GO?@7]DSX>_"[PWK6C>&?A#\*O#NC^)+%=+U>QTS2;:TMM4M%5
MT6WGCCM0LL06610C@J!(XQ\QSJ?$'X!^%_BUX?UG2?%7PX^'OB;2_$0MUU:S
MU:SAO;?4Q;G,`GCDMV67RB,IO!V'IBOEG]HS_@J%XR^#?[,]GXLLM-\%R>)K
MOQSXU\-QZ;>K.B2VFBV_B":V<*)=^]O[,LO-?E=L[E47>FV#]LS]NCXX_LK2
M2OI:^$_';>!O#</B;QU!IW@86EI96\US<B#%]>^)+=H1+';R1CR+74)%>W>1
MHL2Q0&G%R:4NK7IM>_H2TZ;LMTG;Y2]GI\TDMKJQ]7_"[X$>&?@?I=C9>"OA
MW\/_``A9:9;26=G;Z):1:?%:023&>2*-8K=0B-,3(RC`+DL1GFKVG_"_3-)U
M"SN[7P7X-MKK3KF\O+2:)$22UGO':2[EC8095YW9FE88,C,2Q))KXA_X*>-\
M1M6^/OC#5/"6IZS8:7\/_A9:^*IKFW^*.L>%UT%TO-1DDO(M.M4-CJTQCM@/
M)U!X83Y2*SA'8KVFM?MT_'SQ_P#M3:UI'PP^%C>(/AWX.U?2M*U:2>RTP7%S
M'=65E?3W#W<^O6LUFT<%Z"(ETN[#^1Q)F4K#ESJ<.:7]Z_DE)J[\G*__``=;
M*2Y6TMK)KS?+%Z>:4E_5K^^?$C]B[X7_`!C\/^'=)\7?!7X/^*M+\(6_V30;
M/6-#M+ZWT2'"+Y5K'+:LL"8CC&V,*,(O'`KK['X8Z;I<>GK;>#/!UNNDZE<:
MS8B)%06=]<>=Y]U%B#Y)Y/M-QOD7#-Y\N2=[9^)6_;X^+U[^R1<^*?&O_"O[
ME/B-\"?$'Q+T*Q\.66J:3-H4MC:63FWGO5OS--YHU&-A);BTDA,3!78[9!U?
MQ>_;Y^)WPO\`VHK#3-"TRP\1_"NS\4Z%X,UFXD\-1VSZ5?Z@EH/(.IW&O+<7
M$J"[AGS!H\T;+((C*&666/::E"T9=6_OYG!W_P"WU:^S;6NJO=:,H1YY[>]\
MU%)NWRD]--$_,^C-4_91\`:YXL\.:]>_"3X67FN^#V9]`U&?2K:2[T-FD,K&
MUE-L7@)D9G/EE<LQ/4YK3O\`X#^&=5\+VNB77PZ^']SHMCHTWAVVT^6TB>UM
M],F6)9K%(S;[5MI%AA#0@;&$48*G:,?%VI_M[_M+Z/\`""3QC/-\##:CX2?\
M+>:TC\.ZJ9(8((]\VDASJ`#O,'5DO,((-A4VUQO#IW&D?M-_%KQG\?KKX>_#
MNZ\">'Y]4U;Q9?SZKXIL]5\0I:Q::=$$<<=N-0@(\QM3<%$EBBC"ADCX*/FU
MR7@UI:<O_`'RS^Y\R?5V=DTTV24H33OJVHW_`.W.=?\`DKB^WO=TTOHKX2_L
MM^!/@%8V]KX$^%'PO\%6UI=2W\$.@Z9;Z:D-Q+$L,LRK#;*%D>)$1F'+*JJ2
M0`*I^-/V.OAK\2+G1IO$7P:^$>O3>'%F329-1T:UNFTM9F+S"`O:DQ!V)9@F
M-Q))R36]^RK\9I/VC/V9/A[X_FLTTZ;QKX<L-<DM48LMLUQ;I*R`GD@%R!]*
M[ZM:T)0JN,_BB[?=IH91^&UK7Z?YF:MQJR*`+'30!P`+U^/_`"%1]JU?_GQT
M[_P.?_XU6E1611SVCW.J#4=5VV=@2;I=X-XXVGR(NG[KGC'IU/IDW_M6K_\`
M/CIW_@<__P`:HT3_`)">L?\`7XO_`*3PUI4`>>:Q\`/"WB+XQ:9\1-0^&_P\
MOOB!HEN;33O$UQ9PRZQ80D2*8H;MK<S1H1+*-JL!B1^/F.>4\7?L._#[Q9XI
MO-;7X<>!M'UK6M8L=;UW4=*M;>TO?$DUE<)=6RWUPMKYLZ)<Q0S8+Y+0KDE2
MRM9_;M\+>,_&/P$-EX*MO$VH7!UC3I=7L/#6MIHFMZEI:7,;7=O97CS0+!.\
M0(#?:(#MWA98V(:OGKX<_'#QEH__``2>^*OB(7WC#PW/X>U/Q#IVB7_B#6[?
M6=;T/38=0D@#SWR3W44TMHHF43//<8%NK22.0U*FVVY1T<-5TV<7IZN2VW:E
M=*RYG)?"I:J5EWZ2M]RB_2\;7N^7Z?U?]FGP7X@^)UWXVO\`X7?#2]\9ZAI[
MZ3=:_<:?!)J=S9NGEO;/<M;&5H60E3&6VE>,8K(/[%/PM;X-CX='X)_!T_#X
M7?\`:`\,?V%:?V,+G.?/^R?9?)\S/._;GWKY5_X1QK/]KC_A0T?Q&^*+_"ZZ
M\4PR23-\0M6?61='PY+>?V6NLFY_M!8R8H[WR%N`_P`QY\AC&?-O^">OQ@\5
M_$SP3X&^)&M_$SQYK?C*V^,`^'-K97'BBZ?3=9\/QVCQP--IHD%K<33V.W5#
M>>49G9A,L@M\1ATXQG4]DNO+T[RBE]TYI]K7DM59S*4E3]MV3?W1D_\`TB#5
M]KVCM=K].])L[S0-*MK&QTC1K*RLHD@M[>"Y:.*"-0%5$40@*H````P`*L?:
MM7_Y\=._\#G_`/C5:5%-MMW8))*R.>\-W.J#3I-EG8,/M5QDM>..?/?/_+(]
M\_7VZ4WQAX9_X6%X5U'0M>\/>'=;T36+:2SO]/OY?M%K>P2*5>*6-X2KHRD@
MJP(()!K1\+?\@R7_`*_+K_THDKF_VDH=2O/@#XPMM%\36/@S6[W2;BUTW7+R
M410:9=RH8X)6<_=Q(R<X)R1@$X%9U+<CNK^7]7+I_$M;>9YYX6_X)W_!CP;X
M'\(^'+'X$_!T:-X!F-UX=M[C1[>Y_L>X/EE[F%Y;9G6=S#$SS9\QVC5F8D`U
MU?Q"_9A\#_%S1-9TSQ7\*OACXGTWQ'?Q:IJUIJVFV][!JEW%&L45S.DELRRR
MI&B(KN"RJB@$``5^<_Q2_:/_`.&=/A?XO^#^D^$OC_\`"[4_`]]/XF\7ZCH^
MH^*?B':7FI2B*XMH;/7(?/F@M[EY?M<PNEM&81NKV_\`I3L?O7]LG5_"'B3]
MGRPU'Q'K7Q%TC3]0EBETK2_#.KZCX9U_Q%>RPN;;3X_L[V]Z)F+;O(WQD&,F
M8!$D`JM/]W[5>\OSV]=6UHMVTGII::?Q\C]UV_#7\+.[>RYGN=/K7[-G@SQ)
MXT\,>)-0^%_PUO\`Q%X)A6W\.ZK<Z?!+>Z!$O"I:3-;%[=1V$94"NX^U:O\`
M\^.G?^!S_P#QJOAKQYX#^*/[-FK?"3X@_%'4K_QMHWASP_X2\,:]/IWQ8USP
M]/%KKW[VUQ>#1[=%L-7\Z2[M=XN949UMW"QOE8V^]ZVG%*Z3O:4E^6OSO>]M
M>[)ZKTC^6WRV_1'/7%SJG_"469-G8;_LL^!]L?!&^'//E?3MW/3'-_[5J_\`
MSXZ=_P"!S_\`QJBZ_P"1NLO^O.X_]#@K2K(HY_6]!D\2R6+:CH/A_4&TRZ6]
MLS<S>:;2X4,JS1[H3LD`9@&&"`QYYKF?B1^SOX1^,FEZU9>+_AI\.?%5EXD%
ML-7M]8L8;Z+51;,6MO/66V82^4S,8]^=A)*XS7D/_!3[3_''B2'X)Z'\/?&&
MK>"_$>L?$$_9[FTNY((+V2VT'6;Z&UO%1AYUG)<6L`EB;(9`>X!'D/P*_;\\
M6?&SQ)XPB\"ZMIFFZOX]^+$'A*PE\80W&IZ?X'FMO"%C?7]@UG'<6[/.MU;7
MD/D1SPKYTDLNYMI60A'GYHI;:V[ZPC?UN]>UE?>)<HN+3;WC>_E>2M^#?GK;
M9GHG[5__``1]^&_[6,GAE+O1=,\)6'A:QN=.L]/T32]#FM(X9Y1+)Y,=_I-U
M]BE+@GS[(V\Q+`F0E(RGM7QG_92\!?M(V.D6WQ'^%'PR^(<.@*ZZ:/%.GP:R
M;'>$#^6;FV<J7$:;B.6V+G.!7SAJG_!2SQYX$\*1)K.G^"M4U?5Y]>\&>'K_
M`$ZWN(=.U[Q98:I'86L:(T[LD%T)7D,`D=X38W2F>3:&&[^WX9_%_P`3+C0-
M<\?^+?`^E>&_A7KOC&UN/#?B>Z\-^9J5M);H;R22&5&FBM5<-Y,S/;C[1F:.
M3*;8E4C&G%[Q?-+[HRJ-VWNXIR2=F^:.W,VB%*4JKBM))J/SO&%M.EW9M7TB
M]TD>]_"[]FGP7\#_`!5K>N^"_A=\-/"&M^)6#:QJ.B:?!I]UJI#%@;B6*V5Y
M3N9C\Y/+$]Z[G[5J_P#SXZ=_X'/_`/&J^0OV,OA]_P`)+^U7;>(=/\0?$O'A
MGP9:7/C"QU/Q_KVK:9<>(-7CBNA;"PO;R6"V-K;KYFQ(E"KJ4`7&S%?9]=%6
M$H/DGNKK[FUIY/=;73N<]*:FN>.SL_O2>OGK9ZNS5NASWB2YU0Z='OL[!1]J
MM\%;QSSYZ8_Y9#OCZ>_2K_VK5_\`GQT[_P`#G_\`C5'BG_D&1?\`7Y:_^E$=
M:59&IF_:M7_Y\=._\#G_`/C5<-#^S5X+MOC=)\3(_A=\-$^(\T?DR>*UT^`:
MW(GE"':;S[-YY7R@$QOQM`7IQ7I=?!?[3&AL=9_:H^)$_P`2OB1X/U[X3R6=
MQX7N++QEJD>CZ?+'H=E=10OHXG_L^[6>Y<H\4EN[2^>54ARA$2J*#YWLDV[;
MVT3LNN^W4N%-U/<6[MOM>ZM?MWN>[^,O^">_PO\`$^A_$6+3OA7\.O"&N?%/
M1=1T'Q#XD\.Z;::?KE[!?J1<LUTMH7=V8B0F3>"ZJS!L5TO@[]DCX??#[X?>
M(?">B?"3X6Z5X9\7EV\0:5::5;066O-(FR1KN%+4)<,Z\,9%;<.#7QJ__!4G
M]I9?#7BKXB1_!:S;X:>&[K6=,O/M4>G6D.C2:>]Q:M=W&H_VZ]T8UNH`TL/]
MC1M%'))B1_)$DOW-\//"OC^[^$E[IOC;QMH%YXHOTFCAU[P=X=;1H[!'0"-X
MK>]N=05I8R2P:1GC8[<Q8!#:R@U'E>R5K?IZ=?Y7WNFE'.W**;ZM^CT3?KHD
M^OR:;X.#_@G;\$;7P!<>$X_V>?@1'X6O+Z/5)]&7PO8#3Y[N-&C2X:#['Y;2
MJCNH<KN"NP!P37L-A#?Z580VMKI>D6UM;1K%##%=LD<2*,*JJ(<`````=,5\
M#^(/A\OCW]A?2;:Y\;?%R7XB:GXVU_P!X.OK3XG>(=,N6GD\07\$=Q/]EOH1
M>?8[2"2X(GWGRK-U7`.*_0/P]HX\.^'['3UGNKI;&WCMQ-=3--/,$4+ND=B6
M=SC)8DDDDDT+5-^=O6R_-)K[Q/227KZK6WW-J6JZID/VK5_^?'3O_`Y__C54
M+>YU3_A*+PBSL-_V6#(^V/@#?-CGROKV[#KGCH:S;7_D;KW_`*\[?_T.>I&!
MN-688-CII!ZC[:__`,:KRW1/V)?A7X:^&&N>"=.^"/P<L/!GB>=+K6=`MM"L
MXM+U:9"K))<6RVHBF=2B$,ZD@HOH*]DHHLAIM;>IY1H'[+WAWPKXS\/ZMI?A
M/P[IEMX2\/7'AC0M'LG2VTK1[*XDBDN$@MX[957S/L]NI'*A85"JNY]SOB3^
MR=\/OC+X#T3PMXO^$7PJ\5^&/#*HNCZ1K&DVU]8:2$C\M!;P2VK1Q!8_D&Q1
MA>!Q7JM?&,__``4L\4Z+X=^*$L_AW0]2UCX$^%O$6K^-=/MVDMM][:W,JZ3%
M"[2.((KNUMIKIC)YA2.2(^N5*5_<WT<K>EY-_>W_`-O2MNT.$&VFNZBO65DE
M\[?<KO8^AM._9R\'Z1\5XO'EI\,OAQ:^.8+%=,B\10V$":M':*H1;=;H6WFB
M(*`H0-M``&,5T$?@J&'QU+XH7POX77Q-/8II<NKA@+Z2T21I$MVG\C>8ED=W
M"$[0SL0,DU\9Z+^U'^VC/X1GEO\`X26-G;O=6<P\1GPMIUP;"Q>.Y:X==%LO
M%MU-?",QVQW17L4Q$[".UG9`K8GA?]O[XS:)\*?B[X^B\5>!_BSI-KJOAG0_
M!UEI/@6;PX\=SJ\6E(L[I?:LI\M'OG9K2ZFAD,HV-=6X.(ZUYK=?QO)VMW3E
M*36MDW=WMJ1!*2M'9V]+*VO:R5GY*VE]#Z6UO_@G5\#_`!-K6N:EJ7[/'P&U
M#4?$[M+K-U<^%K"6;5G:59V:X=K,M*3*JR$N3EU#=1FNI\+?LN^!?`UUX;GT
M3X4_##1Y_!MG<:=H$ECIEO;MH=K.29X+4I;`P12%CO2/:K9.0<U\_P#A;]J;
M]I*?PUX5\*>+/"GA7X=?$/QUXQDT+1=<\1:+`^G26,6ESZC+.VE:?KUZQFS;
M2P)'_::[O]<=H7RF],_X)B^/?$7Q)_9=NM4\5:[:^)-<_P"$V\6VD]_9W,MQ
M9R+!XAU&%%MC(SNMNB1JD2%FV1JB`D+FFH6C;HOU7Z)V?S03V526[=O_`$I_
MG"_W,W?!7[#GPG^&WA/Q+H/AWX&_!C0-#\9PK;>(-.TW0+.UM-=B7=MCNXH[
M0).HWO@2!@-[>IKL?A=\)='^!_AL:-X+\#^"O"&D`J18Z)$FGVP*HL:_NXK=
M5X1$4<<*BCH!7;44KO\`KRV^X?6_]?UH8&O3ZB]I`)[6RCB^V6VYH[IG8?OX
M^@,8S^=;]9OBG_D&1?\`7Y:_^E$=:5(#AOBI\+]#^-%IK/ACQ1X4\,>-/#6J
M65J+_2=?MH[NQN@DTLB;X9(I$DPZJPW#@JI'(XXF7]@?X.W&D^'K!_@)\$7L
M?"23Q:%;-X<L3%HJ3N9)EMD^R8A$CLS.(P-S,2<DU!^WQ\<;S]GK]G#XA>(-
M)-]_PD4VDVFD:$+&PGU"Y_M*]GDM+0QVUNCS3%9ID<QQ(SD(V`37A'P%_;)\
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M;B31]0O;F>'3+_6K2V4,+!E6".^MVQ(7>2X>,))WWBOXE^)/$?\`P3_N=8^/
M/A/Q9X4\7)>&SBT+POXFD\-:IK]X;OR=.BMYM*U29K9[MV@7R!?RJID(>1E!
M-*]E>/V'I^'P^>NB6NOK8Y=5S?:7EMK\797B[MZ*VO2_J7Q5_9-^'WQV\8:5
MXA\;_"+X5>,M?T)433-3US2;;4;S3E1_,40RS6K/&`YW`*1AN>M.\?\`[*7@
M#XL?$_2?&WBGX2?"SQ+XST'R3IFOZKI5M>:IIWDR&6+R;F2V:6/9(2Z[6&UB
M2,'FOC3XI_M#?&?_`()N_#"Q\/:#?3?$YOAYX:C\6_$%-6L)]<DTX7EY=2+$
M-<U7Q%:SBW(BFMX`EIJ$\:6H>1',D<;3_M<?MN?&GX:VOB&V\6VMSX;NX_%6
MCW/A'PGX?\,3Q:KXJTV'Q5I,!:UU]-5DLK@W%M,8WLI[>RN"+D[HQ"I>2THJ
M48[+FMZ.Z3>E][MJVZ3>R%"+G+DZRY5\G:U[VM:ZT=K72/K'XY?LAZ+\;?@?
M<^`DTG3/!^ES:%-X6@N?#RVD%WIVCSB);K3[9I;*5(+>>.&.-UC0$*B%"CHC
MKJZ]^ROX#\5?%"S\<:K\*/AAJGC;3XH8+7Q#>:;;W&K6Z0L'B5+I[8S`(P#*
M`WRD9'-:/[*_Q(U3XP_`#PUXJUC4O"^JWWB"V-^TOAZ*=-/@21V9+=?//FL\
M*D1.\B1,\D;L88"?)3T&G-.,N66Z?X]?U^]]V+G]I%.]UT_!W^=D^^BOLK<-
M/\&]#NM#.F2^`_`TFFMHS>'3:-!&8#IC`*UCL^S[?LQ``,.-A`^[5C2_AEIN
MA^(_[8LO!O@^SU;_`$C_`$Z!%CN?](,)N/W@@#?O3;V^_GY_(BW9V+CL:*C_
M`(/X[_?U'_7X6_+3T.?\+Z!)X'\-V&C:+H'A_2-(TJW2TLK&RF^SVUG"BA4B
MCC2$*B*H`"J````!5[[5J_\`SXZ=_P"!S_\`QJM*BFVV[L#-^U:O_P`^.G?^
M!S__`!JC[5J__/CIW_@<_P#\:K2HI`<]H]SJ@U'5=MG8$FZ7>#>.-I\B+I^Z
MYXQZ=3Z9-_[5J_\`SXZ=_P"!S_\`QJC1/^0GK'_7XO\`Z3PUI4`<9\4_A=I?
MQR\$7?AGQMX+\&^,/#>H%#=:3KD::A8W)1PZ;X9H&1MKJK#(X*@CD5S<7[+O
MAV'Q9HNHIX3\.QV7AKPQ<>$-'T2-DCTC3--N&A^T0Q6RVP4+(EM;1E3E`D"J
MJJ"^[K?C;X4G\;_"G6],M]=UWPV]Q;$M?Z-,D%[&BD,Z1R,C^7YBJT9=`LBJ
MY:-XY`DB^=?LE:8_QO\`^"=_PQ@\3:KXCNY?$G@326U+4H-<O++5)WDLH6DE
M^W02I<I*Q))E20/DD[LFDM8U&OLV^?,IK\DUZ-CNTXZ[W^5G%Z?-_@73^Q3\
M+6^#8^'1^"?P=/P^%W_:`\,?V%:?V,+G.?/^R?9?)\S/._;GWK8TC]FSP9X>
M^*-OXXL/A?\`#6Q\:6E@FE0>(+?3X(]4ALT01K;+<K;"580@"B,-M``&,5\@
M>$/V9_&/Q=_9VD\2_#7Q%XTUOPIKOQ`FUW3=+\2?'3Q;I!O/#=M875A`T6M0
MO>WR1W-QLU$1C$;))&K8V"N8_9/^/9^.L/@/XOZ/XN^(MAJ6H_$[3O!=CX6O
M_&U[J%@FBOHT;&TFLVG>"\E\EY+_`.W.KW,FU9O.,.$JZ7OU/9K?W7_X%RP5
M_-.:B][14KNZ47-6+IP<WJES?^2\TG;U4')=&W'H^9?H]]JU?_GQT[_P.?\`
M^-4?:M7_`.?'3O\`P.?_`.-5I45(SGO#=SJ@TZ399V##[5<9+7CCGSWS_P`L
MCWS]?;I3?&'AG_A87A74="U[P]X=UO1-8MI+._T^_E^T6M[!(I5XI8WA*NC*
M2"K`@@D&M'PM_P`@R7_K\NO_`$HDKF_VDH=2O/@#XPMM%\36/@S6[W2;BUTW
M7+R410:9=RH8X)6<_=Q(R<X)R1@$X%14MR.ZOY?U<JG\2UMYF)\(/V7O!GP"
M^"\'PZ\&_#CP-X>\#01^5_8EJ@%I-D`,TJ&`^:[;06>3<[GEB3S5?XG_`+(?
MPY^-UK>0^-/@[\)O%T.HZBNKW<>M:/:WZW5ZL`MUNI!+:L&F$"K$)#E@BA<[
M1BOA#QWH5QX5_9X^(OA;PC8>/_AOXP^"TFH^(?&-JWQ]UJ[?36N+:.];7=,E
MDD9M90@-*MEJ<FGV[2RR&>.-IC(?L+]M;X9>,_VC/@OX'N/`DDCI::M#K>JV
M,_Q!UGX?/JE@VGW2")]1TF*6YC*S36\ICV[&\G#$8%75FG%U6[VM?T_'JG_X
M#K9IJ,P334=K\WX=.F_,OO[.+ET/AS]B'X4^#_&>@>(])^!_P:TOQ#X3MTM-
M#U2ST&S@O=&A0.%BMIEM`\*`2.`J$`;VXY->I_:M7_Y\=._\#G_^-5^<6I_'
MEOCAX!U+XEZ)XO\`B)X5E\!^%_`VJ>"=!7QM>M#(;Z[976]19RFL_:Y8_LGF
MW7G^:(_W)25V=OTOK2:<;Q?23_X?M=]?S>C(CO\`)?EMZ+I^2.>N+G5/^$HL
MR;.PW_99\#[8^"-\.>?*^G;N>F.;_P!JU?\`Y\=._P#`Y_\`XU1=?\C=9?\`
M7G<?^AP5I5F6<]K'A]_$5]IEUJ&@>'[ZYT6Y-[ITUQ-YKV$YBDA,L3-"3&YB
MFECW+@[)77.&(/*>,?V9_!7Q#\+>(=#U_P"%OPSUS1/%NH+JVNZ?J&G07-KK
M5XHC5;FYB>V*S3`0P@22`L!$G/RC'-?\%&+F[A_91U.*RU36]&DU#6]!T^6[
MT?4[C3+U(+C6;*"98[FW=)HBT4CKNC=6`8X(KY:^-/[0?C[]A;]I2^^$?P9F
M\5_$X>+#HZV5GXEU5_%ESX.U&>WU:XEC6?5=5LI+D7%MIB.MK/J<9B+/*A*L
ML#RFG+E:W=EZZ2U[+33NTEO8OE?*YIZ1U?DMM.^[T[-GVW:_!;0+'PWX8T:'
MP#X$BTCP3-#<^';%+>-;;0)88VBBDM(Q;[;=DC=T4QA2JNP&`34'Q:^`7A?X
M^-HY\=?#CX>^-#X>NOMVE'7K.'4?[,N./WT'G6[>5)\H^9,'@<\5X+\.OVC?
MVAOB1XF\!^!-7TGP/\)O'M_I6JZ_K<GB31?[5&HV=I?6]K$+.RL-99('D2X2
M60G4+D6^8T(E\S<O=?M*6>KZ)^V#\`=4M?%GBJVT_5M?O=&NM!@OO(TFXC&B
M:K<-)+$BJT\C216^/.>1(_LZ&-8V:1I-;-VG?23;3\T[7]>:-M;.Z]#+927\
MJV\K7M]SOVL]&SU_0O#/_"+7FIW&F>'?#NG3ZW=_;]1EM9?)>_N/+2+SIBL(
M,DGEQQIN;)VQJ,X45H_:M7_Y\=._\#G_`/C5?%/[)GB;5)_CW\,/%+^./&.M
M:]\4+KQG:^*-%OO$EU>Z7;QV%Z4B^SZ:\A@L39R1PVNZ".,_OV68R2N'K[HJ
M%\,7Y?=;2R\M/T*^U)>;_K[_`.KG/>)+G5#IT>^SL%'VJWP5O'//GIC_`)9#
MOCZ>_2K_`-JU?_GQT[_P.?\`^-4>*?\`D&1?]?EK_P"E$=:5`&;]JU?_`)\=
M._\``Y__`(U7G/B']D?X=^+?C+;?$75?@_\`"C4_B#92136_B>[TBVFUFW>(
M`1,EVUJ9E9``%(?*@#&*]8KYX_:S^.<_P1^,MEJ;>(SH>E:/\,O%NO77FVD^
MI6D4MK/H_DW4MC#)&]SY?F2X171R'D573>32O::MOJUW]V+EI]UBH0<WR=]/
MO:1U>K_L=_#7Q!\6;KQ[?_!KX27OCJ^B>"Y\1W&C6LFK7$;P&V='NC:F5E:`
MF(@M@QDJ?EXK1\"?LU>"_A=\*]1\"^&?A=\-/#O@C6%G6_\`#VEZ?!::5>B=
M/+F$MM';")Q(GRON4[AP<BOC[X?_`/!0C]HWQ#\3K+X6:UX>\%^%?B#JOB/2
M]/CU'7_#<<$%E8WNDZW>^8^G:?X@U'?(C:/E=U_"9!,5,<0597]\\-?&2T^-
M7[$6MZQ\5_$S^$(=$UK5?#_B+5_#%]=^'Q=R:9K$^GLUJ\<SW=L+I[90L<4[
M3_OQ&DC.02ZD>2#VM9+RMO;T5]=-[VNTQ)MRC)WULU\^:UO-J,K>2UM='<?"
MG]D7X=?`B.V3P/\`![X3^#5L[UM3MUT+2+73A!=M"UNUPGDVJ[93"[1%Q\Q1
MBN<$BO1OM6K_`//CIW_@<_\`\:KXP^$W@?X@?##Q3^S1<^)/''Q**ZWXKURS
MB\.ZOK4LQM])FL=<OK&#4F8F>\O8H!8QNUU+-L>S4IAS+)+]PUI--/4A63LO
MO6SU>J\M.R,W[5J__/CIW_@<_P#\:JA;W.J?\)1>$6=AO^RP9'VQ\`;YL<^5
M]>W8=<\=#6;:_P#(W7O_`%YV_P#Z'/690?:M7_Y\=._\#G_^-4?:M7_Y\=._
M\#G_`/C5:5%`&;]JU?\`Y\=._P#`Y_\`XU6/I/@2VT'7M<U6Q\*>%;+4_$[Q
MR:S>0$1SZLT<0AC:X<0!IBD2JBER<*`HX&*ZJOC&?_@I9XIT7P[\4)9_#NAZ
MEK'P)\+>(M7\:Z?;M);;[VUN95TF*%VD<017=K;373&3S"D<D1]<RVKN-KNS
M?R6K^6R]6ENT7"$G:W5I?-NR_KYGHX_X)A_L^KI4]B/V9_V>/L-U.ES-;_\`
M"'Z;Y4TJ!U21E^Q8+*))`&(R!(V/O&NXD_9@\#RSZA*WPJ^&+2:OH*>%KYSI
MMN6O=(0;4TZ4_9OGM%'`@;,8'1:^6M%_:C_;1G\(SRW_`,)+&SMWNK.8>(SX
M6TZX-A8O'<M<.NBV7BVZFOA&8[8[HKV*8B=A':SL@5L3PO\`M_?&;1/A3\7?
M'T7BKP/\6=)M=5\,Z'X.LM)\"S>''CN=7BTI%G=+[5E/EH]\[-:74T,AE&QK
MJW!Q';O?E>^BMW;M%*WG?E5[+?7EU(C[[4H_?\T[W\M).VJTZZ'U/8?L,_"7
M2OA)>^`+7X&?!>V\":G>KJ5YX;B\/V::1=W2A0MQ):BT\IY0$0!RI;Y%YX%>
MA>#O"*?#K0(M*\/^&O#6A:7`SO'9Z>_V6WC9V+N1&D`4%F9F)QR22>37RKX6
M_:F_:2G\->%?"GBSPIX5^'7Q#\=>,9-"T77/$6BP/ITEC%I<^HRSMI6GZ]>L
M9LVTL"1_VFN[_7':%\IO3/\`@F+X]\1?$G]EVZU3Q5KMKXDUS_A-O%MI/?V=
MS+<6<BP>(=1A1;8R,[K;HD:I$A9MD:H@)"YJ[.S=^WST7Y7MKZ=!.RC&7G;T
MOSO\>5_>>Y?:M7_Y\=._\#G_`/C5'VK5_P#GQT[_`,#G_P#C5:5%9C,#7I]1
M>T@$]K91Q?;+;<T=TSL/W\?0&,9_.M^LWQ3_`,@R+_K\M?\`THCK2H`Y;Q#X
M<@\0^,4:?1](U9M-6UO;4WP!-G<*UPJ319C?;(`S@,,$!C@\FJ^H_#+3=8U>
M[U"[\&>#KJ_U":SN+JYF17FN9+-_,M'=S!EF@<EHB3F-N5P:XS]MCQ->>"_V
M7OC/J^GZA<Z3J&F^`[VYM+VWG:":UF6WO#'(DBD,CA@"""""!BO!_CE^WS\4
M_AA^U9#IGAW2=,\4_#*T\5Z)X,U::7PW%8?V;J.H):@6[:I-K@GED7[7!/FW
MT6:/;((C(&662,7QJ"W;7WW23T\^57[V78<E:'M'T3^Y:M?<V_2Y]-_$3X#>
M&?B_H>M:9XL^'7P_\4:;XD$`U>TU>TBO8-5\@[H/M"2V[++Y9Y3>#M/3%8M[
M^Q]\-]3^"MK\-KGX-_"6X^'5C-]IMO"LFC6KZ+;R[VD\Q+,VODJV]W;(3.YV
M/4FOFGP5^W+\=+[Q?H7PX\4W'@/P1\7O&VIV]M;Z5KG@&]@L_"-N;34;MI&G
MAUJ>VUWSA8F&+[)=6IC8L\RQO_H]8LW_``4=^.6IVGQ;N-/?X1+9?`#PS<Z_
MXAO/[#U"Z3QB]GJ6M6LT=@JWZ"Q65-(/S2/=_9Y2Z$3A=P:A?W5UU\M+7=UH
M^5M+>]_AN7R3>W1I?.>D5;?WNG2VKLFK_3"?\$^O@M'IFB62_L_?`P6?AKS_
M`.R(!X9L?*TKSVW3?9U^R8B\QN7V8W'DYK1\'_L4_"WX>>(]3UC0/@G\'=#U
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MTL\S!(0#))([.[GEF8DDDDUH_:M7_P"?'3O_``.?_P"-5^</P"_X*,?%CXV?
MM*:5ID<FB>#]5\:^&-,TV>^UZWEOO#6B:C9ZUXHM)UCL;6_9!?7XL46-%OC$
M!`P-U<-#!%<[WAG]M[]IBW^`7P)TC2;/0/B7\2_B?X=O_%-WJVF^$+-([>SM
M?L,?D&PN_$.FQR2E[T,\\5VH4(H%IAR\=-6?*M>FG6UW^"3>MM-MU?1Q?.X]
M;)O_`+>2EKYW=NNI^@'VK5_^?'3O_`Y__C5'VK5_^?'3O_`Y_P#XU7@/[._Q
M]^+_`,6?CW!X=\5:'X4\"6_A_P`%Z+KWB;1I;=M0U0ZA?G48GMH;F"[-M%'$
M]DC[L7&X.R9'$E?2%$H\KL0G?\/Q5_R9F_:M7_Y\=._\#G_^-4?:M7_Y\=._
M\#G_`/C5:5%2,S?M6K_\^.G?^!S_`/QJC[5J_P#SXZ=_X'/_`/&JTJ*`.>T>
MYU0:CJNVSL"3=+O!O'&T^1%T_=<\8].I],F_]JU?_GQT[_P.?_XU1HG_`"$]
M8_Z_%_\`2>&M*@#C_B=\--.^-G@>^\,>,_!W@_Q=X:U,(+S2=:5;^QNPCK(G
MF0RP,C[756&0<%0>H%<1\/\`]C'P1\)_%NDZEX6\`^#?#-GH&D7NC:9HNCPP
MZ?I.GQ7LT4UZ\=M#:JOF3M!`'8YR(1@#<Y;B/VQ/"C^,/VA?`%EX/\9^-[/X
MH#4M+OXM,T[Q'>P:+I>AV]\)=1NM0T^&1;>:.Y@6:U1KI)&:9XQ$4V2.M7X/
M?!O3+/\`X*(>)+KPKXE^)<NC>!-%*>(;74_B)KNMZ9=ZSJ;+/%;BRO+R6W@-
MK:1B7;'$H"ZE!MP$Q12M+7:_.ODH[^CNX>4M-1SNE9/;E?WM?CL]->75V1ZG
M\2?V3OA]\9?`>B>%O%_PB^%7BOPQX95%T?2-8TFVOK#20D?EH+>"6U:.(+'\
M@V*,+P.*NZ=^SEX/TCXKQ>/+3X9?#BU\<P6*Z9%XBAL($U:.T50BVZW0MO-$
M04!0@;:``,8K\^/^"CWQJ\7?"WP5\2/BEH'Q)\;Z)XZT3XKP^`H+"W\27"Z5
MIFAS:="+@_V47-IYL-I-/J8NI(6E0PK*9/L\?EUZ'_PCC6?[7'_"AH_B-\47
M^%UUXIADDF;XA:L^LBZ/AR6\_LM=9-S_`&@L9,4=[Y"W`?YCSY#&,J,G*G[?
MO9^=W&$M?^W*BU[\T=K-J<5"?LGT3^Z,I+_TJ#\DK2;3T7WU]JU?_GQT[_P.
M?_XU1]JU?_GQT[_P.?\`^-5Y7_P3V\9:EX^_8Q\`:GJNKW?B&YDT]H(]6NI1
M-/J\$4LD4%W)*.)7FA2.0R#B0N6'#5[-5R24FD)7MJ<]X;N=4&G2;+.P8?:K
MC):\<<^>^?\`ED>^?K[=*;XP\,_\+"\*ZCH6O>'O#NMZ)K%M)9W^GW\OVBUO
M8)%*O%+&\)5T92058$$$@UH^%O\`D&2_]?EU_P"E$E<W^TE#J5Y\`?&%MHOB
M:Q\&:W>Z3<6NFZY>2B*#3+N5#'!*SG[N)&3G!.2,`G`K*I;D=U?R_JY=/XEK
M;S///"W_``3O^#'@WP/X1\.6/P)^#HT;P#,;KP[;W&CV]S_8]P?++W,+RVS.
ML[F&)GFSYCM&K,Q(!K=^*/['GPV^."72^-/@W\)/%ZW]^-5N1K>C6NH"XO!"
MMN+E_-M6W3"%$B\P_-L15S@`5\62^%M$B^#OBKX2>'&^,GPP^.VB:S=6NC:!
M8?%W6]<M;SQ!J$,-TNM)>-=?:+S38@ZW4\=Y'%&HEF:6T\V=#)]9?MW?!7Q[
M\8_A=X2M?"5Q'<W.B:VFHZ[:#XA:SX`35[1;&[B:/^T=*BFN8P+B6";R]NQO
M)PQX%75FN1S;NK_Y-[7VT?\`X#>SNHJFG=)::/\`"_I\5W;SYO)R[7Q!^SEX
M/\6^._#?BC5?AE\.-3\3>#8Q#X?U>[L()K_0D'1;6=K8R0*/2,J*[;[5J_\`
MSXZ=_P"!S_\`QJOSBU/X\M\</`.I?$O1/%_Q$\*R^`_"_@;5/!.@KXVO6AD-
M]=LKK>HLY36?M<L?V3S;KS_-$?[DI*[.WZ7UI*+C>+Z2?_#]KOK^;W,X[_)?
MEMZ+I^2.>N+G5/\`A*+,FSL-_P!EGP/MCX(WPYY\KZ=NYZ8YO_:M7_Y\=._\
M#G_^-477_(W67_7G<?\`H<%:59EG)?$?X>V?QB\%7_AKQ=X1\)>*?#FJH([W
M2M8"WUE>*&#!9(98&1P&53A@>0#VKC]/_8W^&>D?!B\^'%K\&/A%;?#S4;C[
M7=^%XM%M4T6ZFW(WFR68M?)9]T<9W%"<HISP*K_\%`OCC>?L]?LA>-/$&DF^
M_P"$BFM%TC0A8V$^H7/]I7LB6EH8[:W1YIBLTR.8XD9R$;`)KP+]C7]LW5K3
MPKX"\!PWOBCQ`^F_%&]^'^IZGXYT;4]-U^;23HVH:OIMS+%?)!="<QI90--<
M1GSF29@"75P4DIRE&.^GSU6GJFXV6[O=;,<KQBI]N9^EHMW^:C)7756>Z/?+
M_P#8@^%&J^`?#WA2Z^!_P:N?"_A&YDO-"T>70;-[#19Y'+O+:P&T\N%V<EBT
M:@DDDG-:'Q._9,^'OQL^(&E^+/&?PB^%7B[Q5H2Q)INLZUI-M?ZAIZQR&6,0
MSRVK21A)&9UVL,,Q(Y.:^3/BE_P4R^,7B?2=.M/A;I_A;4->U+4O%]K8O!X$
MUGQ=9ZD=,\0OI.GP2-87<2Z<LT2-(]]=2BWW1/@(`=OH7[?'VGQ;\2)_#^O_
M`!!\5^"M-\-?"K7/&%M=>&O$MUX8\W4[:2WC-Z[PS*TL5LKAO(F>2W'V@&9)
M/D(F56T56>S<G?K[D9.3];0:5[-NWV7<I46ZL\.MTU%]M9**7FN:5VU=+7JK
M'T+X-^`7A?X<_$;7_&'A[X<?#W0O%WBH@ZWKFG6<-KJ.L8.1]IN$MQ)-SS\[
M'FNP^U:O_P`^.G?^!S__`!JOST_X)6_M%?$+XL?$CP=XS^*6E7,NM_&&/Q%'
M97=E\3=6N;?33IEV(7M)O"\D$.GV/EI$(S/$T\WF#]XVZ=B/T=K:I2=.U-]-
M+=O+^DOU,*=15%SQZ_C_`%_P]GHN>\27.J'3H]]G8*/M5O@K>.>?/3'_`"R'
M?'T]^E7_`+5J_P#SXZ=_X'/_`/&J/%/_`"#(O^ORU_\`2B.M*LS0S?M6K_\`
M/CIW_@<__P`:KD[3X&^'+#Q[XA\50?#WP##XH\76J6.NZQ':Q+?ZU;H@1(;F
M<6_F31J@"A9&(```&*[ZO@#]J_XUZ]^PY\6OB%\;-=F\5?$3PY%/=Q>&T\/_
M`!!GCTW2IX-(8G1-4T.1A9QH9X)91?P+-=*T@\U8HHV9H;CS6?5/YWLK?]O-
MI:V3VOS.,97&,FO=_KK?Y6O^.B3E'ZG^%W[(_P`._@>ML/!7P?\`A1X0%E<B
M]MQHFD6VG_9YQ'-$)4\JU7:XCN;A-PYVW$HSAV!T_&O[/GA3XD_#J^\'^(OA
MM\.]?\):G>2:C>:)J5E#=:==W,DYN7GDMY+8QO(T[-*7*EC(Q<G<<U\K6G[;
M_P"TI\-/@7XG\2_$;X?^&_#XCU+PU9Z#K6LV5CHVFR_VEK%O87"30V/B#5W*
M0Q7"3"X,T0.['E';EO>/V<OB-X[^*A^+/@/QCXB\/MXF\#ZE'HJ>*_!FE'3H
MLW.G6]TCI9WDU\D-U!]H&4DDG1AY3E`)#&-9)R3;UM^:Y=/*UUO\B(--)QV_
MX%[^CN]M=6FKW*^G_P#!-[X$Z3?:/=6O[.?P"MKGP\ZRZ5-%X4T]'TQUE,P:
M!A9YB(E)<%,?,2W7FO;/M6K_`//CIW_@<_\`\:K\Q/%WQ'^(MSX"\*>%;2_U
MGQ=X=\*6?Q%\4ZPFJ_&'6O!>J:G#I'B$VEOG5K*&>[G$$$S+Y#R10G=&7;$:
M`?IE\-O%$'C?X=:!K5K!>6UMJ^FV][##>$FXB22)759"23O`8!N3R#R:(^]3
MYEM?]91O\W"5O3?H*=HU.1[Z_ARO\I+[RS]JU?\`Y\=._P#`Y_\`XU5"WN=4
M_P"$HO"+.PW_`&6#(^V/@#?-CGROKV[#KGCH:S;7_D;KW_KSM_\`T.>I&'VK
M5_\`GQT[_P`#G_\`C5'VK5_^?'3O_`Y__C5:5%`&;]JU?_GQT[_P.?\`^-5C
MZ3X$MM!U[7-5L?"GA6RU/Q.\<FLWD!$<^K-'$(8VN'$`:8I$JHI<G"@*.!BN
MJKXQG_X*6>*=%\._%"6?P[H>I:Q\"?"WB+5_&NGV[26V^]M;F5=)BA=I'$$5
MW:VTUTQD\PI')$?7,MJ[C:[LW\EJ_ELO5I;M%PA)VMU:7S;LOZ^9Z./^"8?[
M/JZ5/8C]F?\`9X^PW4Z7,UO_`,(?IOE32H'5)&7[%@LHDD`8C($C8^\:[B3]
MF#P/+/J$K?"KX8M)J^@IX6OG.FVY:]TA!M33I3]F^>T4<"!LQ@=%KY:T7]J/
M]M&?PC/+?_"2QL[=[JSF'B,^%M.N#86+QW+7#KHMEXMNIKX1F.V.Z*]BF(G8
M1VL[(%;$\+_M_?&;1/A3\7?'T7BKP/\`%G2;75?#.A^#K+2?`LWAQX[G5XM*
M19W2^U93Y:/?.S6EU-#(91L:ZMP<1V[WY7OHK=V[12MYWY5>RWUY=2(^^U*/
MW_-.]_+23MJM.NA]3V'[#/PETKX27O@"U^!GP7MO`FIWJZE>>&XO#]FFD7=T
MH4+<26HM/*>4!$`<J6^1>>!7H7@[PBGPZT"+2O#_`(:\-:%I<#.\=GI[_9;>
M-G8NY$:0!069F8G')))Y-?*OA;]J;]I*?PUX5\*>+/"GA7X=?$/QUXQDT+1=
M<\1:+`^G26,6ESZC+.VE:?KUZQFS;2P)'_::[O\`7':%\IO3/^"8OCWQ%\2?
MV7;K5/%6NVOB37/^$V\6VD]_9W,MQ9R+!XAU&%%MC(SNMNB1JD2%FV1JB`D+
MFKL[-W[?/1?E>VOIT$[*,9>=O2_._P`>5_>>Y?:M7_Y\=._\#G_^-4?:M7_Y
M\=._\#G_`/C5:5%9C,#7I]1>T@$]K91Q?;+;<T=TSL/W\?0&,9_.M^LWQ3_R
M#(O^ORU_]*(ZTJ`//OBQ\&?#'QMUB.P\5^"_"'C:QTM[/5+2W\0V45W%97<3
MW`BN(EDBD"RKN?#@!EW'!Y-9?C7]D_X??$GXDKXR\1?"/X5Z_P"+T@2V77=2
MTJVNM26)&W)&+B2U,FU6Y"[L`\BJ'[;'B:\\%_LO?&?5]/U"YTG4--\!WMS:
M7MO.T$UK,MO>&.1)%(9'#`$$$$$#%?/W[1?[>GQ?^&_[2LFD>#;#0]?\`V_B
M71_!5[>7OA2.WBTC5M1CM52*74)-?CN+AD-Y!<$6VD2(R.(?.5UDEC6\E%*[
M?YNT?Q;4;]VE?5%--1YV]+/_`,EL_P`+N7R;/==&_8#^#?ASX=ZSX0T_X!_`
M^P\)^(YH;C5M$M_#=C%IVJ2PG="\]NMH(Y6C/*EU)4],5UVE_`3PQH?A:XT.
MR^'/P^L]%N]%B\-SZ?!:11VL^EQ"41V#1"W"M:H)YPL)&Q?.DPHWMGSO]AW]
ML;5?VQDUC4ET[3M-T;P_I6F6&I1(':YL_$C1/+J=BS;RNVUWVT>,;O,,F6XQ
M7Q_J?Q*\2?L;?L6_"3XS^#O&OCWQ+\1_%_A_4KS5?#GBKQ;K'B?3/$JQ:'?:
MA).+.ZNI/LGV>>V@?S+0P#8[1-GS4VVWRSY6]&UJM4[Z1?;EM]J]E%WVV*$)
M5+*GO]W]Y_._3K+[S[Z^,'[,W@K]H:;19/'_`,+/AGXXD\-NTND-X@TZ#4SI
M;MLW-`9K9O*)\N/)3&=B^@J;XF_L\>$OC7HVJ:=XR^&GPZ\6Z?KCV\FI6NM6
M,-_#J#6^?(:9);9A(8\G86!VY.,5\S_MY_MM>)/";>.-%\-K<:B?`\'PU\11
MVOAFX*:UJ,NJ>*I(+FP#&94VSVUI'&D;;`PN)`[,C@#F/$?_``4(_:-\;:YH
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M]JU?_GQT[_P.?_XU6E12;;=V"26B,W[5J_\`SXZ=_P"!S_\`QJC[5J__`#XZ
M=_X'/_\`&JTJ*0S-^U:O_P`^.G?^!S__`!JC[5J__/CIW_@<_P#\:K2HH`Y[
M1[G5!J.J[;.P)-TN\&\<;3Y$73]USQCTZGTR;_VK5_\`GQT[_P`#G_\`C5&B
M?\A/6/\`K\7_`-)X:TJ`/(OB?^QO\-/C;\0K/Q=XS^#/PB\7>*]/2*.UUK6M
M%M;_`%"V6)R\2I/+:M(H1V+*`PVDDC!-7OB'^SIH_P`2=--E=^'=%M+.Z\16
M7BG4X;&=8!K=]9O#);R79%ONEVR6UJV<AC]FB4L4!0^8?MB>%'\8?M"^`++P
M?XS\;V?Q0&I:7?Q:9IWB.]@T72]#M[X2ZC=:AI\,BV\T=S`LUJC722,TSQB(
MILD=:OP>^#>F6?\`P40\277A7Q+\2Y=&\":*4\0VNI_$37=;TR[UG4V6>*W%
ME>7DMO`;6TC$NV.)0%U*#;@)BBCK9K367_DMI)^CDDK_`,ZMJ%16OUT7KK[O
MWI.ZZ\KOHCUW5_V:?!?B#XG7?C:_^%WPTO?&>H:>^DW6OW&GP2:G<V;IY;VS
MW+6QE:%D)4QEMI7C&*R#^Q3\+6^#8^'1^"?P=/P^%W_:`\,?V%:?V,+G.?/^
MR?9?)\S/._;GWKX2_P""CWQJ\7?"WP5\2/BEH'Q)\;Z)XZT3XKP^`H+"W\27
M"Z5IFAS:="+@_P!E%S:>;#:33ZF+J2%I4,*RF3[/'Y=>A_\`".-9_M<?\*&C
M^(WQ1?X777BF&229OB%JSZR+H^');S^RUUDW/]H+&3%'>^0MP'^8\^0QC,0M
M*C[5+1I/[U"I^51/MSW7:3=2\*G(]US/[G*#_&#7;ELV];'WEI-G>:!I5M8V
M.D:-965E$D%O;P7+1Q01J`JHBB$!5````&`!5C[5J_\`SXZ=_P"!S_\`QJO*
M_P#@GMXRU+Q]^QCX`U/5=7N_$-S)I[01ZM=2B:?5X(I9(H+N24<2O-"D<AD'
M$A<L.&KV:MJGQ/J1'2*.>\-W.J#3I-EG8,/M5QDM>..?/?/_`"R/?/U]NE-\
M8>&?^%A>%=1T+7O#WAW6]$UBVDL[_3[^7[1:WL$BE7BEC>$JZ,I(*L"""0:T
M?"W_`"#)?^ORZ_\`2B2N;_:2AU*\^`/C"VT7Q-8^#-;O=)N+73=<O)1%!IEW
M*AC@E9S]W$C)S@G)&`3@5C4MR.ZOY?U<TI_$M;>9Y99?\$Q/@):?#GP]X2D_
M9V^!U_X=\*1R1Z39:CX?M+]+'S-GFNIFM7;S)/+0R.27D*@N6/-=+XZ_8F^%
M?Q1T<Z=XF^"/P<\1:>UU'?&UU/0K.[A-Q';I;)-LDM2/,6WCCA#8R(XU0':H
M%?&DOA;1(O@[XJ^$GAQOC)\,/CMHFLW5KHV@6'Q=UO7+6\\0:A##=+K27C77
MVB\TV(.MU/'>1Q1J)9FEM/-G0R?67[=WP5\>_&/X7>$K7PE<1W-SHFMIJ.NV
M@^(6L^`$U>T6QNXFC_M'2HIKF,"XE@F\O;L;R<,>!5U)KD<[W5U?\'TOMO\`
M<W9W49@KM=[/U_3XMEYJ2V2;[7Q!^SEX/\6^._#?BC5?AE\.-3\3>#8Q#X?U
M>[L()K_0D'1;6=K8R0*/2,J*[;[5J_\`SXZ=_P"!S_\`QJOSBU/X\M\</`.I
M?$O1/%_Q$\*R^`_"_@;5/!.@KXVO6AD-]=LKK>HLY36?M<L?V3S;KS_-$?[D
MI*[.WZ7UI*+C>+Z2?_#]KOK^;W(CO\E^6WHNGY(YZXN=4_X2BS)L[#?]EGP/
MMCX(WPYY\KZ=NYZ8YO\`VK5_^?'3O_`Y_P#XU1=?\C=9?]>=Q_Z'!6E699S^
MMZ#)XEDL6U'0?#^H-IETM[9FYF\TVEPH95FCW0G9(`S`,,$!CSS7,_$C]G?P
MC\9-+UJR\7_#3X<^*K+Q(+8:O;ZQ8PWT6JBV8M;>>LMLPE\IF8Q[\["25QFL
M#_@H%\<;S]GK]D+QIX@TDWW_``D4UHND:$+&PGU"Y_M*]D2TM#';6Z/-,5FF
M1S'$C.0C8!->!?L:_MFZM:>%?`7@.&]\4>('TWXHWOP_U/4_'.C:GINOS:2=
M&U#5]-N98KY(+H3F-+*!IKB,^<R3,`2ZN"G%5'*"Z6?SNE]ZO#3=IW6B8Y7B
ME/RE\E&+E]S2E\]'\2OTG[5__!'WX;_M8R>&4N]%TSPE8>%K&YTZST_1-+T.
M:TCAGE$LGDQW^DW7V*4N"?/LC;S$L"9"4C*>\?$[]GCPI\;[?0HO&WPX\`>-
M5\,3K=Z0?$%M'JC:9.H`$T+3V[E)/E7YU(;@<U\>?%+_`(*9?&+Q/I.G6GPM
MT_PMJ&O:EJ7B^UL7@\":SXNL]2.F>(7TG3X)&L+N)=.6:)&D>^NI1;[HGP$`
M.WT+]OC[3XM^)$_A_7_B#XK\%:;X:^%6N>,+:Z\->);KPQYNIVTEO&;UWAF5
MI8K97#>1,\EN/M`,R2?(1+J<E*,OLMSDO^W5*<GZKEE9.UY-/1/F*]BY5Y4?
MM1M%]M6H)>:=U=J_NK76-CZ$\*_`'PMX$^*.N>.-$^''P]T;QIXF01ZQX@L;
M.&WU35E&TA;BY2W$LH^1.'8_=7T%=C]JU?\`Y\=._P#`Y_\`XU7YZ?\`!*W]
MHKXA?%CXD>#O&?Q2TJYEUOXPQ^(H[*[LOB;JUS;Z:=,NQ"]I-X7D@AT^Q\M(
MA&9XFGF\P?O&W3L1^CM;5*;IVIO=:6[:[?TE^IA3J1J)SCU_'^O^'L]%SWB2
MYU0Z='OL[!1]JM\%;QSSYZ8_Y9#OCZ>_2K_VK5_^?'3O_`Y__C5'BG_D&1?]
M?EK_`.E$=:59FAF_:M7_`.?'3O\`P.?_`.-5PG_#,G@G_A=$_P`2/^%6?#+_
M`(6)=0FWF\4_V=!_;4T9B$)1KS[-YQ7R@(\%\;`%Z<5Z;7P!^U?\:]>_8<^+
M7Q"^-FNS>*OB)X<BGNXO#:>'_B#/'INE3P:0Q.B:IH<C"SC0SP2RB_@6:Z5I
M!YJQ11LS0Y)2L^J?SO967^)M+6R>U^9QC*XPE)>[_76_RM?\=$G*/N^J_P#!
M-OX2?\*XU;PKX>^$GPU\":/XAU/2=4UB+PMI5EI?]LMIM_%?6\5R$L]LT1DB
M*LKJ?DEE`*EMU>A>#?V>?"7PY^$MUX!\/?#3X=:%X$O8IX+GPYIUC#:Z3<1S
M@B='M4MA$RR!FW@KAMQSG-?*]I^V_P#M*?#3X%^)_$OQ&^'_`(;\/B/4O#5G
MH.M:S96.C:;+_:6L6]A<)-#8^(-7<I#%<),+@S1`[L>4=N6]X_9R^(WCOXJ'
MXL^`_&/B+P^WB;P/J4>BIXK\&:4=.BS<Z=;W2.EG>37R0W4'V@9222=&'E.4
M`D,8UL^62Z:W\[**:^5X[Z=B(2YK23TOOZK?YKMKT>S&V/\`P3M^".F>%X=$
MMOV>?@1;Z+;:B-7AL(O"]@EK%>A`@NEC%GM$P0!1(!NP,9Q7LWVK5_\`GQT[
M_P`#G_\`C5?F)XN^(_Q%N?`7A3PK:7^L^+O#OA2S^(OBG6$U7XPZUX+U34X=
M(\0FTM\ZM90SW<X@@F9?(>2*$[HR[8C0#],OAMXH@\;_``ZT#6K6"\MK;5]-
MM[V&&\)-Q$DD2NJR$DG>`P#<GD'DT1]^'.MK_JXW^;@TO*._13*T)\CWU_"S
M_P#;TWYLL_:M7_Y\=._\#G_^-50M[G5/^$HO"+.PW_98,C[8^`-\V.?*^O;L
M.N>.AK-M?^1NO?\`KSM__0YZDH/M6K_\^.G?^!S_`/QJC[5J_P#SXZ=_X'/_
M`/&JTJ*`,W[5J_\`SXZ=_P"!S_\`QJL?2?`EMH.O:YJMCX4\*V6I^)WCDUF\
M@(CGU9HXA#&UPX@#3%(E5%+DX4!1P,5U5?&,_P#P4L\4Z+X=^*$L_AW0]2UC
MX$^%O$6K^-=/MVDMM][:W,JZ3%"[2.((KNUMIKIC)YA2.2(^N9;5W&UW9OY+
M5_+9>K2W:+A"3M;JTOFW9?U\ST<?\$P_V?5TJ>Q'[,_[/'V&ZG2YFM_^$/TW
MRII4#JDC+]BP6422`,1D"1L?>-=Q)^S!X'EGU"5OA5\,6DU?04\+7SG3;<M>
MZ0@VIITI^S?/:*.!`V8P.BU\M:+^U'^VC/X1GEO_`(26-G;O=6<P\1GPMIUP
M;"Q>.Y:X==%LO%MU-?",QVQW17L4Q$[".UG9`K8GA?\`;^^,VB?"GXN^/HO%
M7@?XLZ3:ZKX9T/P=9:3X%F\./'<ZO%I2+.Z7VK*?+1[YV:TNIH9#*-C75N#B
M.W>_*]]%;NW:*5O._*KV6^O+J1'WVI1^_P":=[^6DG;5:==#ZGL/V&?A+I7P
MDO?`%K\#/@O;>!-3O5U*\\-Q>'[--(N[I0H6XDM1:>4\H"(`Y4M\B\\"O0O!
MWA%/AUH$6E>'_#7AK0M+@9WCL]/?[+;QL[%W(C2`*"S,S$XY))/)KY5\+?M3
M?M)3^&O"OA3Q9X4\*_#KXA^.O&,FA:+KGB+18'TZ2QBTN?499VTK3]>O6,V;
M:6!(_P"TUW?ZX[0OE-Z9_P`$Q?'OB+XD_LNW6J>*M=M?$FN?\)MXMM)[^SN9
M;BSD6#Q#J,*+;&1G=;=$C5(D+-LC5$!(7-79V;OV^>B_*]M?3H)V48R\[>E^
M=_CRO[SW+[5J_P#SXZ=_X'/_`/&J/M6K_P#/CIW_`('/_P#&JTJ*S&8&O3ZB
M]I`)[6RCB^V6VYH[IG8?OX^@,8S^=;]9OBG_`)!D7_7Y:_\`I1'6E0!POQ<^
M!?AOXTSVT7BSP9X.\;Z;8SVU_9VWB"RBNX[&\@,OEW,22Q2*LJB5MKC#+EL'
MFLKQ)^S!X&\9?%FV\>ZO\*OACJOCJR2*.W\1WFFV\^K0+$X>)4NFMC*H1P&4
M!OE(R,&O3Z*%H[KU^>U_N!Z[_P!:W_/7U/-O@-\";?\`9U\*ZKI6@6%NZ:YK
MVI^)-0N+F_W37=[?W<EU.[%+=5QOEVJ`HPB(.<9.;\*?V/?AM\"-?U;5?`_P
M;^$G@W5->@:VU.\T+1K73KC48F;>T<SPVJM(I;DAB03S7K=%%E^%OE:UO2VE
MNP:_C?YWO?UOK?>YY/\`#O\`9'^'?P@\.RZ1X3^#_P`*/"^DSW%M=RV6D:1;
M65O)-;SBXMY6CBM54O%,!*C$91QN4AN:J?$G]B?X6?&6WM(O%_P2^#GBN*PN
M[N_MDUC0K2^6WN+N7SKJ9!+:MMDFE^>1AR[?,Q)YKV.BG=W3[?U^B!:*R.=T
M/PZWAFYOYM-\/^'M/EU:X%W?/;2^4UY,(TB$LA6$%W\N*--S9.V-!T4"M#[5
MJ_\`SXZ=_P"!S_\`QJM*BD*UMC-^U:O_`,^.G?\`@<__`,:H^U:O_P`^.G?^
M!S__`!JM*B@9F_:M7_Y\=._\#G_^-4?:M7_Y\=._\#G_`/C5:5%`&;]JU?\`
MY\=._P#`Y_\`XU1]JU?_`)\=._\``Y__`(U6E10!BV,.KV=S>2?9-.;[7,)<
M?;'&S$:)C_5<_<S^-6/M6K_\^.G?^!S_`/QJM*B@#R+XG_L;_#3XV_$*S\7>
M,_@S\(O%WBO3TBCM=:UK1;6_U"V6)R\2I/+:M(H1V+*`PVDDC!-7OB'^SIH_
MQ)TTV5WX=T6TL[KQ%9>*=3AL9U@&MWUF\,EO)=D6^Z7;);6K9R&/V:)2Q0%#
MZ?11'W;./1W^=T_S2?JD#UW_`*T:_)OTN>::O^S3X+\0?$Z[\;7_`,+OAI>^
M,]0T]])NM?N-/@DU.YLW3RWMGN6MC*T+(2IC+;2O&,5D']BGX6M\&Q\.C\$_
M@Z?A\+O^T!X8_L*T_L87.<^?]D^R^3YF>=^W/O7L5%*RVM_5[_GKZZA=[_UM
M;\M/30Q=)L[S0-*MK&QTC1K*RLHD@M[>"Y:.*"-0%5$40@*H````P`*L?:M7
M_P"?'3O_``.?_P"-5I453;;NQ))*R,72H=7TRV:/[)IS[II9<_;'&-\C/C_5
M=MV/PJMXP\,_\+"\*ZCH6O>'O#NMZ)K%M)9W^GW\OVBUO8)%*O%+&\)5T920
M58$$$@UT=%3)*2Y9*Z&FT[H^=K+_`()B?`2T^'/A[PE)^SM\#K_P[X4CDCTF
MRU'P_:7Z6/F;/-=3-:NWF2>6AD<DO(5!<L>:Z7QU^Q-\*_BCHYT[Q-\$?@YX
MBT]KJ.^-KJ>A6=W";B.W2V2;9):D>8MO''"&QD1QJ@.U0*]DHJFV]^O_``X;
M.Z/-_$'[.7@_Q;X[\-^*-5^&7PXU/Q-X-C$/A_5[NP@FO]"0=%M9VMC)`H](
MRHKMOM6K_P#/CIW_`('/_P#&JTJ*+]/G\WO]XK+^O+8Q98=7DU>"Z^R:</)A
MDBV_;'YWE#G/E=MGZU8^U:O_`,^.G?\`@<__`,:K2HI#.?UO09/$LEBVHZ#X
M?U!M,NEO;,W,WFFTN%#*LT>Z$[)`&8!A@@,>>:YGXD?L[^$?C)I>M67B_P"&
MGPY\567B06PU>WUBQAOHM5%LQ:V\]9;9A+Y3,QCWYV$DKC->C4465K?/Y_TD
M&M[_`-?UJ_O/D']J_P#X(^_#?]K&3PREWHNF>$K#PM8W.G6>GZ)I>AS6D<,\
MHED\F._TFZ^Q2EP3Y]D;>8E@3(2D93WCXG?L\>%/C?;Z%%XV^''@#QJOAB=;
MO2#X@MH]4;3)U``FA:>W<I)\J_.I#<#FO1J*:=H\JVO?YWO?[]?7432;YGO:
MWRV_+3TLNB///"OP!\+>!/BCKGCC1/AQ\/=&\:>)D$>L>(+&SAM]4U91M(6X
MN4MQ+*/D3AV/W5]!78_:M7_Y\=._\#G_`/C5:5%+HET0^K?5F+JL.KZG;+']
MDTY-LT4N?MCG.R17Q_JN^W'XU8^U:O\`\^.G?^!S_P#QJM*B@#-^U:O_`,^.
MG?\`@<__`,:KA/\`AF3P3_PNB?XD?\*L^&7_``L2ZA-O-XI_LZ#^VIHS$(2C
M7GV;SBOE`1X+XV`+TXKTVBC3^O/</Z_4^=]5_P"";?PD_P"%<:MX5\/?"3X:
M^!-'\0ZGI.J:Q%X6TJRTO^V6TV_BOK>*Y"6>V:(R1%65U/R2R@%2VZO0O!O[
M//A+X<_"6Z\`^'OAI\.M"\"7L4\%SX<TZQAM=)N(YP1.CVJ6PB99`S;P5PVX
MYSFO1J*.CCT>_P""_1#N[I]G?Y]_4\'L?^"=OP1TSPO#HEM^SS\"+?1;;41J
M\-A%X7L$M8KT($%TL8L]HF"`*)`-V!C.*]F^U:O_`,^.G?\`@<__`,:K2HIW
M?]?=^21-DOZ_KN_O,W[5J_\`SXZ=_P"!S_\`QJJ\4.KQZO/=?9-./G0QQ;?M
MC\;"YSGRN^_]*VJ*0S-^U:O_`,^.G?\`@<__`,:H^U:O_P`^.G?^!S__`!JM
M*B@#-^U:O_SXZ=_X'/\`_&JQ])\"6V@Z]KFJV/A3PK9:GXG>.36;R`B.?5FC
MB$,;7#B`-,4B544N3A0%'`Q754463W#5;'SP/^"8?[/JZ5/8C]F?]GC[#=3I
M<S6__"'Z;Y4TJ!U21E^Q8+*))`&(R!(V/O&NXD_9@\#RSZA*WPJ^&+2:OH*>
M%KYSIMN6O=(0;4TZ4_9OGM%'`@;,8'1:]/HHWT?]:6_+3TT#KS=?^#?\TGZG
MB]A^PS\)=*^$E[X`M?@9\%[;P)J=ZNI7GAN+P_9II%W=*%"W$EJ+3RGE`1`'
M*EOD7G@5Z%X.\(I\.M`BTKP_X:\-:%I<#.\=GI[_`&6WC9V+N1&D`4%F9F)Q
MR22>37344[O[_P!-/R%;\#-^U:O_`,^.G?\`@<__`,:H^U:O_P`^.G?^!S__
H`!JM*BD,Q[^#5-4CBBDMK")!/#*SK=NY`217.!Y8S]WUK8HHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`".`+4#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"N.U3Q'KT=YX@&FVVFM!HZ([?:G=#+F(2'YA
MP.,CGVKL:\_U3X?Q>(-=\17EW')#-.T#6-QYFZ,E(E^]'G#KN&"&'(XH`LW_
M`(QNY[W1;73I=/TU-3L?MB7.JJQ5B<8A50R9?G)^;H.AK=\*ZS<:_H$5_<VO
MV>5GD0JN=K[6*AT)Y*MC(/H:Y6_L-3O-2LM1UWPK_:=JMBUE+IT#12K#-OR9
M461@I1E`&<A@``170^!](O\`0_#$5EJ$A+B61XHC(9/L\3,2D6X]=H('X<4`
M='1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5POCF
M1T\8>!55V56U.0,`>#^Z/6NTNKNVL;:2YN[B*WMXQN>69PBJ/4D\"O*_$6O7
MGBK7-&U;PSH-]JFFZ#<M<RW('E+<Y4J5@W8,A')X^G>@#UJBL#P[XRT;Q.'C
MLIWBO8_]=8W2>5<1'ONC//XC(]ZWZ`"D9E12S$!0,DD\`4M9MYJ5C*;W3H[N
M%[V.V:1X%<%U4@@$CL,T`-L?$N@ZI<"WT_6]-NYRN\1V]TDC%?7`).*AE\8>
M&8)6BF\0Z5'(C;&5[R,$'TZ]:\XT&*XO(?A[!JMI:Z=;0017%K>HY=KB4)@0
M$X7RRP;=C)W8(&<&NM\1PKXF\4V/AI!FSM-FH:HP4,&`;]U`WLY#,0>RCUX`
M.THHHH`****`"BBB@`HHHH`****`//-5\0>)+9O$][%J>EV]KHTI\JWFM&8S
MJ(ED"[_,7#'..`?QK8\1>(=6T_0=,U&QLK4"YFMEG%Q,P:(2.@(50OS'YB,D
MC'7!K,E^'UM=ZCKUS?/9IJ%]>K=:9?+&#/;E(UQUZ@,#E<X()Z9J]KUGXIU;
MPY8V@L=.^V^=%+=$7SI&#'(KC;^[)(;:>#]WC[W6@#KT;>BM@C(SAA@CZTM1
MV[3M;HUS''',1\Z1R%U!]F(!/Y"I*`"N-UGQU+'K$^A^'=)EU74X,?:'+"*V
MM<\@R2'VYP`3Q795YMX<TJSU?QC\1-.U"W>6TN+BV$D;LPWC83U!SCZ4`<Y(
MUSXDUSRYBOC/58&P8H\Q:-I[?[1Y\QN<<Y/!Z5WVB^#+F#5H]:UW6;C4-0CR
M(((B8;2U!&,1Q`_AEB>WI73V=E:Z?;+;65M#;P)PL<2!5'X"IZ`,/Q!X1T?Q
M(JM?6Y2[C'[F]MV\JXA/8I(.1ZXZ>U<_N\8^"X7:60^*M)C!;.!'?QJ/3^&7
M`!]&)-=Y7!>+VF'Q,\$I&S>6\6H"503@KLB]*`(;76/$?Q%L?-T0R>'M!EX%
M]*H:[N%]8EZ(/]HDGTKJ?#_A31_#.GM9Z;:!5DYFED.^28]R['EC6/\`"E`G
MPO\`#X554&U!..Y).:[*@"@=$TMM)BTIK"W:PA"K';E`40+]W`[8[5+::;9V
M,US-;6Z1274@DG=1S(V`,D_0"K5%`!1110`4444`037UI;RK%-=012-C:CR!
M2<Y`P#ZX/Y4EY?V>GQ"6]NX+:,G`>:0(,^F37G'BY[6V^(&HWEWX<778K?P[
M')Y#)&X4":7)(?G&/[H8^QQ6QIUOIGA[X>Z1-JQMM:ELK8);RQH)FE=APD);
MDYX4>H'-`';(ZR(KHP9&&593D$>HI:Y7PAIY\(>$K>VUF\MX)))W?8TH$<)D
M<LL*$]0N<#UQP*ZJ@`HHK.UK7M+\.V#7NK7L5K`,@&1N7.,X4=2?84`<?XV2
M1OB7\/64,46XO-V!Q_JEQS^=>@UY+J]_X@\4ZYH7B;3/#[06.C2S206^HS_9
M[C4"Z`$1IM./EY&3SSTQ7:^'/'.C^(Y'MHS-8ZE&<2Z??)Y4Z'_=/4>XS0!T
MM%%%`!7#>$"#\1/'6"AQ/:#Y/^N;=?>M3Q'XXTKP]<QV!6>_U:7'E:=8IYDS
M9Z$C/RK[G%<#+9>*/#[Z_JVL:;>)9^()(WE;0+IIKS32@.#RH#+CJ5X&#Q@T
M`>QT5YEI7CC6-.L8[FZ:W\4Z*"%;4]'4^?`N.L\'4="21TP>*[W1M=TOQ!9"
M\TJ^ANX#U,;9*GT8=0?8T`:%<)XL_P"2G>"OO_ZG4?N_[D77VKNB0JEF(``R
M2>U>>ZSXEM-:\1VD/AC1AKVKV(D1;_S"MG9>9A7WR#.6^4?*H)P#B@#3^%?_
M`"2[P]_UZ#^9KL*\ST/6-0^&FD:?H/BBP+Z;"OEPZQIZM)"JYX\Y2,QGGKR#
M^!KT6SOK34;5+JRN8;FWD&4EA<.K#V(H`GHHHH`****`"BBB@"FNEVBZU)JP
MC_TV2W6V+Y_Y9JS,!CZL:PKOX?:!=W%K,L=U;&UFDGA6UNGB"/)C?MVGY0=H
MX&!R?4UU-%`&.OAC2CI,NEW4#W]G*Y=H[^5KGG&.#(21C'&.E<XGAGQ#X00M
MX5O_`.T=/7'_`!*-4E)V*.T,W5?0*P(]Q7=T4`>>6/C?7_&$<D'A?0S9-!*;
M:^O-5("VLH'S(L:G,C+D=<#\ZU=`\`6.EWHU35+NXUS6L#_3K_#&/VB7I&,G
MH/SKRZ-W.O66UV"+\1+L,O.">,>W0GKZGWKW^@#*U_PYI?B6Q%KJ=L)0AWQ2
M*=LD+]G1ARK#U%>?^(?"^LV%CLU*S_X2_2H`6BF+>7JEG_M1N!\Y&`>H).,Y
MKU6B@#R31?&6IZ-H<NIV^IKXL\/VBDW+-^ZU&S4=?,4\/@=<[36Z1XN\<V\4
MD4S^%]$F0,"C![Z=3R#D?+#P1T+,#6IXZL+.'P+XJNXK2!+F;2[@2S+&`[@1
MMC<V,G'O6UH/_(O:9_UZ1?\`H`H`K^'_``OI'ABT:#2[-(B_,LQ^:68^KN>6
M/)Z^M;%%%`')Z[X!T_5+T:GIMU<Z)K"X_P!-T\A#)CH)%Z2#V/YXKAM2>Z\'
M>)=/U+Q!H!GU&XF\BUU#P[(85OI#]V*XA8@9;)YR>^*]EK@_B:H:7P6<<CQ1
M9]L_PR4`(?"VO^+Y$G\77_V/3L[ET739&"NO7$\G5_=1@<5VUG96NGVJ6MG;
MQ6\$8PD<2!5`^@J>B@!&574JP!4C!!'!%86F>$-)T76Y]3TJ)[+[1'LFM+<A
M+>1LYWF,#&_MD=JWJ*`/$=$U&2[30UT+6-=N==;4<W$$US.]O]D$NV1F5_DV
M!2N-O/(Q6I=^(UO]5\1ZKK&GZ]<:+I%VUDHL+C9!&(\;Y&42(SL&R3P0H'?F
MNQ3P5`GAG3]*2]FCN]..^TOXE"R1ODG..ZG.&4\,/TJ7?@%YEU6TM]9DM]+U
M>?S[^T$"L69L"3RW)^0.!SP>IQB@#LT=9$5T8,K#((Z$4M-C18HUC0;44!5`
M[`4Z@`HHHH`****`"BBN0U7Q];17YTKP_9R:]JP;:\-JP$4!]99>0@_,^U`'
MF"AVUFQ(.U5^(MT,;NO(.<=^XSV_&O?J\@M]*U7P?*U]XG\/0ZQ9RZK)J_VC
M22[O83R#+$QG!9!CK^F<5Z?H^N:9X@L5O-*O8;J`\%HVSM/HPZ@^QH`T**BN
M;F"SMI+BZFCA@C&YY)&"JH]23TKA+OQ_=ZPD_P#PBEK#]A@W"?7-28Q6<8'=
M.\A'X#WYX`-OXB?\DX\2<X_XEL__`*`:U=!_Y%[3/^O2+_T`5Y/IL6J^*--U
M72]$O=0U=-2C:VO]?U5FCM57E6%K".O4D8P.F3S73V7C"\\(I::1XRT[[)''
M&D46KVF9+.3`"C>2`8SZ@\>]`'H-%,AFBN8$G@D22*10R.AR&!Z$'O3Z`"N$
M^)I`D\%DY_Y&BS''^[)72:_XGT?PQ:?:-5O8X=P/EQ9S),?1$ZL?I7$:I:^+
M/B"FFWUMI]MH=CIU\FH6D>J*S7%Q+'G9O12!&A#'(R6_J`>G45Q6G?$&.&^_
MLSQ7I\GA^_Z))<.#:W'0?NYNA.3T.#7:9!7<",8SF@!:*.M-\Q-VW>N[TSS0
M`ZBBB@`HHHH`****`/-/%&KR1>,M5M+KQ;<:):VVF03VT<;1*9)6:0'`=26^
MZHP*UIFU"\\$:5J^MWVJZ;<16BR7D.EQDR.[!>J[6/'/`'&3Z5IW'A2&]\0:
MM?7KK-:ZA81630%>5"&0E@<_]-.,=,5%;Z=XLT^QAMH-6TZ\\D,@DO('WNO\
M!8JW+#H3WZ\4`9.A:==^-_AQIT6M:M<XF<O+)93A'GARP$<I7N5(W@=QBNPT
MO2-.T2R6STNQM[.W7I'#&%!]SCJ?<\U2\+>'QX<T;[&UP;B>6:2YN)=NU6ED
M8LVU?X5R>!6U0`5R&N?#[3]1O3JFDW,^@ZSWO=.Q&9><XE7I(,]<]:Z^B@#R
M?7;C6[F]TOPYXF\+Z=K>IN[2Z;<)=%+25D7YFFC8<%0<XPV<D"M^Q^'QO[F&
M_P#&-XFL7$0S#9+'LLK;V2,_>QC&6_*F^(F/_"WO!:YX\B^/_D,5W=`"*JHH
M50`H&``.`*22-)HGBE17C<%61AD,#U!'<4ZB@#D(?AQH=K)J:6GVBWT_4862
M738Y,6RN?^6B)_`PP,8QBN0T&[U/Q;K2>#-3OHQ'X:E!OY89LOJ.P@1#CD+W
M?_:P*]2U6.^FTJZBTR6**]>,K#++G;&QXW$#KCKCOCM7*OX".F1:'/X=N([;
M4--D_?32K_Q^Q/\`ZY9,=2Q`;/."!0!KZ7X-T?2M7O-66)[K4KJ5I6NKMO-D
MC!_@0G[J#L!6_110!6O]/L]4LI+._M8KFVE&UXI4#*1]#7E_CO2=#\-#P=IS
M*4T8:J[2P2&2;Y2C$J,Y.T''R_3@UZS6!X@\.OK6K^'[Y+CR_P"RKPW#*<_O
M`49<?7)'Z^M`')^`%L;OQ'KU_P"&DN(?#4D*1"*0,%>[#-O:-6^Z`NT$8'/M
M65X4M=&\.Q^'[3Q+X0NK+5)+D10ZI-%&Z/<%B4!97+`GC&1C@=,5WC^&[JS\
M27&K:->1VD=]$RWML\>Y'EQ\DR@'AQP#G(8>XS69/X7\2:]<Z2OB/4M,:STZ
M[CO=MC;.CSRQD[-Q9B`O.2`.?:@#MZ***`"BBB@`HHHH`****`"BBB@`HHHH
M`XW4]6\(3>,=-N;KQ#9PZGIC30);F=5^>0!2K9YSZ"NKO;VUTZSEO+VXCM[:
M%=TDLK!54>I)KR.[EU4Z7X\M8K*(Z3=:U-!?7;N\DUO&T$2O(L(4!@JD,#O!
M]CBM3QI9:K=Z=<-'I,.J>'[/2V:T?[:/F?RC^^9<'>5'W1]2#DC`!Z9%*D\*
M2Q,'C=0RL.A!Y!I]8WA*XFNO"6E33VX@=K9!L#[Q@#`.<#.0`?QK9H`****`
M"BBB@`HHHH`****`"BBB@`HHI-Z_WAUQU[^E`"T444`%%%%`!1110`4444`0
M0V5K;FX,-O%&;F0RS;5`\QRH4LWJ<*!^%,BTRP@TXZ=#96\5B4,?V:.(+'M/
M4;0,8.35JB@!L4:0Q)%$@2-%"JJC``'0"G444`%%%%`!1110`4444`%%%%`!
M1110!C^*KZ;3?"VHW5NS),L)6-U&2C-\H;Z`G.>V*SOL<$?CJVLPG[E-&D4+
MZ_O4&3[X[]>37275M#>6DUK<()(9D,<B'HRD8(JG_9$'$^V(ZBD)A2_:%3,J
M]OF/)_D3SCM0!4\(7UQJ'AN"2Z;?+$\MN9<Y\X1R,@DSWW!<Y]Z*U;*SAT^Q
2@L[==L,""-!G/`&.?4T4`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"'`/T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`X7QSKFIVGBKPCH-CJZ:3!JUQ,+B[\J-WQ&JE8T\P%07+;0<$YVXSR
M#QF@?$/Q--KNAV+7G]N1?VKJEC*]E#`C:A'#%&\;@LP1<%R?E900!]X]?6?$
M&GVVHZ-<+<:+:ZP\*--!972H5DE"G:,N"%)SC=VR:CTJP\/S6>GW6F:=8I#:
M^8+0QVJQFV+$B157`,;9R&7`.001D&@#%^'>OZGX@MO$4NJ&0/:ZY<VL,4BQ
MAH(EV;8SLX)&2,Y.?4UV55[6QL['SOLEK!;^?*T\WDQA/,D;[SMCJQP,D\FK
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%4[_4H;!,%9)[AD+16L`#2RX95^5<CC<Z`L2%7<"Q`YH`N45R]KK&J:M=
M3FQ3RI((F!MY8LVXE$O*/./O2;04/E;UB<2;S(0@.Q::GO\`)@OX?L5])\OD
MLVY';Y^(Y,`/Q&[8&&"X+*N<4`:%%%1SSPVMO+<7$L<,$2%Y))&"JB@9))/`
M`'.:`*>NO;Q^'M3DO+R>RM5M)3-=6Y(DA0(=SH0"0P&2,`\CI1H:7$6AV45U
M9P6<T<2H;>`!4C`X4!02%X`^4%@O0,P&XUTU.\U.6U?1X8'TV3#R7\[$!EW$
M8B0#+Y"G#DJN'1U\P9%4[9YO"5A;6$ME=WFG1(0+NTB,C1?.V%:!<MC!0#RE
M*CYODB10*`.DHJ.">&ZMXKBWECF@E0/')&P974C(((X((YS4E`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`<WJNKZF=9O-
M*T^SD=+:RBN)9+=XS<,9FEC58EEVQ@J8]Y9V(P-NPYR#3?"JPAOMDTCV\J'S
M=/,K31.[1A',TLF9+@X+*-Y"[`@V`H#4EG_R4/6?^P58?^C;NN@H`*KWUA9Z
MG9R6=_:07=K)C?#/&)$;!!&5/!P0#^%6**`.7UFYUCPS!'<6+0:C8M+;6B6E
M[*Z21-(Z0JWGX<LN2I(=2Q+,V_@)6A#H?VG[//KTD&IW=O*9H3Y'EPPM\NUH
MXRS88;<AV+,"SX*JVT5_&7_(#MO^PKIO_I;#704`%%%%`&/?:#YEY)J&FWL^
MG7[X+O&=\,Q``'FQ'Y6Z*"PVR;5"AU%:D)F9"9XXT?>P`1RPV[CM.2!R5P2.
MQ)&3C)DHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*X6_\`BMHVGW.H;]-U
MB33].O5L;S4XK4&WAE)P03NWD*>"0IYQUW+GIKK59G1DT:VCU"X#[27E,4"8
M9U;=*%;D-&RE5#,&*[@H.X<+=_"G4;RTU;3)/%6S2-8OUU"_MH].4.TF0T@C
MD+G8K,`0"&*[5&3\VX`].HK+GU=K&_EBO[.2"Q"&1-1#JT`4)N82=#&1M<Y(
MV8"_/N;:-2@`HJG>:K8V%Q:VUS<QI<7;[+>#K)*<@':@Y(7(+$#"CDX`)K/A
MAUK57+ZB8].L&1E^QV\A:X<,I`+S*0(R`WW8\D,H(E(R"`;E%<7!JM]X>OXK
M&_N9)(G0"*WO.6>0I\L5O=G:DQW#RQ'+ME;YG+$`9ZC3=4M-6MVFM'D(1RDB
M2Q/%)&V`<.C@,IP00"!D,#T(-`%RBBL>WUA]9BD.C)F$?*M]<Q,L+$JQ#1KP
M9E!$9R"J,KY5R010!7L_^2AZS_V"K#_T;=UT%<V_A1HTEN+?4I)M4E>%I;O4
MHEN$E$3,T:M$NQ5"ERR^7Y9W`,2?FW4X=4U30Y[>/5#!%#+F"&SDN/,>2147
M8L%T^T2,YVCRY@KEC*P<J@R`=A16?IFMZ=K'FK97&Z:''G6\B-%-#G.WS(G`
M=,@$C<!D<C(HU#5DL<Q0VT]_>#:1:6FTR8;=ACN951?D?YF*@E2`2V`0#/\`
M&7_(#MO^PKIO_I;#705A_P!D7.LI;2:_Y:&"X6XCLK*X<Q!T9&C9WPK2E64L
M`0J_-@JQ4-6Y0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%4[_38=33
MR;II'M&0K+;9`27YE/S\9(^4@KG:P=@P8'BY10!'!!#:V\5O;Q1PP1($CCC4
M*J*!@``<``<8J2BB@`KE]<M?["MIK_2KB>UDO;NWMI(U?=$K3W,<;2I&V520
M>8[<`*S,2ZN<5U%<_P",O^0';?\`85TW_P!+8:`+'AK['=:'8:K;>?(U]:13
M&XN\&>16S(H<CC@R,0J_*NXA0!Q6Q7/^!/\`DGGAK_L%6O\`Z*6N@H`CG@AN
MK>6WN(HYH)4*21R*&5U(P00>"".,5S]_X=OGO?/L]4D\MW.5F_UMLK.K,8)@
M-RC<H<QR"1'V*F$2NDHH`Y/P_8-K47]HZO?7=\]K>W$$,,C*D*F"=XED*(%#
MN?*5\ON"OR@3I765S_@W_D!W/_85U+_TMFKH*`"HYX(;JWEM[B*.:"5"DD<B
MAE=2,$$'@@CC%244`<G/IL-OXCT_1+5I+:SFTRY*>20)+=4G@+)%)C=&CB7:
M0#\HCCV;"N:Z#3=*L=(MV@L+:.!'<R2%>6E<@`N['EW.!EF))[DUEWG_`"4/
M1O\`L%7_`/Z-M*Z"@`HHHH`****`"BBB@`HHHH`****`"BBL<^(;>YO)K'25
M_M"[BWK(8R1!#(H/R2S`%5;<%4H-SC<#LVY(`-2>>&UMY;BXECA@B0O))(P5
M44#)))X``YS4E8]GHUPTIN-:U#^T9OE*PK"(K:(JP8,D>6.[*(=SLY!!*E02
M*Y]+;6/"EFPA72K.PM\RL\$3I9R`E`0T62UIZ[T:2,#SI'4$B@#N**R[;Q#I
MMS<6UO\`:8XI[M#):([K_I48+8>)@2L@*KOPI)564L%R*N7E];V,0DN)-N[<
M$15+/(0I<JB#+.VU6.U02<'B@"Q16&8=3UVW0W!N]$MR[;[>.2,W$J8``:12
MPC!^?_5DMC8P=#E:)/"6D%(3;0R6=W"FV*]MI"MP/F+?-)R9`78N5DW*S'+!
MC0!N45EQWFI6U[-%J%I&]H7_`-'NK3<Y.YP`LD>"5(W#Y@64A'9O+&%K$E^*
M/@J*\:V.O0-MECA:>.-W@5Y`2@,RJ8QD`]6XVMGH<`'7US_C+_D!VW_85TW_
M`-+8:L7.IWEYNAT&&"=EE>&:[N&*PP,N`V`!F5@6QM4A<HZET88J27P]IMW<
M?:-1MH]0G"21H]VBR>7&Y;<BKC:H*OL)`RRA0Q;%`$?A.QN-,\&Z'87D?EW5
MKI]O#,FX':ZQJ&&1P<$'I6Q6''IU]H:32:?<W>HVP3*V%W/O=3N!/ES/\Q)&
M\[9&8$[`&C4&KFF:Q;ZIYL:)/;W4&//M;F(QR1DYQP>&7(8!U+(Q5MK'!H`T
M*KW5];V7D"XDVM/*L,2A2S.Y[`#DX`+'T568X`)'+WWC#[5+)I]C!?6\\L0:
M`FVS=2`L%W);M\T:\.OFSA(U;8?G4FKEAX=ODO?/O-4D\M'&%A_UMRJNS*9Y
MB-S#<Q<1QB-$WLF'2@"3P;_R`[G_`+"NI?\`I;-705ER:)#!;D:1Y>F3J@6-
MH8QY7`0#?$,*XVQ(G9@F0K)G-5Y-?71DAC\1-':DIEK]586A(8CYG.1"2-AV
MR$#+A5:0@F@#<HKF-$^(?A;Q#J$%AINJ>9<W$330)+;RP^<BD@E"Z@/@JW3/
MW6]#B^]UJ.IRW5I9V\^GPIE!J$Z+EF#`-Y49Y.`'P[@+G8P6530!GZM?6]C\
M0_#YN9/+6;3[V%&*G;O:6TV@GHN3\HSC+%5'+`'J*PQX8ACMW\C4=2AOY'5Y
M-1$X>=R`1@APR;/G<B/9Y:ER553@C')U+PJ$GN;F,6H1H_+M[=EL%"Q@1E@`
M[V8&`"P+PA8V8A6D&`#M**YC5/B!X>T.[-GJUQ/9WG[UA;FVDE<QH-QE`C#?
MNROS;NG#`X9'"[>EZI8ZWI=OJ6FW,=S9W";XI4/##^8(.00>000>10!<HHHH
M`****`"BBB@`HHHH`CFA6=`CF0`.K_)(R'*L&'*D'&1R.A&0<@D5E^$[K[=X
M-T.\^SP6_GZ?;R^3;ILCCW1J=J+V49P!V%;%<_X$_P"2>>&O^P5:_P#HI:`.
M@HHHH`R[G1(7,9M?+@`N(YY(6C$D,FV1I"?+/"N6<OO7#;PA)8+M./X(TNTB
ML[G4&22>_P#MM]:B[NI7GG$*74B)&)')8(`B_+G&03U))ZRN?\&_\@.Y_P"P
MKJ7_`*6S4`=!1110`5Y-JOPY\4W5CXDT"UO-'&BZ[J_]HO=2F47$*LRNZB,#
M:Q!1<?,,@'.-PV^LT4`%%%%`!5/4M+M-6MUANTD(1P\;Q2O%)&V",HZ$,IP2
M"01D,1T)%7**`*]G8V]C$8[>/;NVEW9BSR$*$#.YRSMM51N8DG`YJQ110`50
MUW3/[:\/ZEI7G>3]MM9;;S=N[9O0KNQD9QG.,BK]%`'FOA_P7XI36O"-QKDV
MCQVGAJREMXA8O*[W#.GE`MO50H"!3QGE3V;"^E444`%%%%`'"ZQX5UVT\<1>
M)O"PT<%M-EL9K6]WQ*&:4RB4&,'),C98$#.#SELKK^`_#<WA'P3INAW%PEQ/
M;(YDDC!"EG=G(&>2`6QGC.,X'2NCHH`****`"BBB@"O]NM_[1^P&3%T8O.5&
M4C<F<$J3PV#C.,[=RYQN7-BJ]]8V^HV<EK=1^9"^"0&*D$$%65A@JP(!#`@@
M@$$$5EB'4]"MW-N;O6[<.NRWDDC%Q$F""%D8J)`/D_UA#8WL7<X6@#<HKA;_
M`.*VC:?<ZAOTW6)-/TZ]6QO-3BM0;>&4G!!.[>0IX)"GG'7<N>FD&KWE["8I
M(["QC?,H9!)//M<\*<E(T(53D[F*R$8C9<T`&I>(](TFX6WO;Z..<H)&C4%V
MCBR1YKA02D0((,C80=R*C\)VOV'P;H=G]H@N/(T^WB\ZW??')MC4;D;NIQD'
MN*T+.QM[&(QV\>W=M+NS%GD(4(&=SEG;:JC<Q).!S6?>:-<+*+C1=0_LZ;YB
MT+0B6VE+,6+/'E3NR[G<C(22"Q8`"@#8HK#F\2PV#BUU*WDMKYD7RH\CRKJ4
MJ,10S/M1G+;E"L4<[2=H7!K'DO;[Q+>PVR1:E%;*_EW<-I-Y$41#G/F70^9W
M`4#9;DA9%=)'*D$`&Y?>)+.RO)+81SSM!AKN6-0L-HF`2\LKE47:I5B@8OM8
M,%(YJOX,#_\`"/O))!/#YVH7TR)/"T3['NY74E&`895@>0.M2:5X:AL'M[BZ
MN)+NXMTV0+@16]L-NW;#`OR(`"RACND"L5+D5N4`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`>:ZE\*[N^36M.B\3
M/!H.LZD-1N[/[$C2[BP9U27=P&8*1E3C:O7YMWI5%%`!1110!'/!#=6\MO<1
M1S02H4DCD4,KJ1@@@\$$<8J2BB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
:HHHH`****`"BBB@`HHHH`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>sc52d3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sc52d3.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`*;`9D#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]V_#F@QW_
M`(=L)IIM0:2:WCD=A?SC<Q4$GAZN_P#"+VV?]9J'_@PN/_BZ\HU3]K[P9\,O
MB1X$^&^JZ]H,/C;QE%%#I&CK<3S74O\`H\TR-,L4#BW1TM;@H\Q1',$BHS,I
M%>-_`?\`X+3>!?VBOCS<?#_P_P"&?$$>KVOCO5?A[-<WMY86]JE_I]L]S)(I
M,_F20R)'*(_+C>4F-]T:`9I1U>G]6:7ZA+17?]?U9GUV?"UL#_K=0_\`!A<?
M_%T?\(M:G_EKJ'_@PN/_`(NO#_CS_P`%&O`/[-GC_4O#/BIO$!UC1=%C\0ZG
M'HOA37]>ATO3Y&F5+FYFL-.GB@C)MY^9'7B)B>!FK7B3_@HQ\(O"^MS:7/\`
M$KX:W.N6\NGQ3Z1IWB1=0U.W^WSVUO:/):01O.D<DMY:@2,@0"=&+!3FE'71
M:WT_&WYZ!+31Z?U<]G_X1:W_`.>NH_\`@PN/_BZ/^$6MQ_RVU'_P87'_`,77
MF&I?MM?#/0_`.G^*[WXD_"6S\*ZM>36%CK,_C2UCT^\N8?,\Z"*<@1O)'Y4N
MY%8LOE/D#:<<G\3/^"HOP=^&?P#7XGM\0OASKO@5M=M/#0UC0_%%OJ-F+ZXE
MCC6)IHP8E*"02R;G&R)6<\"GY+R_'0-M_P"K'HG[1WQ&TS]FWX#^+/B!J&E^
M+M?T_P`&Z9-J]Y8:-=M+?SP0J7E\E)9XT9E0,V"XR%(&3@'Y]\3_`/!7SX(^
M&/&OC_1A-XXU-?A_X-'C.74K(O+8:W$8;6<V%A*;@>=?".^L"82%Q]M@RWS<
M>Y^%OVG/A_\`&_QIKG@'0?&7PN\6^)-+@D76O#UAXIM[^^LH=RQR?:+5%9T7
M+JIWJ!EP#UKX^^*_P9_8U_8]F\-_#77/AQK"_P#"H9$^(MG::3IGC#Q+%H"2
MN56\O+FSM;A?()T_`BNY#$%LT^0+&N%&_-[WPM:6WOU]=-?D&\?<6J>OII^N
MGS/I[XL?ME?#/X!:GX?M/'DWQ!\)R>(UL_)N;O0=;FTNSFNW\J&VN=2@BDL(
M)S*1'Y;W`.YEZAU)YGP'_P`%-O@/\3[_`,(VWA_Q!\0-6G\>6C7_`(=2W\'^
M)V.L6BFU#W4/^B?/;H;RWWS#]VFY]S#RI-GB_P"U/\"/V'_VFOCG<?&GXN?\
M*W7Q5\/]2TS03XFUOQ[J'AZQMKL6R:G8PHYD@M+AC!<+,I42;E)!)V%5]5N_
M"7[-?[-_A+X5ZQJ.J?"WPGH-CX4F\$>`KW5O'[0VE]HUTELSVMM)/)LNQ(D%
ML0Y,DF`"&PQS6JC>6_X6:;6OGITVU)=M.7M^JO\`J;,W_!2?X$Z?I&OWFI>)
M/''A^3PO<:7:ZC8ZYX7\2:3J<3:G<-:V#+975M'<RQS3JT:R1QLFY2"PQ6/X
MX_X*E_!CP;X4\$ZW;GXJ>(+/QSXQE\"0QZ7X7UQ[[2-4B21Y8;ZRDC2ZMW7R
M_P#5&(S.&#)&Z*[KY;^S)_P3S_8A^"7B;QSX"^%^F?#&#7;"\T[7?%FA6?Q0
MOM0U#3)M&O!<VLUU"]S)+;K;W)5FW!%)(60,#BNBO?$'[''Q\LK;1[7XD?!O
M4I_$'Q`3Q58MH/QB>WOI_%$L8A22UGM+E)UN'1M@AA8!@Y`3YN31M6[I_BO_
M`+;\`;W2]/P?ZV^5SWSX0_M4?#/XZ6_BRZ\+ZQXIOM+\$SW-KJ6JSZ9K-GI3
M26TLT-P+:]GB2WO/*D@E5S;22A2G)&1GQ7P]_P`%9?`]_P"'O`'BC6OAU\;/
M"OPY^*-W]E\+>,K][.XT_6'>VGN;?;:V>HSZDGVB*W<Q+)9JQ)5656;%;WPE
M^'G[.O[-O[7_`(^@T76O`MO\</B5:Q2^)].UOXF76L>(-2M8(GECW6M]-++'
M`D#,0L:*BQ*HQL10/)?!%S^Q?\`OACJWQ1\'>+_!_C+PQ\!;-M=33],^,&H^
M,-*\(;EDCA:STN2ZGL[29MTD4'EPQD%RD94$BHYFES7[?+O_`,#MYE\MWRKT
M7?I;\?Z1[?#_`,%.?V<[J"62'XF?:/)\/Z1XG,<']J2ROI^K3I;Z?(D:H6=Y
MI9(U\I094,B;T4,"=7X;_P#!0'X'_%?XD_\`")Z+XPUPZMOU:*.6^L-9T_3[
MF32YFAU&**^N(H[662W9&+HDK,$&_&SYJX_X#_\`!.7]GK7=)\$?$#P/\/O#
M5W:V^H-XPT#4[7Q5?W<4DUTMLXDW!WCGA7[+:M%"Q>"$V\1B1"BD>D>%_P!A
MSP!X-GT633_`NDI_PC^I:WJ]@LNN7L\<5SK#2MJ3LD@99!.9I<HX9$WX15`&
M+E=+1:ZZ/\/^"1%W2<>MM?+KI]UO^!KQT7_!3S]GQ_#%]K#>-?$MOI]FVFF.
M6XT77[?^U(M1NOLEE<V*O`&OK6:<A$N;42PG<IWX8$]E\%/VN/AK^T-\1=6\
M*>$[SQ]>:QH*(VJ?:_#GB'3[3396@@G%K/=7,$<$5V(KF%FM7D$Z;\-&"K`>
M<_!'_@C;\!_V<?!.H^&?!GPU_L;PYJNM:?XCN-*_X3G7;BR;4;&XCN;:Z6&6
M9T21)88B2@&]8U1]R`+7HNC?L0^"=#_:SN_CE'X7DNOBA=Z8^B_VQ?>+M5O4
MM;%W5VMK>UF9[:WC+KNVPQ(`6<CEVS4;=?/\E;\;_(J5];>5OU_`]@_X1:W_
M`.>NH?\`@PN/_BZ/^$6M_P#GKJ'_`(,+C_XNC[7J_P#SXZ=_X'/_`/&J/M6K
M_P#/CIW_`('/_P#&JD`_X1:W_P">NH?^#"X_^+H_X1:W_P">NH?^#"X_^+H^
MU:O_`,^.G?\`@<__`,:H^U:O_P`^.G?^!S__`!J@`_X1:W_YZZA_X,+C_P"+
MH_X1:W_YZZA_X,+C_P"+H^U:O_SXZ=_X'/\`_&J/M6K_`//CIW_@<_\`\:H`
MH1:#"_B&ZA\[4/+CMH9%7[?/PS-*"?O_`.ROY5YU^V)^T)X=_8N^`VI_$+7]
M)\:Z[I>DSV\4]OHMWNFC$TR1>=))<7$-O!!'OWR33S1Q1HK,S#%>A6]QJG_"
M37F+.Q\S[+!D?;'P!OFQSY7U[=AUSQB_%[X4?\+Q\(-H>M+K%C9-,DYET#QE
MJOA^\W+G`%UI[03A>>5$FUNX.*F5[:>7_!"-KZGSKJG_``5M^#OA/2_`=_KU
MK\1-/LOB!X<U;Q3:76D@^+;>RLM-GAAN&FDT*YOT(_?*_F0F6)$1_,DC9=M>
ME/\`MM_".W^)>B>%9M>\76U]XF@^T:+?7&BZ[#HNMK]B:^Q9ZH\(L;E_LRO(
M$BG9B$<8W*0*?@;_`()O?"OX;Z?96^C^`;.'[#I.M:(DTOB?4[FXGMM8G2XU
M/SII6:2>6XEC1FFE9I01\KJ":XCP?_P11_9X\`_M%V/Q8TCX1Z99_$#3;=+2
MVU1?%NL,(XDL18*/):0PD_9AL)*$G[Q)<[JK_)_?=V^5K?B+^OR_X/X&M;?\
M%3_V>[[P#I?B:U\5^.;S1]:L7U:R>V\*>)IYKG3HXHI9-26%+4R_8(Q-&KWF
MS[.CMY;2!P5'HMO^U%\,]3^.MC\-M/UKQ)K7BJ^TNVUHII%AJ^I6-G9W(F:V
MFNK^WC>TM5F%O,8_/FC+[1M!W+GS7XL?\$>_@3\:_"WPMT?Q!\,;.:V^"MK'
M9>"Y[/QAK&GWF@Q)Y10)=6TD<[E##&RM)(S*R[@022>X\;?L(^!?B/\`M#^"
M?BGK_ABYUKQO\.HVC\-W=[XSU>:UT@O$8I)([-G-KYKH0'D:(NY5"S$JI%>[
MY[_AT?J+6WG;\=-/0]8\2:#%I_AV^GAFU!9(;:21&^WSG:P4D'EZO?\`"+6_
M_/74/_!A<?\`Q=9WBFXU0^&-1$EGIZQ_9)=Y6\=B!L.<#RAG\Q6C]JU?_GQT
M[_P.?_XU4E'DG[;?[3GA']@_]G?5_B9XNM_%&H:%H]S9VLT.G:DB3L]U=16L
M9WW5U!`B!YE+/)*BJH8D\5Y-\%_^"N_P/^,7PFL_%WVGQUH]OJ7BN[\%Z?8Q
MPW'B*ZU34[:U-Y)%:-HDM_!=J8`S*]O+(K%2F=XVU]!_&OX*:9^T/X(_X1OQ
MCX>T_6=&%]9:H+<ZM<V_^D6ES'=6[[HD5ODFAC;&<-MPP()!3XC?!/2_BSXL
M\&ZYX@\/:??:I\/]4?6=!G&KW,7V"[>VFM6DVHBK)F&XE7;(&7Y\XR`1,+I/
MF[Z>2T_'?\`E9VMY_-VT7EK:[/'_`(:?\%)/A'\3-'TV:%_B';:EK&MZOH=C
MHL6DZGJVK3?V9?MI]U>O:Z=]ID@LA<*%^T3B-%\Q`Y1F"UV/PR_;%^$OQA^+
MLG@GP[XFUK4-<S>K;2FUU:#3-5:SD6*\2RU"1%L[UX)&VRI;32-&5<,!L;&`
MW_!-+X81:KH^H:?X3U+P_J6AW>JW=K?Z!X^UW1[S=JEZM_?1R36DT4DT$MTJ
MRF"5FB4CY44<4?L\?\$SOA1^R;\>?%OQ+^'?@.'PKXN\>3S7.ORVGB[5C8ZG
M)+*TK,]BSFTR'=RF(1Y>]@FT,0:C;3F[._KTMY=Q2V?+W5O3K\]CWX^%[8G_
M`%FH?^#"X_\`BZX/XY?$33_@)\.?&7BZ_P!/\8Z]I_A'1#J\FF:&UQ>ZE>!!
M,S1P1"0;Y&"``%@O<E1DUWGVG5B/^/'3O_`Y_P#XU7*^.?!<WQ-LM<T+4(;J
MWMM2L8(IY-+\0WNDW:)OE(,5W:^7<1-D'F-U('<Y(J9\W*^7>VA4;<UWL?,^
MD?\`!8+X3WWPJ\`^,)-#^)LFE_$;Q<?!VEKH5Q;^+VCNQ;^>7F?0KZ_A0;1C
MR1(;DD,1`55V7TCQ7_P4&^"WP]UOQ=IWB3Q!XU\,77@?1;_Q#J8UOPYXBTQ)
M=.L72.[NK1[BW1;Z.-I(\M:&;B1",A@32A_X)?\`PIM_"4FD'PCJTOG>*(?&
MCZK+\0]?EUQ]8AM_LL5VVJ-.;XLD'[H*9]H0D;<$UR'AC_@A[^S?X-\:_$+Q
M%IGP@TZTU?XJ:=J&D>*)U\8:RW]IVM_();N,(92D7F.`<Q!"N,*5'%6K-Z[?
MK96_&]_(A>?E?[W^EOF=5\)_^"B?PO\`C=^U1_PJ/0=.^,`U[^PD\11ZAJ/A
M+7M+TN6V:6:,$3W,49"DPL4F91;RY58Y9'R@YG0O^"I7@O4O$2_;_A]\8M!\
M%2>/)_ANOC:]O+!]&.L1WDEBD9B@U.2_6.6Z01)*UH$!D0N47+#VEOV5_#:_
M'S1_B='X?:U\::)HB^'+>\M_%&HP0S:<K2.EO<6R$6]RJ/+(RF>-RC-N4@@$
M<3X3_P"":'PN\&?$=?%-GX0OIKV'Q%<>+H;"_P#'FN7^B0:Q/))+)?QZ7/*]
MC'<>9+(ZR+`"C-N0J0")CI*-]M;_`'JUO^W?Q[E?8=M]+=EIK_Y-;Y')?M-_
M\%:?@A^RF^K6WB1?C!)K6DSI#_9,'@WQ##<:@AOH+%[BT>YAA@NX(YKF'=+!
M*ZD21A"[21J_H&C?MR?!W7_BGIO@RW\2>)TUW5+J+3T\_2=<M[*UOY;;[4FG
M7-W)"MM:Z@8,/]BGD2Y&Y08@6`/E5C_P0@_9FTOQUXT\26OP>L;77/B#YO\`
M;EW!XUUR-KDR7L5\S1A9@+=A<P12*T(0H4`4J.*[?P5_P2N^$'PW_:I/QMT/
MP-/I_P`4I;:.SNM?C\=:XTNI1)!'`%NHS*8KK<D49<SHYD=!(Y:3YZJGLN?<
M)=>7Y?AO^)Z1\=_BKHO[-_P4^(?Q!\0#Q#>:'X!T^YUF[M["[D>ZDM[>T6>1
M(E>5%9SAL!G49(R0*\1^$/\`P5D^#OQ-^$NC>,KO_A,M"TWQ+K;^'M"@M;^'
MQ==ZU>I9M>O#%%X=O-3(E6!')BE*2Y7&S++GWWXC_#&T^.WP^\;>"_%&BV.J
M^&_%<$NE:M9?VE/;_:+>:UCCDC$D2+(NY&^\K*PR<$8S7$>!_P!@KP/X!E\*
M/;Z+KVJ2>!=6.N>'Y->^(>O:[)I-T;.6RS$U[-,5C^SS2)Y.?*&[=LW`,(5^
M9WVLK?J$K<JMOK?[E;\=SF?B3_P4U^!?PZ^#.C^.(_$7B[Q1IWB/0+WQ-I5C
MX;TG6=6U.[L+3`N)Y+6&,R6D<<A6)Y+L0QQR-LD="#@\9_M]Z#HNH_"73_#O
MPZ^+GQ`UKXR>&KCQ7HFFZ'J&G6\UK901VDDAN7O]3M85<"]A&U)'R=V.!DS^
M-/\`@EI\(_'7A30]%NO!-YI]AX=T[4M(M#HWCS7-'N&L=1G%Q>V<T]I-%+<6
M\LP#F*9W0'HH%;7Q#_X)\^`/B5#X#^V:!K&F3?#'2)="\-W?A_X@Z]X?O-.L
MI$@1[?S[":&65&6V@!\UG)\L'J3DCW??\-?Q^&_S#JO1W]=-O+<YJQ_X*:?!
MD?L[:-\4-2NOB5I/A75!>I>7'_"-:[J2^&YK*8V][#J4MC%<069@F5T:2641
M-Y;M'(\8WU'\'_\`@IS\&OB_\,O&WC!+CXB>'=$\#^)9/"ES)K>BZM;2ZK?+
M<-;1Q6$05GO99I0%2W@#7.717A1V53D?'S_@B3^SC^TUX0\#>'_&?P;T'4=)
M^'%G-8>'K>V\3:KI_P!BBF=9)=S6SQM,[R+O:28N[.SL6+.Q/2>+?^"57P;\
M=?"+QYX!UCX>0ZEX-^)6K)KFO:/<>,-7>UDOEF\_[3;H9/\`0Y&D^9S:^5YG
M\>X<47?SU]-U9_=?YAII;:^O>WZ]-3T_X2_&7PG\>OA]#XH\%ZIK%U8QZH--
MG2^CO]/N[*XBNEAGM[FSNUCG@E4Y!CFC5L$'&""?3\GTKR;X(?L]Z+^RC\%=
M!\`^#=*FTKP?H,]M!I]K<^(K_6)+*+SX]L4<EX9)?+7@*GF;47A0``*]9P?6
MM)6^R3&]M3Q_QQ\(O"7QBO?A7K&L:U):7WPQU5/$.GQ6]Y"B2W)T^YLBDX=6
M)01W<API1MRK\V`0?33XOT?_`*"FG?\`@2G^-?#_`.W9_P`%'_$G[)^IMIMC
MXJ^&GP_MM$\/Z=?V4?C'3K2XNO&[SF19UTLWNO:+;8LEC0S*9Y9#]IC`1#L$
MW<)_P4FURQT*;6H_`L?B#PCX9^&ND_$/Q%K4=^]CJ#17\%X\<5II:QW(+![3
M+B2\"Q1R,?-E,>'S4ER.?1;_`-?(IW<U'=VT]+_\$Z[XI_L"_`/X\?M&ZA\3
MOB#X8\$?$37+[0[+0(;7Q/ING:M8Z=#:S7,RR6R3PL\<KM=,'8/AA''P-I)K
MZ[^PA\,?$47Q`27Q/K$2_$?QQH_C_41%J5HHM[[3/[/^SQ0_NCMMV_LV#>K;
MF.Z3:ZY7;\UZG_P<:>"-,_8LL_C#]E\`36-]XK;PK%=0>)]7ET$3"V>YQ).N
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M8^2T[,4,(667XW?M^V_PJ_82UKXO7_\`PCO@V\U"VO7\&67B34!&NOR_OFTU
M/+8PNTUW%&LJVR$R@/MR64X4=/A\O71IK\=5_P``>K=GW?I?K_P?^"<Q^RS_
M`,$J/@;^R/\`M+:A\5/#E_\`:O$MXFHK;F\ATB+^S_M]P+BZ(GMK2&ZN69QA
M6O)[@Q(62,HK$'LOBE^P+\`_CS^T;J'Q-^(7A?P1\0]<OM#LO#\-KXGTW3M6
ML=.AMIKF99+9)X6>.1VNF#L'PPCCX&TD\E\1?^"I5CX(_:E;X<?V?X+DN(M4
M@T)],F\7"/QK/<S1)(MY;:`+9FFTQ!(KO=&ZC*QQ7$@C*Q@R8GPJ_P""FWCJ
M']F;4/&7Q!^&WANUUJ#X7)\3M*M?#_B:6YBUBV$(9X9Q-:1_89B[IM17NT`9
MLS'8"ZA[T5)?9V^=WI\KA>S<>KM?[UO\[%W]I#_@E#\(?VF]:\07FM>,=>L_
M^$D\4KXJOK5'T>_T^:==+@TSR6L[^RN;9X1#;QNIDC:6.4;XY$X`=XC_`."6
M7PQU;X*^`_!.G_$GQMX?L_`G@B\^'"ZA97ND3WFLZ!=K;K<6-V+JRF@(<6L/
M[R&**4;3M<9.>;_::_X+$ZE^QGX)U*X^)W@_X<^%_$&C:W86-\'^(4\FCPV5
MW;2S17$<HTO^T+J<-%Y;6UKITQ7>LC.L2R21ZWBS_@J-K_PE^,'QJT'Q=IGP
MCL=/\`7.FKH)?QU)971MKZ.U\G4-6$UGMLM-$EP1+>KY@B8>4L4[@,ZO;W>C
MLO*Z25ON?W707;M+[O2_^?Z>14_9F_X(M?L[_LG?$36/$7A*ZGCN+[1]2T.R
M2=M+\S2+>_<-<[;R.U2]O).`JR:A<73QKE5(#,#IV?\`P24^#-CX.M=#7QEX
ML-K9^'/!WAA'.K67F&V\,7AO+!R?L^/,DD8B8XVLO"+$>:O>#O\`@I=X@^+?
MPU\&W?@/P3X#\7^)?%OC"[\'PRVGCV1_",[VVG3ZA)>6>LQ:=(]Y;[(#"62S
M4BX66,C$9<_0G[-WQE/[07P5T'Q:=/\`[(FU2.1;FR$_VA;:>*5X9D27:AD0
M21OM<HA9=I*(25&GO1WZ6_#5?F_O(NGHNM_SU_%?@?.6M?\`!)3X#Z]^V1??
M&VZO1)XFOM1EUG[,8M),<5])8_8C<K=FT_M$@1Y9;=KMK99#O$(8`BW;_P#!
M+;X.V_P<U7P./%7B+^Q]8^$]C\'9G_M.S6==)M/M/EW"D0!1>$W4A9RIC)"_
MNASGZ].:0?SK.-E'E6W_``Z_)M%\SOS?UT?YJYR/PX73?`'@'1]#E\5MKTFD
MV<5HVI:A/:K=WWEJ%\V40)%"';&3Y<:+GHH'%;Q\8Z1_T%-._P#`E/\`&M*B
MJ;N[LF,;*R,W_A,=(_Z"FG?^!*?XT?\`"8Z/_P!!33O_``)3_&M*B@HS?^$Q
MTC_H*:=_X$I_C1_PF.D?]!33O_`E/\:TJ*`,W_A,=(_Z"FG?^!*?XT?\)CI'
M_04T[_P)3_&M*B@#-_X3'2/^@IIW_@2G^-'_``F.D?\`04T[_P`"4_QK2HH`
MYVW\5:6OBB\D.I:?Y;6L"AOM"8)#S9&<]LC\Q6A_PF6D?]!33O\`P)3_`!HM
MO^1NO?\`KTM__0YZTC0!EKXPTD?\Q33O_`E/\:/^$PTG_H*:=_X$I_C7S?\`
M&3X'_%Z'4_CG<>&/%WC36O\`A+/"EDGAF.XUFTL5TR\6XU$W-GI_E1(ML_D2
M6ZK=3(TA9XR\[>4/+\=NO@;\8C\+8XY/!_[0\W@7_A,[J\@\%V_Q;BB\<VVG
M-I,44'FZQ_:P+PC4A<S>1_:SD1S19W*GV9)<K?<G^-K`_BMYV_"Y]Y?\)AI.
M?^0IIW_@2G^-"^,=(S_R$]/_`/`E/\:^6_&FB_%KQE^Q!H?A>\TWX@:IXY\(
MSZ!8>-%T37(]#U3Q=&EO9SZ@=+U+S+5?F,K(9EEM-SP7""2/@GQOX9?L_P#[
M1VF>/O"TVL:9\9]T>LZ=/X?OI_BA!/IWA'0TUFYFN]/UVV%X?[4O6TQHX?.,
M.HDN4Q<QM&;@U;W^7I=*_P`M_3^O6;^[?RO_`%_7;S/OCQ3XITN?PQJ,<>I6
M#N]K*JJMPA))0X`&:T!XRTG_`*"FG?\`@2G^-?('[,/PI^+WA+XZ>)]1\6Z?
M\2;/3/['UZ/Q!J.O>.(]8T/Q->RW\<FF3:18+<RFPBAM!<*ZBWL?];&ICG*^
M8GVB#M_SUJ5K%2?5;=OZ_(KK8S_^$QTC_H*:=_X$I_C1_P`)CH__`$%-._\`
M`E/\:TJ#TJ@,O_A,=)`_Y"FG?^!*?XT?\)AI(/\`R%-._P#`A/\`&OS87X$_
MM"6'[4/QBEU;PC\=O$'@G5$NFL(])^(]W;R2O->^;;G3YG\46D`B7",\,5II
M4L<$9A6=OG6\][^&O@3XW:9_P3EU#P;-8>-(/B/<:7JIL;Z^U^!=3A!N=\5J
M]S)J&HR07+Q2R1V[F\O?+6!'END<A1/_`"[Y^MKV_0'I/EZ7M<^K#XQTDG_D
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MZ$GW+R&X#;)#&070YN5M$F]OQ=OG;=^1<8WWT_X!]S?\)AI/_04T[/\`U\I_
MC0?&&D?]!33O_`E/\:^0?AGX(_:L\0>%/!^O^)O&GBK1==T/PWX674_#<-GX
M9^P^(]4^URKKC7C"">2/_1Q$P6TN84!)\LL<@:7_``4>^%7Q:^(/BS3)?`6G
M_$K58!X?OK71)/"7CB/PW!X>\0/+";74=4C:YM_MMDB@YBVWBX60&TD\P&M)
M+EGR[ZM7Z:=?3^M"8Z[>6_G_`)=?PN?5@\8:3C_D*:</^WE/\:/^$RTG_H*:
M=_X$I_C7Q/\`L&_!K]HKP)^U]K^J?%+_`(235M)N(=0CN=8N]8N?[(NV:X5H
M&L;4>(;NV"[0H"C1-.=$!S*6#K<?=1/:C[*;W:N_+R)YKMKL<_I'BK2X]2U0
MMJ-@HDNE9";A!N'D1#(YYY!'X&M#_A,='_Z"FG?^!*?XT:'_`,A36/\`K\7_
M`-)X:\(_X*!_L[?$+]I71O`6A^`_%5YX-CM_$$EWK>HQ:AJUK&MHNGW:HLBZ
M7JFF7<JFX:#"I<@!MK,C*IJ7?H5IU/=?^$QTD?\`,4T[_P`"4_QH/C'22?\`
MD)Z=_P"!*?XU\0?MN?"7]K3P!X*^%/AWX$^.O$UKIN@:7)#XDU'0O#ND^*-3
MU:]!BVF7_A*-;BDCM6'FE2+RYG!.UW("O72_L/:;^TEI'QJ\GXB#XC?\(Z;G
M6I-3_P"$B/ALZ"T4EY))8'2?L5S<ZLLNQDWI?3-"B>8J!=L0%1BI;>>^FW^?
M0F5TKORV\_ZU/KK_`(3'2?\`H*:=_P"!*?XTH\8Z1G_D*:=_X$I_C7E?B3X8
M>-+/]KG3?%EKXF\9:CX/F\+:K97&B"\LXM-TN\,FG&V:&`)&\LTBQW1$EPTP
MC.Y5:)9"K^7?\$ZOAS\2/`OQ0^(MUXC\/_%+PWX+U<6C:)I_COQ4=<O;-T:;
M=LD.O:UYA=9!YCK)91CRH0ELY+R*HZ[]K_CL5+17\SZ8U_Q)INH6D,,-_9S2
M-=VVU(YU9FQ/&>`#705F^*O^09%_U^6O_I1'6E3`^6?VD/V[=-_9.\1_#_1+
MS3/'6O6.L6\=WXCU/1M)DO++P-IA78FH7\D5K*L$!D#'=</$GDVMY()&:`1R
M9G[6'_!26#]DSXJZMX7F\%_%?XC7EGH^CZM9Z?X"L++6-;U%;Z;5(W,=@XB9
MXH!IH9WC>1L7()15C9Z[/Q9^U+\%/V;-<72/&7C?X(>`_$_BZQM;J[M->\46
M&DZEK<7E"WAEEBE"R3#;'Y2D[AA-H.%Q71>.OV-/A?\`%?P_9:7XF^#/PC\3
M:3I]M:6=I9ZIHMI>6]K!:K*MK%&DEJRJD*W$XC4`!!/)M`WMF=7"W6^_3S0_
M=O:W1??>]_T^X^=?B1^TM\(?VS](\"_\)E\"/%WQ,\):AI&A>)?[2\3^&/#-
M[8^#EUN9[:V%S!>S_:%G#Q,LHM()]H`Y85ZM^U5^T'I?_!/7X5>$M*\*^"_&
M'B=9IXM.TOPEX&\._:IK#38-OVBXBM+*SE,<$$91%'EK$99K>-GB63S%]5\-
M?`SPWX*\,1:+I'P_\!Z7H\-O:V<=A9VL4%M'!:NTEK$(UMPH2%V9HUQA&8E0
M":NRR:;IWQ/@DDL/!]OXVU;39(X6:]1=4O;"VE4N%/E>:\$4MRA(&41KA<X+
MC-2MS6AHKW_X'W$QN]7O:WIW/GOXO_MK>%?$.HZIX;U+PAXF^)7PGU3PSH^L
M:MXCLX=(OM"CTS5I+F*-[RWNC$\T)6#.RVCNG96.Z)/E\SE?C5_P6&T'X&?#
M:Q\3-\*OVC?%&EW4NHXC\+Z%HNK7-K863".34YX(;LR06)D$L8EE5<-;OO5`
MT1D]A\1?L_?`FSOV^)>K?#;X"17/P_EN+H^*KNRT]9/#<D%Q+<W$GVQK?-LT
M=P\\KMO4K(\C-ABQK`\.>%_V7_\`@H+HD-II'AW]F7XX:;X(9Q%%9R:3XE@T
M%KIC(X55AE6W,S(6.-N\H2<XJ=6_=[ZI]N@]$]=MEZ]2/Q7_`,%"(-%^(MQX
M=TOP%\:O%6W55\/V>HZ79Z(MGJ>JMIJ:FME$;BZAD5C:,7,TJ1VRE&1IE?"F
M/X)?\%)/#'QM^.?A'P);Z3\4/#MUXV\.KX@TC4]>L]+L=.OV"%Y["W8S&2[N
M[<`^>+2.:*+Y2TH#H6]VLOAKI^ERP/:^$?"-N]K=C4(6B54,-R+?[*)UQ!Q(
M+?\`<[Q\WE_)G;Q7/^%_V6_`?@GXD6_C+1?A3\,=(\76MG_9\.N66FV]OJ4-
MKC'D+<);"018_@#;?:JT35MO^!_G^!.MO/3[[_Y'H/\`8-U_T&-1_P"^+?\`
M^-4?V%=?]!C4?^^+?_XU6=K7C1O#MYIEOJ$GA^PN-9N39:?%<ZKY3W\XBDF,
M40:,&1Q%#+)M7)V1.V,*2%\,>,I/'/ARQUC19-`U;1]5MTN[*^LM5^T6UY"Z
MADECD2,JZ,I!#*2"""#04:']A77_`$&-1_[XM_\`XU1_85U_T&-1_P"^+?\`
M^-4OVK5_^?'3O_`Y_P#XU1]JU?\`Y\=._P#`Y_\`XU0`G]A77_08U'_OBW_^
M-4?V%=?]!C4?^^+?_P"-4OVK5_\`GQT[_P`#G_\`C5'VK5_^?'3O_`Y__C5`
M"?V%=?\`08U'_OBW_P#C5']A77_08U'_`+XM_P#XU2_:M7_Y\=._\#G_`/C5
M'VK5_P#GQT[_`,#G_P#C5`"?V%=?]!C4?^^+?_XU1_85U_T&-1_[XM__`(U2
M_:M7_P"?'3O_``.?_P"-4?:M7_Y\=._\#G_^-4`)_85U_P!!C4?^^+?_`.-4
M?V%=?]!C4?\`OBW_`/C5+]JU?_GQT[_P.?\`^-4?:M7_`.?'3O\`P.?_`.-4
M`)_85U_T&-1_[XM__C5']A77_08U'_OBW_\`C5+]JU?_`)\=._\``Y__`(U1
M]JU?_GQT[_P.?_XU0`G]A77_`$&-1_[XM_\`XU1_85U_T&-1_P"^+?\`^-4O
MVK5_^?'3O_`Y_P#XU1]JU?\`Y\=._P#`Y_\`XU0!G6VC7!\37B_VK?@BU@)?
M9!ELO-Q_J\<8].Y]L:']A77_`$&-1_[XM_\`XU6?;W.J?\)/>8L[#S/LL&1]
MK?&-\V.?*^O;L.N>-'[5J_\`SXZ=_P"!S_\`QJ@#YS^)7[:6M?"_4OB_'JGA
M'Q)I]O\`#'0K+6+":_U?2X?^$E-U<7D$;+Y:R):VQ>U7][,XE`=RT";!YG+G
M]NGXDSWS>#X/!?AA_BQ:^*+GPY=:7)X_BC\.H+?2(=6:9-1_LDW+,;>YA7RC
M8*P?S,D1IYK?3&M^"+?Q(^J-J'A?PO?_`-N6`TO4C<L)?[0LQYF+:;=`?,A_
M?3?(V5_>OQ\QSX3\0O"G[+WP[_9;ATCQ7X;_`&8]#^"MCK<L$5EJSZ3:^%K?
M58Y9HY46.2`6JW2RI.K`#S`ZR`\AJSE=*_DDO6^_W:?Y#WE=;=OE_GJ:FO\`
M[7NH7'[)7P[^)'A;3Y]3U3XI?V-%H6DZKK%IIUK'/J?EF-;F\CMYPB('.6BB
MF9R`$1BPKRGP#_P5`\5>-=;93X+TVUT?PSXCT_PAXTN1XXM);G3=4O-9GT=/
M[.A&GA;ZV%Q"&,LTEG(49ML+2(T=>[?$OP;\*O"/P0\8:AXWT?X7V_PS\4&W
MU+Q&_B34H6\/7*+#:VL#RBYC-LL0CM[55&`F44@;CD\;X?NOV7_^%C?"C^R;
M+]F3_A+/[*7_`(5E]DO=)_M'^S_WFW^QML7F?9_]=C[+\GW_`'K3F7M/+FV\
MK;?GJ1]A6^_^OE]WGIG_``7_`&S_`!!\;O'KZ'JF@6NC>'_%&BZ]JWA>_MO$
MMMJ5Y?V^E7L5C<B_M!:1"T=GN(F589[D`;U=XG4*WT]_85U_T&-1_P"^+?\`
M^-5X7\-I_@JWQ4^*/_"N;/X(K\2MDG_"=GPO>6+>(!+F3_D)""(3E]^_'GD'
M=N[YKW0W.K[?^/'3_P#P.?\`^-4?8CWMKYE?:?K^B%_L*Z_Z#&H_]\6__P`:
MH.A70_YC&H_]\6__`,:I?M6K_P#/CIW_`('/_P#&J#=:OC_CQT[_`,#G_P#C
M5`'Q+X9_X*8_$#QU\=_'7@31?`>C37?A];Y]`N+CQ+J2V_B%;6Y9'(N(?#DM
MHS^1'+(T-C<7TZR`1>42EP]OZAX6_;2U"[_89UKXN:QI&I:3K7A^.[CO/#37
M8MV@NHIS%%'+)>V-K/;)*##+FZM89(XIE9HN@/#^-I/V(]5^(OQ/N/$T'[(-
M]XF=!_PL$:MJNBS748@NXH\ZFDL9*;;MK=29@/WWD@_.$KV/X:Z#\'_^&=[/
M5/!^@_!?_A4]KHM_!:W>CS67_"/0Z5,V^^2-XH?LXM9&BW3`'RV,>7SMXE7]
MEKO9:]+_`.3"5^=+I?;KTT/*O^&Z/B5<7[>#X/!7A=OBQ:^*+GPY=:9)X_BC
M\.H+?2(=6:9-2_LDW+,;>YA7RC8*P?S,D1IYK>X_LZ?$Q?VA?A?X7\=6%UJF
MGVOC#PWINN0PRM;2RPQW*22K&S(AC;;NQN0X.2<D8KQ[4;K]D/\`X8]T_P"V
M6/[)_P#PS_\`VL?L/G7NB_\`"'?VCNDSY68OL?VC=YN=OSYW^]?0WA>ZE%P/
M[*L]&^P_V;:_95MKP_9_(S+Y?EE8L;=O3`Q@#&<\5W7I\M-?O>I/5?/\_P!-
MC0UG;X=TFZU#4/$5Q8Z?8PO<7-S<&VBA@B0%F=W:,!54`DDG``.:^<?VBO\`
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MMM%>TTJT>-)/LB?8IOM-R=S$)(;>(;5#3J7%>N>&O@=X:\%^&8M%T?X?^`]+
MTB"VM;..PL[6*&VC@M7:2UB$:VX4)"[,T:XPC,2H!-<9^U/<_!?_`(2#P/\`
M\+LLO@?_`&I_:G_%'?\`";WMCY_]H;H_^0?]KBW>?N\K_4_/G9[5I*W.N7:[
MT[KL*%[>]Y?U\SS#]D#_`(*+:I^U9\;IM#;PUK'A7PO?Q7KZ!JFHPZI!>:L;
M:785Q/HD.F,Q022%+74[J50O,?RRF+ZQ_L*Z'_,8U'_OBW_^-5X9\(+OX`VO
M[5?C"#P#9_L_Q_&Z1)G\5QZ!>Z<OBID\V,RF^$,7VHKYK1%C+QN*9Y(KW3[5
MJR_\N.G?^!K_`/QJB/PQ?6VK[Z[KR)C?F?K^BW,_2=)N6U'5`NJ:@-MTH)"0
M?/\`N(CD_N_?'&.@]S7BG[>?[4WB;]D/PMX1NO#N@:AXZU3Q;K;:0EEMOS]G
M"V=S=-+Y>E:/J=W)Q;[<);%1NW,Z@$U[7I%SJG]HZIML[#F[7?F\<;3Y$73]
MUSQCTZGTR>1^/?QP\#_`32]'\2?%#7OAGX+L;6^,>EZKXH\06^G10W;PR*5@
MFN$4"5H3,,*=Q0N.F:F7KV_KYE1WVN>#_&S_`(*=S?LY>%/AS'KWPQ^/'C?Q
MEX\T@ZS<:!\,_",_B&3P_;!D7S;H75G8W$2[I%7;+;1RA@RM$I'/7?LW_MU_
M\+\\9:=I-WX3^)7@^WU^\U>RT/6-4ATY=/UJ33KF6&:../(OH9`D3.1<VD*`
MJZJ[X4OV?C/X3_"O]O/P#X>UOQ!X)^#OQD\+A6O-#O\`48K/Q%8;9,*TMM(]
MO)'AM@!:,\[1SQ3_`()?LV?"_P"&_BK4_&7PW^&/P?T#6M9:>SU#7/#6GVEK
M=7Q6<B>*6X@M@TA$\9#JS'#QG(W+51ZJ7?\`X;^O^&)>JO%]%_7]?\$;J/QK
M\0:?^U/:_#IO#?B:'3;S0+_6K7Q%-?::(=2DM7L5-O;P('E_Y?,.]P(`K(H0
M2JQ=.;_9:_:/\<?%_P"*OC7P9X\\.IX'UKPJD$MLUAJ-U?6NKQNTBRM!)?:/
MIYF$)6+=+;+<0?Z1&/.W96O5-<O]*N_'VGZ?J-KX-D\43Z;>-8VUS?HU_)8;
M[=;LQ(T7F&#>;42[1LR80W)6O*_V)$_9]M[#Q&W[..F?L]);":%-?/PWN]-$
M8E`?R5NOL$.-P'F;1)S]['>B'WZ?KO\`H5/96[K_`(8]LUW2IX+2%WU*]N%%
MY;9C=80I_?Q]=J`_K705S^O3ZB]I;B:ULXX_M=MN9+IG8?OX^@,8S^==!0!\
MC_'7]@?PI^TOJVNZ]J7Q#\6>'=3U[POI6AV]OHWBW5-)LX?LC7,CB]M;2^@B
MOX9OM/E212H&$8D5)$:3<F#^TC_P3@TS]H?XI:=XCD\8?"FS>'3--L&N[SP2
MM_KGATVC%B_AV_-^AT@/G./*N,,`V6Z5N?'OXH_M'>$]0\<V_P`+?!GAGQ'H
M.G>`-/O-*N]7URYTNXM=39-0\P6,46DWBW\N([4F*25`&\M<8E)KG?C_`/M5
M_M">"/$&CZ-X1T.V_M6\T#3);"UU/X8:[KT/B74;C*W"SZK8W$-EHJPO@,+Q
M#QELA<`8^ZVUT3^]Z[+[^FH2NFD^J_#3=]#!\5?\$;_AJO[,VL?#3PAJ7PS\
M+:7XF\-Z'H7B"`>%(_[/\33Z?.\LEY?0VMW;3RRSA_OI<QSQ,JNLY(Q7/^"?
M^"+6B^!_V?/`?@.U^)'P_ET_X?Q:]%::5=>%I[[PU?Q:GJ^GZF+2ZL+G599I
M[.(V3(89+MFD,JN9%,>']P^!7[6/QH^)'Q,6RU[X3ZAX;T*?2Y=?26XTRXCF
MBB@C:TETMW>01_;I+]//B;[C6;*=I)\T>!_L1_MW_MA?'S]IVS\'^-O!?@W0
M?"-V\6H?\)%%\)O&6CK;6B^>\UE<?VJ]M$EZZQQ(KPR3PQM+D?:`,5T1NYM+
M?=OI_2UT%S\L>?L[?-Z?U]Y[]\,?V+-,\$_L(>+/@K=>-/"=O_PED.KPM>>'
M-*;1M.TM-0EF<16=F;V9X(H5E"1HMS\JHH4H`H7&O?\`@GSI?A;5_$U_X)^*
M5S'?:Q+HM]IMQXYU75?&\^C76F7L=W'$LUYJ@F-A(R,SVRNCF25G\_:$C1?V
M>?VG/C)\2_VRU\.^)M/O-+\+V]MK;WNFI\-M:TJ'2)(+F".R1]=NO,L-4,L;
M2.KV30`8;*2`YCJ^//'/[0-Q\9/B(;Z_\1^&?@_X?\56]MI^H^$O#<6J^*YK
M5M-LI2T5O<6DL4FG)<F>.1H(+RZD>=@AMUMF+9_%)2ZVO\E9=/4>R:\_Q>K.
M7?\`X)A7&M?M$_"OXG:M\6/A_-XL^'^NZCK6HZC;>#F%QJ,=[=R7-Q96:W&I
MSV]A"Q=4,OD37>V/"W"*SJUB]_X);:3>_&3]HGQ)'\3/#NBZ7^T%HDNF7UAH
MNC/;7R3N0!=W6H27TMS/^Z`A\BV:SMPC.5C21VD.C\/_`(W?M0WOB_Q-<36.
MCKX5\,^)I(5LM7\!W\FL>(;"?Q1J=F@M+J&ZMX84M],ALY1(;6X+)(LCDAPQ
MQ/V*_P#@JG??M0?MZZ_\);?Q9X#\4/X?M]:N/$&CZ)X4U.SO/`\EG>0V]O;7
M&IR7,UEJ+2^:X:2W2(!H#A/FPE1@K^R7:7W=?O\`ZU">C<GTDK^J>EOF6/V)
M/^"47A;]C+PSX3TK1_%G@73=/\*^.)/&:V7AZQU:VL[IWT:^TMHS'J6M:BT<
MA^V"0R1NJL(54QDGS!]._LP^`])_9O\`V;?`7P^_X2;3M9_X0GP_8Z%]OREO
M]M^S0)#YOE[WV;MF=NYL9QD]:]-+9_PHW9JO:2UN][?AL']?C?\`-F>/&.D#
M_F*:=_X$I_C1_P`)CI'_`$%-._\``E/\:TJ*D#-_X3'2/^@IIW_@2G^-'_"8
MZ1_T%-._\"4_QK2HH`S?^$QTC_H*:=_X$I_C1_PF.D?]!33O_`E/\:TJ*`,W
M_A,=(_Z"FG?^!*?XT?\`"8Z1_P!!33O_``)3_&M*B@#-_P"$QTC_`*"FG?\`
M@2G^-'_"8Z1_T%-._P#`E/\`&M*B@#-_X3'2/^@IIW_@2G^-'_"8Z1_T%-._
M\"4_QK2HH`S?^$QTC_H*:=_X$I_C1_PF.D?]!33O_`E/\:TJ*`.=M_%6EKXH
MO)#J6G^6UK`H;[0F"0\V1G/;(_,5H?\`"8Z1_P!!33O_``)3_&BV_P"1NO?^
MO2W_`/0YZTJ`.=U^_P##?B[0KS2]4FT/4M-U*![6[M+IXIH+J%U*O'(C95D9
M205((()!KYOO_P!BF/P7X)\)6OPU\>>`O"&K>!_$&N:KHXU#PO'J6C6MIJCW
M1>T%C%=VS)Y,=PJ1O%.@Q&04*.4'T3\8_%7B#P-\+/$6K^%?"\_C;Q)IUA-<
M:7H$-_!8/K%RJDQV_P!HG(BA#M@&1SA02<'&#\-G]HO]HS5/AF#X^T[XY?"V
M./QE>6^IZSX9^'^E:]K$-F=.\ZTAL[&S.L`VGVHM&UPT4[<(IF7+NF4FG>/2
MUW]ZMZCZ1OW_`!L]?0]EB_97OK?]F7PU\-]/\=>#=+?X6WVB2^!]6N=,744>
M/3+:T"MJ5F)8%=GG2Z^6VEAV(8"KJZFN`\`_\$TKGP5KC,?B]X-NM)\3>([#
MQ?XSME\&P17.I:I9ZS/K$?\`9TPO"MC;&XF"F*:.\D"*VV99':2NO\9_M#?$
M77_V(-#O(KKQ3HGQ%TB?0-.^)$OACPL-5UOPS)/;V=U?-::>T=TDTRQ749VQ
MQ7819'PDC1D#QOX9?M`?M':IX^\+0ZQJ?QGW2:SIT'A^QG^&$$&G>+M#?6;F
M&[U#7;D68_LN]73%CF\DS:<0X3%M(TAMQMK[3SYEKW=EKZ?\/T(?P>5OPU_X
M/W^9[5\%OV09?@MX\?6K[XB>%_$&A^&=%U[2/">EV/AZ+3[^U@U6]BOK@7MV
M+F47<@>WB5#%#;`_.SK([!E^GO\`A,=('_,4T_\`\"4_QKX__9B^*_Q>\7?'
M3Q-I_BV_^)%YI@T?7I/$&G:]X'CT;0_#-[%?QQZ9#I%^MM$;^*:T-PSL+B^_
MU4;&2`MY;_:(Z`U,?X<>UM/O_P"'97VG?^M$4/\`A,=(_P"@IIW_`($I_C0?
M&.D$?\A33O\`P)3_`!K2H/2F!\'Z3_P3U\<>#_VB/'WC7P]\>/"UE:^(UG_L
MK3K_`$S5;JTM&N)G>5IK2#6K:UCEC2241W&GQ64^^1I'=B\XN/1O#?['3Z?^
MQKJ/PAU'XF:!?0ZQ:Z@UUJ/]G2W!6^N+E;F*91?7]U/+$LGFM,EY<7,L[3']
M_&H"5\VK^T]\?+;]J/XQ^']<\2?'W3_">EQW3Z9=Z/X"2^DT5FO<VB000^%K
MH21R*%A6>*[U4B$R2O;ABS6?OGPU^./Q?NO^"<=_J%S;^,[_`.+@TO5;FPO+
MKPK-]LN(X;G"2K;RV&GAKE(9D$<5Q963W+P.R6QCY,IKV5UM9?=K^(2_B)/5
MW?\`7H0G]BOQ5;W[>,+?XP?#5?BQ=>*+GQ'=:G)X&$GAYQ/I$.DM"FF_VD+E
M6%O;0MYIOV8OYF08W\I?</V<O!&@_L\?#'PSX'L=<M[[3_!_AO3-"M[N9X8F
MN5MD>(,53"*2`"54`#<,#&*^3[KXX?&)?A;%)+XP_:'A\"_\)G=V=OXU@^$D
M4OCFYTY=)BE@\W1O[*)2$ZD;F'S_`.R4)CABSM5_M+_77[,>M>*_$?PG\*ZA
MX\L_[/\`&U]X6TJ?7K7R5A^SWS1R&=/+5W5,2%AM#L!TR<9JUL_2/Y:?<MQ=
M5\_S.JU[7[+5M#O+6U\16NEW5Q`\45Y#-"\EH[*0LJK(&0LI((#*5)'((XKX
MC_:=_P""65Y^V9\&-0\/?$[XI?"OQAJFM>);?7]3:[\%WEOH]XMMIZ64`%M;
M:W#=PW"[/,,T5\B-YDB&'8Q6ON[7]4DT71+R\BLKO4I+2!YDM+79YUT54D1Q
M[V5-[8P-S*,D9('-?"O[1_[>GQTB^%6O>*O@[X/UI'U+Q3::=HD?C[X4^*98
MK"T73(Y;I9[#3K8:JH-R9%2Y\B:`NI3<%977&5NJ[?+71^6O8TAS7]U]_P`O
M\C8^&7_!)KX<^$/"G@_^VM;\#^)/&?@+PWX6\.>'_$\_AZ'[=H:Z+=RSF2S>
M6XEFM_/601D)+E0@):3H/0OVROV3I/VG-=N;K0_B/X5\+0>(O"U]X(\1Q:EX
M?BUI[O2KMXVD^QO]IA^S7(VL`\@N(CN4M`Q05QOPQ_:0_:<^(GA7P?XHN/#7
MA;P_8Q^&O"U_XE\/W?@/6?[2U+4+^[EAU."TEEO(39K;1HDFV:VN'0.#)Q@G
M2_X*/?%7XM?#WQ=I</@'4/B5I<)\/WMUHL?A+P/'XD@\0^($DA%KI^J2-;7'
MV.R=2<R[K-<-(3=Q^6!6]2_M5S[W?I?77MK^)E3VO'R_3\OP(?V-OV"/^&0_
MC'<ZM:_&"36/!D`OETSP^]]JS>7]IF,N9UNM7N=/WJ68^99Z?9R,Q)9\/*DG
MUD?&.D'_`)BFG_\`@2G^-?$W[!WQS_:%\<?M?Z]I?Q6LO&-MI:Q:@)=/&FR6
M_A_1W2X40>1+-X>M%F!0;5>#6]1+[RQA"L6M_NMB"*E:PC;:VGH*-DVDNNOW
M(Y[2/%.EQZEJA;4+!1)=*R$W"?,/(B&1SSR"/P-><?M,_`/PK^U-=^"5UCQ9
MJFDV/A'6)=7=="\27NB7MX7L;FU$:WMC<P7$('VC>=KD.$VD8;(]7T/_`)"F
ML?\`7XO_`*3PUX3_`,%!;/XU:UHG@'1_@GJEYH^L:KX@DCU>\BN[6QCALDT^
M[E_>75SI&K1P*9T@`/V0EF*H'3?FIE:VJOL6KWT/'/\`@HS_`,$EO`_[?4/P
M[CO/%F@36?PYL9+"PLO&5UKFO0_-Y6VZ$EIK>GW+W>(@K3W$\[.#R`V6.Q^Q
MW_P3HL?V6OCT?&EQXU^&M\\;ZK)]KT;PK+IGB+61?7+3"'5M5N-3NY=0@@W8
MBC9$VF.)MWR8//\`[;G[1?[5W[*G@GX4Z-X`T7PGXKU2\TN23Q=XA\4>'_$7
MBT27B&+_`$:)?#&DQLA^>0BXELK>)U48C5@RUTO[#O[5?QM^*/QK;0?'&CW3
M:6USK7VV"?X;Z]H#>'8H;R06,@UF]2"RU1)8O+58K:UCE575W9_+D9KI-I/D
M[N_KU_7_`(8BIJES+M;[U;^OU/:=;^!'@NY_:/A^)VGR>$--\03:#?Z'JLR6
M$!N-<$[61A>YF5E>58%M"BH^?EF(#)CGE?V5O@!K?P:^+'C/QEXT^)WA3Q7J
MWC"*WA>+1[#4-.M(%A:5D"QZAJVI&)%,LFR&T:V@7S92T3LP9>J\37OQ*T3]
MKK3B=:BN/AC>^%M5F6PL_#3LUC?PR:<(7NKOS)&F=A)=&**)8,J)`5F95=/+
M?^"=?Q6^(GCOXH_$:R\2:Y\4?%?@ZU%H_A_5/&GA"7P[>(<S"4-'+H6C<R`Q
M$111WJQ^2Q>Y4R)&9I[Z;V?W7V^_4NI\*YNZ/IC7_$FFZA:0PPW]G-(UW;;4
MCG5F;$\9X`-=!6;XJ_Y!D7_7Y:_^E$=:5,#YW\<_M3WWPYU1=!\/^!?BU\2K
MK1=+MK[6SX5MM'\G0HY8RT2M]NN+9[B1D21A%:"XE`5=R@R1"1WQA_;[^%_P
M"T[Q->>*_&'C/2[+P;HUOX@URX_X0W4;B'2K2<QB,S/%8,J2GS`Q@)\Y425R
M@6*0I<\>_LA^"/CI<:;K>NZ#XU@U1M+@L+FZ\.^+]0\.C5[=`2D5XMA>VXO(
MEWR;$N5D"":4``2.#H>.OV1O`/Q&TC5;*]\%:Y8QZL^FM+)HVN3:-<6[:=Q9
M-;36=W%):F($@&!HR5)!R#BL_>MI:]_P#3FUVM_D><^&/^"KOP7\=^"O!7BC
MPWXT\8>)O"_Q`L-4OM$U'2/#%S>2WAT^^L[&>W2P2U-^\YFO8]J1VS92*5R5
M503Z=HG[47@OQ-^S_K'Q,L?%7B*7PGH*7AOY)-#FM[ZUDM':.X@:REM5N1.D
MB-&83%YF]2NW=Q7E_P`3O^"6WP\\=?".W\+Z+_PMKP+?:;)?2Z=XJT;QA)=>
M)M,DOKVVO;V2&_U">ZD$L\UI#NE;,BC>$=`[9[[]G/\`9'\-_L^?LRCX526?
MC#XA:!="]_M>\\;W]MK5_P"(WO)I);E[Z1V"SF1I7#`H`1P1USKIROOT#2\?
M77TO^=K?B<!X6_X*=>$'^+6O>!_'%OXR^%7B?P]HDOB&YTSQ!JGAB_OC:1B,
MLWV32;V]N8V*RQE%FBC,N\"/>WRUU2_\%`/AJWAMM0/B#XF)<?V@--&AM\.]
M97Q$93"9@PT@Z;_:!A\L,WG_`&?RL*?GX-2Z)^P7\.-'CU2.Z\/_`!*\1Q:M
MI\VFR1^)OB%K'B)+6&7&_P"RK?ZC,+20[5Q+;B.0;1AABH5_X)__``U7PV=/
M_P"$?^)C71OQJ/\`;C?$76CXC640F$*-8.I?V@(?+++Y(N/*PQ^3DU.MODOO
MOK^'XBZ_/\+:?C^!1^&'_!2GX0?%;X?:'XDL?B!K%G;>(+&_O[2UN]**73)9
M>7YZ[%MVS(1-$T2*6-PKAH/-7)H\??\`!1CX:_"CXF^)O"?B#6?B-;ZMX5NY
M+:Z73O!=[KBF.*PTZ^FNB=/L[@PVT<>J6JM+<"(!RXY`W'2\/?\`!/GX/^&!
MI7V3X:W_`)FCWND:C:RSZS-<2BYTJ-XK&9WDNV:1XTD969RQE&/,W[5QU%U^
MS)X'O?&GB[Q#)X'U!M8\=6US9:[<?V@1]MAN+:SM9EV_:=J;H=/M%S&%(\G(
M(9G+/2_R^]Z6?DOO'&VO-Y?+O^'](]$L[.34+2.>'6KZ6&91)&RK;E74C((/
ME]"*F_L.Y'_,8U+_`+XM_P#XU5?2YWT?38+.WT748X+6-8HD\V`[548`R9<G
M@=ZL?VY<G_F#ZE_WW;__`!VCT)C>VNXO]A77_08U'_OBW_\`C5']A77_`$&-
M1_[XM_\`XU1_;MU_T!]1_P"^[?\`^.T?V[=?]`?4?^^[?_X[04']A77_`$&-
M1_[XM_\`XU1_85U_T&-1_P"^+?\`^-4?V[=?]`?4?^^[?_X[1_;MU_T!]1_[
M[M__`([0`?V%=?\`08U'_OBW_P#C5']A77_08U'_`+XM_P#XU1_;MU_T!]1_
M[[M__CM']NW7_0'U'_ONW_\`CM`!_85U_P!!C4?^^+?_`.-4?V%=?]!C4?\`
MOBW_`/C5']NW7_0'U'_ONW_^.T?V[=?]`?4?^^[?_P".T`']A77_`$&-1_[X
MM_\`XU1_85U_T&-1_P"^+?\`^-4?V[=?]`?4?^^[?_X[1_;MU_T!]1_[[M__
M`([0`?V%=?\`08U'_OBW_P#C5']A77_08U'_`+XM_P#XU1_;MU_T!]1_[[M_
M_CM']NW7_0'U'_ONW_\`CM`!_85U_P!!C4?^^+?_`.-4?V%=?]!C4?\`OBW_
M`/C5']NW7_0'U'_ONW_^.T?V[=?]`?4?^^[?_P".T`9]MHUP?$UXO]JWX(M8
M"7V09;+S<?ZO'&/3N?;&A_85U_T&-1_[XM__`(U6?;:S<#Q->-_9=^2UK`"F
M^#*X>;G_`%F.<^O8^V=#^W;K_H#ZC_WW;_\`QV@"AX@@U#2-#O;RWN-;U:XL
MX'FBLK46:SWC*I(BC,JI&';&T%W1<D991DCYJ?\`;;\=>(?`'A&3P_X(AC\=
M>,/$.O:+#H'B7Q=::9:V":3+=K,\][;V5UF9DM@?*@BE0,[_`+TQQF5OI/Q/
M\0;7P+X:U#6M9A?1]&TFWDO;Z^O;NVM[:R@C4O)++(\H5$5069F(``))KP#X
MD?&[]E'XQ?LUMK/BZ\^`OBKX/2:ZY>^UC4_#]]X:?5W9Y7S)+,UL;MFDD<\^
M83(Q/WB:SE=II/73Y:_KL'1>OX6V-/7_`-KR_N/V2OAW\2/"VG3ZGJGQ2_L:
M'0M)U76+33K6.?4_+,:W-Y';SA$0.<M%%,SD`(C%A7E/@'_@J!XI\:ZXR_\`
M"%Z;:Z/X9\1Z?X0\:7*^-[26YTW5+S69]'3^SH1IX6^MA<0AC+-)9R%&;;"T
MB-'7NWQ)\.?!SPC\$O&&H>-_#OA&W^&?B@V^I>(I/$EQI[>'KE%AM;6!Y1<S
M&V6(1V]JJC`3**0-QR>-\/ZY^RG_`,+%^$_]DZ/\!?\`A+/[*7_A6?V1_#_]
MHC3_`-YM_L;;+YGV?_78^R_)]_WK3F7M/+F6G96^'\]2?L*W]?UI]WGIG_!?
M]L_Q!\;O'KZ'J>@6NC>'_%&BZ]JWA>_M?$MMJ5Y?V^E7L5C<B_M!:1"T=GN(
MF589[D`;U=XG4*WT]_85U_T&-1_[XM__`(U7A?PVU7X$2?%/XI+\-]+^%T?Q
M-99!XY;PX^D?VXLN9,'5/LTAN-V_?_KQG.[OFO=/[<NL?\@?4?\`OY;_`/QV
MC[$>]M?,K[3]?T0O]A77_08U'_OBW_\`C5!T*Z'_`#&-1_[XM_\`XU1_;MU_
MT!]1_P"^[?\`^.T'7;K'_('U'_ONW_\`CM`'Q-X9_P""F/Q`\=_'?QUX#T7P
M'HTUWX?6^?0+BX\2ZDMOXA6UN61R+B'PY+:,_D1RR-#8W%].L@$7E$I</;^H
M>%OVTM0O/V&=:^+FL:1J6DZUX?CNX[SPTUV+=H+J*<Q11RR7MC:SVR2@PRYN
MK6&2.*96:+H#P_C35?V%]5^(GQ/N?$VG?LQ7OB9T'_"P1JUWX:FNHQ!=Q1YU
M-)9B4VW;6ZDS`?OO)!^<)7L7PVLO@E_PSM9ZIX/\+_#G_A4]KHE_!:7>C1Z1
M_P`(]#I4S;[Y(WBD^SBU=HMTP!\MC'E\[>)U]EKO9:]+_P"3"5W42Z7V/*_^
M&Z/B3<7[>#X/!7A=_BQ:^*+GPY=:7+X_BC\.H+?2(=6:9-2_LDW+,;>YA7RC
M8*P?S,D1IYK>X_LZ?$M?VA/A?X7\=6%UJFGVGC#PWIFN0PR-;2RPQW*22K&S
M(AC;;NQN0X.2<D8KQ[4=;_8W_P"&/-/^V:/^SC_PS_\`VL?L/G/X;_X0[^T<
MR9\K,OV/[1N\W.WY\[_>OH;PMJ\'VE6TO2Y/[-.G6HM$M'M_)$(,OEE-LFS8
M5(V[3T'IC-+JO3\M?O>I/5?/\_Z1H:R5\.Z3=:AJ'B*XL=/L87N+FYN#;10P
M1("S.[M&`JJ`223@`'-?./[17_!1:S_9VMO$$D?A/XI?$J72M7L]+L-+^']C
M9:YK.LQW&GQ7K74-HWE%X8EE4-Y32$`AR`FXK]+SZE-<Q-')HM^\;#:RLUN0
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M(S$J`37&?M3:U\"CX@\#_P#"[-(^&/\`:G]J?\4=_P`)N^C^=_:&Z/\`Y!_V
MN7=Y^[RO]3\^=GM6DK<ZMM=^K7;^NPH7MKY?U\SS#]D#_@HKJG[5GQNFT-O#
M6L>%?"]]%>OH&IZE#JD-YJQMI=A7$^B0Z8S%!)(4M=3NI5"\Q_+*8OK'^PKH
M#_D,:C_WQ;__`!JO"_A!KO[.MK^U5XPA\`Z3\'X_C=)'-)XKC\/OHB^*F3S8
MS*;X0R_:B/-:(L9>-Q3/)%>Z_P!NW2C_`)`^I?\`?=O_`/':(_#%];:OOKNO
M(F/Q/U_1&?I.DW+:CJ@75-0&VZ4$A(/G_<1')_=^^.,=![FO%/V\_P!J;Q-^
MR'X6\(W7AW0-0\=:IXMUMM(2RVWY^SA;.YNFE\O2M'U.[DXM]N$MBHW;F=0"
M:]KTG5[D:CJA72]0.ZZ4D!X/D_<1#!_>>V>,]1[BN1^/?[0/PY^`FEZ/XD^*
M&J>%?!=C:WQCTO5?%&K:;IT,5V\,BE8)KB=0)6A,PPIW%"XZ9J9>O;^OF7'?
M^OZT/!_C9_P4[F_9R\*?#E->^&/QX\<>,O'FD'6;C0/AGX1G\0R>'[8,B^;=
M"ZL[&XB7=(J[9;:.4,&5HE(YZ[]F_P#;K_X7YXRT[2;OPG\2_!]OK]YJ]GH>
ML:I#IRZ?K4FG7,L,T<<>1?0R!(F<BYM(4!5U5WPI?L_&?PX^#O[>7@'P[K7B
M#X?_``_^,WA?:UYH=]J-AI/B*PVR85I;:1VDCPVP`M&>=HYXI_P2_9]^$/PW
M\4ZEXR^&_P`)_`.@:UK+3V>H:YX:T72;6ZOBLY$\4MQ`0TA$\9#JS'#QG(W+
M51TNI=W_`%_7_`(EJKQ?1?U_7_!&ZC\:_$&G_M3VOPZ;PWXFBTV]T"_UJU\1
M37VFB'4I+5[%3;V\"!Y?^7S#O<"`*R*$$JL73F_V6OVC_''Q?^*OC7P9X\\.
MIX'UKPJD$ML]AJ-U?6NKQNTBRM!)?:/IYF$)6+=+;+<0?Z1&/.W96O5-<\0>
M';OQ_I^G:CI>GR>*)],O&L;:YDLC?R6&^W6[,2-+YA@WFU$NT;,F$-R5KRS]
MB2^_9OM['Q&?V<=#^#B6RS0IKY^&YT,1B4!_)6Z^P28W`>9M$G/WL=Z*?WZ?
MKO\`H5/96[K_`(8]KUW2IX+2%WU*]N%%Y;9C=80I_?Q]=J`_K705S^NZK/<6
MD*/IM["IO+;,CM"57]_'UVN3^E=!0!\I_&S]A.^_:*\76_FZQ;:=\/\`Q)H]
MI=:W:Q%A>G6+*WFBT^ZB7:8SM-Q#.79@R2Z19;5;<Q30U+]D?QEXM_9:AT/5
MM0\--\0M<\;Z-XU\174,LPT]Y+77;&_EAA<Q^8PCL[-+:(LB[_)CW;`25Y/X
M_?M?>)O@=JOCO3=!^">L?$*U\)>`M/\`$D.J:2NCI#I]S*FH%OMPOM1M99(_
M]$C8"VC=L"7)W%!7G/[1O_!7&Z_9U_:"^'O@?_A2?A37[/Q5HVE:GJ.K7_Q"
MT#PM=,UXQ#)I6FZC*DNILF"-L4@S(1'G<<G.+C?EZW7WW;_3YV0.]U+LKKY6
M7Z_BS>^$O_!,WXC?#GQW\%=8_MKP<)/ACX1\,Z'>,)[F7S+O3-&\3V4LD2^2
MN^,S:U:,NYD9DCFR$(0/P?[*/_!*S]H7PO\`%.X_X6=\7_B!=_#[5[J"\U/3
M+;XZ^(-9O#)';:DC16=P-/T^XL[8SW-F_E+<.Y%J-\TF,-N0?\%8E\5_"*_\
M3:/I_P"RI#<:;?:"UWIW_"VA?W^@V-]JEK9W!U>W73(FTZ>$7*JP+2I'+O#,
MWEA9=6]_X*QZ?#XE\76-K\/_`(8ZM/X?BU!XM'TWQNMSXETMK6Y6`'7-.&G@
MZ3'*6&UQ+<?,\:[3OR-Y2E.3G+K?\$FW^(5JSJ/FEI\*OMZ?\.>V_L>_LK>/
M/V??%L-_XE\>:_XO75/">G6>O?VKXFU#5EGUR!I/.NK:&X_<VL+QNJXMTA#E
M07CW#=7S3\7O^"1_Q`\=?\%%M;^+5C9?#-M+U+QCH_B.TU>YGTMM7T^&SAL$
M>/9-X9N+XDM:286WUJV5ED`!C)<M]+?MB_%C4/V=?V4;7Q;>M\*?A[X@DU#1
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M96]-M/F_OMU!1YKV[Z]'T_KT+/@_]A3X_:9_P4)TOXI:I\3?&5QX+C:`R^'X
M/BS<#1+*`6*PO:'1)-#>.]*RAS]J:]@EE+"4B)QLK[IZU^:_[.G_``6.U#]H
M/PEX9UJX^%?PC\*QR_$<^!];M+7XD:?XJ$\3Z)+J-M_9UYI\+6T]Y-(GE);E
M^9%6+(:4M#[Q^PA^W%I/[9OBW6-+'AWX5M_9^F0:I]H\%^,$\5Q:;YKLOV+4
MS]BMOL-^,9^S_O<A)?G'E_-MRV_=]OR:OO\`UYZD2LO>?6WYV_,^LJ*S?^$-
MTC_H%Z=_X#)_A1_PAND?]`O3O_`9/\*DLTJ*S?\`A#=(_P"@7IW_`(#)_A1_
MPAND?]`O3O\`P&3_``H`TJ*S?^$-TC_H%Z=_X#)_A1_PAND?]`O3O_`9/\*`
M-*BLW_A#=(_Z!>G?^`R?X4?\(;I'_0+T[_P&3_"@#2HK-_X0W2/^@7IW_@,G
M^%'_``AND?\`0+T[_P`!D_PH`TJ*S?\`A#=(_P"@7IW_`(#)_A1_PAND?]`O
M3O\`P&3_``H`TJ*S?^$-TC_H%Z=_X#)_A1_PAND?]`O3O_`9/\*`"V_Y&Z]_
MZ]+?_P!#GK2KG;?PMI;>*+R,Z;I^Q;6!@OV=,`EYLG&.^!^0K0_X0W2/^@7I
MW_@,G^%`%/Q_I&J:_P"#-2M=$O-(T_69H&%C<ZKISZE96TXYCDEMTFA:5%8`
ME%FC)QPZGFOE/PG_`,$V_B%X)LK?7+'XL>%Y?B':^(KO7$U#4O".I:SI#K=6
M'V&97M[[6I[\R^6(PK#4A%&D*1I`J%U?ZV/@_21_S"]._P#`9/\`"O*/VU/"
M?B^U_9H\77GPNET;1?%^G:9=75I(WAA=:N;@QV\K+#:P[T47+.$",Z3H#P89
M,XJ9)/3OH_O145S22^[\CDHOV)O$EO\`LS>&?AOI_B;P_IC?"V^T27P/J]SH
MG]HQO'IEM:!6U*S$D"NSSI=?+;2P[$,!5U=37`^`O^"4?B#P3KC,?B9X=NM(
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M/MUW]HD%W(KV\2HT4-L#\[2+([!E^H@1^5?#W[+_`(L^)7B7X\^)++Q2OCJZ
MT^/2==FUZPUSP!!HNB>%[Z*_C33(='U!;6(WT<MJ;AF<7%]_JHV,EN6\M_L\
M>#M)QG^R]/\`_`9/\*(_PX]M;??U_%_,K[3_`*[?<:E!Y%9O_"&Z1_T"]._\
M!D_PH/@[2,?\@O3O_`9/\*!GQGI/_!,?XG>#OVB/'WC;P]\9-'LK7Q(L_P#9
M.GW^AZQ=6EHUQ,[RM-:0:S;6L<L:22B.XT^*RGWR-([L7G%QZ+X:_8,UK3_V
M-M0^$.H^.;*^BUFUU!KK41HMQ<%;VXN5N8IE%]?74\L2R>:TR7EQ<RSM,?W\
M:@)7R8/C?\9K;]J'XQ^']<O_`(V:?X3TJ.Z?3+O1_AS#?2:(S7N;1(((?"MT
M)(Y%"PK/%=ZL1"9)7MPQ9K/WSX:?$/XDW7_!.._U"YT/Q%??%P:7JMS87EUX
M,?[9<1PW.$E6WET_3PURD,R".*XLK)[EX'9+8Q\F4U[*ZVLONU_$)?Q$GJ[O
M^O0VC_P3]^(%O?MXPM_B;X'7XL77BBY\1W6J2_#UI/#KB?28=):%--_M$7*L
M+>VA;S3?LQ?S,@QOY2^W_LY?!VU_9[^&_AGP)8W4U_9>#/#6F:)!<RQI$]PE
MNDD0=D0!%)"YPH`&<`8KXPN?B#\2U^%D,DFN_':#P+_PF=W9V_C6W^#=O+XY
MN=.728I8/-T;^R24A.I&YA\_^R4)CABSM5_M+_77[,EAK'B;X/\`A.\\>:#8
MV'C*[\+Z7<Z[9_88X1;7[QN;A?+5G5#YF05#L!C&XXS5K9_]N_EI]RW0NJ^?
MYGIFO:?<:KHEY:VM]-IEU<0/%%>0HCR6CL"%E59%9"RD@@,I4D<@CBOB']IW
M_@D'XD_;+^#&H>'OB;X^^'OC#4M:\2VVOZFUWX"O[?1[M;;3TLH`+:VUJ&[A
MN%V>89HKY$;S)$,.QBM?9VO^%K"#1;MK72]/-RD+&(+:(QW!3MP,<\XXKX!T
M+XJ_M+6'[*OA72[WP?KU_P#$;1Y-$\0:_KR^#+9)M<TNZN+-GTZ.W\A8(KT&
M>[@G54#01:<\K"$W$,@RM%MWZ6W];IKTMJ7%R5K==/O1Z;\-/^"-?@_P?X5\
M'_VU-X7\2>,_`?AOPMX=\/\`B>?PLGV[0UT6[EG,EF\L\LUOYZR",A)<J$!+
M2=!Z#^V9^Q!K7[3NN7-UH7C/1?"L'B+PM?\`@GQ'%J7A==:>[TJ[>-Y/L;_:
M(?LUR-K`/(+B([E+0,4%?+?[+?[7W[57QBO_`!+I'B/X;_#_`$F>;4-%AT#6
ME^#WB[3+73K:ZGNH[HW]MJ;6OG30)';NPM;@PIYC?OG!!'TI_P`%`+S7O`VA
M>"_[#N/''A?0;S4;B/Q#K?@'P+#XIUNT"VDK6R)9M9WI$,DX4/(+67;A`6B#
MF056G_R^>KO^+WT^9,=)\BZ)?\#\OD9?[''_``36UC]D7XR7.K6WQ,U75_!<
M*WJZ9X>>766\O[3,9<SK=:K<Z=O4LQ\RST^SD9B2SX>5)/K'^=?FG^RK\7/V
MF/%'[6?@_3_BEX3\0:59W4-L-2T;3?#WV?14B;3E9KB:9M`GM_,$S,[HGB.)
MT8>6MO(4$<_Z-KX0T@C_`)!>G?\`@,G^%:<MH)7T6B,URJ32]?+M^@FB?\A/
M6/\`K\7_`-)X:\Z_::_95TS]J6[\$KJ^L>)-)L/"&L2ZLZZ%K>H:)>W9>QN;
M41K>6-Q!<0@&XWG:Y#A-I&&R.VTKPMI<FHZH&TZP98[I50&W0[1Y$1P...23
M^)KC_P!I*\U#P'\++QO!/A/3]<\;:PXTSP_!-82-817LH81SWTD4;F"SBP9)
M9"/NH50-(\:-G4:ZZ[&L;MZ:'SO_`,%%_P#@C/X=_;[A^'<-YJ]C-9_#FQDL
M+"R\8G7]>A^;RMMT)+36M/N7N\1!6GN)YV<'D!LL=K]CK_@ES/\`LM?'H^-+
MCQ%X%OWA?59/M>C>#;C3/$6LB^N6F$.K:K<:E=RZA!!NQ%&R)M,<3;ODP>"\
M7?M*_&;X`?"7P3X3\;^&O#=C\3O[?_L36O$MCX"U?QSI6IV1TZ\O(-0LK33(
M;*>\G+6RP7$4<</DR"67RD@:$O[+^Q_XQ^)WQE\6W%QX[\&^&_"?AVST"PE2
MT?PG=6=[JE]<!F:=)IK@K!&J1Y:T>%YHC<(DDH:)@]QO"Z6VOS;W9G.TDE+L
MK+M9H]%UK]EC0+C]I&'XG:;8:#IOB";0;_0]5E71XS<:X)VLC"]S,I5Y5@6T
M**CY^68@,F.>5_96_91\9?!KXL>,_&7C7QUHOBS5O%\5O`\6CZ1J>G6D"PM*
MR!8]0U74C$BF639#:-;0+YLI:)V8,N-K&E^./#/Q0^,2>)=6E3P9#X9LK[PW
M=^&/`!N+G16>;4EG$$02\DU#4$CCMF*A&0GR<6@#,)<__@F;K'B[XB?#+Q0W
MQ`M_$6K/::](FCZEXF\-'2+V>R,,6(VBET?1Y&97$C%O[/2,"946:X,;L%'1
MZ=OP;U7K<=2WPO75??:Z?IT/I;Q5_P`@N+_K\M?_`$HCK2KG]>\-Z;I]I#-#
M86<,BWEMM>.!59<SQC@@5T%!1X1XX_:]\-_!*_TGP[JUUXFNM2?2[:]>+0?A
M[KOB)=/MY-R1O=3:?#-';!C')@S&/(C=API(U?%?[8OP[\`^-/$WA_7OBI\.
M]!U;P;I-KKVNPZE<I9KI-A<R-%#<3223JB(S@#);CS(LX\V/=Y1^U+_P3D\#
M_MM:UX8USQ9K7B.%M#TR*TMK,>#/#VN6\!X9Y(9-5T>]FMW?"[FMI8PWEH?O
M*&K6_:6_X)Y^`/VISJ$/B+5_'!TW4=$TK1VTZ72K35;,/IMU-<VEX\>HV-S]
MHN%-S.C"X,L+K(2\3.%<1[W+?K=_=T?]?@&E[+:WXZ:?U^)ZGX7_`&EO!7C;
MP<WB/1_BC\-=8\/+ISZP=4L]1@N+(6*2/&]T9DN2GD+)'(ADSM#1L"<J:X^7
M_@HW\#4\.WVK-^T1\!ETG3;V/3;R]/BK3Q;VEU(LC)!))]LVI*RQ2D(2&(B<
M@?*<<5X3_P""8/PG\+_"[POX1==?N=*\-75W-*MGX;T[04UJWN9(YI+.Z@TK
M3[2W,!GM[67]U%'(SVL>YV4R*^1^RA_P23^$O['OQ.TCQ1X9FUJ2\T*8RV,?
M_"#^']*\L?9;FUVR3Z9H]I<W`\NY?FXFD;<JL226W7NVNA.J7F?1FN_&;2?#
M_@;1?$TWBG09O#OB*XT^UTO4;.TDO+>_>_FBAM#&\,K!DEDFB`<?)APQ8+DU
MJ:[XRC\,3R0ZEXE\-:?-#93:D\=RGE,MK"5$UP0TX(BC+IN?[J[UR1D5YIXV
M_9:\/^+?V9=%^&%GXA\>^';/P[<:==Z9K6G6,3ZI:36%W%=V\@^T6<MLQ\R%
M,AX&4C(Q7)_$+]A^3XH^&K:SUKXX?'2YU1=/U+1;S6DT?0H;[4],OO(\^QE"
M:,($C!MT*R0Q1S@LW[TC`$ZM.W?3TLK?COY%+I?YG;WO[;WPOTOX@ZMX5U#X
MP?#'2?$VAPRW5YI>I7T5E=QV\5JMW+<K'+<*SVZ6[>8TZ`QJ%?+#8V(]"_;M
M^$/B7PI;Z_IOQU^"NH:#?:E_8MOJ=MXALI;2>^PC?9$E6[*-/B6,^6#NQ(G'
MS"O+_BK_`,$P_"7Q:U#Q+'>?$?XR:;X=\4:A;ZW<:#IMGI]O:Q:G;6-O9V]\
MD_\`9AO3)&MK`_ER7#P.R;7B>)FB-?\`9U_X)1_#']FNRO(=%U;Q?<+>WE]?
M-$?"NBZ=9I)=Z:NG2XLK#2;:S*^2BMM:`AGR7W@E2]>5OJDK>;TO_7IZ`MUY
M[^7]:'T9\)_B[HOQ^\&P^)/`GCGP3XT\.W,CQ0ZKH4T>I64KHVUU6:&X9"58
M$$`\$8-=1]FU;/\`Q_:?_P"`3_\`QVO(_P!BW]F;P[^Q'\(9/!NA:]X\\2:>
MVHSZ@DNNVRYL_,V@6UM!:VMO:VMK&%"QV]O#'%&.%45ZX/%%MG_5:A_X+[C_
M`.(JI;Z$J_4=]GU?_G^T_P#\`7_^.T?9]7_Y_M/_`/`%_P#X[1_PE-O_`,\]
M0_\`!?<?_$4?\)3;_P#/+4/_``7W'_Q%(H/L^K_\_P!I_P#X`O\`_':/L^K_
M`//]I_\`X`O_`/':/^$IM_\`GEJ'_@ON/_B*/^$IM_\`GGJ'_@ON/_B*`#[/
MJ_\`S_:?_P"`+_\`QVC[/J__`#_:?_X`O_\`':/^$IM_^>6H?^"^X_\`B*/^
M$IM_^>6H?^"^X_\`B*`#[/J__/\`:?\`^`+_`/QVC[/J_P#S_:?_`.`+_P#Q
MVC_A*;?_`)Y:A_X+[C_XBC_A*;?_`)Y:A_X+[C_XB@`^SZO_`,_VG_\`@"__
M`,=H^SZO_P`_VG_^`+__`!VC_A*;?_GEJ'_@ON/_`(BC_A*;?_GEJ'_@ON/_
M`(B@`^SZO_S_`&G_`/@"_P#\=H^SZO\`\_VG_P#@"_\`\=H_X2FW_P">6H?^
M"^X_^(H_X2FW_P">6H?^"^X_^(H`/L^K_P#/]I__`(`O_P#':/L^K_\`/]I_
M_@"__P`=H_X2FW_YY:A_X+[C_P"(H_X2FW_YY:A_X+[C_P"(H`SK>WU0^)KS
M%Y8>9]E@RWV-\$;YL<>;]>_<=,<Z/V?5_P#G^T__`,`7_P#CM9UMXBMAXGO'
M\O4,-:P*!]BGSP\W;9D=>O?GT-:/_"4V_P#SRU#_`,%]Q_\`$4`)]FU8_P#+
M]I__`(!/_P#':\^_::_:"7]ECX0ZMXSUR'6-8T_289)GM=`\-76IW4FR-Y#D
M1R;(4PC9FG>.%.-\B`YKT'_A*;<'_5:A_P""^X_^(K&\>Z?H/Q,\%ZOX=UJQ
MU&\T?7K*;3K^W^R74?GP3(T<B;D4,N58C*D$9X(-&HXVOJ4_'OQ-MOA;X`G\
M3^(->TK2=&MUC+RRV$K,SR,J11(BREY)I)'2..*,,\DCHB*S,`?"?#?_``4X
MT_Q;J^DK8^#?B`VCW=U8Z?JNM/H-M'9^&;N^O9+&U@O(VOQ<L[SHH/V:&=8A
M+&TK1@MM]6\7?`7P#\3_``]XBT3QQH+?$+PWXBU&#47T/Q5HIU?3+%HK>"&.
M."WFA9$C!@$N""?-EE?/S8'G/@7_`()D?LY_"GQ'INH^$_AC_P`(FNFWL.I#
M3]#_`+4TW2;ZZ@G>XM[B\T^!TM+R6"5RT+W,4C0[8_+*B-`J7Q:[77W=5ZD:
M\BOO;4O_``Y_;53XX>+=3\-Q^&O%FAVM[I>J7^AZSJFDV\6G^*+6QG2UNI;4
MQ7LL\062:+:+N&!G60.BNH8CWLV^K'_E^T__`,`G_P#CM>-^#?V3OA?\%/$W
MB+Q5X9T'7;/7-3L[Z!#=7NJW=GIJ74OVBYCLK:XD>VL(YIU621;6.)'9$+`[
M5Q[)_P`)1;?\\M0_\%]Q_P#$4X_"N]M?4KJ^W0=]FU?_`)_M/_\``)__`([0
M;?5_^?[3_P#P"?\`^.T?\)3;_P#/+4/_``7W'_Q%!\4V^/\`5:A_X+[C_P"(
MH`^2+;_@K7I>K_&7XB>`=/\`!?BB_P#%/PWAN+J^L%O/#5O=74$,ZQ-<"VGU
MR.XMH#&?M`FOH[:+R=A+!IH$E]*\!_MP:3\0OV.&^-UHMU_PC(MKF=+*&SM]
M0O;EX+B2V\J![.]FM;@R2Q[8WAG>)]ZL)-I)&-<_\$Z?@W<>.]>\11V7Q-T[
M4-?=I"NE^+_$FEPZ5(\S3326"6US&+%IG9O,-MY>\/(I^660/V.G_LM_#6U^
M%EYX,FT?Q1J7AW5+.\L]0@U34M8U&;5%NC&99;J>XD>:XN!Y48CN)7::%5"Q
MN@XJ5?V=NMM_,)?'=;7_``.$;_@H9J#:3]FA^%_Q+NO'B:Y-H,_@B/3-+_MB
MWEBL8[]YFN#JHTTP_9IH'#I>-DS+&`9`R+Z[\'?B)_PNKPII/B[0[V)M*\4:
M)8:M9-<Z;+!*8)Q))&'B:0,C@-\P/(/&!CGSJ;]@7X-W/@2/03HWCQ5CU>37
M#K">)_$<?B*2]DMQ:R2OK`N1J+[K<+"5:X*F)$CQL15'J'P^TK0/AEI]KX?\
M/Z7+I.@Z'I5EIVG6-MI\RQVD$/FI'&J;,A54*!]/8U2M9W\ORU_';R%U7S_/
M3\#>U.?4]+T^:YDO-/:.WC:1MMB^2%!)Q^^]J^9_#G_!5;P7XB_9N\'_`!*C
MCUZ"U\8ZY::##H<VC1C6-.FN)8E$EU&+PQ1PK%/!.T@E8&*>$KO>6-&^F[W6
M[/4;22&6'4&BF0HR_P!GW`R",'^"O%F_82^!\^CR:;)X#FDL9M)T[0GA==19
M6M+!X'MD.6^]_HMJ'D^_,EK`DK2+$BK.JO\`*W_!_`K33\?3R\SA?A5_P6;^
M`OQRM?%<GA+XC3Z]<>"-0M=*UFPM?A_K[:C;7ER\T<,"6A@%Q-(SP2KMBC<@
MK@XR,^M?M"_M&:E\!H-`@L_#/B+X@:]XHN)8=.T3PWIUL+R5(86FFE9[V^MK
M>-$11G?,K,SJJJS'%<G\,?V`?@W\)M:AU#2]'\?7EY:'3_LTFM^*?$FN?9%L
M)))+..$7MS,(HXFED(C0!/G(((XKNOCY\"_`O[2VCZ;9^*[#Q0S:+<M=Z?>Z
M/>ZMH>H6,CQ/"_E7EB\-PBO&[HZ+(%=6PP/%$[\GN[W^5M/SU$OXGE^-_P#@
M'A?P,_X+%?#S]I']H#0?A[X/O1?WNOQ+)#=W-SH]A)&QM/M31G3+C58]7D*+
M\C/%8R1JZOE]L<C)]:BWU8_\OVG_`/@$_P#\=KQ;P3^Q'\'_`(9^-=,UGP_X
M;\2Z.NBB`V>C6FJ:W%X=AD@A2&&8:0)?[/,R)&F)C;F0,BONW@-7M`\4V_\`
MSSU#_P`%]Q_\16CM96)^T^QGZ1;ZH=1U3;=V'%VN\FS?YCY$73][QQCUZ'UP
M,SXM_$BW^!_PR\0>,?%&O:3I'ASPOI\^JZE>RV;[+:WA0R.Y_>Y.%4\#D]!6
MGI'B&V34M4S'J'SW2L,64YQ^XB'/R<=.A]CW%9_COPWX=^)4.EQZU8ZM=PZ1
MJ5OJUM$(+V./[3`V^%Y$0!90C[75)`R!TC?;N12,YIM>[]_8J-D]=3QOP-_P
M4S^&_C_]G+P7\3M/\42WV@^.[J33-+M-(\,WOB#4I[^))GGLUMM,:Z>26);>
M<MY7F(5B9U=DPY[;X1_M<^%_CKXQ70O"?B"35KX:5%K,KCPIJ<5K;02$!$FN
M9`L,-P22/LTCK.#'*#&/+?;B?&7]C+X:_'#QDFO:E#X^T?4FU2+6;N;PYK.L
M:')>W45E-8)*TEF\<D<GV>;8TD#QR2)#"DC/'&J#K_@Y\&/`?P`CN5\(Z#J&
MDF\MK6SN#Y5]<-<);*ZQ%VEW%G_>.6D)WR,[,[,Q)J]-27I9+Y^MUM\C!T[]
MJUO$'C_XA>&='T/Q9J6M?#S3X+Z:!O#$MA_;;S27<4<%@UW/")R7M&'GDK:G
MS$(G($ACC_8]_:Y@_;-\":UKFAP-HZZ!K,NA7EM>-IVH%+F*.*1PMQIFHW=J
M^!,JD).61U='564BNN\5?#KPKXPU#Q!>7-KXDMM0\4:3#H>H7NG3ZEIUV;2)
MIWC6*:W:.2!U:YG(EA9)`7^]\JXI_`_X/>#_`-GK3+^W\.P^,KF35)5FN[[7
MM4UGQ#J-QM&U$:[U"2>X,:`MMC\S8A=RJ@LV5'K?M^N_I8<KM^[M?]/\SKM>
M@U%;2W,UU9R1_:[;<J6K(Q_?Q]"9#C\JZ"N>U[7X+VSAC2.]5FN[;!>SFC7_
M`%\9Y9E`'YUT-`SY%^)WQ,^-GPY^/NHZUX=L=:\0?"[PKX#T6ZNO#MKHJ2RZ
MG/<3ZFMY<Z?.(_-GOK6.WL7-H'8212,JQ^;+$3QG[4W[=_QT_9Q^#'P-FTCX
M8^.O%6L^+]%M+CQ/J>G_``ZO?$[6-[Y$!FM[NQLKFUFT\,\CLUP$G,>PHEI,
MV0GLOB[]I5?"'BF'PCX7^&_Q.^*>O:7I-G?ZU#X7U73+6/0H[D.+83'4M2LE
M+2^3,56#S"JQY8(&CW2:=^VY\,[KXZ:]\/;R;QUI.O\`A_58]%EN;K3-5;1Y
M;I[*&]2(:E&'LDE:.=0L,LR3.PPL;!HR\]=^OX)V?XM?ATT"6LF]E:VFVRU_
M#\>YQ?Q0_;.^,GPN^(UU9M\(]3\3:#X=N5U75[O1-%U"Y>^T>YBBCM8=/^7]
M_J$=W+*)X]ORP6;R-'#Y\0'$_%3]J_\`:-^$WQVT^PN-'_M#[1X1T"]D\/Z7
M\+]<US3=9UJ:>\6_LK;6[1A;:5M"VRF?4&GC561_+10Y?V[X+_MI_#+]H'Q#
MHMKX5O/&5YI^O:)>Z_9:Q>V.IZ587%G:FQ#RQO>"%YHV%_"4EB1XCME'F!D*
MUS]W_P`%(/A&O@OP'XBTZ/XN:]X?^)&M?V)H=]IW@OQ)*ER_V9KE;D*;<2/:
MO&`4GC5TD!9D+)'*T=1]UI>?_`M]_<G7E?IO^/Y?@5[7XH?'[6?AK>:]J%KI
MFG2W7Q&LM&TS1](\+72:C::)%XD-G<W5U)<32K*D^GJLV^."$1(SR!V!5D\'
M^.__``4W^,7P6\3^+O%6K:3?:7X.\!67B>]U+0[CX8:UIL%HMBDL=@TGB"\<
M:?J(N76*6-+,VY8RK'N?)<?3WB']NGX,^%;_`,11:IXH\1:?:^%[6]O+O5)]
M,UJ/2;E+-&DNTL[\Q?9;Z6%8Y3)%:RRR)Y$V5!B?;GZ[^WY\*=%^%6J^+@WQ
M*DL]#U?3=(O]-N/#NN:=K<$FH7,=O:RKIMY'#=S1.\GR-#$_FF.18A)(A2H:
M?+RKKM\[)?C^)2LY7??;TUM]Q\?_``3_`."V?Q2^/G_!/R;XO>`]!D^*UU=>
M,'\/>3X-^%-[?:OX8@C@23=>Z"NNNT\DKYVO#J*Q1Q21NS-)F"OK3]H'XO?$
M#7O^">^G^+M)U+Q-X!\>:I9V%ZPT3P7J6KZA%(SQO):BQ?3+RZM3*H:)I)=/
MN#:^86:*4I\VU>?MT_!VP\&Z?K4FN>-/)U":XB>R3P_X@DU72Q;L%N);^P6`
MW=A!$63S)KN**)!+&6<"1"W5+^T'\/KCXXV/PYM=6\0ZEXLOM-@UA8;"UU6]
MM(+.<3F&XGO(D:V@CD^S3!&EE0.R!5RS*#=17^'NK?):DQT>KVO^?Z;'R1\4
M?^"AGQV^"?[.WP<O-'^%OQ@\5:EXF:ZCUS5[[X<W7B:^AD@N6B"W5E8)I$]E
M;RK^]CO'L%E$(CSISRLZQ^E_$#]L;XQ6'Q%^)%AI/AF:WN?"^@W=SX>\.O\`
M"_Q'J4?B&YCT]+J*=?$"/#IX1Y&:(6?E?:"8]NY97\M/2_A?^THOQE\??8_#
MOPW^*.H>"VO+NQ3QY_;&FIH,LEJTL4Q6(ZF-1*BXADA#"RPS#<,Q$25C3_\`
M!0[X,V2;;K5/B58ZD^H1Z9#HMWX,\4V^M7<\D%Q<1^3ITEHMW,CQ6ETRR1Q-
M&WV>4!B4(`M6VO7TOM_7ZZE6=UY6^=OZ_I'(S?MB_%_XZ_$N'2?A7X5N/#_A
MV]UVTTM?$/CKX:>(;$6,!TJ^NKFX>TN6L99%6Y@M8%;=''FXV[RQ%9_Q0^+_
M`.T'X:^#WP^UVPU&ZTJY_P"%EZQI?BE9_AE?>)+N311?:E%82+9V,D4Z0>7'
M:?O45B1)%*TFP2>;Z8?VZ/A3<:%KNJ6$WQ6US3_#>JOHM]<Z+X'\5:K&EW')
M<12QQFVM)/.$4EK,DKQ[DB8('93)'N]>\&SZ'\0?"&EZ]HNI76HZ/K=I%?V-
MW#J-P8[F"5`\<BG?T96!'UH].Z;_``=OFB>G*][/U[7^1\3_`+1'[>W[07[.
M_@3P?]C^%_C[Q9>:_P"*?$%O>ZG8_#>\\3?8[.WUBXAL89[2QN+2:T@>S\EQ
M?;;DE%!6VN6<E?8/@A^U=\2/'?[?GC#X=Z]X2U;3_`^EZ$FI:3JD'@35X--,
MP%JLD,NN7CP0SW!DEG*V]M9.GE(K&Z\Q98$^C/\`A%[<G_6:A_X,+C_XNC_A
M%K?^*74/_!A<?_%T0T>OG_7R*GKMY&I16:/"UO\`\]=0_P#!A<?_`!='_"+6
M_P#SUU#_`,&%Q_\`%T`:5%9O_"+6_P#SUU#_`,&%Q_\`%T?\(M;_`//74/\`
MP87'_P`70!I45F_\(M;_`//74/\`P87'_P`71_PBUO\`\]=0_P#!A<?_`!=`
M&E16;_PBUO\`\]=0_P#!A<?_`!='_"+6_P#SUU#_`,&%Q_\`%T`:5%9O_"+6
M_P#SUU#_`,&%Q_\`%T?\(M;_`//74/\`P87'_P`70`6W_(W7O_7I;_\`H<]:
M5<Y;>';8^)[Q/,U#"VL#`_;9\\O-WWY/3IVY]36C_P`(M;_\]=0_\&%Q_P#%
MT`.\0Z)!XET*^TVX:\CM[^![:1[6ZEM9U5U*DQS1,LD;X/#HRLIP000#7RYJ
MO_!-'0_$/[)3?#/6/#?@#Q)]G\5ZEJ>F7?B;38O$K:+:7VKSW$EU$=2@N!)J
M*V<[X>=9%:?F1I5+;OI'Q#X?EM="OI=+BFO=2CMY&M(+K6+JV@GF"G8DDJ^8
MT:%L`N(W*@DA6Q@_,VL_M`_%2U_8+\9?$"UT/P3-X^\)W?B.*\M)=?U1='LH
M=-N[Z$/&0IFO'5;:,;3]E$Q+-NMLA`DEK\K_`*?B4KNR\_T9=_:1_8SNOB=^
MPMXF^!/@GP/I'ACPQH]QINE^';(:_;:99ZIIUL;*Z9W9M,U*.-#,LT+P3V<P
MG$3[\+-D>+?#/_@EC\>O".C_``VMX?B-\(_#_A_P#K=MJMIX,M?!N;/3&6^>
MXN+@76EG2+2[NI(WV!FTF!44!5"NT]Q<>Z_M[?M2W7[-/[,&J>+/"OV+5-7T
MO5++2M3GN]75K+PR9_+D:>\6>^LXE"QRQ$)/=VJG[1"6FC5MU?'^C_\`!8GX
MA/XG^'MO'>>`?$0\4-;PII>FS::NI>)9)=1FMO\`1$B\7W,L:85%66Q@UB$E
M)'>6-EFM[8AK4TU?,M^]DU_6W8SE).C_`';;'U1\.?V.?B[\.OVM?%OQ-\7?
M$[PCXUT/6M#U.Q,$?AF]T_4[.&2X6:SLXV.H36RPVZ+MW1P1M(06=7DD>6OK
M@#`K\^OV0/\`@H;XI_:5_:D\;>!O$*Z5I,&F66K&/P]:-;7.J:(]M-Y:"^EA
M\07-TA*`Y%UH]E&7<*LI/EB?[S'A>WS_`*S4/_!A<?\`Q=$;>SA;:UUZ-_GN
M'_+R5][Z^MD:E!Z5F_\`"+6__/74/_!A<?\`Q=!\+6^/];J'_@PN/_BZ91^:
MR_\`!(WX@:=^U'\8_%7_``KGX!^*O#OCI+K;8ZQ/96\>O/<WOVD23NWA^ZNX
MY(G"SLEY<:C;R31QXA51";3WOX:_L1^/O!W_``3CU#X)[/!NEW-_I6JPQBUU
M)S9V3SW/G1V3&TL+&-[:827"R/;6MFL*,D<=M(`7KYYE_P""KGBJV_:4^+G@
MG5_B+\(?!VG^#5O6T[4M7LS';Z68KT1Q17YF\3V]P)I(]L"_:[7389)YE9)]
M@A6Z]V^&G[<FH>)O^"<E_P#$V:\\.ZIXZMM+U6_MXK'4)6TR\BM+GRC?(EI?
M7RRVT,<MN]P;2\NHT8O&+C<.)C_`[JR^[7\?ZV"7\17WN_OT.)N/^"7WBI_A
M9%9M\*?V>+S1_P#A,[OQ$GPBGU6\'@6P@FTF*Q0Q3?V:4,R3QR7>T:8D?F7<
MN-L@\]OKK]F+X9ZE\&/A)X5\(ZQJQUS5O#'A;2M*O=1S(?MTT$<D;RYE9Y#N
M92?G9FYY)-?&MS_P49\0)\+8[QOBW\";/1_^$SN_#J?%V>'4SX%OX(=)BOD$
M4/\`:H03//)):;AJ;Q^9:2XW2'R%^N_V8O%-U\:_A#X1\6:SIVH:'JGB;POI
M>K7FG?;+I38S3QO(\7[S9+A2<`.H([@$FM(WM+_MV_\`X#I^!/5?/\_\STO7
M[%M5T*\MHV7?<0O&"W0%@0,_G7P'H/\`P2B^)WAO]E3PK\);'Q1X0B\.>!I=
M$\1:+;--=-#%K<%Q9S7<<@$:E[*.6&]N8%/+RWR`K`+6-V^[-?T:'2=#O+J-
M[]GMX6D4-?SX)521GY_:O@'0?^"H'CH_LI^%-6U+P[I8^)7FZ)K'B>.W_M)M
M*M_#VHW%GY-]:Q"X:9I)DO!;Q(TK?Z1:WI'F+;,C8Z7E_P!NW_&WW;Z&FMU;
MOIZ_Y=-2+]EK_@F3^T9X(O\`Q)9>.OBQXPNO#7B;4=&N[FV;XW:_KUU:QV\]
MTU_%87/]GV%Q8PRQ31*L:S2N?)7?.2`U?2O_``4!_94U3]I?0?!<=AX0^&_Q
M*L?#.HSW-[X0\?7L]MHFJB6TE@CG=TM;L&:!W#H)+:0'<^&C<*X^6OV7O^"V
MNN?M07OB32--^%O@N/7['4=%LM"73?CA%KFG:NFHSW4*37,]E;2S6&PVZL89
MK<SXE&Z-",'Z3_X*`_M!WW[,NA>"VM/&G@;X9V?B749[6_\`%WCR2]NM#TCR
MK26>.!ECO+,>;.Z!$+W,8^5L+(Q5"ZUO97G\-_QT_P"!_P`.3'^,]?>L>`_L
MJ_\`!(WXG?`']K3P?XUUS7_!_C-?#\-ND_BG4S976MF)-.6U>TA6?1I-2CC!
M#(C)KJ)M;<\#[I8Y?T;48'K7YI?LJ?\`!5/QU\=_VM/!_@SQ-H^F^"(=>AMA
M/X7:1+G7CYNG+<_:OWFNPZG#`9'W`_V%+&L2@R3IF1X/T;'ABW(_UFH#_N(7
M'_Q=;RORJ^W];_U^)&G.^^E_ZV_K0713G4]8_P"OQ?\`TGAKC_VEO`GBCXJ?
M"N\\+^%]6/AR3Q$PT[4=:AN3#?Z182!EN)[']U(K7FSY8O,`1&<2'?Y?E2=!
MI'AVW?4]44R7_P`ETJC%[./^6$1Y^?GKU/L.PKC_`-I7XCVOP%^%5YJ]K9ZE
MX@\273+8>'-!CU=X;CQ%J<@;[/91-)(%4NPRSL0L<:R2.52-F&%2UK,UA>^F
MY\Q^+?V%?C-\)_A'X*^%O@?Q!JGCOP#X5U_SK.6^^(-WX'U232FTZ\4Z=>WN
MCV:O'!!>-;M;FRAYC,4#11QP&63V;]CW]F'Q[\)_%MQKOQ#\::KXFOET&PTF
MPMT\3ZG>65F5#&Y#P3%89Y`5@1;R2,W$@C=V,9ED5O%M<_X*;:O\(?@IX9C^
M(GA?PUX#^++ZTN@>)]*\:_$(>%]$T)GLKJ\M]1DOHFU!%M+J.U*Q>6TX6=G@
M,C/#*1ZW^Q_^U9J7[6?BRXBA\'IH?AW3]`L-2N=0;Q?=W-Q+<W89HDMH?LZI
M-:,D<KI=&9&=#"PAQ(=FLKW;?=?E_D9Z+E7D[+RNOU-#6/V//[#^)_QA\3:;
MH^E>,+?XF>&;+3I=$\3^(KZ2VU.YAFU*22UGDECNOLVGNMY&@AAC>)09@(,,
M0^?_`,$S/V2-?_8_^&7BC1M9T?P7X;AUS7I-7M=(\,W%O<65COABC8*UMI>E
M6ZJ1$@$:6*L"C/)-.\A*FL?&;Q=X<^*'QBTGQ-?>`?`>@^#_``Q9:[H6NW^O
M7UU:V<4\VI1->ZF\CVJ)&HM(W-O&RA0KC[4=X:+/_P""9?[2^H?M@_#'Q1J.
MN:[X=\1S:%KTFGVNK>%;L+IM];>3$ROFUU;5+=9=YES&MZ\BIY3210F0)4QW
MT_E7W7_,*OQ>]O=??R_Y'TMXJ_Y!D7_7Y:_^E$=:5<]KV@065I#*DE\S+=VV
M`]Y-(O\`KXQRK,0?RKH:"CX@^/\`K7P1UO\`:/\`#?A7Q1>?&#1_B=K>CVT5
ML?!.E^/-+75[.(Q[6GO=#>*VNHK9KM0TDLC+;&X8,8M[`^A^/==^`7AKXEZ]
MX3\0_$#X8V/C/^T4\>:KH-UKYCU=;BTL8\7S6OVWS@B6ELC$!/+*1ER#DL>T
MN_AAX1N_CKX+^(&I:IJ=OXF\"^']0\.0VD>#9M'>/9O.9!Y99G5K*,*5<+AG
MR&R"/*?$O_!/?X4^*OC=J/BVZ\9>.O['U;Q9'X[O/"*-;#1I==CLDLDO_,^R
M?;PPCC0^4+L0%ER8B"5.=I<J22OKZ7OI^"OZ]MRM+ZWM^.W]+T^YY_P?_:?_
M`&8KCX`_"'XA6?Q.^&W@GPUK'A2?PMX)GUSQ(-+N1IV;5;BRC,E^&:XC:WM5
M?YFGB=0"RLQS?^!/[#?P(;3?'7@'P.VJ+/X7\?+XE\331^(/$:ZI#XDFL8)3
M='49+_[5(\EI/%O\N=HW$KJX)+BO+OBE_P`$2O@C\9O@7X#^'OB'XD?$[5-!
M^'GANX\)Z;]KM=$NY38R,IC.)])>.&Y@50D5W;)#<A,AY7R37U-\!OA;X&_9
M[\1>-]4TC6M9OKKQ]J5KJFI?;E#+'+;Z?:Z>@B$<*;5,5I&Q!W?.SD$`A1T7
MC>3N_+SU3U_%^MC*SLETZ_=;_@>AQ7CW_@E7\./B!IOB:WF;7K3_`(22QU*Q
M5(_$&KW%EH7]H1R17,VFV%Q>2V-A,R2R@26]NA42R`?*[`]5X&_8)\&^`M$N
MK&!=2U8W^IZ=J]Q>:_KVLZ[J$MQI\RSV6;N]OYI_*AE7>L(D\H%I/D_>/N]5
M_P"%G:&#_P`?W_D&3_XF@_$[0_\`G^_\@R?_`!-9)VM;3:WYK\2WK_7?1_@?
M/?[17_!(SX*_M6:U8:EXZ\'V6J:KI6M3>(K._M=1U;3;NWU"7R]TZS6M]$X(
M,2%5W;4()4*6)/MNA_"2'PYX\U+Q-:?88]<UFPM-+O;MXKB1KBWM&G:W0AK@
MKE3<SG<!N;?\Q.!C6'Q-T/\`Y_O_`"#)_P#$TO\`PL[0\?\`']_Y!D_^)H5T
ME%;(-W<\J\/?L&^$O"7Q`N_$FEW7B339KV:ZN)=)M?%FOQ>'VDNA(+AO[(74
M1IX,C2R2'%N/WKF3_6?/7$_LD?\`!'?X%_L*ZPM]\*_!6G^%[I=135@_]HZM
M?8N4M;FT63%S>R#B"\N4QC;^\SC<JD?1/_"S-#)/^G?^09/_`(FG#XG:&#_Q
M_?\`D&3_`.)IJ\=M.GRZ!ON>#?M)_P#!*?X/?M=_![3?`/Q#\)Z?X@\):5KM
MWXEM;#[;J=KY6H74EQ+/-YD%XDAW/=3G86*#?@*`%`]G^&?PQ3X0?#K0?"?A
MTZ?I^@^&=/@TK3;7[/--]FMH(UCB3>\[.VU%499BQQR2:T3\3M#S_P`?O_D&
M3_XFE_X6=H?_`#^_^09/_B:-4O+=B:NTWNK_`(ZO\2]]FU;_`)_=/_\``%__
M`([1]FU?_G^T_P#\`7_^.U1_X6AH?_/]_P"09/\`XFC_`(6AH?\`S_?^09/_
M`(F@9>^SZO\`\_VG_P#@"_\`\=H^SZO_`,_VG_\`@"__`,=JC_PM#0_^?[_R
M#)_\31_PM#0_^?[_`,@R?_$T`7OL^K_\_P!I_P#X`O\`_':/L^K_`//]I_\`
MX`O_`/':H_\`"T-#_P"?[_R#)_\`$T?\+0T/_G^_\@R?_$T`7OL^K_\`/]I_
M_@"__P`=H^SZO_S_`&G_`/@"_P#\=JC_`,+0T/\`Y_O_`"#)_P#$T?\`"T-#
M_P"?[_R#)_\`$T`7OL^K_P#/]I__`(`O_P#':/L^K_\`/]I__@"__P`=JC_P
MM#0_^?[_`,@R?_$T?\+0T/\`Y_O_`"#)_P#$T`7OL^K_`//]I_\`X`O_`/':
M/L^K_P#/]I__`(`O_P#':H_\+0T/_G^_\@R?_$T?\+0T/_G^_P#(,G_Q-`#+
M>WU0^)KS%Y8>9]E@RWV-\$;YL<>;]>_<=,<Z)M]6'_+]I_\`X`O_`/':PX?B
M)HZ>(KJ;[9^[DMX8U;R7Y96E)'W?]I?SJ\?B?H9'_']_Y!D_^)H`\-C_`."F
M?PCDU?QI:O\`$;2[5?A_8ZCJ6L75WX<U*VL/L^GS+;WSVUU(%@O?L\[)%(+5
MY2DCJA`9@##J/_!4#X0Z#\)?$7C76/B!;^'-'\*WIT[5+;7?"6K:/J]O<?9!
M>B(:;=)'?2,;4^>!'`VZ)7<95&(Y73_V#?">@_$GQEXJTWXW?&JPUCQ?IE[I
M*7$5Y9-<:1#<W'GCR[E[!KFZ-N6E2U^WRW0M$FD$`CSD7/AO^PUX!\"?LB_$
M#X-WWQ&\?>+-"^)%K=VNK:QJ]OIJ:XYNK86\T[W5KI\'VJY90&:XO%GF=@"S
ML`!4QORZ[V7WW_R\RO=YTGM?YVM^9Z]\1OBYX7_9T^'.H>/-:U+1]'TG5[JU
MEN+FR\.W-Q>:O=W'D6EJJV]N7N+JYD_T>%$1'D;$:`<`#D]/_P""B/POU/1/
M`MZGQ"TF%OB1K4GA[0+&XT"_M]2N;^*X-K-#+9R;;FV\JX`BD:XCC6-WC5RI
MD0-@_&O]E3PG^T[\&O%WP]^(WC*Y\2>$]6U:PU#P];?V#9[_``Q':16OE1;9
M[>:"])N8)9F-U#(C"X,1C**,^0^$_P#@B?\`LX>#=&T&&S\0?%BWU#1=<M]<
MDO\`3_%^H:/'>R6]U<74,/V&P^SZ=:P1R74VQ;*UMS$)&\LH7<M2^*SVNONT
MO\UK_P`$SUY/[UOE?H>_>&/VZ/A_\8_'^N^`="\7Q7WB*TM=3Q')X;U&SM-3
M%C*+:]%E>S*MK>&WF81R_9I)?+;(8#!KV[R-6(_X_M/_`/`)_P#X[7R[\,OV
M'?AS\%?BC+XPTKQAXWU;^R[77XO#/AW49(&TKPT=9N5N[_[-Y=K'</YLR+C[
M5/.(U.U-@P!]+#XG:&/^7[_R#)_\31IRKO;7[_\`AOF/7F?X%[[/J_\`S_:?
M_P"`+_\`QVC[/J__`#_:?_X`O_\`':H_\+0T/_G^_P#(,G_Q-'_"T-#_`.?[
M_P`@R?\`Q-`R2#0KZVU":ZCDT=+BX55FF73F$DH7.T,WFY(&YL9Z9/K5K[-J
MW_/[I_\`X`O_`/':H_\`"T-#_P"?[_R#)_\`$T?\+0T/_G^_\@R?_$T`7?LN
MK?\`/[IW_@"__P`=K.M[;5/^$FO`+RP\S[+!D_8WQC?-CCS?KW[CICF3_A:&
MA_\`/]_Y!D_^)JC#\1-'3Q%=3?;/W<EO#&K>2_+*TI(^[_M+^=`&Y]FU;_G]
MT_\`\`7_`/CM'V;5_P#G^T__`,`7_P#CM4?^%H:'_P`_W_D&3_XFC_A:&A_\
M_P!_Y!D_^)H`NFUU8_\`+[IW_@"__P`=I?LVK?\`/[I__@"__P`=JC_PM#0_
M^?[_`,@R?_$T?\+0T/\`Y_O_`"#)_P#$T`7OLVK_`//]I_\`X`O_`/':/LVK
M_P#/]I__`(`O_P#':H_\+0T/_G^_\@R?_$T?\+0T/_G^_P#(,G_Q-`$>CV^J
M?VCJFV\L,B[7>39N=Q\B+I^]XXQZ]#ZX&E]FU;_G]T__`,`7_P#CM8>E?$31
M[>^U)WO,+<7(DC/DO\R^3&N?N^JG\JO?\+0T/_G^_P#(,G_Q-`!J/A6?5]1L
M+JZ_L.ZNM+E:>RGFTLO)9R-&T3/&QERC&-W0E<$J[#H35T6VK#_E]T[_`,`7
M_P#CM4O^%H:'_P`_W_D&3_XFC_A:&A_\_P!_Y!D_^)H`N_9=6_Y_=._\`7_^
M.TOV;5_^?[3_`/P!?_X[5'_A:&A_\_W_`)!D_P#B:/\`A:&A_P#/]_Y!D_\`
MB:`#7H-16TMS-=6<D?VNVW*EJR,?W\?0F0X_*N@KE=5\=:7K*6]M:W7FS27E
MMM7RG&<3(3R1CH#754`>(^*O^1IU+_KZE_\`0S5&OFK]KK]O^;X-?MI>"_AS
MIOC'X"P:EXB71+B?PYK][<0ZUJ,5W=A+ZXDO)+RUL]/V1.C6\"1WUS<NQV6Z
MH"PZKQ3^QY^U):_"CQ9::1\5M#U'Q1JFJ6=[I%U<36=@=*MQ-=_:K.*8:+<1
MK'Y1L=C3VEU*2EPI==R.)YKQYUKK;YW2^[_@]0VGROLG]^Q[717G'[:?C3QU
M^QW_`,$^]'\0V%AH/BKXLPS^'-!NWEMGNK/4;^]OK.QN)(X1<V*L6>:1HU::
MW3)7<8USCS;1_P!J'X]_"N'P?H?Q`^"OA"X\8?$SQVWA;PLFHZU_PB,7V1-'
MEOY;FZCLKOQ"J8DMIXDV7#,^5+1Q`9>XJ[=NCM?OMM]X1O**DUOTZI6UN?2%
M%>`3_P#!0:;X6?LY+\5/&WP]T^\\!Z3\2=>\'^+M6T:_NDD\(:9::M=:?:ZF
MUH5E:ZC!BB%P5DC*>89%C9057R3]DO\`X+I6G[2_[9_A?X7ZC\!(?!NC>+M:
MN-'M=2O?B#$=>LS]CFOK.2ZT)X(KN%+BWCB<29:$>>JB5W4I2C[SY5K_`,,O
MN"7N*\MMOQ:_0^VJ*_.6^_X+I^+O@=X%N_\`A(/@WX/^(GB9?&OBO2)X-/\`
MB5;:$NF6^F:D+>&P2.[@62YU)DD0QV<0>XGB\N8#]Z8X_NC_`(*%_%S6_P!G
M']C+_A.O`OA6VD\87VJ:%IMGI6L6[71B?4=1M;1HWA6]M4>91<,`INHH]X&Z
M0+EJ7V5)=6DO5VT_$-.?V;TW]-'8[*BOG'0?VE_C3\(O^$(_X7)\.]!T&'Q9
MX^GT-#'IOV;4+G2(O#U[J,DJ65EK6JQ1SBZM#&A^URF1-V8(SM9N3_8N_P""
MT>D_M5?"OXU^([WX+P:?-\)O"</C*PLO"_CZW\6-XFLY5NBJ*UNB&UG!ML/!
M*OFQ^8/,1"-I>FMG>RN_):?C_P`$JS5K];6^]K]#ZZHKXW^*7_!:RS\`?`"\
M\5Z3\)?`_CC4+3Q;'X8&H:'\7;1/`LZOIHU`RKXDO(+>`2J"86MWA5O.78"V
MY-VC-_P5TU:]DTV:S_9[L[&S;2O!-YJ<.N^.KBPU+3[GQ/<RVEG"EO'I\R21
MQ2QYDD:6-O+<,(BV8Z%%O3K=+_P+5+YHGF7+S>K^2=F_OZ'UO17RI\:?^"M[
M?!_]CW3/B%_PH_2]0\43>/=9\!:AI5Q\2+?1O#^FW&F37<<L[:W?Q01!)1:Y
MB62&-Y&?8!N`W2O_`,%5=6N8-+U.+]G^WT_08O#O@K7_`!(-:\;SV6KZ1_PD
MNI2:?##!:)8RI<&%HS(3)/;[D(X1OE#C>7PZZI?-ZH)>[H_ZUM^9]345YI^Q
M5\;=6^.'[8G[2W@'Q5:>$H;/X7^)K&PT&SL-8D?4XK";3K>=99[<QJPCD9W8
M3&1@7,L2KB$/)]3'X8Z'_P`^/_D:3_XJET3?6S^]70KZM=GKZGDE%>N?\*OT
M/_GQ_P#(TG_Q5'_"K]#_`.?'_P`C2?\`Q5`SR.BO7/\`A5^A_P#/C_Y&D_\`
MBJ/^%7Z'_P`^/_D:3_XJ@#R.BO7/^%7Z'_SX_P#D:3_XJC_A5^A_\^/_`)&D
M_P#BJ`/(Z*]<_P"%7Z'_`,^/_D:3_P"*H_X5?H?_`#X_^1I/_BJ`/(Z*].A^
M'FD/XBNH/L?[N.WAD5?-?AF:4$_>_P!E?RJ]_P`*OT/_`)\?_(TG_P`50!Y'
M17KG_"L-#_Y\?_(TG_Q5'_"K]#_Y\?\`R-)_\50!Y'17KG_"L-#_`.?'_P`C
M2?\`Q5'_``J_0_\`GQ_\C2?_`!5`'D=%>G>)/A[H^G^'KZ>&SVR0V\DB-YKG
M:P4D'EJO?\*OT/\`Y\?_`"-)_P#%4`>1T5ZY_P`*OT/_`)\?_(TG_P`51_PJ
M_0_^?'_R-)_\50!Y'17KG_"K]#_Y\?\`R-)_\51_PK#0_P#GQ_\`(TG_`,50
M!Y'17KG_``J_0_\`GQ_\C2?_`!548?AYI#^(KJ#['^[CMX9%7S7X9FE!/WO]
ME?RH`\QHKUS_`(5?H?\`SX_^1I/_`(JC_A6&A_\`/C_Y&D_^*H`\CHKUS_A5
M^A_\^/\`Y&D_^*H_X5AH?_/C_P"1I/\`XJ@#R.BO7/\`A5^A_P#/C_Y&D_\`
MBJ/^%7Z'_P`^/_D:3_XJ@#R.BO3]*^'NCW-]J2/9[EM[D1QCS7^5?)C;'WO5
MC^=7?^%7Z'_SX_\`D:3_`.*H`\CHKUS_`(5AH?\`SX_^1I/_`(JC_A6&A_\`
M/C_Y&D_^*H`\CHKUS_A5^A_\^/\`Y&D_^*H_X5AH?_/C_P"1I/\`XJ@#S+PI
M_P`C5IO_`%]1?^ABO;:Y;5/`VEZ*EO<VUKY<T=W;[6\USC,R`\$XZ$UU-`'-
M^%[C5!X9T_R[/3VC^RQ;"UVZDC8,9'E''YFM#[1JQ_Y<=/\`_`Y__C5?"/[>
M?["NN?M0ZS+J6GZ3\&?'8U#0-.L-,;QQ>6$5UX#FMVD>=K&.^T/6;:5;SS$$
M^Z"%P+9`'?Y##VG_``RU\1#H4]_:_%?3]#\4:+\-=)\.^%[72_$%U9^'=/UZ
M""\BO+N33+<16KP2>=;K'NA<1B)66%&B0&?L.5M>W?T#[2CY?JO\SZZ-UJX'
M_'CIO_@:_P#\:H%UJQ_Y<=._\#7_`/C5?D_^T#\(_P!M[X9_L+Z+X9\,0^&/
MB%\1+CQ?)=ZA9>'OC!KJZ;!I0M'5"NIZCJ=CK4;_`&AD;R?M]S$2A.$0B$>[
M:O\``#XU>*O"?P^DT'Q'-H<^F^&-*MX'\2_&758]4\%:F@_TR:\M[&.>S\32
M,VQB+ZX6)C$441I([&XQ_-?E>Y,I/33>[^[2S]3[J^TZL/\`EQTW_P`#G_\`
MC5'VK5O^?'3O_`U__C5?)^L?`SQM\*/V?_&GB#1O''B+QI\8E\07GBG2+$^/
MKIM-U2.+4;JXL='$-U.EI;026<XM9,1A0=CDR-!"PV/C9\*O'WBW]@S6/AWI
M^O>#O%7CGQW;7MIX@U+Q#XGGL;/3?MXF>=[39;73/';O(L<%L1$IB1094(^9
M+7?R*T3MT[_G_74^F#=:M_SXZ;_X&O\`_&J47.K8_P"/'3O_``.?_P"-5\B?
M$/X&?%OQ'^U.VOZ=XR\.Q>'1JD#V^K/\1]6@6TTE8D$VF-X8CM_[+N'D/G)]
MMEG,Z_:!(N##%$,7X6?L/>-?@3^S)J'@GPE\6)K'4M6^%J>'9;FZ\=ZI?QZ?
MXE2$1QWUB;@R?8+9<R86T2%1\G[CY%VJ.JOMV_KIV]7VU)ZV]/Q=O^#Z>>A]
MJ&YU;_GQTW_P.?\`^-4?:M6'_+CIO_@:_P#\:KX5_:;_`&/OC#:^"=1T'X+_
M`!*MIM.&MV.KZ7!XR^,/B6$QE+:6*[CN[R`3:I/;N[1R):PW]O&'C5F)0/!+
MJ>+OV0?'7A_XP_&KQ#X+\2:6L/Q.N-.U!6N?BWKUC)<B..UBO=-$:Q3II@D6
M&3R]0M"US$C+%''$H#H?YV_+7T*Z7\K_`(GVL;G5@?\`CQT[_P`#7_\`C5"W
M.K'_`)<=-_\``U__`(U7R#X0_97\>>+OAGX/\.^-?B-<:+HNF^,+O5M2TKP_
M\5->N+Z#1VTZ>&#3QKQ^S:E?$7S1W1>8Q%0WE`ND2!_H3]FZVOOAO\%-!T+Q
M;XKTW7=<TJ.2WEOO[3:Z:>-97\C?-+B25Q#Y2L\F79E8LS$EC7*B4W?[_P`[
M?CN=Y]IU;_GPTW_P.?\`^-4?:=6_Y\--_P#`Y_\`XU1_PF.D?]!33O\`P)3_
M`!H_X3'2/^@IIW_@2G^-(H/M.K?\^&F_^!S_`/QJC[5J_P#SXZ=_X'/_`/&J
M/^$QTC_H*:=_X$I_C1_PF.D?]!33O_`E/\:`#[5J_P#SXZ=_X'/_`/&J/M6K
M_P#/CIW_`('/_P#&J/\`A,=(_P"@IIW_`($I_C1_PF.D?]!33O\`P)3_`!H`
M/M6K_P#/CIW_`('/_P#&J/M6K_\`/CIW_@<__P`:H_X3'2/^@IIW_@2G^-'_
M``F.D?\`04T[_P`"4_QH`/M6K_\`/CIW_@<__P`:H^U:O_SXZ=_X'/\`_&J/
M^$QTC_H*:=_X$I_C1_PF.D?]!33O_`E/\:`#[5J__/CIW_@<_P#\:H^U:O\`
M\^.G?^!S_P#QJC_A,=(_Z"FG?^!*?XT?\)CI'_04T[_P)3_&@#.M[G5/^$GO
M,6=AYGV6#(^UOC&^;'/E?7MV'7/&C]JU?_GQT[_P.?\`^-5GV_BK2U\47DAU
M+3_+:U@4-]H3!(>;(SGMD?F*T/\`A,=(_P"@IIW_`($I_C0`UKS5%'_'CI__
M`('/_P#&J\0UC_@HW\-](\%1^(+?6H_$&FW6L3Z%;#P[IVJZ]=7]W!"9Y1;V
M]E9333Q)$/,::)&B"_-OP<UZ3\8/"O@OX\_"OQ!X+\47-K?>'/%-A-IFJ6L&
MJR6;W-M*I22/SH)$E0,I()1P<$C/->#Z3_P3>^'?@+2'7P1\5/BGX+U==;EU
MNVUJ/QH=?OK,S68LY;=/[96^B,+Q*N=\;.&1&#@HN,_>UMV_&Z_0.BMWU]+?
MY_UV]:\7_M8^&O!/P3TOXC76H6%YX1UR.TDTJZTL7FJ3:O\`:R@M4M;:VMI)
M[B27S%VI%&SG/3@UP_AW_@IY\+?%>OZ%IMCKC3W6O2P6R/\`V/K"VVEW,]S+
M:0VFHSM8B+3;I[F&2!;>]:&4RKL";B`;$G[*>@O\#[?X?P_$C6-)TGPS=Z9/
MX,O],N;1=4\*I86UM%$HFN$GCO&:2&>1VNHI`PNF0H0JFN3\)_\`!./P+X.U
MVQNH/BQ\1)K.35+77?$>G3ZUIS6WC+5+:_DU&*]O2+42Q/\`:I-YCL9+6!A'
M&C1&-=E:Z<]NEU_X#;6_G_7I.O+?R_K]/Q^?>>#OVV?!?QS\3^(O"/AZ_%UJ
M^GV=](3-8:E:6NHQ6TOV:ZEL+F>TCM[](9F6.1[66149T#,NY<^R&[U;/_'C
MIW_@<_\`\:KP3X<?LE^%?@IXMU3Q%9_$+Q9XB2UTS5-/\/Z%JNI6<FG^&8+^
MX2ZN8;40P1SRAY8H0INY;AXUC"1LBE@WOA\7Z.3_`,A33_\`P)3_`!I+X4^M
MM1]6NG07[5J__/CIW_@<_P#\:H-WJ_\`SXZ=_P"!S_\`QJC_`(3'2/\`H*:=
M_P"!*?XT'QCI!'_(4T[_`,"4_P`:!G@J?\%*O`4^O>)=-MK7QGJ%UX5GEMKT
MV'@3Q/>0W$T5R;5XK26+2VCO7$J2?+:M*2L,S@%(I&7L]+_:R\-ZI\`;[XH?
M:K?3_!NF0W4][=:G!?:=<V7V:1XIXY;2>U2YCF22-T\IHA(6`4*20#X$?^"4
M?@"S_:$\??$K3?BOXHT7Q'X\M9;*:ZM;/PW<75M!/(&N()+B[TV>6^@=%6)8
MK]KA(XPH4`QPM%Z1X*_8N\"^!?V8&^$UKXWUD>%7L;NT=;:;2]-9))I8Y8[F
M".SM8+>T>W:/,4=K%#!EW:2*5V+5*O[._6WX_P!6!_'9;7_`DG_X*5_#NV\"
M1Z^;C6V$FKR:&='3PKK[^(H[V.W%U)$^CC3CJ*;;<K,6:W"B)TDSL=6/J'P]
M^(*?$^PM?$GA^31]6T?7M*LM0L+RWOF>"[MI?->*5&\KD,K9Z=,>O'BY_89T
M-=(^TP_''XEVOCQ]<FUZ?QO'J&B_VQ<RRV,=@\+6YL#IHA^S0P($2S7!A60$
M2%G;UWX.^&_#'P4\*Z3X3T74(5T+PSHEAI%@;F_\Z4Q6XDC4/(Q)=]H7<2<D
MG)ZU2M9WWTM]VOX[>0=OG^9V)NM6_P"?'3O_``.?_P"-5P?A?]J7POXPO?&D
M-CKWA=F^'=R;7Q(\VI/!%I3A2Q9Y)(50QC;(AD4E!)#-&6#PR*O6^(M;L-:T
M"]L[?Q)#I,]W!)#'?6D]NUQ9LRD"6,2J\9=2=PWHRY`RK#(/@$G_``3A^!VD
MZ3?0>&5LO!%YKVCWFA^(]2\/M96M_P",(;J'8\NJ2M$QO+E9<7"7$F91+O\`
MF*33QRJ.^JTM^(/;3>_X'J7Q6_:I\%_`329K[QQXV^&_@VPM;V+39[C7?%<&
MG0PW4L1FC@9YE4"5X@75"=S*"P!'-9OQ6_;%\*_!CP3H/B#5+V'4].\42&+1
MAX<MM0\276K$1/,S6]OI]I/-+&L:.[2(A1%&6(&*\-^,'[!'C#4/#K7WPX_:
MDUCPO\3[K7/[5N_'/B;PUHOB&\:`V2V;6D5G!'8V,:M'%!ES`[?NSC#.6KM]
M&_8KT+0_V;_A/X'TWXL^)O#&N?"?38].T_Q5X>DTVWO;@?9/LUQNM[FWN;3R
MY0=VPPL8RJ%&4KNI/FY7;=-6\UU?R_I!I=>CN=,?V^O`]UXH\.Z3I=U=>)9O
M$UE8ZE:7'AS1=8URQMK6]YM9[NZL[&6"RBE4%E>ZDB78K/G:I(]C^UZL3_QX
MZ=_X'/\`_&J^1?%'_!(SX&>(/B7X(\2Q:O+8W'@>QTNPMD,&B:A-<KIP1;:3
M[?>V4^HVLVR.-6EL;JV<^6K;@X#5]=CQAI`_YBFG?^!*?XU>EKKN_NOI\^Y.
MM_DOO,[2+K5!J6J;;.PS]K7>#>.-I\B+I^ZYXQZ=3Z9/,_&W]HJQ_9Y\/6>I
M>)+6\==3NQ8V5KHNG:GKVH7DVQY"L5G8V<UQ)MCCD=BL9"JA+$`9KI])\4Z7
M'J6J,VHV"B2Z5D)N$^8>1$,CGGD$?@:\V_;$_9U\(?MH_"M?!_B#Q5_9>D_:
MX[N9(+/1=5BO-F2J36NJV=Y:2*&PXW0%E9%964BHE?[/E_7W%JW436_V[_AO
MX,\#>'_$GBKQCX-^'^F^*I9H-*7QOJDGA2\NY8FV21?9=2A@G613C*-&&`93
MC#`G?/[4O@L_&*/X>'QI\-_^$_F1I(_#/_"50?VS(JQ^8Q6TV^<0$^8D+PO/
M2OF/QK_P17^!?C?X?^#M#N/$2B3P7#>6UK=S>'/"&HH\5S,LSQI87FD3:;9J
M'4$"QM+;)+%MQ=B?0_!G["/AGPO\9;[Q-)\3]8FT"?Q%9^)HO"%K#I%EH_VN
MUTZUL;>:5H[;[6SH+5&"Q7$,'"+Y.U3ON-KV>G_#K]/\B-;:;V/6O&'[3?AO
MP'\7O#7@'5M:\-VWC3Q@7_LC15U"26]N8TBFE:8QI"6CA"V\H\V3;&74(&WL
MJG,^'W[7>@_$[XLZAX(TRUUB'7M/BN+C&IZ!K.E6>H16\L<,TMG>75C';7J*
M\L7S6TLBXD1@2K`UTWCWPWX9^(?B#PGJ5[K4<4W@[5FUBR6"[B"RS&SN;3;)
MD$E/+NI#A2IW*IS@$'S/X:?LE>%_`'[46M?%N]^(VK>)O$^L6\EF1?6GA^R$
M%L6S'`UQ8:?;7ES#$ORQQWEQ.JX#8,BK(%'=)^=_T_X(YW2]WR_/7_@'LVO3
MZBUG;B:ULXX_M=MN9+IG8?OX^@,8S^==!7/Z_P")--U"TAAAO[.:1KNVVI'.
MK,V)XSP`:Z"@9\I_M`?$WX^)XO\`"J_!OPSI6H>&/`5O!J/C.+6Y)M/G\51R
M0`C3])9[62.XF6+S'+^;;QBX>T0SE5N8J\V_;K_;)_:'^&'C>YO/@WX;FOM%
MUKP[X=N])E\4_#;Q'K&F6-Q/)K+WR7$.D6[:I#<&&'3P5:*186"+(D1GWUT/
M[4O_``5H\!_L2?$*Q\$^)U\17&I+X>LM<+0>(O">F+Y$QF1$@AU34;2ZNI`;
M=\K;PRGE`"68+7KWQ(_;4^'OP@\56^C^(/%7C*UN)+>VO+J>#PC?7EAHL5P2
M(6U"[AL7M]/W8)Q=R1$`9.!S4*2<-^N_Z>FA3E9\K6ME]UT[_P!=SR/X8_M(
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M;D_;"^#_`,)?#NK>"_!7A#5/$6LSZM>RZ;??"GQ=J4<%I;R+%;66[2I;J1+V
M0JTHDN8[>WE29=K(86,GU';?MH>%]2_93\8?&*SO/&4OA;P3%JDU[!<Z=;:?
MJ+_V<TJ7">1=+$89-T3KLN3"R$$2",A@.'_92_X*E?#W]K*?6H],U'7]'_L6
MZTRR>8ZMX<\16TTVH7#6UM$+C0[O4(8Y&E4`I.\;`,'P4#,(U<K+3K;NGL%T
MO>>VWHUO_7_`':Y\7?VF/%/Q*9/#>F^`]!\+ZEXA3P_9C6?!VK7=WIT#:*FH
M-J\\BWL"20K=;[/[.(X@SE<W*.#&>;_9L_;0_:`\:_M=>"_!OCCX??8?".O>
M$1>:C>Z=X#UNU_LG5HXRTS7>H7DB64$,K`""U@-Y/\Q$KQ[0S^O7G[;_`,,;
M7X^:#\,?^$\UN7QSXFDOX[#3+;0;BXR+*?[/<O+*EHT4$:3?)YDSHC,0%9LC
M-=/V^OA+)??%B!_B1J5NOP/5SXUNY]&FAL=&*1B5X_M+V@@GD5&4F.!Y'&]0
M5RP!.:.DEMK\TE:_R>K\_D+E?PO?1?-O]=E_PY]``\_6CY:^6?V>?^"I_P`%
M?VNM'\,ZE\+?B)JWCC3_`!-XID\()-::8+1M/ODTVZU+_2(;N"&9(V@LY`KA
M&#.5`R`Y7V;X$?$FU_:$^"GA+QYHNH>(+72/&>D6NMV4-[#:I<Q0W$2RHLBH
MK*'"L,A689S@GK5.#ZK:WX[?>/\`K]/S3/0J*S/["NO^@QJ/_?%O_P#&J/["
MNO\`H,:C_P!\6_\`\:H`TZ*S/["NO^@QJ/\`WQ;_`/QJC^PKK_H,:C_WQ;__
M`!J@#3HK,_L*Z_Z#&H_]\6__`,:H_L*Z_P"@QJ/_`'Q;_P#QJ@#3HK,_L*Z_
MZ#&H_P#?%O\`_&J/["NO^@QJ/_?%O_\`&J`-.BLS^PKK_H,:C_WQ;_\`QJC^
MPKK_`*#&H_\`?%O_`/&J`-.BLS^PKK_H,:C_`-\6_P#\:H_L*Z_Z#&H_]\6_
M_P`:H`TZ*S/["NO^@QJ/_?%O_P#&J/["NO\`H,:C_P!\6_\`\:H`6V_Y&Z]_
MZ]+?_P!#GK2-<Y;:-<'Q->+_`&K?@BU@)?9!ELO-Q_J\<8].Y]L:']A77_08
MU'_OBW_^-4`>3>#_`(.>-](_:+^)M]=>-O&EYX:\4Z#I\>C7%S<V+1^';L3:
MEYT=E;+"(E\N.6T827$,KR80223",*OA_P`2O@)\7=)^`_A31]2C^-'Q*M-+
M\8>(;C7+7PYX_@\/^*=9LYKB_;3+@WR7=B@A0/`S6T5Q`J*T:B$K%Y`^NO$%
MMJ&CZ'>W=O<:WJUQ:P/-'96@LUGO&521%&952,.Q&T%W1<D991DCYJ;]MOQU
MXA\`>$9/#_@F"/QUXP\0Z]HL.@^)?%UIIEI8)I,MVLSSWMO9769F2V4^5!%*
M@9W_`'ICC,K9RMR6?2WKOI_P2GW[O]/\E]XGC31?BUXR_8@T/PO>:;\0-4\<
M>$)]`L/&BZ)KD>AZIXNC2WLY]0.EZEYEJOS&5D,RRVFYX+A!)'P3XW\,OV?_
M`-HW3/'WA6;6-,^-&Z/6=.G\/7T_Q/@GT[PAH::S<S7>GZ[;"\/]J7K:8T</
MG&'427*8N8VC-P?HS7_VO;^X_9*^'GQ(\+Z=<:IJ?Q2_L:+0M)U;6+33K5)]
M2\LQK<WD=O.$1`YRT44S.0`B,6%>4^`?^"H/BKQKKC*?!>FVNC^&?$>G^$/&
MER/&]I+<Z;JEYK,^CI_9T(L`M];"XA#&6:2SD*,VV%I$:.M/^7KLM>97[7LM
M/3_/S,].2W2W^?\`P?N\C3_9B^%7Q>\)?'3Q-J/BZP^)%GIG]CZ]'X@U'7O'
M$>L:'XGO9;^.33)M(L%N93810V@N%=1;V/\`K8U,<Y7S$^T0>*^3_@O^VAX@
M^-WCR30]3T"UT;P]XHT77=6\+W]MXFMM2O+^WTJ]BL;D7]H+.(6CL]Q$RK#/
M<@#>KO$ZA6^G?[!N<?\`(8U+G_8M_P#XU27P12V_X/\`2']I]_\`AC5H/2LS
M^PKK_H,:C_WQ;_\`QJ@Z%=#_`)C&H_\`?%O_`/&J8S\UU^!/[0EA^U%\8I-4
M\(_';Q#X(U1+IK"/2?B/=V\DKS7OFVYT^9_%%I`(EPC/#%::5+'!&85G;YUO
M/>_AIX#^-VF_\$Y-0\%S:?XTM_B1<:7JIL;Z^U^!=3A!N=\5J]S)J&HR07+Q
M2R1V[F\O?+6!'END<A1R?AK_`(*9?$#QU\=_'7@71?`FC37?A];Y]`N+CQ+J
M2V_B%;6Y9'(N(?#DMHS^1'+(T-C<7TZR`1>42EP]OZ?X8_;2U"^_89UKXN:Q
MH^I:3K7A^.[CO?#3W8MV@NHIS%%'+)>V-K/;)*##+FZM89(XIE9HN@,Q2]C;
MI9?=W%+^(F]'?]#Q:Z^!WQB;X6Q1R^#_`-H>;P)_PF=W>6_@J#XMQ1>.;;3F
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M^&?_``4Z\/\`CFZ^*#:AI7Q&T'3_``+9W.MZ)>7NC&WC\=:1;A5FO],>XMH8
MKA%D9#F&26/RKJSD,@,YCCF.L]-[?A_7Y>HY?"F^_P"/3^O^`>??M<?M6_'3
MP1X$N/%-YX"_:4\'>'[[Q3%:V&@_#WPQX>\6>-H[0::OS-&@U&PCM6NUF9WE
MD\W_`%(1EW%*Z3Q]H/QE^,O['7P*U;Q)X=^*FO:Q-9)?>//#O@WQ-#X)\237
M,NGOY1,JWEDL:0W#*9;=;N/G;E9=A0^K?$_]KZ+P-XZOO"NA^'_B/X_\5:?J
MBZ6^D:#_`&+#,^;&.^><27UQ;0B..*:(,&D$A:0;4<`L,+Q9^V=K'B'X7_"O
M6OAGH[>(]6^+T,M[H]EXJUN#PS;VUK%9O=R-/-'9W<@EV*`L20OR6+,BHS5$
MN7V<K[76O;3IY/<K7FCZ/YZG@'B?]G_]K`?'#X47FIW/B3Q1::3H?AV+4)-/
M\03VFEVM]"%_M)KY[77M+$K22AG,CZ3JB,A4"#`>&3]'%.*^$(O^"M=YXD\;
M^"K?0?!^NMX9U[1M"UO6];U0:A]GT2+5(UE4+/IVBWUC^ZB8%I+V\LH2W238
MLDB?;HT*Z/\`S&-2_P"^+?\`^-5M*]G?;FE]]]5Z)[&>G-YV7W=`T0XU36/^
MOQ?_`$GAKP'_`(*9^`_'_P`1/@9IUC\.[/QQ?:NNK1S30^&-5_L^X:(1R`^:
M4UG19I(LD';#J4!WA&99D5HF]NTC2+EM1U11JFH+MNE!(2#Y_P!Q$<G]W[XX
MQT'N:\O_`&S_`(Z>*?V9OAI9ZSX:T74/&VJ7E^EI]@S<_NHRCLTOEZ=I>H7T
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MM*>.=3_:ZU+X9^+O"_\`PC.FM8SWVB:Y;:C<W2ZB$=/+MY#/I%M9FY>!GE:&
MSO+QHA!('V@!VF.DE\[?K_3*J6:M+^[^>GWGOOBK_D&1?]?EK_Z41UI5S^NZ
M5/;VD+R:E>W"B\MLQNL(4_OX^NU`?UKH*"CQ36/"/P]\1Z'XF_X2#2K>::\\
M.Z</$<DFJ1PM:V5M]HEL[EO](5K7RW-S)'<+Y;JT98.&B!7-\;_L<_#7XX:S
MI_B'4_#GB_5`UE:P2"U\:7\.G:_;P?-;F_MX;Y;?4@`>&NTF+`X)(KE_C1_P
M3=T#]J"[\2:]J_BSQYI%UXL\%V7AJVBT/Q5K6BVUF8DO/WUQ!8WT$5\";P?N
MYT(`C9<XD('(?M(?\$A=/_:/\7:;/K&J^`=2TE=$TW0KV;7O`W]J^(--AM,B
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M'3/`]Y96MYJ4/GM!J1%[JU]'#<1R3[T%M%#'&8U\M(\5K&W,^V_S_K]/.TW:
MC=;JR2\MM_1[>OS^N_#GP*\`?#SX47'PG31M=DT3Q5'?R36&L>)YM2U+5EF?
M?>2-=75Y)>2G=,"S^82N]>0,5S'[0VG_``.N[#Q9JWCS4;/PQ;:I?V&CZ[?#
MQT/#JQ:G$T%Q9!I8+Z'R-1`%N8Y5*W)C$2A_+VK7-_LX_P#!-*;]G_\`:SN?
MB2NN>!+J"2'5XR^G^"I-.\2:TU_<Q3B75]4%](FHR0B-DC<VD;`2-@J"P;<;
M_@G;;^'_`(]^-OBSX;\21Z;\3O$NL)J&G:G?Z:^I6>EVGV"ULY=/-J]PH\J8
MVRRRO:O:RR,EN'=E@4%+WFG/M?O9W6GW=2MKV[_?UN5_"W["_P`$?%R^#=2T
M_P`/>*/$MO\`#;Q'<ZMI'G>/M1U:TMM;BNIQ<75S')J,D5U?1W#7"M)<B25'
MWKD$$5TFH?L,?#'7?BGXT\;:EX'\1:OXG\?:,WA[5[W4?$EW>8TXR^=]EM4E
MO&2RC$O[Q1:K%M?####->8Z#_P`$=O!MMX]\1>+M6E\-Z]XROM>36]"UZ[\,
M0OJ'A8CQ'J&N/':S-*TD9?[?Y#/&T9(B#D'=L7E_V*_^">7Q4^"O[>WB#XB>
M*=%^`.@^#H8-:ATR]\(6]ZWC#Q6]]>0S)<>(+J2*&&YGCCB<AU4E6FD4'#,Q
M>CEROL]>FMM/F$M.:2UU27=I/?Y;GT1X#_9,\'^`&T?R-)^(VLR^'M8;7],F
M\2>.M3\0S65XUG/9%TDO[^=PAM[F=?+SY>9"VW>`P[;X7^#=-^#/PXT'PCX;
M\-ZCIOA_PQI\&EZ9:?:8YOLUM#&(XDWR3,[850,LQ)QR2:[(@9I>*+_I_7R#
M^OU,W^W;K_H#ZC_WW;__`!VC^W;K_H#ZC_WW;_\`QVM/-%`&9_;MU_T!]1_[
M[M__`([1_;MU_P!`?4?^^[?_`..UIT4`9G]NW7_0'U'_`+[M_P#X[1_;MU_T
M!]1_[[M__CM:=%`&9_;MU_T!]1_[[M__`([1_;MU_P!`?4?^^[?_`..UIT4`
M9G]NW7_0'U'_`+[M_P#X[1_;MU_T!]1_[[M__CM:=%`&9_;MU_T!]1_[[M__
M`([1_;MU_P!`?4?^^[?_`..UIT4`9G]NW7_0'U'_`+[M_P#X[1_;MU_T!]1_
M[[M__CM:=%`'.6VLW`\37C?V7?DM:P`IO@RN'FY_UF.<^O8^V=#^W;K_`*`^
MH_\`?=O_`/':6V_Y&Z]_Z]+?_P!#GK2H`RVUVZ_Z`^H_]]V__P`=KPG]H?Q3
M^SE<?!>^A^+&G_!^3X>67B"6.]C\73:(=%AUEGDDD607,ODK>%Y)68-^\R[D
M\DU[!\8OAW+\7?A9XB\,1>(O$GA-O$%A-8?VSX?N4MM4TT2*5,UM*Z2+',H)
MVOL)4X(Y`-?+/@#_`()4^(O@3H5E_P`(+\8!-K6B>(+K5](E\6^!],O].L;>
MYT\6,]O]DTT:;ERJJXE21`",%&5G#YRN[^2^]W6@;)6[Z^2L]?OT/8/B3X;^
M#OA#X(^,=0\;^'?"-O\`#+Q0;?4O$4GB2XT]O#URBP6MK`\HN9C;+$([>U51
M@)E%(&XY/&^'];_91/Q%^$YTG1_@+_PEG]E+_P`*S^R/X?\`[1_L_P#>;?[&
MVR^9]G_UV/LOR??]ZM1_L4>)K7]F3PU\-].\3>'],?X6WVB2^!]6N=$_M&-X
M],MK0*VI68D@5V>=+KY;:6'8A@*NKJ:X'P%_P2C\0>"=<9C\3/#MUI'B;Q'8
M>+_&ELO@2.*XU+5+/69]8C_LZ8796QMC<3!3%-'>2!%;;,LCM)6FCJ7>UU9^
M5M_Z_P"&G[&G;;]/R^_RU].^&VK_``)E^*GQ27X;Z7\+8_B<RR#QR_AQ](_M
MQ9<R8_M3[-(;C=OW_P"O&<[N^:]T&O71'_('U'_ONW_^.U\W_!W]AK6?@9XX
MEU[4?&>CZYH'A71-?TKPMIMGX773;VSM]4O8KZX^W7?VB07<BO;Q*C10VP/S
MM(LCL&7ZB44+X(WWZ^7E]P^K?];(SO[=NO\`H#ZC_P!]V_\`\=H.NW6/^0/J
M/_?=O_\`':TZ#R*!GQ7XVU7]A;5OB+\3KKQ-IO[,5]XFD0?\+!&KW?AJ:ZC$
M%W%'G4TEF)3;=M`I,P'[[R0?G"5[%\-;+X(G]G>SU/P?X7^'/_"I[71+^"UN
MM&CTC_A'8=*F;??)&\4GV<6KM%NF`/EL8\OG;QXGI/\`P3'^)W@[]H?Q[XV\
M/?&31K*T\2+/_9.GW^AZO=6EHUQ,[RM-:0:S;6L<L:22B.XT^*RGWR-([L7G
M%QZ-X;_8,UK3_P!C34?A#J/CBROH=8M=0:ZU'^Q;BX*WMQ<K<Q3*+Z^NIY8E
MD\UIDO+BYEG:8_OXU`2HC_"M;6VW2_8)?Q$UM=Z^7<P=1UO]C?\`X8\T_P"V
M:/\`LX_\,_\`]K'[#YS^&_\`A#O[1W29\K,OV/[1N\W.WY\[_>OH;POJ\/VE
M7TO2Y/[._LZU%HEH]OY*P@R^64VR;-A4C;M/0>F,_/7_``[]^(%O?MXPM_B;
MX'7XL77B>Y\1W6IR?#UI/#KBXTB'26A33?[1%RK"WMH6\TW[,7\S(,;^4OM_
M[.7P<M?V>_AMX:\"6-U-J%EX,\,Z9HD%U+&D3W"6Z21!V1`$4D+G"@`9P!BK
MZ._E^6OW/0FVOWG2:_%'XLT.\TO5/#<VI:9J4#VMW9W26TT%S"X*O'(C2%61
ME)!4@@@D&N=UGPUX-^)@_L74/!NA^(%\,!K7[!/;V%T-($]J8FC\MG/D^9:S
M,A7`W12D<JV#VGB#3[C5=$O+6UU";2[JXA>**\A1'DM792%D59%9"RD@@,I4
MD<@CBOFFT_8I^*T!A\33?%CP/=?%*#Q.FO+K$G@"Y&BR1+H[:5Y+Z<NK"4R&
M-VD,JW:KOQB(*-M3Y6[?/^NI7G_2'_&C_@E3^SS\>?@?!\--;^!NDZ?X!@U5
M=;.A>&G'AFREO5C:-9I$TVXM_,8*[`;]PZ'&0"-/XT>&_P!G/X6?!SP'\)OB
M=X;^%VG^!PUMI'A+PSXVGTF2SNI;=%A@BM8;Z8^=,BNJC:&D_>=<MSQ^B_\`
M!(SPEOT/5M>F\->(_'GAG1O#>E:-XINO"T/]H:,^E7TUW+-:.TC/;FY\XH1&
MZE0HRTG0=E^V9^P]K/[3FNW%UH?C+1O"MOX@\*WW@CQ'%J7A9=:>[TJ[>-I/
MLC_:(?LUR-K`/(+B([E+0,4%'7EZ-Z]M-G_6P:7O]W=7W_KJ'VK]FWX\_M)V
MFD_V#\&_&7Q@^&,*FULLZ'J/B3PE%;R)MV1^8US:+')(F,!`K.O0D5[T-=NO
M^@/J/_?=O_\`':^7_P!C?_@FQJ_[(?QDN=6M?B9JVK^#(1>KIGA]Y=9;R_M,
MQES.MUJMSIV]2S'S+/3[.1F)+/AY4D^L5]JK:"[[OUN1&]W=>2]+'/:1J]T-
M1U1ETO4#NNE)`>#Y/W$0P?WGMGC/4>XK`^,GP<\'?M&>%TT/XA?#/0_'6BQ3
MK<II_B+2[#5+595!"R"*=G4,`3AL9&377Z(,ZGK'_7XO_I/#4FNZ=<:KHMY;
M6M_-IMU<0/%#>0HCR6CLI"RJLBLA9200&4J2.01Q4RVO:Y:W/%=7_9%^`WQ'
M\&Z?X%OO@?\`"_7O#_@*5TL?#T_AO1KJS\.27`$K"*V.4MFD#*YVJI8,&YSF
MK'@+]G?X-V/QTUKQOX?^&?@V;XD:7=K:ZAKD%II]QK.D2M8P(ML)S(TMJILS
M`1`I1?+E#;<2$MY#X@_X)R_%SQ/J7B+Q!=?&?P(WC/QII-_X>UZ_'PWN19S:
M=<VMA;_Z/;#6,PW:_80QE>66)C*0(%"\_07P`_9[_P"%&>(_']__`&Q_:G_"
M<ZQ9ZMY?V3R/L7D:/I^F>7G>V_=]@\S.%QYNW!V[FJ'63T=OO=_\M122T73_
M`(;\S*^,'[5/PE^&EC_;/C[Q+X&\.VOA?6ETXWVOZ[I=I'H^JO:M(L!DFN`(
M;IK29F"9$ABE)QM;D^"_P%^$O@;Q)=?$'X=_"GP+H^L>,8#=7/B7P[HVEV]S
MKL-PPG,CW4!#3I*VV3<68.<-SUKA?%O[`&H>&?`GC;0/A+KG@CX:V/C;7%U.
M2&+PO?Q1Z9;FPM;:6&T?2=4TR>WEDFM1,TT<RY\QE*$G?7L_P`^%C?`[X)^%
M_![Z@NJ-X;TV'3A<I;?9XV6-0JA(]SLL:J`JAY))-JKODD?=(Q'9OTM]VH2W
M2Z=?EL:VNZK/<6D*/IM["IO+;,CM"57]_'UVN3^E=!6;XJ_Y!<7_`%^6O_I1
M'6E0,^5?&G[9NC_!W]H&'P3KW@6U_P"$5L_"VD:M?^,#<1^7I][J4]];VEO<
MP&+,<,CV#I]I\PA99X49`&,@H_%7_@I=\*_@?\/_`(5:EXE\.PKKGQ4TFUU>
MRT.TO=*AGMXIXXF.Q[^XM%NG5Y518+;S+J8Y,=N^UMNC\6OBGHNC:MK&@V?P
MA\>?%R\NO#%I:>,CX?T?0IHK?3)$G:"RNO[1GMWO4*27;+:VXN6`D?<BF=!)
MRW[3WCS]E^?6](\`_%SP9#K>E^$-&T[4],36/A8-;TGPY:7IDMX`^W3YETL?
MZ+Y?^DK;K\JHI8HZI'-U;5KK[M;_`-=E\QN-YVC?;UULE?\`/[SNO$_[>OPD
M\#?$"T\-Z[I>H:)J$VKSZ5=->Z1'#'I,<=K#<)?71+9AM)A=6D:2,,^;<I&Z
MHP<)S.I?\%$?#NC^+)!<?!GQG_PB%KX2T;QEJOB!8--C_P"$9L]1>[`-_:RW
M$<V8UM2Q6S%U+RP,:D+YG-_M!?M??LM^!M(\-ZY\0M-N)-%^,FCO9VNH:G\-
M'N)M<M=/O[."VL9;-[`WTRM<:A%);)]G>-@7D0@,C/U7[2,W[.L'[0GA#5OB
M5X)L=:\7?\(U<^*=(\7:G\.H-2;1[+3I8'51?-9/);S"2Z5HH00_F,%`$DL2
MR7'367=KMLG=/[K]-B>FF[5UZW6J\MT;5M^VGH>N^$K[7--^%>O0:-9^-[+P
M/!J.L1V%G:ZK<2ZX='N9;98I9IRD$JL_[Z&(2`H$8Y8IS/CK_@I5X+\">)?M
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M:AX3O_#&K^+LZG<AH(9K6QO[2XFF+^45#6J,N2.AD&[ZL_:5T7P#H7@?P_\`
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MNH:?#;_9Y_,U*73%0V)A'V;S'E\AR/(5F;]W1U;6NKM;RZ/T6_W[:`[JU]$U
M?7MM^?\`D=S\8/VR?!_PL^)B^"[/X;^+/&/BJ?4;33+73M#L-.#7<UQ87=^N
MV2ZN8(D58;*;<TCH`VT`G.1S7B']N+^Q_"'P_P!4TWX'ZOXJD\<>.]6\%/;:
M3?Z6CZ:;"XOX1<,UW+;K(9!8LXC4X4>8#(65!+S_`/P3D^*O[(7QZ\2>+-#_
M`&;[;P?I^J?#O48[K6[+2?AXGAF72[V1+BU64I-I]N3-Y:W,)9,LJEE8@/@_
M17B_]EKP/\0/!:^&]>\.>'];\.KJ!U5=*O\`0]/N+);PRM.;D0O;E/.,KO(9
M,;M[LV<DFFTU9]VGZK2X=''JE;Y_U8^??'?_``5,^%GPFT'PZ_B3PQ#'KOB;
M7M8T>RT>TO\`2HIWBT_5)].-PC7\]FL[R/"I6TMO.NG,A6.&78S#U+X??M2>
M"?B)^U1K_P`)H?"&I:7KF@Z4FLK=:M;6&GIJENP@S):V<LZZC+"K3B-KG[(+
M82QRQ>=YB%*V?B9^PU\*?C9HFGZ7XR\`^"/%FF:3=7-[96FM>%M+OH+.XN9#
M)<31I+;,J22R$N[*`78DL2:O^$?V1?A[X`^*NI>.M!\)^%]$\;ZQ!]EU#Q#I
M_A[3;;5;Z'Y/W<MREN)9$_=1?*S$?NT_NC"IZ/WO/;\"I?W?+_@G??\`"&Z1
M_P!`O3O_``&3_"C_`(0W2/\`H%Z=_P"`R?X4G]A77_08U'_OBW_^-4?V%=?]
M!C4?^^+?_P"-4`+_`,(;I'_0+T[_`,!D_P`*/^$-TC_H%Z=_X#)_A2?V%=?]
M!C4?^^+?_P"-4?V%=?\`08U'_OBW_P#C5`"_\(;I'_0+T[_P&3_"C_A#=(_Z
M!>G?^`R?X4G]A77_`$&-1_[XM_\`XU1_85U_T&-1_P"^+?\`^-4`+_PAND?]
M`O3O_`9/\*/^$-TC_H%Z=_X#)_A2?V%=?]!C4?\`OBW_`/C5']A77_08U'_O
MBW_^-4`+_P`(;I'_`$"]._\``9/\*/\`A#=(_P"@7IW_`(#)_A2?V%=?]!C4
M?^^+?_XU1_85U_T&-1_[XM__`(U0!0M_"VEMXHO(SING[%M8&"_9TP"7FR<8
M[X'Y"M`^#=(_Z!>G?^`R?X5G6VC7!\37B_VK?@BU@)?9!ELO-Q_J\<8].Y]L
M:']A77_08U'_`+XM_P#XU0!0\0^"8+G0KZ/2[70[/5)+=UM+BZTX7,$$Q4['
MDB5HVD0-@E!(A8`@,N<CXM^.GC[XA_"']CFTU3Q/=?&&\\86?C#5[6Z_X53\
M(K75_$.OV<=_=Q6J6MM<VUS9V-KY/D2B:Z$A>&$*LSRR;W^X/[#N@?\`D,:C
M_P!\6_\`\:KR']L?]JK3?V*?AG:>*M?3Q9K5E=7Z:?BQFT>QCMV=6*O-=:C-
M:6<*DJ$7S)U:222.-%=V"U$M%]WYH:UT^9Y#XI^+6K^(?V)=+N/#6J>,;WQ/
MH6I:1H_C;7=-^&\G_"4:9%(EK/<W$6CW-@&>Y^SW$+,%L'`$KLML-OE+Y%\,
MOB?\>-3\?^%H=7_X6MNEUG3K?P]8S_">U@TWQ?H3ZS<PW>H:[<BR']EWJZ8L
M<WDF;3B'"8MI&D-N/LOXF?M!0_#7X,:+XP&G_$'6KGQ))96VE>';/3K2#6;N
MXNROEV[1W7DQ02*&)?[1+&L81]S#%>7>$_\`@I?HOC#7;*U@\(_&:&SCU2UT
M'Q'J,^F:4MMX-U2YOY-.BLKT"<RRO]JCV&2QCNH%$D;M*(VWU=_WFG\RT\[;
M>G^?H9Z<B]/\_P`_T\F<?^R_XL^)7B7X\^)++Q4OCJZL(])UV;7K#7/`$&BZ
M)X7OHK^--,AT?4%M8C?1RVIN&9Q<7W^JC8R6Y;RW^SQX.TG_`*!>G_\`@,G^
M%>!_#K]L6P^.'BW4_#<.A_$G1+6\TW5+_0=8UBRTZ/3?%-M8SI:W4EMY,DEQ
M$JR318%U%;O(DH:,,`Q7WS^PKH'_`)#&H_\`?%O_`/&J(WY(^F_?^MOD5]IC
MO^$-TC_H%Z=_X#)_A0?!VD8_Y!>G?^`R?X4G]A77_08U'_OBW_\`C5!T*Z`_
MY#&H_P#?%O\`_&J!GYC#XX?&:W_:@^,>@:W?_&O3_">E1W4FF7>C_#B&^DT1
MFO<VB000^%;H21R*%A6>*[U8B$R2O;ABS6?OGPT^(GQ)N_\`@G'?ZA=:'XBO
MOBX-+U6YL+RY\&O]LN(X;G"2K;RZ?IX:Y2&9!'%<65D]R\#LEL8^3/;?\%6?
M#VK?&CXB>`=/\*_$J_\`%'PW@N+F^T]=7\(6]U=00SK$UP+:?4X[BV@,9^T"
M:^CMHO)V$L&F@27TGP%^VAX;^('['#?&ZTN/%A\-"VN9TLH4T[4+VY>&XDMO
M*@>S>:UN#)*FV-X9WB?>K"3:21/_`"Y^6_ZBE?VBOIKM]VA\TW7Q!^)B_"R&
M237/CM!X%_X3.ZL[?QK;_!NWE\<W.G+I,4L'FZ-_9!*0G4C<P^?_`&2A,<,6
M=JO]I?Z[_9EL-8\3?"#PE>>/-!L;#QE=^%]+N==L_L,<(MK]XW-POEJSJA\S
M(*AV`QC<<9KSAOV^I&TC[-#\.?C9=>/$UR;09_!$=KH/]L6TL5C'?O,UP;P:
M:8?LTT#ATO&R9EC`,@9%]<^#OC6S^-/A72/%VAZMK#:3XFT.PU6R>XMHX)V@
MG$DB"2-HLHP!Y4@$$D'H,7'9_P#;OY:??N+JOG^9TGB+3=#\,Z%?:E<:/%+!
MI\$ES(EIIC7=PZHI8B.&)&DD<@<(BLS'``)(%?(?AOXG_M"_#RV^(&K^-/AC
MX;U&Q\5:?>ZY\.;+1;"?5;G0G@MS+'I6KPPVL+12RPJC`K+.IN4NHA./-M(:
M^R6T2Z'_`#&-0_[XM_\`XU7S]\*_^"C_`,(_C%K_`,7--T?XAW$TWP2N)(?$
M^U;:=H(X]ZR3QQPH\C1K+#<1$,BON@)"&.2&22(WYM-=-OU_(J5N57TU6OG_
M`,$\(_:X_P""H^F_`WP1<>+;^;P_\&/A_-XIBT33?%'Q#^%.O2372?V:MPT:
M:,7LK^5GN/.03JHCC6W;<C;E>NE\?_&_QE\3OV.O@7X[CA\8>`[7QY8QZIXI
MU'X=?#__`(275],,NGO-:Q0V,]E>RK;R3%`TAM)&4!`6A#EQ]!?%7]JSP5\&
M]0NK/5O$GC*]U.SU"/3)=.T+PG>Z]J'G/;"Z&VVL;*:9HQ"RLTJH8TWJ&968
M`XWCC]L/2=(^'/@?Q%X-L_'WQ6'Q(1KCP]8>%K;3DN;^V6!KA[G=?O:P1QK&
M!_K)59BZ*JL3BIE;DE?:ZU[:;>K#7F7H_F?)WB?XM_M+6OQR^%%MK'A7Q#I>
MGZAHGAVYU33O#OA[$.HWLH4ZFEY+_P`(_JMM"5DW)Y4FJZ6J(N?/^?SH_P!'
M5\':0?\`F%Z=_P"`R?X5\DZK_P`%=OA=;?%KP'X/L=4\0:AJ?C^STF]MC/J?
MAW1GLTU((ULK6VI7=K=W,NQU9HK*"YD7<J[=[HC?6HT.Z;_F,:E_WQ;_`/QJ
MMG=QN_YI?GMZ+9$+XODO^'^9GZ5X6TR34-4#:=8MY=TJH#;I\H\B(X'''))_
M$UX%_P`%,]3\4?#CX%Z?=?#N/7--UB758XYI?#OAF35+IX?+D)0F#1M9>!2V
MTF3^S9P=H3,._P`U??-*TFY;4=4QJE^-MTH)"0?/^XB.3^[]\<8Z#W->;?MD
M?M1Z5^Q3\*8O&'B2;Q#J&FO?1V3?9[S1=-BMV<,0\UWJ<UI90)E=H,MPA=W1
M$#.ZJ<JFV]M5^:_,UCOL?%OQ-_:R_:D^'OP&^%LW@SX;^'=0OM2&HG7]<\>>
M`_%&M7%YY5PJP1I::#H=K=VS-&S'S;S3+-6\OY8FP'D]A\&_M6?$3QA^V/=>
M#H?!N@3>'].UZVTBZTVU^'>MR;;632K6\GO7\12&/3K=H);AU^QS6XGE6-``
MC2J!H^._^"U?[._P4^#O@'QE\1/BK+X'L_B0+DZ+:NMKKTLPMYO)E8RZ.M[;
M&,/@>:DS19.-^Y6`]8TO]M?X;Z[\6H_!5CXV\17FJR7<-A]LM_#EU)HJW4UM
M'=0VS:H+,V"S202Q.D1G#N)4V@EE!UC?F?7?\U_PW_!U,7\';^O/^OD2?&WP
MQXTT[X]_"Z;P[)H\?@2\U>6T\1Z9;^%UN+N1?[.OY$EFO6=EAMA,EL-JPHYD
M*?O]K&)O(?V=?%_B[6_V^_%&BS77Q`\2_#G[%>?+X@\`R:+8Z7?+<1[1:RS:
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MUX>\7ZAX=&KVZ`E(KQ;"]MQ>1+ODV)<K($$TH``D<'H/&O[-/@?XA>'=>TC5
M/`EQ)I?B;3K#2-0M8+L6L4MI8R226D*+%.HB6-I'QY>W(.#D``>1^//^":O@
MOXT_MO?"_P",FL>`_ACK%MX=\*WMIJLVJ:)!<:I>:BSZ:^FW(9H&#FV2UN`L
MCR!XO,`089L<;\4/V#OCY\1/VLO$&N+\29;7P/KFO?:X[V+QWK=N]IH3:6+6
M70E\/1QC327GWR#41.+E/,WJ-Z+64M8)6W3NNF]K?KZ=WH5'2?-VZ_+^O^&/
M8/B;^QW\)?VKOACX?T_4O#>OZMX8T_P]<>'--ET/QC=Z<D^DW0MA/:M/8WT;
M7$$JVEN&$C.&$>#D,V=KQ7^Q[\//&FA^%])OO`VL#2_!>A7/AK2+.TUJ:SM[
M?3KB*"*2W:.&Z190!;6[(TH9HGA22,I(H:O@WQO_`,$B?VK(?V+/@G\,?`?Q
M2C^'M_\`##PQ>:;=W'AWXM:]IJ7.J[XQ;74DATZ9KRQ*(2;!DMQ;D[(9O+R#
M]U_LD?L[>)O@O\3?C)XA\27NCWC?$GQ'8ZY:BQEDD:)8M%T^QE$NZ-`&,UK*
MPVY!1D/!)4=+BKR5]-?GK;\4W_3,U)KE\E9>6S.<U;_@G+\.=2TK3;7^S_BU
M`VG:R=<?44^(NJOKEY/]CFLT5]6DU!M16)(IY-L<=RBC+#&UW5^Q\$_LC?#O
MX>>$+70=)^']U#I-MJO]M"WFOS<B6\^QBR:>4RW#&5G@RK^86$C,SN&=F8^R
MD8%"\UCZE+3^N^YX/X`_8C\`_#9K=;'1/B1>V]C>6E_96FL^/]7UJSTV:U8M
M;FVM[S498K=4W8V1*JE0JD%5`&]\<?V</"W[0E[IMYXAT'QG:ZGHZR0VFJ>'
M?%5YX;U*.&3:9(#=Z=>V\[0.R1LT+.8V:.-BI9%(]:*9ZT@%%E_7W?EH'6Y\
M\_$W_@G]\+?BUX6T?1=4\'^-;'3=#TB?0HH]#\::EH+7=C.5::"Z>QOX7O$D
M9=S?:3(69G8Y9W)ZCX;_`++7@/X1Z7I^GZ#X%U"UM--T.;PY!'-J)N@+":8S
MRP-YURY?=(2Q9LMSC=CBO7R<"D')HLFK?UKO]]W]XM[7_K;_`"1XI^SQ^QWX
M(_9<\17FJ^$=!\??;K[3;?2'DUOQMJ7B#R;.W9V@MX5U"_G6&-#(^%B"CYC7
MK(UVZS_R!]1_[[M__CM:9/S4`Y%5=O<=NIG?V[=?]`?4?^^[?_X[1_;MU_T!
M]1_[[M__`([6G10!F?V[=?\`0'U'_ONW_P#CM']NW7_0'U'_`+[M_P#X[6G1
M0!F?V[=?]`?4?^^[?_X[1_;MU_T!]1_[[M__`([6G10!F?V[=?\`0'U'_ONW
M_P#CM']NW7_0'U'_`+[M_P#X[6G10!F?V[=?]`?4?^^[?_X[1_;MU_T!]1_[
M[M__`([6G10!F?V[=?\`0'U'_ONW_P#CM']NW7_0'U'_`+[M_P#X[6G10!SE
MMK-P/$UXW]EWY+6L`*;X,KAYN?\`68YSZ]C[9T/[=NO^@/J/_?=O_P#':6V_
MY&Z]_P"O2W_]#GK2(R*`,HZ[<?\`0'U#_ONW_P#CM>>?M!?L\^%_VG=+TBW\
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M[FTV&U67?'*)#++,Q?\`>$5C>'O^"<WP?\*>(M#U.Q^'_B*"YT&6"Y2/_A*+
MUK;5+F"YENX;O48&OC%J5TES-).MQ>K-,)6WA]P!'DMA^Q'\5_%W_!-_2?@5
MX@L_#VH:E\-;SPY:0S:SK4D^C?$VPL/L-W=6UUMBEFMK.5Q<66V6*9F6W#M$
MT;^6?"O`G_!#CXI^%_%EO>W`^$*K=^(M-UK1[B'4[XW'P4M;;Q'=:K-IOAP?
M8E\V">VG2W8AM/'R$%'0(J[?\O;-]=_NM+U_'37I?/:GHOE_7;]?4^Z/!O[(
MW@'X)>)O$7BSPWX0U[3]8U.ROH0]UKMQ?6>E1W4OVFY2RM9KJ2"QCEF59)$M
M(HUD9$+!BJX]C&NW0_Y@^I?]]V__`,=KX9_9O_X)I^-O@'^U=JWQ#U5?`-O8
MVUGXN&H>(])O+F3Q%\0_[6U&.\LQJT36T:(+")#%'_I%T.FP0K\J_?.W`J?L
M1]-NVNWZ_,?VI?GW,W^W;K_H#ZC_`-]V_P#\=H.NW7_0'U'_`+[M_P#X[6G1
M0,^9[K_@F[\+;CQYKWB*/P_\3M.O_$#M*5TOX@ZMI<.E2/,TTTE@EMJ$8L6F
M=F\PVWE[P\BGY99`_96/[)W@>T^%M[X,D\*^*=3\.ZI:7EGJ$&J>)+K49M46
MZ,9EENI[B\>:XN!Y48CN)7::%5"QN@XKV1NM`I+2-EMM\NP=;GSO/_P3X^%M
MQX%CT`^$_'@$>K2:[_;$?CG54\127LEN+625]8&H#47W6X6$JUP5,2)'C8BJ
M/4/A]X=L?AG96OA_P_X;FTG0]!TFST[3]/MO)2.SMX?-2-%'F8"A0`!G^'GM
MGN`,FLVU'_%67O\`UYV__H<]/6S^7X;"L4?$"-XFT&^TVYTK7([?4+>2VD:U
MO4M9PCJ5)CFBF62-\'AT964X(((!K@_&7[+_`(%\>>%]$T74/`E[_9OAO1[G
MP]IT-K?_`&/[-IUS;K;S6FZ&X1FA:-(CL8D!X(9!B2*-U]<)QB@'(^M))+YC
M/D3XQ?\`!*_PG\1_ALOA_P`.^*OV@_AC?2:R-<NO$WAOQ_)/XGO91;?9O*?5
M-2EO+H0F)8U,:2*"(HP<JN*[V7]AWP)J/P`\!?#F_P!!\<3:3\-[2*UT74K7
MQ1<Z5K=OLMS;,YO[&Z@N-TL;.)0KA9-QRN,`>^GY1^M*&X-%M&NC:;\[:+[A
M=4^UU]YX'J7[#'PQU#5=#NH_!7B;2[?P_86>E0:9I'B>\TO2+NTM.+:"\T^V
MO8[2]CC7Y0MU%*-GRG*\5[4-;NL_\@?4?^^[?_X[6CM^6EQ[T_\`@O[^OS"R
M_K\#G=(U:Y&HZH5TO4&W72D@/!\G[B(8/[SVSQGJ/<5S7QM^#6C_`+06A6>G
M>(--\<6L=A<?:K>XT#Q5=^'KR&3:R'%SI]Y!/M*L05W[3GD&NWT3_D*:Q_U^
M+_Z3PUI4GKH,^>=2_8$^'&H:+I=K'H/Q/TZZTKS]NJZ9\1]:T[6[X3,K2"\U
M*#4DO+T91,"YFD"[%"X`%3Z!^Q%X(T+XUWGCZ32?B!J6N7FJQZPMO?>+;J72
M8+J.SAM(YO[/^UBTEF6.!2)YHI)PYW"3Y4V^_P!'6A:.Z"R:LSD?%7ANQ\9Z
MKH-[J7AW4+BY\,WQU/37^T1K]FN#;S6Q?"R@-^ZN)EPV1\^<9`(XOP+^S#X7
M^'OQ4N?&5KIGQ%U+7;A[B1#KOCC4]<L[!IB3(UI:7M_-;VA()0&WCCVHQ080
ME:]@)P:`<FFKK5?U?<3UW_KL8&NZK/<6D,;Z;>PJ;NVS)(T)5?W\?7:Y/Z5T
M-9OBK_D&1?\`7Y:_^E$=:5`SQ'Q5_P`C1J/_`%]2_P#H9JC7"?'']JC0_A7^
MT1X.\&:GX;^(%U<_$2YM$M=5L-(@?2[:>\>39`'EN8Y[MXUC>2864$_V>$>;
M.(H_FKS0?M/?&+3_`(S^#O#NI?`/5K?1/%WB"YTT:M:SZQ>'3K"/4#9+>7*I
MI'V>W<HC71CN+F&/R&C,<\S,511ES62ZW2^0I6BG?HKOT?Y_(^AJ*\F_;L_;
M;\"?\$_?&G@_0?%W]IWUYXVM;Z\L9(]3T#1;2)+1K=91)<ZQJEC#O)N8]J([
M.P#G&%-7_"O[9_PM\3>'OA5<_P!J^,K?4OC)H?\`PD/AS2(O!FH:E>&S4P+)
M+<-9)/!;Q1M<0AIY)1!B0.)6C(>G&5X\R]/NW]=F/6^O:_RT1Z517D'@G_@H
M=\"_%7PMG\5:AXXO_"<5GX*L/B!>:?K>@W,-[!H]X=L,\:Q[TNSYA$16S><K
M*5C/SLJGBO&/_!8+]G/3O#OQ83PWXXUGQ9XQ^#_AV[\1ZSX73PGJFGW_`)5N
M41E'VJ"-?ORQ!B"=BL78;58@EH^5[[OT7^74:3;LNK7WNUE\^A]*45XO\._^
M"E?[.OQ%_:(T#X/P?%2*R^*OB"U@GA\-7OA_4;.>&26V%RMO))-"D<<_EG_4
MR,LN<*4#';5_]NW]MOP'_P`$_/&G@_0?%_\`:=]>^-K:^O+&2/4]`T6TB2T:
MW6427.L:I8P[R;F/:B.SL`YQA31+W;)]79>?]69,6I;=KGK-%>7_``E_;4^&
MWQ9\+:AKBWGBC0]'TGX>Z;\2[RZU'1P1#I=\;L1JJ032R2S+]BE)6)71PT9B
M>4.*S_A;_P`%(?V=?CC\&[?QYX+^)U]XLT&\UU_#-I%I'@W6+W5+S44MC=/;
MPZ=';F]E*VX:5F2$JJ*S$@*2'+1M=OPZ:_-#UT??_)/\M3V"BO%_&7_!3S]E
M[P!\1?A_X5U;XX:';ZY\4+*SU'P[$FEWDL=W;W;[+9Y9D1HK7>W&+AHR,'<!
MBH]3_P""G/[.ND6VK33>/O%OV71(M0N;FXC^&OB.2!H-/N#;7]Q%(MF4G@MI
MALFFB+QQ$C>R@BEK^/Y;_<'_``/QV/;**\N^./[?_P"SM^S=\>?"?PS\:?&+
M1]%\:>-H[6;1[$Z9=3I-'=2>7`\EQ$C00+(W0S2(,?-]WFK/C']MGX,^!OBY
MK'@6\\6^)I?$VA:@^D74-KX%UF>S_M!=/;4OL*7RVYLWNFM%,BPB8NPX`)XI
M<R2N]O\`)I/\7^(UJ[+R?RMN>D45C_L3>/=-_;:_99\%_%+28]7T*Q\9:;'J
M$5AJ6G303VV[^']X$\Q?[LJ`QR##(S*0Q]5'P0S_`,Q0_P#@/_\`95<HN+<9
M*S1$9)ZQV."HKOO^%'?]13_R7_\`LJ/^%'?]13_R7_\`LJDHX&BN^_X4=_U%
M/_)?_P"RH_X4=_U%/_)?_P"RH`X&BN^_X4=_U%/_`"7_`/LJ/^%'?]13_P`E
M_P#[*@#@:*[[_A1W_44_\E__`+*C_A1W_44_\E__`+*@#@:*[2'X/^;J\]K_
M`&ACR88Y=WV?KO+C&-W;9^M6O^%'?]13_P`E_P#[*@#@:*[[_A1W_44_\E__
M`+*C_A1W_44_\E__`+*@#@:*[[_A1W_44_\`)?\`^RH_X4?_`-13_P`E_P#[
M*@#@2,BBNTU?X0?V5I%U=?VCYGV:%Y=OV?&[:"<9W>U6O^%'?]13_P`E_P#[
M*@#@:*[[_A1W_44_\E__`+*C_A1W_44_\E__`+*@#@:*[[_A1W_44_\`)?\`
M^RH_X4=_U%/_`"7_`/LJ`.!HKOO^%'?]13_R7_\`LJJP_!_S=7GM?[0QY,,<
MN[[/UWEQC&[ML_6@#BZ*[[_A1W_44_\`)?\`^RH_X4=_U%/_`"7_`/LJ`.!H
MKOO^%'?]13_R7_\`LJ/^%'?]13_R7_\`LJ`.!HKOO^%'_P#44_\`)?\`^RH_
MX4=_U%/_`"7_`/LJ`.!HKM+'X0?;+J\C_M#;]DF$6?L^=^8T?/WN/OX_"K7_
M``H[_J*?^2__`-E0!P-%=]_PH[_J*?\`DO\`_94?\*._ZBG_`)+_`/V5`'`T
M5WW_``H[_J*?^2__`-E1_P`*._ZBG_DO_P#94`<AX4_Y&K3?^OJ+_P!#%>VU
MY^/A=_PC-U:7WV[SO)NX!L\G;G=*B]=Q]:]`H`^=_&7[$_PB^-7C;1_&OB7P
MSKUYXBAM=*6Y:TU#5[.QU7^SYOM-E]MM+>5+6_$$[,\?VF.4*3QQ7NG_``E%
ML?\`EEJ'_@OG_P#B*^'?VS_V,OCI\??B#J7B;X?^.-2\.:/IO@_1[?2]-CU_
MQ!9&_NQ)=M>-:IIVO:?:I<K$T&TWUO+%*XB1I$C$A'LFK>-/BQ??M"67A?PW
M)KK:+_8MIKNL7.MZ*ENFERPHP_LR*]2$VEQ+?2&+S?)>9K58+HY3S[7;"DE&
MWF]/S:^X'J[[Z+7TMI^/H>J:SX`\(Z_\7=$\>76DZE)XJ\-Z=>:3IU]Y%ZOV
M>UNWMWN(_+`$;;VM8#N92R[/E(RV:WB/X3^"?%GQATGQ]J&BZE-XLT/2+W0;
M&^$5ZGDV5X\#W,7EKB-M[6T)W,I9=GRD9.?BK]EWPC^W/KMAXXTGX@^,OB)I
MT&M7GA]M$U?4O#_@>SU'PW`=2;^UHK;[#<7L%WMLBN)[JW0L5RD"M\I^CO%?
MP]^,&H?L'_$SPG)KOB+7/B1)8ZYIWAS6S>66FZOJ"LTRV$YFLEMK>"<H8L/&
ML.T@$A6R:KEM'2VVB]=_S=^^H?:Y7W2_X/IH+K'_``3T^`?B"U^$UOJ'PY^W
M1_`T1IX)\^/49&T98_**(6+$W"JT,+A;@R#?$CXW*&&#;?\`!*_]G6!M;'_"
M#^*)K7Q!I>L:+<V5QK_B&>QM['5I1-J%O;6SW!AM(YI%5RMND>U@"NTBN93X
M2?M(2>*?AO8G4K_^S/A9K,U@;^775$?CBU:QOEM]0U-4D$LJ1`Z?')$WS273
MW4HB*1P2GS7QE%^VU)\#/$W_``C-Q\9K?Q5'#820KK5G\/9[^ZOED=KF#2VA
MFCM(-.D0;&N-06>ZBW1-'!,1(M+F[WW_`#W^_K_2#5->GXI]_(^E?AW^P9\&
MOA;\2M+\7:3X<\5_VWH\JW-J;[6M>U&U2[%F++[<UK<3R6[WQMAY37CQFX92
M=TAR<^CZQ\/_``CX@^+VB>.[O2=2D\5>&].O-)TZ^^SWJ_9[6[>W>XC\L`1M
MO:U@.YE++L^4C+9^9OVB_#/[5FK>%?%FK?#^ZO\`POXGU;P-X1MK<02Z;KS:
M7J<=[J3ZS]BM+R>TL9;L0S6B^9.8(955<-F-56G^Q/XC_:=F\5>'_!7Q*\1>
M,-7NXT76/$FO>(O`>F:!-900S2+'8PMIUQ>:9<27NZ+<8+F22WBMIRZPO/!B
M]Y\KWCHG\M;?*_KL2[15UU2_%7U_+U/?OBS^RM\*_CG=>-)O%7A6_P!5?XAZ
M!;>%]?8C4(3>Z?;RSRP1#RROE,DES,PEBV2`L#O^5<<58_\`!-OX':=H5Y9P
MZ#\0%N+[74\32:O_`,)9XF.NKJ*6?V$7*:H;K[;&YM/W#;)E#QY5@PKZ9`H(
MJ-/Z^_\`,K5N[_K2WY:'SC;?\$[?@18:UX9O+7P3J]G_`,(I;Z?:VEI;7NLP
M:?=K82M-9->VB2BWU"2"9VD26\CF=7);=NYHF_X)U?`6Y\-2:.W@34FTZ31]
M?T%HOM.K<V6NW0N]5BW>9N_?S@/NSNCZ1E%XKZ.VTJC`JKZ??^*U^_KW#56^
M7X;?=T/!/%O[$_P=\<?$71O%.H^%M<DU30XM.BCCBO=7M[&]73I#+8&\LXY%
MMKYK>0EHFNHI6C;!4@@5H:E^R1\)=:\3W.L77A._FU"\\6CQS-*W]HXDUD:;
M_98NBN[;_P`>8$7EX\K^+9O^:O:LC%'45/2S_K5-_BE\T"TV_I=CS?\`9Y^$
M7@S]E?X0Z+X#\#Z?K^F^%/#L1M]-LKN74]3:TBR2(DENFEE\M<X1-^U%`50%
M``[C_A*;?_GEJ'_@ON/_`(BM`KCO2CA:KF;=WJP2ML9W_"4V_P#SRU#_`,%]
MQ_\`$4?\)3;_`//+4/\`P7W'_P`16E10!F_\)3;_`//+4/\`P7W'_P`11_PE
M-O\`\\M0_P#!?<?_`!%:5%`&;_PE-O\`\\M0_P#!?<?_`!%'_"4V_P#SRU#_
M`,%]Q_\`$5I44`9O_"4V_P#SRU#_`,%]Q_\`$4?\)3;_`//+4/\`P7W'_P`1
M6E10!SEMXBMAXGO'\O4,-:P*!]BGSP\W;9D=>O?GT-:/_"4V_P#SRU#_`,%]
MQ_\`$46W_(W7O_7I;_\`H<]:5`&:?%%N?^66H?\`@ON/_B*;_P`)1;#_`)9:
MA_X+[C_XBM3-?/?_``47_9HU+]JCX&Q^&=,\"_#SQQ<278E1?%^H6]O;Z0VQ
M@+RW2YT?5[:6Y7)11-:$!99"&!.#,I-+17&K/<]P_P"$JMS_`,LM0_\`!?/_
M`/$4#Q1;@_ZK4/\`P7W'_P`17C_P"^!^L_\`#+MO\+?'>GW.EV?ANQLM!M[S
M0O$MU;R:G:PVELPDCNK9H+F+9)YENQ_=&7[.S^7%',(5^9O$W_!-'X@6WBCX
M%PV/PH_9K\5Z;\-]`T32=9\0^(M=U-?$EH=.VO"NA.-.ECTU8Y@SM(G[RY5@
MI^SLBR"N5*?+YK[G_2T\R(W<.9Z/>Q]T^*?$EO/X8U!`M_F2UE4;K*=1RAZD
MI@?4UH_\)3;_`///4?\`P7W'_P`17Q#^S+_P3H\8?L_?MB_$[XH:EI_@NVTW
MQ6-<NGOOM^G:UK=[]LN//1//3P]I]];QKA<1RZE>QHBK$$;:DT?W?MP*/LQ;
MZJ[\O(?VFNBV\S/_`.$IM_\`GEJ'_@ON/_B*/^$IM_\`GEJ'_@ON/_B*TJ#T
MH&9?_"56Y_Y9ZA_X+Y__`(BC_A*;?/\`J]0_\%]Q_P#$5^<?A_\`X),?&[PW
M^V!\5O&'@OQ+\+?A-:^-WN&/B:RT"#5]3U.&YOOM,T(6*WL=3M9)0")97UFY
M`+DPI&RVSV?T#\._V1?B=X&_X)[ZM\';^\^&_B+5KS1];LH+J%-3TK3,W$[O
M:VLD0FGN#$\<LJRS"XW1X4".?+$S=^SY[:VO8/M\JV[_`*_TSZ;_`.$IML_Z
MO4/_``7W'_Q%9]MXBMO^$GO'\O4,-:P`#[%/GAYNVS(Z]>_/H:^!_!/_``2L
M\?>'?V;]#\*ZQ\/OV?\`QC8Z#XLO=97P#JVHRQ^&K^"XT\6Z7$\EKH\-D+J*
M<O*J6^BP0X<G'V@O<O\`:'[,7PSU+X,?"7PIX1UC5O[=U;PQX5TK2KW4<R'[
M=-!')&\N96>0[F4GYV9N>235\JU\K?.^_P!WXDJ[_'\&=Q_PE%N#_J=0_P#!
M?<?_`!%`\46X_P"66H?^"^X_^(JSJ222Z?,D;+YK1LJ;F90&QQDK@C\.?2OS
M@^`O_!*+XO?!V_\`B1<>'9?AS\+=1\7>&=0TFTU?PW?Z;<ZB)IF5HB+FW\,Z
M=>1L&7/VF\N]2D4Y8I+*?.$<SO:VR;^?8KI?S2^_K\C]%O\`A*;<-_JM0_\`
M!?<?_$4#Q3;_`///4/\`P7S_`/Q%?GCX!_8"_:0^%_P*T'PG<^*O'GCJ5O&<
MFJ:E#KG[0VJR2S::=+N8Q$^O6FBV.HV\?VLV[B"&&?+QCYD1Y,>O?'7]B#QQ
M\5?V;_A-H?B#1_AO\9M4\$R32:WX;\?:K=?V'K!DM9H8G>Z-I=/<36AD4)-<
M6K/-AI&,4K;@ZGNK3R_'_(4=79^?X?YGUA_PE5K_`,\]0_\`!?/_`/$4?\)3
M;G_EEJ'_`(+[C_XBOE>T_P""5GA#Q=+\%V^('A7X;^,M4^&^@65OK7B6]\/6
MUYKVNW]@ENMFGVNZBEN%LU<3S,!.LK.D"LS1-.DGUT.O6KDHIZ.^K_X`E=V]
M/Q.=T?Q%;)J>J-Y=_P#/=*PQ93G'[B(<_)QTZ'V/<5H?\)3;Y_U>H_\`@OG_
M`/B*-%&=3UC_`*_%_P#2>&O/?VPO@KJGQ_\`@=?>'=).E7$TEU:W<VE:M+-%
MI?B2"&99)=,O7A!=;:Y13%(0DJ[7^>&XCWP29RT_K[RH[V9Z$?%-N#_JM0_\
M%]Q_\11_PE%M_P`\M0_\%]Q_\17Q1H?_``3Z^(.@^"/%Q\%>"_A#\`VUB&PM
M_P#A#?AMXIU#3-*\0"&\2>XFN-2M-.LI;"XF@#6HGM;-YT0Y,KC8D78_`?\`
M8^\>>$/CM\,?&.M:7#IL7A/3/$&CZC9R?&CQ+XO:"*]:QEMYHY-0M8S>DO;S
MJ\5R%$0>)D=_*C1*A[SUTW_"]OO_`.'1,KWLCZF/BFW_`.>6H?\`@ON/_B*!
MXJMQ_P`L]1_\%]Q_\17EWB']F%I?VO--^*FD7C0WR>%]5T.Z;4-2O;V.&6>3
M3FMS;V;R>1#&/LDAE$)A,C>66WGYEX+]A']C_P"*_P"S3\3_`!]K7Q%^)7A;
MXE#QC;:>9-2LO#MYI6I7E[!YPDGG66_NH8U*R*JQ0*D2@`(D*($*6N^FGXW_
M`,M?F4]%='T#KVOP7MG#&D=ZK-=VV"]G-&O^OC/+,H`_.NAK-\5?\@N+_K\M
M?_2B.M*F!\(_M??\%(]=_9-^)"^&-)^&MSXLL;'P[I.J7&H'5/%";Y[Z:>WA
MM(QINAZA:Q.\D"HGVFYMP[S*HP`6'K'QL_;<T3X(Z_J=K=^!?B=J^G^&;"RO
M_%&L6&H68L?":W>?*6Z66_CN92`I9OL<%S@=,GY:K_&K]K/X9_`C4[#PSXV\
M*:[?:AX]TJWTL_8/AWX@\00>(8?L]RZV3S6.F7$,["%;MS;&1F1#*Q4*23GZ
M/XU_9=_:+\>PZHVF_L^>(/&7PET^29%U9+)=>\#V5E*59VAN;=;K3X(9`2&9
M8T7(8'#`G-W<--[O7R]/(':ZTZ;?=J<I_P`/8_#/ASX'P>+?$WPE^.FE:IJ6
MBZ9K.A>'=.C36M4\717SI$G]FPVMX\AP\B_+>):2[2#Y8(95DU7_`(*DV+_!
MB?Q1I?P-_:%76+?PMJGBJZ\.^(H8O#6H:1;V)=3]K2]O48+(RIM:V6XXE!P<
M,%G\#Z_^Q1X=^$FHZ?X;3]CJQ\"_$:^32K^VTS4M"CTGQ/=PLC);2I'$(KJ5
M&E0B-@S*95P!N&=[0/B'^R;\)/@;J4VEWG[*_ACX:I<W7@O4)+36-&LM"6:8
M&:YTF4K&L&^0;GDMFY899E/6M+ZWZ=/R7YK_`"!7OIW7W=?U_P""=M^U5\>=
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M:O\`Q#:^"O&MGK4&BQZ9-:++,)[JXLE>(QW:/LD$-V"-HM6&6':_%#]H7X!_
M'WPUX7\&^/=<^!?B;3_B=#:WN@^&?%.LV4Q\2JTH\AH;&ZCW3-YJ@*!&6$BX
MP&7`J>"?C-^SAX4&N^`_#NL_LYZ:/AOHNH6FL^'M.UW3(?\`A%M+65?M\5Q:
MQH/LMJ)0GG*ZJ@;;O&<5.M[OST^7Z/?\RM'Z:?B8,G_!2?P>O[9&C_!^+P!\
M;KI-<N?L-IXZ@LC+X--W]ADO#:O?+=EX[@)&ZF%XA(&`.W80YK_\$[O^"C&B
M_P#!0+3)OL?A'Q-X=U+3=(M-6U,/KWVBTLA=1K);Q!FDBN)2X\W$L=LT&;>5
M#*)4:,==\'?AU^SW^T?XV3XP_#WPA^SUX]\265T+=?&_AY=-U2^M[B*%8Q&-
M0@@=UD2$HF/,RJ%1P"*]+\#?!#PW\-);&3PW\/O`GAV72[22PLVTVVBM#:VT
MAB,D,9CMQMC8PPDH,`^5'D?*,4E[K3WMIY/N)N\=.Z_"]U\]#P']EG_@I)I/
M[3">#6;X8_%#0-/\6?8+5O$#ZQ9W&AVNI76CQ:LMFK"^6^DQ#*$\W[$L9<$$
MJ.:^K?\`A%[;_GKJ'_@PN/\`XNN5\+?!W0_!6D6.GZ+X%\$Z39:7<1W5I;64
M"6\-I-'`MM'+&J6X".L"K$K``B-0H.T8KJQ=:L?^7'3N/^GY_P#XU52L]AOX
MFUL+_P`(M;_\]=0_\&%Q_P#%T?\`"*V__/34/_!A<?\`Q='VK5_^?'3O_`Y_
M_C5'VK5_^?'3O_`Y_P#XU4@'_"+6_P#SUU#_`,&%Q_\`%T?\(M;_`//74/\`
MP87'_P`71]JU?_GQT[_P.?\`^-4?:M7_`.?'3O\`P.?_`.-4`'_"+6__`#UU
M#_P87'_Q='_"+6__`#UU#_P87'_Q='VK5_\`GQT[_P`#G_\`C5'VK5_^?'3O
M_`Y__C5`!_PBUO\`\]=0_P#!A<?_`!='_"+6_P#SUU#_`,&%Q_\`%T?:M7_Y
M\=._\#G_`/C5'VK5_P#GQT[_`,#G_P#C5`!_PBUO_P`]=0_\&%Q_\71_PBUO
M_P`]=0_\&%Q_\71]JU?_`)\=._\``Y__`(U1]JU?_GQT[_P.?_XU0`?\(M;_
M`//74/\`P87'_P`71_PBUO\`\]=0_P#!A<?_`!='VK5_^?'3O_`Y_P#XU1]J
MU?\`Y\=._P#`Y_\`XU0!G6WAVV/B>\3S-0PMK`P/VV?/+S=]^3TZ=N?4UH_\
M(M;_`//34/\`P87'_P`76=;W.J?\)/>8L[#S/LL&1]K?&-\V.?*^O;L.N>-'
M[5J__/CIW_@<_P#\:H`SO$'A^6UT&^FTN.:\U2.WD:TM[K6+JV@GFVG8DDJ^
M8T:%L`N(W*@DA6Q@_%_QS_;XU3X#_L<6?CWX@?$3X0_!S5(O%^KZ#JE]K":U
MXALUBL[^\M(X-/L(+FVN]0N"8H-[AX@$$TQB51Y:_;_VS5O^?'3O_`U__C5<
M5\;/V@+?X`:!;ZEK^EZQ=PWEQ]FAM_#VB:MXBO6;:6+?9M.LIYQ&`O,A38I9
M06!909EMJ[;?G^I4;/;O?\#Y[^,'[;5SX,_X)HR?%;P[XK^%OB7QA:0:7;W=
M_;^,+:'PU#=7$ML)7\VYU6W@!$$YF2W?4$+EHXQ.VX2-X7\!O^"K?B_XI>+_
M``O9W/BSX:M<7VK:1ID?AY]/N[;6/'L5[J,EM<7NBRV>NZC9O;V,($DDEM+J
M,9-O.)9+0AEC^X[OX_>'/!7PAC^)=AHMQJ&@>+EM=6^T>&O#^J:OJ&J>?#$D
M,[VEE8RW;MY*0J6:+*)&H;:%P.*\(_\`!3OX>^/O%.EZ'I%OXVOM7U9L+9I\
M/_%`GL5^URV?F7B'2@;*+[1!/'YESY29@E^;$;D7_P`O->ZT_3\S/_EWI]_<
M\P_9=_;2U_X\_'KQ)X2U'7O`NKPQ:3KUY>:!H9U*/6_AY-8W\=K;V>L-+=2I
M)+=1R/(NZ"T_X]I-B3H=Z_9S>%[?/^LU'_P87'_Q=>-^#?VV/!GQR\3^(O"/
MAZ_%UJVGV5](3-8:E:6NHQ6TOV:ZEL+F>TCM[](9F6.1[66149T#,NY<^R&[
MU8#'V'3O_`Y__C5*/\./IOWUW_0K[3_JVB'?\(M;_P#/34/_``87'_Q=(?"U
MOC_6ZA_X,+C_`.+I1=:O_P`^.G?^!S__`!JC[7J__/CIW_@<_P#\:H`_-?1O
M^"N_BCPQ^UC\4/!NKZ->?$*U\*RW5OI&@>`_#6HW^LPN+X00M?\`V;5;S48(
M8HR&FEFT6W1L.T)D)MH[OWKX=_MPKXO_`."?&K?$Z^N;;0_&>G:1KE_]CU>T
MUW2K5#IT[PR7)LYU%\UI%N@,KJF%WD%HSG;Z)X!_;B\`^._B+XOTS2_/L[[P
MK%<MKNL:CH&KZ7H\<=E+)#+_`,36YL([*98W2?'ESN,1S,N51R.JTW]J+P[K
M'P!N/BA!J&EMX%M;&XU"35&DND`@@+K*PB-N)208V`4)N8@;0<C,?\N;-]-_
MU#_EY\WI]VA\2^"?^"HVO>-?V;]#\0W'Q*^#7A%KSQ9>Z#J7CS6H[R7PKI@A
MT\7D-LZVNMS6374S,(P;?6KB(;3SYY:UC^T?V8O%=U\:OA#X2\6:UIVH:'JO
MB;POI>K7FG?;+M38S3QO(\7[S9+A2<`.H([@$FN3N_\`@I#\/[+X?V_B&237
MC'<ZK+HJ:2/"GB!O$`O(H/M,D3:0-..H)M@Q,6:W"B-T?.UE)]-^'OQ!C^)U
MC:^)/#\FC:MH^O:397]A>6U\SP7=M+YKQ2HWE<AE;/3ICUXUWOIV^6GZ[DQT
MMKW_`#_38WM4T.VT[3YI_,U`^2AD.=0N`.!GG#$_D#]*_.#X"?\`!7;Q!KU]
M\2)M8NO"OQ&'@[PS?ZY:Z1X'O[!96EMF7"R7,'B;4IXK<@D&>_L-/"@`NJ2'
M[/7Z23ZCJEM`TDEKIJHH)8M?.`H'4D^57D7PM_;P\'_%IM1DTU=8T_3]+TZ3
M5Y=5\0>'-;\/Z3-91X+W$-]?Z?!;3Q!6#[H9'&P[\[/FK+7F;\G\M-_Z[%.U
MEZK\UI\SY-^&'_!:JX\<?L^6/B_6O!?PN\%ZAJ'BX^%S+J'[0VF:AX6L%&GS
M7JW%UK.G"Z6W9O(,0A>`,7EAP6#$KZE\=?VY;S1OV</A-XUL_$7@CX/V/Q&D
ME-[XG\=W=[J7A[1Q':S2QQH\=W8B873QC[/,\\(DC(81LSK'7K5U^V[\%?$'
MP\L_B)-\2_@;?>%-'U&2UM?$[^-+"73K"^,)5XX[L@QI-Y,K`J&#;)"#PW.Q
M\6/VR?"GP;\">'?$6J7D.IZ7XN(_L/\`X1NVU#Q)<:RA@:X\VVM].M)YIHA"
MID,B(45,,6`(-54UB^FVO]=Q0W7S_/\`38\5M/BI\;OBD_P7O/"VK>#?#\_Q
M*T"RU[5?#.K>%M6OKK0[94MWU&XDOCK-F413<10Q1?8GE,LL89?+$LD/UP/"
M]N?^6FH?^#"X_P#BZ\1\4?\`!0_P/X6F\.M)!XIU33_%<%A<Z3J^B>#?$6L:
M->)?,B6A&H6FFRV@,C21@*TH(+KD#(KVX76K$?\`'CIW_@<__P`:JY>2MJ_E
MY?(4>FO0S]'\.V[ZEJBF34/DNE48O9QG]Q$>?GYZ]3[#L*\\_;#^(=Y\`/@A
M?>(M*:.WF2ZM;2;5=6N[V72_#D$TRQRZG>I#(':VMD8RR`/$NU/GFMX]\\?H
M>CW&J#4=4VV=B2;M=_\`ICC:?(BZ?NN>,>G4^F3E_%7XPVOP1\#W?B+Q1)IV
MG:79E(V=9Y[B:>61UCB@AAB@:6>>61DCCAB1I)'=4169@#G+IZKYZK3Y[%QW
MV/COP_\`\%'+KPIX*\7:J?'GP?\`CQH^AQ6#CQCX,U>\\.^%=#N+J\2U-MJU
MX;W58K9(U<7+SI*[)%G=;J/+>3LO@+^WA=?&KX\?#'P^FI?!&_\`#_CO3O$#
MRWWA#XMW/B82W^G-8LMO8RBUMTN&$-UOEB94=1O8?+$/.]5\(_M\>`_%GA_Q
M#JEUJD7@VS\*6R7VK?\`"<V.I^#9;&U=BB73Q:M9VS_9RX*"<*8]ZLN[<"!;
M\`?MW_#'XK^-?#?AWPK\1/AEXHU;QA9WM_HD.C>*(M075(+-T2Y:)X49&,;/
M@J&W?)(0"(WVU3^+77?]?R_0B6^]MOZ^92U_X@>+/#'[7NF^%;[3=-A\`:AX
M7U76;:[M-6U&^UN\N+.33E8-`%1(4'VN0!$-P\IV$&(J4?@OV$/VU+W]L+XH
M>/-)U3P=XZ\"PZ%;:?J&F:;K^A>(-(U&W@N/.!2\DO8HH&N,Q*=EN71=S!9)
MPADKVB#]I?PW>_'F3X8V^L>&[KQ];Z=)JUSHMMJ,DUQ8VR>0"]QLA*P%OM,)
M192K2*Q9`P1BMCX?_M`:/\5?&/B?0?#FH:'K&J>"[E+/6H[:]E=+&9]^(S)Y
M&QG!C=656)1D96VL"*F/2^JL[?>]?T*EMV=U_P`,='KV@065I#*DE\S+=VV`
M]Y-(O^OC'*LQ!_*NAKG]>GU%K2W$UK9QQ_:[;<R73.P_?Q]`8QG\ZZ"J`\K\
M0^`?#'Q+E^&NJ:IK'V:^^'NHC7;".&[B19+AM-N[!DF#`DH(KV4X4J=ZH<X!
M4\7XC_8H^%_B3P*/#\VN7EO9*-?96M[ZUCD$NL7POKB;_5[2\=P`T>01QB02
MY.>;^-GP1^+7Q-\7V^B^$?$VM^&_!OB+1K359=:MM7>*31=2LK>9(K:.-9%E
M\FXFDTZ9TC'E.EC>)*?]("R:&J>"/C%XH_9:ANY(]8TGXC>)/&^C:_?Z5!KJ
M;M"TQ-=L7N+%)EE\K8FEP.LR1.4E=IPH?S?FF[E&SV_S=O7O_30_M+7LO1;_
M`*_CZF;9_P#!.WX?:EKGC+6O%WQ%\4_$#Q3X[\*ZAX,U77=;FT>*Z?3+Q($:
M)([.RM[="@@&TB'G>WF>9A-C/VC?^";WPM_:1MM4AOO%VHZ1;ZQ?65[=6D$.
MAZGI\@M;(6<4+6.IV-W:/&$5'&^%G21%:-DY!\_^$GP<_:8\.>.O@I>ZK-XH
MNK/P_P"$?#-OXI@O/%B207.IP:/XGCU`7($[F=FO+G1O,D"R>8RPN"_D$IPW
M[*7@+]O+Q;\4;K2/B3\0?B9X<\$ZI=07+:S>>&_`=MJFA1"VU)I+2V^Q37\5
MR#/_`&:IN)[968!]L,66(JK3BI.GNHZZ;/5O3SW?_#EU(^S>COMY[Z?Y7/<O
MV>O^":OPV_9M^,'@?QAH/Q#\5&;P'X:B\+V^G?:-'L;/5K>*#R(GU`V=E!->
MO&F3$DTK0PEF,44>XY](^//P,MOC%\0M"\4:+\8O&'PSUS0]/N]+%QX:;0Y_
MMMO<R6\KI*NI6-XO#6T14QA#][)(-8/['WA;X\>&O%L,WQ5\37WB2RUKPGIU
MW>Q3VNDVUMH.N!I%NK2T6SC64PE#&Q,\EP-R_)(H)6OFGXO?`#]IC5?^"B>M
M>(-%M?B1)X)D\8Z/?:5<Q>)KE-#BTR*&P^U1/"GBVVBBC9X[L.C:#=,=[-B7
M<H4^.I%/S=^VNOWW?R,7[L96Z67KHMOZW/3O%W_!(#X&^*?B;X7\6#6$BU3P
MW;6=O))?Z/X:\03:J;:9YEEEN=6TV[N8I'>1R[6DT&2Q8`/A@W2_^"1'PCL/
MB]XT\97'COQ!?:AXXTC5M#OQ+;^'8IC:ZBT;2(][%IJ7]T8A%&D1O+FXV*H'
M-5H=;_:5\,^,/&6H>(-2^)VCZ/8VNJW$UW)H7A[7-`C*3;M/&AV.E12Z[<E@
M$66.]0N8FGVE9?+87_B7JG[3'B7PAX-UY8/BEI=OXBAO-3U70_ANOA'^V_#<
MLAM_L5A._B$"VDAC@$_G/$3,;ES@B$*JS"5FI1TT;]+[IKN[%/JO-+UMLUY*
MY],>$O#_`(9\%^-/%6N6NL0M=>+KJWNKR.2ZB,430VT=L@C``(&R)2<EN2>@
MX'3CQ?HX_P"8IIW_`($I_C7Q-X.L/VQ)_P#@H7I>J:QX@\5V_P`$YF@5O#Z^
M#O"L^FI;&Q7<UWJ*ZPFIQW@G+EQ;6LT"R`!/,B.:^Z#S5?93%UL4?^$QTC_H
M*:=_X$I_C1_PF.D?]!33O_`E/\:TA10,S?\`A,=(_P"@IIW_`($I_C1_PF.D
M?]!33O\`P)3_`!K2HH`S?^$QTC_H*:=_X$I_C1_PF.D?]!33O_`E/\:TJ*`,
MW_A,=(_Z"FG?^!*?XT?\)CI'_04T[_P)3_&M*B@#-_X3'2/^@IIW_@2G^-'_
M``F.D?\`04T[_P`"4_QK2HH`S?\`A,=(_P"@IIW_`($I_C1_PF.D?]!33O\`
MP)3_`!K2HH`S?^$QTC_H*:=_X$I_C1_PF.D?]!33O_`E/\:TJ*`.=M_%6EKX
MHO)#J6G^6UK`H;[0F"0\V1G/;(_,5H?\)CI'_04T[_P)3_&BV_Y&Z]_Z]+?_
M`-#GK2H`RQXPT?\`Z"FG?^!*?XUYC^U;\&=%_:N^%TW@^]\?77AO1;Y_^)E%
M866A:I'JT.#_`*/<0:M8WMNT6[:W$0;<B_-C(/J'B'3)]8T*]M+>_NM*N;J!
MXHKVT6)I[-F4@2QB5'C+J3N`='7(&589!^+_`(X_"CXO>"OV.+31;;PI\;_C
M9XPTWQ?J]W#8Z/\`%.U\&7FLV<E_>&UDU#5HKBWFAMQ;31R)!9@`/'#$88XE
M*I$K6=_+\65'2S\[?A<]V^'OP3T_P/\``O6OAV_Q&U&XT&ZLQIND74,]K9ZE
MH5F;*&W9(IHU";_-6>9&6-$B\Y8XXTCBC4>;_&'_`()E_![XQ_&7P9XOFU'2
M]#3P':6%AH^DZ9X?\,+%9064ID@C@OI=-DU.T"D@+]DO8?+V@Q^6Q+',^)^D
M?$[XB?\`!.#4_!7A/2OC=X<^(&A?V5I#37TME/XBO40V=S.T=V-;M(YT:%WM
MY+A-568%9\2O,NYO%_@/^SS^TMHWB[PNWB'0/BY;W5MJ^D2Z/JB?$Z;^Q]$T
MR/49)=6BUK3;K7-2DN+BXMFDCC`GU90&@*3614I#IS/VOS5G^O\`P?4RT5))
M;6V[(^G_`(<_LF>%?@IXNU3Q#9_$+Q9XB2UTS5-/\/Z%JNI6<FG^&H+^=+JY
MAM1#!'/*'EBA"F[EN'C6,)&R*6#>^?\`"8Z23_R%-._\"4_QKY`_9B^%/Q>\
M)?'7Q/J'B[3_`(DV6F_V/KT?B#4=>\<1ZSH?B>]EOXY-,FTBP6YE-A%#:"X5
MU%O8_P"MC4QSE?,3[1[U,?@CZ;=M?Z97VG_70S_^$QTC_H*:=_X$I_C0?&.D
M$?\`(4T[_P`"4_QK2H/2F,^'-7_X(S_`WQS^T3XO^(/BCQ1XCUZ;Q5-'<FTA
MUJ+1;FUF2Y2Y0OJFFK;:I=)'+%`T45U=RI%Y$.%S#`8O7_!W[(?@OX=?LZZA
M\,=!^(WCS3_#NH6FJ0/<2>+6O]4CEOIO-^TI>W7FSK)"V\1KO\HB1_-CF)S7
MRGX=^$'[8GA?]K_XK7?@?2[N.QU1K@:?J/C[QWJ4FAVL$]]YADT[;?:A;--Y
M(811MH-HMM^[#M*L;QWWT%\//#GQTT?_`()[ZMX3\3>'M:N/BBVCZW':W.D^
M.XKRZD83O]D0:I<0PLEW+%+^Z?R/+3R1OD@)4#/_`)<Z+IM\@_Y>_/?[OZ^1
M1^'O_!-OP;\)_A?I?A[PK\9/B%X;U#0=7N-4TK6M+GT"UDTI+BV%M-96VGQZ
M<-)@M74;S''8J?.+2[O,8N?=O@[X:\,?!3PKI'A/1=0A70_#.B6&D6!N+_SI
M3%;B2-0\C$EWVA=Q)R2<GK7Q3X+^"7Q]B_9QT/3?%G@_X[:IINF^*[V:_P!!
MT7XHKI?BK4K233P+:9+Q]<GE@M8[PN3;2:]<N>),^7MM(_M#]F/1/%GAOX3^
M%-/\>7G]H^-K'PMI4&O77G+-]HOECD$[^8J(KYD#'<$4'K@9Q6VOO?\`;OST
M_3;R(CTTMO\`G^IV5YXGTF[M9(_[6LH_,4KO2Z167/&0<\&OCOPK_P`$=/@O
MHEYXXFU'Q5=:\?'VE7FE:J\FC^%M+FN5N6#R2SSZ;I5K-?/O`;;?R7,;/\[Q
MNX#5]N-VKYA^-7B/XZ>-/B3X@M_"?@C7O"Z>$_#NNC1M:_MO3+C2?%%Y*EJ=
M.\N!I_-$ZLLP87=LD4;;MLKJVXY:7?FG?TZE]%ZK[SA/`_\`P2B\#_"#P[X?
ML?`_Q2NO!=WH?B9_$R:QHOA7P;IFH+*=-NK`1QI9Z1!9'Y+IR7N+6=\%E5ER
M&7U'7?V0?"L_PJ\#^'/#OQ-\7>"=3\`//)IWB31K_36U29KE)%N_.2ZMI[-_
M/:5G8?9@$?:8A%M`&'H^I_''XQ?%GPGKM]X0\8?#[PKI_C\7,NBZIJ^E"Z31
M1X;OH7-R-/NYXIHVU22!EB,LK`^6^U0GR<WIWP;^+=_^WG/J5Y9_$Z/P_/KU
MY->Z_P#\)XJ^$[GPY)I+0V^GV^DI=>9#?I>F&0SK9QN/*D?[8P<1-4KR?(^J
MOY:6MJ&S3\OSO=?A^*/:O!GP#^'_`('7X;PVVHK=67PITAM)\.VM[?QW4=J3
M#%;B\)<%VNU@CDB$VX$)=7"_\M6KTW_A,=)Q_P`A33O_``)3_&O$_P!CG]EJ
M[^"'B/Q=X@OM5\?_`/$[NWL=+T37O'NM^)X=-L+>:18IRVH7]VIN;G_7,T8C
M"1M##LW1RR2^^YP:J7=N[W^9*[=M#G=)\4Z7'J6J;M0L%62Z5D)N$&X>1$,C
MGGD$?@:Y_P"-?@CPS\<O!+:/>>(IM'N(;B&_T_5=*OXH;[2+R%Q)#<PLP>,L
MC`?)*CQ2*622.2-W1NPT,?\`$TUC_K\7_P!)X:\K_;1\%_$;XP?#1?`OPWUA
M_!=]XJWQ7_C,Q^>OANU0!G"0QW5M<O/<?ZE&ADC,2M++YJ/'&LF<N]K[;=^C
M^6YI#?4XG4OV'O#_`(LTJ^E\4_&CX@>+_%LCV;Z5XIU&ZT2'4/#OV2Z2\A^R
MV]K80V!Q<1J[&>UE+X57+(B*O3^!?V?;?PK\0O"GBC5OC1XR\8:YX6AU2T:X
MU8:##_:]M?"TW07*V>GVZ[8GLH'C:$129!#O(AVCSCQ)XZ_:>^&WP_L=-7P7
MK7Q`\16&@:OX>EU70)M!L[?5-57[*=,UYXKZ\C:""1//\VW4R-'-YJB*:-8I
M7\]T/]I3XYW?_!2O1_A^=-^/TVD?VLIUN[?P)IT7PU@TE=*:7]QJKVR7C7YN
MA"'VSR0EGF2,<+LNG;FY8Z;ORU>OS?7\3*6D?:2W_'3I_E^!]?>*O!WA?Q=\
M1=+\2W6M%;W1])U#18DM]12&-H;Y[5Y6++B19`;2/8R.NW<W4X*^=_LH_L2_
M"/\`8K\0ZM>>`-6\2VEKJ>G6FDKIFK>.=2UJQT^WM?,\I+>*\N9?*QYA'!^4
M#"[06!Z7XT_"[QCX@^/?PM\2:%XG\51Z#HFKRC7=!M;NVMM+FMVTZ_07,XV+
M<3L)Y+91%YK1`[7\G<GF+YM\"?"W[2UO^W!K6N_$:V\(M\.;[3K^VL!H?C&X
MN+73T6ZC:Q7^SI-/A/VHPAO.F:>4%FDVLB".`*/Q)+SO\M?Q?YE5/A[[.WFW
M;\#Z*U[Q)IVH6D$,-_9S2-=VVU(YU9FQ/&>`#705F^*O^07%_P!?EK_Z41UI
M4QGRS^TA^W;I_P"R;XB^'^B7FF>.M>L=9MX[OQ'J>C:3)>V7@;3"NQ-0OY(K
M658(#(&.ZX>)/)M;R02,T`CDS/VL/^"DMO\`LF?%75O"\W@OXL?$>\LM'T?5
MK/3_``%86>L:WJ*WTVJ1N8[!Q$SQ0#30SO&\C8N02BK&SU[7X=N_#GAC3=;G
M-GX(L[J33+74?$DSW<<,\EN(#'%<7W[K.SRH'56E)&V%@#A#C#\5_LA_"GXU
M>$--M-=^#_P=\7:!;V=G!I\%_H]G?V<5K;)*+1(5>U9!%$MQ/Y07Y4$\FW`=
MLS]FW6Z^[L.\?PLO6ZU^[3[CS'PO_P`%+]+\:Q^%+[2?!/QFO/#_`(DT/0->
MOM::UT*WMO#,.LSR6]K'>Q2W27)E62-Q(MM#/LQU;-=I^VW^UK-^QUX6T.YM
M=!^(?Q&UO7K]88M"\+Z.^J:BMG&5-W=^3;6LTGEQ(R*"4"--/;QO)$)?,7T#
MPU\#/#?@OPS%HVD_#[P'I>CPVUK9QV%G:Q06T<%J[26L0C6W"A(79FC7&$9B
M5`)K<C\-^5XLDU]?#_AX:Y/:I82:@)<7<ENCLZPF7R=YC5W=@F<`LQQDFJE9
MR]S:]]>W8F-^77M;Y]SY_P#%W_!0O3O#?CQX;#1?''BSP''H6B^(I_&FAR:7
M)IFGV6J2W$<,\Z3M#,Z?N-P%HES(0QW1I\F_A?C=_P`%B]%^"7PZL_%,OPM_
M:.\4:9>3:BVSPQH6C:O<VUA9,$EU2>&*[,D%B9!-&)954AH'WJ@:(R>X:O\`
MLG_!^7XK>'=8OOA'\%3XXT]Y;W0;ZXTJR_M:V9+AKF66UD-KYJE;BX:5FC/$
MDY<G<^3S?[0WPY_9OUOPE:M\5O"/[-]YH/@W4VT>W/BU=+DM-#O[ORYS:I]I
M@*03S[XI#&-K2;T;!R#4MZKE\]'KH-:-M[6_$SO%?_!0B#1/B+<>'=*\!?&K
MQ45U5?#]GJ&EV6B+9ZGJK::FIK91&XNH9%8VC%S-*D=LI1D:97PI;\$_^"DO
MACXV_'/PEX$M])^*'AVZ\;>'5\0:3J>O66EV.G7[!"\]A;L9C)=W=N`?/%I'
M-%%\I:4!T+>R^#?#_AO7+=;[P_H7@.\AT_5)G$^G312+:ZC;HVGS$,D.%N(D
MC>V8\.BHT9P`5K/\+_LM^!/!7Q(@\9:+\*?ACI/BZUL_[.AUNRTVWM]2BM<8
M\A;A+82"+'\`;;[56B:[=>^W^?X$ZVL]_P#@_P"7XGH/]A77_08U'_OBW_\`
MC5']A77_`$&-1_[XM_\`XU2_:M7'_+CIW_@<_P#\:H^UZO\`\^.G?^!S_P#Q
MJ@H3^PKK_H,:C_WQ;_\`QJC^PKK_`*#&H_\`?%O_`/&J7[5J_P#SXZ=_X'/_
M`/&J/M6K_P#/CIW_`('/_P#&J`$_L*Z_Z#&H_P#?%O\`_&J/["NO^@QJ/_?%
MO_\`&J7[5J__`#XZ=_X'/_\`&J/M6K_\^.G?^!S_`/QJ@!/["NO^@QJ/_?%O
M_P#&J/["NO\`H,:C_P!\6_\`\:I?M6K_`//CIW_@<_\`\:H^U:O_`,^.G?\`
M@<__`,:H`3^PKK_H,:C_`-\6_P#\:H_L*Z_Z#&H_]\6__P`:I?M6K_\`/CIW
M_@<__P`:H^U:O_SXZ=_X'/\`_&J`$_L*Z_Z#&H_]\6__`,:H_L*Z_P"@QJ/_
M`'Q;_P#QJE^U:O\`\^.G?^!S_P#QJC[5J_\`SXZ=_P"!S_\`QJ@!/["NO^@Q
MJ/\`WQ;_`/QJC^PKK_H,:C_WQ;__`!JE^U:O_P`^.G?^!S__`!JC[5J__/CI
MW_@<_P#\:H`3^PKK_H,:C_WQ;_\`QJC^PKK_`*#&H_\`?%O_`/&J7[5J_P#S
MXZ=_X'/_`/&J/M6K_P#/CIW_`('/_P#&J`,ZVT:X/B:\7^U;\$6L!+[(,MEY
MN/\`5XXQZ=S[8T#H5T/^8QJ/_?%O_P#&JS[>YU3_`(2>\Q9V'F?98,C[6^,;
MYL<^5]>W8=<\:/VK5_\`GQT[_P`#G_\`C5`'RO=_MM?$/2O'WQ.TN7P/IFM+
M\/=%U'5CH_ACQI;Z[XL5H1OT^"^TJ'3@MF^HQ`O`J7-Q(01^[.)#'ROP[_X*
M._$;XF>&](T^Q\!:/8_$K7-6GLH/#FN>(M4\.P6EK!8&\>>XDU3PY:W@9@KI
M&(;&:)RDA\\".39[)>_L+?`SP1/XC\37'P+^`^D2:I9W@U_57\/6$#7EK,K-
M="ZF-H-\4B[C+YA*L,[LUYM::E^Q9+^RE=+#:_L>M\#H?$`6X5+_`$(^$TUD
MQ`@/B+[(+SRBI&?WFPCM6?V;7ULOS_4;WT[_`(6_SU.Y\0?M>W]S^R5\._B1
MX7T^XU/4_BE_8T6A:3JNL6FG6L<^I^68UN;R.WG"(@<Y:**9G(`1&+"O*?`7
M_!4#Q3XUUQE/@O3;71_#/B/3_!_C2Y7QO:RW.FZI>:S/HZ?V="-/"WUL+B$,
M99I+.0HS;86D1HZ]M\3:'\'W_9Z\3>(=?L?A/>?"/QM#;:YK5[K.KP77A?4;
M<6UK!;SLT\;6OV?R;>U";<1G8K#DY/$>`O%G[)_BKQ]\+Y?"[?LKZCXHM;-[
M+X<MI6J:/-?P6T32H\6D&.(R"-&6=2MM\JD2`@$-6G_+RW2Z=O+^7[[V?^1'
MV$_+?^OZ^_1OP7_;/\0?&[QZVAZIH%KHWA_Q1HNO:OX7O[7Q+;:E>7]OI5[%
M8W(O[06D0M'9[B)E6&>Y`&]7>)U"M]/?V%=?]!C4?^^+?_XU7A?PVG^"K?%3
MXH_\*YL_@BOQ*V2?\)V?"]Y8MX@$N9/^0D((A.7W[\>>0=V[OFO=#<ZOM_X\
M=/\`_`Y__C5'V(][:^975KS_`$0O]A77_08U'_OBW_\`C5!T*Z'_`#&-1_[X
MM_\`XU2_:M7_`.?'3O\`P.?_`.-4&ZU?'_'CIW_@<_\`\:H`^#=5_P""U>B_
M";XO>-M+^*?]E^`O!_AV>YL]&US^VYIV\37*WAMH((99](M]),DF"TBQ:I+]
MGP_F[5@NI+?VKX4_MTZ;\8_V$=2^-FAZII>H1Z=:W[MI]GXGTR>R^U6TLD0M
MVU'RQ`N\JAWXP!*"`_&Z?X(ZC^SS<_M:>-[CX<K\`;CXWW4<L7BT>']8L)/$
MVR&94F%XD,9N%VS&-9/,`^<1AN0N.ZN=-^'_`(G^%-UK4FC?"[4?`_\`96HV
M]S?-<6TVE?V=.Q?4$>3R3%]GD:+=."=C&/+YVU&OLK];;]/4-ZGEV^[0\"\$
M_P#!1+QW\2/!>AVFC^"]#'Q*UG7KS2&T'5O&#Z/8V26M@+]I9Y+K1H]2MY6A
M9-MO<:7#(<F3_4%)W^@OV=/B6O[0OPP\+^.K"ZU33[7QAX;TS7(896MI984N
M4DE6-F1#&VW=C<AP<DY(Q7C%Q#^Q[9_L@P23:7^R5'\`[K63+`SW6BKX/FU0
M;D+*3#]C-S\K+D?/\I'8U]%^%KJ87(_LJST;[#_9MK]E6UO#]G\C,OE^65BQ
MMV],#&`,9SQKW^7RTUOZ[DJ^E_/\_P!-C<.A77_08U'_`+XM_P#XU7COQH_:
MQT7X-7RNVIZAK^EVNF:WJ&I7&EW%G--8OI8MS-;>7Y84RGSR"K.A0I@]>/8C
M<ZN!_P`>.G_^!S__`!JO,M%^#?PS\5?$SQQKVG^`_A)J7C+5(O\`A'O&.HVT
M%K-J=Y&\$+_8=0E6W,KJ8&MV\F8D&-HCMVE:C6]EV_R_`K2QC^,_VJ[;PY\<
M-!\#V9UJ^O-0\8)X1OYW>VBCL9'T&[UI9D`B<RCR[=(RK>6092V2%`;CH/VT
M_%-Y^T=_PBEOX=L6\*WGBF]\#:=K,GBFW74IM8MM*DU)A-IXL2L5H4AD02K<
M23`[&-OL;</5?AG^RWX$^"VDV-AX-^%/PQ\)66FW[:K9VVBZ9;V$-I>-"\!N
M8UBME"3&&62,R`!MDCKG#$'"^+4'P>_9I\;R_&3QUI?P4\`>([U$T>;QSKUW
M9:7>S*RX2U;49H4=@5C&(S)R(^!\M&G-?I9KYNUF-Z_"NGXZZ_E]WG<S?V5O
MC/\`%+XT>,_%UCXQ\-^&/#FD^%IQIZ:MX<\63ZY!?WZLPN+9/M.B6`80859)
M8FD02,T6?,BF6/W`:'='_F,:C_WQ;_\`QJO'_$'[9_P;^`_B2Q\'ZI\1/@CX
M-UC5"M]9:'=>,;'3KF\^V2-(LT=NP5G\^1W8,JGS&9CDDFO81>:N2?\`0=._
M\#G_`/C5-]/N(C_P3.TC2;HZCJ@75+]=MTH)"0?/^XB.3^[]\<8Z#W->=_MA
M?M`R_LH?!*^\40VOBKQEK3.EGHWAW2+$W5]K5X^2L4<=O:S3E519)9&CAE9(
M897V-LP?1-(N=4&H:IMM+')NUWYNW&T^1%T_=<\8].I],GD_C?\`$SP7\$+*
MQ\=?$>^^&OA"WT=GLK/Q#XDUF#3X[%KG:'ACNIXU$9E\M,J&&_RQD':*F1<+
M7N_N.'\._MQ>%?$WPVL_$T5YXRM[:X\(:KXONK:YL+:VN]*33)(8;ZQN8I55
MH;V&:4Q-$X`5X90S+M&:NF_MR6>I?%_2?#*^&_BD-&UW6O\`A'+#Q68=&.CS
MZD+-[M[8HMP;U"D<4H,CVJQ%HR%=MR%MA_@7\%?VQ/">G>*S\/?@?\4]#U2]
MDUJPU@VECK=K=W15('NXI_L\B/*5MHHS(K%L0(I.$`&):_\`!,3X/V?[9D?[
M07_"M]+F^+D,8AAUV;Q)J4ZVJ"V^RJL5JY-M$%A^0;(EVY)&"2:J-^?WMM?O
M_K3\?(C[&F_3]/\`/\/,[#XL?&C7OAI\<OAYX3CT#Q)J.D^.-0DL)_$9O=.A
MLM.D6RO+H1"+:US+,?LG3RDB"2%O.W+Y3>:?`C_@IM\._P!I+]L/7?A+X1\9
MZ;JUSH5K>[KJ/7=.:ZNKRSN%@NH([%4-P$C8MB60()/+=HU>+;*WOGB_6]/M
M-?\`#<.O0>$8]3N-09=`2_U!1/+>BVG9A:AXMQF%L+DGR_F\L2_P[J1M9T^3
MXF+;-!X2/C"/3&E2$WZ_VDEBTH#,!Y7F"`RHH)^X74=Q4KXE?;7YZ:?<QU/A
MTT>GYZ_?L:NNZ5/!:0N^I7MPHO+;,<BPA3^_CZ[4!_6N@KG]>GU%K2W$UK9Q
MQ_:[;<R73.P_?Q]`8QG\ZZ"J&?)?QN_8'\&_M,7_`(FUK6O'GBS1;[Q1X-LO
M#$%OHOC/5M#M[!H5O,S7$%C?017N3=C]W.A`$3+G$C`<;^T=_P`$LO#/[1_B
M[39M8\4?#'4M*71--T*]FU[P>FJ^(-.AM"1(=$U+[;'_`&49U8[_`-S/\Y+<
M]*H_MV?\%'O$?[)^IMIMCXJ^&GP^M]$\/Z;?V<?C'3[2XNO'#SF19UTLWNO:
M+;8LEC0S*9Y9#]IC`1#L$W;)_P`%)M<T_0Y];C\"Q^(/"/AKX:Z3\0_$6M1W
M[V.H-'?V]X\<5II:QW(9@]IEQ)>!8HY&/FRF/#Y^YRRF]$G\M+Z]NK#7F4>M
MM/1M;?AL.^!?[!5K\(?B6OB2^^+TGB*Y.E21S":VAC>;5Q&UG:ZSDRNHN(=+
M*6>-FUPF_P"7)6O!_P!B3_@@KX#_`&3/VG[/XA7WBGX3ZU8PO#>SZ%IGA"YL
M[6]U.'SV@U(B]U>_CAN(Y)]Z"VBACC,:^6D>*M:I_P`'&?@?3/V++/XP&U\`
M365]XK;PI%=P>)M6ET$3"U>YQ).NBG4X9"J%0DVEQJS%2)#&1(?3_B3_`,%>
M?^%3#P?#KWA_X<Z;JVLZ!INOW^C7'Q&0:GJHO<[+;PU"MDW]OS+M*G:ULC2/
M$B.^\E-H\W/?KHOO5TOZ\O(B7+R<KVWMZ-*_R9K?LW?L!:?^S_\`M:7'Q(7Q
M=\,[J"2+5XV?3_"?]G>)-;:_N8IQ+J^J#4)$U&2$1LD;FTC8"1L%06#;K?L.
MZ!H'QZ\;?%KPWXXTK3?B=XFUE-0T[4[^W_M*STNT%A:V<VGFU>Y4>5,;9997
MM7M99&2W#NRP*#:T/]O+Q0?A/XC^(^O?#_1=%^'/AOQ1<Z+/J*^*GGOH-/M-
M2NM/O=5GMS9)'%%"T$<Q3SV/DM.S%#"%EF^-_P"WY:_"K]A#6OB]?_\`".^#
M;W4+:\;P98^)=0$:Z_+^^;34\MC"[37<4:RK;(3*`^W)93C..FW167>SL[?U
MYHMZNSZN_E?\CSW0O^"4OPV@\>^(O%VKZSX)U[QE?:\FMZ%K]WH%L^H>%B/$
M>H:X\=I,TS21E_M_D,\;1DB(.0=VQ>5_8J_8A\??!;]O;Q!\0O%4/[-^A>#H
M8-:ATR]\(&Y;QAXK>^O(9DN-?NI(X8;F>..)R'525::10<,S'T?XB_\`!4JQ
M\$?M2M\-_P"S_!;W$>J0:$^F3>+A'XUGN9HDD6\MM`%LS3:8@D5WNC=1E8XK
MB01E8P9,7X5_\%-?'4'[,NH>,OB#\-_#=KK4/PM3XG:5:^'_`!-+<Q:Q;"$,
M\,XFM(_L,Q=TVHKW:`,V9CL!>J<FW[2.R5EYW6MEWLO451\WNRZM/SO?3Y7/
ML3_A,='/_,4T[_P)3_&D'C#20?\`D*:=_P"!*?XU\3_M-_\`!8G4OV,_!.H7
M'Q.\'_#?POKVBZW8V-\)/B%/)H\-E>6TL\5Q'*-+_M"ZG#1>6UM:Z=,5WK(S
MK$LDD>MXM_X*BZ]\)?C#\:M!\7:7\(K'3_`-SIJZ"7\=265T;6^CM?)U#5A-
M9[;+31)<$2WJ^8(F'E+%.X#.?Y_CH[?B/HG\_P!#[#_X3'2,_P#(4T__`,"4
M_P`:7_A,=(S_`,A33O\`P)3_`!KY1\&_\%+O$/Q;^&G@VZ\!^"?`?B[Q)XM\
M87?@^&6T\>R/X1G>VTZXU"2\L]9BTZ1[RWV0&$LEFI%PLL9&(RY^A/V;OC,?
MV@?@MH/BUM/_`+(FU:.1;FR\_P"T+;3Q2O#,B2[4,B"2-]KE$++M)1"2H.5K
M<E23>G]6=CJO^$QTC_H*:=_X$I_C1_PF.D?]!33O_`E/\:TJ*"C-_P"$QTC_
M`*"FG?\`@2G^-'_"8Z1_T%-._P#`E/\`&M*B@#-_X3'2/^@IIW_@2G^-'_"8
MZ1_T%-._\"4_QK2HH`S?^$QTC_H*:=_X$I_C1_PF.D?]!33O_`E/\:TJ*`,W
M_A,=(_Z"FG?^!*?XT?\`"8Z1_P!!33O_``)3_&M*B@#-_P"$QTC_`*"FG?\`
M@2G^-'_"8Z1_T%-._P#`E/\`&M*B@#G;?Q5I:^*+R0ZEI_EM:P*&^T)@D/-D
M9SVR/S%:'_"9:1_T%-._\"4_QHMO^1NO?^O2W_\`0YZTJ`/*?VI_AEX?_:C_
M`&>_%G@&^\16NFP>)K%K7[7%<`F!PP=&*K(C,H=5W*'0LNX!ESD?.=E^PO\`
M%#PG\$;C1?#/[2?A;2/'DFL#4;/Q=JOAB^\73^'X_)\ETTY=<UR^G@EE0R)(
MSW,L7ERN(X(G=Y&^E/VO_#_CCQ;^S'XUTWX;W[:;XWO-,DCTJX1E619.-PC9
MF15E9-RHQ=`KLI+KC</B'3/A'^T%X/\`V/KZQU+X6_'+QYXB7Q.M]IWA[3/B
M[-X1OKZ+[,(G^WZG<>)]7NK>T0DR1I9ZD?-E11):Q+ODEA;R]%\]=OEO^>@_
MY?5_+3<]^\=?LP:Y\7_V.]4^$_B+Q9\)[:2&^TZ71]2TO3M7LK/RK5K2Z$TE
MM;:Q;WD5P+V*9U:+43C$3LSMO4^?_#/_`()JZ]X+U2-=4^/.B^)-%UC6-%US
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MF)]I`<U,?X<?3YK7^G\ROM/^NG];&?\`\)CI'_04T[_P)3_&@^,=(/\`S%-.
M_P#`E/\`&M*@]*`/S]UG_@E'J7C;XV^/M4U+]H[Q%X>\%>,':1-*\*3?9)YE
M>Z-P]O=07LUYI!AY*/\`9M-MWN%DE$K,LURMSZ]X'_9$N/A_^QIJ7P=@^+]C
MK5G?:?J]K'JVM>'=+GEMY;N8RV^+:`0VC6\.Z4/"8=TN\;9(`H%?.?A[X0?M
MB>%_VO?BM=>"-+O(['5'N!I^I>/O'>IR:':03WWF&33MM]J%LTWDAA%&V@VB
MVW[L.TJQO'??07P\\-?'/2/^">^K>$_$WA[6I_BDVD:Y';7.D^.XKRZD83O]
MD0:I<0PLEW+%+^Z?R/+3R1OD@)4"?^7-EVV_0?\`R]^;U^[^OD<AX"_8%\6?
M#?PAI-S8_'#P1>>/=%\17NL6FJ:OX2GU;3O(NM.2PEAF2ZU:34[F;:@87-QJ
MDL@&(L>0JPK]$?LY>!]!_9X^&/AGP/8ZY;WVG^#_``WIFA6]W,\,37*VR/%N
M*IA%)`!*J`!N&!C%?''@KX(_'Z+]G'0]-\6>#_CMJFFZ;XLO9K_0=%^**Z7X
MJU*TDT\"VF2\?7)Y8+6.\+DVTFO7+GB3/E[;2/[/_9BT3Q9X;^$WA33_`!Y>
M?VAXUL?"VE0:]=><LWVB^6.03OYBHBOF0,=P10>N!G%::^]_V[\]/TV?KW,H
M]+:;_F=7XB\40W>@WT>E:]HEEJ<ENZVEQ=`7,$$Q4A'DB62-I$#8)02(6`(#
M+G(^5;?_`()G>#_!NB^+%\(?$:^TG5/B9HM]I?CN[U74;G6H?$MS<)*Z7Z6\
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MM]JA/DYO3O@W\6[[]O*?4KRS^)T?A^?7[R:]U_\`X3Q5\)W/AR326AM].M])
M2Z\R&_2],,AG6SC<>5(_VQ@XB8<+WI]'J];;)6_KJ.6EG>]E^=^_I^*/4?AQ
M^S?X?\`>$/A+X8;QDFH^%?A-HL-A;:<[QVZ:K>V\<$5I>W`B=8V$"QRLD!C,
M8EECE`#P1,OLO_"8Z0/^8IIW_@2G^->*?L=_LKW?P1\1^+_$%_JGC_\`XG5V
M]CI>B:]X]UOQ/%IMA;S2+%.6U"_NU-S<_P"N9HQ&$C:&'9NCEDE]]-:3ES:_
M/YLA+_(Y[2/%6F1ZEJC-J%@HDNE9";A/G'D1#(YYY!'X&O*OVU?@M+^T_P##
MO3=)\.^//#_@_5--U$7L>HSB_DEC'ENC"&;3=3TV]MW(<@O#=IN0NCJZ.RGV
M71#_`,336/\`K\7_`-)X:\K_`&T_!7Q(^+OPT'@;X;ZQ)X*U#Q5OBO\`QD8_
M/7PW:H`SA(8[JVN7GN/]2C0R1F)6EE\U'CC63*5G^!I'<^0OVDO^").C?M3?
M#GX>Z7XT^*'A?QEJ7@5K^1/^$FA\1:AIBR74R2^=;I%XC@OQ,NS!EO+^\8AB
M`44(J^B^"O\`@G8NF_MC77Q.U'Q;\+UCAUZUU:SOH-!EN/&!A@TFULC:+K4]
MZS06<LD,C2VODS&19'+3EI6*]#XC\<_M/?#?X?6.FKX+UKQ]XBT_0-7\/RZI
MH$V@V=OJFJK]E.F:\\5]>1M!!(GG^;;J9&CF\U1%-&L4K^>Z)^TK\<[S_@I7
MH_P_;3?C]-H_]K*=;NW\"Z=%\-;?25TII?W&JO;)>-?FZ$(?;/)"6>9(QPNS
M2GI4M'SUZ;_TS*?\.\NSTW^7^1]/?%#X'>"OB3\:?`7CYIO"MIXI\$7KS#53
M:02:A=V;6=Y`;(7&1)'#YET)MN67=']W)W#S?X%_L,:;\"?VM=8^*D7QN\8>
M)F\00WZW^E:XFBRB:2ZN(YE'VN&SBNC#`(UCAB>1_+C2-%81IY9](^-GPN\8
M^(OCW\+?$6A^)O%4>@Z+JTHUW0;:[MK;2YK=M.OT%S.-BW$[">2V41>:T0.U
M_)W)YB^;_`KPI^TM;_MP:UKOQ&M_"+?#F^T^_MK`:'XQN+BUT]%NHVL5_LZ3
M3X3]J,(;SIFGE!9I-K(@C@$Q^*/_`&]\M-?O'4UB^ND?G[WZ;L^BM?\`$FFZ
MA:0PPW]G-(UW;;4CG5F;$\9X`-=!6;XJ_P"07#_U^6O_`*41UI4RCY\L?VNO
M#/A[]HJS^$FI7WB32=73PI!XE35+B&S31WC83G[*LQS(+A8[6XFVL@'E0R,'
M.Q@,3X;_`/!1WP#\0M"L=3DOO&OAW2;[3O$FKF\UG3[2W6WM=#O+6TNI)$7=
M(ID:[B>)-F\KN#K&X$9Z_P`5_LK^`?C/9K?>)O`MSK5WJEGID5S.;XQB=++S
MVMU`6X7"8N[I'4`":*XDBE#QL4J74/V1/AUK)NOM7P_O+E;^VUNSN%DORR21
M:Q<0W.HKM-Q@>;-;PN"!F,H/+*`D%1TO?L[>MM+_`#W7^8:75NZ^ZVMOG9G@
M_P"T3^U1^S/\=;O2-$^*_@?QIXPM;.UO=8M(/&/P,U.\;38X#;I/<BSO-)-S
M'$!<1[KI8/(4*5>56VJW;:3^W_\`L[?!+]HW0OV;-/\`B!#X3\96^FHVC^&K
M?PY)8Z9#9):-<J8+A;-;%85@B?&V4*#&R<,"M=GX(_8F\!^!)M8DBT;XF:Y+
MKFD7.@W4GB;X@ZOXC=;*YV&>&)M0U&<PA_+CR8MK?(.:I3_L"?#&Y^*</C"3
MPCXT;48;[^TUL3XSU(Z&;K[(;-IVTK[?]@:1K<LC,T!+;F+9)))'16^;\WT^
MX'JK]>GX'F'@K_@J]^S%^VY\.O%FF^%?'R_%C1['4=)\->(=#.@+LF75]1AT
MR$O!?VT27%J9IU\QDWJ$SPQ*JUW]L7_@K)X!_8>^-3>`/$G_``D%QJD&BVVM
M^8OB3P?HD)@FDN(T6)=7U*REG<&V?*P1R!<H"<L!7IG@[]A[X?\`@G0IM+M]
M#^)&HZ5)=Z;>QV&L_$#5]8M+*73[N*\L_LT-WJ,L=LL<\,1V0JBLL:HP9!MK
MTG3?!NG:5\0]6\56_AO4H_$&N65IIU[=?:8SY]O:O.\";#-L7:US.<JH)W\D
MX7%RM96WOKYJRM^-PC;7F^7X?\$\"F_X*V_L]VW[3D?P9D^+EZOQ2DMQ<+X<
M&AW+7.XVWVH6^X69C^TF+_EWW^<7(39O(6M[X4_\%#_AI\6?`B^(+;Q%X]TF
MSA\+P^+KX:MX0O+3^S+*95,2S2&S\G[0^[]W`DC23`%HED7YJZR+]ECPG;?&
MF;Q]:Z3\0M-UVZN?MMS;:?XWU*ST6[G,8B:6;2HK];"5V4#<SP,6*AB2P!JE
M\/\`]C'X<_#7X8:SX-TOP3KS>'=?TV#2+Z"_U^XU":6U@5U@C6>XNY)D\I9"
M(RCJT8";2-B;9^QKO^'7Y]@6DK7TT]3E/!?_``4O^%?CWXVV?P[L?$?Q"@\8
M7T4<T>CZEX*O]-U1$>01B62PN+*.\BMQD%KJ2!;91UF!!%7/$7_!23X+>$_V
MR;?]G_4OB9JEG\7+Z$W%MHDN@702XC%L]R62Z^Q_96'E1R=)3\R,GWP5J;P9
M_P`$\/A/X&\;V_BJV\#^+M0\6VMU;W<7B+6O&&H:QK4;0%_*7[==W\MQY2K)
M,GE>9Y9CGGC*E)I%;0U']AWX=ZM\:_\`A/IO"_CK^WUU0ZV((_&NI1:.+YK8
MVK7/]F+?BP\UH692_D9.XDDL2:G6R^=_T_#?^F'5^BMZ];^1PNG_`/!7+X#Z
MGK?A/3/^$^\?V>I>/)[>'PY9WWP[UNSN-<6='DCGMHYM,5I;;9&[&Y4&%`N6
M=017JUE^TSX7OOVE=0^$ZZ]XF;QII]O#>2VT.EK<Q1V\L32I-++#"ZVT1V.B
MO<F)9)%*1EV!%<E\8/\`@G;\(OCUX>T/1O%/@+Q1?:+X?TVPTBWTV'Q5?6=E
M<6=C*);2"Z@@ODCO$BD`<"Y63Y@"<FN\?X!^$Y?C9#\1O^$-U"/QI;HT*ZK#
M?>5*86A$+0.JW`1X2JQDQ,IC+PQ2%?,B1EO3IW?W6T^=]R=;_)??U)?A_P#&
MSPS\4M>ATW0_%VHWVH26DU\UL;$12VL4-TUI)YZO;J8'%Q'+&(Y=KEH9L*?*
M?;VPT6Z(_P"0QJ7_`'Q;_P#QJO/_`('?!&S^!FH>+-2MH/$VNZ]XVU5M6U?5
MM3.GK<W#!%CAA`MQ#$L,,2JB*J`GYW=GEDDD?T+^W+K_`*`^H_\`?=O_`/':
ME;*Y6MWZZ"_V%=?]!C4?^^+?_P"-4?V%=?\`08U'_OBW_P#C5']NW7_0'U'_
M`+[M_P#X[1_;MU_T!]1_[[M__CM,`_L*Z_Z#&H_]\6__`,:H_L*Z_P"@QJ/_
M`'Q;_P#QJC^W;K_H#ZC_`-]V_P#\=H_MVZ_Z`^H_]]V__P`=H`/["NO^@QJ/
M_?%O_P#&J/["NO\`H,:C_P!\6_\`\:H_MVZ_Z`^H_P#?=O\`_':/[=NO^@/J
M/_?=O_\`':`#^PKK_H,:C_WQ;_\`QJC^PKK_`*#&H_\`?%O_`/&J/[=NO^@/
MJ/\`WW;_`/QVC^W;K_H#ZC_WW;__`!V@`_L*Z_Z#&H_]\6__`,:H_L*Z_P"@
MQJ/_`'Q;_P#QJC^W;K_H#ZC_`-]V_P#\=H_MVZ_Z`^H_]]V__P`=H`S[;1K@
M^)KQ?[5OP1:P$OL@RV7FX_U>.,>G<^V-#^PKK_H,:C_WQ;__`!JL^VUFX'B:
M\;^R[\EK6`%-\&5P\W/^LQSGU['VSH?V[=?]`?4?^^[?_P".T`<!^U!\7?\`
MAF/X!^*/'EU)X@UJ/PW9&Y6PLXH#->2%E2.,8A)`+LH+8.T9.#C!^=M#_P""
MC'CC4_@!J_BV^\-^#O"FI>']:CLM87QAXPO_``?HVA6,L.Z&\N[G6?#MG>IY
MLV((ECT^6.1W&)LK((_KGQ%#'XNT"\TO5/#<VHZ9J4#VMW:726TT%S"X*O'(
MC2%61E)!4@@@D&O*)OV"/@3=?#RW\(2_LZ_"Z3PC:W[ZI!HC^#]'.G07;H(W
MN5M]OEK*R*%+A=Q4`$X%3K=^BMZWU_R#33U=_2Q4^+?[1/C?X5?L71_$H>!?
M%6M>,6L[&23P=I8DU"6.>XFBB<;[73YKEH(1(TK.EFTOE1L3`'_=CQ'X4?\`
M!5#Q9\1-6_>>#]'M=+\/:WHOASQB1XIN+35-#OM7OOLEG'#INI:'974F-]O+
M(+I+-MDI,*W`"E_HJR_8V^$ME\,=8\$?\*8\*S>!]>O(;Z]\-W&D6%QHLDT,
M4$,3+9.Q@C");0;51%4&/=C<23)X<_9"^$?@S6_"^I:1\#?`>F:EX&BD@\-W
M=GX9TJ"?P_&[R.Z6;KAK=6>65B(RH)D<GECFKKGN]NWEV_K4G["BM[:OY'F/
MP7_;1\0_&[QY)H>IZ#:Z-X?\4Z+KVK>%[^V\36VI7E_;:5>Q6-R+^T%G$+1V
M>XB95AGN0!O5WB=0K?3W]B7/_08U'_OBW_\`C5>>Z=\#?`_PTU7QEXH\.?#+
MP]X9\3>+X9)==UK3M)L;2^U=OF;?=3Q$23D%F;+ECDD]37H7]MW6?^0/J7_?
M=O\`_':%\*76VOF5K=VV%_L*Z_Z#&H_]\6__`,:H.A70_P"8QJ/_`'Q;_P#Q
MJC^W;K_H#ZC_`-]V_P#\=H.NW6/^0/J/_?=O_P#':`/@[5?^"U>B_";XO>-M
M+^*?]E^`O!_AV>YL]&US^VYIV\37*WAMH((99](M]),DF"TBQ:I+]GP_F[5@
MNI+?VKX4_MT:;\8_V$M2^-FAZGI>H1Z=:W[M86?B?3)[+[5;2R1"W;4?+$"[
MRJ'?C`$H(#\;K'P1\0_LVW7[6GCBX^'-I\([CXW7$<L7BT>'[[1I/$VV&94F
M%XD,QN%VS&-9/,`^<1AN0N.YN/\`A6?BCX4W6M2^'/!^H>!_[*U&"YOF73)M
M*_LZ=B^H(\GF&+[/(T1:<$[&,>7SMJ7?V2?6V_3U'O4\K[?=H>!>"?\`@HEX
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M+);ME5!61HSPQ!B+?-KVV_4K2WS(_B?^U_#X&\=7WA70M`^(WQ`\5:?JBZ6^
MD:#_`&+#-)FQCOGG$E]<6T(CCBFB#!I!(6D&U'`+#!\6_MGZQXB^%_PKUKX9
M:.WB/5?B]#+>Z/9>*];@\,V]M:PV;W<C3S1V=W()=B@+$D+\EBS(J,U1_&C_
M`()4_L\_'KX(0_#/6_@;I.G^`8=576_["\-2#PS92WJQM&LTB:;<6_F,%=@-
M^X=#C(!&Q\<_!?[/7P6_9=\/^$?BOX5^&>C_``?\,BTTS2K#QV^E?V):/#$8
M[:-3?RF,RA%8*22Y^8Y.2:F5^5ZV=U9^76_]?,-VNUG?]#CU_;)^*'C6T^$.
ML>!_!?AG7-!^+VF6&J6$6H^-9+76+2&:*.:ZE>WMM%NK86]M%*I,[7B)(S1Q
MK^\EA23ZF71+H_\`,8U+_OBW_P#C5>,>+_VT/@+\'OB-HFBZ]XU^%OA?Q:VG
M16VCV&H>)=&L=2:RN6C,4=O&]RLGDRM%%M5!M<QIC.T8]G77;K_H#ZE_WW;_
M`/QVM96Z+37_`(8F/3T,_1]*NFU'5`NJ:@NVZ4$A(/G_`'$1R?W?OCC'0>YK
MR_\`;.^.GBG]F?X:6>L^&]%U'QMJEW?I:"PS<_NHRCLTOEZ=IFH7TN"JC;!9
MRXW[G,<:O(OJ&D:O<C4=49=+U`[KI20'@^3]Q$,']Y[9XSU'N*X[]I/P5\-_
MB5\+;S_A;_@?PGX@\$Z&K:K>?\)A9Z;=Z7IXB5BUS)]J<Q1A%W$R'&T9Y`K.
MI>VC[?<:1MU1\V>*/^"O]K\.O!'@N34/AC\?/&WC3Q,MV^I>&_AMX/N=>N/#
M26\ZQ&2\2]L]/NX$;S(RHFM8I2&!\O:49O5;#]NK3=0^,K>%5\/_`!3ATF#7
M;7PS<>*+FQTRWTNUU.YLX+R"T>&25=0WO'<PJ6%H41W*NR;6VYWPW^&_[*'[
M9?PCTW1?"/P_^`OQ5\!^!+B6#3]/TBP\/ZYI'A^>;$DB11Q-)#;N^0S!0I;(
M)S7;Z%^S9\'_``+^T`OB^S^%_A"T^*&I1RW=MJ[V5@VN""*""SD^S2NYFBMT
MB:"-DB*QKYHR`9#NM:2L_P"M?\K_`)^1CJXZ;ECXL?&C7OAI\<OAYX3CT'Q)
MJ&D>.-0DL)_$;7NG0V.G2+97ET(A%M:YEF/V3IY21!)"WG;E\IO-/@1_P4W^
M'O[2/[8>N?"7P?XRTW5KC0K6]W74>N:<UW<WEG<+!=01V*H;A4C);$L@02>6
M[1J\6V5O?->\4:#?^-M%TC4M-LYO$<2S:OI-E<S6;7JK$!!-=01M+O`072QM
M(@^47(4D>9@FG>)-"U_Q]J'V;3;2\\4:#"EI>^5-9R7^GPSXE2.3$IDC238K
MA6P&V@X.,U"W3Z:_/HON9<[M6CH]/P=W]ZT-/7=+G@LX7?4KVX47=MF-UA"G
M]_'UVH#^M=#7/Z[JL]Q:0H^FWL*F\MLR2-"57]_'UVN3^E=!5#/D;XH?#/XU
MVOQ]U#XA>!;[6KW1=%\!:+:Z;X6DUI8=)\3SF?4VU*W6%Y`EM?")M.>&[=47
M<B1-)Y32[.,_:BU/]KWX?_!?X&Z?\+_"?B+Q-?PZ):1^-I],\2:!!K%G?QP0
M+(UPVL1S07L!;SB\=O)#-*ZC%W`OS/>_:?\`VMKCX-_$-/#Y\??L^_!^&ST&
MSU#3W^)6D3W4WCV>57+PV#I>V87R61$?REO9=URA,*?NQ/>_:$_;7\6?`OQ!
MXBU&W^$O@G7/!?A'PUX?U[6Y;G6)])U*R?4KBZ@:*WA>QD-RR&%#MG6R*C.2
MS,4CSYHI.3>E[OMU_/6_R*UE4LEK;_)&O\4/$/[5'A'XB74GAG1;3Q=X<T&X
M77$B=],L9?%4-S%%`=%3?-FV:TF:ZNO/=L/'':Q"2=FF-<5\4O!_[57@CXYZ
M=<:#J7Q,\4G_`(1'0+3[;I,OA>'PE?:W%/>?;Y-5MK^1;Z"U826Y)TJ))FC!
M&]W2,+SG[8O_``53US]D+X6_"WQEJOPO^%?V7QQX8U3Q'J&FWGC./3[?3X8+
MK25MY$U">U1I6%K?R2/:PV4T\DBK'`)-N9/1_CW^WI#\(-<^'FI6?A'P'J'@
M_P`<_#W6/&$,=YJ$NG:Q=7-I'8S1PV\$MJ,Q+%=-),SJ)$B264QKY!CETC[N
MKZ-WOY)Z>EE\[=R;7BDOM+3TNM?6_P#5K'16WPN^/&H?#>[O]:\7^)M1\2:A
M\1K&Y@T>&33-/M-%\/6WB0O^ZEMDCEE$VE!#,D\\I<+L$:LSHWA'QU\=_M9_
M#_Q-XO\`&\/AWXR:A'X3L?$\]II%JGAZZ\-:BX26'1UTRUTYIM8GEE'DNPU"
M"94D+-MC52IW;G_@K?I%G\-8-8;P[^SU<?:?%">&QXCM?BM%)\/XBVG3WV^3
M7CIBXE7[/Y3PBU8J\]O\Q$AV['[//_!0WQ-\8;J/7+[X-^%H?A_?>(/^$?M;
MNPU=I]9DN/[%CU)?LUG]D,5[;2-O$5R;BV:1)(F%OCEXDM)1\KW[722^>S7S
M&FFU)K2]_N;_`.&/%_@I^TC^VA\9/^"?LWB?PWX*^.5U\2KKQ@]IJ/AKQC'X
M>\(^)M$TU(%,9L+V]T6#3KJ)Y,/)-+I[/B1X40,GGCZT_:"\*?$SXJ?\$^-/
ML;JQ^)J?$F]L[":]M?"%_8:1K$=VCQR-'+)'JUG%Y.Y=MPMIJ4+2(9!#+'N&
MWYU_9=_X+*ZU^TWI6L16OP%^&.E:]'J^F:5H]C%\8=#UM)FOI9(U.H#38KFZ
MTUT*+E)+9^=ZY#)M/O?[;G[1'_"@_&WAO1O^$M^"?P7TG5K*>\E\9?$;26O-
M'N+B-XU73(`+S3XQ<,KO-E[K<4A;9!(/,>&IVE\VK>5DM/U\R(NTM]D[_-_T
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M9MJQX<2NW[JA26LK]7K^/X6=OF&BY=.B:^]+IZJY//J?[2_[0/Q(B6UT_P`?
M?`OP7=:[:PW#7:^%+[6+33TTJ^-Q+%Y<NH0?/?\`V%1O$C@;L1A-QJA\4/@]
M\>Q\'?A[/IGB'XM6^N>'_B7K.H:Y8^&=7T.34-4T.>^U+['O?5-UO)%'#)9D
M0>8NV,L!&9(HA'D_\$M_^"GUK_P46^(WCSPY?_#;X>^%W\)6=EJ-C=^'?B#I
MGC&'5[:YEN8P\@M8D>R<>0I\FX59@)1O1",'[4'@_21_S"].^OV9/\*N6EF_
M)_EI_P``+WO#MH_ZZ[[GPI^T/<?ME?#/P)X0L_ASX5\2^*FG\4>(+K6Y]-\4
MZ!%JUE:OK%Q)I_F?VQ'-!<67V*2/%M!);S_*B?:+4(0WK_P0UWX_3?M\^,;;
MQ?HGBK_A3LFAI)HVI3S^'[/2;>^46JM;PV=N]SJDKN?M,OVFXNHHE!,0MOD2
M>3Z,_P"$/TG/_(+T_P#\!D_PH'@_23_S"M/_`/`9/\*F/N^>^_G_`)="I>\N
MVVQJ45F_\(;I'_0+T[_P&3_"C_A#=(_Z!>G?^`R?X4`:5%9O_"&Z1_T"]._\
M!D_PH_X0W2/^@7IW_@,G^%`&E16;_P`(;I'_`$"]._\``9/\*/\`A#=(_P"@
M7IW_`(#)_A0!I45F_P#"&Z1_T"]._P#`9/\`"C_A#=(_Z!>G?^`R?X4`:5%9
MO_"&Z1_T"]._\!D_PH_X0W2/^@7IW_@,G^%`!;?\C=>_]>EO_P"ASUI5SMOX
M6TMO%%Y&=-T_8MK`P7[.F`2\V3C'?`_(5H?\(;I'_0+T[_P&3_"@#F_V@O!$
M_P`2?@GXJ\/V^BZ;XBDUS39K'^RM1UBXT>TU%9%*-#+=V\4LT*,I(+1QN<$_
M*<U^?=]_P2?^*GBW]DU?!^I?"K]E+P[K4_B\:_J&B>#[R:Q\*7BBRDMDG@LK
MS1+RT@N%41(XGLKQI0TDB36LB0^7^C'B'PU!:Z'>R:7H.AWFJ)`[6EO=8MH+
MB8*=B22K%(T:%L`N(W*@DA6Q@_#_`.T?^WQXK^!7[(6A^+M7@^#?@_Q9J'CG
M6/#%Y-?V(NM&@2SNK^)(H9+R^TNW>4I:H3)<7MJ9!',T4#R%+:LY65Y/K9/[
M]/Q*N[)^;M]S_0^FO@]\*->\0?LW1_#OXBZ:VD_V-8V&C->^&?$>H6JZJD=G
M:O)-;7"SB_@C%P9H`)9S+(L!9R1+MKX_OO\`@D'\1K7XM_"#6K>Z^'^L6GP_
MT'PYI22:F;"Y7PQ)IH59?[/@N]!N[AHW*^8&M+_2Y2QY<%(Y$^F+CXSV_P`1
M_P!BA?B'X5\1?#3P_J=GHEKK>KZC>^%KS7-/T]&LXKR5#8^=87F7@E1XED,<
MFR6)C&=P!\UT*^_:87Q/\/='U?6/@1'K_C!Y-1O="7X4W<4VAZ5!+']HGN;D
M>))8EF5)H(PD*W`^TSJJEX4DN%VE?VMWHTT_N3_#5F,/X/*MFOGT_$M?"+]B
M#Q)\,/VT?'GQ4/@KX7^!=%US1M1L9W\/ZI%?7VNF61)?M%T%T6QN/M,CQ++(
M]U?WZH3(D:+YC2C[-48%?`7[+_[>FM?'[]LSXF?#S55^&*Z3X>.N1Z99>&XM
M(U6^MXK2X\J":\N[+7KJXMW>,%F2YTFU5)&$7F^8%67[M_X0[20?^07I^/\`
MKV3_``J?^7<'Y:>A7VY=[Z_<C3%!Z5F_\(;I'_0+T[_P&3_"@^#M(Q_R"]._
M\!D_PH*/A_6/^".OBCQK\;O'VJ:E\>O&?A[P3XP=I$TKPI&]I/,KW1N'M[J"
M]EO-),/)1_LVFV[W"R2B5F6:Y6Y]?\#_`+"VO>`/V-M2^#L'Q*;6;2^T_5[6
M/5M:\*Z=/+;RW<QEM\6T"PVC6\.Z4/"8=TN\;9(`H%?*/A[]HG]I+PU^U_\`
M%;1='^&_Q"^*]G8O<+H^C7ND:3HNF:(DM]B*Y+W&FV$%S'%;AO*6'7[J2X"`
M.L1EDDL?H'X=_%#X@7/_``3XU?4_$W@?QUHGQ=MM'UR:".;P987FINUK.Z13
MQVMI+)9M*4DB:*W,V^?RV*),`2T:>Q\K;>5OZ_JX_P#EY;K?\="GX`_X)K?$
M3X;^$=+N+'XN>&+SQ[HOB&\UBTU35_!-UJVG>1=:<EA+#,EUJLFIW,VU`PN;
MC5)9`,18\A5A7Z&_9R^#EK^SU\-O#7@2QNIK^R\&>&M,T2"YEC2)[A+=)(@[
M(@"*2%SA0`,X`Q7PSX(^+_Q>US]G#0[CQ-<?'#P[9IXKO;+6/$^D_">/5/$H
MMET\36B064NA033VK7+&-KIM!MB"@CQM'VN3[1_9EL=8\3?!_P`)WGCS0;&P
M\977A?2[G7;/[#'"+>_>-S<+Y:LZH?,R"H=@,8W'&:UU][7M?[M/N6_J9QM9
M6\_SU_$]1U.U^W:?/"&53-&R!F0.!D8R5/!^AZU\1>'O^"2'B^7P_P"-=%\0
M?&2>;0O%7AN^\/6]EHL7B.VALDN`JA1!?:_>VT$"JH7RM.@L3M^1)(HOW9^R
MM3\+:9::?-)%I=B\D<;%56T1B2!P`O&?ID9]:_.+X"_'[]H+3+WXD7+>%_&G
MQ%OM-\-:A>:+9>)/"5WH^G+?1LIA8Q/X3TIPI^8?9[;4-4F((1/-_P"/D8Z<
MTO1W\U;8UU23\U]]U9FSX`_X(.K\'O@7H/@'PW+\$I-$L_&<GBB]TS5?!VNZ
MIX:N%;2[FSVS:3J&O79N7,DL3_+=6Z`Q1N5=HE#?1.I_L*^)/#_P>^$^D^#?
M'6@Z7XL^%*7$-GJ6M^%#JVDS17-M);S1)8I=P201HL@6!4NOW4<:QL95SGYC
M\`_MR_'ZW^!F@W7C[PQ\--%\5:YXS?0_[1T+X->.[Z&VL%TNYO!(FA7EM9:E
M=2"6!4+V[O$$E+,5\I@WKWQS^(/Q`O\`]G#X2ZY?6/CKX=-KTLS>+;_P%\/!
MX@URP(M9FM-FF3V=_-;PW$JQLZO;2R0;EB=XSND%UO@?-MI\]%8SA\2LK;_G
MK]Y[=\-_V0;3X?\`@_X2^&&UZ^U+PK\)M&AL;;37B^SIJMY;QP16EY<")EC8
M0+'*R0&,QB66.4`/!$R^RGK7QO9_"3XQ?%!O@K=3^,/''@/7=;T"RU3QOIUG
MX?\`#RZ%I;6Z6[7D.+C2[NX^V7,LWE+"MZB1HL\JL?($<WUO_P`(=I'_`$"]
M/_\``9/\*TG>[;?5_-A'R[+_`(8-%^;4M8_Z_%_])X:X_P#:6^!S?'[X:QZ3
M;ZG#H^K:;J5EKFE7EQ8KJ%K#>V=PES;FXMF91/#YD:[D#QOCF.6&14E3H-)\
M+:9)J.J*VG6+>7=*J`VZ':/(B.!QQR2?Q->=_MB6NM>$?@=>7O@S2YH[Y;NV
M2_O-)T.+5=5TO3FF5;N[L[-E87-S%`9'CCV2DLN1!<L!;RY2MI?NOOT-(WN>
M8_$W_@GCXR_:%T;Q'>?$7Q]X"U[Q5JEG8:7;"Q^'\EIX;GLK6^6]^S:EITVI
M7$VH12R!D>,WD2>6Q551FD=['[/_`/P3;C^"OQ;^'/B_[/\``O3;SP'::WIQ
MMO!OPM/AVV>VU#[*Z_9%.HW!LY4D@E+N#(LJW4PV1LS.WF&A?%WXC>$/!/C#
M4O!G_"SOB;X>LX;`+KOQ)^$$VG:KHUU+>)%<FWTBST_2KS5+>&U8SF*&V#EQ
MM2X<LT<79_`;XK_$'QY\>/AA'JD]KJ?@W6M-\00:RZ?`CQ!X36;4+=K%[,R#
M4I9)=/'E2SA'F)BG,4JJ2[(L-4='[OG^3O\`?^-S*33>N^G]?+\#W;5_V6=#
ME_:0@^)VEPZ;H/B.;0+_`$/4[ZQTN!=0U3SVLC!-+<$$N;=;0JBR+(/WO8`A
MN#_8@_X)\?\`#$WC+Q7J%O\`%+QYX\LO%%K:1/;^);32?M/GPM,SW<]U:6=O
M+=7$AF.Z28L[$L7:1B&79\0Z!XVT+]K[366/3=6^&EWX8U6>+1[#PS'#)!J$
M,FG>2+B_EE97ED#W7E(HMD"^9O$I0.G!?L(>/_B_\5OBCX\A^,7P=UGX=VJ6
MVGWND6MY:Z--INGL_G+-:07=G=W$EXP"QLTSB/)R?*@#+%4T_+M^%_\`/7^D
M7.]E?:Z_+^D?47BK_D&1?]?EK_Z41UI5S^O>&].T^T@FAL+.&1;NVVO'`JLN
M9XQP0*Z"J`^8?%7[;FM?#7]H7P=\);;X6_$#Q#J7BC2#J>FZKIT>B_V9)9V_
MV5+J9FN-7@G`@:[A#@P!WR3&D@%:'CO_`(*0_#3X<_$?6/">H>+II-;T*[;3
M+HVW@[5KC3QJ(M/M@TU;]$-D;]X"K):"?SG+HH0LP!["[T'P7!\4/#OBK4M)
MO+CQEX+TN[T"ROXY7"06]PUN;E!'Y@1@[VD!#.A8>7QMRP/`ZM^RE\#==^--
MUX^O/"&M7&O7FIKKEQ;MK-]_8\^I+;"U74'TL77V!KP0JJBX,'FC:I#[@"(]
M[E2\G?UOI;RM^)6E[_UYGG*_\%S_`(*^"?V6/A/\4_B9XMD^&.F_&"S-UH]G
MJGA+5[B567;O1VBB("_,-LI`BE4%HV=`6KZ,^#G[0MO\</'/Q`T'1;@K<?#G
M6(-%U&>?3P(+J6:PMKY'MV6X8M'Y5W&,L%.X-P0`Q\'UC_@FQ^S3KWP[T'PG
M<^#?&O\`8/AO0+KPK96T/C;7(2='N76273II$OP]Q:;E79!,SQQA0$50,5[9
M\+-'^'_P5U7Q)?>&M%U+3[OQ=>0:AJ\KSR7!O)X;2"SC<^9*VW%O;0IA<`[-
MQ!8L3M[MY?A]ZW^5_FS/73\3T+4?"L^KZC875U_8=U=:7*T]E/-I9>2SD:-H
MF>-C+E&,;NA*X)5V'0FKOV;5O^?W3O\`P!?_`..UB?\`"Z-+_P"??4/^^$_^
M*H_X71I?_/OJ'_?"?_%5!1MFUU8_\ONG?^`+_P#QVE^S:M_S^Z?_`.`+_P#Q
MVL/_`(71I?\`S[ZA_P!\)_\`%4?\+HTO_GWU#_OA/_BJ`-S[-JP_Y?=/_P#`
M%_\`X[2?9=6_Y_=._P#`%_\`X[6)_P`+HTO_`)]]0_[X3_XJC_A=&E_\^^H?
M]\)_\50!M_9M6_Y_=._\`7_^.TOV;5_^?[3_`/P!?_X[6'_PNC2_^??4/^^$
M_P#BJ/\`A=&E_P#/OJ'_`'PG_P`50!N?9]7_`.?[3_\`P!?_`..T?9M7_P"?
M[3__``!?_P".UA_\+HTO_GWU#_OA/_BJ/^%T:7_S[ZA_WPG_`,50!N?9]7_Y
M_M/_`/`%_P#X[1]GU?\`Y_M/_P#`%_\`X[6'_P`+HTO_`)]]0_[X3_XJC_A=
M&E_\^^H?]\)_\50!N?9]7_Y_M/\`_`%__CM'V?5_^?[3_P#P!?\`^.UA_P#"
MZ-+_`.??4/\`OA/_`(JC_A=&E_\`/OJ'_?"?_%4`;GV?5_\`G^T__P``7_\`
MCM'V?5_^?[3_`/P!?_X[6'_PNC2_^??4/^^$_P#BJ/\`A=&E_P#/OJ'_`'PG
M_P`50!N?9]7_`.?[3_\`P!?_`..T?9]7_P"?[3__``!?_P".UA_\+HTO_GWU
M#_OA/_BJ/^%T:7_S[ZA_WPG_`,50!N?9]7_Y_M/_`/`%_P#X[1]GU?\`Y_M/
M_P#`%_\`X[6'_P`+HTO_`)]]0_[X3_XJC_A=&E_\^^H?]\)_\50!;M[?5#XF
MO,7EAYGV6#+?8WP1OFQQYOU[]QTQSH&WU8#_`(_M/_\``%__`([7,0_%C38]
M<N+HPWWES011*-B[LJTA.?FZ?./UJV?C/I9'_'OJ'_?"?_%4`?.OP;_X*P>#
M?CE\=OB-X$T*/4+J\^&)U,:O/;KINH7,K:?,L%QY&D6FI3:S(/,.U&_L\+(0
M-I)=-V)\0O\`@LUX!^%_[.VA_$;6K?6M+M_$'BK4_!UEI&J0Z9H]\;[3Y+J.
MZ,DU[J<%E"B_9)2#+<HS;HT"F1Q'7HOPR_9U^#?P@^+UQXYT'PUKUKKTSW\L
M*S:S>W6G:;)?2B:]DL[":Y>TLWGD&Z1K:&-G+-N)W-F+7?V;/@UKO@.'P[_P
MCWBC3;&U\07WBFVN-(\0:AI6I6>I7LD\EW/#?6MU'=0^:UU<!DCE5"LK)MV?
M+4>]R+O;7UNKE>[=^NGI9V^=[?B:2_M2:3H?[)MG\;O#_AG6]8TWQQ9:?X@7
M3-%\+_\`$ZU(W<5O'$\ZM<)$A2'RA)//,L,44.YI1&@:N2^'G_!47P[\29OA
M!'9Z#XZM?^%S74EGI-Q=^%BEA92+%>RKYMZ+HVDZR)87#(UE-<AD,,F?*FBD
M>71/V0_@[I/P8U+X<S6/C34?`MQ?Z??Z5H\^M7$:^%&L(;6.U72YXIDN;/8]
MJL_F)+YIGEFD,A+FN@\$_`'X._#W0?!^FZ;X7UGR?`OB"Z\5:1-=ZI=WMVNJ
MW27*7%Y/<37#S74LBWEQN:X>3)DSU52-7R\S?2^GI_F1%/EL][?C;_,H?#S]
MNZU^-WQR\<_"Z+PSXRT/5?"^F75[+>:QH4=K;WUM'.UMYB(MV]S;+*X<P->6
M\`N8XY)(/.1&8?0IM]6Q_P`?NG_^`3__`!VOG/P%^RS\&?A!\0-2\7>%?#.N
M:?XANX-4CM5GUJ^NM-THZC,MQ>FSL9;E[6R\^=5>0VT,98CG.3GW`_&;2S_R
MPU#_`+]I_P#%5*^%+KU_KT#7G?;H;WV?5_\`G^T__P``G_\`CM'V?5_^?[3_
M`/P!?_X[6&/C/I8_Y=]0_P"^$_\`BJ/^%T:7_P`^^H?]\)_\50,V_LVK?\_N
MG?\`@"__`,=H^RZM_P`_NG?^`+__`!VL3_A=&E_\^^H?]\)_\51_PNC2_P#G
MWU#_`+X3_P"*H`W/LVK?\_NG_P#@"_\`\=K-M[;5/^$FO`+RP\S[+!D_8WQC
M?-CCS?KW[CICFK_PNC2_^??4/^^$_P#BJIP_%C38]<N+HPWWES011*-B[LJT
MA.?FZ?./UH`ZC[-JW_/[I_\`X`O_`/':3[-JW_/[IW_@"_\`\=K$_P"%T:7_
M`,^^H?\`?"?_`!5'_"Z-+_Y]]0_[X3_XJ@#<^S:O_P`_VG_^`+__`!VC[-JW
M_/[I_P#X`O\`_':P_P#A=&E_\^^H?]\)_P#%4?\`"Z-+_P"??4/^^$_^*H`W
M/LVK_P#/]I__`(`O_P#':/LVK_\`/]I__@"__P`=K#_X71I?_/OJ'_?"?_%4
M?\+HTO\`Y]]0_P"^$_\`BJ`+6CV^J?VCJFV\L,B[7>39N=Q\B+I^]XXQZ]#Z
MX&E]FU?_`)_M/_\``%__`([7+Z=\6--M+R_D:&^VW4XE3"+D#RHTY^;KE3^&
M*N?\+HTO_GWU#_OA/_BJ`-S[-JW_`#^Z?_X`O_\`':/LVK?\_NG_`/@"_P#\
M=K#_`.%T:7_S[ZA_WPG_`,51_P`+HTO_`)]]0_[X3_XJ@#<^S:O_`,_VG_\`
M@"__`,=H^S:O_P`_VG_^`+__`!VL/_A=&E_\^^H?]\)_\51_PNC2_P#GWU#_
M`+X3_P"*H`O:]!J*VEN9KJSDC^UVVY4M61C^_CZ$R''Y5T%<7=?$NQ\1-;6<
M$-XDLUW;X+JH7B9&.<,>P-=I0!XGXK_Y&G4O^OJ7_P!#-9]>-?MA_M(?M*?#
M[XP_"W2_AM\(_'>I_#FUUO0DUG6=`@T34I/$EM/D7=LRW-ZDMA!$F`9F@`=V
M!^T6R18N=?X2_P#!)[4/A7XG^'NLVOQ8\30WWP_N+GR?LDVIPQZG9W&M'4I;
M6[1M1D6X1H6:VQ,)(U8^;''&0$!1]]Q;TBY.+?562=[;M.ZM;7?336:TN1-+
M62BI)='=M6OLFK>FJUWMZ=17GO\`P4)/[27B;]I+X8^&/@;JVJ:%X>O]#UJ^
M\17L=Q9:;9BXAEL%M$DO[K0M82-V66Y*PB!#(%<[_P!W@^??$3XJ?MG>!_`O
MQ`\,K-X?U#6/AW\'+?65U_2_`=WJ5[XP\4S6^HHT&G7'FQ69>&:WM':,:>YD
M\[_4P"1%11=Z?M/7UTYK_P#I+MZKOIM&FW-0OO;TU:2O\Y+Y7?0^@Z*\5^*'
M[7/[6'@+XP7/P[T?X2Z;XGGUK[%KGAWQO%H-V=#L-'6W>34;/4T^U)C5TDB\
MJ!$EBCG-W$^V-8Y%KYL_X;Z_;D^.7[/7C)M7\!S>!]3T;6?"&K:9J?AKX3^+
MHKJ33)]6*:I93V-YLN)[BWA2)YULF=6A:58Y&#B9+C'FGR+>Z7WM*_HG>[_N
MRM>ROCS>YSOM?N]KI:=7IIO[R\[??M%>)Z9^V1^U9J/_``5#MOAZOPK\)_\`
M"C?MXM9]6FT+7[?5#9?V<)SJHU%HCI(C:X(B%GYC78;Y610&E5?VS]*_:]^)
MO[9?B/P[\$_%%QX0\%Z7X(TZ\LKV^N;#3-+?5YKG4$E/FW'AW57O"B16Q>WC
MFMBBE3NS*&68W:@U]J]NEK)O6^VUM=GH[--+2*OS)OX4F_FTM+7OO?3I[RNF
MF_:Z*\7_`&T/VG_VD_V>/&/Q"/@CPS=>,H]/\(^%$T.5O!.H:IH<.KW6HW\.
MIW;Q:>K:A/$D,=LTD-N\\D"O&XC8%M_G\7_!1W]K/_AF'P1KVI_"6VT+QI>6
MOB3^V!;_``O\4ZU::EJ%A=I%IEC!8Q-%?:=#J$#-*M_>!XHQ'AH\MM`K.[71
MVZ]'^/DMY-I13DTB6FFD]VD^G5)KR5KV;VC9N34=7]445X7X7_;4_:U\0_\`
M!3#3?`=U\&?"^C_!F:Z2&^GN--UN35K*V.FBX>__`+76+^Q7073>0+9)&N"P
M(**N95XG6/VW/VWD\):UJUG\._"2S-H7B_7=+TZ3X6Z_)/;R:-J?V:PTV5AJ
M:^=/J=N1-"Z)$<*2D4ZG@>B4GLU)][**;>U^B>U[M./Q>Z.*YG:/>*^<M%O^
M-]DT_A:;^JJ*\'\&?MM?M9>*O^"DVD^")O@[X7TOX+74\4=Y<W.CZ^FKVMJV
MF+<MJ']J&$:05%RWD"T#FZW`JT:C,J\'^T!^T_\`ML>(/@;\0%TGPK8:;<>(
M-`\?#PZF@_#W5XM<\/3:1?);:66GDO9(YI]1MC)+!MMXLL$>,2J"I*EX1YGV
MD_\`P%7M\^GG=.S32=%*I-175Q7_`(%=_@DV_*S5U*+?UI17I/[.FN:IXE^`
M?@W4-<N)[K6;S1K66^FFT2[T6268Q*7+65VS7%NQ;.8IF+J>&)-=G6E:GR3<
M.S:^XQHU.>"G:UTG]YX'17OE%9FAX'17OE%`'@=%>^44`>!T5[Y10!X'17M5
MK_R-U]_UYV__`*'/6E0!X'17OE%`'@=%>^44`>!T5[5XQ_Y%'5/^O.7_`-`-
M:5`'@=%>^44`>!T5[Y10!X'17OE9MK_R-U]_UYV__H<]`'BM%>^44`>!T5[Y
M10!X'17OE%`'@=%>U:)_R$]8_P"OQ?\`TGAK2H`\#HKWRB@#P.BO?**`/$_"
MG_(TZ;_U]1?^ABO;*S?%/_(,B_Z_+7_THCK2H`^=_CA^W/\`#?\`9'\4_"7P
MCXZ\<2Z#K'Q5N$TW187>S1$8+&@=_,`;RS--;PC8';=.K$"-)9(Z/[5__!2?
MX3_L.:WKEO\`%3QIXG\*Z=X?T_2M0NM5&AOJ-H%U*>_@MTQ:6\TRMOTZ8,SQ
MK&#)"`Y9]H]&TGX/^&];T/7I-0\(W6L?\)YHUOI.NB\N%NH-1LD@:);<1RS%
M8X-LLQ\M%12TTKE=[NQY'XA_L'?#;XH:WI>K:IX7^($.O:-IMEH]IK6F>.]4
MTO5TM;1;I88VO;74([A^+VYWL\A:4R`R%RB%5[W)TYK_`"MV]5WZWV5M:]S7
M?;3_`!76OFFKJUM++5\SY<_2?^"C?PC\0ZAX3ATWQQXTU2'QKI6E:WIM_9>"
MM3N=-CL]3D:*PENKR/3S;V0F=&4"ZDB8%3N"UM?MJ_MJ?#__`()^_#?2_%7Q
M.\:7FB:1K&KP:/;.?L:L\L@9W?$BJ"L4*2RL`2Y6,JBR2,D;Z'@G]D?X?_#S
MP)'X:TGP/K,6CQ6&EZ8(I]9ENI#;Z9.]Q9(TLMTTC&.61VW%BSYPY8``=K+X
M0T^?XDQ^+I/#NK3:_#IK:1#/)>*\=O;/(LLB1Q&?RD+ND9=U4.XBB#,1&@6Z
MEN?]WM=[]MTO5Z)N_5R2TY7G&_+[V]OQMJ_2^J7ROK=>:>.OVX_`'PU^,'_"
M%ZQXD\81W9L-.U/^T[/P]+J6CPV]_+/%;RW%Y:VTL-G$6@?][=M#$<_*[;7V
M<#\<O^"Q7[//[-/@G3?$GCKXH>+/#7A_6M5N=%T_4+KP/JWV>]NK<*95B==.
M(=!NP)5S&[1RJK,T4@3KO^'=WPH76M+O(_!OCBV@TFWM[*+2[?QQJD&CSVUO
M<2W%O;3Z>FH"TN+>%YY!'#-$\<<96)5$:J@=\2?^">GPK^*OAG3]'U+P?XZL
M=/TVPO=+2/0_'&J:&US9WDQFN;:X>RU"%KF%Y"6\N<NJ[F"@`D&9;KEVN[^G
M3YO9]%>ZO:SN/+S>]M9??U^6S7I;K=+XT_X*%_"GP'X[O?#5[XT\:W&KV-PM
MBZ:;X*U+4X9KQK5+Q+&&:VL)(I[QK9UF6UB9IVCRX0J"1;^#?[>GPK_:!^+U
MOX#\'^/]>UGQ1<>'[;Q.;5?#MU#':V%RI:!IYI+-8;>5PK_N)728%'!C!5@.
MRT7X$^%?#U]9W5IX/U2.XL-97Q#`[:AYC+?#3_[-$QW7!W?Z)^[VG*G[V-_S
M5QWA#]A#X7^!OB_X2\=:?X'\3?\`"1>`K"XTWPXUUXGO+RST.&X79/\`9[.:
M]>VBDE4`/(L0D8`98XJM.:/;KW^%[?\`;]MW\*?5Z1KR^=EZ7OK\N7;S?9>]
M[3_8EU_T&-2_[XM__C5']B77_08U+_OBW_\`C5']MW7_`$!]2_[[M_\`X[1_
M;=U_T!]2_P"^[?\`^.U)0?V)=?\`08U+_OBW_P#C5']B77_08U+_`+XM_P#X
MU1_;=U_T!]2_[[M__CM']MW7_0'U+_ONW_\`CM`!_8EU_P!!C4O^^+?_`.-4
M?V)=?]!C4O\`OBW_`/C5']MW7_0'U+_ONW_^.T?VW=?]`?4O^^[?_P".T`']
MB77_`$&-2_[XM_\`XU1_8EU_T&-2_P"^+?\`^-4?VW=?]`?4O^^[?_X[1_;=
MU_T!]2_[[M__`([0`?V)=?\`08U+_OBW_P#C5']B77_08U+_`+XM_P#XU1_;
M=U_T!]2_[[M__CM']MW7_0'U+_ONW_\`CM`!_8EU_P!!C4O^^+?_`.-4?V)=
M?]!C4O\`OBW_`/C5']MW7_0'U+_ONW_^.T?VW=?]`?4O^^[?_P".T`']B77_
M`$&-2_[XM_\`XU1_8EU_T&-2_P"^+?\`^-4?VW=?]`?4O^^[?_X[1_;=U_T!
M]2_[[M__`([0`?V)=?\`08U+_OBW_P#C5']B77_08U+_`+XM_P#XU1_;=U_T
M!]2_[[M__CM']MW7_0'U+_ONW_\`CM`%"WT>X/BB\7^U=0#+:P$OL@W-EYN/
M]7CC'IGD]>,7_P"Q+K_H,:E_WQ;_`/QJJ%OK%P/%%XW]E:@6:U@!3?!N7#S<
M_P"LQSGUSP>G&;_]MW7_`$!]2_[[M_\`X[3`XO1/CMX$\377C"WTWXK>'=0G
M^'K,OBF.VUC3I6\-%5=F%\%!-L0L<A/F[<!&/8UA^(?VQ?@_X1^%&C>/-6^/
M'P_TOP/XBG:VTGQ%=^)])ATG5)5W[HX+IL12L/+DRJ,2-C>AQS'A?X'_`!:\
M.?M4?$'XAMXJ\)SZ7XOT2WT;3])'@ITN-+^R/=R64DMS_;16XVM>2^:JPP^:
M%0*82"6R?@Q^RY\4O`'[,_B#X>ZUXZT^ZNM?UR]U%M:\/>%#HT]K:7]])>7T
M$:R:M<E9F,\Z0W`<>2&1C'(R;FCWG'3>RW[WLT[7]>ME_,]!OE4O*[VWM:Z>
MMNNFMK_W5J>OQ_&3P;-\'/\`A8B?$[0V^'_V,ZA_PDXU73SHWV8=9_M>WR?+
M&#\^[;[UG^&_VD_AOXR\)>'-?T?XQ>$M5T'QAJ7]C:!J5GKVF3VFN7V7'V6U
ME4%)Y\QR#RXRS91N.#7E_P`>?V3O%7[1/[-NN?#61--^'^D:7K>F7'@?_A'C
M<J-*L=-DM9K=+IK:_LYRS20/\MI-;&)&C5969#(WD>F?\$A?&5P_AW5-8^/_
M`,9+KQ%H>KV.H+M@T[4]-M8+;44O?L]F=:DU+5(/,:.,NTNI3AGCC+(T44,$
M>M/EE4L](MQUZJ+LVVNZ3:MT:ZWL9U.:-*\=9I/3IS).R3?2Z6O5/YGTAIO[
M77PE^)_BK7?!/AGXW>`_%'C338+Q+KPYIOB72[S4X6@#+.DEM$3,OED$."`5
M.0<&O6O[$NO^@QJ7_?%O_P#&J\T/PMO+3XD^,O'6N"\U;4K[3&TG15-O###X
M=TW8KRPK^_<O)-.#)+*`I=8[=-G[E2WI?]MW7_0'U+_ONW_^.U*^"-][:^O_
M``UK^=[-K5U]IVVOI_7K>WE:Z3ND?V)=?]!C4O\`OBW_`/C5']B77_08U+_O
MBW_^-4?VW=?]`?4O^^[?_P".T?VW=?\`0'U+_ONW_P#CM(9\M^#_`/@JK\/O
M$'[0/C[X>:M=>+/".I?#M97U"?5[_P`/-)<[;I+6$0Z=;74VJYN9)8O($EE&
M9?/@`^>X@23UCPU^T19>*_V9+KXI6D/CYM+M;*\O#I']EVS:RYM7EC>%;=5(
M\TO$P"EP.1N*\X\$\*_LW?L=?'/]I7QEHL=CX#^*GC2WEN+G5O`>J^+K/Q19
M^&YUN&%U/%H4]W-!82^?,RR.D$95I67*^:X?TSPG^SC\!?#_`.RGJ7A_PWX/
MT+1_@S=:9JBWL&BZQ#8Z";:X?S+RX9H+I8@Z-"2MQD26X1A&\8R*EW]@FW9\
MN_1O77TOUVT>C*_Y?62TOMU2TLO7?=]>EM>?\&?\%)=,^)OP=\.^*O"O@_XM
M>++[Q7J=WINEZ#HS>'+RXO5M83-/=17R7ITJ:V5,#S(KY\R$Q`>:KQK[7\'?
M&UG\:_"ND^+M#U?6&T?Q1H=AJUE)<6L<%PT$XDD021M%E&"GE2`020>@Q\Q3
M>!/V/=/_`&:U\62>,-/@\!:EXDDU!?B"WQIN%NKO5FMOL3K_`,)'_:WVIW-O
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M-)+=H6N,721J5&Z59&C\Y\,OG/OQES<L[6O9<OKK>_D_=7WOI9[+ENK_`#]-
M-OQ_!=;KG_`W_!0[X3>/O%5OHL/CKQ=HVH7UG-J-DOB/PAJ'A^/4;6&)YI+B
MVEO["&.XA$4;OYD3,I5202*W/B_^T['\-?"G@^^T71?B;\0M2\>`RZ-HFA:?
M86NHS0K;FYDFE&I-:16ZI&!E9I$DW.J!"QVCD'_82^!_@NWL]'U;PQXAO/\`
MA(;NVL=+@\2^.K_5)F:V66Y2QL#>ZA(\,/E1S%[2V*Q2PI(LD;Q!EK4_:%UG
MX(_M'^/8_AQXQUZQ7QUX1BDUY-+TGQ\N@>)M&@,!26XW6-]!>PP-!*0YW"-T
M<;LC%%9^X^1^]TOM9:O\-UI9)N^ONJ"?/KM^.NB_'9]6[6TURO`/[>C?$KXF
M>`]"TOX?_&!M*^)%DNJZ'X@ED\,QVDUA]GCG>]DM#?\`]I101^;%&[/9@K++
M$F-TD8;Z*_L2Z_Z#&I?]\6__`,:KPO\`9(^-O[/OCO6[JS^"/B#X?^*+S1-!
MT_1IK/PEXKTW5?[,TNS,RV<7DP73B&)#/*`0J[BW).!CW3^V[K_H#ZE_WW;_
M`/QVMZG*G[FVMF]VKZ>6V_G?T6<=7KY??;7^NUBAH^CW#ZCJH&JZ@NVZ4$A(
M/G_<1')_=^^.,#`'?)/#?M%_&^^^`,7AF&Q\/?$+XA:SXNU-]+T_2?#AT6*Y
M9TM9[IY&?4)[2!46*WD_Y:[B<`*<\=SH^L7":CJI&E:@VZZ4D!X/D_<1#!_>
M>V>,C!'?('!?M3_#/P3\5_`<&H?$2'Q-H&C>"II-<76;#QG<^%9-(*P2Q2S-
M?65[;R)&(990^Z39M8Y'&1C*]M/+^OZ_#<UAJ[?U_7]:['C/Q@_X+,?`/]F+
MPOH-Y\7_`(A^(?A/K&NW]WI?_"/ZYHXNM4L;JU9%GCF6PAN8E1?,C(F61H'6
M12DC#FO6]+_:]\#>(?BO#X.TGQ)XXUS4II(H3J&D^#[_`%#08))84GCCEU:&
MQ?3XG,4D3;9+A2/-CR`74'#N_P!@7X8ZAX;T6RL_#?Q$T;^QUN#%J>A?$'5]
M(U:^^TR":9KO4+348[N^,D@$A:YEE);YLY)-;D7[(W@ZT^+<?C:TTGXF:;KG
MVF&\GBT_Q_JMGIFH3Q1I$LUUI\6H+9W4C1QQJ[SPNT@1=Y;`JZ?3VGSM^B=_
M/=OMK:[RE>UZ?RO^%VK=+7T[O39:OQ$^/.G_``V^-'@GP+>2>/+K5O'5S);6
MEY;:&&TJT*6US<9GO6A6!6*VKJ(4=YLLK>6(]TBU_`_[2GAOXD_'C5OA_H>N
M>(M2U#1;.>YNM2AL[?\`LKS8+A+>XM8[C9B6>&1U618PRQN&C9A(CHO0_$*_
M\-WOBCP7_P`))8^1JUOK#S^&H[G4;>WEN+\65TK+"GGKYSBU>Z8QX;"!WQ\F
MY?/OA]^RK\!_A-^TO-XH\)_"+X>^%_BM-IMQ<376D:;I=CJT]K<3#SKAUB=7
M<22KM,S`DDLN[YF!F'QQYMO>OW?NOEMZ/67DF_(NK\+Y-[1W_P`7O/YJRCYW
M7F>O:]I<]M:0.^I7MPJWEMF.180K?OX^NU`??@UO5@Z]JD]S:0(^FWMNK7EM
MF21H2J_OX^NUR?;@5O4`?)7QV_86\>?'J_\`'6K>'?B]XH^'UEXR^'^G^'+;
M3='@TF6WU*XBCU#<;XWNF74L<7^EQJ#;2(VTR\;@AKGOV@_V%_C)\2-?T6RT
M'Q9=:9I,?A_2]&BU?3/BAX@\,S>$)(`4NYX-*L83::NT@.Y3>R1%2`G"@&NP
M\;?MF:-\&OV@+?P3KW@6S_X16T\*:1J]_P",#<1F/3[W4I[ZWM+>Y@,68X9)
M+!T^T^80LL\*,@#&04?BQ_P4M^%7P+^'WPIU+Q-X=A&N_%;2+36++0[2\TF&
MXMXIXXF.Q[^XM%NG5Y5C6"V\RZF.3';N%;;G",7>W5Q3[W2J65]UHYO1JT;2
MTBTVZG-%\LM'%/[I*F[VV=_<M=.[=M9:*]\"?V9_CWX5^)BZOXT^)UCK.G2:
M5+=36EO>WC0C7$C:QMG2$A%%BUGLGEM]V/MFZ0!CB2O`_P!B#_@F%^T?\)OV
MG[7Q!\2OBUXRUCX>>9%J5WHDOQQ\0^)'^WQ>>T8MP^GV!CLO,>+=:S2W`=8M
MLK3#BOI#Q1^WO\(?`OQ`M/#>NZ3J&B:A-J\^E737VCQPQZ3'':PW"7UT2V8;
M2875I&DC#=YURD;JC!PG,ZC_`,%$_#NC^+9!<_!?QG_PA]GX1T;QEJOB!;?3
M$_X1FRU%[L`W]K+<1S9C6U+%+,74IRP,:D+YG12E)S]I'5Z+TO=QOLDTMKVM
MRJ^J,ZEO9N$OAW^2:6G=7TLKK5I63L,_9W_8^^*W@;]LY?&_B_4;/5-#LK;6
MX6U-_B)K&L3ZP]Y<P/;,FBW5J+/2!%%$R,EE<%&RNY7PI2IX\_X)M:OXI^,_
MQ$\=:E)X9^(-OKWBN#7-(\!>+9WE\)O"FFV5J\LL2V["/4?.M0\=S+'>"%(E
M6)(S/,:ZZV_;3T'7O"-]KVF_"G7H-%L_'%EX'AU'6(]/L[75;B77#H]S+;+%
M+-.4MY59_P!]#$)04",<L4YGQS_P4M\$^`O$OVC4/A?KUC\/(X]=E/C:^_LN
M'3;T:1'*;H6T2W#W`(FA>(F[CM5^4NK.@+5C"2IQ55?93C?TY)_?;ELMFO=2
MW1I4]Z4J4OM/5>MX^N]TW>Z>[1D^`?\`@F]X_P##7C#Q1X@G\>:U8ZA_PD\F
MN^&;'2/'.MV.CVJ7'BG4]5N_M=A"T=K<R2V5Y;PD313*7C9>%`=L7]B?X>_M
M"V/[?/B"^\:^!?'WA/X=Z;;ZTLOB+7/BRWB"S\=W,UY";*>WT);B>+2%CA6<
MK%$40+*%*[E55UA_P5_^#MG^SJOQ*U3P3J&AZ+J&MOH6B"_UKPDEOXCECC$D
MTUIJ:ZNVE&"++(SR7L8,L;PJ'E`C/M'Q<^,=UH_[*4?Q(^'OPK_X3;4+JWM;
MV#0;Z*33+A+:1T\Z618;6ZN&,,1>3R[:WN)9=@6))"ZYTO[.7.]HZ-=/?2LW
MZ:.][)ZRVT4I.K)_S3;E?KI)W7;=M)6O_+:Y[A17QKXI_P""I?PO^%'PU^'>
MH>+M!T%O%7CXS*-"T+4K-6L6AN&MYHP=:&E3S7$<P$362V_V_P`T21K:L8W(
M[_Q?^V7X1\*Q>.]3B^%_C#5O!_PXL+FZUOQ/;6&F0V,-Q;VR7,EBL%Q=17K7
M`CD09^S>4&8J90RN%.5W<5TO?Y.S^2>E]N;W=]">;9=[>MWJE;O;6V]M=M3Z
M+HKYU^+_`.V7X-^%?Q.7P79_#7Q9XR\57&HVFF6NG:'I^FAKN:XL+N_7;)=7
M,$2*L-E-N:5T`;:`3G(YOQ!^W#_9?A'X?:IIGP-UCQ4_CKQYJW@A[;2+_2D?
M3#8W%_"+AFNY;=9#(+%G$:G"KY@,A94$LK5I+JTOFVDOQ:\AW]WGZ6;^23;?
MW1?K9I:GU=17QSX[_P""I_PJ^$WA_P`.R>)O"\,.N^)M>UC1[+1[2_TF*X>+
M3]4GTXW"-?SV:W#R/"I6TMO.NG,A6.&4(S#U+X>_M1^!_B+^U1X@^$L'@_4M
M*US0=*CUE;K5[:PT]-4MV$&9+6SEG74985:<1M<_9!;"6.6+SC(A2BG[_P`.
MN_X;_=JO5-;IH<O=;4NEK_-V7]=FGL[GNE%9O_"'Z1_T"]-_\!D_PH_X0_2/
M^@7IO_@,G^%`&E16;_PA^D?]`O3?_`9/\*/^$/TC_H%Z;_X#)_A0!I45F_\`
M"'Z1_P!`O3?_``&3_"C_`(0_2/\`H%Z;_P"`R?X4`:5%9O\`PA^D?]`O3?\`
MP&3_``H_X0_2/^@7IO\`X#)_A0!I45F_\(?I'_0+TW_P&3_"C_A#](_Z!>F_
M^`R?X4`%K_R-U]_UYV__`*'/6E7/6_A72V\47D9TW3_+6U@8+]G3:"7FR<8[
MX'Y"K_\`PA^D?]`O3?\`P&3_``H`P_CY8WNJ?!'Q;:Z;I^N:KJ%SI-S%;6FC
M7GV/4+B1HF"K!-]KLS'(21AA=VY!Z31GYQ^=-M^S/^TVO[)#:7-:_'9=<7QZ
M^I16`\5-<WT^GMIJQ;68>-H+NVM$G!98AXANR\I=V@1&1(?TR_X0_2/^@7IO
M_@,G^%>)?MQ?'+4_V6?!&@ZEX3^$H^(5WK&IFRN$AL-4EM],B$,DGG2C2=+U
M.\^9D5%VVACR_P`\B?*&SERQYI/[2BONDFOG?3T-(N3LETN_OBT_P///!0^)
M3_\`!->\\)>*/`?Q9^(WQ(\%6=OHDT.D>*Y?!VH>++V)(I%EM]7DU"*Y6W1F
M6*:Z:=FE,,[)]K5E,O!_"/P+\9/AQK/[/M])\-_VE]4OM"U/4AXO;5/B+IUU
M9V^G77]H"*VN+:;Q'.E[]GFN+5HYY/M%S]GMES(9!Y->Q:?^WI\-="_8%\-?
M'KQMI>B>"=*\0V-LPT_4IH;/;?SOY26:SWBVRC,V0))U@"H#)((E5]O)_LS_
M`/!0:U_:6A^$6J:3X(^%M_X6^)&LZMX8U#4=!\:+K$FAZI81W\VR-$L$CN;>
M6&R6196EA<"YC/DE<,>B/,ZDI;NZOVYK:[=[]7=723]Y7YY./L8QZ6=N[7?7
MJM]$KM-V]W3C/V:/A1^T?X6_;(\>:U\0K/7;SPE?_P#"0;M3O=;NQI(M&G=M
M/6QM4\1W5LT@A$"$-H=@5596,QDR+C[[KYK\*_&_Q%XH_:.\<?#W5/AU\/;?
M2?#FD7=Z=?\`#?B>75YM,E!A-I:ZC!)IMLEG=7%O/]H6*.XG94C)/R/'(_T%
M_P`(?I'_`$"]-_\``9/\*B/\&G;:VGHF]_.]^WH:2O[2;>[=WZM+;RMJ:5%9
MO_"'Z1_T"]-_\!D_PH_X0_2/^@7IO_@,G^%(#XCUK_@CCXH\;?&_X@:IJ7Q[
M\:>'O!/C!VD32O"<;VEQ,KW1N'M[J"]EO-(,)R4?[-IMN]PLDHE9EFNEN?7_
M``-^PGKWP^_8RU+X-V_Q,;6K.^T[5[6/5];\*:=/-;RW<YEM\6T"PVC6\.Z5
M7A,.Z7>"LD`4"OD_P_\`M%?M)^&/VPOBQH>B_#7XA?%BTT][A-'T:]T?2-$T
MS1$EOL17)>XTVP@N8XK<,8EAU^ZDN`@#K$99)+'Z#^'7Q.^(%Y_P3UU;4_$W
M@7QUH?Q>M]'UR:".;P787FINUK.Z13QVMI+)9M*4DB:*V:;?/Y;%$F`);-<J
MP]U\+CMW5GM?>ROJN[L])6JS]OR_:YG]^F_KINNFVUZ?@#_@FI\0_AOX/TJY
ML?B]X8O/'VB^(;W6+35-7\$W6K:;Y%WIR6$L,R76JR:G<S;4#"YN=4ED`Q%C
MR%6%?H;]G'X.VG[//PU\->`["[FO[+P9X9TO1(+F:)(I+A+=)(@[)&`BDA<[
M5`49P!BOA?P3\7?B]K?[-FA7'B:X^.7AVT3Q9?66L>*-)^$L>J>)1;+IXFM$
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MS9)NR75_E;=OIJM-GU5D=YX*_8D\83_$W1?&GCKXA>'M?\1Z;XW3QA/_`&'X
M4ET>QF6/0+K1DM8XI;^ZDC^6Y$QD:5\LA4*`P*R:1^PMK&G?M06_BZ3QIHTG
M@FP\77?CNTT)?"RIJZZM<Z8^G2>9J?V@J]J(Y96$8M5FSL4SLB;#X7\,?VO/
MCG<ZF+Z^^%=CXXT&&T1-3MK/X1:_X,U#1]2N%D2VLXO[2FF&HQ+<"-)KRW18
M(HV:5BB"O6/VW9O&'@#X>?#Q8[[Q5X?M[JXDB\7^(?AG\/4\2:E!,ME(T*V]
MA+:Z@\=M+<@!G-O,R`(IDCW&0:5*CIKV_;32VMVKI='K&+OU]V46TTW/\1^R
M?:W7;WOFM)S33LTFXR2M9>[_``E^$7_"N;[Q%JE_JEQK_B+Q1J,MW>ZC/O7;
M;B23[)9Q1L[B&"WA8(J1[59S-,5\R>5F[.OC?]GGX1?&+QQ\4OA_K'BOQAXX
MT2UB\,Z?K_C7P_=^'_#L&BM?SV[1G2K,+I;W7RS1R33O_:+-"/)C7S//WP?6
MW_"'Z1_T"]-_\!D_PK2I3<'RM[:?=I]VFGEKLT2I7=_G]^OZ_+;HTC1/^0GK
M'_7XO_I/#7GW[4_[+MC^USX:TWPGXGU*\C\`FX^UZYI-A<76GWFLO$5>U47U
MM/%-;QQ3*)F$?S2-'$-ZH)$D[+1_"NERZCJJMINGLL=TJH#;H=H\B(X'''))
M^I->$_\`!0:XO_!.B^`3HNH_$3P?HM_X@D@\0:K\/O`4?BO5[>U&GW;Q#[-_
M9FH[8VN4MU:06_&0-R[JQJ<K7O*ZT_K7^NVII3<D[QT>OY'/>)_^"<7C33/`
MEGX8\#?%31]%T72]`UCP5IX\0^%KG7[JP\.W_P!E*6:S_P!I0,]Q:FW\N*YF
M\S,/EK)')(C32^=^'_\`@FM\5-._X*8:+\0GTK]G^W^&VAZNNL-XGCM;V7XE
MZQMTIK-;&>X$4<`L%E92ENSR"-8(2&9E&.%^-_[4?[4GPH^&_@K_`(5_X#\.
M^)--U&^U0MXH^(OPQ\2W.KZK813QK9_:-*\.:>\UA=21M(Q>XMK='5$(AB<M
M$/==&^/OCR]_:RM?#>M:!IOA?PW+>V=O!I<7P7\3:X-5@EM(9&N1XDA:/3[)
M1/)*GEW5JKQBW_>;/,!77#RDZD:L7KMKO=OFU3][FYFWRZR;YI.+5V8UFE3=
M-JRUVVL]&E;W>5I))_"ERQ33LCWCXH_LQ^'_`(E?&GP#X_-CHUGXJ\#7[SKJ
MITN.34+NS:SO(#8BXXDCA\RZ$VW++NC^[D[AYI\!_P#@G3)\!OVM]:^*L/Q<
M^(7BAO$5O?IJ&DZ[9Z/*LTEU<1S*/M<-E%=&&!8UCAB>1_+C2-%81IY9ZCXU
M^%/&>G?'WX5S>'9-&3P'>:Q+9^)-+M_"RW%W*G]G7\BS37K.RPVPF2V&U84<
MRE!Y^UC$WFOP'^)?QB\;?MQZUHWC?X):_P""_AJVF7Z:1.]MH5UIF8+N-+>Z
MDN[>]EN&FN82S^088A$&";9/+>X:*/\`%ARZ/W[=E[KYO+WEM:[N^CNUIB/@
M?/JK4]NOOOE\_=E=MO1*RN[Q3^I/%/\`R#(O^ORU_P#2B.M*L'7O#>G:?:03
M6^GV4,RWEMM>.!59<SQC@@5O4`?-'QF_:`^%/PI-UI'C2UM]8OM>\+V]MXBB
MT_X;ZIXH\K1MLWEQZM)8PSI!:'S+LJ+LQQ,#<E00)2,WX]ZI^RSXUU3PC\/O
MBI=_LVZBVGV%K<>$M&\7Z-ISVWV:X4I#_9BW3^4ZLD`&VVSM58\@!DST_C']
MFE?'>N0^(O#_`,2_BU\,]0U;2[6RUR/PM:V<MOKB0H5B+_;M/NO)=%>11+:-
M`[*PW,WEQ%+'Q;_8[\!_&31/&MCJ4WC*#_A.]$TCP_J%S#%+)=I:Z9<3W%OM
MFFADD9R]Q)O:4R;LYX8LQF7.J;DE>71;7M>U^VZL];7>B*C9U5S/2V_JDG^"
MU5M4HJ_5<C\3_C7^R[/IL.L^,/%G[.UQHOQ`T:6V.O:I9V,VD:UI^E7L,1MI
M;]Y3;.EM>7<2I!))E99&V+N5]NE\;M&_9Q\0?M$>$[KXC6_P!U+XFG0Y?$?A
MW4_$'AZRN-3@TS3V69KJ"[F8M'%"9#*K!U``E=>(Y&7(_:D_X)K?#W]JSP)X
M'T/5/$'Q"T'_`(5]H$WAW2;_`$S2K*>\ABE-B?M"M>Z?<+#=H=/@:.Y@6*6)
MB[(RMM*]1\4OV,?"OQ9\/>$=+U#Q-\3(;7PGX7O/"F407$^KVUPMI^^NYKBU
MEE>XCEL;:=71DW2(?,$B,T9UE9-N/1RMWVGRM=FWRWUZR]5G'6,4^J][LG=:
M>:Y5;;=)^0EM^TU^S[<?`X>)8?BG^SS)\-;;7#*-534=-.AQ:LLPO2WG"Y\@
M70F87&<^8';S.IW5YC<_";]C7]I3XE>*O"=G'^SK<?$'XD6=S#JW]B6EMI'B
MCQ/:7ENEU<2Q75K/%>W,$\$H=YX)&212X+G#@=!XB_X)\+KFM:+KO_"Y?BZW
MC;3?$*Z]-XPN/#^D2ZRXCTR[T^&WBC72TTZ)$CO)3O:RD=@[@MDHR;_PN_X)
M]_#'X4?#QO#-G_PF5Y8W7B1O%6H2W-N1/JE\^G?V?,TS16Z?+)'N<A`FUV.P
MH@6-<YQ3YE9-6M;NWRIWTVM>^FME'5.Y<9-).[3NW\U=QZ[WM9WW;=E;7R#X
M`?`K]A7X.?LL>)O`_A7Q!^SAK7P?T'7DU37--U[Q'#XIT;1M3D0QH\IU"_N$
MMI66%P%)3)1R!G<:]D_:7F^"_P`-/A/X?^&?CKPCX5\3>$KJ!#I/@;2?A=>>
M+84M;78%E32;"&Y,=M"S1*)3"L4;21KN#.@/!_LV?\$BOA)^RYJL-UX>NO$'
M^BZCIVHVZP^"/#^D21M92-)#')<:;HUK<7"$D!OM$LK':#N#%F/M7QS^!T/Q
M<\5Z;XBT/QU\2OAGXHTVUDTXZOX9T^VEDO+-W61K:6#4;&[MF42*KJXA$J$,
M%D57D5[E+F2<KN[U]%%*+WM?FTW?+%:7=DXBN634;*RT]7*\EM>UM=O>D]4E
M=GD/Q0C_`&.E^`/PVC^(#?LJZ7\-[B&:?P-8>+]#TG3].A4E3<"RMKQT6)U9
MU$J(BNC'#@-Q6]HEK^RS\4?CS)J&FWW[+OB+XG>($N/#LES;6.D7FO:DL=GL
MN+$NLIGD"V8"O"2<0\%=E8O[7?\`P2Z\`_MI^`_#7A_Q?XN^)DUKX=TV?3FF
MNM(TW79M1:;&^[?^UM,O$@NP2^R>T6!XQ*R(50(J]]\#/V./!/P!T;1[+2=1
M\=7BZ+X7N?"<4MW$RRR6L]T;IY6:&WCQ-YC$!DV@#^'/-2[OF;ZN7SNG9^=V
MDI7M=2OI:S:T45'LOE[T=$O+625]XK6\M,?]CC0/V:=;?48/V?9/V:;QO#M[
M'J%_'\/=-TJ0Z9=2130)/*+&7]U*T1GC#MABAD4$C<*]2\7_`+-7A7X@^"5\
M-:]X2^'>N>'$U`ZLNE:AX7AN;%;TRM.;D0NQ3SC*[R>9C=O=FSDDUX[^P_\`
M\$Z?`?[!_P`0?%7B;PYKGC+7-4\865M8ZB^H>&=(T_SQ!)-(LTATO2K-KBX9
MIY-\]P99'R,L3S7TI_PE-K_SRU+_`,%]Q_\`$5I*SY6M]/DUM^2:[?(762MI
MT\TUK^+:\][:V/-_B;^Q5\-OC7H=AI?C+X;_``E\7:;I5U<WUE::UX+M;^"S
MN+F0R7$T:2EE2260EW90"[$EB3S5[PA^RKX*^'WQ5U+QUH/@GX9Z'XXUJ#[+
MJ'B'3_"<%MJM_#\G[N6Y1A+(G[J+Y68C]VG]T8[K_A*;7_GEJ7_@ON/_`(BC
M_A*;7_GEJ7_@ON/_`(BLX^[K'^KZ/[RI:Z/^NOYZA]EU?_G^TW_P!?\`^.T?
M9=7_`.?[3?\`P!?_`..T?\)3:_\`/+4O_!?<?_$4?\)3:_\`/+4O_!?<?_$4
M`'V75_\`G^TW_P``7_\`CM'V75_^?[3?_`%__CM'_"4VO_/+4O\`P7W'_P`1
M1_PE-K_SRU+_`,%]Q_\`$4`'V75_^?[3?_`%_P#X[1]EU?\`Y_M-_P#`%_\`
MX[1_PE-K_P`\M2_\%]Q_\11_PE-K_P`\M2_\%]Q_\10`?9=7_P"?[3?_``!?
M_P".T?9=7_Y_M-_\`7_^.T?\)3:_\\M2_P#!?<?_`!%'_"4VO_/+4O\`P7W'
M_P`10`?9=7_Y_M-_\`7_`/CM'V75_P#G^TW_`,`7_P#CM'_"4VO_`#RU+_P7
MW'_Q%'_"4VO_`#RU+_P7W'_Q%`%"WM]4_P"$HO`+S3_,^RP9;[&^TC?-CCS?
MKSGG(Z8YO_9=7_Y_M-_\`7_^.U0M_$EN/%%Y)Y>H;6M8%`^PS[N'F[;,CKUZ
M'GT-7_\`A*;7_GEJ7_@ON/\`XBF`?9=7_P"?[3?_``!?_P".UY-^V1X0^$.L
M?"N*^_:"7X*77@C2+Q)H[CXAZ592:5973@QHP:^E\I)6#L@((8[B!UQ7K/\`
MPE-K_P`\M2_\%]Q_\17@?[?'[+%Q^V1X8\'QZ)XNUKP1K?@O6VUFSO%LM=2.
M4O:7%JZ.=+O]-O%^2X8@QW:#(PRNI*U%2]M%?5?FORW*A:^KZ/\`+]3>\'ZQ
M\*/V:_@[JGQ&TSQE\,?"OP_\430:U=^*)M02/1[P210VUM(MY)=>2(?*CMX8
M41Q&J+&D8`P*\E\8>/?V)?'/B_P9J&O^+/V-=8UYL7GA.YU#^P;B\/FWLKB6
MP=YR_P`][YS;H3\TWF')?=78?#KX5_&SP;^R7K'@*'XIZ;8>,[?-CX<\97OA
M35/$=Q:6I1`UQ<17=RKSW/F&8Q"::41((%FDO62269WP7_9/U'PAX/\``.A>
M,/$^G^(M+\&ZE>>(+RTTCP=J.F0^(=7EN3<0WUR;F\O)&:.:2>=E9V\RY:*8
M&/RE0[:.JG?W4XV?7EMT[-+36UG[NUVL=52M]IIIKI?S[J_:]UKT2E1^%OA+
M]F6#XZ>/'^&,?[-?_"XM-M]0/B;_`(133-*7Q1;EI,7?VLV\AN4+3$"0RC_6
M$;LFOI3[+J__`#_:;_X`O_\`':^8_AO^RGXJ^&W[1?C+XA:C\0FF\/ZU9:FD
M/A/0]#U_3-+\RYD243SP7>K7=@)EV,SS6EG:/++--([?O'4_3G_"4VO_`#RU
M+_P7W'_Q%1'^'!=;:KHGV7D:2M[236U]'U:TU?F'V75_^?[3?_`%_P#X[1]E
MU?\`Y_M-_P#`%_\`X[1_PE-K_P`\M2_\%]Q_\11_PE-K_P`\M2_\%]Q_\12`
M^6_!_P#P5G\%^(/V@?'WP\U;[1X1U+X=K*^H3ZO)I#27.VZ2UA$.G6VJ3:KF
MYDEB\@2649E\^`#Y[B!)/6/#7[3/_"5_LR77Q2M-/UQM+M;*\O#I']@LVLN;
M5Y8WA6W6X(\TO$P"EP.1N*\XX/4/^"9O[//B/XA:UX@\1?#I_&2ZU,UR=$\4
M07^N^'M.G>1Y)9[32[OS+.UE=Y'+/#$I_>28($DF[JO#_P"QA\%_!_P0O?AK
MH?@(>'_`.HVE_97.@:3:WVGV$J7KK)<.8H=@\[<BF.8?O80,1/&"09]YTK?:
MMOYZZ_E_D[CNO:7^S?;RTT_/KUW5M>"\&?\`!3>'XF_!WP[XJ\*^!/''BR^\
M5ZG=Z;I>@Z-;Z->7%ZMK"9I[J*^35SI4ULJ8'F17SYD)B`\U7C7VOX._$7_A
M=?A72?&&A7T+:3XHT.PU:S:YTR6"4P3B22,/$T@9'`;Y@>0>,#'/F:?\$\?@
MI'X.FT==$^("R7&LOX@EUH>*_$P\12WKVJV;R-J_VK^T"K6RK"8S<;#&H7;@
M`5ZQ\/=+\/\`PQLK7P_X?TJ;2=!T/2;+3=.L;;3IECLX(?-2.-4V9554*!].
M^#6WN^]_V[;[O>_&UO*[TV6:OI?S_/3\-]OGN;VI2ZII>G7%U)>:>T=O&TK!
M;%]Q"@DX_?>U>)_"']OWPQ\9;#P7-8WDVFR>,+"[OY+?4M-2WF\/"VM;>[DC
MOU^U'R6-O=02H5+H\<BR*YC=';VZ\UZQO[26":'4FBF0QNOV"X&5(P1]RO.;
M']F;X6Z=XJ\+ZW%X1N/[2\'^'6\):9*]O?.J:6R*GV65&RMPH5<*9P[)OEVD
M>9)NQES\L[;V7+ZZWOY/W5][Z6>JY;J_S]--OQ_!=;KD_`W_``4@^&?C[Q5;
MZ+#XONM&U"^LYM1LE\1^!=;\/QZC:PQ/-)<6TM_%#'<0B*-W\R)F4JI()%;G
MQ?\`VK[GX:^%/!]_HOAKQ5\0M2\>`RZ-HFA:)%:ZC-"MN;F2:4:E>6D5NJ1@
M96:1)-SJ@0L=HY_2O^">OP0TW2+BQF\,^,-:MYFM1&-=U[Q#K+645NY>.VMF
MNYY6MK4Y*O;0%(98R8Y$=#MKO/C]\#?`O[3.CZ;9^+-/\5,VBW+7>GWNCWVK
MZ%J-E(\3POY5Y8O#<(KQNZ.BR!74X8$8IU$^1^S^+IV_7?MI:V^ONS'XO>V_
M'^E^JTTU\S\`_P#!0;4/B5\3/`>A:7\-?'S:5\2+)=5T/Q!+#H<=I-8?9XYW
MO9+0ZS_:44$?FQ1NSV8*RRQ)C=)&&^BOLNK_`//]IO\`X`O_`/':Y/X;_#/P
M1\()HW\,^'[C1A;Z-8>'H8[>QNA%;Z?9>;]EMXT*E42/SY<;0"=W).!CK/\`
MA*;7_GEJ7_@ON/\`XBM:G)>T-KO5[VOI?IM;YWZ6)C?=^7_!_'\+%#1[?5#J
M.J[;S3U872[R;-SN/D1=/WO'&!CGD$]\#AOVB_V@-<^`,7AF&Q\)^(/B%K/B
M[4WTO3])\.6MA%<LZ6L]T\C/J&HVD"HL5O)_RUW$X`4YX[G1_$EO'J.JL8]0
M_>72L,6,YQ^XB'/R<=.AYQ@]"*Y+X]_!3P7^TII6D6OBB'QM%_8-\=1T^ZT'
M5];\.WMI.89("RW.GRP38,4TBE=^TAN0>*SE?IY?UU_KMN7&W7^OZ_J^QX3\
M8/\`@M5\$?V8O"^@WGQ?\<+\)]8UV_N]+_X1_7/#MU=:I8W5JR+/',MA)<Q*
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M7,EM:7EMX9N6TJT*6US<9GO6D6!6*VKJ(4=YLLK>6(]TBU_`_P"U-I/Q)^/&
MK?#_`$+41J6H:+9SW-UJ4.DO_97FP7"6]Q:QW'GXEGAD=5D6,,L;AHV82(Z+
MV7B?2_#_`(RU70;[4M/U*YNO#-^=4TU_LEVGV:Y-O-;%\*H#?NKB9<-E?GSC
M(!'GWP^_8T^!/PE^-<OQ&\*?"+P?X7\=7$%Q!-K>D>$18W<ZW#B29G:*%=[N
MPRTC9<@L-V&(*A\<>;;WK_<^7[G:_IIO8JI;E?L][1W[\WO??&UO/?N>FZ]!
MJ*6D!N+JRDA^V6VY8[5D8_OX^A,AQ^5;U8.O:_!>VD$:1WJLUY;8,EG-&O\`
MKXSRS*`/Q-;U`'R;X\_9!U[XC_MO_"WQA#JWQ0M_A]#X4O9?$4&E_$O6=*TL
MZK$^F_V9G3[>^CC93&M[N5(3%)SYP8E<\;\5-(_;"\0?M:^(K#0[[Q%IG@6^
MU[[/IEY;-X;7PM:>'&TL*\A,BMK8UM;TR&,A6L\B/<#'N%?0?B#Q!?Z?KU];
MV]]>0P0W$D<<<<S*D:AB`H`.``.,"JG_``E>J?\`02U#_P`"'_QK.5-."I]$
MI+UYI<S;\ULGTCH:*HT^;KIKZ*R_S]3X!U;X6_\`!0;X2_L)?`?P7\*6\=>'
M_&'A/PI=IXFEOD\%ZY-?ZM$\:V]C<M<W,:1V3J',5W;O/<!3BXB:0[U^^OV1
M_#'Q+T?XF_&74OB`NJ0Z9X@\1V-[X8M[G4TNX;6S&BZ?'.D$:RR"W07J7>4^
M7+;G`(<,TG_"5ZI_T$M0_P#`A_\`&C_A*]4_Z"6H?^!#_P"-=/MFY3DTKRO\
MKR4M.VR26R5^K;>/*M$ME_E;7\7??7LDE[917B?_``E>J?\`02U#_P`"'_QH
M_P"$KU3_`*"6H?\`@0_^-9%'ME%>)_\`"5ZI_P!!+4/_``(?_&C_`(2O5/\`
MH):A_P"!#_XT`>V45XG_`,)7JG_02U#_`,"'_P`:/^$KU3_H):A_X$/_`(T`
M>V45XG_PE>J?]!+4/_`A_P#&C_A*]4_Z"6H?^!#_`.-`'ME%>)_\)7JG_02U
M#_P(?_&C_A*]4_Z"6H?^!#_XT`>V45XG_P`)7JG_`$$M0_\``A_\:/\`A*]4
M_P"@EJ'_`($/_C0![917B?\`PE>J?]!+4/\`P(?_`!H_X2O5/^@EJ'_@0_\`
MC0![917B?_"5ZI_T$M0_\"'_`,:/^$KU3_H):A_X$/\`XT`>V45XG_PE>J?]
M!+4/_`A_\:/^$KU3_H):A_X$/_C0![917B?_``E>J?\`02U#_P`"'_QH_P"$
MKU3_`*"6H?\`@0_^-`'K5K_R-U]_UYV__H<]:5>(CQ+J2S-(-0OO,8!2WGMN
M(&<#.>V3^9IW_"5ZI_T$M0_\"'_QH`XO1/\`@GI8Z)^U3\:/&%SI/AOQ5X0^
M*W@_3M'N-'\2WMSK!U*^@N]2GF6[6Z69?L96[@CCC5F6-(RBQ(B(I^=_$?\`
MP14OOAQ^Q;X4\$^`?AG^SUXD\;ZEXB/BOQTWB::YT[PW)J$UN\,SV.G6]C-9
MRB%)7CLTN[5H+;8DI@ED+Y^O/^$KU3_H):A_X$/_`(T?\)7JG_02U#_P(?\`
MQJ'33AR=+)?)2<K>E]UY+L6ZC<^=[_JX*%_7E5O.[O>YX/\`$+]B3XF?&_\`
MX)>:K^SPN@Z5X#E\+#0=$TB:\\7KK]OXJTVQ_L^ZG#W<FG?N5D9)[3,^GR*1
M$6-J8G$1^?\`P/\`\$/?C5X<^,GPU\475Y\!Y(?!WV2"TL%T'1C9>%H(M<N;
M^4Q6R^'$BO+F6&=%-S8C0Y`\2EBY`DK[X_X2O5/^@EJ'_@0_^-'_``E>J?\`
M02U#_P`"'_QK=5&JWM_M74O5I6;^?5*RWLDFT\I1O1]A]FUOQNONM\]+WLK?
M.O[-O_!-'QM\`?VL-8^(FJ_\*_M[&WL?%XU#Q'I-Y<R>(_B)_:VHQWEF-6B:
MVC1!81(8H_\`2+H=-@A7Y%^]J\1F\2ZE<0M')J%])'("K*T[%6!Z@C-._P"$
MKU3_`*"6H?\`@0_^-9QTIQIK:*LOO;_-O;0J6LY3>\G=^K_KJ>V45XG_`,)7
MJG_02U#_`,"'_P`:/^$KU3_H):A_X$/_`(T`>V45XG_PE>J?]!+4/_`A_P#&
MC_A*]4_Z"6H?^!#_`.-`'ME9MK_R-U]_UYV__H<]>2_\)7JG_02U#_P(?_&F
MCQ+J2S-(-0OO,8!2WGMN(&<#.>V3^9H`]NHKQ/\`X2O5/^@EJ'_@0_\`C1_P
ME>J?]!+4/_`A_P#&@#VRBO$_^$KU3_H):A_X$/\`XT?\)7JG_02U#_P(?_&@
M#VRBO$_^$KU3_H):A_X$/_C1_P`)7JG_`$$M0_\``A_\:`/6M$_Y">L?]?B_
M^D\-:5>(IXEU*)G9=0OE:0[G(G8;C@#)YYX`'T`IW_"5ZI_T$M0_\"'_`,:`
M/;**\3_X2O5/^@EJ'_@0_P#C1_PE>J?]!+4/_`A_\:`/;**\3_X2O5/^@EJ'
M_@0_^-'_``E>J?\`02U#_P`"'_QH`]:\4_\`(,B_Z_+7_P!*(ZTJ\>\/^(+^
M_P#$.GQ3WUY-$UW%E))F93AU(X)]:]AH`^</B'\<O`GA?XTZ3X.U'5O$\WC#
MQ1:0:RFF:)X,U;7186US.T44UU/9P2Q6L)E611+<-$G[MSD!6(\J\$_\%._V
M7O&=YY$GQX\%Z"6O]6T^.;6KF*QM7?3;J*VN";AY/)CW//"T22NDDL<JNB,I
M)'2?'3_@F#\'?VI_CSX.^*WB;6[VQ\5>'K'2(&2V_LIS(-/N6N[<)<7-K+>V
M#"61P[Z?<6KR*0'9MJXRK/\`X)!_!Z"\\3M-\0?&MY;>)-*\8Z-%:S:EI?EZ
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M8;5W`E2&-;P;\<?@K\1OBM)X#\/?'3X7:]XXAFGMI/#NG>(K"ZU9)8-WGQFU
M2<RAH]C[U*Y7:V<8-9GC[_@G3\)?B'^S5J7PSNO%&OV=K<>,;OQ[INOV.L6U
MOKGAS6;C49=0^U6-P(]L+1RSR(A*,?*8HQ?<Q/E7[/G_``0K_9]_9B^/OA+X
M@>$_%7B2WOO!.IG5M+M+JYT:YV3/9R6LR/>O9'49(9?-EF>%KLQ">5Y%5":S
MIZR2GHM-=]TOR=].JM9W;M5;1-T]=7;T3E;[UR^CYM-%?L?AW^WE^SI\1/!4
M_B`?'7X=Z#I<?B*_\+12Z[K5CIIN[ZSE\N5(EEN`6W921.C-'+&^-KJ3ZE\?
M]6\)_LP?#"X\8^-/$=Y8:#;W-K9F2RT.[U2XEGN9X[>WBCM[599Y7DFEC15C
M1B2PKYS^*/\`P0<_9_\`C'!)!X@\8^)-3LVU77-0C@O1X?OEM(-8O!>WEG`U
MQITCP)]HWNEQ$RWD?FNJW(7:%^FOVD/V:/AC^U)^S];_``O\2S6"^"[>[TNX
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M'=A=I\J_9^_X(M_`K]G[P'\4/#EOXM\0:]IWQ>\*Q>$/$7VR31;"2YM8OM`6
M<MIUC:^9>'[3)ON9O,DD(4R%R,DT][TT];+IZW6ZT:UT=S3W/E?R]YWM_P!N
MV?JFM;Z>GGX_?`\?"+_A8'_"^?A3_P`($;_^R_\`A)?^$DL/[(^UXW?9_M7V
MCR?.QSLW;L<XJ/Q'^T1\"O!WB#3=)U?X_?"72M5UJPBU33[.\\3:?!<7UI*A
MDBN(HVN`TD+H"RNH*LH)!(KS?XI?\$;_`(/_`!R\-7D?C;XA>)O&'B;4/$$7
MB*X\2ZU!X:OKF6:/3AIJ1M8R:8=*9%M@JAFLC*&56\S<JD:N@_\`!(?X$^$=
M$_LO1=>U[1]+2#P=;Q6EMJMIY<*^&;R2\L2-T+-F6:5_/))W@_)Y9YJHQ3=G
MIK'S]UKWGTUB]EU6GF9W?)?KRMV_O7T5^S77\%L>@ZC\8O@YH_P8L?B1>?&W
MX9VOP\U2X-I9^*)M?L8]%NY@SH8X[PS^2[AHY%VJY.8V'53BOKGQX^"/ACQ;
MX?T#4OCM\*]/U[Q9;VMWH>FW/B.PAN]9ANCMMI;:)K@/,DQXC:,,'/W2:X7X
MN?\`!(SX(?&7X00^#]5\1:A);VGC;6/'EK>72Z+JSV][JDEP]U%]FO[*XLI(
M?](<();=Y(]J,L@<;C=T;_@E#\#/"_@N[\/:/K6K:1I-UHGA/0%@MM3M/]'M
M_#NHR:C9E&:%COEGD;SRQ(<8VB-OFHIV>L]-8Z;Z./O:]XRT3LKK6R*GH[1U
MW_\`2K)V\X>\UWTN=3\)_C7\-OC9\2OBEX3\.^-[.^UOX-WR:?XGMTB1I+.1
MK=9RP19#(R+EHRVT#S(I4&2C8Q?V>?VK/A'^U'XAT32_"/B[Q)]K\4:4^N:"
M=<\#:SX>A\0V2")GGL9=0MX([Q56:)SY#.0DBL<*<UZ%\-?V:O!OPL^)OQ>\
M2:?XTU::/XT7D6I:QI5Q>6+65A=)916336I6$3J7A@BW+++(@*955RV?-_@+
M_P`$T_A[\&&\$PZQ\5/'7Q*TOX:>&+GPEX2TWQ+?:/#;^'[&XMXK6;RSIUE:
M2RR-;PI%YEP\K*I8KAF+&(WY==^6/DN?EES*^MES\JCH_=;N[CG;F]W;F?F^
M6\>5]+NW-S:K5*R:WL>(?VO_`-GOPW\/M8\5R?'KX;WWAOPWJ=EH^LZEIFJV
M^I6^B75Y<"WMTNVMY9!;*TIP7FV(@5F9E568)HO[6/P3\6?&OX?^`M!^+7A/
MQ)K7Q.TS4-6\.S:1?6U[9:C#92K%,(YXYBLCE_-54CW,?LUQP!$V/,/A]_P0
M>_9]^%7PXUS0?#OBW7]#O]8N-"GAU[38_#UCJ.FKH]ZM[9(@ATU+><^>JM)-
M=PSSS;5$DK[5QZ=\%/\`@F]\.O@7\:_#7Q$TWXE^,[_QAHMUK]WJM_?7^E-_
MPEDFLRV\MV;V*.S2.,*UI;>6+-;;:(1G=N?=K347)<][7=_3E7+WWE?F?V59
M)2OS**C=GR;Z6^]W[=+<NUV[OEV-/XV?'KX;_`'X@+X3UOQ%XHU/Q,NGC5;C
M2O"_@;6/%%WI]HS%$GN8],M[AK:-V5PC3!!(8Y-N[8V/(/C=_P`%?_V0_P!G
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M'V@2M8R2K<(OD_O#NC!502<`&N;T+]K/X`^*[E%T?X[?#O6K-M/U'59=3TW4
MX+S2K2VT_P"S&\>>^BD:V@\H7ELS++(K;9@P!`)&'K?_``21^`GB']LN^^-]
MU>B3Q1?:A+K)MC'I!CBOY+'[$;E;LVG]HD"/++;M=M;+(=XA#`$3^)?^"5GP
M=\5?`/PG\.KCQAXH70_!WPUU+X6V4T>K6(NI=,ODLTFFD8P%#<@646UE14&Y
M\QMD;;IV:O+1VVWL[2Z];24%LKIN7NOW4HVYU%O3J_G'IKNFWOHU;56D^PT'
MXX_!7Q3\)=8\?:7\=/A=J7@7P[.MKJOB.U\16$VDZ9,Q0+'/=+.8HG)EC`5V
M!)D3^\,]?\+M,\)_'#PE'K_@KQYX=\8:#-*\":EHES#J%H\B-M=!+#*R%E8$
M$9R#P:\E_:2_X)W>'/BOX(^(:^"?BE=?#WQMXV\3:!XOLM>>"RU:#P_J6CPV
MD%J\5FX1)(S'9INCE=@6=B"!A1W'_!/;]G7_`(8J_9W/A'Q%\3;#XD>)M1UW
M5/$>L^(CI]MHRZE>7]Y+=2NMI"[QPC,F-JL1D$@*"%!"SYN;2R5O-VC^KGO:
MUHVOS/EAW48-;O?RW_+W;-7O=Z1LN;O(O@]YFKSVO]HX\F&.7=]GZ[RXQC=V
MV?K5C_A1W_44_P#);_[*MVW\5Z6OBB\D.I:?Y;6L"AOM";20\V1G/;(_,5?_
M`.$QTC_H*:;_`.!*?XU)1R?_``H[_J*?^2W_`-E1_P`*._ZBG_DM_P#95UG_
M``F.D?\`04TW_P`"4_QH_P"$QTC_`*"FF_\`@2G^-`')_P#"CO\`J*?^2W_V
M5'_"CO\`J*?^2W_V5=9_PF.D?]!33?\`P)3_`!H_X3'2/^@IIO\`X$I_C0!Q
M>L?![^R=(NKK^T?,^RPO+M^SXW;03C.[VJQ_PH[_`*BG_DM_]E6[XJ\5Z7<>
M%]2CCU+3Y))+6555;A"S$H<`#-7_`/A,=(_Z"FF_^!*?XT`<G_PH[_J*?^2W
M_P!E1_PH[_J*?^2W_P!E76?\)CI'_04TW_P)3_&C_A,=(_Z"FF_^!*?XT`<G
M_P`*._ZBG_DM_P#94?\`"CO^HI_Y+?\`V5=9_P`)CI'_`$%--_\``E/\:/\`
MA,=(_P"@IIO_`($I_C0!R?\`PH[_`*BG_DM_]E5>+X/>9J\]K_:./)ACEW?9
M^N\N,8W=MGZUVG_"8Z1_T%--_P#`E/\`&J%OXKTM?%%Y(=2T_P`MK6!0WVA-
MI(>;(SGMD?F*`,+_`(4=_P!13_R6_P#LJ/\`A1W_`%%/_);_`.RKK/\`A,=(
M_P"@IIO_`($I_C1_PF.D?]!33?\`P)3_`!H`Y/\`X4=_U%/_`"6_^RH_X4=_
MU%/_`"6_^RKK/^$QTC_H*:;_`.!*?XT?\)CI'_04TW_P)3_&@#D_^%'?]13_
M`,EO_LJ/^%'?]13_`,EO_LJZS_A,=(_Z"FF_^!*?XT?\)CI'_04TW_P)3_&@
M#B['X/?;+F\C_M';]DF$6?L^=^8T?/WN/OX_"K'_``H[_J*?^2W_`-E6[H_B
MO2XM1U5FU+3U62Z5D)N$&X>1$,CGGD$?4&K_`/PF.D?]!33?_`E/\:`.3_X4
M=_U%/_);_P"RH_X4=_U%/_);_P"RKK/^$QTC_H*:;_X$I_C1_P`)CI'_`$%-
M-_\``E/\:`.3_P"%'?\`44_\EO\`[*C_`(4=_P!13_R6_P#LJZS_`(3'2/\`
MH*:;_P"!*?XT?\)CI'_04TW_`,"4_P`:`.2'PL_X1F[L[[[=YWDW<`V>3MSN
ME1>NX^N:[^L'7O$NG:A:00V^H64TS7EMM2.=69L3QG@`UO4`?%O[7W_!2K6/
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MO2-N]E:-NS=FVRG**?,UI;\N5W]-?>\I)76A\]?#O_@K3X@_:`^#/P[\7?#3
MX<^%?$<7C3PMKWBR\?4O&-UI=C:6ND7L%G-]FD_LN2>X,K3;XO.M[8E%_>")
MCM'IG[6W[<K?";]FKPCXD\(6-Y=^+/B8UDGANP;PWJ/B*:VBF1)[B\GT[3`]
MW/%:VQ>1UA(!?RT,B>8''?>$_CM\//'.N6^FZ7XAU*ZO;N#5KF*/S+]-\>EW
MBV-\<M@#RKEU3!.7SN3<N6JCH/[4_P`&_$6N>"])A^)OAV#7OB)I<&M>&=%O
M?$QLM6UNSG1GBF@LII4N'5E5SQ'D;&!`*D"I)35H=6K>G-/W=+7NERIJSO"3
MW?NQ&\6G+[*=_6T==;VLW=K9\R6G7Y8\7_\`!:N]\*^'?A3JEYI_PL\'2>+/
M#VLW/B73/B7XKN/`LND:MIMQ8PRV4#W-I),TK?:)7CMY;5'EC,<A>(?*_5?%
M7_@K[=?"OX+_`!)^)FL>"?#?A'X=^`9=,T]=1\7>(]1L[VXO[ZUTNZC@GL[#
M2;^6W58]19&<>:PFA"[-CF6/VS7?VV_V>_"^H:_::G\<_AGIUUX4<1ZW#=?$
M&VADT=S*(0MRK7(,),I"8?'S$+UXK=^._P`>/`G[.'AK0M5\37WBZ:W\3:@N
ME:3#H.G:QXAO-1N6MYKD)%;:?'/,X\FWFD+!-H6,DD<4N:\.;OL^EW*_Y/EB
MKZ:-WM8I1]]*VR;:ZV2W?HM9/JK_``[KYQ\&?\%>M:^-'P)\`^./A[\.?#?B
M*R\5>$O$'C+49+[Q?=:;:6=EHUY#:W'V1SICS7+2M+OA$T%J2J_O!"QVC4^)
MW_!5S4O@C\"/B-XN\8>"?!_A^^\$VVB:M:0W7CQ8=-NM,U5Y!!-<74MFDD5S
M''!.\EI:V]Y(Q1$M_M,CA1[1I'[6?P9U73_`\TGQ*T31YOB6/^*6L-:\02:1
MJ6N.'$;10V=U)'<-,LC*C1>7YB.=K*&XKK9O'_@6VL6NI/&&EQVRZA/I+3-X
MD(C%[`LC36V[S<>=&L4I>/[RB-R0-IP5-%+ETUTOTM)W3VO9.,.EM6]9+EFG
M>\>;7O;K=:/K;:4NMU;9)WL_L_\`Q<LOC]\"O!OCK39+&;3_`!CHMGK5L]G)
M/);O'<0I*IC:>&"9DPXP9(8G(QNC0Y4==7C4'[7_`,";KP%H_BJ+XS_#V3PO
MX@U/^Q=+UA?'D#6&I7_/^B03_:/+EGX/[M&+\=*]3_X1:U_YZZE_X,+C_P"+
MK2I9R;BK*^BWMU2OUT:_/J13ORI2=W;?OTO]Z?Y&E16;_P`(M:_\]=2_\&%Q
M_P#%T?\`"+6O_/74O_!A<?\`Q=9FAI45F_\`"+6O_/74O_!A<?\`Q='_``BU
MK_SUU+_P87'_`,70!I45F_\`"+6O_/74O_!A<?\`Q='_``BUK_SUU+_P87'_
M`,70!I45F_\`"+6O_/74O_!A<?\`Q='_``BUK_SUU+_P87'_`,70!I45F_\`
M"+6O_/74O_!A<?\`Q='_``BUK_SUU+_P87'_`,70!I45F_\`"+6O_/74O_!A
M<?\`Q='_``BUK_SUU+_P87'_`,70!I45F_\`"+6O_/74O_!A<?\`Q='_``BU
MK_SUU+_P87'_`,70`6O_`"-U]_UYV_\`Z'/6E7/6_ANW/BB\C\S4-JVL#`_;
MI]W+S=]^3TZ=!SZFK_\`PBUK_P`]=2_\&%Q_\70!Q_[67QEOOV=OV8_'_CS3
M-'?Q!J'@_0+S5[;3E8+]KDAA9U0DD!5)'))``R<CK7POX/\`^"R>H:G^R!XE
M\=>)/C'\%_!&H>'_`!';:3#JVH>$K/4M'UDSP9CT^T&E^+[RWEO`Y#R.=03[
M/$0\T$41$]?HQ_PBUK_SUU+_`,&%Q_\`%UPOQ[^,W@W]FK0=*U#Q1-XT>/7-
M0&E:?;:'I>M>(+Z[N3#-/L2UT^.><@103.6V;5"')'&<Y1TEK;F22\M;W7F]
MOS36CN-VXV6UV_-6Z^2W_P`MUY#X[_;MN+/_`()S-\2M)^(7P'M_'&EZ5I$N
MM7LFO6E[X8LKZX2UFGMXY&U"VB9I(IF^RK-?0I(TMN6F",7KYO\``'_!9OQE
M\2=`M;FS\=?!?2]<LX[7['X6U;P^JZQ\4Y9+^XMY%T'[)XAN8-G[GR4EMY=2
MC:4%BRX:%/N'7?%_PW^`7PDD\:36NN>']%\0W46H/;V6D:I_:NIWMX5VYTZ&
M,WLMY(2NZ/R3-E3N4;3CSK2_^"FOP'UF\:WM]>^(S26MVEAJ@;P;XJ0>&YWE
M\I(]5+6@&ELQ(8"]\G,;+)_JV#GH4KUGIK=/E71V5XKRN]FNUU<PE_!23TL_
M>[^?X7T>FNMKGGGP,_X*!^*/CA\=G\+R>,OA#X@M]1'B&UUGP1H.GRKXJ^':
MV1F2&75)SJ,H*NT:Q$-96Q,ES%C@$'[AKP31_P!KWX8?$OQEJ7@W0]4\8S:T
MUMJ`L[B[T+7;71]5:T!6=;349X5L;PH0<K!-)D*Y`(5B/:?^$6M?^>NI?^#"
MX_\`BZSC_#CZ;]_/_AV_4O7GEZ[=MM/Z2]#2HK-_X1:U_P">NI?^#"X_^+H_
MX1:U_P">NI?^#"X_^+H&?`<'_!7'6_"G[3WQ)\-W&J:3\3I=&^U6>C>&?ASH
M2^*5M6CO8XH9KR;2;V_U6U:))F%ZUWI4$>Z();*TD>+ST3X6_P#!3>X\4_\`
M!/35/B)J5QH,?Q'TVUUV5=.OM#O_``Y%=QZ9?-;2Z@FGWSB[^R0QM!+.1(5C
M)>-I8V!V^H>`OVD_A7JGC7QTFF6_BK2=/T1KN]U[Q9=:3J6G>'[RYL66SO`=
M2D5(9I;<10QERY5U3;$\GV>=8>F\-?M`?#OQ7^SY)\4K77=9C\$0P7$\E[=I
MJ5G/$+>5X94:UF5;E95EC>/RC'YC.`H4D@&=J"4OY5[WR=G?M>^NC:6^FCE?
MV]UW>GW:+TTZ:-ZK4^1#_P`%2O%%I&UG+\</V8IO"]QKL6G0?&./1Y4\#PN;
M":Y?37C.N%'O@T2_,-04!9E_=%@:^L_V,OBWK7QV^"^@^+/$$>FKJVL:5$\L
MVG0/!8Z@JW-U''>6R/)(ZV]Q&B3QAI'(CF3YFZGCX/\`@H%\'I]$N+H7GQ46
M\M[]--;0Y/`_BM/$+2M"9PR:2UF+]X?*5F\Y8#$-IRX((KTKX0>,/#7QOT*U
M\4>&M0U2^T'6=.M[FTFEDO+28@R3JRR13;)HW5E*M'(JLC!@55LBM?YOE\M/
MUWZ7W=WJ9:W6O?YZ_IMU^2T.WUZXO+30KV;3;6&^U"*!WM;::<V\=Q*%)1&D
M"L45FP"P5L`YP<8KY:T7XE_'NTU.X\>2?"7XC0Z??^*81=^`CK?AZZU9=.71
M#"SP2/J/V)(?[1"286ZCE959C'\Q0_3W_"+6O_/74O\`P87'_P`77FO@W]IG
MX4^/=5\>6>G^-%63X9RM%XEDO+^[LH-,"M+&\IEF*1R0K);W,331LT:RVT\9
M8/%(JPEJ_E\K/5_.Z3O?I:SU->B=M+V]6]E^#:[^:T/'M$\$?M0>)7T/Q'J7
MC#Q-X=N](T;PV]QX5M8/#<NGZU?/?3?VREW*UM).`EKY./LT\"D@["S$BG_\
M%(_A7\6OB#XLTN3P#I_Q,U6!?#U[:Z+)X1\<Q^&H/#WB%Y83:ZCJD;7-O]ML
MD4',16\4!9`;23S`:]Q^*'QQ^%OP1T?4-0\:?$;PSX0T_29+>&^N=;\6KI\-
MD\X8P+*\LRA&D"L4#$%PIQG!K(\=?M/_``O\"?#KP[XK_P"$CUGQ-H?C!@-"
ME\(1:IXJFUI=C2&2V@TQ;B6:((I9I$0HHP2PR,KFBI*:VB_E=IJSOKUO'6Z=
MFK-#C)^K:7S2:Z;6TM+2S3:E=-GSS^R!\$/V@?!G[>_B#5O$5UXZ7X;R/JLE
MW>>)-4>:'6-\V;1+6V'B+4K>,`MO#PZ;I.U(@OEXD,2?<U?./_#P[X(O=Z%'
M%X@\<W46OPV4R7=MX:\27%EI@O)VM[==0N4MC#ILC2JRF.]>%TQEU4<U[Y_P
MBUK_`,]=2_\`!A<?_%U>JA&'2.GW/7YJYG%+F<NLK/[TK/YV^8:)_P`A/6/^
MOQ?_`$GAJ?7KB\M-"O9M-M8;[4(H'>UMIIS;QW$H4E$:0*Q16;`+!6P#G!QB
MLG1_#=O)J.JJ9-0_=W2J,7TXS^XB//S\]>IYQ@=`*YSX\?%3P;^S3\/)/%'B
M_4/$-II*7=MIZ"PBU/5;NXN;F9(((8;6T66>:1Y9$4+'&QR>F,FLZFJM>U]+
M^;T5KZ7OMYFD;WO:_7[MSYKU#XI_M00>)?&7BG3/@_\`$>WLO%FF7ECH_AB;
M7O#%Q<>&]46RT]+6^D>343`MF9EO3M@DDD;.Z2VR5KW[]FCPWX\T7QG\4[KQ
MK)J#6FL>(+*Z\/B>^2XCCM!H6EQ3B%%=A`GVZ.])CPF7+N%(<,SM1_:/^%WA
MGX?>&_$_B;QA_P`('I/BZZ6PT@>-+Z[\+75[<L6"VXMM1,$ZS-L8B)HP[`9`
M((-6'_:"^$L7QJC^&K?$[PFOQ&FSY?A4^,$&M28B,QQ9^?YQQ$#)PGW06Z<U
MK'W7**6K376ZU4GYW7X1LMDK1S72ETM?Y.R3_P#)=.GQ=6V?)O[6'[,?[24'
MA[7K'PGXL^)GC72KCQQ_:+D:Q#!K&HV#:-9QQB'[%J^@+;VT-XER&AAO+4LV
MV1HY]TGF?8W[+FC^)/#W[.O@NP\86\EKXFLM)@@U"*2^EO94D5`/WDTT]S(\
MF`-V^YN6#9!N+C'G/2\6_%_P;X%^,WA?P#JEUXLMO$7C)93I!%CJ\FG73112
MS/$;]4-I',(X)7$4DRR%4)"D8SG_``Z_:%\"?%CXGZKX3\/S>/-0OM&>XBN-
M0_L+7HM#:2"3RIHXM5>%;":1),HR13NP9)%QE'"S3TBX1^U9_P#@"Y=/2VOG
MV'4UDI2Z:?\`@3O^/0]'\4_\@R+_`*_+7_THCK2K!U[0(+*T@E22]9EO+;`D
MO)I%_P!?&.59B#^(K>I`>'>,?V4]-^,GCOX>^-+]+B&\\(VT:FUM]16.SU^$
M;)8(KZ-K9S(L%PJW$6QT*2`_,RNZMB?#W_@GQX?^&_PN;PI9R:M<V?\`PDVF
M>)5NKK5XWNHSIMQ;RV%BK"T"BS@CM8($3;O\I3ES(S2%MAX.\6>(_P!J;3_%
MLU]X#\/^&?#?@.]\.:+>QZW)>ZK=7EZ^G3-+<63VT44"0O9N`%N9C("I(CY`
M\)TO]EG]H34_`_C'P_\`\+$\#^%?^$VT8:)J^HWWQ+U[QQ]MGFF3[5JT%K=0
MV8TQQ`+B-+*PEBAS>AA)']DB#JC>*CR*SUDET4N=M/R;<8R;M=.2T:YY1)6<
MKR\DWUY;*_K92>B_E:NGR)_2OP\_8XTWX:^*;+5[%KZ:YL;7Q#:1K/JBM&4U
MK4TU*Z)"VH.4FC58\$;4)#!S\U>3^(?^"1UGX@^)'PIUH?%3XW6&A_".RT2S
MT_P=9^.5B\+ZL=)D62VGOK'["4FF9D0NZE,^6FT(5!K!^%'["GC3PC\//"OP
MWU[XL>'_`/A7?ASQC=:T(_`6L:MX%E71Y[&[V:/#';7LT\4%O?S0R1*M]M\E
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M=J6D_!GXL:OX%UZVUKQ)H7C;5!:Z#XA=='OK*4[EL+L9%Q=I,@:UQ^[_`(#C
M'@OQ2_8B_:)T7P-X9T_X1^,/@OX(T-=?NM8O?`=EXVU[0=&\)1.END4&E7VF
M1PO.J^5/+Y-S:+9"6[D9K.;"X4J:4YP>UU=K9\OPOH^LK.UNDG&^ASNT*D=W
M&3:>ZY[J2?36T7+6[3]U-H]HTW_@DAIN@>!_^$7TOQ]\0M+\,ZEI<&C>(]*M
M;_2%M_$]G#-/*D$N=(+V4*K<RQ)%IC6<4,1"Q)&54CHOBG_P3@M?C1\9/'WB
M'7M29=!\::(MC;:+8W!B&C:F\#6MUK*R212)+=26J6D"AXO+5()`RRB>0&[H
M_P`(?'$/QGN/MWQ.M;KX;QR3:];6TOB":759]3GM#;26,YV+&=,CD:6Z1%./
M-E1!%%%`BMYGX=_8A\;:%X+\/K#\5Y--USP-X"\+Z#X9MM+\>:K8Z):ZM8-,
M-0N+BRA*6]W#,AMT47,,P818:-.=UZR;E-Z_B^;F4K;;-*RT6L9*VAG[JC>*
M^7HXM=][WD]])1=]GN_'K_@E+J/[2-MX;N/$OQS^.D?B+PY]I@.O:3XBTK2;
MK5[&=HG?3KV"VT>.SN+/=$&,3V_[S)$ID4(J_5FC6FI:%I%K8V^GZ6L%G"D$
M:K=&-0JJ%`"I`%7@=%``[`#BODE/@_\`'Q?^"F__``G=Q\1/`%]\$>5@M(?&
M.L6.L6D/D8%JVE8ET:XB$VXF9HTO&W;A<HJ+#7U]_P`)CI'_`$%--_\``E/\
M:FF_W2:TOK;L_P"F[]')R>M^9U)?O'?6W7NOZ2M?5*RTV1]JU?\`Y\=-_P#`
MY_\`XU1]JU?_`)\=-_\``Y__`(U1_P`)CI'_`$%--_\``E/\:/\`A,=(_P"@
MIIO_`($I_C2*#[5J_P#SXZ;_`.!S_P#QJC[5J_\`SXZ;_P"!S_\`QJC_`(3'
M2/\`H*:;_P"!*?XT?\)CI'_04TW_`,"4_P`:`#[5J_\`SXZ;_P"!S_\`QJC[
M5J__`#XZ;_X'/_\`&J/^$QTC_H*:;_X$I_C1_P`)CI'_`$%--_\``E/\:`#[
M5J__`#XZ;_X'/_\`&J/M6K_\^.F_^!S_`/QJC_A,=(_Z"FF_^!*?XT?\)CI'
M_04TW_P)3_&@`^U:O_SXZ;_X'/\`_&J/M6K_`//CIO\`X'/_`/&J/^$QTC_H
M*:;_`.!*?XT?\)CI'_04TW_P)3_&@`^U:O\`\^.F_P#@<_\`\:H^U:O_`,^.
MF_\`@<__`,:H_P"$QTC_`*"FF_\`@2G^-'_"8Z1_T%--_P#`E/\`&@`^U:O_
M`,^.F_\`@<__`,:H^U:O_P`^.F_^!S__`!JC_A,=(_Z"FF_^!*?XT?\`"8Z1
M_P!!33?_``)3_&@"A;W.J?\`"47A%GI_F?98,C[8^T#?-CGROKQCC`ZYXO\`
MVK5_^?'3?_`Y_P#XU5"W\5Z6OBB\D.I:?Y;6L"AOM";20\V1G/;(_,5?_P"$
MQTC_`*"FF_\`@2G^-,`^U:O_`,^.F_\`@<__`,:KRO\`:_\`V7+C]LCX4'P9
MK&IG1-#N+E)[Z"VLM&UB'4U3YDBF@U?2KZW9%D"2`K$KAHU(8#(/?>/]7TCQ
M'X$UK3]OA?7_`+=8SV_]F:K>(EAJ.^-E\B=MDN(GSM<^7)A6/R-]T_!&M?L#
M>+O&7[`>F_"'6/A[^SH)?#OC.^U_0;"R\<1R:/HUM<W%[.GE0W_AB[M&>)+U
M[589;"2/9^]1XI%14RGJFFKVY?S_`$T=M>M[+?2&C33[_E?\=OGI=Z'T)X4_
M8'U;0?V<++X:2>.-9@TWPKJ.GW7@S4=,%C;7WA*&P2%+:.(2V4UO.Q,4C.9H
M6BS<.L44$:11Q\QHW_!)^WTG7_$]])\2/B5?1?$:Y@O/B!9W.H:.T'CZ:'Y5
M:\VZ.'MP8!';E-/>T0QQ+\N\O(^#\0O@'\2OCW_P3:G^#NI7/@;PSXC\/MH^
ME0RPZIIT.F>*[*R-I)<JT*:=<6EI;3[)X%B:PFC>-59[2)9#;Q^-_#;_`()H
M>-O"&N?"F'4OAS^R+J&G^!=<369-<M=2L])\5:8D-^MW;6=I=Z?X9M8/(CD$
MTTGE6]HUR;CR6,:I+-==-/\`C-7LKK7NFHZM>:2YD]W!<]I*-^>5O8JZOH].
MUN;3OI=I-+3G?+HYV^KO!/["_P#PJ/Q"=;D\6^+/$&B^'1JMYX<\.:G>:>=-
M\+R7OFF9[9H-.ANY6$<TT:_:KF;"2MSNPP^A/M6K_P#/CIO_`('/_P#&J^)_
MV>_V-=:^"W[;'Q-^)<>E_"+PGX9\96>L&>'1]2L-7U?6+FZN$G25[C^PK*_B
MWN)97BFU*^B5I1'&BI'&R?;'_"8Z1_T%--_\"4_QK./\.#\MNJ\GU;]=2Y65
M2:7?[]%K;9>BT#[5J_\`SXZ;_P"!S_\`QJC[5J__`#XZ;_X'/_\`&J/^$QTC
M_H*:;_X$I_C1_P`)CI'_`$%--_\``E/\:0SXVNO^"3OA'XD_M1>./%GCCQEK
M'BWQ'K$MOJ8T[2=6M/!^HZ=;>9$]F;N]T&TLM2OEBN+%_L[7EQ(B"!<(TL)F
M/H?A+_@G-IG@3]G?4/A;I7B3QXO@[4X]5:X@O_%1U>Y>YOKD7(NA<WMK-,LE
MO("8D#B%B[M/'.[,Q^=],_8:^+%]^T9\4-6\)ZI\'_@KH?B:_OA_:\TUOXOU
M+6HKN>TN;F2"6VM-(U2S%UY1CG,^K7+1F()`D:16UPGHOPM_92^(?PW_`.">
MFJ?`V;7_`(,W4EY:ZZMK>:)-<Z#IUFL]\UQ::>+0BY/V:6.6:.5Q(/(0I&L-
MR`SLHZ8=6T]W;Y=;:WM;67O76R:C<EKB.^N^GE9ZZ:^6B[M-M=K<?\$YM4N=
M8B\2-\6/B4?B5#?+<KXY^T:#_:_V=;:6W6Q\C^Q?[.^SA9Y6S]D\W<Y/F<XK
MUOX%?"G_`(4+X7M?"NCPK=6^F6:&2XO;_=<7LTL]S--<RLD"J999I)9'"(B!
MG.U0,*OQ4?\`@F]>0QMJ-O\`"/\`91M_#]SKL5]=?!R/7RO@>Y\NPFMQJ3S?
MV)M:^,DD?R'3L!85(FW9S]:?L9_#VW_9Q^"7A_P??ZIX>671=,CB$6G7`_L^
MP#7%U*ME;%@A:"V21((R40F.)"43.T:_S?+MV_K;?=V>AFMXZ=_S_7?76VVF
MIZCK46N:KH]W:PK;Z=-<PO%'=VU[F:U9E($B"2W=-RDY&]67(&5(R#\O>&_^
M"/\`\._!>BZE9Z1-\0+=M<\*WW@_5);WXBZKK'VZQN\M)^ZOA/#!()RUPIMX
MX@)&?*E'9#]0ZUXUM8='NWTZ^T2YU!87:UAN=0$$,LH4[%>15<HI;`+!&(!)
M"MT/PI\*?V#OC1\)(OB=?P_&WX7W6M_%SPUJ,6L3:/I]_H%Q:^()&FFM=4%T
M;Z[,KQM.UKOCBMF6VBM0%(MHXAC&W.V]-'KK?9Z*VNJNG;ND]'=;_95GK=:=
M-UJ^GNNS5_.VJLZG[97_``1;^*'[1GA6,>$_VH/B)X-\:3ZS!JE]XONH[9M4
MDA@LIK2.SA_LB'2HXX2EQ(7WI(SG:,@`Y^C-8_8]\3^*_A!\+])N?'%YX7\:
M_#&TCM[;Q5X.M=/T\W#?8S:3A+&]LKVTAAE7!\L1DQE5".H!!^//^"C6G_ML
M>)/A[>:A\/?#OA#6M=\0:[8!_#/AKXP7\%AIVGVUC<)),=0\[0KJ&22YDA?R
MK<LC^4?-W`!3[I\4OV<]4^,_[+?P,T^^\(^"/'MQX/M8I?$7@/XP>,QJ4%].
M^GM$9+S45M=12[N[>=MRR&%E<L[*\?"FE?V=2W\\;KO[JLUY):.VE_BUN9*W
M-3T^S*WEKJGTNWJKZV^'2Q-XO_X(P?#SX@^-?!>L:];QZU'X-A@5;>_TSP_<
MSZG-'=RWKW$NHOHQU*)Y;J:25UM;N"+<S!$1696^O/M6K_\`/CIO_@<__P`:
MK\QO%_\`P1WUOQ/\0/A?=6^K?#C28_"-GI:2:S#K.F74WAG[)J4U\EGI5M=^
M'IKJ*"!9%MXVMM5L-ZHKM$C!@_Z<_P#"8Z1_T%--_P#`E/\`&K^S_P!O2T^>
M^G?=6T[$KXE_AC^6WRV[]RAH]SJ@U'5=MGI[,;I=X-XXVGR(NG[KGC'/')([
M9/,?M%?![5OVB/A%J_@Z;4Y/#=EKD?V:]N+!=/OWN+=N)+=X-2T^[M9(I%)5
MU>!LJ3@CK73Z/XKTN+4=59M2T]5DNE9";A!N'D1#(YYY!'U!KR;_`(*!?";3
M_P!JK]E_6O!-OI?@GQ?-J4]M-'8:]XB72[%9(9EFCF9S8ZA'(8I$1Q#/9S02
ME0LB,A(.-;X=5?;\U_5GH]FTM3>E\6CMY_U_P_:[/(?B%_P1FT?QQ\-?A]X=
ML?B7\8?!\GP]MKS3X=1\->*K339-8L;FX^T/I]W:KIIL6L58*JV<5M';B-(X
M_+,:(J]=X>_X)QW^F_'#7/%%YX\UZ7PSJGBS3O%\?@JRCTRST87EC965M;/-
M*-.:]=D>QBEQ%<PQ?*B>5M#"3PKXI_LB?M)6G[.OP;\)_#7QA\#/#`\%FZ37
M=#L/$^J^$[&-3<L]M/:W.AV]HD]PL!(D2:QCL'F>20V+`I''V^@_!'XSZC^V
MWJ_BJY\2QV/A6U\66%W8ZQ>?%_4Y%?2(]-LDN[./PS#`-*E6>=;M?/G>*:-Y
MFE2-?+A!Z:-U7=G;5Z]/CB[]OB_>:;)-QO.\3GJ:TG=7]WYOW6FM==5[NNKO
M9VC9GO/Q[_99U_XZ_%OP'XL7Q_XP\(GX?WIU&QTK1+C2FL;NX:*:"1YS=Z5<
M3G?;W$L)"2H`K;E"R`./.OV?/^"3?@?]FO\`:GU+XM>'K=?[<U"YU*[2V-MI
M%JL$M_*TMP7O+72X=1NUR[A8[V[N(UW*=NZ.)H[W[5'PAUSQW^V#\'/B-X-\
M*?!/5)OA_=S/J/B'7/$TFFZ_]CGM;NUDL;?RM-N2T*_:1<!6N$5Y(]I5<^:/
M*OV-_P!@[QG^S[^WMXH^)FO>(_AGJ&EZY>:U/<ZR'TBZU[6(+NZ:6UMF=-#M
MK^W6%3$I\W5[U-MLL8B"E&@RH_$K::3U^[37^;2W;7EON:5MGU^#]?\`TG=V
MWOK9Z'V[KT^HO:0"XM;*.'[9;;FCNF=A^_CZ`QC/YUO5@Z]XET[4+2"&WU"R
MFF:\MMJ1SJS-B>,\`&MZD,^2_BC^VWXN^`OQ\U#3;C1M%O?A+X,\`:+K_B&_
MB@F;5M&DOI]3A%\Q#^7)8P#3D\Y1&)(TF>;>4B9#Q?[5/_!:C1?V-O@O\"]<
M\7:?X=AU3XO:)9ZJ;C4]0O=(T;?)!`\MO;W$5G>C[06F!1+DP0*@+2W47RE_
M=O'?[5OA#X'3:/H>K:I\1-0UBXTR"]>P\*^!M4\4R6$+@K&]P--L+DVZNR2"
M,SE?,\J3;NV/C4T?]K/X8ZW\;-1^&L7Q<T.'XAZ7*8I_#-U?6=KJ[8MDNF>.
MVEC666,0R!S)&K(,."P*.%4/6ZO?Y1YN97]9+77ELD[II)U+<W-:VB5O.T$G
M\VF[=>;2S5WY3\4?^"L&B_!3XC76A>*/"=YIMOH%PMYXDOTU*.>+0-"GBB^P
M:L^Q2)%N+J=+7RT8XDANF5Y$@+-Q'Q3_`."NVO?`_P".NG>&_%?AKX9Z"+[P
MAH'B.7PUJWCH:?XNEN;^>\CFL-*M#;NNKW2>1$@A!M1YC!?,?S!Y?TI\-_VH
M/AS\9O&,.@^#?BKI'B_4IK:ZNL:'>6FI0QI;&U$X>:&-HHW7[;:GRW8.5G5@
MI7)',>(_^"AOP%\*:5H>H7O[0G@!=.\2:W)X<TZ\B\0Z;/:SZC$GF26QE0,B
M.BE=V\J%,D:DAI$#73T<>97NU\U=QLO5VNU]JZ22:BHE?DEK;1Z]G\5_DD]'
M]G5[-OF;3]N+QUK_`,,[OQ8O@CPUX?T,_$>Q\#Z7+-KDNI7>I1?\)(=&O+B6
MW6"%+8[5\R'$\Q)?YU4)A_'_`!Q_P7&M/"OQ9UZT6S^&4WAOPC;>)[K5],L_
M&1U'QG9+HL<P<W^E1VZG34>6$E6#W1:(@[4<A3]9R_M*_#6'QOXF\,O\8_"*
M^)/!-FVH^(M*;7M,%]H-JJHS3W<.-]O$%D0EY`J@.ISR*XKXB?M+_L^?%W]F
MK7_$'B#XI?#GQY\(C?0Z#KUZ;O2]>T".>66%5@O"D<L**&EA9O-PJ*P=RJ_,
M,9<WLVH/5W:?JHQC\N9-Z:-RM;0U5G4U6EU=+LFVUZ\NFNJM<^:1_P`'!FBZ
M7^PO'\<]5T/X>P>&-6\4OX9T;5;'Q7K-]H,ACB$DDM[,N@C4+)BV^..%M.=Y
M&57PD+"8?0G[0G[;&H:+_P`$\M/^,GA/7/ACX1NM9L]/U&UNO&&L6DVC>3.Z
M,\<4_P!MM+:XFDB+BW#WEM')(T>^2(;MMKX/>(_V9_V6O@YH^K>`/&7P5^'/
MP^\>ZIY6E7OA^XT'1]&\1Z@<Q[8)(42&YN#Y13"%G_=$?PX'J6L?%OPCX>^*
M&F^"-0^)6C6/C36D,NGZ!<:G81:I?($D<M%;,HED&R&5LJI&(G/13C:K%/FC
M&ZUC;NK)<R?=MZWTLGM8RIR::D]=)-_-OE?DDM.MVF[GQ;\4_P#@O!X;_9U_
M9U^#?B;Q'<^%=<OOB@;I/[9O/M7AO0;B6VN6MYK>UEM1K$#3A^%9KO["Z(TO
MVY(WC+^F>/\`_@K!9^%?B'\2=&L].^',LWPYT*\U63P_J/Q!BM/&FJRV^GI?
MDP:/':S!K)HW&+L7)!".ZQL@5G]>\+_M7>$/&WQ=D\%Z/J_Q&U+4HKF>S?4K
M;P+J<GA\30!_.3^V!I_]G91D>-O](XE1HC^\!2JMA^W-\#]4\#W7B>U_:%^&
MEQX;L;TZ=<ZM%XMT=[&WNA&93`\P.Q9?+!?82&V@G&!FB_,W+O=KLDW[NVZ3
MT\]%IK>E%IJ.NED^[MNO5I/S3N_)>7R_\%7M/^*WQ+A\,?!'3?`/Q>>^UVTT
M&TU>S\>11Z/YTNE7VI2F6YMK:ZV>4MEL*HLCDS*<`#!S_B?_`,%$_B!\/?@W
M\//&"Z3\([?3_$/Q-UCP5KU[XG\2W/A_3]-M;:^U*VM62;R+A1+)]CC!>3"F
M1E18_P!\#%[%XH_;?^"?@BWU6;6OV@OAMH\.A7D>GZD][XLT>W73[F3SA'!,
M7($<C_9[C:C88^1+@'8V/5;"S;5;"&ZM=>O+FUN8UEAFB^S/'*C#*LK"/!!!
M!!'!!H5KIK9--^FC<?*Z3\]>MB7?EY6]7%I/S::4ODVGIIIYZ?#'[1'_``7$
MTW]DKP'X/O/&NE^&;;4/&'BGQ!HUM<ZE?7VCZ2\.G:Q<6"11W$5I>K]M>..)
MR+@V]L/G>2X@4HI]B^!W_!2G1OC5^WYXR^!,5OX5L=3\+:$FN1+#XF&IZO<P
MD6HD>:VM;>2TM422Y,>R6^%RQ0.+;R9$E;Z*_L2Z_P"@QJ7_`'Q;_P#QJC^Q
M+K_H,:E_WQ;_`/QJE2T^/7?RW7N_<]^ZTLMRJFM^73;SZZ_>M/)Z^1I45F_V
M)=?]!C4O^^+?_P"-4?V)=?\`08U+_OBW_P#C5(#2HK-_L2Z_Z#&I?]\6_P#\
M:H_L2Z_Z#&I?]\6__P`:H`TJ*S?[$NO^@QJ7_?%O_P#&J/[$NO\`H,:E_P!\
M6_\`\:H`TJ*S?[$NO^@QJ7_?%O\`_&J/[$NO^@QJ7_?%O_\`&J`-*BLW^Q+K
M_H,:E_WQ;_\`QJC^Q+K_`*#&I?\`?%O_`/&J`"U_Y&Z^_P"O.W_]#GK2KGK?
M1[@^*+Q?[5U`,MK`2^R#<V7FX_U>.,>F>3UXQ?\`[$NO^@QJ7_?%O_\`&J`-
M*O#_`-O']JG4_P!E?X30WV@^'?$6N:[K,LEK:7%CX0U?Q)8Z+LB>1KN]ATR&
M2;RE"A53,?FR.B&2)#)-%Z]_8EU_T&-2_P"^+?\`^-5QOQP^+VE_L]>%(=:\
M07OQ`N[&:<6X'A[PA>^)+A&VL^YX-.LIY4C`4YD9`@.`6!8`XU_X;2ER^9I1
M=IIN/-Y'SUX^_P""EMY<_P#!,;2OC%X5U3P'9^+#9:&^O0^()(-+M=`N+U;:
M299+74]0TT*QCG#P17%];^;'+#(DDBL@E^6OA_\`\%TOBSXE^)'@W1]7U3X*
M^'[?5KVT@E2^TN!+OQ!;3:K/`+RQ2/Q'+YL4MJJ)`=)&N!KB.;S#"AC!_0[0
M?B=X%\+?L_0_$[PU=>(+SP;XMBA\2)-X7\(3ZE>:O]M$;+=?8;.R>[EDD#HS
ML8BX`)?`4D<CHO\`P47^%GB"#PW<6WB;XF?V?XJOTTJRU&7X<:U#I\%ZVH/I
MHM;NZ?3!!93B\0P&*Z>)U<KD`.I/;MB6^7>2]SL]/<VONG9-7=]5=*W-%/ZM
M&%^GQ=_[WSTNKNW1[M^&?LN_\%-_%W[1?[:'CSX:ZEXE^$M_X>TV+Q%'::?H
MEIMUNW%G<^5!YW_$TGNHRL6];@WVEZ>GG;5@:=&1G_0&O)=1^/?A+7?BAXD^
M&MEXPOK_`,9:+HDVJWNGI9;H881Y:LC7`@$/FKY\!:$2><J7$3E0LB,?2/[$
MNO\`H,:E_P!\6_\`\:K&/\*'IO\`S:O7[]/D:R=ZL_6]OY;I-+[FFO)KU-*B
MLW^Q+K_H,:E_WQ;_`/QJC^Q+K_H,:E_WQ;__`!JD!\!P?\%<=;\*?M/?$GPW
M<:II/Q.ET;[59Z-X9^'.A+XI6U:.]CBAFO)M)O;_`%6U:))F%ZUWI4$>Z();
M*TD>+ST3X6_\%-[CQ3_P3TU3XB:E<:#'\1]-M==E73K[0[_PY%=QZ9?-;2Z@
MFGWSB[^R0QM!+.1(5C)>-I8V!V^H>`OVH?A[JGC7QTFF7GBK2=/T1KN]U[Q9
M=>%GT[P_>7-BRV=X#J4EJD,TMN(H8RY<JZIMB>3[/.L/3>&OVCO!WBO]GR3X
MI6OC#68_!$,%Q/)>W>DO9SQ"WE>&5&M9K9;E95EC>/RC'YC.`H4D@%;4$I?R
MKWOD[._:]]=&TM]%9RO[>Z[OW?NT7IITT;=UJ?(A_P""I7BBTC:SE^.'[,4W
MA>XUV+3H/C''H\J>!X7-A-<OIKQG7"CWP:)?F&H*`LR_NBP-?6?[&7Q;UKX[
M?!?0?%GB"/35U;6-*B>6;3H'@L=05;FZCCO+9'DD=;>XC1)XPTCD1S)\S=3Q
M\'_!1#X8SZ)<70\0?%1;RWOTTUM#D^&FN)XA:5H3.&326TP7[P^4K-YRP&(;
M3EP017I7P@\>:7\;M"M?%/AGQ!JE[HNM:=;W-K<2V0M9F4R3J4DAFA22)T96
M5HY$5U;<K`$8&G\WR^6GZ[]+[N[U,NJU[_/7]-NOR6AW&M:U9^'-'N]0U"ZM
M['3["%[FYN;B01PV\2*6=W8X"JJ@DD\``FOA7X4_\%A]<UR+XG:IX@\`:];:
M1I_AK4?&7@5+SPEKGAH:O9V;3;K*6[U"W$%Q<O;);7@DM`R".YD78?LQEE^X
MO[$NO^@QJ7_?%O\`_&J\U\&_M3_#WQ[JOCRST_XD*LGPSE:+Q+)>1QV4&F!6
MEC>4RS0)')"LEO<Q--&S1K+;3QE@\4BK$;\S?D]/U?DFX[6[7M(VTY5==5K^
MGS5UU[I75SY=_:J_X."?A7\`O"&MZ]X?U;X>^,O#NFZSIVAVWB*#Q7/<Z%-=
M7-G<W;PRW&EV&H212(MOM"B%PS.-[1#D^G?M"_MR^(?AU\!_@[XBU#Q)\'_@
MM+\3%674O$?BR^_X2#POH#&Q>[2U6X2YTU+EYL;8Y1,BML<JD@P1UW[7^@_L
M[>+/"K2?'W5_A#J>A^%;F(EOB!'H<UKH\]RI\KF]B*0O,J-MZ%PAQD"K\_QY
M^%7[/OP.\%WGAWQ!-<>!]8ACL_"=E\/_``Z?$$5Y;I$77[#9Z3:3N]ND:9+1
M1F-%QD@$9GW>2=W]J-O)65T]M6^]]++O>8WO"W\LK^;OHUOHEH_/732WQQXO
M_P""P7QCT'X@?"_2;.S^%NJ7/BZSTN<Z/8)I\NJ>*4FU*:VFO+*VN/$5OJ%M
M;S6T:W%OY6GZD-C[FD8*ZI^G5?./_#QOX2O=Z%'%XT\<W46OPV4R7=MX&U2X
MLM,%Y.UO;KJ%RFGF'39&E5E,=Z\+IC+JHYKWS^Q+K_H,:E_WQ;__`!JM.EG_
M`#2_/;_MW;R[(E;IWZ1_+?Y[_JPT3_D)ZQ_U^+_Z3PUY1_P4"^/FL_LT?LOZ
MUXN\/^(OAQX8U73Y[98[WQO=Q6^EE&F42QKYUY9127+Q[UACEN[>-I2@>5%R
MP](T?1[A]1U4#5=07;=*"0D'S_N(CD_N_?'&!@#ODGG/CQ\8M`_9I^'DGBCQ
M?XD\0VFDK=VVGH+#1I-5N[BYN9D@@AAM;2VEGFD>61%"QQL<GIC)K.HKI*]M
M5^:T^>WS-*;L[VOO^6_RW/C7XI_\%X/#?[.O[.OP;\3>([GPKKE]\4#=)_;-
MY]J\-Z#<2VURUO-;VLMJ-8@:</PK-=_871&E^W)&\9?T:'_@K/;S_MGS?"G^
MQ?AZOV?Q'8>'/L)^(44GC2Y-W8VUVM[!H<=JRRV47VH"687@");W$BAP@#>X
M:C^T[X!\,_#[PWXG\3?$3_A`])\772V&D#QI%'X6NKVY8L%MQ;:C!!.LS;&(
MB:,.P&0""#4.E_&CX2^&?CO>?#VQ^*'@33_B=KUR;R[\-0:MI46O:C.MLI,L
MEH%$\CBVB0[BI(BB7G:HQM'^,W-7U>FW6+MY6C=-^:=N^+_A>X_LZ/>VC2EY
MZ]-FT]>BXC]JC]MZS_9G_;!^#GA#5_B1\)-!T'XAW<VG7V@ZXRVVOY-K=R6]
MY;W#7J((7N(8;8(UJ^^27`D#%5KRK]C?_@J-XG_:,_;V\4?#/68="TW3]/O-
M:L[71++3].N-6TT6%TT*3WTT.OSWD$<JIN!N=&M$+3Q1B4DQF;ZA\6_&WP_X
M%^,WA?P#JFO>++;Q%XR64Z01X>GDTZZ:**69XC?K:&TCF$<$KB*299"J$A2,
M9S_AU^TGX7^+'Q/U7PGX?UKQYJ%]HSW$5QJ'_"'WT6AM)!)Y4T<6JO8K832)
M)E&2*=V#)(N,HX6*.Z>^D_GY]?A=[OY*UC2KJFMOA_7_`-*7Y7UU/1_%/_(,
MB_Z_+7_THCK2K!U[2Y[:T@=]2O;A5O+;,<BPA6_?Q]=J`^_!K>I`?._B?]E.
M^\6^-%\:>$O'GQ4^%^MZUI%CI^LR>%T\/W$&N1VHD-LTJ:I9WFQHQ-*`T(B+
M*^'W;4VZVL?LA>'=;O\`7KJ6T\7+/XB\9V?CF\>.XL5+7UM9VUG&@X_U)CM8
MR0<MN+88#"CS_P`>?\$T?!7QK_;?^%OQFUCP#\+]9M_#OA2]L]5FU30X+C5+
MS46?37TVZ#-`P=K9+:X59'D#Q>8`@PS8XWXJ?L&_'WXB_M:^(M<C^)4UIX'U
MS7OM<=[%X\UNWDL]";2Q:RZ"OAZ.,::2]QOD&I"=;E/,WJ-Z+6,K^S3Y;MJ3
MMZ332OOJXJ?9):7E:,M%%7>NFGSO%IZ>C<>[;UM'FDO9_@U^S)X-\+>$OA[/
MX1_MZ[TGP5X%G\#Z'<V]SIES;7.GS_8\SMM!BDES91$$`1G=)F-@0!Q7PO\`
M^":UK\)_@_I?A+3_`(B?'2Z;P_XN3Q?HFJWM]H,UQX?=;4V@T^RMOL@L+73A
M"\BK:Q6JI%YK>7Y>%V_*?C7_`()"_M70_L5_!#X8>`_BJGP]U#X7^%[S3;NY
M\._%S7]-2YU7?']FNI)#ITS7EB40DV#);BW)V0S>7D-]W?LC_LZ>*/@I\3?C
M+XB\37NC7C?$KQ'8ZY:BQFDD:)8M%T^QE$NZ-`&,UK*PVY!1D/!)5>Y_Q)R4
MMF[/^:U1232\VY3_``>]ESZ\JA);K5=KQY6K]?=]W[[:)-^3?%K_`()76/Q.
M\#>(O#W_``G'Q271+ZRUV+P]HM['H=QI/A6ZU>&YBN+J,100WET0MY<X2[NY
ME/FDL"P1E[;P]^PA8II^I-XK\2?$[X@ZUJVL:!J]QK.M'0K>YQHMVMY8VRQV
M-M;6XA68.6/D^:PE8>9PFSZ3HK",G&UNEK>L7=/U3Z[]-BY)/?S_`!5G\FEM
ML?'/[1G_``2;\,_M">+&UZW\:?'OX>ZQ/JM]J=Y<>$?$>GV2ZI'>?9S-8W44
ML4L4]D6MHR8)$97Y$GF*%5?>O!7P5TGP'\7]8\;6.BZQ_;.M:#IGAR93]A2&
M*UL'NGA$:H5*DM=R;@#L^5-JK@Y],HI4_<@J<-$K)+LDK?E?[V]VQR]Z3E+=
M[^=VGKWU2^Y=$?/OPS_9%U#X/>)Y_P#A&_B!\8-+\$RW-_=Q^"4_X1UM'M7O
M&FEE\N=K,ZBH$\[S(/MAVOA1^[`CKS7]EW_@DCX;_9I^)5GXOOO'W[0WQ:\1
M:=JMOJUK??$7Q38Z]<6[P66H6<<22-&CK$$U.Y?:&!#[2"!N#?9E%.#Y?A[)
M?).Z_'KN*2YE9[:_CHSY3^-O_!-K2_BW\!;7X?Z+X\_:`^%5A#XGU+Q5<:EX
M`\4V>AZGJ,]_<75S/!<2HC"2W\RZ<A"N?W<>68J2?<_@GX#@^`_P;\)^"-)T
M_P`07>E^#](M-%LY[V>UDN9H;>%84:5E=59RJ`L55023@#I7<T41?*G%;.S?
MR5E]R'+WI*3W5_Q=W][U,W^V[K_H#ZE_WW;_`/QVC^V[K_H#ZE_WW;__`!VM
M*BD!F_VW=?\`0'U+_ONW_P#CM']MW7_0'U+_`+[M_P#X[6E10!F_VW=?]`?4
MO^^[?_X[1_;=U_T!]2_[[M__`([6E10!F_VW=?\`0'U+_ONW_P#CM']MW7_0
M'U+_`+[M_P#X[6E10!F_VW=?]`?4O^^[?_X[1_;=U_T!]2_[[M__`([6E10!
MF_VW=?\`0'U+_ONW_P#CM']MW7_0'U+_`+[M_P#X[6E10!SUOK%P/%%XW]E:
M@6:U@!3?!N7#S<_ZS'.?7/!Z<9O_`-MW7_0'U+_ONW_^.T6O_(W7W_7G;_\`
MH<]:5`&;_;=U_P!`?4O^^[?_`..UY'^V;^RQI_[;?PMM_"'B'^W-+T>*^2^F
MBBT3PUK4=XR*P19(-8M+Z#"EMP9(ED!`PX!(.[^VW\"=1_:?_9`^)GP[TB_M
M]+U;QIX;O=(LKJYDF2W@GFA9(S+Y)#F+<1O49#+N5E=24;XM^%__``1;\867
M_!/'XW?"OQ-K6@1ZM\0I;N\\+Z'I>JM9^&_#MPVEK9Q><NF:=IEK/&\P-PZ#
M3%02;)"LTR"8YR7/S*2TBDUYOF6B\TM?E9VO<VII*4/>MS-I^2MN_)WL?1Z_
ML6ZGKG[*^N?"/Q'XR\;:]X=U`V]G97%WI'A_4;FSTZ".!%M94U&"[M[MI&B:
M262>%@6F81)`BQHG'^$/^"7$7@.Y^'<>E_%/X[VNB_#.9[K2]!`\*-HKS/.9
M3(UF=-\F$JN(8A;+"MM&"+<0&21G]`^)_P`-?C!\;O@OX@\!Z#K&G_!NXT?4
M;'3K'Q&Z2:Y_PD^EI:6[W+)%:W5E<6/F3/-;;TN$G186DC:-GC=?BOX)_P#!
M%'XT?"_7/@_+K'_"@?$%U\-=1LI[+7K.;6-,NM`M(=7N[R6UAMY$N?.5X[G<
M#9W&DEG58KHWMNFQ^A6^L)M[RC[W6UE:7RO=J33<E)R]ZW-R:^PVU46[=F]'
M&_FKZI/2R5TWR_77@_\`X)Y?#_X)_&"[^)/AVU^*UGK$>E:O:FSU#Q_J6J:2
M3J$PN;J8VMS>RH&:52^U`(]SE]AD5'3Z,_MNZ_Z`^I?]]V__`,=KY;^#/_!,
MGP7\%?VJOBY\;I/!/PYT/Q%K=O+I?AC_`(1K28;'[!IC0))<S7/EPQ>;?W5V
M9VDE;S"(UB17`,@;ZVJ(Z4H1[+;HKMNR^^[T5FVNES22_>SEW>_>R2N_NMN[
MI)WU,W^V[K_H#ZE_WW;_`/QVC^V[K_H#ZE_WW;__`!VM*BD,^,-0_P""1OA3
MX@?M!^+_`(A>/-:^)'BF_P#$EZEQ;QZ7+IG@VYM8XVMI;=+C4-"6QU#4#;S6
MZF$W=S(L:K%\AEB$[=OX2_X)\>'_``)^SOJ'PMTK6OB^O@[5(]5:X@O_`!!;
M:O<O<WUR+D70N;WSIEDMY`3$@<0L7=IXYW9F/TQ11'W8*G'16M^%M>[\WKHG
M>Z0/6?.]7OK_`%_7S/EFX_X)\37.L1>)&^)OQM/Q*AOEN5\<[/"_]K_9UMI;
M=;'R/[/_`+.^SA9Y6S]D\W<Y/F<XKUOX%?#BT^`OA>U\+Z/I^N75KIMFA>>\
MFMGN[R:2>YFGN9BK+'YDTTLDC;%5=S-A$7:*]+K-M?\`D;K[_KSM_P#T.>JO
MO\OPT_KON]2>5;^OXN_]=MEH5M:O+[5='N[6&SUO3IKF%XH[NV:T,UJS*0)$
M$C.FY2<C>K+D#*D9!^7O#?\`P21^%W@O1=2L](B^,5NVN>%;[P?JDM[X[NM8
M^W6-WEI/W5]<SPP2"<M<*;>.("1GRI1V0_7E%1RI-R6^U^MK-:/=73:=MT]2
M^9Z+SO\`--->MFDU?;H?G=^V5_P1M^(?[1GA6,>$_P!I;XS>#?&D^LP:I?>+
M[JPTMM4DA@LIK2.SA_LB32HXX2EQ(7WI(SG:,@`Y^C-8_9/UKQ7\(/A?I-SX
MN\8>%_&OPQM([>V\5>#M+T33S<-]C-I.$L;U+VTAAE7!\L1DQE5".H!!^A:*
M>RE%;2:;]4K+TTW2T>[NR>57B_Y4TO1N[_'9[K961\8^+_\`@CE\+_B#XU\%
MZQKVF^(-:C\&PP*MO?Z#X4N9]3FCNY;U[B747L#J43RW4TDKK:W<$6YF"(BL
MRM]>?VW=?]`?4O\`ONW_`/CM:5%.^ENEV_F]_P"ON%RZW\DODMCGM'UBX34=
M5(TK4&W72D@/!\G[B(8/[SVSQD8([Y`YC]HKX7W'[1'PBU?P=-<>)O#=GKD?
MV:]N+"RT34'N+=N)+=X-2AN[62*125=7@;*DX(ZUVVB?\A/6/^OQ?_2>&M*I
ME%25F7&3B[H^)_B%_P`$>/#/CCX:_#[P[8_$#]H3P?)\/;:\T^'4?#6OZ5IL
MFL6-S<?:'T^[M5MS8M8JP55LXK:.W$:1Q^68T15Z[P]_P3U;3?CAKGBB\\9?
M$*7PSJGBS3O%\?@JRL=!L]&%Y8V5E;6SS2B!KUV1[&*7$5S#%\J)Y6T,)/JJ
MBKC-QGSQWO?Y\RE_Z4E)=GJM2)14H\LMFK/S5K:O=Z::]--CQ#X]_LU:E\=?
MBWX#\6+XT^*7A$_#^].HV.E:(GA]K&[N&BF@D><W=I<3G?;W$L)"2H`K;E"R
M`./.OV?/^"5OPY_9K_:GU+XM>'M,\1?VYJ%SJ5VEL=,\.VJP2W\K2W!>\M;6
M'4;M<NX6.]N[B-=RG;NCB:/ZTHJ8^Z[K?7_R;?\`KITL5+WM)>7X;?UUZF#K
MVJ3W-I`CZ;>VZM>6V9)&A*K^_CZ[7)]N!6]6;XI_Y!D7_7Y:_P#I1'6E0!XG
MXK_Y&G4O^OJ7_P!#-9]>4?'K_@H_\'O@C^U;X7^$_B%O$EYXV\8?V3-,FG76
MF+'8/JMRT%L!;3W,=[=`R*S.+*"Y,,>'EV*03Y_X-_X+*?`;5+J1?$&E?&#P
MS:K-XH)O6\(:A?0P6N@WL5K<W,J0VS3A")5D9DBDB@"2I-+&\;)13]_X?[W_
M`)+;F^ZZ_0<HN.C_`+O_`)-?E^^S/I>BJ'[8'QI^'_[%_P"S1>?%;Q"WB#6/
M#-I-80@:9=6$;S?;+F&WA<2W<L%LD>Z9&:269$5-S$X%>/?"'_@J=\`OBIX+
M_MB23Q_I9F\3CPA8VFG6$/C.75]0-B+_`&6LGAMM3@FVV^]G"2EH_+82*F5W
M5&+DW%;IV?J[*WK>2T\T+[*FMGJO1)MOTLF[GN%%<KX1_:W^#?B*R\-S:AJW
MB?PS_P`)AXTU3P!HIU:P98;W5["YN+>2`SQ))!"96MI3")Y(VE`PJ[\H.-^#
M/_!4K]DS]H+]I2S^$/A#XL7.K_$#4I[NVLM/_L74;>&^>U\X3>3=2VBVTJ@P
M3`,DI5S&=I;BICJTEN]ON3?W)IOLG<)>ZFY:);_>U^<9+U3['KE%?,]O_P`%
ML_V5_"'@./7?B1XP\2?"];_Q1K/AG3+/6M"U%KG4#IMV;:2Y"QV;;8F.TEN5
MC8M&S"2.1%^A_P!KSXW?#S]C;]F.Z^+.NR:YKGA6WDL(XVTF\L%-P+VXAMX)
M%FNI8+98MTZ,TLDR(J98M@5/,N15%L[:^<K67J[K3<KE?M/9?:UT]&T_DFGK
ML:-%>,_L_?\`!2CX._M$KHO]EV/C2S_MSQD?!,<PU'0]6L8KL:3+JIE-]IM[
M=6;Q"WA=6$4[RQR%0\:!@U=!^SY_P47_`&7?VI/"/Q&U[P3\4Y-0TOX1VQO/
M%TUYIMYI9T6$"4EW6ZMHF8#R)1\@;E<=2`;E%J]^BN_)63OZ6:U\R==//;S;
M;22\VTTEY'HU%>5_%#_@II^RS\#_`(177C?QI\2-:\(:+9:TGAZXMM:\-:KI
M^KV]\]NMTD3Z;+9+?*&@=)0Y@"%&#!L$4Z?_`(*5_LOK=:5';?$#Q)JT.M:?
MI>IVUWI7A36-2L1#J;.FGB6YM[%X89;B2-XXX9765I%,>S?\M+_-+YM72]6M
M4NJU6@N96OTLW\D[-^B>C?1Z'J5%>:_$[_@H]^R]\%_V;].^+/BSXF7_`(>\
M$:KK5SX<MY[[1-0AU#^T;>26*XM7T\VGVR.2)X9`X>%=N`3@,I*G_@HM^S-)
MJ?A^WM?'_B'5(O$VG:1J]I?:;X8U:_TV&UU6Y:UT^2YO(;)[>T\ZX5H@+B2,
MJZE6"D$4XQ<GRQWNE\VKI>K6J6[6NPY/EW\W\D^5OY2T?9Z;GI-%8O[-_P`;
M?"'[2OQS^,?@72],\9:;=_!S7H=!O;N_L98;;49)+2&X+PR-`(R`92NT.SE0
MDFT1RQLWM'_"E]+_`.?C4/\`OM/_`(FEO%2Z22:\TU=/YH'I)Q>Z;3\FMT>8
MT5Z=_P`*7TO_`)^-0_[[3_XFC_A2^E_\_&H?]]I_\30!YC17IW_"E]+_`.?C
M4/\`OM/_`(FC_A2^E_\`/QJ'_?:?_$T`>8T5Z=_PI?2_^?C4/^^T_P#B:/\`
MA2^E_P#/QJ'_`'VG_P`30!YC17IW_"E]+_Y^-0_[[3_XFC_A2^E_\_&H?]]I
M_P#$T`>8T5Z%#\)M-DUVXM3-?>7#!%*#O7<2S2`_P_[`_6KG_"E]+_Y^-0_[
M[3_XF@#S&BO3O^%+Z7_S\:A_WVG_`,31_P`*7TO_`)^-0_[[3_XF@#S&BO3O
M^%+Z7_S\:A_WVG_Q-'_"E]+_`.?C4/\`OM/_`(F@#S&BO0M>^$VFZ7H5[=1S
M7S26\#RJ&==I*J2,_+[5<_X4OI?_`#\:A_WVG_Q-`'F-%>G?\*7TO_GXU#_O
MM/\`XFC_`(4OI?\`S\:A_P!]I_\`$T`>8T5Z=_PI?2_^?C4/^^T_^)H_X4OI
M?_/QJ'_?:?\`Q-`'F-%>G?\`"E]+_P"?C4/^^T_^)JG#\)M-DUVXM3-?>7#!
M%*#O7<2S2`_P_P"P/UH`\]HKT[_A2^E_\_&H?]]I_P#$T?\`"E]+_P"?C4/^
M^T_^)H`\QHKT[_A2^E_\_&H?]]I_\31_PI?2_P#GXU#_`+[3_P")H`\QHKT[
M_A2^E_\`/QJ'_?:?_$T?\*7TO_GXU#_OM/\`XF@#S&BO0M.^$VFWEY?QM-?!
M;6<1)AUY!BC?GY?5C^&*N?\`"E]+_P"?C4/^^T_^)H`\QHKT[_A2^E_\_&H?
M]]I_\31_PI?2_P#GXU#_`+[3_P")H`\QHKT[_A2^E_\`/QJ'_?:?_$T?\*7T
MO_GXU#_OM/\`XF@#@?"G_(TZ;_U]1?\`H8KVRN+NOAG8>''M;R":\:6&[MP!
M(RE3F9%/11V-=I0!X'XW_8\^%/QT\2>'_%7BKP]X@OM:T^WTSS%M=0U>ST_4
MS8S"YL_MMI;R):WZP3DR1_:8Y0A)VX!K%L/^":WP`TV_\27$?@C7V;Q79:_I
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M?6M`G\B]B^P7;VTUJTFU-JR9AN)4VR!E^?.-P!'S'\._VKOVFOCK\&?AWK6C
M^#--^'^K:MX6U[7?$,?B_P"'.JFX^TV%[!!9V2V"ZC$UC->PO),(Y+BY9`F%
M\\`O7IG[6WQP^*"?LU>$?^%<^"/'K?$#Q\UD+B+0;&PGO?"5L42>^E+:J\%@
ML\<>Z&)+IUW32*?*D".E:U)2C>3NWS?/F<G%2^;@]7JDDW9<K>--1:C!:)Q:
M\DDE=?=+97O=J-W=&YXT_8O^#/Q$_9[\1?"O6O!-UJ'@/Q5JMUKFI:;(NI;I
M;ZXO6OI;A)PPFAD^U,9%,3KL/";0`!R/PO\`^"7_`.SO\%/'^A^)/"?@37O#
M]WX9U)-9TJRLM6UZ/1]/O5LOL/VF/3A/]C65K;,;N(=T@)+%B2:\:\7_`+:O
M[1WA[P[\*;S5/#?B;P'K+>'M9M?&EC<?"#5_'5O/K-I<6*6^Q-#E;R%N8FN)
M8YENY+=59T(E=,Q]5\5?VQOVC/`GP7^)/CZX^'MU8P>'I=,T[0O".@?#?4/&
M?B.YN+FUTN>>XVIJEC'>6\$ES>V[>3L&8/,\S]T\3D;0O4IOYKLI<L;=[M)Q
M6ZBXR:BFF5).;4*G6^_=ZSO][YN[NE=IH[?5?^"7'[/.L_;UE\&^+HXM4O\`
M4K^]AMO$7B.VAO/[2G6XO[:2..Y5'LIYD$CV3`VK.6;RLLQ/M'Q4^'/@WXU^
M"K7P[XET6^U#1;*_L=3@M4M;RV6*XLKF*ZM7!B"G$<T,3;<[3MPP*D@_+?@S
M]KO]IOXQ_`GP#XBT;P)9>"M8OO"7B#Q#X@M/%7P[U7[9-=:?>0PV>GI8IJ$;
M6%Q?0O)*J23W3)MPOG@%SJ?$[]K']H3X2?`CXC:I>^$]-UKQ-I%MHFK>'GT;
MX>:]?H\-\\AN=.&GV\\TU_>VD<)&\3V<+R3P^<;-,R%2_=QM_(U9=FI.,;?.
M+MV2N[7C<C+GFGUE?7Y)RN_1J_>^E[.WT-\8OA#X#_:`;03XP\/WFN+X9O9=
M0TY);:]C2&:6TGLY&94"B0-;W4Z%7#+^\SC<%(\R^%O_``3@^`OP?\,>)M%T
MGP=XEO-+\8^&X?!^K6^N:QKVNI<Z/")1#8C[=/,8X8Q/*$6/;L#D+@8Q[+^S
M_P".M2^)_P`"O!OB36-.U32-6U[1;/4+VQU+2&T>\LYI84=XYK-IIFMI%9B&
MA::4QD%2[D;CUU.=/V<I0^3\]U\]&UZ.PHU'-1GVM;RUYM.VNNG74^:V_P""
M<7P.?PTVGMH/Q`>Z?5!K)UU_%GB9O$@N1:FS!&L&Z_M`1_9B8O*%QY>QBNW!
M-7A_P3\^`T<+1P_#^XM86B\.P>3;?VG!$D>@3M<:2JHC!5%O*S-P!YF<2>8.
M*^AJ*(R:=UO=/YQ^%^L>CZ=!<JY>3I9JW2S=VO1O5KN?/^O_`+"7P8\0^"4T
M!O#/B?3;.'Q'J'BV"YTC5=<TK4K74[]IFO9HKVVFCN8A-]HF#QI*L95]NS:`
M!(?V%?@>-%NM-C\!W%MI][IN@:1+;6RZE!%]ET.Z:[TN)51@$$$[L^5P9,XD
M+KQ7OE%3'W5:.FW_`)*K1_\``5HNRV*DVW=^?XOF?WRU?GKN>9_#GX*^!?A+
M\5?''C3P_I.OZ?K_`,1[F"]\0OYNIRVM]<0P);QS+:NS6\,GE1QHSQ1HSB--
MQ;:,=U_PE-K_`,\M2_\`!?<?_$5I44=$NB22\DMDO)=`W;;W>K,W_A*;7_GE
MJ7_@ON/_`(BC_A*;7_GEJ7_@ON/_`(BM*B@#-_X2FU_YY:E_X+[C_P"(H_X2
MFU_YY:E_X+[C_P"(K2HH`S?^$IM?^>6I?^"^X_\`B*/^$IM?^>6I?^"^X_\`
MB*TJ*`,W_A*;7_GEJ7_@ON/_`(BC_A*;7_GEJ7_@ON/_`(BM*B@#GK?Q);CQ
M1>2>7J&UK6!0/L,^[AYNVS(Z]>AY]#5__A*;7_GEJ7_@ON/_`(BBU_Y&Z^_Z
M\[?_`-#GK2H`S?\`A*;7_GEJ7_@ON/\`XBC_`(2FU_YY:E_X+[C_`.(KY,_X
M:!\86?QX_:(\)KXH^."Z7;^&EO?"FLWGPBOKJR\.:BOVY+M-.D@TA(]22'_0
M'BB=[IYSN"-*-X'A-[^U3^U$G[']K<6-A\5Y-8/CLZ=J'B.\T6Z;5AI?]FF=
M'MK9/!"7*1_:PD+/)X?G7YG`N,,'BGG3CS>47_X$^7\'OT[-E.+3Y?-K[H\W
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M%7_^$IM?^>6I?^"^X_\`B*^,/@9\6/BWXQ^.SVVM:]\7KQ6'B&+QAX;U[P$F
MC^%?#L$1F6RDTO4SID#7K,RP*`M_=AXYI7/"!A]PU,=81GW5_P"NGW717VG'
ML[?U_P`'4S?^$IM?^>6I?^"^X_\`B*/^$IM?^>6I?^"^X_\`B*TJ*!F;_P`)
M3:_\\M2_\%]Q_P#$4?\`"4VO_/+4O_!?<?\`Q%?GMHW[6?QPL_VJ_BSI_@G0
M_BU\:+K3Y[G2K>&/2QH>B^&_])MY8A+9ZQI^E6S/;6UP[1&UUJYEOU=7EV0M
M`]IZC\+?VDOC(?\`@GIJDGB#PO\`%73_`(T6UKKKV3:WX5MI]1NK>TOFCCN2
MFFI)8"Y^S21F*#"M<O"[103Q\N)WI*LMFKKHVK7TOOIK=:>>DK#TJ^RZWMW[
M=M=;Z=>Z3:3^N/\`A*;7_GEJ7_@ON/\`XBJ%OXDMQXHO)/+U#:UK`H'V&?=P
M\W;9D=>O0\^AKX1/QQ^+=I&RK\0OVG;CX476NQ0?\)M)\'D'CBU<6$TCVJ:0
MOAX-]A,ZPC[4^EGYI&03#`S]9_L9:SXP\0?!?0;SQXVI3>*)]*B-Q/J-DEC?
M7<7VFZ%O/<VZ1QK!<26XBDDB$<?ER.Z;$V[17+OY6_%7_J_RNM2.;5+O?\';
M^K?/70]*_P"$IM?^>6I?^"^X_P#B*/\`A*;7_GEJ7_@ON/\`XBK&M:M'H.CW
M=],EU)#9PO/(EM;R7$S*JEB$BC#/(Q`X5%+,<``D@5\*_"G]K/\`:FTZ+XG:
MKXH^#OCZ"'6O#6H^)/`UKK&E:5<6^EW\#3/!I!32KR6Z=);0VK9O%AF-S'=(
MI'F0PQQ&2<G%Z65[O;J]]E=)VOO:V]D]>5V375I6ZZZ7]%=7[73VNS[B_P"$
MIM?^>6I?^"^X_P#B*/\`A*;7_GEJ7_@ON/\`XBOS:_X*-?\`!>R__8W^'MYX
MHM_#^O>'O#=_KMAHFAZAXE^&>K6]_<.UC<7%VPTO4KO29KF-)(X8_.BE58O-
M!(E)"U[Y^T+^T-XUUK_@EGHGQ'\*^,_$%YX^UKP_:ZQI>H_"KP3/KMOKM]+:
MM+%`EC-::A-'8R.0&>14=`%S+$213CJI2Z1E&+]9*Z_#7N^B9,=7&/62;7I%
MV?XZ=EU:LSZI_P"$IM?^>6I?^"^X_P#B*/\`A*;7_GEJ7_@ON/\`XBOBG]HC
M]HOXI>)_BGYW@G6/CGX=6\TO1[WP1HFG_"Z9]&\3S32O]IBUNZO-(FDTS#*(
MW66XL7BC._;DAS]T55G:[[M?=_7KW2)C)-V79/[_`.O3M<Y[1_$EO'J.JL8]
M0_>72L,6,YQ^XB'/R<=.AYQ@]"*O_P#"4VO_`#RU+_P7W'_Q%&B?\A/6/^OQ
M?_2>&O*/^"@7B;Q5X2_9?UJ]\%^)/$GA7Q)'/;&UO=!\+7'B.^<"96>!;>"P
MU!XQ,H:(W)LKD0"0R&)]H4YU)J*N_+\=/ZMKV3>AI"+D[+^OZ^[O9'J__"4V
MO_/+4O\`P7W'_P`11_PE-K_SRU+_`,%]Q_\`$5\!_%/_`(*'?'?X(_LZ_!N\
MT?X5_&+Q9J7B@W4>NZO?_#>Z\37T,D%RT06ZLK!-(GLK>5?WL=X]@LHA$>=.
M>5G2/N-!_;P^+'B7]MO5_!-CH]C>>']#\66'A^XTBS^&_B*=OL<^FV5W<7TG
MB4NFF6S6[74C?9I;<2RI`J#9).FW:%-RJ>R6]VON:C]UVO1>\[1]XRE.T/:/
M:U_P;TMHW9='J]%>6A]B?\)3:_\`/+4O_!?<?_$4?\)3:_\`/+4O_!?<?_$5
M\^?M4?&_Q#\(_P!L'X.0:;J7Q;N?#FLW<UGXET70_A]<ZYH`M7M;L07=Q?6V
MFS26\PO!:H1]KC58SO>/9NDJ[\&?`_Q-/[8?BJ^N_BA\3M8^&F@PR6W]C^(]
M$T6UL[_4;@K,HL9+?3+>Z:TM(65!*T\HEDE*ER;>3?G#WK6_O:]N7OZZ)>;2
M=F7/W=_+_P`F_P`K-OR5U='M6O:_!>VD$:1WJLUY;8,EG-&O^OC/+,H`_$UO
M5F^*?^09%_U^6O\`Z41UI4`?F?\`M\_\%,?$7[*/[3=GX"TN^^#WA[2E\':5
MK@N/$NGZ%)=WD]S+>1R8;4_%>AY11;1G]S'.<NV]DR@;V_XW_MEZMX!U'6H_
M#_@?P+KFB^&;GP=;W6MQW+33:HVN:K8VQ6UL8XMA3[/-<.DIO6Q((1LE5F(^
MD?#?B`P)HNC?V[H,.J7FF?;;73Y(_P#2Y;>/RDDD5/.#,B-+$K.%P#(@.-P%
M;WV75_\`G^TW_P``7_\`CM$+QBNOO7OW5WIZ=-.VJ>Q7,G54[:)+3Y+\[=NN
MG<^9OV#?VV]#_;0UW4;-K/X"6]Q;Z='J::1X6^(<7B3Q#IBLP#1:KI_V"W:Q
MFC+JCJ'F"RAT+#`+?/'[,7_!4CQ-\8_V^X_AGJD/PEN-'D\9:]X<ETK3-+TC
M^V+.WLI+Y()VV>);C4<DVT)D:318HP)&;=&@60_I!]EU?_G^TW_P!?\`^.T?
M9=7_`.?[3?\`P!?_`..U46E.,NB337>[W\K+1?>9M-TY0ZO9]M&OGKK\K;'P
MSHW_``4$\3:CKWQ`M7\*?#\1^%/%&B:):%=,EW20WOQ`U;PU*TG[[EQ9V$,B
MD8`F9V(9"(UL?LI?\%$/&'QF\!^#?$WB#X,^!O\`A%]<&GZ;=ZEHVN2OJUQJ
M=QX=AUEA;:2]B4\C=(85W7YDR`<-TKZ=\$_M6>`?B9\5]5\!^&_BU\+/$'CC
M0C,-2\.Z;JEM=ZMIQA<1S>=:QW)EC\MR%;<HVL0#@UU7C_Q';^!/`^K:SXJ\
M0>%M&\-Z;:27&IWVJQ"WL;6W529'FDDF")&%SN+$`#.:F4K4I-=5=/HMM?31
M^5W=WM9]$I1E4FE&UY:+K'2UOOL_/;2]S\^/&'_!<;2_!WPD\:^(E\!_L_\`
MB"[\%6NDZA>C1/C%9W&EV,-]-<QO#=W,FG12Q7T"VLCM90V\\\FY%B65R5'I
M7[1__!2G_A1GA7Q5XHT;X9^'O&.CZ=X%\(^*M)LI[Z'PXIFUJ]U*!VO=1OQ'
M#9VD<=I"?,FB1E9F##+@)[5^Q)X9^!5MX+UC4OV<&^`<?AV\O5M]5NOAMIFG
MBRGNHD#!)WL)=C2HDH(#G<JR`\!N?:)H]4MX6DDU#2XXXP69FLG"J!U)/G55
M72+6ST=^RMJM;Z/2SW6KUNDL823;=NEK>:<7?O=VDFO[VFVOQ[^S_P#\%&IO
MC/\``_P/XJNO@WX9M=2^(=S<:)H]CH'C?2?%5C-K,4Y'V0ZAIXD@\G[*LMTT
MPRT:6=VK1!DC\[[$_P"$/TC_`*!>F_\`@,G^%<3;6?@_QI\0?"OBR&\^&^K>
M*M0TB=O#>LI8P3ZA<Z:_DO.;.<2F1K9MUNS^4Q0[HB>JUU'B'7Y/"5G#<:MK
M_A_3+>XN8;.*6[A\E))YI%BAB4M,`7DD=451RS,``20*J716L[_KHO7_`("U
M:YG$4UUNK?U\OOV;OJDKW_"'Z1_T"]-_\!D_PH_X0_2/^@7IO_@,G^%'V75_
M^?[3?_`%_P#X[1]EU?\`Y_M-_P#`%_\`X[698?\`"'Z1_P!`O3?_``&3_"C_
M`(0_2/\`H%Z;_P"`R?X4?9=7_P"?[3?_``!?_P".T?9=7_Y_M-_\`7_^.T`'
M_"'Z1_T"]-_\!D_PH_X0_2/^@7IO_@,G^%'V75_^?[3?_`%__CM'V75_^?[3
M?_`%_P#X[0`?\(?I'_0+TW_P&3_"C_A#](_Z!>F_^`R?X4?9=7_Y_M-_\`7_
M`/CM'V75_P#G^TW_`,`7_P#CM`!_PA^D?]`O3?\`P&3_``H_X0_2/^@7IO\`
MX#)_A1]EU?\`Y_M-_P#`%_\`X[1]EU?_`)_M-_\``%__`([0`?\`"'Z1_P!`
MO3?_``&3_"C_`(0_2/\`H%Z;_P"`R?X4?9=7_P"?[3?_``!?_P".T?9=7_Y_
MM-_\`7_^.T`'_"'Z1_T"]-_\!D_PH_X0_2/^@7IO_@,G^%'V75_^?[3?_`%_
M_CM'V75_^?[3?_`%_P#X[0!0M_"NEMXHO(SING^6MK`P7[.FT$O-DXQWP/R%
M7_\`A#](_P"@7IO_`(#)_A5"WM]4_P"$HO`+S3_,^RP9;[&^TC?-CCS?KSGG
M(Z8YO_9=7_Y_M-_\`7_^.TP#_A#](_Z!>F_^`R?X5Y)^VA^TEX-_8@^$<?C3
MQ)X6@U+1_MJ64S0ZGH&CK;%U<JS3:O?65N<E-H1)6D8L,(1N(];^RZO_`,_V
MF_\`@"__`,=KQO\`;8D^'6F_#G39OC)\5;#X9>'1J`6TU$>.]1\"K<7)C?$)
MNK74;5I<H';RF=E.S=MRH(RK<W+[KL]-_5?GL73M?57W_+]#H;/XF6/B3]G#
M1?B)X=^%GB?Q%)KVEV>JVOAB&STVPUP)<JC^7(M[<P6\<L:OEU><8V,%+'`/
MAF@?\%5/AGJ_C3X=:+>?#7Q#X<D^)4YM--NM=U'PKIEN+A=1GT]X8C-JRMJ#
MK+`'(TQ;S,=Q;,I8S(#K>(OV:/@K\/\`]AK7]$\5_$JSM?@'XH@MG:]U#QK=
MZ5H]MIDD4%O;VEO?P7T&RSE14!`E/VIIY&F:9YG9N+\->!/V3Y]7^'>CVWQ\
MT?7&U;[+-X1T*^^.VN:K9^(EBO'%OY5C/KDD.H(+J)HU#1RJ6A\O!$85>KW7
M7T3Y>9:==5K%^:^;=KII;X:^POUL]>FEM5O=?=9/5-O3T[PM^V3X8^)?B^'0
M;?X8^+M"TGQ*FJVWAKQ;?V^D+I.OSV*RF5($AO)+V)ML,SK]HMH<K"_0X!^A
MO^$/TC_H%Z;_`.`R?X5\M?"OP1^S[X<^/_BS3O`_Q$\(ZU\3-%M]4FO/"<?C
MV\UB7PWYK[KPVVCS:C-#II+OM8P6\6T2;.%8J?J7[+J__/\`:;_X`O\`_':Q
MC_#B_+?OY^?JDO0M_')>?W?Y?>_4/^$/TC_H%Z;_`.`R?X4?\(?I'_0+TW_P
M&3_"C[+J_P#S_:;_`.`+_P#QVC[+J_\`S_:;_P"`+_\`QV@9\U^$O^"@_P`/
M/$'QN^('A"^\(QZ)'\/8I!=O<WNDS:O/,MTEM&HT:&>34D2Z::#[&[6X:Y+'
MY$#VQN>U\-_M/^!]<_9+NOC!=>$=4T;1[%+P7&DWEA9MJD4]K=RV;VY$,LD!
MD:>(HI$QC^9275<D>,:-^RW^S'\<OVEO&FAZ_P"*/#/QN\8Z?-<ZG<^%_'.O
MWGC33O"GS11W<=E87]W/:VC1R",RK&GG6XNXT8QPS01GN/A=^R7\`=-_98N(
M_`<G@'3?@O?:=JT\S^&=5GM/#=Q!=2"2\NV>VO5MVDC:'Y+DGS+41;8GB52*
M5_W"<M^5._39Z]M]+ZKW=%O=M/V]DM+[=5MIW\[7OKOL5T_;UT8:]+X8F^`7
MQ,M_B2MY'!%X)D3PU_:MS;O;R7`O4G75#I_D;895^:[67=&P$9ZUZQ^SYX]\
M-_M#>#;/Q7IN@/IMGJ=FF[3]1M8%NM.N([BY@N()1$TD8ECEB>-O+=U)CX9A
M@U\SQ>%/V1=1^!TWBF/XZ>#YO"UAX@03>/$^-6JM?0:D;5HUM'\0#6?M8!MW
M;%H;GR]K%O+[U],?L]Z)H.D^`-&M_AWJWAR^\&C1K232+S3W?4+6]MG:9DF2
MX\]S.7)9VF:1VD+EBQ)+'7^;Y?+1?=??K=:JRT,M;J_G^>GW;/:STUW.]D\)
M:/%&S'2M.PHR?]&3_"OF#PI_P4R^$_C']CV?XPVG@GQ8MO"Z1)X5DT>S7Q%<
M-);+>P[(O/-N5DL6%V)//$:P;F=D,<BI]/R6FK-&P:^TW;CG_0GZ?]_:^9/#
M7P+_`&;;#X-VWQ*TS6_A:WP_T3P:W@A/%4>NO)H]OHL.^T,3WGVTPEH]TT'V
MAG,R;Y4\P;W!YZG/[.HXM7LK-[)^]=OR>B\M7K;EET4U'3F3W7_#>O6W6UKJ
M]UU6D_MS?!6\T?Q)>ZA%J_AF'PGH4WB74CK_`((U/2D_LZ`*9[FVDGM5COHX
MMZ;GLWG4>9&<D.A:_P#%7]J+PC\./V8+KXM6'P[\8>*O#-@DMQ>6]KX?BTC4
M[2TB,GFW;VVK/9/Y*B,L-H+R*R-&DBL#7FGP'_X(I_LY?`[5O&WB'P+X'TBQ
MG^*VCW.E:_=Q:OK%W'J]C=NLTJKYE^ZH'8*P>+:0/ND"O3/VX/"OPW\3?`:;
M1?C;XXT/PCX#U:YCL9IKKQ1>>$X;Z1U=5M7NH+^W>19%+@P&0J^.5;`QT5N5
M-<N]U=/OS/3JWI9='>^UU;&C=_%MKJNW*M>R=[OJK6T>IM>/?B_H?P\^.7@/
MP7>?#_6)K?XA/-;6'B&"WTXZ7;745K<71MIE:X%V)##;2,&2W>/[H+@G`](_
MX0_2/^@7IO\`X#)_A7SC\0/V=/@[J_QK^%OA;Q#\1+R+XA>%+7[;X-T2;XH:
M];ZM=10K*&NOLPU99;]O+,Z23S+,S1F1'9DRM?1WV75_^?[3?_`%_P#X[4Z<
MMUW?W7T^?1KI;=O4%>^O9??;7Y/1KOY*R*&C^%=+EU'55;3=/98[I50&W0[1
MY$1P...23]2:S/BYXA\(_!+X8:]XNU[3[./2/#MC+?W7DV2RS.J*3LC0#+R,
M<*B#EF95')%:>CV^J'4=5VWFGJPNEWDV;G<?(BZ?O>.,#'/()[X',_M`?`KP
M[\>_AQ/H?Q'M?#/B#PA;S1ZE>Z?JMI(=-N/LY\U?M41G$<T*LH<QS!HR45BI
M*@C.HVH[V\^RZOY+7S\MS2G;F5T>>6W[='PDM?A)H?BK6M#\1:'<:YK=UX87
MPX/"%SK'B"UU>V6=KBP>STR*Z=I8TMYI"T6^-HU$BNR,K';A_:Z^#=Y?>`[2
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M7[/NE^(-8D^`_P`3O"OC[4-&TRVT>[2V^(E_XV?0;%6;R;:-+G4[K[%"60X2
M,1JWE`8.P8C#ZI<^NCV_Q2L^FRY4^EU)]+.ZNB?)WCOTT5UUWU:^5K)Z?1^O
M>&].T^T@FM]/LH9EO+;:\<"JRYGC'!`K>K!UZ#44M(#<75E)#]LMMRQVK(Q_
M?Q]"9#C\JWJ0'@.B?"+Q#JG[0UK\0+[Q79C2=+\&W'AOP_I5GX0NENK![LV,
ML]Q<W;7$D5UB2S4HB6\("N0S28W'X?\`#7_!`KQGHGPCU_PY=?'+P#J-[J^N
MZ?KUI./V=;*QTG2I[6*ZB,PT6UN8M,NKF1;DJ9[RWG*A$*J)(X9(ON'1/CAX
M@N_VI=)\+Z7IOC"3PGX;\!WE]KKMX6NX=/N=1+Z:UBEM?RP+#=2^2]X#';3N
M%.X2!648^9/V4_\`@H-^U1^U??KHMO\`#/5_AW)/XAM[+_A)/B%\%-7\/P6E
MD^GZC<2-_9HUJ;SMD]I:Q>?]NB4M>A3$&5?,>'NHJ5/HDUZ*JVM^\TY7ZQ:3
MNM"INWQOKKY_NUNNJY;*UMV[)W;/5_$O[`=UXB_:^M/B<WBCPZOV76K75TU&
M3X<7$GC:TAA1`VE6NN?:@MOIDK(P>U6S(:.XN%+;I3+6Y\!O^"?W@W]GSXNZ
M;XZT-+6T\5-K'B'4O$.KVGA)[74?%,&IW4]S%:75RN9)([5I8P@D+J?(0JL>
M`%QO!7[4G[1&B>"=4U[Q-\.;'Q)-=>!;OQ+I>AZ+X;O]*O-/U&TFAA.G3RSW
M$XN);E9'GCC2.&1%A9`+@D25X_#_`,%1?V@I_P!C.R\<+\*?'$?B@>+/[,NM
M,N/@1XECU^;3Q`79XM!2]DB5_,:,">365@,8D;/GJ+5G1E>,84]NG_;TO9OS
MWCK?=:J]]<N2\K-:W7WQCSKR>DGKW=GMIZ/\`O\`@G+KGP1_:XO/B,WQ.O-4
MT5_$/B#7[31&\.Z^SVYU:>YG:WQ<ZK/IT*H]P"TMGIUK/+Y*@R@23++[;\=/
MA/K'QW^!&CZ'?>)ET_QIHFHZ9KT&LVOA6\_LJ74K&YCN8VDT]IS(]JTL8W0?
M:@^WI,K`.,K]O'Q_XX\'>`_"\OABY\<:!H=_J+)XEU[PAX>&O>(-%MQ;2O;_
M`&>P^Q7YD$MT((966SN#%'([;5`,L?AG[%?[1?[27Q$CT'3]5TW7[;2[>XUF
M^UW7/''A2]NK_4+>T?2_(M;%4TSPX(6N$NKQ8VN;'<'MG8"=%(J8._N+_EW9
M^G)[R:?=;VW=MGH7.3D_:/5U6[^;E>]UMKM?972NNF;^W%_P34^,7[>EGX+/
MB;XZ?#K1-0\(75U*ESIG[/B74FR4VQ1K6;4;Z[NM/N4:!S]HM)XV.Z(X5H58
M[5[_`,$T]0\4?MK^*OBE?ZE\/]/M]2\5VFO:?J-M\/+VY\;0V\.F6EJUFFM-
M<(+6UFD@E$MLEM(LD,TH,@:9MF#^R]_P4/\`VE/VC?A)XXF_X5/XF\*^)--\
M0>'=,T.]\;?"'5/"T;VVH7WD7L[:;_:UV]S'9PCSFE2\B4[L.L2KYC=-\3OC
M]^U;X7^'?B*0:/H>J7JQ>(M!L6\.>`-1M[Y+ZRM+F>RUB,3W=W']FN7BCACM
M6BDW/*K"X?(B-1I_8[*7X^SD_75P5N[=E92:)2OI?1VCY?:27DG[SOY:M-I/
M>U;_`()M>'[W4OV?]4CN?#MQXB^!_AU?##:UJGP\>^U"]MA#;HL]E,9%:PNX
MG@:2&4FX6(SR?NV+$UP?[)O_``2:US]GO1?$EEXA^*]EXN;6_%6A^)HKRP^%
MO_".W3'3=2COF6]-K/Y>H7$WE!6OKB,W67=GEE!"#V/]HSX_?%?X1>,OB%<Z
M'HNKZEH-CHWAA=*N%\)7NNV^F7%W>W\.HWBVEBJWFHF");1WM8)`X&PYB5FD
MKAX?C[^T?>>([[Q1H<NG^(?!NB>%]"U"?3+[X3:UHEWXHO);[4(KZ*P@N;I+
MK3I5ABMV9;E;TJ&C<1HK9DJ$I>U=9;\UV^TK\][=-=;I:W:5_>2SGRN"C+;E
M5O31)7ZOWK-7TT;LN5O[#_X2FU_YY:E_X+[C_P"(H_X2FU_YY:E_X+[C_P"(
MK2HK,T,W_A*;7_GEJ7_@ON/_`(BC_A*;7_GEJ7_@ON/_`(BM*B@#-_X2FU_Y
MY:E_X+[C_P"(H_X2FU_YY:E_X+[C_P"(K2HH`S?^$IM?^>6I?^"^X_\`B*/^
M$IM?^>6I?^"^X_\`B*TJ*`,W_A*;7_GEJ7_@ON/_`(BC_A*;7_GEJ7_@ON/_
M`(BM*B@#-_X2FU_YY:E_X+[C_P"(H_X2FU_YY:E_X+[C_P"(K2HH`S?^$IM?
M^>6I?^"^X_\`B*/^$IM?^>6I?^"^X_\`B*TJ*`.>M_$EN/%%Y)Y>H;6M8%`^
MPS[N'F[;,CKUZ'GT-7_^$IM?^>6I?^"^X_\`B*+7_D;K[_KSM_\`T.>M*@#-
M_P"$IM?^>6I?^"^X_P#B*\A_;3^$WB+]I?X40^&?"OBV7P5(]XL]Y=S:7XBW
MSPJK#RDDTG5-+N4RQ!.9V1@"#&<@K[A7S?\`\%/?B%XV^'/P"L;KX>ZOXZTC
MQ--JL<43^&=%N=3DEC\N0LL_D>'=>:.,8#;OL:`LJKYR9VMCB.3D]]76FGS5
MOQ-*/-S>Z[:/\M2M\.OA'\7?A_\`L?WGPWT7Q[X3\)^(M%L[?0O"?B6U^']S
M?1Z=8PVT,/VB2P\RW@^T%UE>.)288%,*/]JV.\OEWA__`()T_$#3-8\"SGXM
M:+HG_"+WD=YJE]X4\%>*=#U3Q$W]HR7\_P!ID'B&2WNO-DEF)6_MKQ%>YN65
M`)B@[31_VKKSQ?\`\$Y;C7KS7OC5_P`)YX1TNQL/$MSX*\`1W?BR765M[>::
MWM]-DL[NT\^1I%21/+:.V:5TE>W>)_+\#\&_M-?'Y/&7P=E3Q-\=O&,>H74,
M&OZ'<?#*^\-'RI-7G"O=W=QX/:VED6RDACE`N='C'V(R(V+E63L]YXG>\^:.
MN]VUI):;/=V2O=.VJ.=V^KWVC9Z;:=4_397;>CL[W/H#X:_LB>(?AOXATN;6
MO'.GZWX-\`MK=WX4TRS\$7NF:E`^H>>"+^_>\FBNE2.XD7$=M;`N$<XV!:^H
M/^$IM?\`GEJ7_@ON/_B*^,/@9\6/BWXQ^.SVVM:]\7KQ6'B&+QAX;U[P$FC^
M%?#L$1F6RDTO4SID#7K,RP*`M_=AXYI7/"!A]PUC'^'%]&M/^'Z^MWZE?;DN
MM]?N73IZ67H9O_"4VO\`SRU+_P`%]Q_\11_PE-K_`,\M2_\`!?<?_$5I44%'
MPGJ?_!.#QM\2?BCX^FU_XQ:QX)\!^)KV5[?P_P##W0-0@AU&!Y8;D_;;369]
M3TJ,M*)A.MG80?:][O,Y6>6WKMO"'[#WB#PE^R)JOP@F^*VL>)--U8:S<OJV
MM>"1]OBO+N^^VVK*+/[-#Y$,C2&6(QEYS*=DMLH5!XUHW[6?QPL_VJ_BSI_@
MG0_BU\:+K3Y[G2K>&/2QH>B^&_\`2;>6(2V>L:?I5LSVUM<.T1M=:N9;]75Y
M=D+0/:>H_"W]I+XR'_@GIJDGB#PO\5=/^-%M:ZZ]DVM^%;:?4;JWM+YHX[DI
MIJ26`N?LTD9B@PK7+PNT4$\?+J+_`-G4E\/+=+K:W2_6VMT[=4]'8DKXBSUE
M=Z[ZZ;I=]-&NB35[)V+K]C?XE7/Q,A^)W_"T?"*_%R&^0_;1\+=3_P"$;-@E
ME/:B'^S?[5^T?:/W[,;C[=@A57RL*"/:?V9OAY:_L]_#ZQ\+&^U#6)K&T$ES
M>#2I[=;BYFN;JXG9(<.88C+,_EQEFV)M3<VTFODD_''XMVD;*OQ"_:=N/A1=
M:[%!_P`)M)\'D'CBU<6$TCVJ:0OAX-]A,ZPC[4^EGYI&03#`S]9_L9:SXP\0
M?!?0;SQXVI3>*)]*B-Q/J-DEC?7<7VFZ%O/<VZ1QK!<26XBDDB$<?ER.Z;$V
M[1I9^]\ORNO33TN]==S-6NK>?YZ^NOK;;38](F\2VLL3+Y>I#<",_P!GW'_Q
M%?&G@?\`X)5:9X*^$]CX%3QQJLW@^+PM;6-YI'_")2+:WWB&WTW^SHM=(W$K
M^Z$<AMLD&>W@E$BNC%_MV<LL#[?O;3CCO7Y^?#OXT?M67_[(%OX1UBW\9K\5
MM6\)Q>,(_'3>$+:-M/@>Q-Q-IKVODBV_M6.^7[&D#09,$\4Q25XI@>2MR>RJ
M\Z;5E=+=KWM%UNES2Z6LGNHVZZ//IROJO^']'\+77FLTXN1SOP0_X(K^(OAO
MK?QFEU[XTZ;K>G_%KPCJ7A46^B_!FT\+S69NY$9+N[N+%TEU*:)595>Y)DS)
M(PD4N^[Z?_:`_9;M_%/[&FL?!OX3R^&OA3I.MV=QILI_X02YO[*WM[D2?:3%
M:V\]H%G=Y#)YK.PWEBR.6)KYL^`/_!3#]I#XBWOQ?TNX^"OQ"6Z\%>#=1U7P
M[=>)OA)J/AFWU/5;9TC@LTG74;I=3\_<S;H8;-L196(A]L?OO[;7C'XJ?"?]
M@[5-6C\5^)_^%K6:2S:?/\,_A]-JG]I7>)7M[-]/E@U61+<CRTEF)3++N$D`
M<(.[$<RC%3>FENGVY?-^]S/K=/2]TCDP]G*\-[MZ]'RQOY+3E72SOV;+'Q1^
M"?Q4^(_CCX/:XOQ&\$V,GPUO/[3U.(_"_5)5UN[>UN;.8PG^U5^RQ-;W3[$;
MSV2158NZYC/T)_PE-K_SRU+_`,%]Q_\`$5\Q_&?]J+6-&_:*^`^JZ#>?'`^$
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M:2U[K;J[JR^;TML]GH=%*_,K.WF]EY_+>_3<^4?B9_P2GUC5?`WA_P`)Z=XV
MT3X@>';'X@7?CBXMOBO\.UURRC-WI][%=0G3].73[6Y1[RY6X2/;`(I'ED)E
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M(?,$UI$R;K-D"%T97)#KR/\`P3W_`&(]<_8NUW5KK7/'5KXN@O=)M-)M;?3O
M"&K:<EJD#.R[?MFH7X@A&]A'9V(M+.'>^RW&5V:WC/X^>)O`7_!12/P[#>?&
M+7O".K>$[QI=+C^'EQ<>'-+U9#9O:>1JT>GHFZ:'[9O$]^T2N%0F)BJGSK_@
MD7\9/C;\3/%/BJ'XL:U\4M<MH=(L9;1O%/@9_#D-O<EY1,5\S1=+*2R*4S:P
MOJ44`B/^G2;U+XX76*]GVEOKIS3NNO6[_P"WHOM:\1L^?O';KI&S^6B=][26
MNM_L?7M?@O;2"-([U6:\ML&2SFC7_7QGEF4`?B:WJS?%/_(,B_Z_+7_THCK2
MH`^;_'?[6*?#3XAKX*TGX6?%SXA:AH_A?3_$NKWGAK4=,BL]*M+J2ZABW+>:
MG:RR/FQN#LMXI"`J@9+!:Z#4_P!L#X6Z1/X,,^J^-AIWQ`L;/4-$UA-"U^31
M9HKOBV6745@-I;2RG:JPSRQREI(UV9=`V?X\_8@\'_'GQ#8>+=<T[Q)%K,VA
M6FBW$VB_$77_``_#J5C"TTL4%U;V$\,-PJM<SG$JOQ,ZY*G%<[\5/^"27P+^
M-/[17A#XK^(?A1H=QXZ\`VME8^'[ZU\1ZE8P:7!9LSVL4=K;LEMLC+M@&(C&
M`<@`!>]9+S_#6_J_AMM;WKN6EB?+S-PVY5;_`!6COY7YN^G+HM;Z.@_\%"_@
M]XS^#_BOQMH.I>.M4TGPGX=;Q5)'/H^L://JVFA&<7-@-02W2\A8#`EA9HP7
M0%QN7/:M^TG\-T^,T/@(ZUXA_P"$@FE%L)!;:JVE)=&/S19/J00V27ACPXM6
MG$Y1E;R\,"8;G]CKP7=^"8_#DG@W36T:+PC_`,((MO\`V]>C&BX4?9=V-W1%
M_>9\SC[_`%KF+#_@FQ\*M(_;);]H"Q\`6FF_%J6`VLVMV7BK5+5+F(Q^6R2V
MD;+:RJPP6#Q-N8!SEP&&ON\ZM?EUOWW?+;IJK7[.]KI:S*_*[;].VRO?T=[=
MU;9O2SX^_;$\)^!?V8=4^*<6@?$37M-TWQ`WAB/1],G#ZMJ%Z-:_L94A22Z2
M(A[K!4M*I*$$@-\M-UC]M?X>VWB_X6Z3I2^,/$B?%A+>?3[[3)I#:Z3!<1R/
M;37IEGC>(3&*5$15>4M#+E`(Y&7M7_9Q\/R?#E?"3>%]-_X1]=>7Q.+7^VKO
MC45U,:JL^_;OXO@)=F[9_!MV?)6-X:_8O\"^#;RZN-*\#:/I\UYXE/B^1X-:
MO$(U,B4><N!\B#SYV$*XB#S2.$#.S'-7TO\`S)O_``^[=>K]ZSZ62ZWC4K<C
M4=_>MVU^%OTV:\[Z\O++IOCQXOB^!WPJU;Q4GA_Q5XJCT6+[1<6.F:Y:V<RP
M#F28RZA>VMJD<:;G<R3KA5.,G`/B_A7_`(**^#M7^"/C#QQK7@7XU>$8/!/A
M2U\9:AH^I6ANM8:QN9+Q(-EO975QEV%E(Y#,JI'(C.RC>4]+^+7[*&@?'+X%
M6GPW\4:;K&I>%;-K6157QWK-OJ$KVSK)"TM_%(MY,RNJONDF8LRJS$D`U4\$
M?L9^$_`?ASQ1I<&B:EJT'C32%T'6YO$'CG6=>O-0L5-R5@:YOI)I@H^V7`!#
M@@28!PJA9ES\M11W^S?]?5^MK=;V6D>3FAS;77-Z75[?*_;6VUG?C_!W_!1/
MX3^+_B'+X=DB^+'A]K?PO%XNGU/Q#X5U_1M,M+*0S_ZZXN8D6!QY#_ZW8KDA
M8V=]RKIW?[>OP=T_PI9:I<:O\0+634-6.A6^CS>%O$L?B![W[-)="'^RFMA?
M@M;Q22J3`%=$)4L*EU'_`()[_#_7-.M[34O#>J:O;P>')?"4L>H^/]=O1J&F
M.TK>3=^;*WVMHVFD:*6X\R2`L#$Z$+B']F/_`()O_"_]CGP9X>\._#OP-'H>
MA^$]9N/$&C6<WB_5M0BTV]GMI;6:2(73R;5>*:4&,?)ND9]N_P":MO=YGVZ=
MW[[T?;W+:Z^]?2VISQYE%7WTO_X`KV]:E_\`MVW71>YQ^&;66-6$FIX89&;^
MX!_(OFE_X1:U_P">NI?^#"X_^+H^U:O_`,^.F_\`@<__`,:H^U:O_P`^.F_^
M!S__`!JLRUYA_P`(M:_\]=2_\&%Q_P#%T?\`"+6O_/74O_!A<?\`Q='VK5_^
M?'3?_`Y__C5'VK5_^?'3?_`Y_P#XU0,/^$6M?^>NI?\`@PN/_BZ/^$6M?^>N
MI?\`@PN/_BZ/M6K_`//CIO\`X'/_`/&J/M6K_P#/CIO_`('/_P#&J`#_`(1:
MU_YZZE_X,+C_`.+H_P"$6M?^>NI?^#"X_P#BZ/M6K_\`/CIO_@<__P`:H^U:
MO_SXZ;_X'/\`_&J`#_A%K7_GKJ7_`(,+C_XNC_A%K7_GKJ7_`(,+C_XNC[5J
M_P#SXZ;_`.!S_P#QJC[5J_\`SXZ;_P"!S_\`QJ@`_P"$6M?^>NI?^#"X_P#B
MZ/\`A%K7_GKJ7_@PN/\`XNC[5J__`#XZ;_X'/_\`&J/M6K_\^.F_^!S_`/QJ
M@`_X1:U_YZZE_P"#"X_^+H_X1:U_YZZE_P"#"X_^+H^U:O\`\^.F_P#@<_\`
M\:H^U:O_`,^.F_\`@<__`,:H`H6_ANW/BB\C\S4-JVL#`_;I]W+S=]^3TZ=!
MSZFK_P#PBUK_`,]=2_\`!A<?_%U0M[G5/^$HO"+/3_,^RP9'VQ]H&^;'/E?7
MC'&!USQ?^U:O_P`^.F_^!S__`!JF`?\`"+6O_/74O_!A<?\`Q=>+_MN_MB?#
M_P#8'^'FD>(/&EQJ3+X@U-=(TVU'B6STLW4_E23,/M.IWUI9Q!8XI&S+<)NP
M%7<[*I]H^U:O_P`^.F_^!S__`!JN%^.W[/6E_M(:-I=GXHTR[5M%O/M^GWNB
M>+M3T#4;&8Q/"S17E@8+A`T<LB,JR!65B&!%1+FM[OE]U]?P*CRWU\_RT_$Y
M7Q9^U9X7\,?L:P_&R#2?%&N^'9M.M=4^Q:3XBL+J9()Y(T,C78U`::(H0YDE
MG^V>0D<<C^:57->7^&O^"J?@?QOX)C\4:#X%^)GB/PK8VT%WXCUS1?$^@:GI
MWA.*6XEA#7,]OK3I<!1"\C_8#=;%!#8D#1CU#P7^Q%HW@CX0:UX%M;SQM_PC
MNL:@-0`@^(>KZ?>Z?M\O$5O>6AAN8T9H]\C>:9+B26:2=YI)9';G]%_X)??"
MWP_J\-[:^%]<67S4GOT?XE>(I8/$4J3O<++JL37!CU23S)&^>^6=B@5"2B*H
MVO'G;Z732[*VJ??5]'TT=F9/F]FDOBUN^C[6^Z^VSU5T-\+?MH:'\3/%\.@Q
M>!_B;H^C>)DU6V\-^*M3O[)M&\136*RF:.&./4)+Q"5AF=1<VL0987S@X!^A
MO^$6M?\`GKJ7_@PN/_BZ\8\,_L6>#?@]XEUCQ9HNAZA#J,D&H20PW?C76-3T
MW2#=%I+AK'3[F1[2R+DL/]&BB^5F085B#[/]JU?_`)\=-_\``Y__`(U6<?@B
MGO;7U_KR7H5]IOI?3T_KS?J'_"+6O_/74O\`P87'_P`71_PBUK_SUU+_`,&%
MQ_\`%T?:M7_Y\=-_\#G_`/C5'VK5_P#GQTW_`,#G_P#C5`SYK\)?\%#O!/B'
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M5M_.W^>CW6FBWN/^+=?#?;LM/^"]^N^AR:?M^V8UZ7PQ-\&_C?;_`!)6\C@B
M\$R:MHO]JW-N]O)<"]2==8.G^1MAE7YKM9=T;`1GK7K'[/GQ#T;]H7P;9^+-
M,M_$6F6NJ6:;['4;QEO;">.XN8)[>;RII$\R*6)XV"2.FY&VL0<GA9/^"<7P
M_E\/+8MI/BXW<>HC5%US_A:GB;_A(A,(&MPO]K_:?[0\GRF9?(\_R>2=F>:]
M.^%W@&'X0Z9;^&_#NC:?I^DZ/IUO;V]N=1FF*H'G.YI9$:261F+,[R$NS$LS
M,S$U6FORM]VOX^ORV(UNK^?YZ?AZ?/<ZF3PS:Q1LQDU+"C)_XF$__P`77S!X
M4_X*=?#7QC^Q[/\`&&TT/XG+;PND2>%9"%\17#26RWL.R+[6;<K)8L+L2>>(
MU@W,[(8Y%3Z@>?5I$*M8Z;AA@_Z<_P#\:KQO1OV!?AKX?>P:S^'NBPMIGA!?
M`ELW]MWK,FCK$T*P$D$LZQ221K.V9U2611(`[`XU/:<DU#>RY?)ZWOZ^ZO+5
MZVY9;T^33F75?=U_S\[6NKW5'2?V[OA%>:/XDO=0U3QUX9A\)Z%-XEU(Z_H.
MO:4G]G0!3/<VTD\*QWT<6]-SV;SJ/,C.2'0M?^*O[5/A[X<?LP77Q:L/"OQ2
M\5>&;!);B\M[6"72-3M+2(R>;=O;:M/9/Y*B,L-H+R*R-&DBL#7G/P6_X(K_
M`+//[//B3QYJ_@_X2Z;H^H?$S2[K1?$LO_"8:S<?VE:7,@DGBVRR,L>YU!W1
M!&&,`@<5[?\`M"_L\Z7^U)\++KP7XRTV\N/#=]\MU;:5XOU31'NDVLIBDFL3
M#*\3*Q#1LY1N-RG`QT5.71PWZKI\3TZMKELNCO?5:6QI7VG]_6UE;M9\U^ZM
M;1ZE'Q[\9K#X>?'+P'X+O/#'CN:W^(3S6UAXA@U*$Z7;745K<71MIE:\%V)#
M#;2,&2W>/[H+@G`](_X1:U_YZZE_X,+C_P"+KQKQ5^PIX3\;:QX#U#4[?QM<
M7GPU"?V!*/BMXFC:!T#KYLVVY'VJ5DDDC>6Y\QWC=HV9D)6O9?M6K_\`/CIO
M_@<__P`:J=+?-_=?3Y_EW>X*_7LOOZ_+_@Z+8H:/X;MY-1U53)J'[NZ51B^G
M&?W$1Y^?GKU/.,#H!69\7/%'A_X)?##7O%VO7.L1Z1X=L9;^Z\F\N)9G5%)V
M1H'R\C'"H@Y9F51R16GH]SJ@U'5=MGI[,;I=X-XXVGR(NG[KGC'/')([9//_
M`!O^!NB_M)^"/^$9\>>$M`\5>&VNH;R?2;^]EDL;YX7#QK<0^7Y=Q&'"MY4H
M>,LJDJ2H(B5[6C_7=^JZ=WVW-(<JE>6QYM;?MW_#&U^$FA^*M:7XBZ'<:YK=
MUX87PX-*U36/$%KJ]LL[7%@]GIGVIVEC2WFD+1;XVC42*[(RL=N']L+X4WE]
MX#M+77?%6H7WQ*AEGT&TL=+UN[N9(X9X;>X:XBBB9[,033QQS_:A%Y#%A+LV
M/MY#7/\`@E?\*9['2;'PWX-3X8Z3I>O?\))_9_P]\27OA"">]^PSV/F?\2Y8
M7A+0SD.;=HFE,<8D9U7:?3OAK^S3X>^$-QX;F\/^&+*TN/">E7>C:;/+KMY=
M3);7<\5Q<^:\H9IY99H(Y'FF+RLX9BY+N6UCR\UY;7Z=N5WMO;W[6WM&^[,]
M4K+L_OYM/_)=]KRVLMJI^,]A:_M-/\,;SPOX]L;F709_$.GZY)J$,FEZM#;R
M6T<\<(CO'NEEC>[B!$MO&K?-M9@.?/?V%_V_/!_[>^K>)K/P[X5^(GAN3PI%
M;O?'6M7L)O)EF:5?LDJV&HW3VMY&8CYMI=K#/%N7=&,\=GXQ_8R\+^/_`(]0
M?$K5M+UVZ\4V]C+IB`?$'7(]+^RRHJ2P'34E%DT<GEQET,!5WC1V!90P9^SG
M^Q3X1_95U.2\\':-JZW#:;#HT+:WX]UOQ!]@LHCF.UMAJ$LXMH0<?)"$4[4R
M#M7$4=OWG9[=[R:?3IRI_-^M5-GR=U]UE===]7]RTZ>G:]H$%E:02I)>LRWE
MM@27DTB_Z^,<JS$'\16]6#KT^HO:0"XM;*.'[9;;FCNF=A^_CZ`QC/YUO4@/
MCOXK_LFZQXP_:"U+XN>$_%?A;0_&%GX!T;P]X=-Y?.L=S);SZI+?6&H(JG%E
M<I>6HWIODBE@64(6A59.)_:I_9E_:"UKX+_`OPU\)?B'\,[&/P'HEGIOB:QU
M#QEKGAU9[B""",7-I>:7B28C9*JQ7D4EK\P>2VF.U4[#]H?]N;4/A'\7;/P7
M-\7O@7\`]-T_P[IVH6VI_%#36NE\7O<>:LB:>?[6TY5%KY*"7F9BUS'E8@%,
MNY_PWAX\\-_'KQ?I>J^"O"=]\.-#\;VO@JUURTUZ>#6/M-SI5G=Q$V!MY(98
MO-N2K3?:XF53Q"Y3=),912NG;6__`(#+E7EK*IHM^9W24M752\I.<ETL_3EC
M\](P5VMU=.\=#'^*/P;^.J_$:ZU;P/\`%SPVNEZ/<+KVAZ?K?B*=DU+4+B**
MVN['4/+MR/[/C07-Q`L8)^T72`1PI;QAN)^*?[%/Q.M/CKIVO>"_'>FZAY/A
M#0/#R>*M4^*^LZ/J5A>V$]X\^HW.EVMM)::UO%RKB"^F$19'3"+(S'U;]G']
MNKQK\7]>\`WOBKP;X7\%^'?'?@#4?'=M;6^OOJEY%;PG23!YT\D-M#`Q6^N`
M\8$BCRXF\X991XOX2_X+8ZQ\7_@7X/\`'_A72_@7:Z/<?$EO`?BR;5OB/=C3
M-`;[$;A(_P"TETQ;62<N40R6YN+5F,:Q3S^=YD713A*$XP2UNM.WONDE_=2E
M[NC5M+ZF,[>RDY/2S3?>T?:/U;2;N[WNTM-#UBT_9+U9_AG=Q:I\0V\0>+M4
M^(]CXJNI]7\87U_IUMI=GXD.HV]K:V\I,5LZ66V+$,2!W1%>1E17'@_QY_9C
M_:(L/$WB_P`>>'M2\/\`B'Q?I-CXH;P[=V_Q;U*[N-8FO4EATR./1KR*VTS2
M##"\2226EVK$1LVZ20JU>B>.?^"V&E^"]>\>0Q^'_!>L+X2TS7+Z/1=/\=)-
MXLL&TJ&:65M:TO[(!I%M*8&2.=IYOFGM0\:-*52]H7_!5+Q)\4/@=XBUKP7H
MGPB\4>)-#\5^&M`MIO#'CY_$WA/4AJU_!;&$ZK'9P-#=1*[-*@MY?)62WDQ/
MO\JN=4_:4_9QVEM;?]YRTTUUWBM->[31LY6J<TM[]=KQO-K>UK/?HM$U8^>_
M@E\!OVP/B!_P3VFTFXN=+^%_Q@N?&+WFL:/XS^,7B#5M'U/3!`BPBQU33]6N
MM6L8T8!F@6\!DE60NYA<0GZV_:$^`FI_'S_@GEI_PU\46_@?Q]XNDL]/&HV^
MN>,O*T]KRW=)?/-V^E7*W0BE175+K3GCGV`31L&?/E?[3'_!=+3?V1M)\/6?
MC[PIX9\->*M0\0WOA[4$O?$U\/#XN+5HMT5EJ4>EN9IG2XB91=P64"CS#+/$
M`C2?36A?M)^)O&7[5TW@'1_!>EMX<TCP[IOB'6=>O?$7E7-LM^;Y88+>TBMY
M4N'5[(;V-Q&@67<K.5"MI+]]#GCM)Q=UM>,5:S\TD[]&TU:Z,X_NY:[Q4M^S
ME9Z=;-\MO*S3LSY$^*?[(G[25I^SK\&_"?PU\8?`SPP/!9NDUW0[#Q/JOA.Q
MC4W+/;3VMSH=O:)/<+`2)$FL8[!YGDD-BP*1Q^E^/_@-\7O%?Q#^)-S#XRT?
M=XBT*\T[PQXG3XNZUI\FA/)IZ1PQMX?MK1--9TNQ(QOA)Y^)-ZJNU(5T/@7^
MW[=?%#]H.[TO7/C)\!_"CV>IZM:3?":[TQ_^$_MX;(W"*[RG5@=TD<"WGRZ:
M1Y$@"EQB<^6_LG?\%[O^&W]271/A;X+\"^-/$-QXAM]#AFL_&.JVFB1K-IVH
MWPDFN+[0[:Z5U739%9([.5?WT161CO5'3;J-RANTY/K93=KWVWT3N]/=;Y;H
M)14+<VT6EV3<=;6TZ)W5DKN]N:S/1I?@9\8/C]\2X=2^(_C31?`OA>77;2XO
MM`\"_%?6',UA#I5];M&EW'::?+&TMY/:RLD83(@W&0L`IS_B?^PUJGB/X-_#
MRPL]=T6_\0>`_B;K'C$6UO\`$;6/"]I>6-]?:E,$:ZL$:7STCO(3\T3#*2QA
MPDKLV7^TK_P6GN/V5/V?;SXE>-O"OP[\)>';KQG?>#O#S:UXPU=I-8ELKG4+
M>XDD73]!O3;DFR5HE(9761][Q%%67['^`?Q<M/C]\#?!OCJPM9[*Q\9:)9ZW
M;V\Q!D@CN8$F5&(X)`<`D>E*'O?O(?8E%OREI)?>HW:Z>5PFN5>QE]J,DO36
M,O\`TIJ_DM['PY^T1^R+^T.?`?@_1_A/\1OA?9VNG^*?$&MZU87WC/7?#N]+
M[6+B]MIH+O2\/+.D$YC,%W'-9AR6>&YPFWV/X'?#;XK>$/V_/&7C/Q-XN\+Z
MC\+-<T)+6Q@N/'^IZEJ5O?(+5!Y6FK!:Z3:6[+%,[,L4UT99&/VCRY/)B^K:
M*5+]V[KSW_O*S_X'E9;))54]^[?6U_D[_G^.N[;>;_PF.D?]!33?_`E/\:/^
M$QTC_H*:;_X$I_C6E12`S?\`A,=(_P"@IIO_`($I_C1_PF.D?]!33?\`P)3_
M`!K2HH`S?^$QTC_H*:;_`.!*?XT?\)CI'_04TW_P)3_&M*B@#-_X3'2/^@II
MO_@2G^-'_"8Z1_T%--_\"4_QK2HH`S?^$QTC_H*:;_X$I_C1_P`)CI'_`$%-
M-_\``E/\:TJ*`.>M_%>EKXHO)#J6G^6UK`H;[0FTD/-D9SVR/S%7_P#A,=(_
MZ"FF_P#@2G^-%K_R-U]_UYV__H<]:5`'+^/]7TCQ'X$UK3]OA?7_`+=8SV_]
MF:K>(EAJ.^-E\B=MDN(GSM<^7)A6/R-]T_#=]^Q+XRU__@F%XD^"-_\`#O\`
M9C.J2:OJEQX8L#XOGFT+P[%>7-W<PW,!;1`T%Q9M<B.)(H`"J;A+%G8/T,KY
M=_X*J?MO^(/V'?A)X5U;P]#H-O/XFU\:1/K&N?8?[-T:,6MQ<;Y!?:KI-NS2
M-"(E#W\)S)E1(P$;9RDH>]W<?O3T?WOY=+/4TC=V7:[_``=_PZ==+W17^.&F
M>-OVM_V/?&G@WQ5\/OA7I^O7EQ;V-GINI^,;'5=*OHX_(D>]$MUHM["H642>
M2MQITC.(D=T@9L1_+?PT_P""4OB_P!XC^#E[9:'^SWH^J?#N\22774UJQU6:
MTM/[9N-0-M%:77AH@,JW$Y$FF3Z,IDN2JQ11P0!??_B7_P`%,Y=._P""9$7Q
M<\.>)O`4/BZ$Z3:ZA+KEI'#IMA<74UON\Z"/4V@@\ZWE\RV:;5$M)!/;2&]\
MB03'POX5_P#!:;QIXA\:?"R#5/'WP'UBS\7ZI'IFH:7X7L=/O-<F9]5EM5>.
M!O%(/EF$P`2:8NM)YT5YR1$$;II1:Q%H_$I13[726OSNFW9/5)6CH<\[?54W
M\+3LNMG_`,,[>C>ZN?3?@3]B'X8_#S]IOQ[\7+/P;\(?#?B"\T^YTS0Y?#6F
MVEM>W,=PHFO;V]E2&-Y;RXG^3!,@2.(%7W3S"OI;_A,=(_Z"FF_^!*?XU\\>
M"OB-\7_%7[2OQ`\/WWBSX8>)OAOX3TZY34GTGP=>Z;J&G:A,HDM-.^U/JMS%
M/-';,);AOL\6!+;[5'FD1_3-9Q_A0MM;1=M7^;N]-'>ZT:-)?Q)][ZOY+\EI
MKK=6>J9F_P#"8Z1_T%--_P#`E/\`&C_A,=(_Z"FF_P#@2G^-:5%(#\W],_8:
M^+%]^T9\4-6\)ZI\'_@KH?B:_OA_:\TUOXOU+6HKN>TN;F2"6VM-(U2S%UY1
MCG,^K7+1F()`D:16UPGHOPM_92^(?PW_`.">FJ?`V;7_`(,W4EY:ZZMK>:)-
M<Z#IUFL]\UQ::>+0BY/V:6.6:.5Q(/(0I&L-R`SMQD'_``5QUOPI^T]\2?#=
MQJFD_$Z71OM5GHWAGX<Z$OBE;5H[V.*&:\FTF]O]5M6B29A>M=Z5!'NB"6RM
M)'B\]$^%O_!3>X\4_P#!/35/B)J5QH,?Q'TVUUV5=.OM#O\`PY%=QZ9?-;2Z
M@FGWSB[^R0QM!+.1(5C)>-I8V!VS&WU5):QY=M&[)/>^BMOI:.NFCDAR_P!Z
M][XN9][7]V]K:N_WMI]4CRD_\$WKR&-M1M_A'^RC;^'[G78KZZ^#D>OE?`]S
MY=A-;C4GF_L3:U\9)(_D.G8"PJ1-NSGZT_8S^'MO^SC\$O#_`(/O]4\/++HN
MF1Q"+3K@?V?8!KBZE6RMBP0M!;)(D$9*(3'$A*)G:/EP_P#!4KQ1:1M9R_'#
M]F*;PO<:[%IT'QCCT>5/`\+FPFN7TUXSKA1[X-$OS#4%`69?W18&OK/]C+XM
MZU\=O@OH/BSQ!'IJZMK&E1/+-IT#P6.H*MS=1QWELCR2.MO<1HD\8:1R(YD^
M9NIVZ3]8WW_E5OP[Z_R^Z8JUXV[2_P#2M?Q[:=];GI$_BW298'4:KIN64@?Z
M2G^-?G[\._\`@F#XB\(?L@6_P)N/%_P[F^&-YX3BFU32%OYV67Q*MB898D)0
M*=*GO?+OW!4.9TE#1.EPZK^BD\GE0.PZJI(K\_/AW_P5.^*7BW]D"WDN]!\%
MP_'35O"<7CO31'IM]_PC;Z!)8F^.HO%YQEQ"5>Q>(7.YKGR&W1QSKMX\1[/V
M-;G^'E7-Z>_:WIK+RY;O1,[://[O+_,K>NOYZQ[OFY5JT<Q\`?V/OVK/"E[\
M7[/Q+\5/A7H>B^*/!NHZ)X3;PS\0O%5]<6.I.Z"RO7CU.2:"P,,8DXTY(D!D
MQY3*L83WS]MK]E*S^+?[!VJ?"?PG8^!_'^IW22BPN/B9XON[W^RKF02D:BEY
M/;W]PUQ#))F)0%"*=J/$JJM>*?`'_@X0\-_'&]^+^EZ7HOA?Q-K/PD\&ZCXK
MGM]`UG5%>X:Q=(Y+6Y6_TNUCMI'>0!?L\U[&-LF9,!&D]]_;:_:X\:?LM?L'
M:I\3-<U;X0_"WQ?I*2W(L=>OIM<TG4BHE>'3X)VDTQS=SHB8(5@C;U"3`!SW
MXGGM%STU5GIK[\M=?[U]M;6M]DX\+:]H>>G9\D='_P!NVWTU=WJSGOC/\*/'
M'Q#_`&BO@/\`$JR\"?L^KXF\`N[^(-6N?&UPNIV\$]I=VLVGV5P-&9Y[93<B
MX!D:`221[3&F?-'U;_PF.D?]!33?_`E/\:^8_C/_`,%'/#/PZ_:*^`]G9_&'
MX'MX%^+CO!]CN;V)M3O4>TNY;;4+*]%^L36TEQ##;!?LT@>27"RABJU]75EK
MR_.7R=]5VT^_776X1M=6_EC]UM'_`%\M+'/:/XKTN+4=59M2T]5DNE9";A!N
M'D1#(YYY!'U!KSW]LK0-?^-W[/.O>#?`7C#PIX9UCQ5&-+N=9U*629=,L93M
MN9(HH)(Y)9C%N1%$T&#)O$JE`&]1T3_D)ZQ_U^+_`.D\->?_`+97[2,?[*?[
M/.O>+H[&XUG6HHQ9Z#I%M:7%Y<:SJ<QV6UM'!;I)/+ND(+"&-W$:2,%.TUE5
MY>6TO+3OJM/GM\SHH\_.G!V?1]O/Y;_F?'>I_L>_&KX4_!;P;\.=`\4>"_&'
MAG1_'-SJB6OA?QMJWPKLK+0Y]/O6&F-+:37U[!;6]])"8$MY9<J8HRL441->
MT?"_]G'Q=/JWP?F\>?%*^N+#P'HNH#5=.TCQ[J<:WVHO?6D^G+/.IAEU.&UM
MHIK=I;LAKG.Z6)S+(!YNO_!9&^\%?`70+[Q1H_@O1?&TOC.?P9JT_CR_U#X7
MZ%`%L[J]M=49=3M)KRVM[N"W41QO$Y$TC1B1_++GUKX7_M\>)/C=JWP?L_"O
M@#0KS_A9&BZAX@U*]N?%;16&F6=C?6EI/-92I9R-J$<WVKSK5RD"SQ"-F,(D
M^7ICSNHK:NZL]M?9NS>VO)>7-+5-7;3.=\J796EIY<^O=?%[NFC5DKJQD^,_
M@SXDB_X**1_%+PKX7^!FGZ/>>$[SPSJWB.3Q)-;^(]4,QLY899[>'3L3+;/:
M>6D;7P)29F5XB-C>=_\`!(O]@C4OV"_%/BJ\US3/@WX;M]<TBQT\?\(MK<=]
M-</;O*P#,FDZ:?*3S7P]XU_>R%QYMX^S+^K>,_V\[#X9?\%%(_A-K/Q(^$LF
MGZMX3O-7L_#B`P^*-/O[<V;1P2$7DAN/M$,UQ-'%'9QR;("5,H#&O.O^"1?_
M``4B\8?MS^*?%5CXJ\2_"/Q`-(TBQOX%\%6Z#R9)7E64R-%JVH[86"Q^4MXE
MA>'$N^SCV$+C@_A7L_Y9?=S5+K3K?G:\GV-,1\+Y]-8?-VC9^GPKUV\_L?7O
M$NG:A:00V^H64TS7EMM2.=69L3QG@`UO5F^*?^09%_U^6O\`Z41UI4`>/Z)^
MT7X-T_XTZ#\);CQE?6?Q`U+PY#K]KI+6!6.6T/F(-EPT'D&0_9YR(?-,Q2"1
M]A1&84?!_P"VE\,_'OC&]T'2/B#J=YJ5AK\_AF1!I$JQ/J$-K-=RQ1RM:B.5
M5AMYSYL;-&6B9`Y<;:\3_:$U']G;Q!\7Y-+\8_&32_`7Q6UK2?#NEV-K;^.M
M%TG7-*ELYKR>RGLH9I/.6:?^TYXR'1UEBE";,,V[U2P_8A\#^"O%]CXBLM/\
M5:1#H%Q!?6UJE[9+96BV^BS:.B'<2_EBUF9B6?=YBABVW*G.I*2I.<;7UMV^
M_I;1-:][K8IQ7M>1;67K=Q6ENSE>S[:6ZOM-"_:3^'OB#P%-XGA^*6DV^AV>
M@6GBJ]N;V]L[+^S=*ND>2WO;I)HT>VAD6.4J\P0'RI!U1@+E_P#'#P?9?`34
M/BE#\0(=4^'NFZ1/KTNO:2]OJ=G)8P1M)+/$UO$_G*%1CB,,3C`!/%?,/P5_
MX)M?![QS^PK'X.^%.O?$[0?A?XT@TO7]%U/PKJMCIMU:7T`1EUNSG6,.EU<"
M.%G+!H=T2R111.SNWIWPI_9B\(1_L?\`C;]G^/Q5XT\>6L]EJ'ASQ3K.H:MI
M-WXF634+<M(U[-"B*UX8+A'$D\32.K1N_F;MS=%:-I5(PZ;7^5[[;-VV6B3W
ME:*H\KG!U/A;U:WMW7R]=6UJH\TMKQ'^U=\'_$/P%NO$7C[QHW@SP!K%TV@S
MGXH:(?!]MJ,CQ%S`8-:M;9I5>/<1\A5PK@$[6QT&M_M8?"?PIK-[I>I?&[P+
MINH:7:I>W=I<^(]*AFL[=S"$ED1L%(V-Q;@,0`3/%@_.N?,/CE_P3'\%_$CX
M#Z;\._`%Q\3/V;_#]AJIU>8_!G4M/\'S:G*T!A=;GR4*2HRE2P*@EHT.?E`K
M1^&W_!./P)\,/@V?!%I8>,K[2Y-=\/\`B&:>]GTZ2YN;C18=-AM%D8*%9"NE
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M.5U=1UVL^ZZZ='U\KVN[7?JW]B77_08U+_OBW_\`C5']B77_`$&-2_[XM_\`
MXU1_;=U_T!]2_P"^[?\`^.T?VW=?]`?4O^^[?_X[4E!_8EU_T&-2_P"^+?\`
M^-4?V)=?]!C4O^^+?_XU1_;=U_T!]2_[[M__`([1_;=U_P!`?4O^^[?_`..T
M`']B77_08U+_`+XM_P#XU1_8EU_T&-2_[XM__C5']MW7_0'U+_ONW_\`CM']
MMW7_`$!]2_[[M_\`X[0`?V)=?]!C4O\`OBW_`/C5']B77_08U+_OBW_^-4?V
MW=?]`?4O^^[?_P".T?VW=?\`0'U+_ONW_P#CM`!_8EU_T&-2_P"^+?\`^-4?
MV)=?]!C4O^^+?_XU1_;=U_T!]2_[[M__`([1_;=U_P!`?4O^^[?_`..T`']B
M77_08U+_`+XM_P#XU1_8EU_T&-2_[XM__C5']MW7_0'U+_ONW_\`CM']MW7_
M`$!]2_[[M_\`X[0`?V)=?]!C4O\`OBW_`/C5']B77_08U+_OBW_^-4?VW=?]
M`?4O^^[?_P".T?VW=?\`0'U+_ONW_P#CM`!_8EU_T&-2_P"^+?\`^-4?V)=?
M]!C4O^^+?_XU1_;=U_T!]2_[[M__`([1_;=U_P!`?4O^^[?_`..T`4+?1[@^
M*+Q?[5U`,MK`2^R#<V7FX_U>.,>F>3UXQ?\`[$NO^@QJ7_?%O_\`&JH6^L7`
M\47C?V5J!9K6`%-\&Y</-S_K,<Y]<\'IQF__`&W=?]`?4O\`ONW_`/CM,`_L
M2Z_Z#&I?]\6__P`:H_L2Z_Z#&I?]\6__`,:KE=4_:0\(Z)JWB:PO=:T>SOO!
M6GIJWB&WGUFPCFT&S='=;F[4SYMX62.1A)(%4A&.<`UDZ!^V;\-?%7P;O/B-
MI?C3PCJ7P]TTN+OQ/:^)=,FT:U*,%?S+M;@PKM9@#EQ@D`]:5]WVU^6WYZ!9
MW2[Z?.U_RU]"YXVNO#_[-7@?5O$#0^)+?3[B^-[?Q>%_"4NL7UY=3NJM.;33
MK.6XF=CM+R"-B`-S$`$CAOA7^WG\-_C+XB\+:7H?B3XBK<^-+J^L-(?4_`&K
M:3;W%U9>?]JMVGN].BBBFC^S7&8I61SY+X4XKTOXFZH/$?PIUQ7OM<\*Z?=Z
M;,7U^PO+&&73(3&2US'+,SQ(47+!W5E&,]J^3?BKX]_9\D\??!.WT_\`:9TO
MX8V_@>"SU'P;X7TCQAX.6UUB*:"6UAG"WT<]S.EQ;SRPJT4H5P^Y/W@$@=/X
M_9R\DK=-'OZ6T23NKJRM<F;]SGCV;]=OSOJV]/.Y[[X1_:6\+_&G6/&'AWP]
MJ?C^\N_#*W]K?7-[X+U'3]'EFM97MIXH=1GL8[2X99E="()G)V,1D*2/5_[$
MNO\`H,:E_P!\6_\`\:KXY^"?P=^#=_\`MK_$[X@>'?B?;?$/XNV6G:AI7B#3
M;>?P@M_H$4CQHT-[_95K!J$JPFVCA1;^6<IY?0R#=7V-_;=U_P!`?4O^^[?_
M`..T1UIPEU:N^U_+R^_U*EI4G%;)V7?IOY_)>@?V)=?]!C4O^^+?_P"-4?V)
M=?\`08U+_OBW_P#C5']MW7_0'U+_`+[M_P#X[1_;=U_T!]2_[[M__CM(#Q?P
M%^U#\/=4\:^.DTR\\5:3I^B-=WNO>++KPL^G>'[RYL66SO`=2DM4AFEMQ%#&
M7+E75-L3R?9YUAZ;PU^T=X.\5_L^2?%*U\8:S'X(A@N)Y+V[TE[.>(6\KPRH
MUK-;+<K*LL;Q^48_,9P%"DD`^":A_P`$C?"GQ`_:#\7_`!"\>:U\2/%-_P")
M+U+BWCTN73/!MS:QQM;2VZ7&H:$MCJ&H&WFMU,)N[F18U6+Y#+$)V[?PE_P3
MX\/^!/V=]0^%NE:U\7U\':I'JK7$%_X@MM7N7N;ZY%R+H7-[YTRR6\@)B0.(
M6+NT\<[LS$5_9)OXK+S2=MGMZ))M*V]G[H_XME\-_P`-+=_.]U\E:SN0?\%$
M/AC/HEQ=#Q!\5%O+>_336T.3X::XGB%I6A,X9-);3!?O#Y2LWG+`8AM.7!!%
M>E?"#QYI?QNT*U\4^&?$&J7NBZUIUO<VMQ+9"UF93).I22&:%)(G1E96CD17
M5MRL`1@>-W'_``3XFN=8B\2-\3?C:?B5#?+<KXYV>%_[7^SK;2VZV/D?V?\`
MV=]G"SRMG[)YNYR?,YQ7K?P*^'%I\!?"]KX7T?3]<NK73;-"\]Y-;/=WDTD]
MS-/<S%66/S)II9)&V*J[F;"(NT56FORM]VOX^GSW(]ZZ^?YZ?AZ_+8[E]&N$
M0LVL:EA1D_)!_P#&J\1T/_@H!\(_$G[+5U\:+'XE:E<?#NSD\F6_&BS"Z64L
MJK$+(VGVLR/YD;(@A+2))&ZAD=6/MLFL7$L;*='U+##!^>W_`/CE?-7A?_@F
M/X#\):+INFVL?Q$;3M-\'Q^$1:/J=E]GN&BT]]-CU62,`(=16RDD@\T`(48`
MQG9&4QJ.?)/DMS67+VOJW?RT25NKN]$S>GR:<]]U?TV^^]GZ)JUVK>E>!?VN
M?A/\38?$3>'_`(U^#]7;P?;?:_$,5MKNFO-X>BYRU['C?:XVL#YP0J58'!!`
MA\<_M<?#OP'\"O\`A9K>/]0\0>`5FDA?6_"VFMXFM8O+:1)7<Z=;3E(HGBD6
M25@(XRA#LIKP/X=?\$:?#/@K4O'LVL?$K]I;X@6?CSPMJ/@XZ=XO\7V.K6/A
M_3[UXGFCTZ)H@+?'DQJJ_,FU%!5L#'T'^U#\`W_:=^`>J?#MM4\=^!]'UJV-
MA>W/AS^R/M4]HT;1O;?Z9%<QHC*W)2-7&T;77G/14Y%9PN_+_MY_^VV?DV][
M6>-*[TGI_P`,O_;K]M$N]UI^*?CAX>\%?&+PMX$U+7O%EOX@\:)*VCD>';B3
M3KMHXI9GB-^MH;2.810RN(I)5D*H2%(QGN/[$NO^@QJ7_?%O_P#&J\+\>_LB
MZY\0_%'PQUB\^*7QH@O/A?,MW;&W@\+!=:N?)FMY+B\#:>WSR6]Q+$RV_DQA
M6W(B.`X]T_MNZ_Z`^I?]]V__`,=J=+?-_GH_N^?DM@5^O9??U7]?CN4-'T>X
M?4=5`U74%VW2@D)!\_[B(Y/[OWQQ@8`[Y)B\;ZS9_#;P9JWB+7O$UUI>AZ#9
M3:CJ%Y.L"Q6EO$ADDD8^5]U44D^PJ71]8N$U'52-*U!MUTI(#P?)^XB&#^\]
ML\9&".^0.1_:3^".G_M4?"RX\%^)+;QE9^'=0N8)M1AT;58]-GU&**02"W:X
MBE$\<;.J%C`\<A"XWA2P:)<UO=W_`*U^6_Y&D.7F]^]O+?Y>?:^G<YC4OVH?
M@MJOPC\,_%/Q%\3?"^A^%5OIET?6_%CV>BFPOE$]M-$!?1126UT@%S#)$P25
M<2HRCYA75:E^T3\.]&M/"=Q>?%[PK:V_CX0MX8DFUS38T\1B9HUA-D2,7/F-
M-$%\K=N,J`9W#/A>K?\`!+S3]`ET$?#WQI\7OA^ND>,I?&SW+:I:>*=1%[-I
MESI\[0W.MF]9#,MP'D,PG'R-L6-I&>O3O@[^R%X=^#'B'P7K%G:^+M5U;P3H
MVK:/;WFHS:>TEZ=4O8+Z]NIO+"*LTEQ`&Q"(HE$CJ(PNP+K'E<O*_P`[<K;M
MW]ZT;NVFO+T,]5]S^_FLM/\`#[SU>NE^KZ:+XZ>'7^.UY\-Y/$'BJU\66>DO
MKACNO#T]O8W%FC0K))!?26BVD^QIX0ZQ2NR%P&`YKF_V9/VT/A_^V!=W4/@/
MQ5XTO&MM-M=95M4\'W^AQWEC=&06]U;O?6,"W,,ABDVR0EU.WKR,U_''[+.H
M>.?VGM/^)TGCGXM::VFZ3<Z'#X=L6T&+2A:7(A,Z>8;4WRL\EO!+O6Z#H\8V
M,JEE//\`[$W_``3_`-%_8;U[Q!J&AZM\0/$<WB6.-;T:K;>'K);B96+-=S_V
M;:69O+R0GY[J\,\[8/[P;GW9T=5^\TT?WWE;OHUR?/F\BJFB?)W7W65_G?F[
M=-]3WK7M+GMK2!WU*]N%6\MLQR+"%;]_'UVH#[\&MZL'7M4GN;2!'TV]MU:\
MMLR2-"57]_'UVN3[<"MZ@#P^;X,Z7XC_`&E/AG\49/%FGV<G@?PEJGAUM)9$
M9KHW[Z?(93+Y@\OR_L.-FQMWF]5VX;Y]^)7_``23\.?%#]K_`%[XE:A\1/"$
MNG^(O$(U^Y:7PU%-XK6+^RQI[Z*NLM=X&BR*"SV1M"'$DB[_`)MP^\J*F5.+
M2BUHDU\I2YG][U_!:%>TDKZ[V_!67X'Y0_&C_@W:T/XT_LK_``A^%U]\7/AU
M;V/PC\/W^CV%S!X)FM56\N)$=-9@2VUB%H[_`!&/.,\EQ!</\YA1@,?>'[,O
MP-T_]GOQO\3M<N?&^G>(+CXE:W9ZU*/+6W^Q/!I5EIY7)FD,F\V9EW';CS=N
M#MW-[=16WMI7D[_%>_G=J3^]I?));)(SY5IY;?E_7FV]V[YO_"8Z1_T%--_\
M"4_QH_X3'2/^@IIO_@2G^-:5%9E&;_PF.D?]!33?_`E/\:/^$QTC_H*:;_X$
MI_C6E10!F_\`"8Z1_P!!33?_``)3_&C_`(3'2/\`H*:;_P"!*?XUI44`9O\`
MPF.D?]!33?\`P)3_`!H_X3'2/^@IIO\`X$I_C6E10!F_\)CI'_04TW_P)3_&
MC_A,=(_Z"FF_^!*?XUI44`9O_"8Z1_T%--_\"4_QH_X3'2/^@IIO_@2G^-:5
M%`&;_P`)CI'_`$%--_\``E/\:/\`A,=(_P"@IIO_`($I_C6E10!F_P#"8Z1_
MT%--_P#`E/\`&C_A,=(_Z"FF_P#@2G^-:5%`&;_PF.D?]!33?_`E/\:/^$QT
MC_H*:;_X$I_C6E10!F_\)CI'_04TW_P)3_&C_A,=(_Z"FF_^!*?XUI44`<];
M^*]+7Q1>2'4M/\MK6!0WVA-I(>;(SGMD?F*O_P#"8Z1_T%--_P#`E/\`&M*B
M@#Y%^+?_``3>^'_Q'UKXYR:9XA\+^$]-^-O@>+PI<6>FZ/:*NFWJW.HW3ZL?
MG"33O-?^8<HK[X=_F;F#+PO@W_@D-X3A_95^,7@?QA\1M'\;>+_BU)<72^)M
M4MKG5!X:NFTH:5#<6BZGJ%[>^9';[@6>_9B)'1#%&0@^]**E1232[<ORYN9+
MRL]5;5>AI[:?M%5OJG?Y\JCKWT26NCWW;OXWIW@B/Q]X0\3>$OB2_P`,?$7A
M.&\M$\,0"W^U-]F@MK9DGO8[@M']J2^2:2,Q?*B)`0=X)'F?P<_8+T#P!X<_
M9_T'Q%X_TOQ=X9^`/A];.QTF6S2WMM4UF-(8K;6)%,[J'MXTG$41#^6]P9`^
MY%(^L**TYWS.?5V;\W%-)]K^\W?O9[J+6,8I0]DOAM:WD[:>FEO-73T;O\(_
ML[?\$M-)_9L_:7UKXE-\5F\0:;8V_B5?#/AJ$W5O;:2NLW@NYXS%)?S62B,H
MD:"PL[$,!NE$SX8?;G_"8Z1_T%--_P#`E/\`&M*BICI"--;15EZ7;_-LJ5W.
M4WO)W?K_`%V,W_A,=(_Z"FF_^!*?XT?\)CI'_04TW_P)3_&M*B@#-_X3'2/^
M@IIO_@2G^-'_``F.D?\`04TW_P`"4_QK2HH`S?\`A,=(_P"@IIO_`($I_C5"
MW\5Z6OBB\D.I:?Y;6L"AOM";20\V1G/;(_,5T-%`&;_PF.D?]!33?_`E/\:/
M^$QTC_H*:;_X$I_C6E10!F_\)CI'_04TW_P)3_&C_A,=(_Z"FF_^!*?XUI44
M`9O_``F.D?\`04TW_P`"4_QH_P"$QTC_`*"FF_\`@2G^-:5%`'/:/XKTN+4=
M59M2T]5DNE9";A!N'D1#(YYY!'U!J_\`\)CI'_04TW_P)3_&M*B@#-_X3'2/
M^@IIO_@2G^-'_"8Z1_T%--_\"4_QK2HH`S?^$QTC_H*:;_X$I_C1_P`)CI'_
M`$%--_\``E/\:TJ*`,'7O$NG:A:00V^H64TS7EMM2.=69L3QG@`UO444`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
